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Behind every number is a human face 
 
– William H. Foege, MD
The first edition of 
 
Family Planning Methods and Practice: Africa
 
, pub-
lished in 1983, became widely known as “The Yellow Book.” The
influence of this book could be felt internationally. Besides helping
educate health practitioners in Africa, it helped health professionals in
the Western World learn more about the people of Africa. For me, the
book contained important lessons that proved useful on my trips to
northern and western Africa.
Both health and the quality of life in Africa have changed pro-
foundly since the publication of the first edition, in many ways
because of family planning. Recent data show a striking decrease in
infant mortality, accompanied by an increased life expectancy and a
decline in fertility, for all the major regions of the continent.
 
1
The practice of family planning also has caused other important
changes. In addition to changing individual behavior and fertility,
family planning has changed the dynamics of family life and the char-
acteristics of national populations in Africa and around the world.
Moreover, it has led to international meetings that addressed abortion,
the role of women, and the impact of an increasing population on
family life.
In the years since the first publication was distributed, individual
lives have changed. My own family of four children began before we
recognized family size and population change as issues of global, not
just local, importance. Our first daughter was born before oral contra-
ception was available. Abortion was not legal in the United States.
Women underwent voluntary surgical contraception only if that was
approved by at least two physicians. More than 30 years have passed
since the birth of our youngest child. To my deep sorrow, my wife died
without seeing any of her grandchildren. Two of our daughters are
married. Although my wife and I started our family before we were 25


























were older than 30. Now I have two grandsons and a granddaughter.
One of my daughters has two children and expects that she has com-
pleted her family. All of our offspring have a clearer understanding of
the importance of family size to themselves, their community, their
nation, and indeed, the entire planet. This was not so when my wife
and I started our family. Changes like this, although they are in a sin-
gle family, have implications for the future of humanity.
Profound changes have occurred in the years since the first edi-
tion of this book. In 1992 African ministers of government met in
Dakar and issued a declaration on population for Africa. In preparing
this declaration, they reviewed key global documents and the state of
their own continent. The declaration dealt with a broad spectrum of
human concerns. Its principles covered population and economic
development; fertility, families, and family planning; mortality, mor-
bidity, and the acquired immunodeficiency syndrome (AIDS); urban-




In 1994, Egypt hosted the Third International Conference on
Population and Development, which was sponsored by the United
Nations. A new emphasis was placed on reproductive health rather
than population policy. Controversies arose about abortion and the
empowerment of women. Differences on these issues were resolved
and conferees issued a Program of Action at the conclusion of the
meeting. Africa, and Egypt in particular, emerged as a place where the
world could convene to consider important global matters in a secure
environment.
Besides political changes, the world is intensely concerned about
the global human immunodeficiency virus (HIV) and AIDS epidem-
ics. Infections caused by HIV have seriously influenced Africans, their
families, and their communities. Human behavior, including intimate
sexual practices, plays an important role in transmitting this disease.
The fundamental changes in personal lifestyles required to interrupt
this contagion are likely to require more from people of Africa than
from people of many other places.
The first edition of  
 
Family Planning Methods and Practice: Africa
 
has played an important role in improving health for Africa. The book








family planning. It helped everyone recognize how families and family
planning affect the health and life of people, especially the people of
this continent.
The unique character of both the first and second editions of
 
Family Planning Methods and Practice: Africa
 
 is seen immediately in
their tables of contents. The authors focus specifically on Africa, even
though the lessons they teach are important for all of us. Both volumes
address issues that are simultaneously profound and global, intense,
and personal. They deal with health benefits for countries and individ-
uals and with basic human behaviors that influence future genera-
tions, today’s families, and the day-to-day life of adolescents.
This new edition still emphasizes family planning methods and
practice as they relate to Africa. It gives current information about the
menstrual cycle and contraception. It introduces significant new top-
ics. The chapter on HIV infections is especially important. The sec-
tion on reproductive behavior and population change will be critical
to public health officials. The expanded section on “Providing Family
Planning Services” has greater depth and breadth because it includes a
chapter on education and counseling, as well as one on quality assur-
ance. This new edition brings important ideas to the provision of ser-
vices for family planning. Prevention, education, and the quality of
clinical service get greater emphasis. It also discusses, in detail, new
approaches to contraception, such as long-acting hormone implants.
Program management, as well as clinic management, is an important
part of this new edition.
I hope readers will find this version of what has been called “the
Yellow Book” timely, informative, and even more interesting and use-
ful than the first edition.
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A new mother asked me for protection against sexually transmit-
ted infection. She was concerned about her husband's promiscu-
ous behavior. I suggested that she talk openly with her husband
about her concerns. She was worried about sexually transmitted
infections, especially the “slim disease,” which is the common
term for acquired immunodeficiency syndrome (AIDS). Because
she wanted to get pregnant again, she was also concerned about
possibly infecting an unborn child. I gave her educational mate-
rials and a bag of condoms. She shook her head, saying her hus-
band would refuse to wear condoms and would feel insulted.
Her husband, I said, had two choices if he cared for his wife and
children: to be faithful to her or at least to wear condoms. I
encouraged her to have her husband, a college-educated high
school teacher, to come talk with me. 
Two weeks later, the woman returned with black and purple
bruises over her face. "Doctor," she said, "I came just to show
you what your condoms and advice have brought me." She had
been badly beaten by her husband.
Six months later, this woman tested positive for the human
immunodeficiency virus (HIV).
 
Providing contraceptives in Africa is a challenging task—especially in
the era of the AIDS epidemic. In many African countries, ignorance of
sexual matters is considered a sign of purity. Most people in Africa
find it difficult, even shameful, to talk about sex and its various conse-
quences. These general attitudes have kept millions of young people,
especially young women, from seeking accurate reproductive and sex-
ual information from reliable sources.
Although the African family is still a strong and extended net-
work of obligation and protection, traditional practices have eroded
rapidly in recent decades. While it is normal and healthy for people to


























risk for sexually transmitted infections (STIs). There are more than 30
STIs; ignoring them can adversely affect a person’s life. When cultural
beliefs equate ignorance with virtue and when discomfort and shame
overshadow common sense, people cannot take good care of them-
selves and their loved ones.
Studies have shown that Africa has one of the highest fertility
rates in the world as well as the majority of cases of human immuno-
deficiency virus (HIV) infection and AIDS, especially among hetero-
sexual couples. Whereas men make up the overwhelming majority of
AIDS cases in Western countries, African women and men are
infected in almost equal proportions. And yet, it would appear that
many of these women do not engage in risky behavior. They confine
themselves to monogamous sex. However, they are the victims of
another cultural characteristic: gender inequality. Too often, it is the
sexual behavior of men that exposes their wives to serious infection.
During my many years of medical practice and public health
research in Zaire, time and time again, gender inequality created barri-
ers to community health. My team and I conducted a field study on
the perinatal transmission of HIV among women receiving prenatal
care in an upper middle class clinic in Kinshasa. After a precounseling
session, women were screened for HIV antibodies and other STIs. The
screening was free of charge, and women were encouraged to bring in
their spouses or partners for a free STI screening. Only 1.6% of the
male partners participated.
As a male physician, I must always remember that the female
gender so lacking in equality includes my own daughters, sisters,
mother, and grandmother, whom I so cherish. Would I allow another
person to place their lives in jeopardy? As a husband, I may desire
more children, but my wife is the one who faces the physical challenge
of the pregnancy, delivers the child, and takes the major role in rear-
ing. How could I have a pure conscience if I insisted on having a child
when my wife was hesitant?
The way we define a problem determines how we approach its
solution. Being of African heritage, I personally cannot accept that








their health; control their sexuality; and make informed choices about
education, marriage, and childbearing—is an inevitable element of the
African culture.
Cultural practices are hard to change, but culture is never static.
None of us can change what we have done in the past, but once we
learn more, we are responsible to act more wisely in the future. 
Let us rise up, O African people! Let us make positive changes in
the lives of women—for the future of our families and nations.












This second edition of 
 
Family Planning Methods and Practice: Africa
 
 is
the product of collaboration between African and American colleagues, the
Centers for Disease Control and Prevention (CDC), and is supported by the
United States Agency for International Development (USAID). 
In addition to the principal authors, nearly 100 individuals contrib-
uted to this second edition of 
 
Family Planning Methods and Practice: Africa
 
by writing, reviewing, or editing various chapters of the book. Several per-



























, MA, CHES, had the difficult task of keeping current
the information on human immunodeficiency virus throughout the lengthy
development of the book.
The knowledge and wisdom underlying this book grew from the dedi-
cated work of hard-working, devoted practitioners who were so instrumental
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, who played a large role in writing both editions.  Dr. Stewart died May
1998, as the book was nearing its final production phase. As an obstetrician/
gynecologist, Dr. Stewart provided excellent and empathetic care to many
women and their families. His interest in the health of African families
stemmed from his work as a Peace Corps staff physician in Malawi and
Kenya during the 1960s. More recently, he traveled to African nations to




































































































































































Many individuals, both African and American, contributed to this second edition of 
 
Family
Planning Methods and Practice: Africa
 
.  They helped ensure the completeness, accuracy, timeli-





















Benefits of Family Planning
 
The little boy was small and feeble. He still did not crawl very
well. He did not smile much. The traditional birth attendant
slowly shook her head and then turned to check the mother's
growing belly. The mother herself was weak and she had swollen
up too much with this pregnancy. She would need to be deliv-
ered in the hospital again because of the toxemia. Another baby
coming to the family—coming only a little more than a year
after the birth of the young boy sitting unsteadily by his mother's
side. The husband was deeply concerned about the health of his
wife and child and the baby to come. Maybe this time the
mother and father would reconsider and use a contraceptive.
 
The decision of when or even whether to have children is a basic
human right. The International Conference on Population and Devel-




Everyone has the right to the enjoyment of the highest attain-
able standard of physical and mental health. States should take all
appropriate measures to ensure, on a basis of equality of men and
women, universal access to health care services, including those
related to reproductive health, which includes family planning
and sexual health. Reproductive health care programmes should
provide the widest range of services without any form of coer-


























freely and responsibly the number and spacing of their children
and to have the information, education and means to do so.
With this right come both benefits and risks. Family planning
programs provide services that help people achieve the number of chil-
dren they desire, reduce the number of unwanted pregnancies, reduce
the risk of sexually transmitted infection (STI), and improve the
health of women and children. Family planning can help couples
reduce the factors that place the health of women and children at most
risk: 
• Age at pregnancy (too young or too old)
• Too many pregnancies
• Pregnancies spaced too closely together 
Family planning also helps improve the future by allowing par-
ents to better plan their lives. Poverty and lack of education limit the
opportunities for individuals and families. Through family planning,
however, individuals can obtain greater prosperity and security for the
family because they can have a better chance at receiving an education
and devoting more time to earning an income. Women can better ful-
fill the many roles for which they are ultimately capable: mother, wife,
wage earner, community member. In turn, a man can better expand





ERTILITY AND MORTALITY RATES 
 
In general, the countries with the highest rates of fertility also have the
highest rates of maternal, infant, and child mortality. African people
have long valued fertility, and as a result, many couples have large fam-
ilies. The average number of live births per African woman is 5.6. (See




 number of pregnancies required to produce the
5.6 average number of live births would be higher because not all
pregnancies come to term and a number of infants do not survive.
Compared to women elsewhere in the world, women in most sub-
Saharan countries bear children at younger ages, have larger families,






























Each time a woman in one of the world's poorest countries
becomes pregnant, her risk of dying from that pregnancy is as much as





  Because of the high fertility rate, poor health conditions in
general, and inadequate availability of medical care, the risks of preg-
nancy are higher in Africa than anywhere else on earth. An African
woman's chance of dying from pregnancy-related causes—obstructed
labor, postpartum hemorrhage, pregnancy-induced hypertension, post-





 In contrast, the risk of maternal death in industrialized
nations averages 27 per 100,000 live births. (See Table 1:2.)
 

















































A rate of 700 maternal deaths per 100,000 live births means that
a woman's risk of dying from a single pregnancy is about 1 in every
140 live births. Over a lifetime, the average African woman, who has





 However, many African woman have as many as eight children
with even more pregnancies. For these women, the risk of maternal










A mother's death represents one end of the spectrum of preg-
nancy complications. Experts believe that pregnancy-related morbid-
ity far exceeds pregnancy-related mortality. However, illnesses that do
not result in death but leave women weakened or in poor health are
not measured in most developing nations. Family planning would
reduce the risk of pregnancy-related morbidity. 
Family planning services also reduce the risk of STIs, which are a
major public health problem in Africa. As of 1996, more than 13 mil-
lion adults and 650,000 children in Africa were infected with the
 






Lifetime risk of 






















































human immunodeficiency virus (HIV).
 
29 Rates of other STIs remain





majority of infertile African men and women have diagnoses associ-














In contrast to the significant risk of death from pregnancy-related
complications, the risk of death from using contraceptives is exceed-
ingly low. Table 1:3 shows the risk of death associated with contracep-





risks by introducing hormones that affect the cardiovascular system or
the development of some cancers; others may involve the risks of sur-




 health risks by providing protection against certain reproduc-
tive cancers or STIs such as HIV, which causes acquired immunodefi-
ciency syndrome (AIDS). All contraceptives decrease the risk of


















The highest risk of death worldwide for children under 5 years of
age is borne by children in sub-Saharan Africa (200 deaths per 1,000
births); children in northern Africa (140 deaths per 1,000 births) have
the next highest rate. (See Table 1:4.)   Infectious disease and malnu-




However, child survival has improved in some African nations over the





























AMILY PLANNING BENEFITS TO WOMEN'S HEALTH
 
Simply providing contraception to women who desire it could reduce




 Family planning also pro-
tects women by preventing the risk factors that contribute to maternal
mortality and morbidity. The highest risks of mortality are those for
pregnancies among women who are too old (over 35), too young


























Family planning allows women to avoid becoming pregnant at
the ages that pose the greatest risk to their health and the health of







  These older women, generally multiparous, may have a flac-
cid uterine wall from repeated stretching during previous pregnancies.
 
Table 1:3  Safety of contraceptive methods
 
Method Chance of death in 1 year of use
 
None, with pregnancy resulting 
in an African woman
1 in 120
Oral contraceptive
Nonsmoker 1 in 66,700
Heavy smoker 1 in 1,700
Intrauterine device 1 in 10,000,000
Diaphragm, condom, spermicide None




Laparoscopic tubal ligation 1 in 38,000
Hysterectomy 1 in 1,600
Vasectomy 1 in 1,000,000
 
Estimated pregnancy risks are based on the average mortality rate in Africa.  
Estimated risks of contraceptive methods are derived from U.S.-based studies.
 




















The weakened walls can lead to malpresentation, uterine rup-
ture, hemorrhage associated with rupture, and hemorrhage associated
with a flaccid uterine muscle. An abnormal placenta is more common







Younger women and primigravidas tend to be at a higher risk of
developing pregnancy-induced hypertension.
 
1,28 The increased risk
among younger primigravidas may reflect not so much increased phys-
iological risk, but socioeconomic differences between younger moth-
ers and women who have their first child at ages 20 to 24. For
example, women who have their first child at very young ages may be
from poorer families and have less access to, or make less use of, prena-






Table 1:4 Infant and child mortality
 



































































Contraceptives allow a woman to avoid pregnancy and child-
bearing once she reaches her desired family size. A mother's risk of
dying climbs steadily as the number of births increases. Women who
have had five or more births are 1.5 to 3 times more likely to die from







If all women had five births or fewer, the number of




















Family planning can improve women's health by preventing or
delaying pregnancies among the women who are most likely to have a
high-risk pregnancy:
• Women who have had previous pregnancy complications
• Women who have a chronic disease
• Women who have anemia (hemoglobin less than 10 gm)
The high rates of maternal mortality and morbidity in many
developing countries can be partially attributed to the norms of living
there: frequent pregnancies, prolonged lactation, heavy work, and
food customs that are unhealthy for women (for example, women eat
with the children after the men have satisfied themselves). This combi-
nation of factors produces a "continuous cumulative nutritional
drain" on women; their bodies do not have time to replenish stores of
vital nutrients.
 
15,22 As a result, they are less able to combat infections
associated with pregnancy, incomplete abortions, childbirth, puerpe-














One of the fundamental goals for family planning is to make
"every child a wanted child." Some unwanted pregnancies are aborted.
Although not conclusively documented, many maternal deaths related
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to pregnancy are associated with incomplete abortions, whether self-
induced or induced by a trained or untrained practitioner. 
The major causes of maternal mortality related to abortion are
hemorrhage and sepsis; the latter is an infection that spreads from the
uterus to the abdominal cavity and then to the overall body. These
conditions, which are caused by retained fetal or placental tissue, can
lead to septic shock and death. In Addis Ababa, Ethiopia, post-abor-
tion complications rank as the most common cause of maternal death,
and are particularly common among young, unmarried women who
have no other children.17
IMPROVING HEALTH THROUGH NONCONTRACEPTIVE
BENEFITS
In addition to providing protection against pregnancy-related
risks, a contraceptive may offer protection against STIs and reproduc-
tive tract cancers. Hormonal contraceptives such as pills, injectables,
and implants protect a user against cancer of the uterus and ovaries,
cysts in the breast or ovaries, ectopic pregnancy, and pelvic inflamma-
tory disease (PID). Barrier methods such as condoms and diaphragms
can protect women against STIs such as HIV and gonorrhea as well as
related problems such as ectopic pregnancy, PID, and cancer of the
cervix.
FAMILY PLANNING BENEFITS CHILDREN'S HEALTH
Many African families still measure their riches by the number of
healthy children they bear. Family planning programs, along with
diarrheal treatment programs, mass immunizations, health services,
and nutrition programs, help contribute to children's well-being.23
Family planning contributes indirectly to children's health,
development, and survival by reducing the risk of maternal mortality
and morbidity. The death of a mother is traumatic; losing a mother
has an immense impact on the emotional well-being of the family
10 FAMILY PLANNING METHODS AND PRACTICE:  AFRICA
members that survive her. It also may affect the physical health of her
survivors since many women earn a living and most are directly
involved in the hygiene and health care of children.  
Family planning contributes directly to the survival, health, and
development of children in three ways:21
• Encouraging women to space births at least 2 years apart
• Planning births during the mother's optimal age—not too
old or too young 
• Preventing further pregnancies in a mother who has had
numerous pregnancies already 
SPACING BIRTHS
Infants born at least 24 months after the previous birth in their
family have lower mortality rates than children born at shorter inter-
vals. (See Table 1:5.) The exact reasons why birth spacing saves lives
are not fully understood, but experts suggest that it improves infant
birthweight and child nutrition.
A pregnancy occurring too soon after a previous pregnancy may
result in a spontaneous abortion, a stillbirth, or a low-birthweight
baby who is much less likely to survive. On average, babies born less
than 2 years after the previous birth in the family are about twice as
likely to die in the first year as babies born after at least a 2-year inter-
val.21
Even older children who are spaced too closely face an increased
risk of death during the toddler and childhood years. Closely spaced
siblings compete for food and other resources. A young child may be
weaned too soon because the mother stops breastfeeding when she
becomes pregnant with another child. This practice has long been rec-
ognized in some societies and has even found its way into the language
through the word "kwashiorkor," which means "the child displaced
from the breast too soon" because the mother is pregnant again.27
Children born within 2 years of a previous child are 1.3 times more
likely to die between the ages of 1 to 5 years than those born after a
longer interval.20
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PLANNING BIRTHS DURING OPTIMAL MATERNAL AGE 
Women who are very young or very old are more likely to have
an infant or child who dies:
• Children of teenagers are 1.2 times more likely to die during
the neonatal period, 1.4 times more during the postneonatal
period, 1.6 times during ages 1 to 2, and 1.3 during child-
hood to age 5.20
• Children of older mothers are more likely to be born with
congenital abnormalities, including Down's syndrome, heart
defects, and cleft palate and lip.11
However, these congenital anomalies are a relatively minor cause
of infant death in developing countries.9   Most of the excess death
associated with older maternal age is probably linked to the additional
risk associated with a greater number of births an older woman will
likely have had.
PREVENTING A LARGE NUMBER OF PREGNANCIES PER WOMAN 
The eventual size of the family directly affects an infant's or
child's chance for survival because it determines what proportion of
the family resources and food each child receives. Studies also show
that birth order affects the nutritional status of a child. In many areas
of the world, families know too well the effects of limited resources
Table 1:5  Estimated average mortality rates for children born to 
women with two kinds of reproductive patterns
Mortality rate per 1,000 live births
Good spacing pattern Poor spacing pattern
Teenage mothers 92 165
Mothers ages 20-34 67 120
Source:  Hobcraft (1989)
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such as food. More children means more mouths to feed, and the
more mouths to feed, the less food for each. The third, fourth, and
subsequent children are likely to eat fewer calories and proteins, thus
making them more susceptible to illness, including fatal illness. Much
of the risk associated with high birth order is probably the result of
close birth spacing.20 On average, the seventh or later child has a
smaller chance for survival than a child who has a lower birth order.12
FAMILY PLANNING BENEFITS WOMEN AND 
THEIR SOCIETIES
Family planning reduces health risks of women and gives them more
control over their reproductive lives. With better health and greater
control over their lives, women can take advantage of education,
employment, and civic opportunities.
In delivering family planning services, providers have a unique
opportunity to enhance the lives of women:19
• Help women learn to make informed choices. In many
countries, women report they have little or no say in deci-
sions about having children. Women need to learn how to
make these decisions and gain confidence in their abilities so
that they can apply their decision-making skills and confi-
dence to other arenas in their lives.
• Support women’s choices. The provider needs to listen to
and encourage women. The provider can give information,
engage women in discussion, help them recognize their
needs and desires, and answer questions. When the woman
makes a decision, the provider can acknowledge its value.
• Encourage women to recognize their strengths and build
on them. Through counseling, women can recognize their
abilities: performing household chores, planning their time,
saving money or food staples, caring for their children, help-
ing their husbands and in-laws, and supporting their friends
and neighbors.
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• Improve women’s skills in communicating with their hus-
bands and with people outside their families. The provider
can help establish avenues for communication during joint
discussions with the wife and husband. The couple’s
improved communication will increase the adoption of con-
traception as well as the continuation and more successful
use of the couple’s chosen method. Ideally, communication
about family planning also will open opportunities for dis-
cussion about other issues in the couple’s lives. Women’s dis-
cussion groups are useful in helping women feel respected
and less isolated. These groups can consider ways to discuss
issues with husbands.
• Create new images and models of competent women and
caring men. By treating and portraying women as compe-
tent and men as caring, family planning workers can help
men and women adopt and accept these perceptions.
Throughout the world, not just in Africa, women suffer from
having a lower status than men. They have fewer rights, lower salary
levels, under-representation in politics and decision-making positions,
less economic power, and inadequate protection from violence.2   The
Program of Action adopted by the delegates of the International Con-
ference on Population and Development, held in Cairo, Egypt, calls
for an end to discrimination against women:25
• Ensure that women can have economic parity with men:
property ownership, credit, right to negotiate contracts, and
right to inheritance.
• Eliminate discrimination against women in the workplace
and in educational institutions.
• Eliminate violence against women in the home and the com-
munity in times of war and of peace.
• Enact laws to remove barriers to the advancement of women.
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FAMILY PLANNING IN AFRICA
Sub-Saharan Africa has the lowest rate of contraceptive use in the
world.  Several factors have contributed to this low rate: difficulty in
getting contraceptive supplies, not enough family planning clinics, a
largely rural population, low socioeconomic levels, high rates of infant
and child mortality, and the high value many cultures place on large
family size.
The percentage of married women of reproductive age using
contraception ranges from 4% in Niger to 48% in Zimbabwe to 75%
in Mauritius.30  (See Table 1:6.)  Less than 20% of women use a con-
traceptive in Burkina Faso, Madagascar, Malawi, Niger, Nigeria, Tan-
zania, Togo, and Uganda. In contrast, the rest of the developing world,
excluding China, has a contraceptive use rate of 43%; the developed
world has a rate of 68%.
As contraceptive use increases, total fertility rates decrease. In
Kenya, for example, contraceptive use increased threefold during the
1980s, a rise associated with a decrease in family size from 8.3 to 6.5
children per woman.5 
As contraceptive use increases in Africa, so will family survival.
Planned pregnancies, which are generally safer for the mother, pro-
duce children who are usually healthier than children from unplanned
pregnancies. Sub-Saharan Africa stands out as the region having the
highest unmet need for contraception in the world.3 (Most recent esti-
mates of unmet need include women not using any contraceptive
method who state they want to space out their children or that they
have reached their desired family size and wish to have no more chil-
dren.  See Table 1:7.) 
The woman’s place is not in the kitchen anymore; 
her place is everywhere there is human activity. 
The hour has come to revisit our prejudices against women.
— Brigadier General G. Miyanda, Vice President of Zambia
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The woman with an unintentional pregnancy is less likely to
receive prenatal care, which is instrumental in reducing the risks of
pregnancy for both mother and child. The child of an unwanted con-
ception is at greater risk of being born at low birthweight, dying in the
first year of life, and not receiving sufficient resources for healthy
development.13 Family planning is vital to family health.
REPRODUCTIVE LIFE PLAN
Family planning allows individuals and couples to plan at least
one aspect of their lives: whether and when to have children and how
many. Such planning increases the likelihood that mothers and their
children will enjoy the health benefits of birth spacing and having
intentional, rather than unintentional, pregnancies. 
Every person, whether from a traditional or modern culture,
already has at least a partially developed reproductive life plan. Cul-
tural expectations about when to marry, when to bear children, and
how many children to have can be strong and can form a person's
future. In the process of accepting or challenging these expectations, a
person is actually forming a reproductive life plan.
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Table 1:6 Family planning methods currently used (in percentages) 










Burkina Faso 10 6 4 <1 0 2
Cameroon 14 10 4 1 0 1
Egypt 47 2 45 1 0 13
Ghana 20 10 10 1 — 3
Kenya 33 6 27 6 0 10
Madagascar 17 12 5 1 0 1
Malawi 13 6 7 2 0 2
Namibia 30 3 26 7 <1 8
Niger 4 2 2 <1 0 2
Nigeria 6 3 4 <1 0 1
Rwanda 21 8 13 1 0 3
Senegal 7 3 5 <1 0 2
Tanzania 18 5 13 2 — 6
Togo 12 9 3 1 0 1
Tunisia 51 9 41 10 0 9
Uganda 15 4 9 1 — 3
Zambia 26 12 14 2 0 7
Zimbabwe 48 6 42 2 <1 33
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Table 1:6 Family planning methods currently used (in 
percentages) by married women of reporductive age, 
18 African nations —Continued
IUDs Condoms Injectables Vaginal
Periodic
abstinence Withdrawal Other
1 1 <1 <1 4 0 2
<1 1 <1 <1 7 2 1
28 2 1 <1 1 1 <1
1 2 2 1 8 2 1
4 1 7 <1 4 <1 1
1 1 2 <1 9 2 <1
<1 2 2 <1 2 2 2
2 <1 8 <1 1 <1 2
<1 <1 1 0 <1 <1 2
1 <1 1 <1 1 1 1
<1 <1 8 0 5 3 1
1 0 0 0 1 0 2
1 1 5 — 2 3 1
1 0 0 1 7 2 0
18 1 1 1 7 3 1
<1 1 3 0 4 1 3
1 4 1 <1 2 5 5
1 2 3 0 <1 4 2
Sources:  Bureau of Statistics [Tanzania] (1997); Central Statistical Office [Zambia] et al. 
(1997); Central Statistical Office [Zimbabwe] (1995); Curtis SL and Neitzel K (1996); El-
Zanaty F, et al. (1996); Statistics Department [Uganda] 1996.
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Sub-Saharan Africa 38.9 15.9 23.0 0.41
North Africa/
Middle East
59.8 40.9 18.9 0.68
Asia 60.8 46.7 14.1 0.77
Latin America 67.2 47.8 19.4 0.71
Potential demand = current users (met need) + nonusers (unmet need)
Source:  Bongaarts and Bruce (1995)
Reproductive life plan
1. Would I like to have a child in the future?
2. How many children would I be happy having?
3. What are the things that I would like to achieve most in life, 
and by when?
4. Of all the things I could do in life, what might be the most 
important to accomplish?
5. This goal would be affected by or would affect childbearing 
in what ways?
6. How old would I like to be when I have my last child?
7. How concerned would I be if I were to become pregnant 
before I was ready?
8. What would I do if I were to become pregnant before I 
wanted to?
9. How compatible is my life plan with my religious beliefs, 
my husband’s (or wife’s), my community’s?
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Kaway had been blessed with as many boys and girls as she
wanted. Although her husband Kantinka had thought he would
want more children, he agreed that adding more members to the
family would be more of a burden than a help. He could
remember times when water and food were scarce, and he feared
for the children he already had and loved. On the advice of a
village elder, he and Kaway placed herbs in her vagina before
intercourse. However, it soon became clear that the herbs did
not work, as another baby was on the way.
 
Each society hands down traditions from generation to generation by
teaching certain attitudes, practices, beliefs, legends, customs, and
habits. There are traditional beliefs and practices in all areas of life,
including reproduction. Throughout history, the traditional family




The creative and occasionally life-threatening techniques used to limit
childbearing show how intensely women and men have tried to con-
trol reproduction and sexual practices.
 
WHAT ARE THE TRADITIONAL METHODS?
 
Modern family planning methods are an extension of the traditions


























and sometimes safer than most traditional methods, many traditional
methods continue to be widely used. Many of the traditional methods
may be ineffective; others are harmful.
The rapid rates of modernization, urbanization, and social
change experienced in African countries make it difficult to determine
how often traditional methods of fertility regulation are still used.
Reports from earlier in this century indicate that use of these methods
was widespread. More recent reports suggest their use continues, at
least to some degree. Among the traditional methods, withdrawal is




 (See Chapter 19 on Coitus Interrup-
tus.) Table 2:1 shows the percentage of women who use a modern
method and the percentage who use a traditional method. In Ankole,





How important these traditional practices are to your clients will
depend to a large extent on where you provide family planning and
other maternal and child health services. People working in urban
clinics and hospitals will probably see fewer individuals who actively
use traditional approaches to child spacing. On the other hand, health
workers in rural settings are more likely to provide services to women
who frequently use traditional means to regulate their fertility. Some
rural providers may themselves use traditional methods and believe












Table 2:1  Family planning methods currently used (in percentages) 










Burkina Faso 10 6 4
Cameroon 14 10 4
Egypt 47 2 45
Ghana 20 10 10
Kenya 33 6 27
Madagascar 17 12 5
Malawi 13 6 7
Namibia 30 3 26
Morocco 42 6 36
Niger 4 2 2
Nigeria 6 3 4
Rwanda 7 3 5
Senegal 7 3 5
Tanzania 18 5 13
Togo 12 9 3
Tunisia 51 9 41
Uganda 15 4 9
Zambia 26 12 14
Zimbabwe 48 6 42
 




























Abortion has concerned people for centuries, and it has been
employed, to some degree, in most societies. Perhaps more important
than traditional contraceptives and abortifacients are the cultural prac-
tices related to reproduction and sexuality that affect fertility. See
Table 2:2. In the most desperate of circumstances (in Africa and else-
where), unwanted offspring have been subject to infanticide, and
women pregnant outside of marriage have been disowned and, in rare
circumstances, put to death. These practices can only be condemned


















     Among the African nations, there is a tremendous range in the per-
centage of people who rely on breastfeeding for contraception.
Because lactation has definite contraceptive effects and is so wide-
spread, it is one of the most important contraceptive methods cur-
rently limiting female fertility.  (See Chapter 12 on Lactation and
Postpartum Contraception.)  In addition, many cultures discourage
sexual intercourse while the mother is breastfeeding. Surveys indicate
that lactation and postpartum abstinence are still important in their
effect on fertility in some parts of Africa. 
 
Table 2:2  Traditions that may decrease fertility in a society
 














 systemic preparations that prevent 
pregnancy
 












• Traditions leading to 
 
death of women who are pregnant or 
































     A number of customs and traditions increase the likelihood of
abstinence in a society. The culture may encourage postpartum absti-
nence for a variety of reasons, ranging from multiple wives (polygamy)
to concern about postpartum infection, healing of the episiotomy (or
tear), or maternal depletion syndrome. Because of mistaken notions
that semen pollutes breast milk or that sexual intercourse causes mal-
nutrition in the suckling infant, abstinence may also be practiced to
space births so that each child will receive enough breast milk to sur-
vive.
In addition to abstinence after childbirth, and especially during
breastfeeding, there are other culturally mandated periods of absti-
nence that affect fertility. The value placed on virginity in many areas
prohibits the beginning of sexual activity until a girl is married. In
some areas, women are supposed to abstain indefinitely from inter-
course once they have become grandmothers. Thus, there are areas in
Africa where abstinence shortens a woman's reproductive period at
both ends of her reproductive life span, determining when she






















Without a clear understanding of the process of pregnancy,
women and men worldwide have tried countless methods to avoid
pregnancy. The traditional methods outlined in Table 2.3 highlight











































     Historically, certain societal traditions have increased the likelihood
of male or female infertility.
 






















Condom-like materials: cecum and bladder of various animals, linen 




: Lemon juice; cola drinks; vaginal pill made of tannic 





 of alum, white oak bark, hemlock bark, red rose leaves, raspberry 
leaves, roots, zinc sulphate, sodium bicarbonate, coca cola
 
Removal of semen from vagina
 
 by mechanical methods (such as wiping 




















































     Prostitution
 
 can increase a woman's risk for sexually transmitted
infections, which can lead to pelvic inflammatory disease (PID) that,
in turn, may contribute to infertility. Prostitution has also contributed
to the transmission of acquired immune deficiency syndrome (AIDS).
 
Female genital mutilation (circumcision)
 
 has caused serious
PID and infertility in women because of infectious complications that
frequently follow the genital mutilation procedure. Some of these pro-
cedures merely entail removing the prepuce of the clitoris and the pos-
terior, larger parts of the labia minora. A more extensive procedure
called “excision” or “reduction” removes the glans and the adjacent
parts of the labia minora. The most extensive procedure is called "exci-
sion and infibulation." The entire clitoris, all of the labia minora, and
part of the labia majora are surgically removed, and the vaginal open-
ing is almost entirely closed. Female genital mutilation is still com-




These operations are rarely performed by medical personnel, and
complications can be very severe. One of the significant long-term
complications is impaired sexual functioning. A study in Egypt com-
pared 1,900 circumcised women with a similar group of uncircum-
cised women. Half (50%) of the circumcised women reported having
difficulty in permitting penile penetration or suffering pain during
intercourse. Fifty-six percent of these women failed to achieve orgasm
during intercourse. Perhaps because of these problems, 60% of the cir-
cumcised women engaged in sexual intercourse far less often than did




Male genital mutilation (castration)
 
 of men (making them
eunuchs) was an ancient practice that rendered them incapable of
impregnating women.
 
PLANTS AND OTHER SUBSTANCES
 
Locally available plants have traditionally been used in a variety of
ways to control fertility. More than 500 different plants and sub-































 is said to have an estrogenic effect and has been







either drunk as teas or rubbed on the breasts, are used by women to









 or labor-inducing agents.
 
9
Women often place household substances such as aspirin, lemon







may also place substances, many of which can be harmful, in their
vaginas following intercourse. These douches may contain hot water






Family planning providers must ask clients whether they have been
using a traditional practice. Assess the effectiveness and safety of these
practices as well as their compatibility with the various modern meth-
ods of contraception. Some clients may find modern methods easier to
understand when they are compared to the beliefs about traditional
methods.
While traditional practices are slowly disappearing, there is
ample evidence that some traditional forms of fertility regulation are
still fairly common. As one who delivers family planning services, you
must be able to determine whether a woman is using a traditional
method to regulate her fertility, whether she is using the method con-
scientiously and effectively, and whether use of the method is causing
her any problems. Only when you have these facts will you be in a
position to help her make family planning decisions that she will be


















 A TRADITIONAL METHOD?
Ask the client whether she uses any means to space her births.
These questions may serve as a guideline:
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• Do you breastfeed your children? How long will you breast-
feed before you begin to supplement the child's diet? How
long will you breastfeed before weaning the child com-
pletely?
• Do you completely abstain from sexual intercourse while you
are breastfeeding? How long will you abstain? How long are
you supposed to abstain?
• Do you use any means of contraception at all, especially
methods that you have not received from a clinic or health
professional?
If the woman answers "yes," and she breastfeeds and abstains for a
substantial period of time after giving birth, she is probably a family
planner. Additional information is needed; specifically, you must deter-
mine how reliably this woman adheres to traditional family planning
practices or the lactational amenorrhea method (LAM, see Chapter 12
on Lactation and Postpartum Contraception), and how effective her
method of choice is. 
WHAT ARE THE CLIENT'S PLANS FOR FAMILY SIZE?
Use these questions as a guide to getting the extra information
you need:
• How many children do you have? How many do you and
your partner want to have?
• How far apart are your children in age? How far apart should
children be spaced for health or economic reasons?
• How long will it be before you want to have another child?
If the woman has more children than she intended or if her chil-
dren are more closely spaced than she had desired, recommend a mod-
ern method of contraception. The traditional method she has used
may have required long periods of sexual abstinence that she and her
husband have found difficult. Modern contraception may be easier for
her to use and will allow her greater sexual activity. 
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If the answers to these questions reveal that the woman is con-
trolling her fertility to her satisfaction through traditional means, you
need to investigate the safety of her method. This step may be more
difficult. If the woman is effectively spacing her births through a com-
bination of breastfeeding and abstinence, there is nothing safer. If this
is the case, the best course of action is probably to recommend a bar-
rier method of contraception as a backup to her traditional practices.
For example, you might recommend that the woman use foam or con-
doms just in case her or her husband’s resolve to abstain should
weaken.
Completely replacing her traditional practice with a modern
method of contraception may not be productive. In many places, par-
ticularly in rural areas, there are still difficulties in maintaining a con-
sistent supply of contraceptives. If you cannot guarantee that your
client will be able to obtain the supplies she needs, you may be doing
her a disservice by disrupting her traditional practices and replacing
them with interrupted coverage from modern contraceptives. Further-
more, some types of oral contraceptives (the combination pills) should
not be prescribed to lactating women. If used improperly, they can
decrease the milk yield and shorten the period of lactation (see Chap-
ter 12 on Lactation and Postpartum Contraception and Chapter 13
on Combined Oral Contraceptives). In cases where the period of sex-
ual abstinence is directly related to breastfeeding, improper use of a
combination pill could expose a woman to another pregnancy sooner
than if she had followed her traditional practice.
In the case of traditional contraceptives, however, it is difficult to
determine how safe they are for the user. There are many types in use
and many different means of using them. Active agents have not been
identified for many of these substances. The decision about the safety
of these methods must be yours.  If you have any doubt at all about the
safety of her contraceptive, recommend a modern method.
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IS THE CLIENT WILLING TO SWITCH FROM TRADITIONAL 
TO MODERN?
In general, if a woman is willing to use a traditional contracep-
tive, she may be willing to use a modern method, especially one that is
similar. For example, women who are accustomed to using traditional
barrier methods that require vaginal insertion may be more willing to
switch to a diaphragm or foam. Similarly, women who use traditional
methods that are taken orally may be candidates for the pill. Stressing
the overall effects on her health may convince her to switch to a mod-
ern method.
Before you recommend such a switch, however, you should try to
determine how receptive the woman is to changing her method and
using modern contraception. If she is resistant to change, try to deter-
mine the source of that resistance. Consider the following questions in
each case:
• Will giving the woman contraception put her in disfavor
with her husband? Is he aware that she is receiving care at
your clinic?
• Will it open her to criticism from the other women in her
group?
• Will she be in disfavor with her mother?  Her mother-in-
law?  Her grandmother?
• Does she have the freedom to get to the clinic when she
needs to, or is it difficult for her to leave her household?
If the woman appears to be socially free to use modern contra-
ception, recommend that she do so. If she is not socially free, your
responsibility goes beyond providing contraceptive services. Counsel
her about the pressures she encounters, reinforce her decision to use a
modern method, and help her develop good justifications for the use
of her method. Assure her that she can contact the health clinic for
further reassurance, for answers to questions, or for help in discussing
with others their concerns about her use of the contraceptive. It is
preferable to schedule a return visit, even if her method of choice does
not require it, to check on her progress and to help her with any prob-
lems—medical or social—she may be having with its use.
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It is difficult to make comprehensive recommendations to all
women regarding the use of traditional family planning methods. The
preceding series of questions are intended to help you arrive at a suit-
able solution. Whatever the method, it must be not only safe and
effective, but also suitable for the woman so that she continues to use
contraception effectively.
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People are the most important and







Population-related goals and policies are integral parts
of cultural, economic and social development, the principal










In Benin, Côte d'Ivoire, Mali, Niger, and Uganda, the typical woman
who survives to age 50 will give birth to more than seven children; her
life expectancy at birth ranges from a low of 46 years in Uganda to a
high of 52 years in Côte d'Ivoire. In contrast, the average woman in





Why should these statistics concern family planning practitio-
ners? The principle of voluntary family planning demands that indi-
viduals have the right to achieve their reproductive life goals, whatever
they may be, but individual reproductive behaviors also have aggregate
consequences, because they influence the health and determine the


























It is only natural that those involved in family planning and
reproductive health would want to understand how the use of contra-
ception, the effectiveness of various contraceptive methods, the preva-
lence of abortion, and the duration of breastfeeding affect fertility in a
population. Fertility, however, is only one cause of population change.
This chapter also briefly considers the two other causes of population
change: mortality and migration.
 
CAUSES OF MORTALITY 
 







In developing countries, the major causes of death are
infectious diseases. In developed countries, causes of death are concen-
trated among degenerative diseases such as cancer and cardiovascular
disease. This shift occurs primarily because infant and child mortality
are much higher in developing countries. Poor nutrition makes chil-
dren more susceptible to infection and less able to withstand illnesses
that otherwise would not prove fatal. Improvement in living condi-
tions implies better nutrition, sanitation, water supply, and access to
public health measures such as vaccination against tetanus, measles,
and other common diseases. With such improvements, children sur-
vive to adulthood, when degenerative diseases become the primary
causes of death.
Reproductive and sexual behavior affect mortality in three major
ways:
• The number of children women bear, the ages at which they
bear children, and the length of intervals between births all







births are associated with higher rates of infant, child, and
maternal mortality. Reducing the number of children that
women bear would reduce maternal morbidity and mortal-
ity. (See Chapter 1 on Benefits of Family Planning).





































• Unprotected sexual intercourse increases the risk of sexually
transmitted infections (STIs), including the human immun-
odeficiency virus (HIV). Pregnant women infected with
HIV may transmit the infection to their infants during preg-
nancy or childbirth or through breast milk. By the year
2000, as many as 110 million adults worldwide will be
infected with HIV. By the end of this century, 90% of all







on infant and child mortality rates and on population
growth is devastating in certain areas of the world, particu-
larly sub-Saharan Africa and Asia. (See Chapter 5 on HIV,




The estimated population of the world in mid-1995 was 5.702 bil-





1995, approximately 86 million people—a number comparable to the
populations of Mexico (94 million) and Germany (82 million), the
eleventh and twelfth largest countries in the world—were added. At
the current growth rate, the increase in population is substantial:
• 234 thousand more people every day
• 10 thousand more people every hour
Should this growth of 1.5% continue, the world's population
will be 12.0 billion in 50 years, and it will be 25.3 billion in 100 years.
Of course, such growth could not continue indefinitely. Indeed, the
annual growth rate has fallen after peaking at 2.06% per year in the




  Table 3:1 shows the population size and





















































































































































































































































































































 5,702 24.4 8.9 1.55 44.7 7,024 61.6 3.1 32.1 6.3 63.8 67.7 42.9 57.8 49.4
More Developed  1,169 11.9 10.3 0.16 431.8 1,232 9.6 1.6 20.0 13.2 70.4 78.1 73.6    — 51.7
Less Developed  4,533 27.7 8.6 1.91 36.3 5,791 67.4 3.5 35.2 4.6 62.1 65.0 35.0 55.4 48.9
Less Developed
(Excl. China)




 720 41.3 13.0 2.84 24.4 1,069 89.8 5.8 44.6 3.2 53.3 56.4 30.8 21.5 17.1
Sub-saharan Africa  586 43.9 14.3 2.96 23.4  892 94.6 6.2 45.7 3.1 50.8 54.0 26.8 15.4 10.9
Northern Africa  162 31.9 7.8 2.41 28.8  219 62.9 4.4 40.8 3.5 62.6 65.2 44.6 39.3 35.4
Algeria  28.4 30.4 6.4 2.40 28.9  38.0 55.0 4.4 38.7 3.6 66.0 68.3 49.6 47.0 43.0
Egypt  61.9 30.3 7.8 2.25 30.8  80.7 61.5 3.9 39.7 3.6 62.4 64.8 44.0 47.1 44.8
Libya  5.2 41.9 8.1 3.38 20.5  8.9 68.0 6.4 47.6 3.0 61.6 65.0 85.4 — —
Morocco  29.2 27.7 5.9 2.18 31.8  38.4 57.3 4.0 40.3 3.9 73.2 81.2 46.5 41.5 35.5
Sudan  28.1 41.4 11.6 2.98 23.3  41.5 76.9 5.9 46.2 2.2 54.0 56.0 26.5 8.7 5.5
Tunisia  8.9 25.3 6.2 1.91 36.3  11.2 43.0 3.4 36.6 4.9 66.9 68.7 60.0 49.8 40.4
Western Sahara  0.2 46.7 18.3 2.84 24.4  0.3 147.5 6.9 — — 45.7 48.0 — — —
Western Africa  199 44.9 14.0 3.09 22.5  311 85.8 6.4 45.6 2.9 51.7 54.5 22.9 7.8 3.7
Benin  5.4 48.7 17.8 3.09 22.4  8.3 86.0 7.10 47.4 2.8 45.9 49.3 30.1 9.2 0.5
Burkina Faso  10.4 47.3 18.9 2.84 24.4  14.5 93.9 6.90 48.0 3.2 44.1 45.8 14.5 7.9 4.2
Cape Verde  0.4 36.2 8.6 2.76 25.1  0.6 50.0 4.26 45.0 5.8 63.5 65.5 44.1 — —
Côte d'Ivoire  14.3 49.9 15.1 3.48 19.9  23.1 92.0 7.41 46.7 2.1 49.7 52.4 39.0 2.9 0.5
Gambia  1.1 48.0 21.0 2.70 25.7  1.5 90.0 5.90 44.6 2.4 43.4 46.6 26.0 11.8 7.0
Ghana  17.5 41.7 11.7 3.00 23.1  26.6 81.0 5.50 45.3 2.9 54.2 57.8 35.8 18.9 9.3
Guinea  6.5 43.7 19.4 2.43 28.5  9.3 143.0 5.81 44.3 2.7 42.1 46.7 28.8 — —
Guinea-Bissau  1.1 42.7 21.3 2.14 32.4  1.5 140.0 5.79 43.3 3.1 41.9 45.1 21.7 — —
Liberia  3.0 47.3 14.2 3.31 20.9  4.8 126.0 6.80 46.0 3.7 54.0 57.0 43.8 6.4 5.4
Mali  9.4 51.4 19.7 3.17 21.9  15.0 103.6 7.33 45.9 3.8 44.9 48.3 22.0 4.7 1.3
Mauritania  2.3 39.8 14.4 2.54 27.3  3.3 101.0 5.40 45.3 3.5 49.9 53.1 39.1 4.1 1.3
Niger  9.2 52.5 18.9 3.36 20.6  14.8 123.0 7.40 49.1 3.2 44.9 48.1 15.2 4.4 2.3
Nigeria  101.2 43.1 11.8 3.13 22.1 162.0 71.5 6.27 44.9 2.9 55.0 57.6 16.1 6.0 3.5
Senegal  8.3 43.0 16.0 2.70 25.7  12.2 68.0 6.03 44.6 2.9 48.3 50.3 38.5 7.4 4.8
Sierra Leone  4.5 46.0 19.0 2.70 25.7  6.4 143.0 6.20 44.2 3.0 44.3 47.1 35.4 — —
Togo  4.4 46.5 10.9 3.56 19.5  7.4 85.5 6.86 48.7 2.2 55.5 59.8 30.3 33.9 3.0
st. helena  0.0 13.2 8.2 0.50 138.6  0.0 21.4 1.12 27.7 8.8 73.4 77.3 42.8 — —
Eastern Africa  226 45.6 15.5 3.01 23.0  345 106.5 6.4 47.4 3.0 48.5 51.5 20.6 16.7 11.6
Burundi  6.4 46.0 15.7 3.03 22.9  9.5 102.0 6.60 46.4 3.9 48.4 51.9 6.3 8.7 1.2
Comoros  0.5 46.3 10.8 3.55 19.5  0.9 78.5 6.83 48.0 2.7 55.8 60.3 28.5 — —
Djibouti  0.6 38.1 16.1 2.20 31.5  0.8 115.0 5.80 41.0 2.2 46.7 50.0 76.6 — —
Eritrea  3.5 42.4 16.4 2.60 26.7  5.2 135.0 5.80 — — 46.0 49.0 16.9 — —
Ethiopia  56.0 46.3 15.6 3.07 22.6  90.0 119.8 7.04 49.3 3.4 48.4 51.9 14.7 4.3 2.6
Kenya  28.3 44.5 11.7 3.28 21.1  43.6 69.0 5.68 47.8 3.4 54.2 57.3 26.8 32.7 27.3
Madagascar  14.8 43.9 11.8 3.21 21.6  23.3 93.0 6.13 46.1 2.8 55.0 58.0 21.9 16.7 5.1
Malawi  9.7 47.4 20.1 2.73 25.4  14.7 134.0 6.73 48.3 2.5 44.2 45.4 16.5 13.0 7.4
Mauritius  1.1 21.1 6.5 1.46 47.5  1.3 18.5 2.35 29.6 5.5 65.0 73.0 43.9 74.7 48.9
Mozambique  17.4 45.2 18.5 2.67 26.0  26.9 148.0 6.50 46.0 2.4 44.9 48.0 32.8 — —
Reunion  0.7 23.1 5.6 1.75 39.6  0.8 8.0 2.32 30.6 5.8 69.0 77.0 73.4 67.0 62.0
Rwanda  7.8 40.1 17.1 2.30 30.1  10.4 117.0 6.20 47.6 3.2 44.8 47.7 5.4 21.2 12.9
Seychelles  0.0 22.6 7.4 1.52 45.6  0.0 11.9 2.71 31.5 6.9 67.5 73.2 49.8 — —
Somalia  9.3 50.2 18.5 3.17 21.9  14.5 122.0 7.00 47.5 2.7 45.4 48.6 23.5 — —
Tanzania  28.5 45.0 14.9 3.01 23.0  42.8 91.6 6.25 46.7 2.5 47.0 50.0 20.8 20.4 13.1
Uganda  21.3 51.8 19.2 3.26 21.3  32.3 115.0 7.30 47.3 3.4 43.6 46.2 11.3 4.9 2.5
Zambia  9.1 47.3 16.7 3.06 22.7  13.0 107.2 6.50 49.6 2.4 46.9 48.6 42.0 15.2 8.9
Zimbabwe  11.3 39.1 12.0 2.71 25.6  15.3 52.8 4.40 44.1 2.8 52.4 55.1 26.7 48.1 42.2
mayotte  0.0 48.1 10.3 3.78 18.3  0.2 76.4 6.74 49.5 2.4 56.2 60.8 13.2 — —
Middle Africa  83 45.5 16.4 2.92 23.8  127 107.5 6.3 45.8 3.0 47.0 50.8 33.5    —     —
Angola  11.5 47.2 20.2 2.70 25.7  17.6 137.0 6.38 44.9 3.0 44.0 48.0 37.0 — —
Cameroon  13.5 40.4 11.1 2.93 23.7  21.2 65.0 5.91 44.2 3.4 55.6 59.8 41.2 16.1 4.3
Central African 
Republic
 3.2 41.6 21.5 2.01 34.5  3.9 135.5 5.34 43.1 3.5 40.0 42.8 38.9 — —
Chad  6.4 43.7 18.0 2.57 27.0  9.3 122.0 5.89 41.4 2.9 45.9 49.1 21.7 — —
Congo  2.5 39.6 16.9 2.27 30.5  3.2 108.7 5.18 43.6 3.4 44.2 48.1 57.8 — —
Equatorial Guinea  0.4 40.0 14.2 2.58 26.9  0.6 99.1 5.26 42.6 4.0 50.6 55.6 37.0 — —
Gabon  1.3 37.3 15.5 2.18 31.8  1.9 94.0 3.95 39.2 5.8 51.9 55.2 73.2 — —
Sao Tome and
Principe
 0.1 34.5 8.6 2.59 26.8  0.2 61.8 4.37 46.9 4.4 61.8 65.7 45.8 — —
Zaire  44.1 47.9 16.4 3.15 22.0  69.1 107.6 6.64 47.8 2.7 45.8 49.6 28.8 7.9 2.5
Southern Africa  50 31.4 8.3 2.32 29.9  67 48.7 4.2 37.8 4.4 62.3 67.4 59.0 49.8 48.3
Botswana  1.5 30.7 7.3 2.34 29.6  2.2 38.7 4.15 43.3 3.3 60.3 66.4 26.5 33.0 31.7
Lesotho  2.1 31.2 11.8 1.94 35.7  3.0 79.0 5.20 40.7 4.4 58.0 63.0 22.3 23.0 19.0
Namibia  1.5 37.1 10.1 2.70 25.7  2.2 56.6 5.40 41.7 3.7 57.5 60.0 32.3 28.9 26.0
South Africa  43.5 31.0 8.0 2.30 30.1  57.5 46.0 4.11 37.1 4.5 63.0 68.0 63.4 53.0 51.7


































Table 3:1 1995 World Population Data Sheet of the Population 




























































































































































































































































































 3,451 24.4 7.9 1.65 42.0  4,242 62.1 2.9 32.7 5.1 63.9 66.5 32.5 61.8 54.8
Asia (excl. China)  2,232 28.1 8.7 1.94 35.7  2,857 68.4 3.5 35.8 4.6 62.3 64.4 34.9 44.9 34.9
Western Asia  168 31.1 7.0 2.41 28.8  242 50.7 4.3 38.8 4.2 65.3 69.3 58.2     —     —
Iraq  20.6 43.3 6.8 3.65 19.0  34.5 62.1 6.64 46.9 3.2 65.1 66.9 69.9 18.0 10.3
Saudi Arabia  18.5 36.1 4.1 3.20 21.7  30.0 24.0 5.50 42.6 2.3 68.9 72.3 78.8 — —
Syria  14.7 41.1 5.8 3.53 19.6  23.6 39.0 5.90 49.2 4.4 64.9 67.4 50.9 — —
Turkey  61.4 22.9 7.2 1.57 44.1  79.2 53.0 2.70 33.3 4.4 64.3 69.5 51.4 62.6 34.5
Yemen  13.2 50.1 14.3 3.58 19.4  21.9 109.0 7.70 51.8 3.0 51.7 52.9 25.1 9.7 6.1
South Central Asia  1,355 30.7 9.5 2.12 32.7  1,772 79.3 3.8 37.6 3.9 60.2 60.6 27.3 39.3 30.2
Bangladesh  119.2 35.5 11.7 2.38 29.1  160.8 108.0 4.26 41.5 3.0 55.5 55.0 17.0 44.6 36.2
India  930.6 28.5 9.2 1.93 35.9  1,182.7 74.0 3.40 36.0 4.1 60.3 60.4 25.7 40.6 36.6
Iran  61.3 35.5 7.0 2.85 24.3  83.7 55.6 5.04 44.3 3.5 65.6 68.0 57.0 65.0 45.0
Pakistan  129.7 39.0 10.0 2.90 23.9  187.7 91.0 5.60 41.0 3.0 60.8 60.6 32.0 11.9 9.0
Uzbekistan  22.7 31.4 6.5 2.49 27.8  31.9 37.4 3.80 40.8 4.2 66.1 72.4 40.6 — 19.0
Southeast Asia  485 26.5 7.8 1.87 37.0  601 53.0 3.2 36.8 4.0 62.2 66.2 30.5 50.7 43.6
Indonesia  198.4 24.1 7.8 1.63 42.5  240.6 64.2 2.81 36.5 3.9 61.2 64.9 30.9 49.7 47.1
Myanmar  44.8 28.3 8.9 1.94 35.7  57.3 47.5 3.61 36.0 4.0 57.9 63.1 25.0 — —
Philippines  68.4 29.7 8.7 2.10 33.0  87.2 49.1 4.08 39.6 3.4 62.8 66.4 48.8 40.0 24.9
Thailand  60.2 20.2 5.9 1.43 48.5  68.7 34.5 2.20 31.3 4.1 68.0 72.0 18.7 65.5 63.6
Viet Nam  75.0 30.0 7.1 2.30 30.2  92.5 42.0 3.73 39.0 4.7 62.9 67.3 20.6 49.4 37.0
East Asia  1,442 17.0 6.5 1.05 66.1  1,628 40.1 1.8 26.1 6.8 67.8 71.8 35.2 86.8 84.0
China  1,218.8 17.7 6.5 1.12 61.8  1,385.5 44.0 1.86 27.2 6.2 66.8 70.4 28.1 89.7 88.7
Japan  125.2 9.6 7.1 0.25 277.3  130.4 4.3 1.46 16.4 14.0 76.3 82.5 77.4 64.0 47.0
Korea, North  23.5 23.0 5.5 1.75 39.6  28.5 26.4 2.36 29.6 4.1 67.1 73.4 60.9 — —
Korea, South  44.9 15.4 5.8 0.96 72.2  49.7 11.0 1.63 24.4 5.4 67.7 75.7 74.4 79.4 69.0




 293 15.2 8.6 0.66 104.7  334 7.9 2.0 21.9 12.6 72.3 79.1 75.4 70.9 65.8
Canada  29.6 13.8 7.0 0.68 101.9  33.6 7.0 1.67 20.9 11.8 74.4 81.0 77.0 73.1 69.0




 481 25.9 6.7 1.92 36.0  601 43.6 3.1 34.1 5.1 66.3 71.6 70.2 61.5 50.9
Central America  126 28.8 5.5 2.34 29.7  163 36.6 3.5 37.4 4.0 68.4 74.2 64.9 59.7 51.4
Guatemala  10.6 38.6 7.7 3.09 22.4  15.8 48.0 5.36 45.4 3.2 62.4 67.3 38.4 23.2 19.1
Mexico  93.7 27.1 5.1 2.20 33.9  117.7 33.7 3.10 35.5 4.2 69.5 75.5 71.3 65.0 56.0
Caribbean  36 22.7 7.6 1.51 45.9  43 38.7 2.9 30.6 6.8 67.2 72.4 59.9      —     —
Cuba  11.2 14.0 7.2 0.68 101.9  12.3 9.4 1.82 22.4 9.2 72.1 77.9 74.0 — —
South America  319 25.1 7.1 1.81 38.4  395 47.2 3.0 33.2 5.4 65.4 70.5 73.5 63.8 51.4
Argentina  34.6 20.5 7.9 1.26 55.0  40.8 23.6 2.82 29.9 9.1 68.1 74.9 87.2 — —
Brazil  157.8 24.6 7.5 1.71 40.5  194.4 58.0 2.88 32.3 5.2 64.0 68.7 76.6 65.8 56.0
Colombia  37.7 24.0 6.0 1.80 38.5  46.1 37.0 2.67 32.9 4.5 66.4 72.3 49.6 66.1 54.7
Peru  24.0 28.5 7.4 2.11 32.9  30.3 60.0 3.54 36.4 3.9 64.1 67.9 70.4 59.0 32.8




 729 10.9 11.7 -0.07 -928.2  743 11.5 1.5 19.8 13.4 68.5 76.9 71.8    — 44.9
Northern Europe  94 12.9 11.4 0.16 442.5  97 6.9 1.8 19.6 15.3 72.8 78.9 84.7 73.3 65.8
United Kingdom  58.6 13.1 11.3 0.18 385.1  61.0 6.6 1.82 19.4 15.7 73.6 79.1 91.5 72.0 71.0
Western Europe  181 11.0 10.1 0.09 741.4  187 6.0 1.5 17.9 14.7 73.3 80.3 80.6 76.9 69.3
Belgium  10.2 11.8 10.6 0.12 577.6  10.4 7.6 1.61 18.2 15.6 73.1 79.8 96.6 79.0 75.0
France  58.1 12.2 9.0 0.32 216.6  61.7 6.1 1.65 19.9 14.5 73.6 81.8 74.0 81.0 66.0
Germany  81.7 9.5 11.0 -0.15 -465.2  81.2 5.8 1.30 16.4 15.0 72.9 79.3 85.3 75.0 72.0
Netherlands  15.5 12.8 9.0 0.38 182.4  16.9 5.9 1.57 18.4 13.1 74.0 80.0 89.0 76.0 72.0
Eastern Europe  310 10.5 13.9 -0.34 -203.8  315 16.9 1.5 21.8 11.7 62.5 73.3 68.2    — 22.4
Czech Republic  10.4 11.7 11.4 0.03 2310.5  10.5 8.5 1.67 21.1 10.0 68.9 76.6 75.3 68.9 44.9
Poland  38.6 12.4 10.1 0.23 301.4  40.2 13.7 1.79 23.7 10.7 67.4 76.0 61.8 — —
Romania  22.7 11.0 11.6 -0.06 -1155.2  22.2 23.3 1.44 21.7 11.4 66.1 73.2 54.5 57.3 14.5
Russia  147.5 9.4 15.6 -0.62 -111.8  149.5 19.0 1.39 21.8 11.5 58.9 71.9 73.0 — 22.0
Ukraine  52.0 10.7 14.2 -0.35 -198.0  53.0 14.9 1.60 20.8 13.3 64.0 74.0 67.9 — 15.0
Southern Europe  144 10.6 9.2 0.13 515.8  144 10.7 1.4 18.0 13.9 72.5 79.2 60.3    —    —
Greece  10.5 9.8 9.4 0.04 1732.9  10.2 8.3 1.35 18.7 14.0 74.6 79.8 62.6 — —
Italy  57.7 9.4 9.5 -0.00 -6931.5  56.5 7.4 1.21 15.5 15.5 73.6 80.3 67.9 — —
Spain  39.1 9.9 8.7 0.12 577.6  39.0 7.6 1.24 17.4 14.6 73.4 80.5 64.1 59.4 38.0




 28 19.1 7.5 1.16 59.6  34 24.2 2.5 26.2 9.8 71.3 76.4 70.6 65.2    —
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Why is fertility high in some populations and low in others? 
Childbearing ages have biological limits. Between menarche and
menopause, a woman has about 35 years in which she can produce
children. These limits constrain fertility, and they vary somewhat





 For several reasons, however, the fertility impact of this dif-
ference of 7 years is likely to be small, at most a difference of one child




Different populations vary in the proportion of females at each
age who are sexually active and therefore exposed to the risk of preg-
nancy. In many populations, sexual intercourse is confined primarily
to marriage. Thus, age at marriage, the proportion of women ever
marrying, and patterns of divorce and remarriage are powerful causes
of fertility levels. Increasing women's age at marriage lowers total fer-
tility by removing younger women from the risk of childbearing and
raising the age at which women bear children, thereby lowering the







Raising the age at marriage has other effects as well. The
most important is to enhance the status of women, allowing them to
stay in school longer to acquire job-related skills, to work outside the
home before marriage, and to enter marriage with more physical and
emotional maturity and financial security. Such social changes are
themselves likely to stimulate a demand for fertility control.
 
10 Because
raising the age at marriage so profoundly alters the social fabric, gov-
ernments may be unwilling or unable to use this potential instrument
of public policy.
Both the spacing between the initiation of sexual activity and the
first live birth and the spacing between one live birth and the next vary
across populations. The shorter the average interval between births,
the greater the number of births that can be squeezed into the child-
bearing span.
The birth interval can be divided into three parts: the period of
postpartum non-susceptibility following a birth during which a
woman is not at risk of conception, the waiting time to a conception






































The last part, the pregnancy period, does not vary from






















Consider a typical developing country in which contraceptive use
is low but prolonged breastfeeding is nearly universal. Postpartum
non-susceptibility lasts an average of 12 months. When not using con-
traception or breastfeeding, young wives typically take about 6
months to become pregnant (also called waiting time to conception).
Pregnancy lasts 9 months. In such cases, the interval between one
birth and the next is 12 + 6 + 9 = 27 months, or 2.25 years. The aver-
age fertility rate per year is therefore 1/2.25, or 444 births per 1,000
sexually active women.
A common effect of modernization is a decrease in breastfeeding
but an increase in use of contraception. However, the decrease in
breastfeeding often occurs before the increase in the use of contracep-
tion.
What if breastfeeding were completely abandoned in our typical
population? The period of postpartum non-susceptibility would
decrease to only 2 months. In this case, the typical interval between
births would also decrease to 2 + 6 + 9 = 17 months, or 1.42 years.
The average fertility rate among sexually active women would rise to
706 births per 1,000 sexually active women, a rate 59% greater than
the 444/1,000 among breastfeeding women. Obviously, breastfeeding
has an important contraceptive effect in a population, even though no
individual woman may dependably rely on it to prevent pregnancy for
very long. (See Chapter 12 on Lactation and Postpartum Contracep-
tion.)
As the use of contraception increases, the interval between births
lengthens. If all women used contraception that reduces the monthly
risk of pregnancy by 80%, the waiting time to conception would rise
to 30 months. This rise would more than make up for the decrease in
postpartum non-susceptibility.  The interval between births would be
2 + 30 + 9 = 41 months, and the fertility rate would fall from 706 to






































Many people assume that one abortion will prevent one birth,
but we can easily demonstrate that this statement is false. Return to
our developing country with a birth interval of 27 months among
young women (a period of postpartum non-susceptibility of 12
months, 6 months to get pregnant, and a pregnancy of 9 months).
Imagine that every other pregnancy is aborted. In that case, the wait-
ing time to conception would consist of the following: 6 months to
get pregnant the first time, 3 months of pregnancy until the abortion,
1 month of postpartum non-susceptibility following the abortion, and
6 more months of waiting until the next pregnancy. The total waiting
time to conception would be 16 months. Compare this waiting time
with the regular waiting time to conception among young wives,
which is only 6 months. Thus the waiting time to conception is 167%
longer for someone who aborts a pregnancy than for someone who
does not abort.
However, the birth interval for someone who aborts (12 + 16 + 9
months) increases by only 37%, from 27 to 37 months. Therefore, if
every other pregnancy is aborted, the fertility rate would decrease by
only 27%, not by 50% as one might initially expect. The reader may
object that an abortion certainly prevents one birth. However, this
way of thinking ignores the fact that the next birth occurs sooner
when a pregnancy is aborted than when it results in a live birth. In
summary, while an abortion prevents a particular birth, it reduces the
woman's lifetime births by less than one if her reproductive behavior


















Syphilis is an important cause of fetal loss among women and causes
primary or secondary infections; it also may contribute to low fertility
among certain tribal groups in Burkina Faso and the Central African
Republic.
 
7 Untreated pelvic inflammatory disease (PID) is a major
































(a belt extending from the west coast of Cameroon and Gabon
through northern Zaire into southwest Sudan) is thought to be associ-
















When food supplies are so short that there is famine and starva-
tion, fecundity, and hence, fertility are reduced. But when malnourish-
ment is chronic and food intake is above starvation levels, there does





Migration is linked to economic, social, and political conditions.
When assessing the determinants of migration, investigators have tra-
ditionally emphasized "push" and "pull" factors. Push factors include
extraordinary events such as wars, floods, famines, and political/reli-
gious persecutions as well as more ordinary circumstances associated
with depressed economic settings: high unemployment, low wages,
and little hope. 
Pull factors attract people to a location. They often are associated
with economic opportunity: good jobs, high wages, and good public
services such as education and health care. They also may include an
attractive environment, religious freedom, and proximity to family or




The historical record suggests a relationship, although a loose one,
between socioeconomic modernization and fertility decline. But his-







Allowing couples to decide the number of children they
want to have and providing information and technical assistance to










 METHODS AND PRACTICE:  AFRICA
the status of women, could sharply reduce fertility.4,19 Many women in
developing countries desire increased spacing between children or ter-
mination of childbearing, according to considerable evidence from
surveys.27
Voluntary family planning can play an important role in aiding a
nation's development.13,17,28 Although slower population growth
would benefit development in most developing countries, it would not
automatically make poor countries rich. However, involuntary family
planning might well undermine development.
Experience in China illustrates an alternative to voluntary family
planning that is clearly effective in reducing fertility and the rate of
population growth. However, it is unlikely that many other govern-
ments would have the authority to enforce China’s compulsory poli-
cies. Recent experience with mass sterilizations in India suggests that
coercive or compulsory policies to bring down the birth rate are more
likely to bring down the government instead.
Government attempts to lower fertility too quickly can bring
unintended consequences. From 1979 through 1983, the government
of China vigorously promoted the policy of one child per family.
What would be the consequences if the one-child policy were strictly
adopted? By the year 2035, about 25% of the population would be
aged 65 and over, versus only about 5% today.6  The traditional family
structure would change radically in ways that would jeopardize the
family's ability to care for the elderly and reduce its potential as a pro-
duction unit; there would be no brothers, sisters, aunts, or uncles. The
one-child policy may have already had the unintended side effect of
causing female infanticide, due to a cultural preference for sons.2,3,29
Finally, attempts to increase fertility can create great problems. In
1966, the government of Romania introduced pronatalist policies,
including a decree banning virtually all abortions; in addition, impor-
tation of oral contraceptives and intrauterine devices (IUDs) was dis-
continued. The result was as instantaneous as it was stunning.21,22
Within 8 months the monthly birth rate had doubled; within 11
months it had tripled. Inadequate hospital care for the babies and
their mothers caused infant and maternal mortality to rise sharply. As
a consequence of unsafe illegal abortions, maternal mortality increased
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to a level 10 times that in any other European country. In the 23 years
the policy was enforced, more than 10,000 women died from unsafe
abortions. Many women who did not resort to unsafe abortions bore
unwanted children whom they placed in institutions. Such large-scale
warehousing of children overwhelmed these institutions and severely
degraded the quality of care. The educational system had to absorb a
huge increase in students. Other problems, such as employment and
housing, also arose. The government action certainly had the result of
increasing fertility, but obviously the government had not thought
clearly about the consequences. The policy was reversed immediately
after the Ceaucescu regime was overthrown in December 1989.
REFERENCES 
  1. Adegbola O. New estimates of fertility and child mortality in Africa, south of the
Sahara. Popul Stud 1977;31(3):467-486.
  2. Aird JS. Coercion in family planning: causes, methods, and consequences. Con-
gressional Record-Senate 1985:S7776-7788.
  3. Banister J. China's changing population. Stanford CA: Stanford University
Press, 1987.
  4. Bongaarts J. Population policy options in the developing world. Science 1994;
263(5148):771-776.
  5. Coale AM, Watkins SC. The decline of fertility in Europe. Princeton NJ: Prin-
ceton University Press, 1986.
  6. Coale AJ. Population trends, population policy, and population studies in
China. Popul Dev Rev 1981;7(1):85-97.
  7. Gray RH. Biological factors other than nutrition and lactation which may influ-
ence natural fertility: a review. In: Leridon H, Menken J (eds). Natural Fertility.
Liege, Belgium: Ordina Editions, 1979:217-251.
  8. Hatcher RA, Trussell J, Stewart F,  Cates W, Stewart GK, Guest F, Kowal D.
Contraceptive Technology: Seventeenth Revised Edition. New York NY: Ardent
Media, 1998.
  9. Haub C, Yanagishita M. 1995 World population data sheet. Washington DC:
Population Reference Bureau, 1995.
10. Henry A, Piotrow PT. Age at marriage and fertility. Popul Rep 1979;7(6), Series
M(4).
11. Knodel J, van de Walle E. Lessons from the past: policy implications of historical
fertility studies. Popul Dev Rev 1979;5(2):217-245.
12. Mann JM, Tarantola DJM, Netter TW (eds). AIDS in the world. Cambridge
MA: Harvard University Press, 1992.
13. Menken J (ed). World population and U.S. policy: the choices ahead. New York
NY: W.W. Norton, 1986.
14. Menken J, Bongaarts J. Reproductive models in the study of nutrition-fertility
interrelationships. In: Mosley WH (ed). Nutrition and human reproduction.
New York NY: Plenum Press, 1978:261-311.
46 FAMILY PLANNING METHODS AND PRACTICE:  AFRICA
15. Menken J, Trussell J, Watkins S. The nutrition fertility link: an evaluation of the
evidence. J Interdisciplinary History. 1981;11(3):425-441.
16. National Research Council. Contraception and reproduction: health conse-
quences for women and children in the developing world. Washington DC:
National Academy Press, 1989.
17. National Research Council. Population growth and economic development:
policy questions. Washington DC: National Academy Press, 1986.
18. Preston SH. Mortality patterns in national populations. New York NY: Aca-
demic Press, 1976.
19. Robey B, Rutstein SO, Morris L. The fertility decline in developing countries.
Sci Am 1993;269(6):30-37.
20. Sherris JD, Fox G. Infertility and sexually transmitted disease: a public health
challenge. Popul Rep 1983;11(3), Series L(4).
21. Stephenson P, Wagner M, Badea M, Serbanescu F. Commentary: the public
health consequences of restricted induced abortion—lessons from Romania. Am
J Public Health 1992;82(10):1328-1331.
22. Teitelbaum MS. Fertility effects of the abolition of legal abortion in Romania.
Popul Stud 1972;26(3):405-417.
23. Trussell J. The impact of birthspacing on fertility. Int Fam Plann Perspect 1986;
12(3):80-82.
24. United Nations. Report of the International Conference on Population and
Development. Cairo Egypt, September 5-13, 1994.
25. United Nations. World population prospects: 1990. New York NY: United
Nations, 1991: Table 11.
26. VanLandingham M, Trussell J, Grummer-Strawn L. Contraceptive and health
benefits of breastfeeding: a review of the recent evidence. Int Fam Plann Perspect
1991;17(4):131-136.
27. Westoff CF, Ochoa LH. Unmet need and the demand for family planning.
Comparative Studies No. 5. Columbia MD: Institute for Resource Develop-
ment, July 1991.
28. World Bank. World development report, 1984. New York NY: Oxford Univer-
sity Press, 1984.
29. Yi Z, Ping T, Baochang G, Yi X, Bohua L, Yongping L. Causes and implications


























Adolescent Women and 
Reproductive Health
 
For Alusa, the cost of pregnancy was great. She stopped going to
school. No longer could she dream of a life of more opportunity.
For Alusa, the cost of childbirth was pain. Her too small body
tore. Now her husband turned away from her in disgust. She
was only 16 years old, yet she bore the heavy burdens of an adult
woman. 
 
For most of human history, marrying early and having children soon
thereafter have been expected events in a woman's life. Today, how-
ever, in Africa as elsewhere, more young women are enrolled in school.
Increasing urbanization means that families have less need for large
numbers of children. Traditional values have given way to more mod-
ern lifestyles and attitudes. In the past, adolescent childbearing was







These rapid social changes have made adolescent
fertility less acceptable. Adolescent fertility is not increasing in most
African countries; however, Africa has the highest rates of adolescent
fertility in the world.
In Africa, the social conditions that underlie early childbearing































. Social conditions in rural areas limit
educational opportunities, and women marry young. Early
marriage and, therefore, early childbearing are expected and
even desired. However, having children early can have nega-
tive consequences because these young mothers are often




Young urban, educated women
 
. Social conditions in urban
areas promote education and delayed marriage. Premarital
fertility is strongly discouraged because it may hurt a school-
girl's future education and employment opportunities. How-
ever, because safe, legal abortions are generally not available
in Africa, an adolescent’s decision to terminate a pregnancy
poses great health risks.
In most parts of Africa, high fertility is still valued, and mother-







To date, much of the focus on adolescent fertility has centered
on the health and educational consequences of early childbearing
among a very small group of women, primarily unmarried women
enrolled in school. However, married adolescents actually have higher
birth rates. Because of rapidly changing circumstances and expecta-
tions, concern about early fertility may soon broaden to encompass
married women as well.
 




 is not easily defined. In general, it is the period of life
between childhood and adulthood. Demographers sometimes include
only those aged 15 to 19; at other times, they include youth up to age
24. This chapter uses both age groups in presenting data. More than a
demographic category, adolescence is a culturally defined phenome-
non. It is a transition period that can influence a young person's future
life course.
For African adolescents, increasing modernization has changed
























mented, and elders traditionally responsible for educating and prepar-
ing young people for sexuality and parenthood are no longer able to







More young women are enrolled in secondary school, yet





















 in Africa often involves a sequence of stages and steps






Thus, it can be difficult to deter-
mine the age at which a woman first "marries" or whether she is "mar-
ried" when she gives birth. Many births defined as premarital occur
among couples who eventually marry.
Most women in Africa marry before the age of 20 (see Figure 4:






The highest rates of early marriage are in
Cameroon, Benin, Ghana, Côte d'Ivoire, Nigeria, Mauritania, and
Senegal, where between 70% and 80% of women marry before age
20.
The more education a woman receives, the later she marries. In
Kenya, Ghana, Senegal, and Zimbabwe, for example, about one-third
of women with secondary educations report marrying before 20, but

















Large proportions of adolescent youth are sexually active (see Fig-
ure 4:1). Among urban women aged 20 to 24, three-fourths in
Botswana, Liberia, Togo, and Uganda and two-thirds in Ghana and
Kenya report engaging in premarital sexual activity before age 20.
Adolescent exposure to intercourse varies by educational level; in
Botswana, Burundi, Ghana, Kenya, Liberia, Nigeria, Togo, Uganda,
and Zimbabwe, women who have attended secondary school are more
likely than women with no schooling and women with primary educa-




























Figure 4:1 Marriage and sexual experience among female 
adolescents
 
*Data on sexual experience of never-married women not available.
Sources:  Balepa et al. [1992]; Barrere et al. [1994]; Gaisie et al. [1993]; Katjiuanjo et al. [1994]; Kour-
gueni et al. [1993]; Malawi National Statistical Office [1994]; Ngailaba et al. [1993]; Population Refer-
ence Bureau [1992]; Republic of the Sudan Department of Statistics [1991]
 
Rates of sexual activity are not likely to be greater among school-
girls than among their married peers. However, sexual activity among
unmarried adolescents is socially proscribed in most countries; thus,
its occurrence draws greater attention. There is a good deal of debate
over what motivates schoolgirls to enter and maintain sexual relation-
ships. Both African and Western observers point to the weakening of
traditional controls on adolescent sexual activity outside of marriage.
Many traditional African societies transmit information and values
about sexuality and family life through age-prescribed rites of passage
or initiation ceremonies. As families move into cities, adolescents may
be separated geographically from kin, who traditionally taught the
young about values and life events. An adolescent's school and peer
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Traditional norms may be further eroded by adolescents' expo-
sure to nontraditional values through novels, radio, and television as
well as through formal schooling. Adolescent and older men may pres-
sure young women to become sexually active. The phenomenon of
"sugar daddies," older men who bestow gifts and money on young





 Young women may be forced into sexual relationships


















Adolescent fertility rates, presented in Figure 4:2, range from 51
per 1,000 in Burundi to 230 per 1,000 in Niger. In many countries,
more than 20% of women aged 15 to 19 have given birth to at least
one child (see Figure 4:3). In Nigeria, Mauritania, and Sudan, more
than 15% of girls have given birth before age 15. However, in most
African countries, the proportion of women giving birth before age 15
is much lower, ranging from about 3% in Benin, Ghana, and Mali to
7% in Kenya and Côte d'Ivoire. By age 20, most women in most Afri-




In some African countries, such as Burundi, Ghana, Kenya, and
Zimbabwe, adolescent fertility actually appears to be declining. In
other countries such as Botswana, Liberia, and Mali, adolescent fertil-
























Africa. Forty-three percent of women aged 20 to24 in Botswana report
having had a premarital birth, but in Mali, Burundi, Ghana, and Nige-
ria, the figure is less than 10%. In Kenya and Liberia, about one in five




























Figure 4:2 Female adolescent fertility rates*
 
*During the three years before the survey in each country.
**Ever-married women only.
Sources:   Balepa et al. [1992]; Barrere et al. [1994]; Gaisie et al. [1993]; Katjiuanjo et al. [1994]; Kour-
gueni et al. [1993]; Malawi National Statistical Office [1994]; Ngailaba et al. [1993]; Population Refer-
ence Bureau [1992]; Republic of the Sudan Department of Statistics [1991]
 
Figure 4:3 Childbearing among adolescent women
 
*Ever-married women only
Sources:   Balepa et al. [1992]; Barrere et al. [1994]; Gaisie et al. [1993]; Katjiuanjo et al. [1994]; Kour-
gueni et al. [1993]; Malawi National Statistical Office [1994]; Ngailaba et al. [1993]; Population Refer-
ence Bureau [1992]; Republic of the Sudan Department of Statistics [1991]
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The proportion of women experiencing a premarital birth by age
20 appears to be increasing in some countries. In Botswana, 34% of
older women (aged 35 to 39) but 43% of women aged 20 to 24 report
having had a premarital birth by age 20. Kenya and Liberia have expe-
rienced similar increases, with about 12% to 13% of women aged 35
to 39 but about 20% of women aged 20 to 24 reporting a premarital
birth by age 20.
In Kenya almost half of all first births are premaritally conceived;




The first pregnancies of unmarried women are much more likely to be
unintended than those of married women. In Botswana, Ghana,
Kenya, Liberia, Togo, and Uganda, 51% to 87% of the first pregnan-
cies of never-married women are unintended; the proportion for mar-




















Although a large proportion of women aged 15 to 19 report





generally low. More than three-fourths of adolescent women in
Botswana, Kenya, and Zimbabwe and 50 to 75% of adolescent women
in Ghana, Liberia, Senegal, Tanzania, Togo, and Uganda report that
they know of a modern method (pills, injectables, intrauterine devices







However, very few sexually experienced adolescents are cur-
rently using a modern method of family planning. (See Figure 4:4.)
The low levels of contraceptive use among adolescents are paralleled by
high estimates of unmet need for family planning. See Figure 4:5 for
estimates of unmet need for several countries. In most, the unmet need
for family planning is higher among sexually experienced but never-
married women, who are eager to avoid unintended pregnancy.
Focus groups conducted with youth in Nigeria and Kenya reveal
that, while many know of modern contraception and where to obtain
it, they also rely on traditional methods or believe that modern contra-






























Figure 4:4 Current use of modern methods of family planning 
among female adolescents, by marital status
 
*Data on never married women not available.
Sources:   Balepa et al. [1992]; Barrere et al. [1994]; Gaisie et al. [1993]; Katjiuanjo et al. [1994]; Kour-
gueni et al. [1993]; Malawi National Statistical Office [1994]; Ngailaba et al. [1993]; Population Refer-
ence Bureau [1992]; Republic of the Sudan Department of Statistics [1991]
 
Figure 4:5 Unmet need for family planning among female 
adolescents, by marital status
 
*Data not available for never-married women.
Sources: Malawi National Statistical Office [1994]; Population Reference Bureau [1992]
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FEMALE EDUCATION AND ADOLESCENT FERTILITY
 









believed to be a simple one: increases in educational attainment are
accompanied by decreases in fertility. However, this relationship is
actually more complex. Education may change reproductive behavior
and affect fertility in a number of ways: by increasing knowledge of
reproduction and contraception, by delaying entry into marriage or







 In turn, an early unplanned pregnancy may cause a woman
to leave school, lowering her educational achievement. In addition, a
woman enrolled in school is likely to be separated from the commu-
nity that traditionally educated her about sexuality and discouraged
her from behaviors that could result in an early pregnancy.
In fact, women enrolled in school are at greater risk of experienc-
ing an out-of-union birth, because they are less likely to be married
than their peers who are not in school. Among unmarried girls, those
who expect to go to secondary school may delay sexual activity longer
than their peers who do not expect to continue school. Women with a
secondary education are less likely to give birth before age 20 than
women with no education. Women with no formal education are
more likely to marry early and are thus at less risk of premarital preg-
nancy.7
FEMALE SCHOOL ENROLLMENT RATES
Even after two decades of substantial improvement in school
enrollment rates of girls, Africa lags behind other regions. In some
countries, including Madagascar, Tanzania, Kenya, Zambia, Lesotho,
Zimbabwe, Cameroon, Botswana, and Mauritania, nearly as many
girls are enrolled as are boys. In other countries, such as Benin and
Chad, only a third or fewer of primary school students are girls.
At the secondary school and university levels, many more males
attend than females. Females account for more than 40% of secondary
enrollment in only eight countries (Botswana, Congo, Gabon, Kenya,
Lesotho, Madagascar, Swaziland, and Zimbabwe). In several countries,
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including Burkina Faso, Burundi, Chad, Ghana, Malawi, Mali, Niger,
Rwanda, Tanzania, and Uganda, less than 10% of female adolescents
are enrolled in secondary school.7 
CONTRACEPTIVE KNOWLEDGE AND USE
The level of contraceptive knowledge may vary according to a
woman's marital status. If ever-married women are more likely to be
sexually active than their never-married peers, they may be more
knowledgeable about contraception. On the other hand, never-mar-
ried women are likely to have received more formal education, includ-
ing sex education.23 
Contraceptive use increases with education. Among women aged
15 to 24 in Kenya, 4% of those with no education have ever used
modern contraception. This proportion rises to 10% among women
with primary education and 19% among women with secondary edu-
cation. Contraceptive use by women aged 15 to 24 with a secondary
education ranges from 11% in Burundi and Senegal to 54% in
Botswana.7 
PATTERNS OF ADOLESCENT FERTILITY CHANGE
Trends in adolescent fertility over the last 20 to 30 years fall into
three distinct patterns.7 
PATTERN I
In countries such as Botswana and Kenya, adolescent birth rates
are not increasing and may even be decreasing, but the proportion of
births occurring outside marriage and to girls still enrolled in school is
growing. Rates of female secondary school enrollment are high (between
31% and 36% of women aged 20 to 24 have attended secondary
school), and marriage is often delayed. Premarital pregnancies and births
are increasingly seen as mistimed events with negative consequences.
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PATTERN II
Countries such as Liberia, Uganda, and Zimbabwe seem to be
following a path similar to that taken by the first group, but at a slower
pace. Increases have occurred in female school enrollment (but still
fewer than 12% of women aged 20 to 24 have attended secondary
school), age at marriage, and premarital childbearing.
PATTERN III
In countries such as Burundi, Ghana, Nigeria, Senegal, Mali, and
Togo, very little change has occurred in adolescent childbearing, female
education, or early marriage. Almost all women marry before age 20 in
Mali, and fewer than 1% of adolescents are enrolled in secondary
school. In Togo, levels of early marriage and childbearing have remained
unchanged despite increases in secondary enrollment rates from less
than 1% in the 1960s to 18% in the 1980s.
CONSEQUENCES OF EARLY SEXUAL ACTIVITY 
In Africa, as elsewhere, the consequences of early childbearing are
determined in large part by the surrounding social context. The
impact of early childbearing may vary greatly according to a woman's
level of education, the social reaction to adolescent fertility, and soci-
ety's expectations.
FEMALE GENITAL MUTILATION
Genital mutilation, also known as female circumcision, is prac-
ticed in a number of African cultures as a rite of passage to woman-
hood. The practice contributes to early marriage and fertility. The
combination of female circumcision and early birth is highly trau-
matic and potentially fatal for many African adolescents. Female geni-
tal mutilation is widely practiced in Cameroon, Mauritania, Chad, the
Central African Republic, Sudan, Egypt, Niger, Mali, Burkina Faso,
Kenya, and Tanzania. The most extreme form, infibulation, involving
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removal of the entire clitoris as well as the labiae minora and majora, is
practiced in Mali, Sudan, Somalia, parts of Ethiopia, and northern
Nigeria. The procedure itself can lead to hemorrhaging, shock, acute
infection, and death. It can also complicate childbirth, prolonging
labor and leading to the birth of stillborn or brain-damaged children.
SOCIAL CONSEQUENCES
Regardless of their motives for sexual activity, most schoolgirls
who become pregnant suffer common consequences, and it is among
schoolgirls that these consequences are likely to be most devastating.
Beyond the hazards of an illegal and unsafe abortion, their futures may
be drastically changed by a birth that forces them to leave school. In
fact, leaving school is one of the most serious consequences of early
pregnancy, for both individuals and society. In 1986, an estimated
11,000 girls in Kenya dropped out of school because of pregnancy. In
1982, 18,766 Tanzanian girls were expelled because they were preg-
nant. Every year, 10% of the women enrolled in secondary school in
Botswana, Kenya, and Mali are reported to drop out because of preg-
nancy.7,11
In the past, adolescent women who became pregnant were mar-
ried and unschooled; society had invested few resources in them.
Increased education and rising expectations for young women have
transformed the social and economic environment. The education of
women represents an investment of scarce social and personal
resources. Leaving school because of pregnancy results both in an indi-
vidual loss of opportunity and in a squandering of scarce social
resources.8,11 
SEXUALLY TRANSMITTED INFECTIONS
Aside from pregnancy, the greatest risk of sexual activity is becom-
ing infected with a sexually transmitted infection (STI). Women are
biologically more at risk of acquiring an STI from a man than a man is
from a woman. (See Chapter 6 on Sexually Transmitted Infections.)
The negative consequences of STIs can include infertility. Human
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immunodeficiency virus (HIV) poses an especially dangerous threat;
the risk of acquiring HIV is increased when women have other STIs.
Many of the negative consequences of STIs—pelvic inflamma-
tory disease (PID), infertility, ectopic pregnancy, and cervical cancer—
do not appear until later in life. The inability to have children may
leave a woman ostracized in many African societies.26
Both the detection and reporting of STIs are poor in sub-Saharan
Africa. Infection rates appear to be quite high. Young women are more
likely to become infected with HIV and other STIs than are young
men or older women.7 A study at Kenyatta National Hospital in
Nairobi found that 36% of pregnant women aged 15 to 24, but only
16% of older pregnant women, had an STI. The study found that
adolescents, who comprised one-third of the syphilis cases, were twice
as likely to be infected with the disease than older women. Another
Kenyan study found that one-third of rural women aged 13 to 15 had
laboratory evidence of gonorrheal infection.26 
Cultural practices and adolescent behavior may worsen both the
spread and the sequelae of STIs among adolescents. Older, adult men
who have sexual intercourse with much younger women expose their
partners to their entire sexual histories. Young women in polygamous
unions also face an increased risk of infection.7 In addition, older
urban men increasingly seek out young women, who are believed to be
"clean" or virgins to avoid infection with HIV.3,26 Adolescents may not
recognize the symptoms of STIs, or they may be reluctant to seek
treatment.
PREGNANCY AND DELIVERY
Pregnancy and delivery pose major health hazards for adoles-
cents. Maternal mortality is highest among women who are very
young or very old. Women less than 20 years old suffer more preg-
nancy and delivery complications, such as toxemia, anemia, premature
delivery, prolonged labor, and cervical trauma, and are at higher risk of
delivering low-birthweight babies. The infants of adolescent mothers
suffer higher rates of infant and child mortality.18 Worldwide, preg-
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nancy-related complications are the leading cause of death among
women 15 to 19 years old.10 
Contributing factors, other than biological age, that put young
women at greater risk include the environment in which their preg-
nancies occur. African women of all ages bear the highest risk in the
world of pregnancy-related illness and death because of their poor liv-
ing conditions, inadequate nutrition, and insufficient health services.26
These conditions and their consequences may be worse among young
mothers. Adolescents with unintended pregnancies are particularly
likely to have poor nutrition, fail to get prenatal care, and attempt to
hide their pregnancies.18 
The health concerns of early fertility are not affected by a
woman's marital status.11  However, unmarried women are at greater
risk for the consequences of unintended pregnancy than are their mar-
ried peers. Married women find it easier to obtain modern methods of
contraception and feel less compelled to obtain an unsafe abortion to
conceal a pregnancy.
Eclampsia
Pregnancy-induced high blood pressure is the primary pregnancy
complication among adolescents. High blood pressure can lead to
preeclampsia (toxemia), which in turn can lead to eclampsia.
Untreated, eclampsia can cause congestive heart failure, paralysis, kid-
ney failure, blindness, chronic hypertension, or death. A study in
Nigeria found that 40% of women presenting with eclampsia were age
15 or less.23,26
Anemia
Adolescents may also be at a higher risk of developing anemia
and hemorrhage, conditions made worse by malnutrition. One study
in Nigeria found that 60% of adolescent women, but only 15% of
women aged 24 to 30, had anemia. Pregnancy, which depletes a
woman's nutrient and iron reserves, may be especially harmful to very
young adolescents, whose bodies are still developing.23,26
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Vesicovaginal fistula
A common consequence of early childbirth for both circumcised
and uncircumcised women is vesicovaginal fistula (VVF), a tearing of
the wall between the bladder and vagina that leads to constant leaking
of urine. Two-thirds of the cases of VVF in northern Nigeria, where
the condition is not rare, are reported to be the result of obstructed
first labor.23,26 In Kenya, one study found that 45% of all cases of VVF
were among adolescents.26 Women suffering from VVF are ostracized
from society and often turn to begging or prostitution to survive.10,26
Obstructed or prolonged labor
Obstructed or prolonged labor is more likely to occur among
adolescent mothers, especially very young adolescents.23 Cephalo-pel-
vic disproportion (CPD), which occurs when the baby's head is too
large to pass through the mother's pelvis, is a common complication
during delivery. CPD occurs primarily in very young adolescents,
whose physiological development is not complete. CPD is attributable
not only to age but also malnutrition, which leads to an under-devel-
oped bone structure. CPD requires prompt cesarean delivery to save
the life of the baby and possibly the mother. In the absence of surgical
delivery, women may experience uterine rupture, vaginal tearing and
fistulae, and severe lesions. The child may be crushed during delivery.
CPD is a manageable condition, but adolescent women are less likely
to receive the prenatal and delivery care that could reduce the prob-
lems associated with CPD. A study in Kenya found that 70% of the
young women delivering at a local community hospital experienced
difficult labor.26
Abortion
Abortion probably poses the greatest direct threat to young
women's health. In many African countries, abortion is illegal and
dangerous. In fact, one-fifth of all maternal deaths in east and central
Africa and as many as 54% in Ethiopia are due to complications of
induced abortion.13
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Evidence suggests that adolescent women are more likely to seek
abortion than older women and, thus more commonly suffer from
abortion-related morbidity and mortality.3,10,26 Adolescents also are
more likely to seek abortion from non-medical providers, to seek abor-
tions later in pregnancy, and to delay seeking treatment for complica-
tions.26 (See Chapter 23 on Education and Counseling.) A study
conducted at a major Nigerian hospital between 1985 and 1988
found that 72% of the women presenting for treatment of complica-
tions of illegal induced abortions were between the ages of 13 and
19—58% were primary or secondary school students, and 81% were
unmarried.1  Likewise, in Sierra Leone, women aged 15 to 24 com-
prised 81% of the women presenting at hospitals with abortion-
related complications, and, in Zambia, women under 25 represented
59% of abortion-related hospital admissions. A study in Nairobi,
Kenya, found that 67% of abortion-related deaths were to women
aged 10 to 25.3  In Nigeria, illegal abortion is believed to be the lead-
ing cause of death among unmarried women aged 15 to 24, particu-
larly those in school.26
POLICIES AFFECTING ADOLESCENT REPRODUCTIVE 
HEALTH IN AFRICA
Adolescents are a low priority in both policies and programs at the
national level in Africa. In many countries, pregnant students are
often forced to leave school. In some countries, only married women
can get contraceptives. Yet many other countries have started family
life or sex education programs or raised the minimum legal age for
marriage.
Current policies that affect adolescent reproductive behavior or
its consequences are surveyed in Table 4:1, which provides an over-
view of five categories of policy: the provision of family life or sex edu-
cation, policies regarding schoolgirl pregnancy, abortion laws, access
to contraception, and minimum legal age of marriage. In many
instances, information about these policies is not readily available. For
example, there is very little information on school policies for preg-
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nant students or access to contraception for adolescents. In addition,
the table does not include any information on policies regarding
female enrollment in secondary school, employment for teenagers, or
efforts to improve the status of women, all of which affect adolescent
reproductive behavior. Few nongovernmental organizations provide
family planning services, vocational training, and formal schooling for
adolescents who have children and were expelled from school. Some
examples are the Tanzanian UMATI, Pathfinder International, the
Maria Clementine Foundation, and the Botswana YWCA. More are
needed.
FAMILY LIFE EDUCATION
Family life education (FLE) has been widely implemented
throughout Africa. FLE curricula combine sex education with infor-
mation on family roles and family life. In a sense, FLE is an attempt to
institutionalize the kind of education that was previously provided by
tribal elders. Twenty-three African countries offer FLE in primary
schools, and 27 provide FLE at the secondary level.
However, there are several barriers to FLE's success:
• In countries where school enrollment rates are low, FLE has
very limited influence on adolescent behavior.
• Adolescents may be exposed to the risk of pregnancy before
they receive any FLE. Some countries do not offer FLE until
secondary school. FLE has also been criticized for not reach-
ing older youths. Several countries have instituted FLE in
teacher's training colleges or at the university level.
• The content and quality of FLE curricula vary widely. Some
schools focus on population education and exclude sex edu-
cation and family planning education. In addition, teachers
may be unqualified or unable to teach FLE successfully. They
may lack training, materials, or time.3,7,17
• There have been few, if any, evaluations of the impact of FLE
on adolescent sexual behavior in sub-Saharan Africa. In the
United States, studies have found that sex education pro-
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grams have little impact on adolescents' behavior. The same
may be true in Africa. In fact, African adolescents' knowl-
edge of reproduction remains low across all education levels.
In focus groups in Kenya and Nigeria, many youths com-
plained that the information they received in school regard-
ing reproduction was often incomplete and did not describe
how to prevent pregnancy or STI transmission.5
SCHOOL POLICY
There is little information on school policies regarding preg-
nancy in most African countries, but in general, schoolgirl pregnancy
is not tolerated. Expulsion or requiring a pregnant student to leave
school for a while are common responses. In Botswana and Kenya, for
example, young women may be allowed to return to school a year
later. In Liberia, they are permitted to transfer to night school. School
administrators and teachers contend that these young women are "bad
influences." In some countries, nongovernmental organizations are
allowed to provide formal education to girls who were expelled
because of pregnancy.
ABORTION
Access to abortion is almost universally restricted across Africa. A
few countries prohibit all abortions; 12 countries permit abortions
only to save the life of the pregnant woman. Several countries permit
abortions when the pregnant woman's physical or mental health is
endangered. However, even in countries where abortion is legal, the
requirements may be so great as to make abortions very hard to get. In
many countries, the number of illegal abortions is far greater than the
number of legal procedures.13  Such is the case in Zambia, for example,
which has one of the most liberal abortion laws in Africa. Abortions
may be performed only in a hospital setting, and a woman must
obtain the signatures of three physicians before her abortion is autho-
rized.13  These laws may pose barriers that are especially burdensome to
adolescents.
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CONTRACEPTIVE ACCESS AND SERVICES
A few countries limit access to contraception for all women, and
several restrict access for unmarried adolescents even further. The
national government of Swaziland is exceptional in its explicit promo-
tion of contraceptive availability for unmarried adolescents. Kenyan
president Daniel Arap Moi, in contrast, has publicly stated his opposi-
tion to contraception for unmarried adolescents.4 Even in countries
where formal bans do not limit adolescents' access, there is often strong
resistance to providing contraceptives to unmarried teens.3,23 Require-
ments such as spousal consent or medical prescription for contraception
also deter adolescent contraceptive use.  For most of sub-Saharan Africa,
the national family planning service policies developed since 1990  have
officially sanctioned reproductive health services for unmarried adoles-
cents. Some examples exist in Uganda, Tanzania, Botswana, and Togo.
Even where there are no formal policies against providing family
planning to adolescents, the stigma attached to visiting a clinic serves
as a formidable barrier to contraceptive use for many adoles-
cents.3,5,7,8,23,26 As contraceptives become increasingly available in phar-
macies and other local commercial outlets such as patent medicine
shops, adolescents' access to family planning may increase.8
AGE AT MARRIAGE
Early marriage may provide women with security, improved
nutrition, and social support; however, the biological and physiologi-
cal factors of young maternal age remain a potential health hazard for
both a woman and her offspring (see Chapter 1 on Benefits of Family
Planning). Traditional norms prescribing early marriage have persisted
despite legal efforts to change marriage patterns. Laws banning early
marriage have often not been observed or enforced.7 In countries such
as Ghana, Kenya, Nigeria, and Côte d'Ivoire, the legal marriage age
varies according to major administrative divisions, religious groups, or
ethnic groups, which suggests that governments have had little success
in changing marriage customs.23  In Côte d'Ivoire, 41% of urban
women and 43% of rural women marry before the legal age of 18. In
Senegal, where the legal age for marriage is 16, 16% of urban women
and 36% of rural women are married before age 15.7
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Table 4:1  Survey of policies related to adolescent fertility in sub-
Saharan Africa  
Country













Benin prim and sec
FLE in workplace











Burundi prim and sec medical risk — —
Cameroon in progress health risk; 
rape or incest
— 16
Cape Verde prim and sec ? — —
C.A.R. prim and sec save life of woman — —
Chad prim and sec save life of woman — —
Congo prim and sec broad medical — 18
Côte d'Ivoire prim and sec save life of woman restricted for all 18
Ethiopia sec narrow medical — 12-15a
Gabon in progress narrow medical no Rx if 
under 25
15
Gambia in progress broad medical married only no min
Ghana in progress broad medical — none-21a
Guinea prim and sec broad medical — 17
Kenya sec certified health risk proscribed for 
unmarried youth
9-18a
Lesotho in progress health risk — 16
Liberia prim and sec, TC save life of woman — 16
Madagascar prim and sec severely restricted by Rx for 
adults only
14
Malawi in progress save life of woman — —
Mali prim and sec prohibited permitted for 
birth spacing
16-18a 
Mauritania prim and sec narrow medical by Rx only —
Mozambique prim and sec, 
TC, univ
save life of woman permitted for 
birth spacing
—
Niger prim and sec narrow medical — 16
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Rwanda prim and sec save life of woman — 21
Senegal in progress health risk — 16
Seychelles prim and sec save life of woman,
 rape or incest, 
birth defects
— —
Sierra Leone prim and sec, TC save life of woman illegal 
under 18
15
Somalia prim and sec, TC health risk — 18
South Africa — health risk, with 
authorization
— 21
Sudan — save life of woman — —






Tanzania prim and sec, TC save life of woman married women 16
Togo prim and sec save life of woman 
or health risk
— 17
Uganda sec and TC physical or 
mental health
— 18
Zaire prim and sec prohibited — —











— Information not available.
prim: primary schools
sec: secondary schools
TC: teachers training colleges
univ: universities
aVaries according to major administrative divisions, religious groups, or ethnic groups.
Sources: Bledsoe and Cohen (1993); United Nations (1989a), United Nations (1989b), United Nations 
(1990)
Table 4:1  Survey of policies related to adolescent fertility in sub-
Saharan Africa  (Continued)
Country
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STRATEGIES FOR REDUCING ADOLESCENT FERTILITY
Each provider plays a key role in helping adolescent clients make the
complex decisions about whether to be sexually active, how to protect
themselves if they are sexually active, what to do if pregnancy or an
STI occurs, and where to seek support to pursue an education while
learning to care for a baby. Each provider and clinic should create a
positive atmosphere that lets young clients know they are welcome
and will be treated with respect. An adolescent's decisions, health, and
future can be significantly influenced by effective client-provider inter-
action.
Nations that seek to reduce sexual activity and fertility among
adolescents will find the task puzzling and challenging. It is difficult to
find successful models from other nations or cultures that have
mounted strategies to reduce the pregnancy and childbearing rates of
very young women. Many Western nations, such as the United States,
have achieved little success in changing the reproductive patterns of
these adolescents. Moreover, having thousands of cultures within
Africa makes it impossible to suggest general strategies for the entire
continent. In many African nations, adolescent childbearing is desir-
able in the context of marriage but undesirable outside of marriage.
However, a pregnancy that occurs during the mother's adolescence
poses medical hazards, whether the woman is married or not. STIs
threaten the fertility and health of the married as well as the single
woman. These risks can be reduced to some extent simply by provid-
ing adequate family planning and medical services to young women to
help them delay childbearing and to protect against STIs.
Success in reaching acceptable levels of adolescent pregnancy,
childbearing, and STIs will most likely come when strategies are devel-
oped and implemented at local levels. In addressing these issues, the
health care providers must try to deliver positive messages and involve
adolescents’ peers and traditional birth attendants.  However, medical
interventions alone cannot solve most public health problems. One
useful guide to follow when considering potential strategies for inter-
vention is to focus on three major influences on health: (1) the medi-
cal system; (2) the personal behaviors of the adolescents themselves;
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and (3) the political, social, and economic community environment.
Listed in Table 4:2 are several strategies that have been used to reduce
adolescent fertility: providing medical services, encouraging personal
behavior change, and creating a community environment that meets
adolescents' needs.
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Table 4:2  Strategies for reducing adolescent fertility
Medical Services Personal Behavior Community
• Provide a broad variety of 
contraceptive methods
• Educate adolescents about 
making a life plan—
deciding when pregnancy 
would fit into their lives
• Educate youth about family 
planning—through 
schools, churches, commu-
nity leaders, and media
• Accept adolescent clients • Encourage both young 
men and women to say 
"no" to sexual relations
• Rally commitment among 
community leaders to pro-
vide services to adolescents
• Train medical staff how 
to serve adolescent clients
• Encourage men to use 
condoms
• Gain acceptance of the 
concept of confidentiality
• Remove barriers to 
providing contraceptives 
(see WHO guidelines)
• Instill a commitment to 
avoid pregnancy and HIV 
infection
• Acknowledge the sexuality 
of adolescents
• Dispense a 1-year supply 
of contraceptives to each 
client
• Expect men to accept the 
consequences of their 
actions with women
• Take constructive rather 
than punitive measures
• Honor the adolescent's 
desire for confidentiality
• Discourage older men from 
having intercourse with 
virgins in order to avoid 
infection
• Educate workers in drug 
dispensaries to maintain 
confidentiality and be sensi-
tive to adolescents' needs
• Make clinic hours and 
locations convenient for 
adolescent clients
• Provide prostitutes and 
their clients condoms 
and education on how 
to use condoms
• Improve the education of 
women
• Increase staff sensitivity 
to the embarrassment 
and consequences that sex-





• Increase women's status 
in the society
• Include family planning 
discussions in all medical 
encounters
• Raise the legal age for 
marriage
• Acknowledge that many 
adolescents are sexually 
active and need protection 
from pregnancy and sexu-
ally transmitted infection
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HIV, AIDS, and 
Reproductive Health
 
Theresa was 17 years old when she married. She had a baby 
right away, and another one 3 years later. The second one was 
sickly and died before his first birthday. Soon after, her husband 
became ill with tuberculosis. He went to the doctor for medi-
cines, which he took for 6 months. After he had been well for 
nearly a year, he began having diarrhea and weight loss. Theresa 
again became pregnant, but her husband died before the baby 
was born. 
When she found out that her husband had died of AIDS, she 
asked the doctor many questions about the illness and how it 
was spread. It surprised her that people could have a silent virus 
that could make them sick after many years. She realized her 
husband may have become infected before they were married. 
She had never had sex except with her husband, nor had she 
ever received a blood transfusion, so she knew that she could not 





 the virus, and if that was why their second baby died. 
Theresa and her child went back to her village to live with her 
mother. She was afraid for the baby she was carrying, but he 


























Acquired immune deficiency syndrome (AIDS) is a fatal disease that
has no cure and no vaccine to prevent it. The disease is caused by the
human immunodeficiency virus (HIV), a retrovirus transmitted from
an infected person through unprotected sexual intercourse (vaginal,
oral, or anal), by exchange of body fluids such as blood, or from a
mother to her infant during pregnancy, childbirth, or breastfeeding. 
Some people mistakenly think that HIV can be transmitted
through insect bites, dirty water, handshakes, coughing, sneezing,
shared food, bad air, or witchcraft. It cannot be transmitted in these
ways. Some people mistakenly believe that HIV can be cured or that a






Still others mistakenly believe
that they can tell who is infected with HIV simply by looking at them
or wrongly think that young people cannot be infected.
Most people who are HIV-infected do not feel sick and do not
know they are infected until years later, when the symptoms of AIDS
finally appear. Because people with AIDS usually lose weight, it is







HIV can cause AIDS, HIV-1 and HIV-2. HIV-1 is far more common.
 
GLOBAL HISTORY OF HIV-1
 
AIDS was first described in the early 1980s, and HIV was identified as
the cause a few years later. The infection has become a worldwide epi-
demic. In some areas, men who have sex with men have the highest
rate of infection. In other communities, people who share bloody
injection equipment (needles or syringes) have the highest HIV preva-
lence. In still other areas, heterosexual transmission is the most com-
mon route of infection.





route. For example, a man who became infected by re-using contami-
nated injection syringes may pass the infection to his wife by having
sex with her. If his wife is pregnant or becomes pregnant later, she may
then pass the infection to her baby. The routes of transmission are the
same around the world, but differing patterns of human behavior
















frequently have unprotected sex (sex without a condom) or share
injection equipment are most likely to become infected. They can
then expose others to their virus.  In general, the more sexual partners
a person has had, the higher that person’s risk of becoming infected
with HIV and of infecting others. However, it does not take multiple
partners to become infected; a person with just one HIV-infected
partner is at extremely high risk.
 
TRANSMISSION TRENDS OF HIV-1 IN AFRICAN 
NATIONS
 
Africa is the continent most severely affected by HIV infection. In
sub-Saharan Africa in 1997, an estimated 4.0 million people were
newly infected with HIV, 530,000 of whom were children.  This
amounts to 11,000 new infections per day.  As of late 1997, an esti-







It is not possible to test entire populations for HIV, so the
exact numbers of HIV-infected people are not known. The general
prevalence of HIV infections is extrapolated from studies of specific
groups who can be routinely tested for HIV (such as military person-
nel, pregnant women, or people with sexually transmitted infections
[STIs]). See Figures 5:1 and 5:2.
In addition, most of the available statistics describe the final
stage, AIDS, and not HIV infection. Therefore, when reading about
AIDS cases, keep in mind that these statistics do not include most
people infected with HIV, who are not yet sick. AIDS statistics also
can be misleadingly low because of the difficulties with diagnosis and
delayed reporting. 
In African countries, heterosexual contact accounts for more






In some areas, men and women are







Women are often infected at younger ages than men. HIV
prevalence is highest in women aged 15 to 25 years; it peaks in men 5
to 10 years later. The number of reported AIDS cases among women




























Figure 5:1 HIV-1 prevalence in high-risk populations, which 
include commercial sex workers, their clients, and sexually 
transmitted disease patients
Figure 5:2 HIV-1 prevalence in low-risk groups, which include 
pregnant women and the general population
 
Source for Figures 5:1 and 5:2:  U.S. Bureau of the Census, Population Division, Interna-
















The next most common route of HIV infection in Africa is from
an infected mother to her newborn. This vertical transmission can
occur either during pregnancy, delivery, or breastfeeding and is associ-
ated with more advanced disease in the mother, severe prematurity,
and other factors. 
The most efficient route of HIV transmission is through blood







This route affects primarily women and chil-
dren, because transfusions are most often given to infants with malaria
or sickle cell anemia and women with obstetrical complications. In
Africa, injection drug use and other means of HIV transmission




Between the early 1980s and the 1990s, HIV seroprevalence
rates increased dramatically in many groups:
• Men attending STI clinics in Nairobi, Kenya: 3% were HIV-
infected in 1981; 23% were in 1990.
• Adults in Abidjan, Cote d'Ivoire: about 1% were HIV-
infected in 1987; more than 7% were in 1991.
• Pregnant women in Nairobi, Kenya: 2% were HIV-infected
in 1985; 13% were in 1991.
• Blood donors in Nigeria: none were HIV-infected in 1987;




• Pregnant women in Free State, South Africa: 4.3% were
HIV-infected in 1993; 11% were in 1995.
• Pregnant women in Kwazulu/Natal, South Africa: 9.6% were
HIV-infected in 1993; 18% were in 1995.
 
3
Although some countries have been able to slow the incidence of new
infections with aggressive prevention programs, infection rates are still
increasing in many regions.
Other groups, such as commercial sex workers, men who have
sex with commercial sex workers, military personnel, truck drivers,
and people with other STIs have higher than average rates of HIV




These individuals are also
more likely to be infected with HIV and other STIs and are often


























In general, the rural epidemic is several years behind the urban





HIV-2, a retrovirus similar to HIV-1, causes a similar illness, but the
symptoms progress more slowly. HIV-2 is transmitted by the same
routes as HIV-1, but it is less easily transmitted by the perinatal route.
Mothers infected with HIV-2 pass the infection to their infants in up to
8% of births. Some authorities believe HIV-2 is also less easily trans-






Among individuals with HIV-2, however,







transmitted by blood transfusions. A Cote d'Ivoire study showed that
7.4% of blood donors were infected with HIV-2 in 1986-1987. The
same study showed that 15% of children who had received multiple
blood transfusions had HIV-2, and that none of the children who had
never been transfused had HIV-2. The children who had received
blood transfusions were also much more likely to have HIV-1, which




See Figures 5:3 and 5:4.
 
PROGRESSION OF HIV INFECTION TO AIDS
 
After becoming infected with HIV, most people will not immediately
notice any illness.  After a few weeks, some infected people become ill
with fever, sore throat, enlarged lymph nodes, rash, and general fatigue





, and the symptoms disappear within a few weeks. By the time
the newly infected persons would test positive for HIV, about 6 weeks
to 6 months after becoming infected, they feel healthy again. (See
















Figure 5:3 HIV-2 prevalence by country for high-risk urban 
populations:   commercial sex workers, their clients, and sexually 
transmitted disease patients
Figure 5:4 HIV-2 prevalence by country for low-risk urban 
populations:  pregnant women and the general population
 
Source for Figures 5:3 and 5:4:  U.S. Bureau of the Census, Population Division, Interna-


























The duration of apparent wellness that follows can last for years.




, and it may extend from less
than 6 months to more than 10 years. The infected person looks and
feels fine and is able to work or care for the family without impair-
ment. However, the immune system gradually loses its ability to fight
infections. 
People who discover their infection during this phase sometimes
have trouble believing they are actually infected. The health care
worker may suggest that the infected person bring his or her sex part-
ner for counseling and assessment. HIV-infected people may be fearful
that others will find out about their HIV status and stigmatize, blame,
or avoid them. They may fear being abandoned by their spouses. Mar-
ried couples may need help in dealing with the fear and mistrust that
may ensue. Peer support groups for HIV-infected people, available in
some areas, may provide a safe place for discussion of how to handle
these challenges.
 







Symptoms Acute retroviral 

































Negative Positive Positive Positive
 
















Before developing the symptoms of full-blown AIDS, the infected
person may begin to notice some unusual symptoms such as candidiasis
(a fungal infection) in the mouth or vagina, worsening of skin rashes,
and fatigue. Once referred to as AIDS-related complex (ARC), this set





Once HIV has weakened the immune system, bacterial infec-
tions become more severe, last longer, and are harder to treat with
antibiotics. Tuberculosis, bronchitis, and pneumonia are more com-
mon and severe in patients with AIDS. Fungal and protozoal infec-
tions often will not go away, even with treatment, and may cause
death in a short time. Viral infections can become chronic, with per-







infections, because they take advantage of the opportunity of an
impaired immune system to cause major, life-threatening illnesses.
When opportunistic infections or certain rapidly growing cancers




. Cryptococcal meningitis, esoph-
ageal candidiasis, cerebral toxoplasmosis, and invasive Kaposi's sar-
coma are examples of such diseases. Other symptoms during this
phase include severe weight loss, anemia, prolonged diarrhea, extreme
fatigue, dry skin, rashes, and thin or wispy hair. HIV can directly
interfere with normal functioning of the brain, the gastrointestinal
tract, and other body systems (see Table 5:2). 
Survival after progression to AIDS is usually short. In African







but individual survival varies widely. Even in areas with exten-
sive diagnostic and medical resources, a person with AIDS may live only
a few years. Death is generally a result of opportunistic infections, severe
weight loss, or any of the cancers commonly seen with AIDS.
Aggressive treatment for HIV infection, available in settings with
extensive medical resources, involves the use of 2 or more antiretrovi-
ral drugs to reduce the actual number of HIV (viral load) in the body.
These drugs must be taken several times a day for life, because they
only help while they are in the patients’ body.  The person can still


























system. Because of the expense of such treatment, it has been unavail-
able to most people with HIV in 1998.  Medical treatment also seeks
early diagnosis and rapid treatment of opportunistic infections. The
type of   opportunistic disease seen in AIDS varies from region to
region, depending on what bacteria, fungi, viruses, and parasites are
common to the area (air, water, and people).  In some locations, a par-
ticular opportunistic infection may be so common and so lethal that
HIV-infected persons are given a specific drug to prevent such an
infection, rather than wait for the infection to occur and then treat it.
For example, in a group of Abidjan patients who were treated for
tuberculosis, daily co-trimoxazole (trimethoprim 160 mg. and 800
mg. sulfameth-oxazole) prolonged survival and greatly reduced hospi-




 Whether this will
hold true for people without TB or people in other regions remains to
be seen.  With aggressive treatment, a patient’s life may be extended a
year or more.
 
Table 5:2 WHO case definition for AIDS surveillance in adults 
and adolescents
 
For the purposes of AIDS surveillance, an adult or adolescent (>12 years of age) is 
considered to have AIDS if at least two or more of the following major signs are 
present in combination with at least one of the minor signs listed below and if these 




Weight loss greater than or equal to 10% of body weight
Chronic diarrhea for more than 1 month




Persistent cough for more than 1 month*
Generalized pruritic dermatitis
History of herpes zoster
Oropharyngeal candidiasis
Chronic progressive or desseminated herpes simplex infection
Generalized lymphadenopathy
The presence of either generalized Kaposi’s sarcoma or cryptococcal meningitis is 
sufficient for the diagnosis of AIDS for surveillance purposes.
 
*For patients with tuberculosis, persistent cough for more than 1 month should not be considered a 
minor sign.
















HIV TRANSMISSION AND CONTRACEPTION 
 
Several contraceptive methods reduce the risk of HIV and other STIs,
although a few may actually increase risk of these infections (see Table
5:3). No matter what other methods of contraception a person is
using, if he or she is at any risk because a sex partner is HIV-infected
or because the partner’s HIV status is not known, advise him or her to
use condoms with every sexual act. No other contraceptive method
besides abstinence provides this degree of protection.
  Studies of contraceptive use and HIV transmission are particu-
larly complex because both the choice of contraceptive method and
the risk of HIV transmission are related to sexual behaviors.  For
example, women who use hormonal contraceptives may engage in sex-
ual behaviors that place them at increased risk of HIV—such as
reduced use of condoms.  Further studies are needed to clarify the true
risk associated with the hormonal methods themselves. 
 
Until then,
women using oral, implantable or injectable contraceptives should be







Because a women’s HIV status does not seem to affect fertility, it
is important to provide contraceptive counseling and contraception to
women with HIV.  Women known to have HIV infection should be
counseled that they can infect their partners, and that among contra-
ceptive methods, only condoms can reliably reduce HIV risk to unin-
fected partners.  Again, this requries that condoms be used in addition
to other types of contraception, and that they be used consistently and
correctly for every sexual act.
Condom use reduces the risk of HIV and other STIs effectively, but




 In several studies of
heterosexual couples, consistent and correct use of condoms reduced
by 90% to 100% the risk of HIV transmission from the infected man






Consistent condom use is also highly





























Table 5:3 Contraceptive effects on sexual transmission of HIV
 
HIV Transmission Risk




Pills Conflicting data:  
several studies seem to 
show higher risk with 
pill use; many show no 
increase
No clinical studies; 
increased HIV shedding 
on hormonal contra-
ception in one study
May vary depending 
on composition of pill
and other factors
Injections Studies in monkeys 
showed increased risk 
with progesterone; most 
studies in humans show 
no increase in risk
No clinical data





male or female, 
latex or synthetic
Offers excellent 
protection from virus 
when correctly and 
consistently used
Offers excellent 
protection from virus 
when correctly and 
consistently used
May be used in 
combination with other 
contraceptive to reduce 
HIV risk
Vaginal spermicides:  
sponges, foam, films, 
suppositories, and 
jellies (nonoxynol-9)
Conflicting data:  daily 
sponge users had higher 
HIV risk; non-sponge 
spermicides have shown 
some protective effect 
against HIV in one study
No clinical studies; 
spermicides inactivate 
HIV upon contact
Frequent use of 
nonoxynol-9 may cause 
vaginal or vulvar irri-
tation; some STI reduc-




Most studies show no 
increased susceptibility 
to HIV
No clinical observations, 
but some IUDs increase 
amount and duration of 
menses:  sex during 
menses poses higher risk
Not considered safe for 
women at risk of STIs.  
HIV-infected IUD users 
must have continued 




Reduction in risk when  
practiced consistently 
with stable partner; 
Some transmission 
still occurs
Males are still exposed 
to female vaginal and 
cervical secretions, 
although duration of 




No clinical studies 
on HIV; unlikely to 
reduce risk
No clinical studies on 
HIV; unlikely to reduce 
risk
Semen and vaginal 
secretions still contain 




No clinical studies 
on HIV
No clinical studies on 
HIV
Risk of other STIs is 
less, but HIV can 
invade through vaginal 
wall (unlike STIs 

















Although some studies have suggested that condoms are not very
effective in preventing HIV transmission, those studies usually did not
ask how frequently condoms were used. In those studies, people who
used condoms rarely or occasionally may have been misclassified as










Two cross-sectional studies, one in Italy and one in Tanzania,
have shown that women with a history of intrauterine device (IUD)







In a recent Italian study, women who used an IUD during
a stable relationship with an HIV-infected male partner appeared to





 However, women who had an IUD inserted or removed during
the relationship had a significantly increased rate of HIV infection.
 
41
The association may be related to inflammatory changes in the uterine
mucosa that increase the number of HIV target cells available to
become infected. 41
In cross-sectional studies, IUD users were no more likely to be
infected with HIV.19 More recently, a prospective study of women
attending a family planning clinic in Tanzania showed that women
using IUDs were not at increased risk for HIV seroconversion.30
Thus, the risk for HIV infection associated with IUD is uncertain.
IUDs have been associated with pelvic inflammatory disease (PID),
but most IUD-associated PID is thought to be attributable to STIs.
For this reason, IUDs are not generally recommended for women at
risk for STIs, including HIV.  Women known to be infected with HIV
may safely use IUDs if they have continued access to medical care, and
a stable, mutually monogamous relationship.68
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HORMONAL METHODS: ORAL CONTRACEPTIVES, 
IMPLANTS, AND INJECTABLES
Whether oral contraceptive (the "pill") use has any effect on HIV
transmission is controversial. In Nairobi, women who had taken oral
contraceptives were more likely to be HIV-infected than were those
who had not.51  Commercial sex workers and women attending STI
clinics also showed an increased risk for HIV if they used oral contra-
ceptives.47 In contrast, an Italian study suggested that women who had
taken oral contraceptives were slightly less likely to be HIV-infected.43
Other studies conducted among commercial sex workers or women in
stable relationships have not found a significant increase in HIV risk
among oral contraceptive users.16,30 In these studies, it is almost
impossible to rule out the possibility that other factors accounted for
the difference in HIV risk. Thus, it is difficult to tell whether an
increased risk of HIV is attributable to oral contraceptive use or to
other characteristics.
Of 10 published studies with data on Depo-Provera use, only
one reported an increased risk of HIV among women using Depo-
Provera.17
VAGINAL SPERMICIDES
The role of vaginal spermicides (sponges, foams, suppositories,
films, and gels) in reducing the risk of HIV infection is controversial.
Alone, they are not currently recommended for preventing HIV infec-
tion in women. Although spermicidal ingredients (nonoxynol-9,
octoxynol, benzylkonium chloride, and menfegol) kill HIV under lab-
oratory conditions, their usefulness in preventing HIV transmission
during sex is less certain.23,27,32 
  Nonoxynol-9 can be irritating. Four groups of women were given
intravaginal doses of nonoxynol-9 on different schedules: every other
day, daily, twice a day, or four times a day. The women who received
the spermicide more often than every other day had vaginal irrita-
tion.49 Women who used menfegol spermicidal foaming tablets more
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than once per day had more genital lesions, even though they did not
report problems.23 Frequent use of higher doses of spermicides may
cause genital irritation that could actually increase the woman's HIV
risk. Whether vaginal spermicides affect HIV transmission from an
infected woman to an uninfected man has not been fully investigated. 
 Although observational studies have suggested that prostitutes
using nonoxynol-containing spermicides were less likely to have HIV
infection, randomized trials have not shown that these spermicides
protect against HIV. A Nairobi study found a higher rate of HIV con-
version in commercial sex workers using the vaginal sponge, which
contained high doses (1 gram) of nonoxynol-9, than in commercial
sex workers using inert suppositories.31 The increased risk may have
been due to chemical or mechanical irritation from daily, near-contin-
uous sponge use, and may not hold true for women who use sponges
infrequently, or women who use nonoxynol-9 creams or suppositories.
COITUS INTERRUPTUS
Stable couples in which the man was HIV-infected and the
woman was not demonstrated that coitus interruptus (withdrawal of
the penis before ejaculation) was somewhat better than unprotected
intercourse with ejaculation at keeping the woman from becoming
infected. This method cut the HIV sero-conversion rate of women by
half in one study41 and by a larger percentage in another.16  These stud-
ies examined only stable, heterosexual couples. The findings may not
hold true for women with several HIV-infected partners. Coitus inter-
ruptus has not been studied as a way to reduce HIV transmission from
an infected woman to an uninfected man.
Coitus interruptus probably decreases a woman’s HIV exposure
by reducing the amount of semen that enters her vagina. However, the
seminal fluid that emerges from the penis before ejaculation may con-
tain some HIV.27 Although coitus interruptus may be better than
intercourse with ejaculation at preventing HIV transmission, a num-
ber of women have become infected while their partners reported con-
sistently practicing withdrawal.
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DIAPHRAGMS AND CERVICAL CAPS
No information is available regarding the usefulness of the dia-
phragm or cervical cap in preventing HIV transmission. Case reports
have shown that vaginal contact with HIV-containing semen is
enough to infect a woman. Any barrier that covers only the cervix or
the cervix and part of the vaginal wall does not adequately protect the
user from HIV transmission.27
VOLUNTARY STERILIZATION
Voluntary sterilization (tubal ligation, hysterectomy, or vasec-
tomy) has not been clinically studied to find out if it alters the rate of
HIV transmission. Because all the elements for HIV transmission
remain in place after such surgery, sterilization would not be expected
to increase or decrease this risk.27
FERTILITY AWARENESS
Fertility awareness methods have no known impact on HIV or
STI transmission. They may have some use in risk reduction when an
HIV-infected man and his uninfected wife want to have a child. Some
couples in these circumstances do not wish to adopt a child or use
semen from an uninfected donor to impregnate the woman. Fertility
awareness methods can be used to time the unprotected sex act to the
woman’s days of maximum fertility, so the woman’s exposures to HIV
is minimized. (See Chapter 18 on Fertility Awareness.) There is no
guarantee the woman will escape HIV infection or the risk of passing
it on to their baby.  Be sure the couple understands the need to use
condoms for all other sexual intercourse. If a couple is determined to
pursue this option, they should be fully informed of the risks to the
mother’s and the fetus’ health.  If the woman is fearful of risking infec-
tion or shows signs that she feels coerced, her wishes must be
respected.
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FACTORS FACILITATING SEXUAL HIV TRANSMISSION
The chance of getting HIV when having sex with an infected partner
varies considerably for each person. Some individuals had sex with an
infected person one time and contracted HIV. Other individuals had
sex with an infected person many times and did not contract the infec-
tion, but many such persons did eventually contract HIV.
Certain factors increase the danger of getting HIV when having
unprotected sex (sex without a condom) with an infected person:
19,30,40,41,43 
• Gender (most studies suggest HIV is two to three times more
easily transmitted from an infected man to a female partner
than from an infected woman to a male partner)
• Anal intercourse (more risk to receptive partner)
• Advanced HIV disease
• Any STI, especially genital ulcers, in either the HIV-infected
or uninfected partner
• Frequent intercourse (>2 times a week)
• Sex during menses (if the female is infected)
• Uncircumcised male partner (increases the risk for unin-
fected men of getting HIV)
• Use of vaginal drying agents
SEXUALLY TRANSMITTED INFECTIONS
Almost any STI increases the chance of HIV transmission, par-
ticularly those that cause genital sores or ulcers.60 In a Malawi study of
HIV-infected men, those without urethritis had about 17,000 HIV
copies/ml of semen, but those with urethritis had about 125,000 HIV
copies/ml.26 Only two weeks after urethritis treatment, the viral count
dropped to 37,000 HIV copies per ml. In women, a similar correla-
tion was seen between a current STI and detectable numbers of HIV
in cervical and vaginal secretions.22
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Rapid, effective treatment of STIs curbs the spread of HIV. A
study in Tanzania found a dramatic reduction in new cases of HIV
among men and women who received improved STI treatment ser-
vices.24 Sometimes infected partners may provide the only route for
finding and treating women, because women often have no symptoms
of their STI.60 For example, in a group of rural Ugandan women, 65%
had reproductive tract infections, but only 8% reported a vaginal dis-
charge.45 Women with untreated STIs are not only more likely to
become HIV-infected and pass on their HIV infection to others,  but
they are also more likely to experience infertility, chronic pain, and
perinatal complications, as well as neonatal blindness, disfigurement,
and death. (See Chapter 6 on Sexually Transmitted Infections.)
BLEEDING, ABRASIONS, AND VAGINAL DRYING AGENTS
Any sexual or hygiene practice that causes friction, abrasion, or
irritation may lead to small breaks or tears in the woman's genital
mucosa. Thus, almost any intravaginal product such as douches, tam-
pons, or substances to dry or tighten the vagina will increase the risk
of HIV infection among women having sex with HIV-infected men.37
"Dry sex" (removal of vaginal secretions before intercourse) and use of
intravaginal herbs, leaves, or powders are likely to increase the trans-
mission of HIV infection during sexual intercourse.28 Any sexual prac-
tice associated with bleeding in either partner would also be likely to
increase HIV transmission. Breaking the hymen, if traumatic or asso-
ciated with bleeding, is thought to magnify the risk of HIV transmis-
sion from an infected man.10 Finally, if an HIV-infected woman has
sex during her menstrual period, she is more likely to transmit the
virus to her partner.46
FEMALE GENITAL INFIBULATION
The effect of female genital infibulation (circumcision) on HIV
transmission has not been studied. The woman's husband or partner is
expected to separate (defibulate) this tissue during her first sexual
intercourse. Because defibulation routinely tears tissue, the opened
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wound comes in direct contact with semen. This wound provides HIV
a direct portal of entry into the bloodstream of the woman. Scarring
that may occur as the defibulated area heals may lead to repeated epi-
sodes of intercourse-related tissue trauma and bleeding.
HIV IN PREGNANCY, CHILDBIRTH, AND 
BREASTFEEDING
HIV TRANSMISSION DURING PREGNANCY AND CHILDBIRTH
HIV can be passed on from an infected mother to her child
before birth, during delivery, or while breastfeeding. Studies to date
have shown that between 23% and 42% of babies born to African
mothers infected with HIV-1 will become infected via one of these
routes. The risk may be higher if the mother acquires the HIV infec-
tion during the pregnancy or if she has symptomatic or advanced dis-
ease during the pregnancy.33 Other factors associated with increased
HIV transmission from mother to infant are premature rupture of the
membranes, preterm delivery, invasive procedures performed during
pregnancy (particularly amniocentesis and amnioscopy), chorioam-
nionitis (infection of the placenta), STIs during pregnancy, hemor-
rhage during labor, and bloody amniotic fluid.35 Some of these
conditions can be prevented by good prenatal care and careful intra-
partum management.  In particular, screening for and treating STIs
(both symptomatic and asymptomatic infections) before pregnancy or
as early as possible during pregnancy can help reduce HIV transmis-
sion. If the woman has an STI, her partner(s) will need treatment in
order to prevent reinfection.
In a multicenter study, HIV-infected pregnant women were
given the antiretroviral drug zidovudine (also called ZDV, AZT, or
Retrovir) several times a day during the second and third trimester of
pregnancy and intravenously during labor and delivery. The newborns
were given ZDV syrup for the first 6 weeks of life. Infants whose
mothers were treated with zidovudine had an 8.3% chance of infec-
tion versus 25.5% in the untreated group.56  These infants also had a
temporary drop in their hemoglobin level (about 1 gram), with spon-
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taneous resolution after the ZDV was completed.  A shorter course of
zidovudine was tested on pregnant women in Thailand between 1996
and 1998, in which the HIV-infected women took 300 mg. of zidovu-
dine twice a day starting at 36 weeks.  During labor, they took 300
mg. every three hours by mouth until delivery.  In that study, the HIV
transmission rate was 50% less for infants whose mothers took zidovu-
dine (9.2%), versus infants of those who had not received the drug
(18.6%).  This study greatly simplified the previous regimen, and even
though the reduction in HIV was somewhat less, the much lower cost
may make it feasible for countries with limited resources.  No intrave-
nous drug was used, and the infants were not treated after birth. None
of the infants were breastfed, however.  In areas where artificial feed-
ings are not feasible, this regimen is not likely to be as effective in
reducing perinatal HIV transmission.66
Zidovudine has not been widely tested in adults in African
nations and will require careful monitoring during initial use in Afri-
can populations. We do not know if some other drug regimen or type
of treatments may be more useful to reduce mother-to-child HIV
transmission. One treatment recently tested in Malawi was vaginal
cleansing with a 0.25% chlorhexidine solution every 4 hours during
labor and delivery.9  The entire birth canal and external genitalia were
wiped with a cotton swab soaked in the solution.  The infants were
cleansed in the same manner immediately after delivery.  This regimen
did not reduce HIV transmission from mother to newborn, except in
a subgroup of women whose membranes had been ruptured for longer
than 4 hours. In these women, transmission rates were 25% in the
vaginal cleansing group versus 39% in the control group.  Whether
this finding was due to the intervention has not been ascertained, but
there were no ill effects reported from the cleansing. In fact, the same
study suggested that the chlorhexidine cleansing reduced neonatal and
maternal infections in the early portpartum period.  Infant mortality
from sepsis also was reduced.69 Additional studies are needed to
answer some of the remaining questions as well as produce an effec-
tive, less expensive, and more practical methodology for women in
countries with fewer resources.14
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HIV TRANSMISSION DURING BREASTFEEDING
Infants who escape HIV infection during pregnancy and delivery
may still become infected by breastfeeding from an infected mother.
If the mother was not infected with HIV previously but became
infected during the breastfeeding period, the infant's risk of serocon-
version is around 29%.18 If the mother was infected with HIV before
the pregnancy, the infant's additional risk of contracting HIV from
breastfeeding is estimated at 14%.18
Breastfeeding provides optimal nutrition, protects infants from
many life-threatening infectious diseases, and provides some natural
contraceptive benefit (see Chapter 12 on Postpartum Contraception
and Lactation).  For these reasons, continue to promote breastfeeding
among HIV-negative women and women of unknown HIV status.  A
woman known to have HIV infection should be informed about the
risk of HIV transmission through breastfeeding and about other possi-
ble feeding options, so that she can make her own decision about
whether to breastfeed.  HIV-infected women may consider using com-
mercial infant formula only if the family has reliable access to suffi-
cient formula for at least 6 months and has the resources—clean water,
fuel, utensils, skill, and time—to prepare it accurately and hygieni-
cally.64  (See Chapter 12 on Lactation and Postpartum Contracep-
tion.)  If a woman chooses to use artificial feedings, teach her how to
prepare the feedings and how to feed the infant from a cup.  Then ask
the mother to demonstrate the preparation and feeding so you can be
sure she is able to do it safely and correctly.
Some mothers may be stigmatized for using artificial feedings,
and some families cannot afford the additional costs for fuel, equip-
ment, and supplies.  HIV-infected women who breastfeed must be
treated promptly for breast infections and cracked or bleeding nipples
because these might increase the baby’s risk of acquiring HIV infec-
tion.  For the same reason, quickly treat an infant that has thrush,
ulcerations, or other problems of the mouth.64  An HIV-infected
woman who breastfeeds may possibly reduce the child’s risk of HIV by
stopping breastfeeding when the infant is a few months old.15
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INFANT OUTCOMES
Most HIV-infected babies become ill within the first year of
life.50 Others will not show symptoms for a year or more. The baby
with HIV may not gain weight normally or may have repeated bouts
of pneumonia, bacterial infections, diarrhea, severe oral candidiasis,
and other illnesses. In African countries, the death rate is 21% to 37%
for infants born to HIV-infected mothers versus 2% to 4% for infants
born to uninfected mothers.33 Infected infants who survive their first
year are likely to die at a young age and rarely live to age 12.
The HIV-infected woman considering pregnancy will need to
choose another guardian for the child when she becomes too ill to care
for it. The World Health Organization (WHO) estimates that, since
the beginning of the epidemic, nine million children under age 15
have lost their mothers to AIDS. Of these maternal orphans, 90%
have been in sub-Saharan Africa.63 
HIV PREVENTION EDUCATION
Reproductive health care workers are critical agents for HIV preven-
tion, especially where the prevalence of HIV infection is high. Your
patients may not be aware of the routes of transmission of HIV or
how they can protect themselves. Every patient should have some
skill-building on HIV prevention. Ask each patient, "What do you do
to protect yourself from AIDS?"25 Your female patients must under-
stand that protecting themselves is the only way to protect their
unborn children.
Many reproductive health care patients are already infected with
HIV, and most of them are not aware of their infection. These clients
need to know how to protect uninfected partners and children. Indi-
vidual and collective human behavior are the key to HIV contain-
ment, and information is the first step to behavior change.
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HIV PREVENTION AND SEX
The only way to prevent death from AIDS is to avoid contracting
HIV infection.  Although vaccines against HIV are being developed, as
of the late 1990s, none have been proven effective in humans. Preven-
tion of sexual transmission of HIV is difficult, complex, and requires
accurate information, decisions by the patient and partner, and many
changes in behavior that may not be easy to master or maintain. Pre-
vention messages to the client should remind her or him: “If you are
not infected now, you may still become infected.” The following mea-
sures will reduce a person’s risk of HIV infection (see Table 5:4):
• Mutual monogamy with an uninfected partner
• Abstinence from sex
• Avoidance of alcohol or drug use in situations where they
will make a person more likely to have unprotected sex 
• Correct use of condoms and water-based lubricants during
sex (anal, oral, or vaginal) with anyone who has HIV or
whose HIV status is unknown
Even though STIs and HIV have been associated with having
multiple sex partners, advice to limit the number of partners becomes
less important as the prevalence of HIV climbs. For example, in
Kigali, Rwanda, the HIV prevalence among women who had only one
lifetime sex partner was more than 20%.2 Their male partners had
become infected during previous or extramarital sexual relationships,
and the women's risk was directly related to their partners' sexual
behavior rather than to their own behavior. It does not take many sex-
ual partners to be exposed to HIV when the overall prevalence is
greater than 30%, as it was in Kigali. 
In the Kigali study,2 some individuals were fearful of condoms
because they mistakenly believed that condoms could cause sterility or
illness in women. This study also found that condom use among cou-
ples increased when the male partner came in for HIV testing and
counseling.  Male partners who refused HIV testing were least likely
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to use condoms, and the rate of HIV seroconversion among their
female partners was twice that of the group in which the men were
tested and counseled. Thus, men should be targeted for education to
reduce HIV infection in their wives, sex partners, and children.2







Hand-to-genital masturbation or mutual masturbation
All sexual activities, when both partners are monogamous and known, by testing, 
to be uninfected with HIV
Possibly safe
Wet kiss with no broken skin, cracked lips, or damaged mouth tissue
Vaginal or rectal intercourse with latex or synthetic condom used correctly
Oral sex on a man using a latex or synthetic condom
Oral sex on a woman using a latex or synthetic barrier such as flexible plastic wrap 
or a modified male condom (cut open and spread over vulva), especially if she 
is not menstruating or having a vaginal infection with discharge
All sexual activities, when both partners are in a long-term, monogamous 
relationship and trust each other
Unsafe in the absence of HIV testing and mutual monogamy
Any vaginal or rectal intercourse without a latex or synthetic condom
Oral sex on a man without a latex or synthetic condom
Oral sex on a woman without a barrier, especially if she is menstruating or has 
vaginal infection or discharge
Semen in the mouth
Oral-anal contact
Blood contact of any kind, including menstrual blood, or sex that causes tissue 
damage or bleeding
Adapted from Hatcher, et al. (1994)
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An uninfected woman considering sex with a man of unknown
HIV status must consider the possibility that he is HIV-infected and
realize that she can choose safer activities to reduce risk to her and her
future children. These alternatives must be discussed before they pre-
pare for sexual activity. Likewise, an HIV-infected woman considering
sex with a man of unknown HIV status must consider that he may be
uninfected and talk with him about measures they can take to protect
him from infection. To protect their wives and future children, men
who know that they are uninfected need to take steps to stay that way.
Men who are already infected with HIV must act to keep uninfected
sexual partners from contracting the virus.
Women who are interested in protecting themselves from HIV
are often doubtful that their sex partners will agree to safer sex mea-
sures. Women often say that their main reason for not using condoms
is that the man refuses or does not like them. Because women are fre-
quently economically dependent upon their partners, they feel that if
they become demanding about such a difficult subject, the man may
retaliate or leave. The health care worker may suggest that a woman in
such a position come in with her partner for HIV prevention counsel-
ing or even HIV testing. Remind your patient that a man who refuses
to use condoms with her may be more likely to refuse to use them
with his other partners as well, thereby posing a higher risk to all his
partners. 
Women who are least able to negotiate with their partners for
safer sex tend to be younger and disadvantaged by poverty, war, lack of
education, and poor job opportunity. Young girls are sometimes forc-
ibly seduced by older men, or men who may give them gifts or
money.4 Unmarried or divorced women may set up arrangements with
one or more men to provide sexual services in exchange for material
support. These partnerships may not be stable, and the man often has
other sexual partners as well. Women who are unable to find work
sometimes sell sexual encounters to feed themselves and their children.
Some of  these situations are not considered prostitution, but they are
still very risky for the women.7  Keep in mind too that women and
girls are sometimes raped, a practice that may dramatically increase
during war and civil unrest.
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The vulnerability that stems from poverty and limited job oppor-
tunities often means that women do things that they would rather
not. A few organizations help women gain property rights, improve
their education, receive job training, or get business loans. Learn if any
such organizations are in your area so that you can refer women in
need of such assistance. Encourage your patients who want out of a
risky situation to create a workable plan to do so. Most important,
respect a patient's autonomy, even if you do not personally agree with
her choices.
Teaching your client the facts about HIV is an essential step, but
knowledge alone will not reduce risk. Most people do not absorb this
information and translate it into action after hearing it only once. It
takes many small steps to action. When a client returns after an educa-
tional or counseling visit:
• Applaud any behavior steps in the direction of safety.
• Be sure that you teach in a way the patient can understand.
• Listen and try to understand the client’s questions and con-
cerns.
• Allow the client to determine what steps to take toward
reducing HIV risk and protecting her or his family.
• Offer to teach or refer the client's partner, if the  partner is
unwilling to accept information from your client.
If your client does bring in a sex partner, either or both of them
may want an HIV test. They may choose to take other types of pre-
cautions, such as using condoms. He may elect to cease extramarital
relationships or use of commercial sex workers. Each step toward safer
living must be supported.
PREVENTION AND BLOOD TRANSFUSIONS
Blood donors have differing HIV prevalence rates, depending on
their country and region. Volunteer donors are less likely to be
infected than paid donors.8 In Uganda, donors recruited by family
members were more than twice as likely to test HIV-positive than vol-
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unteer donors recruited by the national blood center.61 All donated
units should be tested by a sensitive HIV screening test and positive
units discarded. If confirmatory testing is available, the donor should
be counseled about his or her HIV-positive status and advised never to
donate blood, semen, or tissue. (See the section on HIV test counsel-
ing, this chapter.)  One blood collection center in Zimbabwe defers all
donors with a history of genital ulcer or STI. This step reduces the
number of HIV-infected blood units which must be discarded,
thereby saving money,39 and lessens the chance that the collected blood
will test negative for HIV during the "window period" (described
below), even though the infection can be passed on to the recipient.
THE HIV TEST
TEST METHODOLOGY
Standard HIV testing does not detect HIV directly. Instead, it
detects the antibody to HIV produced by the infected person's
immune system. It is like seeing an elephant's footprints—even
though you don't see the elephant, you can see that he's been there.
This antibody can be detected in blood, or with some of the newer
tests, in saliva or urine. 
Because a delay occurs between infection and antibody produc-
tion, the HIV test is not helpful immediately after exposure to the
virus. Most people take 6 weeks to 6 months to show a positive test after
HIV infection has taken place. During this window period, the HIV
antibody test will be negative, even if the person is infected and is
capable of infecting others. After an infected person has produced
enough antibody to be detected on the HIV test, future HIV tests will
be positive.
If the HIV screening test is negative, the person is considered
uninfected, assuming that the window period has already passed.  A
negative confirmatory test is not needed. A positive screening test is
generally confirmed with a more specific test, however, because of the
high rate of false-positive screening tests. Some fairly simple confirma-
tory tests are available.11 Different combinations of rapid screening
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and confirmatory tests are being used for areas with limited resources,
which helps to reduce costs and technical demands. All HIV testing is
subject to error, and laboratory workers with less experience have
higher rates of false results. Be familiar with the testing procedure and
speak with the laboratory personnel who perform the test to under-
stand the screening accuracy in your area.
SCREENING TEST LIMITATIONS
If the only available test on-site is a single screening test, advise
your client that a negative result can be relied on unless he or she is in
the window period.  If the screening test is negative, the post-test
counseling for negative tests should be used. If the screening test is
positive, the patient must be advised that the first part of the HIV test
was positive, then referred to a location that can perform a confirma-
tory test.  Because this patient is likely to be infected, advise safer sex
precautions until the confirmatory test is completed. If the confirma-
tory test is negative, the post-test counseling for a negative test is used
at this time. If the confirmatory test is positive, the post-test counsel-
ing for positive results is used.
TESTING INFANTS
Up to the age of about 15 months, the infant carries the mother's
HIV antibody. Therefore, testing a newborn with the standard HIV
antibody test will actually test the mother. After the age of 15 months,
the maternal antibodies are cleared from the child's blood, and the
child can be tested to determine its HIV status.33  It is very important
that HIV-infected infants and children, who are especially vulnerable
to infection, receive immunizations (see Table 5:5).
In some research centers, tests that directly detect HIV can be
performed on infants as young as 6 months. Because it is possible that
an uninfected baby will become infected later through breastfeeding,
such tests are more useful in situations where artificial feedings can be
safely used. The tests are also relatively expensive and technologically
impractical for widespread use at this time.
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Table 5:5 Immunizations recommended for children with HIV 
infection
Vaccine Recommendation
Measles vaccine Children with known or suspected HIV 
should receive measles vaccine at 6 and 9 
months, because of their risk of severe 
measles.
Diphtheria-tetanus-pertussis vaccine Administer the same dose and schedule as 
for immunocompetent children.
BCG BCG is not recommended for children 
with symptomatic HIV.  In regions where 
the risk of TB infection is high, it should 
be given to asymptomatic children.  BCG 
is not recommended for adults.
Oral polio vaccine (OPV)*
Enhanced inactivated polio vaccine
(IPV)
Children with AIDS should receive IPV.  
Asymptomatic children may be given 
OPV on the usual schedule.
Yellow fever May be given to asymptomatic children, 
but not to those with symptoms.
Pneumococcal vaccine Administer to HIV-infected children at 
2 years of age.
Hepatititis B vaccine Administer the same dosage and schedule 
as for immunocompetent children.
Live vaccines (e.g., typhoid, varicella 
zoster, and vaccinia)
Live vaccines are not generally 
recommended for people with HIV.
NOTE:  In urban areas, children may also be given Pneumococcal vaccine at age 2, and an annual influ-
enza vaccine each year starting at age 6 months.  Adults with HIV also may benefit from these immuniza-
tions if they are available.
*If OPV is given to a person, close contact between the OPV recipient and the immunocompromised 
infant should be avoided for approximately 1 month after the vaccination.  OPV has not been harmful 
when administered to asymptomatic HIV-infected children, but some immunocompromised children 
may be unable to limit the vaccine virus’ replication, which can result in severe, progressive neurologic 
involvement.
Source:  WHO (1998) and Scarlatti (1996)
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HIV COUNSELING
HIV counseling is a unique opportunity to learn about the patients'
needs, risks, and understanding about HIV and AIDS.  The counselor
can correct misinformation and help the patient reduce the risk of get-
ting HIV if the client is HIV-negative, or the risk of giving it to others
if the client is HIV-positive. Your patient may have received inaccurate
or incomplete information from friends and family. He or she may
have heard about HIV and AIDS from other sources, such as pam-
phlets, posters, and mass media campaigns, but may not have changed
his or her behavior. Sometimes a person will mistakenly change behav-
ior in ways that do not actually reduce risk, for example, by taking
only younger sexual partners, or by selecting partners who "look
healthy." 
The health care worker can use this time to emphasize facts and
to teach patients how to effectively reduce the risk of HIV and AIDS
for themselves and their families. The two-way conversation with the
health care worker not only helps to highlight actual risks for that
patient, but also gives the client a chance to ask those questions that
are personally important to him or her.  Counseling may include refer-
ring the patient to support groups, post-test clubs, and other services
that improve the patient's and family's well-being.
PRE-TEST COUNSELING
Counseling before the HIV test must be a complete and thor-
ough review of facts. The client cannot be expected to absorb much
information at the post-test counseling session because of emotional
reactions to the test results. All important information must be given
before HIV testing, and 15 to 30 minutes should be allotted for this
session. It is usually impractical for the primary care provider to spend
this much time with a patient; other workers—counselors, assistants,
or even volunteers—can be taught to perform this important task.
The first component of pre-test counseling is a basic explanation
of what the HIV test is, including test limitations. For example, if the
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patient is in an ongoing sexual relationship with someone suspected to
have HIV, the test will need to be repeated 6 months after the last
unprotected sexual contact with that person. If the patient was
recently transfused, it is best to wait 6 months before HIV testing to
avoid the window period, when the test may be negative despite actual
infection. Pre-test counseling also is used to ascertain that the client's
consent to be HIV-tested is an informed and voluntary one. 
The client must understand that the test detects antibody to
HIV, the virus that causes AIDS. Even if the HIV test is positive, the
client may be healthy for months or years. The health care worker
should advise on the possibility of a false positive or false negative test.
This possibility depends on the types of HIV tests available and the
expertise of the laboratory personnel performing them.
PRE-TEST DISCUSSION OUTLINE
1. Explain that the virus is in the semen, vaginal, and cervical secre-
tions, and blood of infected people. Review the routes of HIV
transmission:
• Having sex (use language that the patient understands)
• Receiving an infected blood transfusion
• Giving birth (the infant is at risk)
• Breastfeeding (the infant is at risk)
• Re-using blood-contaminated injection equipment
2. Your client also must understand ways the virus is not transmitted:






• Sharing dishes or eating together
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3. Discuss measures that the client can take to avoid exposing sex
partner(s) to HIV, in case she or he is infected:
• Devise a plan for informing partner(s) that she or he is tak-
ing the test and why they will be using condoms or other
precautions
• Rehearse what the client will say to the partner
• Allow the client to bring in the partner so that the client can
talk to the partner in the presence of the counselor and ques-
tions can be answered
• Set up a time to counsel and offer to test the partner for HIV,
if that is desired by the client
4. Review confidentiality of the test with the client:
• Who will receive the lab result
• Whether the result will be reported to the local health
authority or the government
• Where the test result will be stored, and who will have access
to it
• How and when the client will receive the result (if a couple
wants to receive their results together, they should consent
separately to do so)
5. Legal ramifications of the test vary from country to country, and
sometimes from state to state. The counselor must know the
local regulations that apply to HIV test results and people with
HIV infection and be able to discuss them with clients.
6. Set up an appointment for the client to return for test results:
• Allow enough time for both the screening and confirmatory
tests to be completed before the return date.
• Help the client cope with anxiety while waiting for the test
results.
• Assist in developing specific plans about who the clients can
talk with, post-test clubs that may be available to them, and
any local resources, including the possibility of a return visit
to the counselor.
Often, the client may not be entirely comfortable with a frank
discussion of sexual practices. Health care workers, too, must work to
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overcome their own discomfort with discussing sexual matters openly,
because understanding is essential for preventing transmission of this
deadly virus. HIV is commonly a topic of much misunderstanding
and unfounded fears. Occasionally, people are more afraid that they
will get HIV from sharing a meal than from sexual activity. Pre-test
counseling is an excellent time to dispel such mistaken notions.
POST-TEST COUNSELING
Positive HIV Test Result
Greet the client and seat him or her in a quiet, private place. Be
sure you have adequate time to deal with the emotional reactions that
may occur. Gently explain that the results were positive, meaning that
he or she is HIV-infected, but may not develop AIDS for some time
(if the patient has not already developed AIDS). Allow the client to
react and ask questions, keeping in mind that a wide range of expres-







Often, people ask for specific predictions about their survival and 
how long they can expect to be healthy. Help your patient understand
that the future is dependent on many factors, most of which are
unknown at this time. 
• You can transmit HIV to others through unprotected sex or
by donating blood to them. Women can pass it on to unborn
children or through breastfeeding infants.
• You may have contracted the virus from a current or a past
sex partner or through receiving a blood transfusion. You
may or may not already have transmitted it to a more recent
partner. 
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• Stay as healthy as possible to try and slow the onset of symp-
toms and progression of disease:
— Avoid unprotected sex to prevent STIs.
— Get a tuberculosis skin test and follow recommendations
for prevention.
— Eat nutritious foods.
— Get adequate exercise.
— Get enough rest and sleep.
— Try to stop smoking.
— Obtain recommended immunizations (see Table 5:5).
— Reduce or stop alcohol and other drug use.
• If area support groups exist, give them a try.
• Be sure you have adequate condom supplies if you have a sex
partner or partners.
• Know how to use condoms and use them correctly, every time. 
• It may make it easier to practice safer sex in your relationship
if your partner comes in for testing and counseling as well.
• Remember that drinking alcohol or using mood-altering
drugs may cloud judgment, and increase likelihood of unsafe
sexual behavior.
• Learn sources of good treatment. Unscrupulous people in
every country prey on the hopes and fears of people with
HIV and AIDS, promising miracle cures in exchange for
large sums of money. Such predators can bankrupt entire
families with their lies.
Negative HIV Test Result
Greet the client and seat her or him in a quiet location. Explain
that the results were negative, which could mean several things:
• The client may not have been exposed to HIV.
• The client may not have been infected when he or she was
exposed to the virus. This may not be the case next time the
client is exposed. 
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• The client may have become infected very recently. If he or
she was infected less than six months ago, the test may not
yet show the infection.
Discuss with the client how to avoid HIV infection in the future
(see Table 5:4):
• Abstinence
• Mutually monogamous sex with an uninfected partner
• Use of condoms and water-based lubricant during sex (anal,
oral, or vaginal) with anyone of unknown HIV status
• Avoid alcohol or drug use, especially in situations that may
make you more likely to have unprotected sex
SAFETY FOR THE HEALTH CARE WORKER
In many medical settings, a small risk of HIV transmission from a
patient to a health care worker exists because of invasive examinations
and procedures. These procedures may bring the health care worker into
contact with infectious materials such as blood or amniotic fluid, which
may then be accidentally introduced into the body of the health care
worker.  Blood is the single most important source of HIV in health care set-
tings.  Blood or bloody fluid has been implicated in every documented
transmission of HIV to health care workers in clinical settings to date.
Other body fluids have been found to contain HIV, but so far have not
been implicated in work-related HIV infections (see Table 5-6).
Because of the seriousness of HIV and other blood-borne infec-
tions, precautions must be taken to decrease the health care worker's
chances of exposure. All patients must be treated cautiously, as if any
one of them may have potentially serious infections. The practice of
treating all patients as potentially infectious is known as universal pre-
cautions, and includes:
• Wearing waterproof gloves (rubber, latex, or vinyl) to clean
infectious spills
• Using disinfectant solutions to clean infectious spills
• Handling sharp instruments carefully until they have been
sterilized
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• Using waterproof gloves for pelvic and genital exams
• Using gloves for any procedures that may involve contact
with or potential spilling or splashing of potentially infec-
tious bodily fluids
• Educating health care workers about the risk of HIV and
hepatitis B, how they are transmitted, and how to avoid
them in the health care setting
Accidental HIV exposures most often occur when blood-contam-
inated sharp instruments, such as needles or scalpels, break the skin of
the health care worker. Rarely, infectious materials enter the body of
the health care worker through open lesions, broken skin, or mucous
membranes (eyes, mouth, nose).  Because there is no easy way to tell
who is HIV-infected and who is not, it is important to guard against
injury with contaminated instruments or splashes by infectious body
fluids with all patients. Analyze each work setting and each procedure
for specific potential risks, and take action to reduce those risks.
Table 5:6 Potentially HIV-infectious versus non-HIV-infectious 










Any secretion visibly contaminated with blood Vomit
Breast milk†
*Unless visibly contaminated with blood.
†Because HIV has been found in small quantities in some breast milk and is implicated as a route for 
transmission to nursing infants, gloves may be worn by workers in situations with exposure to large vol-
umes of breast milk.
Source: Centers for Disease Control (1988)
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The risk of contracting HIV, even with injury, is extremely small.
U.S. data show that, after a puncture wound with a hollow-bore injec-
tion needle or sharp instrument which was contaminated with blood
from an HIV-infected patient, the HIV seroconversion rate averages
0.3%.21 The risk appears to be smaller for splashes on mucous mem-
branes or broken skin. 
A 1995 case-control study of European and U.S. workers showed
variable levels of HIV risk from different kinds of workplace expo-
sures.57 Groups of health care workers who had become infected with
HIV from exposures at work were compared to those who had
reported work-related exposure to HIV but had not become infected.
The researchers sought to determine which factors were associated
with increased risk of work-related HIV infection. All of the workers
who acquired HIV infection had been exposed to the blood of an
HIV-infected person. Almost all (94%) had a needlestick injury with a
hollow-bore (injection) needle previously used on an HIV-infected
patient; the rest had sustained punctures or lacerations with other
sharp objects such as lancets or scalpels. Many more workers with
deep punctures or wounds were in the group who actually contracted
HIV infection. Other high-risk conditions were terminal illness (end-
stage AIDS) in the source patient, puncture with a visibly bloody
device, or injury with a needle that had been placed directly in the
vein or artery of the source patient.
This same study showed that workers who did not seroconvert
were more likely to have taken zidovudine after the exposure. In 1996,
because of this apparently protective effect, the U.S. Public Health
Service recommended that workers reporting a parenteral exposure to
HIV-contaminated blood be offered a 4-week course of antiretroviral
medications, called post-exposure prophylaxis, in an attempt to abort
HIV infection.58 These recommendations were based on a small study,
however, and not everyone who took antiretroviral drugs avoided HIV
infection. Potential candidates for this prophylaxis must be apprised of
this and the potential for side effects and toxicity of the drug(s) to be
used.
Post-exposure prophylaxis, if used, is best started within 1 to 2
hours of the HIV exposure, but no later than 72 hours after exposure.
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Even without antiretrovirals, 99.7% of workers exposed to HIV-con-
taminated needlesticks would be expected to remain uninfected.21
Toxicity, expense, refusal by the health care worker, low risk of sero-
conversion, and lack of drug availability are common reasons for not
using post-exposure prophylaxis.
If a health care worker has an HIV exposure by injury with a
contaminated needle or instrument or by contact of potentially infec-
tious fluid (see Table 5:6) with broken skin or mucous membranes,
the following steps must be taken as soon as possible:
• Immediately wash the area thoroughly with plenty of soap
and water. In the case of eye or mucous membrane splashes,
rinse with large amounts of water.
• Apply disinfectant to broken skin after cleansing.
• Report the injury to a supervisor.
• If the source patient is known, see if it is possible to find out
if the patient has HIV.
• If the source patient is unknown or is known to be HIV-
infected, proceed with HIV testing of the health care worker.
• Request an HIV test on the health care worker as soon as
possible, preferably within 24 hours, but certainly within 1
or 2 weeks.
• Repeat HIV testing 6 months and 12 months after the injury
to determine if HIV seroconversion took place. If the worker
has used safer sex measures and had no blood transfusion
during the year and still seroconverted to a positive HIV test,
it is assumed that he or she contracted HIV from the work-
place exposure. 
The initial HIV test is a baseline test, which takes advantage of
the delay between exposure and conversion, or the window period. Its
purpose is to determine if the worker already was HIV-infected at the
time of the exposure. If the worker is positive at this time, the HIV
infection is not related to the proximate injury. The employee must
also be counseled pre- and post-test, much as a patient would be. (See
the sections on Pre- and Post-Test Counseling, this chapter.)  Advise
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the worker to use barriers and practice safer sex with partner(s) until
he or she completes the follow-up HIV tests.
These guidelines will help prevent many occurrences of occupa-
tional (work-related) HIV transmission and track those that occur. It
is easy for health care workers to over-estimate their risk of becoming
infected with HIV at work while downplaying risk from off-the-job
activities. Most health care workers contract HIV by the same routes
others do.12 It is important for those in health care to be aware of all
risks and to make adjustments to reduce them if possible.
Theresa and her two children lived quietly with her mother, 
helping with the house and farm. She was afraid to tell her fam-
ily what had killed her husband, and every day she wondered if
she was infected. She refused all offers of courtship, because she
knew that if she carried HIV, she could give it to the man she
loved. After nearly a year, she found out that a clinic where her
aunt lived could test for the virus. She left her children with her
mother and took a little money she had saved, saying only that
she was going to visit her aunt. She had to wait several days for
the test, and more for the result, but she felt very lucky when she
found she was not infected. She went back to her mother's vil-
lage and decided that, before she considered remarrying, she
would find a way to avoid exposing herself, and her future chil-
dren, to such a risk again.
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"How long have you had this discharge?" asked the nurse. “A few
weeks” was the answer. "Does your husband have a discharge?"
The answer was “no,” but the patient added that her husband
was frequently away from home on business. Out in this rural
clinic, the nurse did not have diagnostic equipment. She
checked the algorithm for discharge and other complaints. The
woman's symptoms and risks were suspicious of a sexually trans-
mitted infection. She was treated with spectinomycin.
 
Sexually transmitted infections (STIs) are a major public health prob-





 Like diarrheal disease, malaria, measles,
malnutrition, and tuberculosis, STIs are costly to society and result in





 STIs can lead to severe health consequences, especially in
women and children.
 
34,37 In addition, STIs facilitate the transmission




  Sequelae of STI include
chronic pain, infertility, ectopic pregnancy, and genital cancers in
adults and severe illness or death in newborns. Long-term conse-
quences of STIs are evident when examining patterns of infertility in
Africa.  An estimated 85% of infertile African women have diagnoses






























 In parts of sub-
Saharan Africa, where STI prevalence is high, as many as 30% to 50%




Because most women attending family planning centers are at
risk for both pregnancy and STIs, family planning clinicians can serve






Often, the family planning
clinic is the only health care provider routinely seen by clients at risk
for STI. Thus, family planning clinicians must be able to diagnose and
treat STIs in their clients. The World Health Organization (WHO)
has distilled practical considerations in case management for STI con-




• Educate persons at risk on the modes of disease transmission
and the means of reducing the risk of transmission.
• Detect infection in asymptomatic persons and in persons
who are symptomatic but unlikely to seek diagnostic and
therapeutic services.
• Effectively manage persons who are infected.
• Treat and educate sex partners of persons with an STI.
In this chapter, we provide general background about STI man-
agement in the family planning setting and review current approaches
to diagnosing and treating the most common STIs.
 
OVERVIEW OF SEXUALLY TRANSMITTED INFECTIONS
 
The term "sexually transmitted infection" has gradually replaced the
term "venereal disease."  This shift in terminology recognizes both an
expanded awareness of infectious disease transmitted through sexual
contact, as well as an expanded array of diseases. Today, more than 20







usually transmitted during unprotected sexual intercourse with an
infected partner. This includes vaginal, anal, and oral intercourse.
 
30
STIs can also be transmitted from the mother to the fetus during preg-


















STIs are caused by bacterial, parasitic, or viral pathogens. Some of














, hepatitis B virus
(HBV), and human immunodeficiency virus (HIV).  There are also a
variety of syndromes associated with STIs. Some of these syndromes,
such as pelvic inflammatory disease (PID), are actually complications of
STIs; some are caused by genital tract infections that are not transmit-
ted by sexual intercourse (such as bacterial vaginosis), but are associated
with it. The organisms, symptoms, diagnoses, and treatment regimens
for those STIs most common in Africa are listed in Table 6:1. 
















 are fully curable with anti-









HIV, cannot be cured, although their complications can usually be







Laboratory testing is preferred for diagnosis,
but most African health clinics do not have the resources to perform
serologic tests or cultures for STI. Consequently, microbial causes of
infection usually cannot be identified. As an alternative, clinicians in
Africa and throughout the world are diagnosing STIs presumptively
by clinical signs and symptoms of infection (such as genital ulcer, vag-
inal or urethral discharge, or pelvic pain) rather than microbial causes
of infection.  We have included a detailed discussion on "syndromic
management" of STIs later in this chapter. 
The acquired immunodeficiency syndrome (AIDS) warrants spe-
cial mention. AIDS is caused by HIV, which gradually destroys the
immune system, and the disease usually results in death. Although
AIDS is now pandemic, Africa has been most severely affected. An
estimated 13.3 million adults and more than a half million children in






Most (80% to 95%) cases of HIV
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TRENDS OF SEXUALLY TRANSMITTED INFECTIONS 
At least 333 million new cases of curable STIs occurred worldwide in
1995. There were 170 million new cases of trichomoniasis, 89 million
of chlamydia, 62 million of gonorrhea, and 12 million of syphilis.38
Because routine surveillance for STIs is rarely conducted in
Africa, little is known about the epidemiology of STIs on the conti-
nent. Most data on STIs originate from small studies of selected popu-
lations, typically asymptomatic pregnant women.11,30 These studies
indicate that STI rates are high in most parts of Africa. For example:
• In a review of several studies of family planning and prenatal
clinic attendees, each of three STIs—gonorrhea, chlamydia,
and syphilis—infected, on average, 10% of persons tested.37
• In a hospital-based study in Nairobi, Kenya, nearly one in
four adolescent women attending a prenatal clinic was diag-
nosed with gonorrhea, chlamydia, or herpes.22 
• In a study of prenatal clinic attendees in Cameroon, 15% of
women were diagnosed with gonorrhea, and 21% were diag-
nosed with trichomoniasis.27
• In a Mozambique study, as many as 10% to 15% of primary
health care clinic visits were for treatment of STIs.1
Overall STI rates are believed to be highest in sub-Saharan Africa
and lowest in North Africa. STIs are also common in areas of Central
and East Africa. Rates of STI are moderate in most areas of West
Africa but high in Cote d'Ivoire. Patterns of transmission may vary
widely across the continent.31 
Gonorrhea is probably the most common bacterial STI in
Africa.21,31 Rates of chlamydia infection are likely to be comparable to
rates of gonorrhea, but little is known about the prevalence and inci-
dence of chlamydia.4 Chancroid is increasingly common among com-
mercial sex workers in Africa and is important because of its apparent
ability to facilitate HIV infection.11 Although less common than chan-
croid in most areas, syphilis may cause severe reproductive health
problems.4  Ulcerative STIs caused by genital herpes, chancroid,
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donovanosis, and lymphogranuloma venereum infections may
together account for nearly 50% of all diagnosed STIs in Africa.31
The same sexual behaviors may result in different STIs in various
areas of Africa, depending on which infection is most prevalent.23 For
example, the prevalence of genital ulcer disease is high in many parts
of East, Central, and Southern Africa.28 In East Africa, 50% to 70% of
genital ulcers are due to chancroid.32 Similarly, in sub-Saharan Africa,
the majority of genital ulcer disease is caused by chancroid.11,21 How-
ever, in West Africa, genital ulcers are much less common and are usu-
ally caused by genital herpes or syphilis, not chancroid.21 When
symptoms and signs may be due to any of several STIs, a presumptive
diagnosis can often be based on the local epidemiologic profile of
STIs. For example, if a patient's symptoms and signs are indistinguish-
able between syphilis and chancroid, and treatment for both infections
is not feasible, the clinician may treat for the more prevalent STI and
provide adequate follow-up to verify cure.20
COMPLICATIONS OF SEXUALLY TRANSMITTED 
INFECTIONS
Complications from STIs are more severe and more common among
women than men:
Pelvic inflammatory disease is a potentially life-threatening con-
dition that results from complications of N. gonorrhoea and C. tra-
chomatis infections. PID increases the risk of tubal infertility, ectopic
pregnancy, and chronic abdominal pain.11 In many African hospitals,
PID is the most frequent reason for admission to gynecological wards,
accounting for up to 40% of admissions.25  
Tubal infertility is associated with PID and results from inflam-
mation and scarring of the fallopian tubes following ascent of infec-
tion into the upper reproductive tract.36 Tubal occlusion prevents the
egg from passing through the fallopian tubes. Nearly 75% of infertility
in Africa is related to gonorrhea or chlamydia infections that have
extended into the upper reproductive tract.4,7 
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Ectopic (tubal) pregnancy is a potentially fatal condition that
results when a fertilized egg implants outside the uterus, usually in the
fallopian tubes. Ectopic pregnancy occurs when an ascending infec-
tion in the reproductive tract partially blocks tubal passages. In one
Kenyan hospital, ectopic pregnancy was the most common reason for
emergency surgical admission.37 
Genital cancers are potentially fatal diseases that have been asso-
ciated with STIs. HPV, which causes genital warts, is associated with
the development of cervical neoplasia.33,37 
Chronic pain may be experienced by patients with STIs such as
genital herpes and PID, which may cause persistent or episodic genital
or abdominal pain. 
FACTORS AFFECTING RISK
Family planning professionals should be aware of factors that affect
the risk of transmitting or acquiring STIs.
• The risk for STIs differs from the risk for unintended preg-
nancy during sexual intercourse. The risk of pregnancy per act
of intercourse ranges from 0% to 20%, varying with menstrual
cycle stage. The risk of STI transmission exists during any act of
unprotected intercourse with an infected partner. The exact risk
per coital episode depends on the transmissibility of the particu-
lar STI and the sex of the infected person. For example, the risk
of acquiring gonorrhea from a single act of intercourse with an
infected partner is approximately 25% for men and 50% for
women.6
• STIs cause more severe, long-term complications in women
than in men. The increased severity of complications from STIs
among women results from several factors. First, asymptomatic
infection is much more common in women than in men, result-
ing in delayed diagnosis and treatment at more advanced stages
of disease. Additionally, the diagnosis of STIs is more difficult
because of physiological differences. When present, infection is
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more likely to ascend into the reproductive tract of women than
of men. Finally, the fluid dynamics of intercourse make STIs
more easily transmitted to women from a single sexual encounter.
• STIs facilitate the transmission of HIV. An interactive relation-
ship exists between STIs and the sexual transmission or acquisi-
tion of HIV.36 Ulcerative STIs (such as chancroid, syphilis, and
genital herpes) may facilitate HIV transmission by acting as a
port of entry for infection.4,31,33 The high prevalence of ulcerative
STIs may partially explain corresponding high rates of HIV
transmission, especially in sub-Saharan Africa.24 One Kenyan
study estimated that 75% to 98% of HIV infections were attrib-
utable to genital ulcer disease.14 Non-ulcerative STIs (such as
chlamydia, gonorrhea, and trichomoniasis) also may facilitate
HIV transmission by increasing the number of target cells that
can be infected.
In addition, the presence of HIV affects the natural history
of many STIs and their response to antimicrobial therapy.31,37
The immune dysfunction caused by HIV may make ulcerative
symptoms more persistent and more invasive by affecting the
clinical course of infection. In Kenya, the failure rate of single-
dose therapy for chancroid increased following a rapid rise in
concurrent HIV infection.34 HIV immunosuppression may also
increase the severity of other viral infections such as HSV-2,
HBV, and HPV.4,31 
Concurrent HIV infection should be considered among cli-
ents with STIs. Similarly, clients with HIV infection should be
evaluated for other STIs. In Tanzania, community-based pro-
grams emphasizing syndromic treatment of STIs resulted in a
significant decrease in HIV incidence.12
• The type of sexual activity affects the risk of acquiring STIs.
Some types of sexual activity may increase exposure to infectious
STI pathogens through irritation, inflammation, or tearing of
delicate mucosal surfaces. In some African cultures, women
insert drying agents and astringents such as leaves, herbs, and
powders into the vagina prior to intercourse. However, intravagi-
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nal drying substances may lead to inflammatory reactions or
abrasions of the vaginal surfaces and may facilitate STI and HIV
transmission.2 Other types of "dry sex," such as intercourse with
minimal or no foreplay, may pose similar risk. Additionally, anal
intercourse increases the risk of mucosal tearing. Couples should
use condoms during this activity.
• Certain population groups may be at increased risk for STI. In
general, rates of STI tend to be higher in men, residents of urban
areas, unmarried persons, and young adults.4 Certain subsets of
the population, such as commercial sex workers, their male cli-
ents, long-distance truck drivers, and members of the military
(and their sexual partners) often have the highest rates of STI
because they have a number of different sex partners.37 These
population groups are defined as "core transmitters" of infection
because their behaviors sustain continuing high levels of STI
within a community.3 The purpose of identifying core groups
with high rates of STI is to find ways to reach those with both
the greatest need for preventive services and the greatest tendency
to transmit STI to others.  
SEXUALLY TRANSMITTED INFECTIONS IN PREGNANCY
Transmission of STIs to the fetus may occur during pregnancy
through placental transfer or during birth through contact with STI
microorganisms. Many STI pathogens can be vertically transmitted to
the fetus, including T. pallidum, C. trachomatis, N. gonorrhoea, HBV,
HSV-2, HPV, and HIV. (See Table 6:2.)  Some of these microorgan-
isms can be fatal or severely debilitating to the fetus and result in spon-
taneous abortion, stillbirth, prematurity, low birthweight, and neo-
natal death, or cause severe illness such as pneumonia, meningitis,
blindness, or respiratory tract disease.5 (See Table 6:2.) One study
found that congenital syphilis was the fourth leading cause of perinatal
mortality in Ethiopia;26 another estimated that congenital syphilis was
responsible for 30% of perinatal deaths fruitin Zambia.15 In Kenya,
the risks of gonococcal ophthalmia and chlamydial ophthalmia for
infants born to infected mothers were estimated to be 42% and 37%,
respectively.34
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Worldwide, mother-to-infant transmission accounts for a high
percentage of HIV infections among children.9 Approximately 23% to
42% of infants born to HIV-infected mothers will develop HIV infec-
tion themselves.19 In Africa, vertical transmission of infection to new-
borns is important because so many women of reproductive age are
HIV-infected.31


























































































0.01-20 Pediatric AIDS 22-39% Pregnancy 
prevention
Zidovudine
1Percent of pregnant women with evidence of infection.
Source: Cates (1995)
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Because an STI may greatly harm a fetus, clinicians should rou-
tinely consider whether pregnant women may be infected with STIs
that may be harmful to the fetus, including syphilis, gonorrhea,
chlamydia, and HIV. Where available, prenatal screening for syphilis
has been shown to be cost effective for preventing reproductive mor-
bidity.16 Pregnant women with curable STIs should be treated. Drugs
that may harm the fetus, such as the tetracyclines, should be restricted;
however, metronidazole can be safely prescribed after the first 3
months of pregnancy. Additionally, the use of 1% silver nitrate solu-
tion or 1% tetracycline ointment dramatically reduces the transmis-
sion of gonococcal and chlamydial ophthalmia to the neonate.34
DIAGNOSIS AND TREATMENT
Diagnosing and treating STIs are often perceived to be too costly and
too advanced for many developing countries. Actually, the direct costs
associated with diagnosing and treating uncomplicated reproductive
tract infections are substantially lower than the costs of managing
complications from the infection.37 STI control has been shown to be
highly cost effective in many developing countries in terms of dollars
spent per number of healthy years of life saved.13
In Africa, it is usually not possible to diagnose the infecting
organism because most clinics lack the capacity, resources, training, or
laboratory support to comprehensively examine clients for STIs. Cul-
tures or other diagnostic tests are rarely available. Even when tests are
conducted, results may not be available for 1 to 7 days, requiring cli-
ents to return to the clinic to obtain test results and treatment.39 Even
if they are infected, some clients may be unable or unwilling to return
to the clinic because of financial and transportation barriers.
In the absence of laboratory tests, clinicians have begun manag-
ing STIs by using a syndromic approach—identifying groups of symp-
toms and signs of infection without laboratory tests and treating for all
possible infections with drugs of proven local efficacy. Syndromic
diagnosis can be implemented with minimal economic input and is
currently practiced in primary health centers in several countries,
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including Botswana, Nigeria, Tanzania, and Zimbabwe.20 In many
parts of East, Central, and Southern Africa, clinicians diagnose genital
ulcer disease without laboratory facilities and rapid diagnostic tests.28
 WHO has developed simplified guidelines for STI syndromic
management. (See Figures 6:1, 6:2, 6:3, and 6:4.) These flow charts
outline actions for managing symptoms and signs of genital ulcer, ure-
thral discharge, vaginal discharge, and lower abdominal pain in the cli-
ent. Because clients may present with two or more concurrent STDs
(e.g., coexisting gonorrhea and chlamydia), clinicians should treat cli-
ents for all the listed STIs that may possibly cause the indicated symp-
toms and signs. When possible, clinicians also should conduct a
genital examination to confirm signs before diagnosing STIs with the
algorithms.20 The algorithms are intended for use when no laboratory
is available:
Example 1:  A client reports the recent onset of a genital ulcer or
lesion with pain. The exam reveals a single, non-recurrent, open
sore in the patient's genital area. Without further information,
treat the patient for both syphilis and chancroid infections and
follow up appropriately.39 
Example 2:  A client complains of vaginal discharge. The
patient is determined to be at risk for STI under the WHO-rec-
ommended risk assessment. In the absence of diagnostic tests,
treat the patient for both cervicitis and vaginitis. (*At risk: the
patient has a symptomatic partner or meets any two of the fol-
lowing criteria: age under 21; single; more than 1 sex partner;
new sex partner in past 3 months.)39
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Figure 6:1a  Flow Chart for Urethral Discharge
Figure 6:1b  Flow Chart for Urethral Discharge with Microscope
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Figure 6:2  Flow Chart for Genital Ulcers
Source:  WHO, 1993
Figure 6:3  Flow Chart for Vaginal Discharge
*Positive = partner symptomatic or any two of the following: age  <21; single; 
>1 partner; new partner in past 3 months.
Source:  WHO, 1993
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Figure 6:4  Flow Chart for Lower Abdominal Pain
Source:  WHO, 1993
The availability, cost, and efficacy of antimicrobial therapies vary
widely within Africa. Many drugs are expensive. Furthermore, there
has been an increase in the number of strains resistant to standard
treatments, especially treatments for gonorrhea and chancroid
infections4,11,31 Consequently, WHO has recommended several possi-
ble treatment regimens for each STI. (See Table 6:1.)  Clinicians
should use the most effective treatment available to them. WHO rec-
ommends that drugs used for treatment of STIs in all health care facil-
ities should be at least 95% effective to reduce the risk of developing
resistant strains of infection.39 If WHO-recommended drugs are
unavailable, providers should use drugs recommended on their
National List of Essential Drugs or by their National Sexually Trans-




• Acceptable toxicity and tolerance
• Organism resistance is either unlikely to develop or will 
be delayed
NO
Missed or overdue period,








moving cervix), or vaginal
discharge
YES
• Treat for pelvic
inflammatory disease
• Provide condoms
• Educate for compliance
and risk reduction
• Notify partner
Follow up after 3 days




NO Follow up if pain persists
Not improving: refer Improving:  continue treatment
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• Single dose
• Oral administration
• Not contraindicated for pregnant or lactating women
Drugs should be prescribed in recommended doses to ensure full
cure and to prevent multiple drug resistance to infection. When possi-
ble, provide short-term or single-dose therapy instead of multi-dose
therapy. Doing so will eliminate the need for patient compliance and
minimize the chance that resistant strains will develop in the popula-
tion.  If limited resources prohibit you from treating all possible STIs,
treat for the STI most prevalent in the area. Also counsel clients on the
importance of preventing reinfection. In all listed algorithms (except
for vaginitis), sex partners should be treated for the same conditions as




• Education on risk reduction and prevention
• Promotion and provision of condoms
• Partner notification and treatment
• Clinical follow-up where appropriate
The accuracy and efficiency of syndromic management are being
evaluated. WHO reports indicate that syndromic management for
urethral discharge in men and genital ulcers in men and women is
valid, feasible, and cost effective.39 Symptomatic case management for
women with and without symptoms and signs of vaginal discharge is
being studied. Although less accurate than laboratory diagnosis, syn-
dromic management permits diagnosis and treatment of clients during
a single visit and requires minimal resources. Symptomatic clients may
be diagnosed and treated earlier. Early treatment decreases the dura-
tion of infectivity and reduces the likelihood of serious complications
from STIs. Unfortunately, many STIs are often subclinical—especially
in women—and cannot be detected without laboratory confirma-
tion.37 Clients without symptoms and signs of infection may be
missed by syndromic diagnosis. Conversely, presumptive treatment for
all possible STIs expends valuable resources through “over treatment.”
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Because patterns of disease, availability of resources, and levels of
drug resistance among STI pathogens may vary across clinics and
regions, the WHO algorithms should be viewed only as guidelines and
should be adapted to the needs of the population. The guidelines
should not replace clinical judgment. The algorithms in this chapter
have been developed specifically for clinics without laboratories,
microscopes, specula, etc. Clinics with laboratory capability should
consider using other algorithms. 
PARTNER NOTIFICATION
The timely referral and treatment of sex partners of infected clients
prevent both a reinfection of the original patient and a further spread
of STIs throughout the community. Outreach and community-based
workers can notify exposed sex partners, although this process is labor
intensive and often impractical. Educating the index patient to bring
her sex partner(s) to the clinic for evaluation is probably more cost
effective.13 In Ibadan, after a program was implemented to explain
symptoms and signs of STIs and modes of transmission, referral rates
among the sex partners of infected clients increased considerably.17
Equally important, referral of sex partners helps to identify per-
sons with an asymptomatic STI, who would not otherwise know they
are infected. Because men are more likely than women to be symp-
tomatic and to seek early treatment, notifying and treating their
exposed female partners is a useful way to identify women with an
asymptomatic STI.37 Family planning programs should coordinate
with STI programs to ensure that partners of infected clients are evalu-
ated and treated when infected.
INTEGRATING PREVENTION SERVICES
When STI-related services can be offered in the family planning
clinic, clients are not required to make separate visits to the STI clinic
or other primary health center for care.10,20 In addition, family plan-
ning programs that routinely screen for STIs can identify women with
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asymptomatic disease who may be at increased risk for complications
from infection.20 Family planning clinics lacking the resources to diag-
nose and treat women with STIs can refer clients to appropriate higher
level care. Thus, clinicians in family planning should be familiar with
their local STI program and primary care centers.
The family planning visit also provides an excellent opportunity
to educate clients about modes of STI transmission and prevention of
future infection. Ensure the client understands how to take any pre-
scribed medication for infection. Use language that the client under-
stands, and encourage the client to ask questions. Strategies employed
to reduce incident STIs, such as regular condom use, may also reduce
HIV infection. 
Services for diagnosis and treatment of STIs should be widely
available, highly accessible, and affordable. Some family planning
clinics have already extended their range of services to include evalua-
tion, diagnosis, treatment, and counseling for STIs. The Gambia Fam-
ily Planning Association, for example, treats women with candidiasis
and trichomoniasis infections but refers women with other STIs to
government clinics.20
SEXUALLY TRANSMITTED INFECTIONS AND 
CONTRACEPTION 
Family planning providers can minimize their clients' risk of STIs by
supplying them with contraceptives that protect against both preg-
nancy and infection and encouraging their use.8 Contraceptives vary
in the amount of protection they provide against STI pathogens. (See
Table 6:3.) Condoms are highly effective in protecting against both
bacterial and viral STIs, including HIV, and should be used for barrier
protection against STIs, regardless of whether other contraceptives are
also used. Vaginal spermicides such as films, gels, and suppositories,
when used alone, can help prevent infection with bacterial STIs such
as cervical gonorrhea and chlamydia, but their protective role against
HIV and other viral infections is uncertain. Other contraceptives,
such as the diaphragm, protect against cervical infections but provide
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insufficient protection from other STIs, such as HIV, that may infect
women through the vulva or the vagina. Hormonal contraceptives,
which provide the most protection against pregnancy, are associated
with reduced risks of symptomatic PID but offer no protection against
lower genital tract bacterial or viral STIs. Clinicians providing any
contraceptive method should counsel clients about STIs and infertility
and encourage condom use.
GUIDELINES FOR MANAGING PATIENTS
Family planning providers should consider the following guidelines
when managing clients with STIs.     
Table 6:3  Effects of contraceptives on bacterial and viral STIs
Contraceptive
Method Bacterial STI Viral STI
Condom Protective against all Protective
















Intrauterine device Associated with PID in first 
month after insertion
Not protective
Natural family planning Not protective Not protective
Source: Cates and Stone, 1992
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ASSESS FOR MULTIPLE STIS
Treat for all possible STIs that might cause the symptoms and
signs of infection. Coexisting infections are common, especially gon-
orrhea and chlamydia.39 Test for HIV infection among clients with
STIs when possible.
PRESCRIBE RECOMMENDED DRUGS AND DOSES
Although signs may appear to improve with lower doses of medi-
cation, the infection may not be completely cured and, in some cases,
will become resistant to treatment. Multiple resistance to antibiotics is
common for gonococcal and chancroid infections in many African
countries and often requires more difficult and expensive treat-
ment.11,31  In the case of drug resistant infection or other treatment
failure, prescribe an alternative recommended therapy and provide fol-
low-up. The increased cost of new, non-resistant drugs should be
weighed against the costs of inadequate therapy (such as reinfection,
complications from infection, further spread of infection within the
community, and multiple drug resistance).
COMPLETE ALL MEDICATION
Encourage clients to complete all prescribed medication, even if
symptoms subside. Occasionally, the symptoms may disappear with-
out treatment; however, their disappearance does not indicate cure—
more severe infection can follow. Discuss with the patient what disease
she or he has, how it is transmitted, why it must be treated, and when
and how to take prescribed medication. 
PREPARE CLIENTS FOR SIDE EFFECTS OF TREATMENT
Some drugs, such as erythromycin, may cause nausea. Recom-
mend the patient take the medication after meals to reduce nausea.
Again, stress the importance of completing the full dose of the medi-
cation for the prescribed length of time.
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TREAT SEX PARTNERS
Interrupting the chain of transmission is crucial to STI control.
For curable STIs, further transmission and reinfection can be pre-
vented by referral and treatment of sex partners. 
RECOMMEND ABSTINENCE DURING TREATMENT
Encourage clients to avoid sexual intercourse or to use condoms
until their medication is finished and their symptoms and signs of
infection have disappeared.
PROVIDE ENOUGH CONDOMS.
Provide condoms to all clients and counsel them on the impor-
tance of preventing reinfection and infertility, especially if a woman
wishes to bear children. Condom use will minimize contact with
infectious ulcers and discharges and will help to prevent HIV infec-
tion.
PROVIDE COUNSELING AND FOLLOW-UP TO CLIENTS
Advise clients to return to the clinic if symptoms do not subside.
Counsel clients to seek health care as soon as possible if they suspect
they may have an STI. Teach clients how to recognize symptoms of
infection, but emphasize that many STIs are asymptomatic, especially
in women.
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Children are the cloth of the body. 
Without children you are naked.  
 
—Yoruba Saying (Nigeria)
Fertility is important to all societies. The inability to have children has
traditionally been a source of pain, anxiety, and shame. The more
important children are to the fabric of a given culture, the more
important it is for couples to be fertile, and the worse the conse-
quences if a couple is infertile. Couples who are unable to bear as
many children as they wish may feel anguish or emotional pain. Sev-





     In most of Africa, a man's wealth is measured, in part, by the num-
ber of children he has. Children are important as farm workers and as
a source of support in old age for their parents. Male children also play
an important role in certain ethnic groups where, for example, a
grandchild is the only person who can replace his departed grandfa-
ther, particularly with respect to the practice of certain rituals. Simi-
larly, a wife’s value to her husband may be determined by her ability to
bear healthy children. A wife may be deserted or divorced summarily



























    Many African doctors are becoming convinced that infertility is a
problem that deserves attention in family planning programs. Family
planning providers must recommend only safe, effective means of
delaying or spacing children that will not impair future fertility. Sexu-
ally transmitted infections (STIs) are the leading cause of preventable
infertility. (See Chapter 6 on Sexually Transmitted Infections.) Other
infectious diseases, poor nutrition, and limited access to adequate
health care for abortion and childbirth are also important factors in
reducing fertility. If family planners are to serve the needs of general
reproductive health care in their community, they should provide
some degree of initial evaluation and counseling for infertility. This
problem not only concerns the woman, but also the couple.
          In this chapter, the term "infertility" is used to mean either a
woman's inability to conceive and bear a living child or a man's inabil-
ity to impregnate a woman. The following definitions are adapted
from the World Health Organization's (WHO’s) definitions of infer-






  The couple has never conceived despite






The couple has previously conceived
but is subsequently unable to conceive within 12 months,






  The woman is able to conceive but







The couple has difficulty in conceiving jointly
because both partners may have reduced fecundity. In this
sense, "subfertility" is used interchangeably with the term
"subfecundity."
 
EPIDEMIOLOGY OF INFERTILITY IN AFRICA
 
There is a recognized belt of subfertility and infertility in Africa
extending from the West African countries of Senegal, Mali, Burkina








Central African Republic, Zaire, Zambia, and southwest Sudan, to the







 Infertility also exists in other parts of Africa, but the
prevalence is lower. In the South, Lesotho has a high proportion of





belt" corresponds quite well with the acquired immune deficiency syn-









Normal spermatogenesis and ductal system (sperm count,




Functioning reproductive anatomy and physiology:
— Adequate sexual drive
— Ability to maintain an erection




Ability to have normal ejaculation into the vagina




Functioning reproductive anatomy and physiology:
— Adequate sexual drive
— A vagina capable of receiving spermatozoa
— Normal cervical mucus to allow sperm to pass to the
upper genital tract
— Ovulatory cycles
— Patent fallopian tubes that permit the sperm and ovum to
meet and allow the fertilized ovum to migrate to the
uterus
— A uterus capable of developing and sustaining the con-
ceptus to maturity




























Normal immunologic responses to accommodate sperm, fer-




Adequate nutritional, chemical, and health status to main-
tain nutrition and oxygenation of placenta and fetus 
      Psychological, anatomic, or physiological alterations can interfere
with the occurrence of pregnancy. A large study by WHO suggests
that male infertility is a causative factor for 43% of infertile couples in
Africa and the sole cause for 8% of couples. Female infertility is the
sole cause for 37% of infertile couples (see Table 7:1). The diagnoses
of infertility are noted in Table 7:2.
 


















Primary 48 77 60 71




No cause found 
in either
5 13 10 14
Female causes 
only
37 37 25 31
Male causes only 8 8 22 22
Causes found 
in both
35 35 30 21
Became pregnant 15 15 13 12
 








     In most developing countries, the major preventable causes of
infertility are STIs, postpartum infection, and postabortion infection.
Tubal occlusion and pelvic adhesions resulting from STIs and compli-
cations of pregnancy cause almost 75% of all female infertility in






Most cases of infertility reported in Africa are
due to secondary causes, possibly reflecting the higher rates of
acquired infertility from postpartum infections and STIs.
 








No demonstrable cause 16 31 35
Bilateral tubal occlusion 49 14 15
Acquired tubal abnormalities 12 12 12
Anovulatory regular cycle 14 9 9
Anovulatory oligomenorrhea 3 7 9
Ovulatory oligomenorrhea 4 11 5
Hyperprolactinemia 5 7 8




No demonstrable cause 46 58 41
Accessory gland infection 11 3 12
Idiopathic low motility 1 5 8
Primary testicular failure 7 11 13




























FACTORS AFFECTING REPRODUCTIVE PERFORMANCE
 



















demonstrated that the effects
of age on fertility are moderate and do not begin until the woman is
about 35 or older.
 
27 Older women take longer to conceive, but both
clinicians and patients must carefully distinguish "waiting longer"
from "never being able to conceive." Most "infertile" couples conceive
eventually, whether or not they are treated. Table 7:3 shows the effects
of age on fertility. The age of the woman is complicated by a host of
other factors, including frequency of intercourse, age of the male part-
ner, and the cumulative effect of medical and gynecological problems.
 








Kenya 1.8 5.1  8.7 15.8 26.2 37.4 63.8 24.8
Lesotho 1.3 5.7 14.8 24.5 39.7 61.2 83.1 37.3
Senegal 1.7 4.1  7.1 12.6 31.0 48.4 74.6 28.2
Sudan (North) 3.7 6.8 11.7 20.8 29.0 56.0 79.6 30.3
 
*A women was defined as infecund if she reported an inability to have a child, or if she had an interval of 
5 or more years without a pregnancy while she was continuously married and not using contraception.




















The age of a man has a significant effect on coital frequency and
sexual function, which directly influence the chance of pregnancy.
However, the age of a man appears to have little effect on the ability of


























Another barrier to optimal fertility is a misunderstanding about
timing and frequency of intercourse. For example, the cultural taboos
that delay intercourse until after menses may prevent conception in
some women with short cycles and long menstrual periods. Patient















How frequently couples have intercourse directly affects pregnancy
rates
 
22,35 (see Table 7:4). Although the sperm count may be slightly
decreased by frequent intercourse (once per day or once every other
day), the motility and number of sperm in a normal man should still























































Having intercourse prior to ovulation is essential to maximizing
the chance of pregnancy (see Table 7:5).  The ovum has a life expect-
ancy of only 12 hours if it is not fertilized. In fact, the opportunity for
fertilization is thought to last only a few hours; thus, intercourse dur-
ing the 24 to 48 hours before ovulation ensures that sperm are present,












If a woman's uterus is anteflexed (tipped slightly forward, as 70%




 be with the woman on her back,
with hips supported and elevated by a pillow. This position would tilt
the vagina to allow the semen to pool near the cervix. Having the
woman remain in the position for 20 minutes or so after intercourse
may give sperm more contact time with the cervix, allowing more
sperm to ascend to the fallopian tubes.
 
Table 7:5  Probability of conception by day of coitus
 










*Calculated for ovulation day












Chemicals or other materials in the vagina may affect sperm via-














Exposure to multiple partners increases the risks for STIs and
pelvic inflammatory disease (PID), which can cause irreversible tubal
damage and ectopic pregnancy. Having multiple sexual partners also
increases the risk of cervical intraepithelial neoplasia and other condi-
tions that may require treatment, such as freezing the cervix, laser
treatment, conization, and, possibly, hysterectomy. Some women
develop antibodies to sperm, a condition that some clinicians believe
is more likely to occur in women exposed to multiple partners. Regu-
lar use of condoms (except when pregnancy is desired) may help to
















The relationship between STIs and PID is discussed in Chapter 6.
 
Gonorrhea and Chlamydia. 
 
Gonorrhea and chlamydia are
major causes of cervicitis and PID, which are associated with tubal dis-
ease and pelvic adhesions. In men, these organisms cause urethritis,
epididymitis, and, possibly, accessory gland infection. These infectious
diseases may cause between 10% and 90% of all infertility, depending
on the geographic region and particular group studied. Although PID
is the major cause of tubal infertility, chronic cervicitis may produce
subfertility in some women. Chlamydia, despite its milder signs and
symptoms, apparently causes more severe subclinical tubal inflamma-





quately treated chlamydial salpingitis may appear to improve while
tubal damage worsens. PID from any cause produces tubal scarring.
When both tubes are scarred, adhesions either completely occlude the
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movement of sperm and ova. Other pelvic adhesions (scars) may limit
tubal mobility, motility, or contact with the ovary, thus interfering
with capture of ova. Many of the same factors that cause pelvic dam-
age and impair fertility also increase the likelihood of ectopic preg-
nancy, which may further damage the reproductive system.7
 Human Papilloma virus.  Human papilloma virus (genital warts)
is a frequent precursor to cervical dysplasia. The effect of that disorder
on fertility depends on treatment, which may be a required hysterec-
tomy (should cervical cancer be diagnosed), cryosurgery, a cone
biopsy, or similar treatment of the cervix for simple dysplasia. Scars
from cervical treatment or damage to the cervical mucous cells suffi-
cient to cause cervical incompetence are associated with preterm deliv-
eries and possible pregnancy loss.
 Mycoplasma. Although mycoplasma are frequently found in
patients with other STIs, it is not known whether these organisms
cause damage.
PARASITIC DISEASES
Filariasis.  This parasite can damage the lymphatic drainage sys-
tem of the external genitalia. In men, this condition can result in
inflammation and swelling (sometimes dramatic swelling known as
elephantiasis) of the scrotum, testes, epididymis, or vas deferens. In
the tropical areas where this disease is prevalent, it may be a significant
cause of male infertility.39 In women, filariasis may decrease coital fre-
quency, but little is known about the direct effects on female fertility.24
Malaria. In women, malaria may cause high fevers and impair
fetal and maternal nutrition. Infestation of the placenta may lead to
spontaneous abortion or fetal loss.39  In men, severe malarial fevers can
raise the scrotal temperature enough to alter spermatogenesis. In some
areas where malaria is endemic, 60% of men suffer malarial fevers high
enough to affect semen quality.24
Schistosomiasis.  Caused by a waterborne parasite common in
many African countries, schistosomiasis has not been directly linked
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to male or female infertility.24 Severe chronic infection causing liver
damage may harm the individual’s general health, sex steroid hormone
metabolism, and sex drive.39 
Toxoplasmosis.  Transmitted primarily through cat feces and eat-
ing raw meat, toxoplasmosis may damage a developing fetus and cause
fetal wastage in women who have a primary infection. Primary infec-
tions generally resolve spontaneously and confer immunity against
later infections. Toxoplasmosis is not a significant cause of infertility.39
Trypanosomiasis.  Known as African sleeping sickness, trypanoso-
miasis causes high fevers that may affect sperm production. It may also
interfere with pituitary function, leading to menstrual disorders and
fetal loss in women and feminization and impotence in men.24
OTHER INFECTIOUS DISEASES
 Leprosy (Hansen's disease).  In its lepromatous manifestation,
leprosy can cause testicular atrophy in some men with untreated infec-
tion and has been associated with male infertility. Neurologic damage
from leprosy may result in impotence. In some couples, decreased
coital frequency may stem from the psychosocial consequences of the
disease. No female infertility caused by leprosy has been identified.39
 Mumps. If it leads to orchitis (testicular inflammation), mumps
may cause secondary testicular atrophy in the small number of men
infected after puberty. Bilateral orchitis occurs in perhaps 1% of adult
males with mumps; most will recover without impaired fertility.39
Tuberculosis.  Tuberculosis is more prevalent in populations suf-
fering from poverty, malnutrition, overcrowding, poor housing, or
poor working conditions. Tuberculosis of the genital tract may
develop in men or women following primary pulmonary infection,
which is often unrecognized. Infection and inflammatory response
may damage the fallopian tubes or the epididymis and vas deferens.
Genital tuberculosis may cause a large proportion of infertility cases in
Africa, which has a high prevalence of untreated tuberculosis.39 One
South African study found positive M. tuberculosis cultures in 21% of
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women seeking infertility services who had no indications of infection
other than infertility.30
Postpartum and postabortion infections. These preventable
infections cause high rates of maternal mortality and secondary infer-
tility. Postpartum infections are most prevalent where traditional birth
attendants may introduce contaminating organisms by using unsani-
tary tools or methods. Postabortion infections are most common
where safe, legal abortions performed by trained medical personnel are
not available. Untrained practitioners or the use of folk methods are
likely to introduce contaminating organisms or lead to an incomplete
abortion, two serious risk factors in life- and fertility-threatening pel-
vic infections.39,54  In the WHO study, 76.2% of African women with
infection-related infertility cases had a history of either postpartum or
postabortion complications.53
Sickle cell disease. In men, sickle cell disease has been docu-
mented as a cause of recurring priapism, with possible impotence from
tissue and nerve damage leading to male infertility. In women, sickling
crises or alterations in placental blood flow or oxygenation have been
clearly associated with an increased rate of fetal wastage.31
Nutrition. Severe malnutrition is associated with infertility and
fetal wastage. Even moderate nutritional deprivation leading to a drop
of 10% to 15% below normal weight can interfere with menstrual
cycles in women.24 The percentage of body fat should be greater than
22% to permit regular ovulatory cycles.15 Poor nutrition can weaken
the immune system and increase the chances of acquiring an infec-
tious disease, which can compromise fertility. Likewise, many infesta-
tions or diseases such as hookworm and malaria can lead to anemia,
which may cause fetal and maternal mortality.24 Obesity also may lead
to less frequent ovulation or to less frequent intercourse, thereby con-
tributing to fertility problems.40
Toxic agents. Toxic agents may well emerge as one of the princi-
pal causes of infertility among couples with no anatomic cause. Expo-
sure can occur from occupational hazards (e.g., farming, factory work,
mining); contaminated air, water or food supply; drug ingestion; or
other sources.
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Lead, toxic fumes, and exposure to pesticides are suspected of
causing or contributing to infertility.50,54  In women, lead poisoning
reduces the likelihood of fertilization and increases the likelihood of
fetal wastage. Cases of spontaneous abortion among agricultural work-
ers have been reported. In men, exposure to lead can reduce both sex
drive and sperm count. Pesticide exposure can also reduce sperm
count.50
Smoking or alcohol use. In men, smoking tobacco and drink-
ing alcoholic beverages may cause poor sperm quality. In women, both
smoking and heavy alcohol use are associated with lower conception
rates3 and increased rates of spontaneous abortions. Smoking also
appears to increase slightly the risk of placenta previa. Smoking and
alcohol use also negatively affect the developing fetus and may result
in low-birthweight babies.42
Medications. In men, narcotics, tranquilizers, antidepressants,
some antihypertensives, and drugs such as guanethidine and methyl-
dopa may cause impotence. Amoebicides, antimalarial drugs, nitro-
furantoin, sulfasalazine, cimetidine, certain antihypertensives, and
methotrexate may affect sperm production.5,34,38  In women, habitual
use of narcotics or barbiturates apparently decreases regularity of ovu-
lation. Systemic, powerful anticancer drugs exert many tissue effects
that may include testicular or ovarian failure, even after only one cycle
of chemotherapy. Many other prescription medications, including tet-
racycline, several antiseizure medications, some antidepressants, some
tranquilizers, and coumadin, are clearly associated with an increased
risk of fetal defects. Many of these drugs may also be associated with
fetal wastage.42  If possible, couples attempting to conceive should
avoid all medications.
Surgery. In men, sexual function may be reversibly or irreversibly
impaired by surgery involving the penis, scrotum, prostate, or pelvis,
all of which may cause nerve damage. In women, ovarian, cervical, or
uterine surgery for benign processes may cause subsequent difficulties
with fertilization or ovulation or lead to fetal wastage. Adhesions from
any pelvic or abdominal surgery may interfere with conception.
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Female circumcision. The removal of part or all of the external
female genitalia, a ritual practice in parts of Africa, causes infertility in
some women. The immediate consequences of the surgical procedure
performed on prepubertal girls may include infection, hemorrhage,
and shock. Later consequences (especially in women who undergo the
extreme forms of the procedure) may include infection ascending into
the reproductive tract and scarring that causes infertility related to
improper drainage of urine and menstrual blood, difficulty with inter-
course because full penile penetration is precluded, perineal tears and
upper genital tract infections.24,39 (See Chapter 2 on Traditional Prac-
tices.)
Radiation. Exposure to radiation may be occupational, acciden-
tal, iatrogenic, or a therapeutic component of cancer treatment. The
dose and type of irradiation, as well as the site or focus of energy, may
produce different results. Therapeutic radiation treatments in both
men and women can sometimes be tailored to minimize gonadal
exposure to optimize future fertility and gonadal function. In men,
irradiation may cause chromosomal aberrations33 and increase the risk
of testicular cancer.5  In women, irradiation may cause ovarian failure,
fetal wastage, or fetal damage.42
Physical exertion or heat. Some highly trained female athletes,
such as long-distance runners and professional dancers, may experi-
ence reversible amenorrhea without any apparent long-term detrimen-
tal effects on their fertility.15 However, they may be at increased risk
for bone loss.19 Men who take frequent hot showers or whirlpool treat-
ments or whose occupations involve working in high temperatures
(for example, furnace workers) may subject the scrotum to tempera-
tures high enough to reduce sperm production temporarily.44  There is
no evidence that endurance training leads to male infertility.2
Tight clothing. Jockey shorts and tight pants are thought to
have the same suppressive effect on sperm production as do hot show-











The family planning or primary care clinic can provide preventive
infertility counseling and medical examination for early diagnosis and
treatment of STIs. Routine screening of sexually active individuals for
STIs prevalent in the population also may prevent adverse conse-
quences of the diseases. Family planners who desire to prevent infertil-




Be up to date in their knowledge on preventing, diagnosing,









Begin or continue public health education efforts so that the
consequences of untreated sexual infection may be fully




Work within the community to ensure that all individuals,
including minors, have access to early and confidential diag-




Encourage sexually active young people to use condoms, dia-
phragms, and spermicides, which can be used along with oral








Historically, clinicians have been concerned about whether IUD use







risk is apparently small for noninfected couples in mutually faithful
relationships. In addition, the Levonorgestrel IUD may be associated




  Recent studies suggest
that previous risk estimates of PID among IUD users may have been
high.
 
9  Family planning workers should take the following actions: 
1. Be conservative in using IUDs for nulliparous women who
plan to have children. Many clinicians refuse to insert IUDs
into nulliparous women.
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2. Avoid recommending the IUD to women who are at greater
risk for STIs and PID (especially adolescents).
3. Screen for STIs in all patients in whom an IUD is inserted.
4. Never insert an IUD into a woman with an untreated STI.
5. Consider giving antibiotic prophylaxis to women who live in
areas where incidence of STIs is high. (See Chapter 15 on
Interuterine Devices.)  
6. Assume that a vaginal discharge in the presence of an IUD
signals an infection until proven otherwise. (See Chapter 15
on Interuterine Devices.)  
7. Be certain that clients are aware of the danger signs of a pel-
vic infection and that they know where to go and what to do
if these signs occur.
THE PILL
Compared with IUD users or those who use no contraceptive
method, women who use oral contraceptives have a lower risk of
symptomatic PID, possibly because they have decreased menstrual
flow and myometrial activity, as well as a less penetrable cervical
mucus.9 (See Chapter 13 on Combined Oral Contraceptives.)  Oral
contraceptives may also protect against tubal damage.9 The pill
appears to decrease the likelihood of acute gonococcal pelvic infec-
tion.36 Although the relationship between oral contraceptive use and
chlamydia infection risk is still being clarified, it is now accepted that
the risk of cervical infection with chlamydia is enhanced among oral
contraceptive users (as compared with non-users).9,49  The risk of
ascending infection is currently unknown, but oral contraceptive use
may lessen the damaging effects of inflammation.9
Amenorrhea and temporary infertility following use of the pill do
not appear to seriously threaten female fertility. These symptoms are
most commonly found in women who have irregular menses before
beginning oral contraceptive therapy.
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Because an increased risk of cervical cancer among pill users
appears likely, screening for cervical cancer and early diagnosis and
treatment of STIs is important. (See Chapter 13 on Combined Oral
Contraceptives.) Family planning workers should take the following
actions: 
1. Educate patients about the relationship between the pill and
PID.
2. Urge pill users at high risk for STIs to use barrier contracep-
tion as well and to limit their number of sexual partners.
BARRIER METHODS
The use of condoms and other barrier methods can reduce the
risk of STIs such as chlamydia and gonorrhea, both of which are asso-
ciated with PID and tubal infertility.9 (See Chapter 6 on Sexually
Transmitted Diseases.)  Clients who have had a previous episode of
PID especially should be counseled about barrier methods to avoid
infection.
Unprotected intercourse can lead to the development of sperm
antibodies in women, although it is unclear whether immunity to
sperm causes infertility. The use of condoms has been widely encour-
aged to reduce the risk of developing immunologic reactions to
sperm.42 
STERILIZATION
Family planners have expressed concern over the number of
requests for sterilization reversal, an expensive procedure with uncer-
tain prognosis. Table 7:6 shows the reasons for requesting reversal in a
survey of 100 female patients.
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Family planning workers should take the following actions: 
1. Emphasize the permanence of the procedure.
2. Avoid using the term "tying the tubes" to describe steriliza-
tion procedures; to some patients, such reference might
imply that "untying the tubes" is feasible.17  (See Chapter 21
on Voluntary Surgical Contraception.)
3. Make efforts to assure clients have access to reversal proce-
dures. This may require changes in laws relating to health
insurance and in public funding of health systems. 
ABORTION
Although complications after an abortion rarely occur if it has
been performed by trained medical personnel in a modern medical facil-
ity and with modern, sanitary, safe equipment, there is a slight risk that
subsequent fertility may be reduced. No epidemiologic evidence sup-
ports a fertility risk to women experiencing first trimester vacuum abor-
tions. However, a slightly increased risk to reproductive performance
exists when larger cervical dilation is used for some dilation and curet-
tage (D&C) abortion procedures or when the abortion is performed in
the second trimester.20  The most obvious way to prevent these rare
occurrences is to prevent the pregnancy (and thus the abortion).
Table 7:6  Reasons for requesting reversal of sterilization
Reason Percentage
Change of marital status 63
Death of child 17





Source:   Gomel (1980)
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When abortions are performed by untrained personnel without
adequate attention to hygiene or appropriate equipment, the risk of
complications is much higher. Illegal abortions are frequently provided
in unsafe conditions. In addition to postabortion infections, perfora-
tion, hemorrhage, scarring, incomplete abortion, and cervical lacera-
tions are more common in illegal or “homemade” abortions. (See
Chapter 22 on Postabortion Care: Treating Complications and Provid-
ing Contraception.) Illegal abortion is a major cause of maternal mor-
tality in Africa. (See Chapter 1 on Benefits of Family Planning.)
THE INFERTILITY EVALUATION AND 
THE FAMILY PLANNER
Triaging (sorting by urgency) is the important task of the first counse-
lor to see the infertile client or couple. A couple who has had sufficient
exposure (about 12 months of unprotected intercourse) deserves to
discuss the topic with their provider and have their fertility investi-
gated or be referred for a workup, rather than simply be given advice
to "wait and see."  Begin an infertility evaluation as soon as is reason-
able, if the following conditions apply: 
1. The woman is in her late 30s. Because a steep decline in fer-
tility occurs after age 40, women over age 35 should receive
priority for early assessment.
2. The woman reports irregular menses. This symptom could
signal sporadic ovulation, a condition unlikely to improve
spontaneously unless the woman is an adolescent. It could be
a sign of premature ovarian failure (early menopause). Irreg-
ular or abnormal bleeding may be a symptom of pelvic infec-
tion or other gynecological disease, making evaluation
necessary. Many of these problems are easily and successfully
treated.
3. The medical history for the couple includes mumps in the
man; repeated miscarriages, ectopic pregnancy, or PID in the
woman; or previous pelvic surgery or other serious medical
problems in either partner. Because time is not likely to
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improve such problems but will cause the couple's fecundity
to steadily diminish, diagnose the cause of subfertility and
begin infertility treatment promptly.
4. The woman has severe progressive dysmenorrhea or dyspare-
unia. These symptoms may suggest endometriosis or other
pelvic disease.
5. The woman used an IUD in the past; had a pelvic infection;
had surgery on an ovary, a tube, or the uterus; or has any
finding that might suggest damage to her pelvic organs (e.g.,
endometriosis, ovarian cyst, fibroid). An early assessment,
including a laparoscopy, can lead to an early diagnosis and
treatment or to reassurance that "more time" is needed.
6. The couple lives in an area with a high endemic incidence of
STIs.
Even if economic, personnel, and laboratory resources may be
limited, some basic initial services can be provided by most family
planning programs. The following services may help some couples
improve fertility and may provide the first steps for those who need
further evaluation or treatment. Evaluation begins with the first four
items listed and, where resources and training permit, includes all of
the following: 
1. Educating the patients
2. Gathering pertinent historical information
3. Providing a thorough physical exam
4. Providing a resource for reassurance, counseling, and emo-
tional stability, including referral as needed
5. Systematically evaluating the possible defective areas:37
• Counseling couples about fertility awareness techniques
(see Chapter 18 on Fertility Awareness) and optimal coital
timing 
• Checking couples for asymptomatic sexually transmitted
infections (STIs) that could cause subfertility
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• Determining whether ovulation takes place, as indicated
by basal body temperature or cervical mucus records (or
urine luteinizing hormone test kits where available)
• Analyzing semen 
6. Making a plan and initiating treatment based on informa-
tion gathered, and counseling couples with potentially seri-
ous or undetected fertility problems about their options for
further evaluation and treatment
7. Reassessing progress at predetermined intervals
8. Referring couples to other infertility specialists or adoption
agencies as needed, explaining the anticipated short- and
long-term costs and chances for success with further treat-
ment, and discussing the options of adoption or remaining
childless
HISTORY AND PHYSICAL ASSESSMENT
Before beginning the evaluation process, explain the main steps
that will be needed for diagnostic evaluation and describe the capacity
of your facility. The history and physical exam may indicate the need
for further evaluation. Explain that your approach is only one of many
potential testing options. A recommended schedule of evaluation is
described in Table 7:7. Clinics that carry out only a few of these items
should provide referrals for the remaining services. If referral becomes
necessary, try to ensure that procedures are not duplicated unnecessar-
ily and that an orderly evaluation can be continued. Following a stan-
dard set of guidelines, such as the WHO flow sheet of the
standardized approach to the infertile couple,54 will enhance the effec-




























Ask about the individual’s attempts to conceive. Interview each
individual about exposure to the factors that influence reproductive
performance, including anatomical, infectious, and toxic factors.
After interviewing the couple together, the counselor should interview
the man and woman separately to obtain confidential information.
 
Physical Examination of the Woman
 
Visually evaluate the hair distribution and body and breast devel-
opment for signs of endocrinopathies or developmental deficiencies
 
Table 7:7  Fertility assessment schedule
 
The initial assessment of the couple should proceed in a systematic manner, with 
the objective of completing the first line of infertility evaluation within two or three 




Family planning clinic visit (ideally day 5-10 of menstrual cycle)
Previous medical records obtained
Complete medical history of man and woman





Man obtains physical exam if not already completed
Semen evaluation








Blood tests on day 22 of 28-day cycle: serum progesterone, etc.
 
More Extensive Tests (if available)
 
Laboratory tests, if indicated, such as anemia screening, thyroid or prolactin level,
or progesterone level at mid-luteal phase to confirm ovulation
Hysterosalpingogram on day 5-10 of cycle when not bleeding
 
Source:   Gomel (1980)
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such as hypogonadism, adrenal hyperplasia, hypothyroidism, ovarian
dysfunction, and hyperprolactinemia. Perform a complete pelvic exam
(palpation of uterus and adnexae and a speculum exam of vagina and
cervix) to detect any uterine hypoplasia, adnexal tumors, or cervical
lesions. The exam should indicate whether dyspareunia may be a
problem.
Physical Examination of the Man
Visually inspect sexual characteristics to identify endocrinopa-
thies such as hypogonadism or Klinefelter's syndrome (the genetic
XXY anomaly often associated with infertility). A penile exam can
reveal hypospadias (displacement of the urethral opening) or phimosis
(constriction), cysts, cryptorchidism (undescended testicles), vas thick-
ening or absence, hydrocele (fluid accumulation in testes or along
spermatic cord), or varicocele (dilation of the veins of the spermatic
cord in the scrotum).
Semen Evaluation
Usually, arrangements must be made with the laboratory before
the man brings in a specimen for a semen evaluation. (Table 7:8 gives
directions for obtaining a semen specimen.) The technician will need
2 to 5 cc and will look for directional motility in over 60% of sperm
present, 60% normal morphology, and a count of at least 20 million
sperm/ml. If the sperm count is at least 15 to 20 million, the absolute
number of sperm is probably less critical than their motility and mor-
phology. The presence of bacteria or white blood cells, as well as
semen viscosity, also should be recorded. More than one evaluation
may be necessary to assess accurately the sperm and semen status, par-
ticularly if the results are borderline—WHO recommends two sam-
ples taken at least 2 weeks apart. (Table 7:9 provides the WHO criteria
for semen evaluation.52)
Following the initial history, physical exam, and basic diagnostic
laboratory procedures, inform the patient about the further tests that










































Patients should be instructed on how to record basal body tem-
peratures and chart mucus changes, as described in Chapter 18. This
documentation often helps verify ovulation, determine the timing and
frequency of intercourse, and educate the client about the physiology
of the menstrual cycle. The timing of various tests also can be recorded
and guided by this documentation.
Mucous assessment can be used to verify ovulation.  At a visit 1
day prior to ovulation, a small amount of cervical mucus is drawn into
a thin catheter from the endocervical canal and evaluated by micro-
scope. Abundant acellular, watery cervical mucus that exhibits ferning
and has a spinnbarkeit of greater than 8 cm is good evidence of a nor-
mal ovulatory cycle pattern.
 




Abstain from intercourse (no ejaculation) for at least 3 and no more than 5 













Keep the semen specimen close to body temperature.
 
Table 7:9  Criteria for a normal semen sample
 














































































Economic considerations are critical in deciding whether to
introduce specialized services. The more technology-driven evalua-
tions and treatment far exceed most people’s financial resources and
are too expensive for most health programs to provide. Careful consid-
eration must be given in determining the extent of services to be cov-




Consider performing a diagnostic laparoscopy when pelvic
pathology (such as anatomical abnormality or damage or obstruction
of tubes) is suspected or when the patient has a history of PID.
 
COUNSELING ABOUT TREATMENT POSSIBILITIES
 
Frequently, the role of the provider in infertility is to reassure (intelli-
gently) and intervene at the right time. A principal responsibility is to
tell the patient when the time has come to consider adoption, to dis-
continue therapy, or to proceed on some other course.
Often, simple instructions about intercourse technique and tim-
ing are helpful.  Encourage the couple to maximize the chance for
pregnancy by having intercourse two or three times weekly, with spe-
cial attention to the two or three days immediately preceding expected
ovulation.  Avoid use of any vaginal products—including lubricants,
douche, or drying agents.
Infertility therapy, like any other medical therapy, is generally
directed toward curing or improving diagnosed anatomic and physio-
logical problems. In addition, comprehensive infertility treatment
seeks to maximize the chance of pregnancy by optimizing all condi-
tions for conception. For many patients who have no identifiable
cause of infertility, the comprehensive approach is the only therapeutic
option, provided that all possible diagnostic tests have been adequately
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completed. As the treatment of identified problems is well outlined in
general references, it will not be described in great detail here.
Male infertility may be treated with insemination from donor
sperm in cases of azoospermia or impotence. Particular attention must
be paid to guaranteeing that the semen does not carry any organisms
that produce STIs, including human immunodeficiency virus (HIV).
Criteria for preparation, storage, and screening have been developed
by the American Fertility Society. Its current recommendation is to
use sperm that has been frozen and quarantined for 6 months. If the
donor is still HIV antibody negative after 6 months, the sperm may be
released.18
Female infertility may be treated with a much wider range of
approaches:
1. Cervical mucus problems impairing conception may be
treated with insemination or uterine instillation of a small
amount of specially prepared sperm.
2. Cervical incompetence interfering with continuing preg-
nancy may be treated with cerclage, bed rest, or both. Cer-
clage is the passage of a strong suture material around the
cervix, like a purse string, to prevent premature dilation.
3. Ovulation disorders can be treated with drugs to induce ovu-
lation (such as clomiphene citrate, which suppresses estro-
gen's suppressive effect on ovulation). In women whose
ovulation is suppressed by hyperprolactinemia (high blood
levels of the pituitary hormone prolactin), ovulation may be
induced with drugs that suppress prolactin, such as bro-
mocriptine.
4. Damage to ovaries, such as torsion, surgical removal, hemor-
rhagic cyst, or premature menopause that has eliminated pri-
mordial follicle tissue required to produce new ova, can be
overcome only by some use of high-technology fertility med-
icine with ova donated from another woman.
5. Uterine or tubal abnormalities may be corrected by surgical
procedures (in some cases "microsurgery"). Some congenital
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anomalies, such as true bicornuate uterus, may not be ame-
nable to surgical repair. In the case of tubal damage caused
by endometriosis, hormonal suppression of the displaced
endometrial tissue may be prescribed before or instead of
surgery. Tubal or pelvic scarring due to PID may be
improved with microsurgery of the tube or laparotomy to
allow lysis of pelvic adhesions. Currently, the delicate cilia
and mucosa of the tubal lining cannot be surgically regener-
ated, and the body's capacity to repair itself is low. In vitro
fertilization may be the only way to bypass damaged fallo-
pian tubes. 
High technology approaches to overcoming infertility have had
some remarkable developments in the past 15 years. These expensive
methods require expert practitioners and procedures and result in suc-
cessful pregnancies at rates near the normal fecundity rates. The fol-
lowing are two of the major high-technology approaches: 
• Gamete intrafallopian tube transfer (GIFT) involves placing a
mixture of ova and sperm into the fallopian tube. It is used
primarily for unexplained infertility and where the fallopian
tubes appear normal. National surveys in the United States
indicate a pregnancy rate of 29% per treatment cycle.26
• In vitro fertilization (IVF) involves placing mature ova (har-
vested during laparoscopy or transvaginally using an ultra-
sound-directed needle to aspirate the oocyte) with specially
prepared sperm in a laboratory tissue culture medium and
incubating them to allow fertilization. Fertilized ova that
have successfully attained a certain maturity (generally
between two and eight cell divisions) are placed in the uterus
via a transcervical catheter. Surveys in the United States indi-
cate a pregnancy rate of 19% per treatment cycle.26
GIFT and IVF frequently use ovulation stimulation drugs to
increase the number of ova ready for harvest. 
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COPING 
The effect of permanent infertility, coupled with the stresses of fertility
evaluation and treatment, may damage a couple's relationship or an
individual's self-concept. Explore the coping mechanisms that are
used in the client’s cultural context. In some cultures, for example, an
infertile man may ask a close relative to father his children.  Infertile
women may be encouraged to adopt a relative’s baby. In some cases,
the husband of an infertile woman may divorce her and marry some-
one who can provide children.  Family planning agencies should
remain sensitive to the special needs of infertility patients.
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The Menstrual Cycle 
and Disturbances
 
Female fertility is cyclic, unlike male fertility, which is relatively con-
stant. Ovulation occurs only once a month and is regulated by a hor-
mone system that involves the hypothalamus, the pituitary gland, and
the ovaries. When a woman understands her menstrual cycle, she can
better plan, diagnose, and prevent pregnancies. When providers
understand the menstrual cycle, they can better assist the client in




The menstrual cycle is regulated in the hypothalamus. During
puberty, the hypothalamus begins secreting hormones that stimulate
the pituitary gland to secrete follicle-stimulating hormone (FSH) and
luteinizing hormone (LH). In turn, FSH and LH stimulate produc-
tion of the ovarian hormones estrogen and progesterone and interact
with them to regulate ovulation and menstruation. Anything that dis-
rupts the balance of these four hormones during the cycle can disrupt


























Figure 8:1 Menstrual cycle events: hormone levels, ovarian, and 
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MENSTRUAL CYCLE LENGTH 
 
In this chapter, the menstrual cycle events are described for an average
28 day cycle; but a normal menstrual cycle can last anywhere from 21
to 35 days. The menstrual cycle can be divided into two distinct
phases:  The first phase begins with the onset of menses and ends at
ovulation and the second phase spans the time from ovulation, until
the first day of the next menses. The length of the second half of the
cycle is very consistent, usually 14 days. For some women, the length

































Days 1 - 2
 
The menstrual cycle begins with the first day of men-
strual bleeding. The lining of the uterus begins to shed, because levels
of estrogen and progesterone have declined from the previous cycle.
During the first few days of the cycle, numerous ovarian follicles begin
growing. These follicles are balls of cells, each containing an oocyte.
During a menstrual cycle a woman may have 10 to 20 follicles grow-
ing. The cervical mucus is thick, cloudy, and scant.
 
Days 3 - 5
 
 For most women, bleeding will end sometime during
these days. About one-third of the endometrial lining remains after
the bleeding ends.   
 
Days 6  - 11
 
Estrogen, produced by the ovarian follicles, is primarily
responsible for stimulating regrowth of the lining during this time,
and thereby ensuring a nutritious home for the potential embryo. This
lining will be shed at the end of the cycle if pregnancy is not attained.
The hormone levels are generally low during this period, but the pitu-
itary sends increased amounts of FSH to help mature the follicles.
Most of the 10 to 20 follicles grow briefly, then recede. One remains
to mature. Because it is so receptive to FSH, the remaining follicle
continues to grow and produces the oocyte for that cycle. It is also


























Days 12 - 13
 
Estrogen production accelerates, triggering a sudden
increase in LH.  As LH reaches its peak, estrogen production is tempo-
rarily inhibited, causing its level to dip. This combination of hormonal
surge and dip is thought to cause ovulation.  A slow increase in proges-
terone production also begins here just before midcycle. Because of
the temporary midcycle dip in estrogen level, a brief interval of midcy-
cle endometrial bleeding can occur. Ovulation takes place 34 to 36













 onset of the next menses. The ovary releases a
mature egg (oocyte).  As the follicle ruptures it releases 1 cc to 10 cc of
follicular fluid, and the barely visible oocyte passes into the fallopian
tube. Lower abdominal pain is often associated with ovulation. The
cervical mucus at ovulation is copious, thin, and clear. This mucus can
be stretched into a strand several inches long (this type of mucus is





































Days 15 - 28
 
After the follicle ruptures at ovulation, the follicle
walls collapse, and the follicle cell becomes the corpus luteum. The
corpus luteum stays in the ovary and secretes increasing levels of estro-
gen and progesterone. The increased progesterone causes a change in
cervical mucus, making it scant but thick and sticky. 
The endometrial lining is now preparing to support an embryo
and allow implantation. Progesterone levels reach their peak in the
middle of the luteal phase, and FSH and LH levels fall. If fertilization
and implantation occur, progesterone will continue to be released by
the corpus luteum until the placenta matures. If fertilization does not
occur, the corpus luteum disintegrates and the levels of hormones

























FERTILIZATION AND EARLY PREGNANCY 
 
A woman is most likely to conceive if fresh sperm are present in her
reproductive tract when ovulation occurs. Sperm can live in the
woman's reproductive tract for as long as 3 to 5 days. The ovum can
be fertilized near the day of ovulation, possibly for as long as 12 hours
after ovulation; the woman’s monthly fertile interval ends the day of




Fertilization involves a complex series of events that occur over
many hours. Usually a single sperm attaches to the oocyte. The zona
pellucida, a gelatinous halo that surrounds the oocyte, responds by
blocking other sperm. The successful sperm releases enzymes that
allow it to penetrate the zona and induce final maturation of the
oocyte chromosomes. Fertilization usually occurs while the oocyte is
in the outer third of the fallopian tube. 
•
 
Day 1 and 2 following fertilization
 
:   Cell division begins and con-
tinues for the first 2 days in the fallopian tube, creating a ball of
cells called a morula. 
•
 
Day 3 following fertilization
 
:  The morula reaches the uterus,
where it continues early embryonic development for another 2 to
3 days before beginning implantation.
•
 
Day 6 following fertilization
 




Day 12 following fertilization
 
:  By this time, the embryo has
implanted just under the endometrial surface, nourished by
maternal blood pools, and the placenta begins to form.
Fertilization, early embryonic development, and implantation are
complex processes. Many oocytes and sperm are abnormal and incapa-
ble of fertilization; some carry chromosome abnormalities incompati-
ble with embryonic survival. After fertilization, many precisely
coordinated events must occur for development and implantation to
be successful. As a result, spontaneous loss is very common: approxi-
mately 50% of embryos do not survive. Because most of these losses
occur during the first 2 weeks after ovulation, the woman is not likely
to recognize the spontaneous pregnancy loss. Spontaneous loss is


























It is important for health care providers to understand the intri-
cate functioning of the female hormonal cycles and physiology so they
can provide patients with the most appropriate family planning
choices. With the exception of barrier methods, all present forms of





Menstrual cramping, or dysmenorrhea, may occur with ovulatory
cycles. Some women may experience cramping throughout their
reproductive lives, some only intermittently, and others experience
cramping rarely or never. Uterine cramping is caused by prostaglan-
dins released when the lining of the uterus sheds. These prostaglandins
cause uterine muscle to contract and smooth muscle contractions in
the digestive tract cause other symptoms such as nausea and diarrhea.
Many women find their cramping pain is relieved by resting,
applying gentle heat to the area, or taking common medications such
as aspirin or ibuprofen (a very effective prostaglandin inhibitor).
Combined oral contraceptive pills can prevent dysmenorrhea because
they suppress ovulation. In some cases, progestin-only contraceptives
may relieve dysmenorrhea.
When evaluating menstrual cramping, rule out the possibility of
infection or early pregnancy because cramping pains may also be
caused by disorders that may need treatment:
• Pelvic inflammatory disease (PID) (See Chapter 6 on Sexu-
ally Transmitted Diseases.)
• Fibroid tumors (leiomyomata)
• Endometriosis or adenomyosis
• Endometrial cancer



























For most women, the menstrual cycle lasts between 24 and 32 days,
with 3 to 7 days of bleeding. The average woman will pass about 15
ccs of bloody fluid. Some women will have spotting (light bleeding) at
mid-cycle, which is triggered by the temporary drop in estrogen levels
occurring with ovulation. Hormonal contraceptives can alter men-
strual bleeding patterns, causing amenorrhea, spotting between peri-
ods, or heavier bleeding. (See chapters on various contraceptive
methods.)
A woman who experiences abnormal bleeding needs to be evalu-
ated to discover the cause. Table 8:1 lists several reasons for abnormal
bleeding. In rare cases, a woman with abnormal bleeding may need
emergency care. Heavy blood loss can lead to shock. Early symptoms




During the years before menopause, the ovaries gradually
become unable to respond to the hormones released by the pituitary
gland. Estrogen production drops and the production of FSH and LH
increases dramatically. With these changes, fertility decreases, men-
strual cycles become irregular, and menstrual flow tapers off. Some
women may experience hot flushes—reddening and sweating of the
skin lasting a few minutes and occurring throughout the day. These
symptoms gradually improve within the first few years after meno-
pause. Other menopausal symptoms include problems associated with
persistently low estrogen levels: vaginal dryness and diminished blad-
der control. These symptoms generally begin months or years after
menopause. Once women reach menopause, their need for calcium
increases. Advise clients about how to increase calcium in their diets.
Because uterine cancer is more common among women who have































• Spontaneous bleeding in early pregnancy
• Spontaneous abortion (miscarriage)
• Ectopic pregnancy
























• Benign fibroid tumors
• Infection
• Endometriosis







• Corpus luteum cyst





• Pelvic Inflammatory Disease (PID)
• Hormone treatment
• Thorazine or other psychiatric drugs
• Aspirin, antiprostaglandin drugs
• Anticoagulant drugs








































In some women, menopause symptoms can be severe. Many of
the symptoms can be treated with hormone replacement, if it is avail-
able. Many women report fewer hot flushes, less irritability, and
improved vaginal lubrication. In addition, hormone replacement ther-







risk of uterine cancer can be decreased by combining estrogen treat-
ment with at least 12 days of progestin each month.  The risk of breast
cancer needs further study because research results conflict.  Advise cli-
ents to examine their breasts for masses and to have their breasts exam-
ined professionally as well.
Not every women can take estrogen treatment. Women with the
following conditions should not take this therapy:
• Unexplained vaginal bleeding
• Active liver disease
• Chronic impaired liver function
• Recent blood clot formation (thrombosis)
• Cancer of the breast
• Cancer of the endometrium
A typical regimen consists of conjugated estrogen 0.625 mg with




  For some women who can-
not take estrogen, medroxyprogesterone acetate 10 to 20 mg daily or
Depo-Provera 150 mg every 3 months are alternatives to protect
against hot flushes and, possibly, bone loss. Estrogen-containing vagi-
nal cream helps alleviate vaginal dryness. Women who must avoid
estrogen should be advised to avoid herbal preparations such as gin-




























Adnexal masses are extremely common. In some cases, the client may
complain of pain in the lower abdomen (usually one-sided), tender-
ness, pain during intercourse, or a sense of fullness in the abdomen.










This is an emergency condition that must be ruled out whenever
a mass occurs in the adnexa. Signs and symptoms may include vaginal
bleeding, mild pregnancy symptoms such as breast tenderness or nau-
sea, persistent pain that is one-sided or more generalized in the lower
abdomen, a uterus size that is smaller than last period dates would
suggest, or tenderness in the area of the fallopian tube. In some cases, a
woman may have no signs or symptoms of an ectopic pregnancy.
Internal bleeding from a ruptured ectopic pregnancy causes severe
pain and can lead to shock. Frequent, careful follow-up, with daily
examinations, may be needed until the diagnosis is clear. (See Chapter
9 on Pregnancy Diagnosis for further discussion.)
 
CANCER OF THE OVARY
An ovarian enlargement that persists, is larger than 5 cm, or
occurs in a women over age 30 needs a full evaluation. Rule out the
possibility of pregnancy or infection. If pregnancy and infection are
ruled out, obtain an image of the mass, either by x-ray or ultrasound.
Even if the results are reassuring, surgery is likely to be necessary.
FUNCTIONAL OVARIAN CYST
Sometimes a normal ovarian follicle or corpus luteum can be
unusually large. These cysts occasionally are as large as 8 cm to 10 cm
in diameter and can disrupt the menstrual cycle. Rarely, a cyst causes
pain from leakage or torsion (twisting) of the adnexa. In most cases,
THE MENSTRUAL CYCLE AND DISTURBANCES 195
however, the cyst and its symptoms resolve within a few weeks. If the
ovary is 5 cm or smaller in a client who is younger than 30 years of
age, not pregnant, and does not have an infection, arrange for a fol-
low-up pelvic exam in 2 to 4 weeks. 
VAGINAL HYGIENE
A woman's vagina normally maintains its own hygiene. Menstrual
blood is not dangerous or dirty. Absorbent materials attached to
undergarments or tampons placed in the vagina are sufficient to
absorb blood and prevent the staining of clothing. These absorbent
materials should be changed frequently throughout the days of blood
flow. 
Douching is unnecessary to maintain vaginal hygiene. Moreover,
douching is associated with an increased risk for PID and ectopic
pregnancy.2,3  Pregnant women especially should be warned about the
risks associated with douching.
A persistent vaginal odor or abnormal discharges that does not
clear on its own can be a sign of vaginal infection. Make certain the
vagina does not contain any retained materials such as a tampon or
other inserted items. Evaluate for infection. (See Chapter 6 on Sexu-
ally Transmitted Infections.)
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Tazana had been married more than a year and still had not 
become pregnant. Always, it was "Tazana, when will you bring 
us grandchildren?" or "Tazana, have you no fruit to bear?" A 
few months ago, her monthly bleeding came late and raised her 
hopes falsely. Today, she was nearly 2 weeks overdue for her 
period. She felt tired and nauseated. Tazana hoped the doctor at 
the clinic could tell her whether she was pregnant—or whether 
she was sick, late, and still to await her turn at motherhood.
 
"Is my patient pregnant now?"  You will ask yourself this question
many times in your work as a family planning clinician. Sometimes
the clinical situation is confusing. It is especially important to remem-
ber the possibility of pregnancy when evaluating a woman who has
undergone surgical sterilization and has an abnormal menstrual pat-
tern or possible pregnancy symptoms. When pregnancy occurs after
surgical sterilization, the risk of ectopic (tubal) pregnancy is high.
 
6
Skills for diagnosing early pregnancy are also essential so that your
patient can begin pregnancy precautions and prenatal care during the
first few weeks of her pregnancy, when the fetus is most vulnerable.


























• You should be able to diagnose ectopic pregnancy early.
Detecting ectopic pregnancy before rupture could save your
patient's life and increase the chance that her future fertility
can be preserved.
• You should know how to ensure that your patients with an
unintentional pregnancy get adequate counseling and to
allow them to make a well-considered decision before pro-
ceeding on a course of action.
• You should know how to avoid inserting an intrauterine
device (IUD) in a patient who is pregnant and not to use
medications that are contraindicated during pregnancy.
• You should be able to evaluate a woman who has missed one
or more periods for causes of amenorrhea and to detect prob-
lems such as retained pregnancy tissue or continuing preg-
nancy after a spontaneous or induced abortion.
 
Figure 9:1 Detecting an ectopic pregnancy before it ruptures can 












Careful evaluation to detect pregnancy is especially important
before inserting an IUD because of the risk of septic spontaneous
abortion. It is also important before any medical treatment, such as
extensive x-rays or toxic medication, that might cause injury to a
developing fetus.  It is prudent to check carefully for pregnancy before
performing surgical sterilization or initiating long-term hormonal
methods such as implants or injectables.
 
CLINICAL EVALUATION IN PREGNANCY
 
Based on findings from a good medical history and physical examina-
tion, you can be quite certain about diagnosing pregnancy in most
cases. If the pregnancy is not normal or you are not certain, a preg-
nancy test may be helpful. Otherwise, repeating your clinical evalua-
tion and examination 1 or 2 weeks later usually makes the diagnosis
clear.  Pregnancy diagnosis has the following goals:
• To determine whether the patient is pregnant
• To estimate the duration of pregnancy in weeks as accurately
as possible



















The very first exam gives the most reliable estimate of pregnancy
duration. Try to be exact. This information may be important later if a
decision about inducing labor is necessary. Write down the dates of
the patient's last few menstrual periods and record her current preg-
nancy symptoms, the date they began, and the date of your examina-
tion. Carefully evaluate and record the size of the uterus (in weeks)
and the estimated date of confinement (EDC) after the first exam. Use




























Most patients first notice symptoms of pregnancy about 4 weeks
after the last menstrual period. The first sign is usually sensitivity of
the nipples, which may soon be followed by breast tenderness. These
symptoms can begin just before the menstrual period is due or during
the first week or two after the period is missed. During the first 4 to 12
weeks of pregnancy, other signs may appear:
Missed periods Weight gain 
Breast tenderness or swelling Mood changes
Nausea (morning sickness) Fatigue
Urinary frequency Change in appetite or eating habits
Feeling warmer than usual Change in dreams (more vivid)
Symptoms of nausea, breast tenderness, and fatigue are usually
most intense between 6 and 10 weeks of pregnancy, when pregnancy
hormone levels are at their peak. By the 12th week, these symptoms




Increase in breast size
Blotches of pigment on face (pregnancy mask; chloasma)
Protruding lower abdomen
Darkening of nipples
Vaginal discharge (wet mucus)
Fluttering fetal movements (15 to 16 wks)
Fetal movements and kicks (18 to 20 wks)





The first signs of pregnancy include a slight softness of the uterus
and a sense of increased flexibility at the junction between the cervix,
which remains more firm, and the body of the uterus, which is softer
than normal. These signs are subtle and may give a hint of pregnancy
as early as 4 or 5 weeks after the last menstrual period. Often, one












luteum cyst that is supplying hormones for the first few weeks of preg-
nancy. The woman's breasts may also seem slightly swollen and may be
more tender than usual on examination.
By 6 weeks of pregnancy, the uterus should definitely feel soft
and just barely enlarged, so you can be quite certain about the diagno-
sis of pregnancy. By 8 weeks, the uterus has enlarged to the size of a
small plum and begins to have a definitely rounded shape; the body of
the uterus feels like a bulge that begins at the junction with the cervix.
You may also notice that the woman's thyroid gland is more promi-































There is no way to be absolutely certain a patient is not pregnant.
Even a Sensitive Urine Test Kit cannot detect early pregnancy until
implantation is completed about 7 days after ovulation, and the
patient's history can be misleading. Even visible vaginal bleeding does
not provide infallible assurance:  bleeding can occur during early preg-
nancy and may even signal pregnancy problems such as threatened
abortion. Still, it is possible to be reasonably sure about pregnancy if





 likely under the following circumstances:
1. The woman has had a regular pattern of monthly menstrual
periods and meets one of the following conditions:
• She has not had sexual intercourse since her last men-
strual period.
• She has used an effective contraceptive method correctly
and consistently.
• She has had a normal menstrual period within the last 7
days.
2. The woman has been pregnant and meets one of the follow-
ing conditions:
• She had an abortion within the last 7 days.


























3. The woman is fully breastfeeding and meets one of the fol-
lowing conditions:
• She delivered within the last 8 weeks.
• She delivered within the last 6 months and has not yet
resumed menstrual bleeding.
Bleeding during the first 2 months after delivery is considered
postpartum bleeding, and is normal. After 2 months, when bleeding
resumes it indicates that the interval of lactational amenorrhea has
ended and potentially fertile menstrual cycles are returning. Lactational
amenorrhea provides effective contraceptive protection during the first






(the infant receives breast milk
exclusively or almost exclusively, day and night, with only occasional
tastes of water or food). A woman who does not breastfeed after delivery
may resume fertile menstrual cycles as soon as 4 to 6 weeks after deliv-
ery. (See Chapter 12 on Lactation and Postpartum Contraception.)
Evaluating the possibility of pregnancy in a woman who does not
have regular menstrual cycles can be confusing. If the patient's history
is not clear or if you are not certain about how reliable the information
is, it may be prudent to wait so that you can document the events of
the next menstrual cycle. An exam at the time of ovulation can verify
ovulatory mucus. If a microscope is available, you can check for mucus
that dries in a crystal fern pattern (called spinnbarkeit). The next nor-
mal menstrual period should begin 13 or 14 days later. If it begins on
the expected date, you can be quite certain the woman is not preg-
nant. Be sure the woman uses an effective contraceptive method or is
able to avoid intercourse during this interval. Alternatively, a Sensitive














Sometimes it is not possible to reach a definite diagnosis during
the first exam. The most common reason for uncertainty is very early
pregnancy—an exam 1 week later, when signs and symptoms are
clearer, may solve the problem. Abnormal pregnancies can also cause
confusing signs and exam findings. The following discussion presents














Bleeding in early pregnancy is common.  Sometimes bleeding is
the first sign of a problem, but it can also occur in a completely normal
pregnancy.   A woman who has a normal pregnancy may report an epi-
sode of bleeding that seems like a normal menstrual period, or she may
have had bleeding that is lighter or shorter than normal or at not quite
the correct time.  In this situation, the woman's uterus will be about 4
weeks larger than you would expect from her last bleeding date. Other
causes for a larger than expected uterus are shown in Table 9:1.
Bleeding can also be a sign of problems such as ectopic preg-
nancy or threatened spontaneous abortion (miscarriage). In these situ-
ations, the uterus is usually smaller than you would expect from the
date of the woman's last period. The bleeding pattern with both these





Of all the pregnancy problems, ectopic pregnancy is the most
important to keep in mind, because emergency treatment may be
needed. Internal hemorrhage from ectopic pregnancy is a leading
cause of maternal death.
 
Table 9:1 Reasons for a difference between size of the uterus and 
period dates
 
Uterus smaller than expected Uterus larger than expected
 
Fertilization later than dates suggest Fertilization earlier than dates suggest
(ovulation was delayed) (pregnancy began before last "period")
Spontaneous abortion: threatened Uterine leiomyomata (fibroids)
Incomplete, or missed abortion Twin pregnancy
Incomplete abortion procedure Abnormal uterus (such as bicornuate)


























Vaginal bleeding associated with ectopic pregnancy may not be
very heavy and may be intermittent. The woman may have pregnancy
symptoms such as breast tenderness or nausea, but these tend to be
less intense than during a normal pregnancy, and she may have no
clear symptoms at all. She may also have abdominal pain, especially if
the pregnancy has progressed to 6 weeks or more.
Pain may be one-sided, or it may be more generalized in the
lower abdomen; once pain has started, it tends to be persistent and
does not usually have the crampy, intermittent pattern that is com-
mon with uterine cramps or contractions caused by spontaneous abor-
tion. The uterus is likely to be smaller than last period dates would
suggest, and there may be tenderness in the area of the fallopian tube
during exam. In some cases, the ectopic pregnancy may be palpable as
a mass in the area of the fallopian tube or ovary. 
As the pregnancy progresses to 7 weeks of gestation or more,
internal bleeding or rupture becomes more and more likely. Internal
bleeding causes severe pain, with abdominal muscle guarding and
rebound tenderness when the abdomen is palpated. As blood inside
the abdominal cavity is irritating to the bowel, bowel sounds may be
 
Table 9:2 Risk factors for ectopic pregnancy
 
History of prior ectopic pregnancy
History of prior pelvic inflammatory disease (PID)
History of gonorrhea or chlamydia
History of appendicitis
History of prior abdominal surgery or pelvic surgery
Bleeding or spotting during early pregnancy
Uterus smaller or firmer than last menstrual period date suggests
Became pregnant while using an intrauterine devices (IUD), 
progestin-only pills, or progestin implants
Became pregnant after tubal sterilization
Became pregnant despite using emergency postcoital pills












diminished or absent, and vomiting may occur. Irritation of the dia-
phragm may also cause shoulder pain. Internal hemorrhage also causes
hypotension and a drop in blood count, and it can lead rapidly to
death.   
Diagnosing an ectopic pregnancy early is tricky. Early suspicion







and a slide pregnancy test (2-minute agglutination test) is
likely to be negative,
 
3 because the pregnancy hormone levels are lower
than normal in most cases of ectopic pregnancy. Be alert, especially if
the woman has one or more risk factors for ectopic pregnancy (see
Table 9:2). If ectopic pregnancy is a possibility, make sure the woman
understands the danger signs shown in Table 9:3. Frequent, careful
follow-up, with daily exams, may be needed until the diagnosis is
clear. If the woman has symptoms that strongly suggest ectopic preg-
nancy, every effort should be made to arrange for further evaluation.
Culdocentesis, to aspirate fluid from the abdominal cul-de-sac, may
show that internal abdominal bleeding is occurring. If available, a sen-
sitive pregnancy test and ultrasound evaluation may be helpful. Signs
like hypotension or a dropping blood count, however, mean there is
no time for delay; immediate surgery can be lifesaving.
 
Table 9:3 Early pregnancy danger signs  
 




• Sudden intense pain, persistent pain, or cramping in the lower abdomen, usu-
ally beginning on only one side or the other
• Irregular bleeding or spotting with abdominal pain when period is late or after 
an abnormally light period
• Fainting or dizziness persisting more than a few seconds, which may be a sign of 





• Last period was late and the bleeding is now heavy, possibly with clots or clumps 
of tissue. Cramping is more severe than usual
• Period is prolonged and heavy:  5 to 7 days of heaviest bleeding






























Bleeding associated with a spontaneous abortion may be heavy
with clots; the woman may have cramping. The cervix may appear
partly dilated. In some cases, clots and tissue visibly protrude from the
cervical os. Bleeding can be heavy enough to cause anemia. Immediate
referral for surgery (vacuum aspiration) may be needed to remove
remaining pregnancy tissue and stop hemorrhage. Because the risk of
serious infection is high with incomplete abortion, if you suspect
retained tissue, it would be wise to perform a vacuum aspiration of the
uterine contents. There may be retained tissue after incomplete spon-
taneous abortion or after an attempted abortion procedure. The
woman with retained tissue is likely to have persistent bleeding and
cramping, and she may develop signs of infection such as severe uter-
ine tenderness, increasing abdominal pain, fever, and malaise. The
vaginal secretions and blood may appear cloudy and abnormal, with a
slightly sweet or foul odor. Immediate, intensive treatment for infec-




Be especially careful if there is any question of trauma or you suspect
that an abortion procedure may have been attempted.
When the spontaneous abortion is complete, uterine bleeding
subsides to a light flow and cramping stops, usually within a few
hours. Pregnancy symptoms also subside promptly, and the uterus
feels firm and non-tender during the pelvic exam. If the woman has
no further bleeding and cramping episodes, feels well, and has no
fever, she may not require any treatment. Schedule a follow-up exam








If the fetus stops growing, the uterus will be smaller than the woman's
period dates suggest it should be. On a follow-up exam, the uterus will
not have grown. If ultrasound or quantitative blood pregnancy tests
are available, it may be possible to make a definite diagnosis. Other-
wise, it may be quite difficult to be certain about what is happening. It
is possible that a non-viable pregnancy could remain in place for












If the woman's uterus is larger than menstrual dates suggest, con-
sider the possibility of a twin pregnancy, a uterine leiomyomata
(fibroids), or a uterine abnormality such as bicornuate (two-horn)
uterus. If the rate of growth is very rapid and significantly larger than
it should be, consider trophoblastic disease (molar or hydatidiform
pregnancy). As pregnancy hormone levels are very high with tropho-
blastic disease, a woman with this disorder is also likely to have preg-
nancy symptoms, such as nausea, that are more intense than average.




Pregnancy tests detect human chorionic gonadotropin (hCG) in a
pregnant woman's urine or serum. This hormone is produced by pla-
centa cells and first appears at very low levels soon after implantation,
which occurs about 7 days after ovulation. hCG production rapidly
increases, doubling approximately every 2 days. When the woman's
first missed period is due, the serum level of hCG has reached 50 to
250 mIU/ml and can be detected by sensitive pregnancy tests. When
she is 6 weeks pregnant, the level is high enough (several thousand
mIU) to be detected by all commonly used pregnancy tests.
Pregnancy hormone levels peak at 8 to 10 weeks of pregnancy,
then decline to a lower, steady level until the end of pregnancy (see
Figure 9:2). This explains why symptoms caused by hCG, such as
nausea and fatigue, are usually most intense during the second month
of pregnancy.
Pregnancy hormone production is often abnormally low in
ectopic pregnancy and in spontaneous abortion. In these situations, a
slide pregnancy test (2-minute agglutination test) is likely to be nega-
tive even though the woman is pregnant. The hormone level is simply
too low to detect unless a sensitive pregnancy test is available. Abnor-



























Figure 9:2  hCG levels during normal pregnancy
 
Source:  Braunstein et al.  (1976) with permission.
 
After pregnancy, the source of hormone production in the placenta is
gone, and hormone in the bloodstream is gradually cleared. Because
the level will have dropped to less than 50 mIU/ml 2 weeks after a
full-term pregnancy, even a sensitive pregnancy test will no longer be
positive at that time. When abortion occurs during the first 3 months
of pregnancy, however, the starting level of hCG is very high. In this
case, the level may still be high enough 2 weeks later to cause the preg-
nancy test to remain positive. Even a sensitive test should be negative,


















There are several different kinds of pregnancy tests. Because they
differ in sensitivity and design, interpreting positive and negative
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Slide Pregnancy Test (2-minute agglutination test)  
 
This test can detect pregnancy when the hCG hormone level is
1,500 mIU/ml or higher, which occurs at about 6 weeks of pregnancy.
Slide tests involve mixing a drop of the patient's urine with a drop of
test solution that contains antibody. If the patient's urine contains
hCG hormone, it binds with the anti-hCG antibody in the test solu-
tion. Binding of the test antibody prevents clumping (agglutination)
of latex particles in a second test solution, which is poured onto a
slide. If the woman is pregnant, the second solution does not clump. If
clumping occurs, it means the test is negative. (Note:  some slide tests
work by direct clumping, where the results are reversed; be sure to read
the directions with your kit carefully before performing a test.)
Incorrect results can occur if the woman has protein in her urine
or abnormally high levels of certain other hormones. These include
luteinizing hormone (LH), which is high at ovulation, thyroid stimu-
lating hormone (TSH), which is elevated because of hypothyroidism,
or follicle stimulating hormone (FSH), which is elevated after meno-
pause. Because these hormones can cross-react with antibodies in the
slide-test solution, the test can show a positive result even though the
woman is not pregnant. On the other hand, certain medications, as
well as urine that is too dilute, can cause a negative test result even
though the woman is pregnant. The test is most likely to be positive if
the urine used is the first the woman voids in the morning.
Slide agglutination tests are easy to store and use and are rela-
tively inexpensive. The information they provide, however, does not
add much to clinical management because a clinical history and a
physical exam can also provide an accurate diagnosis by the 6th week
of a normal pregnancy. Because slide agglutination tests cannot detect
a low hormone level, this test is not reliable in diagnosing ectopic
pregnancy and is not helpful in verifying pregnancy prior to IUD



























Sensitive Urine Pregnancy Test Kits  
 
These tests can detect pregnancy when the hCG level is 50 mIU/
ml or higher, which occurs within about 10 days after ovulation (some
kits are even more sensitive). Sensitive kits use two antibodies to link
hCG hormone in the woman's urine to an enzyme that changes color.
Sensitive kits are easy to use, but they are more expensive than
slide tests and not as easy to store. They are reliable, however, for diag-
nosing ectopic pregnancy and for verifying that a woman is not preg-
nant prior to biopsy, x-ray, IUD insertion, or medical treatment that
should be avoided in pregnancy.
False results are not common with sensitive urine pregnancy test
kits, and cross-reaction with other hormones is not a problem.
 
Intermediate Sensitivity Tube Tests
 
Tube tests based on agglutination that are similar to the slide test
are available to detect hCG levels of about 200 to 1000 mIU/ml. They
are somewhat more expensive than slide agglutination tests but not as
easy to use, and they may require more time to perform. Depending
on availability and cost, however, tube tests may be a useful alternative
to the Sensitive Urine Test Kits described above, but not quite as sensi-
tive.
Blood Pregnancy Tests
A quantitative blood (serum) test can be used to measure the
exact level of hCG; this test can accurately detect levels of hCG as low
as 5 mIU/ml. Called Quantitative Beta-hCG assay, this test can help
identify a non-viable pregnancy such as missed abortion or tropho-
blastic (molar) pregnancy. Sequential hCG levels may also help diag-
nose ectopic pregnancy.
Quantitative Beta-hCG assays, like radioimmunoassays and
radioreceptorassays, require sophisticated laboratory facilities and do
not provide immediate results. When a simple yes or no (positive or
negative) answer is the goal and Sensitive Urine Kits or Tube Tests are
available, more costly blood tests do not have any clinical advantages.   
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PRIORITY SITUATIONS FOR PREGNANCY TESTING
In most cases, pregnancy test results do not make a crucial differ-
ence in clinical management. There are some situations, however,
when having a pregnancy test available can be very helpful:
1. To distinguish between pelvic infection and ectopic preg-
nancy. The early symptoms of a pelvic infection and an
ectopic pregnancy can be very similar:  abnormal bleeding,
pelvic and abdominal pain, abdominal tenderness and
guarding, and uterine and adnexal tenderness. As the prob-
lem progresses, signs of internal hemorrhage that indicate
ectopic pregnancy, or significant fever and sepsis that indi-
cate an infection is present are likely to develop. Making the
correct diagnosis as soon as possible may be a matter of life
and death. Having a Sensitive Urine Test Kit available to
diagnose ectopic pregnancy quickly and early could save a
woman's life.
2. To avoid unnecessary vacuum aspiration surgery. Symp-
toms of incomplete abortion can be similar to symptoms of
early pelvic infection or of spontaneous degeneration of a
uterine leiomyoma (fibroid). If the woman has not passed
recognizable tissue and if pregnancy has not been diagnosed
prior to the onset of signs associated with a spontaneous
abortion, distinguishing incomplete abortion from these
problems may be tricky. If a Sensitive Urine Test Kit result is
negative, incomplete abortion is not likely and vacuum aspi-
ration surgery can be avoided.
3. To confirm pregnancy problems. Pregnancy testing may be
helpful when a patient is referred for an evaluation of rare
pregnancy problems. A quantitative Beta-hCG level, or two
quantitative Beta-hCG tests obtained several days apart, can
confirm diagnosis of trophoblastic (molar) pregnancy or an
abnormal or non-viable pregnancy. Alternatively, an ultra-
sound evaluation can be used to help diagnose rare problems. 
4. To avoid unsafe or unneeded abortion surgery. Routinely
performing a Slide Urine Test (2-minute agglutination)
before planned abortion is reasonable. A negative result
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shows that the pregnancy hormone level is below 1500 mIU/
ml, which means that the woman is either not pregnant or
has been pregnant for less than 6 weeks.  If the woman is not
pregnant, an unnecessary procedure is avoided.
AVOIDING PREGNANCY TEST INTERPRETATION ERRORS
Sometimes, the results of a pregnancy test do not agree with
other clinical signs:
1. Any test can be wrong. Laboratory error is always possible.
Specimens could be mixed up, or there could be a problem
in performing the test. It is essential to follow kit instructions
precisely and time the steps carefully. Be sure to follow rec-
ommendations for storage; respect kit expiration dates.
2. Know the test being used. Interpreting results depends on
understanding both the sensitivity of the test and what it will
and will not detect.
3. False results are common with slide agglutination tests. A
slide test is likely to be negative, even though the woman is
pregnant, if the test is performed either too early or too late
(after about 16 to 20 weeks, when the hCG hormone level
has dropped). Results can also be negative with an ectopic
pregnancy, threatened or missed abortion, or when the
woman is pregnant but her urine is too dilute. Protein or
blood in the urine could cause a positive test when the
woman is not pregnant, as could a cross reaction with thy-
roid or menopause hormones.
4. False results are not common with Sensitive Urine Test
Kits. A false result could occur if this sensitive test is per-
formed incorrectly. For example, there could be excessive
rinsing or the person performing the test could have red-
green color blindness. Unusual medical problems such as
severe kidney disease or cancer can also cause a false result. 
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COUNSELING AND PATIENT INSTRUCTIONS 
FOR OPTIMAL PREGNANCY
Often, a visit for diagnosing pregnancy provides an important oppor-
tunity for patient education and family planning counseling. If the
patient is pregnant, precautions for pregnancy can be reviewed and
arrangements made for prenatal care. The importance of diet, includ-
ing adequate intake of folic acid (0.4 mg daily) and calcium (at least
1,500 mg daily), needs to be stressed, as well as the importance of
avoiding alcohol6 and other potentially toxic exposures. If the patient
is not pregnant but would like to be, she may need information to
maximize her chance for fertility. Because she is not pregnant, this will
be a good opportunity to begin planning for optimal pregnancy. If the
visit is a pregnancy “scare”—the patient is not pregnant and does not
want to become pregnant—this is an ideal time for her to learn about
and to initiate effective contraception.
INSTRUCTIONS FOR OPTIMAL PREGNANCY
1. Think about medical risk factors (your own, your partner's,
and both your families) that may affect pregnancy. You may
want to talk to a physician if either family has hereditary
problems such as sickle cell anemia or Tay-Sachs disease. If
you have any serious medical condition or take medication for
any reason, talk to your health provider before you become
pregnant. Your medications may need to be changed to avoid
problems in pregnancy, and you will want to be sure any med-
ical conditions you have are under control. This is especially
important for problems like diabetes or tuberculosis.
2. Be sure your diet is as good as it can be, and take a daily vita-
min supplement if possible. Ideally, start several months
before you become pregnant. Pregnancy can deplete impor-
tant vitamins and minerals like iron and calcium, so you will
need to be sure to get plenty of good nutrition. The vitamin
folic acid, 0.4 mg daily, is specifically recommended to
reduce the chance of spinal defects in your baby.
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3. Avoid exposure to potentially toxic agents. Do not drink
alcohol, do not smoke, and do not use any illegal drugs.
Avoid excessive caffeine, and avoid x-rays of the abdominal
area.
4. Try to avoid being exposed to a sexually transmitted infec-
tion. Avoid intercourse or use condoms if you have any
chance at all of being exposed to a sexually transmitted infec-
tion. Infections such as herpes, gonorrhea, chlamydia, or
syphilis can cause serious or deadly complications in your
baby.
5. Try to avoid being exposed to contagious illnesses. Fever can
cause problems in pregnancy; try to avoid contact with peo-
ple with contagious diseases, such as influenza.
6. Avoid contact with animal feces. Toxoplasma infection is
transmitted through cat feces, and other animals carry infec-
tious organisms as well. Do not handle feces during preg-
nancy. If possible, wear gloves when working with soil, and
afterward wash your hands with soap and clean water.
7. See your health provider as soon as possible if you think you
may be pregnant. Having your first pregnancy exam early
will help in getting accurate dates for your pregnancy. If pos-
sible, schedule your exam within 2 weeks after missing your
period.
8. Watch for the danger signs of possible pregnancy problems.
Signs of pregnancy problems like ectopic pregnancy (which
is also called tubal pregnancy) and miscarriage are likely to
occur during the first month or two of pregnancy. Remem-




1. Coustan DR, Haning RV, Singer DB. Human reproduction: growth and devel-
opment. Boston, MA: Little, Brown and Company, 1995.
3. DeCherney AH, Minkin MJ, Spangler S. The contemporary surgical manage-
ment of unruptured ectopic pregnancy. J Reprod Med 1981;26:521-529.
4. Kase NG, Weingold AB, Gershenson DM. Principles and practice of clinical
gynecology. Second edition. New York: Churchill Livingstone, 1990.
5. Kennedy KI, Visness CM. Contraceptive efficacy of lactational amenorrhoea.
Lancet 1992;339:227-230.


























Nonke came many times to the family planning clinic. She 
asked questions about the contraceptive she used. She did not ask 
why she had pain when her husband entered her during their 
lovemaking. She was embarrassed to bring up such matters. Yet 
she desperately wanted to do something so she could give her hus-
band more satisfaction and so she too could experience the plea-
sure she heard her friends mention.
 
Contraception is a significant part, but still only a part, of family plan-
ning. Family planning, in turn, is a very small part of sexuality (see
Figure 10:1). Family planning practitioners have a unique opportunity
to supply sexual counseling services to patients who might have no


























Figure 10:1 Sexuality, family planning, and safer sex
 
TAKING A BRIEF SEXUAL HISTORY
 
If you have time to ask only one question of each patient, a rea-
sonable choice might be:
 
What do you do to protect yourself from AIDS?
 
The patient who responds, "Who, me?" can be encouraged to
look closely at whether there is any risk for sexually transmitted infec-
tion (STI) in her or his present or past sexual relations. The patient
who says, "I use condoms every time I have sex" can be praised, rein-
forced on correct condom use, advised about where to get free or inex-




























If you have 2 to 5 minutes, ask these 10 questions to get a basic
history:
  1. Have you had a sexual experience with another person in the
past year?
  2. (If yes to question 1) With how many different people? One?
Two or three? Four to 10? More than 10?
  3. (If yes to question 1) In this past year, have you had sex with
men, with women, or with both?
  4. Can you tell me about your sexual life before this last year?
  5. Have you ever had a sexually transmitted infection of any
kind?
  6. Have you ever shared needle or injection equipment with
another person for any reason?
  7. Have you ever felt for any reason that a sex partner put you
at risk of infection?
  8. What do you do to protect yourself from AIDS?
  9. What do you do to protect yourself from unplanned preg-
nancy?
10. Is there anything else about your sexual lifestyle I need to
know to take the best possible care of you?
If you have longer than 5 minutes, add questions about specific
sexual practices, gynecological problems related to sexual function,
relationships, alcohol and drug use, and sexual dysfunction.
It is appropriate to allow patients to defer the sexual history until
a later visit or to decline to discuss sexual issues altogether. Once you
have expressed your view that the sexual history is a normal and valu-



























THE PLISSIT COUNSELING MODEL
 
The PLISSIT counseling model was developed for health care workers
who are not psychiatrists, psychologists, or sexual therapists but who
wish to address the sexual needs and concerns of their patients and






It consists of four stages:





 is telling the patient that being sexual in his
or her own way is acceptable. Permission giving from a knowledgeable
professional figure is quite powerful. However, health care workers are
not required to give permission for thoughts, feelings or behaviors that
violate their own professional value system. Furthermore, professionals
ought not approve of behaviors that threaten the physical or psycho-




 usually involves discussing anat-




 involve skill-building such as changing
position for intercourse and other activities, using lubricants, or using




 will probably prove too time-consuming and
involved for all but those who are specially trained and wish to devote
considerable time to such work. Intensive therapy may be necessary
for body image problems, relationship problems, identity issues,




Sexual arousal may be caused by a dream, a fantasy, a memory, or any
of the five senses: taste, smell, sight, sound, or touch. Couples can enjoy
a wide range of intimate sexual expressions—from holding hands,  hug-
ging,  kissing,  massage, and  dancing to petting,  mutual masturbation,




















individual to individual and from culture to culture. One common fac-




. People need touch-
ing for nurture, for solace, for expressing simple affection, for
communicating, and for sexual gratification. This chapter does not
describe specific sexual practices but discusses the physiology of the sex-
ual response, the contraceptive’s effect on that response, and informa-
tion for counseling couples on sexual dysfunctions. Researchers
describe four physiological stages of sexual response as listed in Table
10:1.
One significant difference between men and women has to do
with the ease of attaining multiple orgasms during a single sexual epi-
sode. Women are physiologically capable of moving between plateau
and orgasm one or several times.
Men have a refractory period that follows ejaculation. During the
refractory period, they have difficulty achieving a second erection, and
after they attain an erection, it may be difficult to have orgasm and
ejaculate. The length of the refractory period gradually increases as
men grow older. It may be only 5 to 15 minutes in an 18-year-old, but
by the age of 60, the refractory period may be 18 to 24 hours. The
length of the refractory period varies widely. In general, the more fre-


















Virtually any portion of a woman's skin may give pleasurable and
exciting sensations when caressed, providing she is willing and not dis-
tracted. Women vary greatly in what sort of stimulus produces
orgasm. It is common to find healthy, normal women who are orgas-
mic by some means but are not orgasmic with penile-vaginal thrusting
alone. However, regardless of the method by which they are produced,


























Breast and nipple sensitivity tends to be high in most women,
but some women do not find breast caressing particularly arousing.
For most women whose genitals are intact, the glans and shaft of the
clitoris, the inner surfaces of the labia minora, and the first inch and a
half of the vagina are the most sexually sensitive areas of all. Indeed,
the clitoral head (glans) may be so sensitive that direct touch is some-
times or always uncomfortable. Some women have an area of sexual
sensitivity beneath the anterior wall of the vagina about halfway from
the hymenal ring to the vaginal vault. (Genital mutilation or circumci-
sion can interfere greatly with these physiological sensations and can
 












Lubrication and dilation of the 
upper vaginal canal. Both men and 
women have increased muscle tension, 
increased heart and respiratory rate, and 
increased blood pressure. The focus of 
attention becomes more centered on 
sexual matters.
Plateau Sustained engorgement, muscle tension, 
elevated heart and respiratory rates, and 
elevated blood pressure for a period that 
may last from minutes to hours.
Orgasm Rhythmic contractions of pelvic 
voluntary and involuntary musculature 
in both sexes. In men, this action can 
result in ejaculation of semen. Orgasm is 
a beginning of relief from tension.
Resolution Gradual loss of muscle tension, 
progressive relaxation, and often a sense 
of drowsiness and contentment. Blood 
vessels open to drain pelvic and genital 
engorgement, and gradually (usually over 
a period of minutes) the individual 
returns to a nonexcited state.
 




















leave a woman with little or no feeling or with painful sensations.)
Women may respond sexually to anal stimulation.
Ejaculation of fluid from the urethra at orgasm should be
regarded as a normal female sexual response and not as urinary incon-
tinence. Usually, a folded bath towel under the woman's hips is suffi-
cient to keep sheets and bedclothes from becoming dampened. The


















Men tend to find genital sexual stimulation more intense than
whole-body touch arousal. Nipple stimulation may be as arousing for
men as it is for women. The genital sites of highly pleasurable sensitiv-
ity (in order of decreasing response to touch) are as follows:
• Area of frenular attachment on ventral surface of penis, just
behind the glans
• Coronal ridge of glans
• Urethral meatus
• Shaft of the penis
• Penile base, which is located within the perineal area between
the area of scrotal attachment and the anus
• Scrotum and testicles (gentle manipulation only)
• Perianal skin
 
EFFECTS OF CONTRACEPTION AND SAFER SEX 
ON SEXUAL FUNCTION
 
The family planning provider should remember that contraception
and sexual practices can influence the client's ability to function sexu-
ally. Generally, candid communication can help the client avoid or






































Worry about human immunodeficiency virus (HIV), genital
warts, and other incurable viral sexually transmitted infections often
affects a couple's sexual experience. The clinician's task is to help























For men, the subject of pregnancy may cause concern, but their
level of concern tends to be lower than that for women. Among
women, feelings about pregnancy have an impact that men generally
do not feel. For couples trying to conceive, instructions to have inter-
course around ovulation can be stressful for both partners. The fear of






Reassure patients about the naturalness of sexual feelings associ-
ated with breasts. In cultures where the breast is considered an erotic
object, some new fathers may be confused about their feelings about
their partner’s breasts while milk flows from them. Some fathers














Decreased sex drive is an occasional side effect of oral contracep-
tives. Patients with this symptom will frequently report it. However,
young women who are virgins may not realize that their desire is
affected by the pill. Another concern is that couples who use the pill
may be reluctant to interrupt lovemaking to add condoms or other








































Some women who request diaphragms may initially feel uncom-
fortable about inserting the device. A poorly fitted diaphragm may
cause discomfort and thus inhibit sexual enjoyment. A diaphragm that
is too large may press too hard against the tissues; one that is too small
may become dislodged when the vagina expands during sexual excite-
ment. The extra lubrication these products supply is pleasant for some






Some men lose their erection rapidly after ejaculation, and others
maintain a relatively erect penis for some time. All men should hold
the rim of the condom at the base of the penis as they withdraw to
prevent the condom from slipping off. For couples with any STI risk,




 the penis comes in contact with the





















, he must pull out and move away from his partner when his
desire is to push deeper, clasp, and hold more firmly). This method may
leave some women without orgasmic relief. The couple should make a
special effort to continue sexual play after withdrawal to make sure
both partners have achieved gratification and relief of sexual tension.
Semen remains on the penis after ejaculation. Thus, the man
should not put his penis back into the vagina until he cleans his penis






Couples may achieve satisfaction with sexual abstinence as long

























individual needs. However, the couple practicing sexual abstinence
may lose a major method of nonverbal communication in their rela-
tionship and may find it difficult to compensate by communicating in
less intimate ways. They must make special efforts to maintain or
strengthen other forms of communication.
FEMALE AND MALE SEXUAL DYSFUNCTIONS
When anything occurs to distract a person from excitement, then
erection (in men), lubrication (in women), and orgasm or ejaculation
may be impeded. Medications that affect the autonomic nervous sys-
tem or have a sedative effect may cause a change in sexual function. 
LOSS OF DESIRE
Loss of desire may follow previous experiences that have caused
embarrassment, pain, or inadequacy. Other important reasons for los-
ing desire include the following:
• Estrogen deficiency with secondary vaginal atrophy (whether
postsurgical or postmenopausal) commonly leads to dyspare-
unia, which is painful penis-in-vagina intercourse. This con-
dition often can be treated successfully with topical or
systemic estrogen therapy.
• Birth control pills may diminish desire in some women, but
diminished desire in pill users is more often associated with
psychological factors (depression, grief, suppressed anger,
etc.).
• Chronic fatigue affects both male and female sexual respon-
siveness. Any time a primary care-giving parent has a young
child and complains of diminished responsiveness, then
chronic fatigue should be considered as an important con-
tributing factor.
• Debilitating diseases and conditions such as childbirth, sur-
gery, cancer, chronic dieting, and excessive weight loss may
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temporarily or permanently diminish desire and responsive-
ness.
• Medical disease may negatively affect sexual responsiveness.
About half of female diabetics will eventually become anor-
gasmic. Organic pelvic or genital disease may lead to dys-
pareunia and eventual secondary loss of desire.
FEMALE SEXUAL DYSFUNCTIONS
Anorgasmia
Primary Anorgasmia. Some women are orgasmic during their
first sexually exciting experience, and others never learn to have an
orgasm. Women who have primary anorgasmia sometimes achieve a
relatively low level of sexual excitement and may think of intercourse
or other sexual activities as pleasant. They may get most of their
reward from touching, holding, kissing, caressing, attention, and
approval. However, women who regularly achieve high levels of sexual
response without orgasmic release of tension may find the experience
frustrating. Emotional irritability, restlessness, and pelvic pain or a
heavy pelvic sensation may occur because of vascular engorgement.2,4
Women who have not yet had an orgasm usually have some com-
bination of the following:
• Sociocultural inhibitions that interfere with normal sexual
response.
• A lack of knowledge about sex and sexuality, which interferes
with normal sexual development.
• A lack of opportunity to practice in a safe, secure, socially
acceptable, and private atmosphere (alone or in a relation-
ship) in a situation that offers approval and support. 
• A partner who ejaculates prematurely.
• A partner who has primary or secondary difficulty in achiev-
ing an erection.
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• Genital mutilation (circumcision) that removes part or all of
the clitoris, scars the genital area, or constricts the opening to
the vagina. Often, vaginal intercourse is painful not only
because of scarring from this procedure but also because of
associated infection.
Secondary Anorgasmia. Secondary anorgasmia is the loss of
ability to become orgasmic. The cause may be alcoholism, depression,
grief, medication, illness, estrogen deprivation associated with meno-
pause, or an event that has violated the patient's sexual value system.
Situational Anorgasmia. Women who are orgasmic in some sit-
uations may not be in others. A woman may have an orgasm from one
type of stimulation but not from another. Or a woman may achieve
orgasm with one partner but not another, or have an orgasm only
under certain conditions or only with a certain type or amount of
foreplay. These common variations are within the range of normal sex-
ual expression. 
Encourage a woman with situational anorgasmia to explore alone
and with her partner those factors that may affect whether or not she is
orgasmic, such as fatigue, emotional concerns, feeling pressured to have
sex when she is not interested, or her partner's sexual dysfunction. 
Family planners should consider recommending the female-
above position for penile-vaginal intercourse, as it may allow for
greater stimulation of the clitoris by the penis or symphysis pubis or
both, and it allows the woman better control of movement. Bridging
is the combining of a successful method for sexual stimulation with a
desired technique so that the body learns to associate orgasm with that
technique. If, for example, the woman is readily orgasmic with manual
stimulation but not with penile-vaginal thrusting, she is encouraged to
combine those two regularly until her body has learned to associate
high levels of excitement and orgasm with penile-vaginal thrusting.
Random Anorgasmia. Some women are orgasmic but not in
enough instances to satisfy their sense of what is appropriate or desir-
able. Often such women have trouble giving up control and allowing
themselves to respond fully. Therapy can be aimed at helping them give
up the need to keep their sexual feelings under control at all times.
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Dyspareunia
Dyspareunia (painful intercourse) often can be resolved, even
when long-standing, self-perpetuating pain is a factor. Clinicians
should consider dyspareunia to be primarily a physical, rather than an
emotional, problem until proven otherwise. In most instances of dys-
pareunia, there is an original physical cause. Among many African
women, dyspareunia results from the damage caused by vaginal cir-
cumcision.
When pain occurs, the woman may be distracted from feeling
pleasure and excitement. Both vaginal lubrication and vaginal dilation
decrease. When the vagina is dry and undilated, penile thrusting is
painful. Even after the original source of pain (a healing episiotomy,
for example) has disappeared, a woman may feel pain simply because
she expects pain. In brief, dyspareunia can be classified by the time
elapsed since the woman first felt it:
• During the first 2 weeks or so, dyspareunia caused by penile
insertion or movement of the penis in the vagina or by deep
penetration is often due to disease or injury deep within the
pelvis.
• After the first 2 weeks or so, the original cause of dyspareunia
may still exist with the woman still experiencing the resultant
pain. Or it may have disappeared, but the woman has antici-
patory pain associated with a dry, tight vagina.
Dyspareunia is treated by the taking following steps:
• Carefully taking a history.
• Carefully examining the pelvis to duplicate as closely as pos-
sible the discomfort and to identify a site or source of the
pelvic pain.
• Clearly explaining to the patient what has happened, includ-
ing identifying the sites and causes of pain.
• Removing the source of pain when possible.
• Prescribing very large amounts of water-soluble sexual or sur-
gical lubricant during intercourse. Discourage petroleum
jelly. Moisturizing skin lotion may be recommended as an
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alternative lubricant, unless the patient is using a condom or
other latex product. Lubricant should be liberally applied (2
tablespoons full) to both the penis and vulva or introitus. A
folded bath towel under the woman's hips helps prevent
spillage on bedclothes.
• Instructing the woman to take the penis in her hand and
control insertion herself rather than letting the man do it.
• Encouraging the couple to add pleasant, sexually exciting
experiences to their regular interactions, such as bathing
together (in which the primary goal is not cleanliness),
mutual caressing without intercourse, and using sexual books
and pictures. Such activities tend to increase both natural
lubrication and vaginal dilation, both of which decrease fric-
tion and pain.
• Recommending a change in coital position to one admitting
less penetration for women who have pain on deep penetra-
tion because of pelvic injury or disease:
— Maximum penile penetration is achieved when the
woman lies on her back with her pelvis rolled up off the
bed, compressing her thighs tightly against her chest with
her calves over the man's shoulders. Minimal penetration
occurs when the woman lies on her back with her legs
extended flat on the bed and close together while her
partner's legs straddle hers. 
— If no vaginal penetration is tolerable, the couple may sub-
stitute interfemoral intercourse, in which the woman lies
with her legs straight and her ankles locked (crossed). A
triangular space between the upper thighs and vulva per-
mits stimulation of both vulva and penis. 
Vaginismus
Vaginismus is a painful or spastic contraction of a woman's pelvic
floor muscles that occurs with attempted penetration of the vagina.
Young women may be unable to begin having intercourse without
pain. 
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Primary vaginismus. Vaginismus is commonly seen in the gyne-
cological examining room among young women who appear afraid of
their first pelvic examination. Rather than being uncooperative, such
young women are actually suffering from a reflex they have not yet
learned to control.
Secondary vaginismus. Vaginismus is sometimes a secondary
process. A woman who had severe dyspareunia from some physical
cause, such as the structural changes caused by female circumcision,
may develop secondary vaginismus as a reflex. Women who have been
raped, sexually abused, or examined by a rough clinician also may
develop secondary vaginismus.
In general, women who have vaginismus are strongly motivated
to change. Many of them can learn to break their cycle of spastic con-
tractions even with one limited pelvic exam performed with extreme
gentleness (including a one-fingered vaginal exam and omission of the
rectal exam). Allow the woman to be in charge of the exam; do noth-
ing without her knowledge and permission, and explain all parts of the
examination in detail in advance. As the exam progresses, reassure the
woman that her pelvic findings are normal (if they are normal). A
partner can be counseled to show the woman the same degree of gen-
tleness and communication.
Some women may require vaginal dilation as part of the treat-
ment of vaginismus. The best vaginal dilator is the woman's own fin-
ger, which she can insert with the aid of a little lubricant.
MALE SEXUAL DYSFUNCTIONS
Rapid (Premature) Ejaculation
When ejaculation during intercourse occurs without any sense of
voluntary control and within a minute or so of insertion of the penis,
it may be termed rapid because the time available for sexual pleasure is
quite limited for both people. Although a few men tend to ejaculate
rapidly as a response to anxiety or stress, most men who ejaculate rap-
idly have done so consistently from their earliest experiences with a
partner.
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Erective Difficulty (Impotence)
Primary erective difficulty (inability to sustain an erection suffi-
ciently for insertion) is not common and usually has to do with high
levels of anxiety about sexual performance. 
Secondary erective difficulty is quite common. Its cause may be
psychological, but more likely it is due to organic disease or use of
pharmacologic substances. In general, erective loss caused by organic
disease is persistent and progressively worsens. Men with this problem
may lose sexual desire. In contrast, men whose erective loss is prima-
rily psychogenic sometimes have a history of acute onset with a spe-
cific precipitating event. Thereafter, the erective loss does not occur on
all occasions or with all partners. Night-time erections usually con-
tinue.
Organic Erective Loss. Organic erective loss is usually associ-
ated with one of four types of organic disease.
Testicular failure.   In rare cases, sexual dysfunction is caused by
testicular failure associated with low serum testosterone.
Endocrine disease.  Diabetes mellitus is commonly associated
with sexual dysfunction in three different circumstances:
• Diabetic men have the same sorts of psychogenic erective
loss as other men.
• Previously undiagnosed diabetics who are not in good meta-
bolic control may experience dysfunction, but this condition
is usually reversible with good metabolic control.
• Men with long-standing diabetes and diabetic neuropathy
may develop erective loss or loss of sexual responsiveness over
time. This loss is usually not reversible, and these men may
be candidates for a penile prosthesis.
Vascular disease.   Any disease that obstructs arterial blood sup-
ply to the genitalia may affect erection. 
Neurologic disease.  Any lesion from the spinal cord to the genital
innervation may interfere with erection, ejaculation, or both. A man
may have suffered cord trauma, a cord tumor, multiple sclerosis, or
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diabetic neuropathy; undergone surgical procedures; or have some
other cause of this injury.
Generally debilitating disease. Debilitating diseases that affect a
man's sexual function include cancer, chronic malnutrition, and star-
vation.
Pharmacologic Erective Loss. Other than alcohol (both acute
intoxication and physical damage from chronic usage) and addictive
drugs, three major kinds of pharmacologic agents are commonly asso-
ciated with loss of desire, erection, ejaculation, or orgasm in men (and
women):
• Antihypertensive therapy (including diuretics)
• Antidepressants and antipsychotic agents
• Anti-ulcer therapeutic agents (except simple antacids)
Any pharmacologic agent that affects the autonomic nervous sys-
tem or has a potentially sedative effect may cause a change in sexual
function. Because the change in function is often dose related, chang-
ing the type of medication or dose may relieve the loss in sexual func-
tion. Remember that alcohol or drug use is a common cause of both
sexual dysfunction and problems with relationships.
Psychogenic Erective Loss. By the age of 40, many men have
experienced one or more occasions in which they wished to have an
erection but were not able to get one. A man tends to react to this
experience in one of two ways. He feels some sadness and regret but
does not worry unduly, or he views the situation with alarm and anxi-
ety and suggests to himself that something in the apparatus is broken
and, perhaps, it will never work properly again. On subsequent occa-
sions, the man with the first reaction has little thought of the previous
incapacity, whereas the man with the second reaction evaluates his
performance repeatedly and, by so doing, rapidly distracts himself
from feeling sexual excitement and pleasure.
When there is psychogenic erective loss, encourage both partners
to concentrate on sight, sound, smell, touch, and taste and to fill their
minds with sensation rather than allowing themselves to become dis-
tracted by thinking. Performance anxiety can also be relieved by tem-
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porarily forbidding the couple to insert the penis but instead
encouraging them to practice touching, caressing, and kissing and to
share other sensuous and erotic experiences. Under such circum-
stances, erection usually returns rapidly and intercourse can occur.
Ejaculatory Delay
Delayed ejaculation almost always occurs with vaginal or anal
intercourse rather than with masturbation, unless this problem is
related to medication or disease. It is often caused by performance
anxiety, but it also may be a learned behavior (anger at partner, unilat-
eral contraception decision, etc.) or may occur in a man who finds
masturbation more stimulating than sexual activity with his partner.
Treatment begins with having a man masturbate to orgasm with
his penis close to but not inside the vagina. For example, over a few
days a man masturbates until he ejaculates on his partner's vulva, then
progresses to ejaculating in the vagina.
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Family planning decisions should be made on a completely vol-
untary basis, but also on the basis of thoroughly informed choice 
on the part of individuals and couples. A decision about child-
bearing cannot be called voluntary if individuals and couples 
have not been previously educated and informed about the 
meaning of family planning to their lives and the lives of their 
children and about the methods of family planning that are 
available.
 
— Dr. Fred T. Sai 
Choosing a contraceptive is an important decision. A method that is
not effective can lead to an unwanted pregnancy. A method that is not
safe can cause medical problems. A method that does not fit a person’s


























selves should make the decision about their contraceptives. In making
that decision, they need to consider the feelings and attitudes of their
partners. Through counseling, you can help your client choose the
most suitable contraceptive. You also can influence the user's motiva-






Encourage clients to edu-
cate themselves about the various methods available.
Demographic and Health Surveys indicate that married women
of reproductive age in Africa are less likely to use a method of family
planning than are married women of reproductive age in other regions
of the world. The percentage of married women at risk for pregnancy
who report using a method of family planning ranges from 5% in
Uganda to 75% in Mauritius. The percentage who report using a




See Table 1:6 in Chapter 1 on Benefits of Family Planning.
The prevalence of contraceptive use is lowest among young
women and highest among women in their late 20s through their 30s.
Once women have two or three children, they are more likely to use a
family planning method. Education also plays an important role in
whether a woman will use a contraceptive method.
Most married women in Africa know about family planning.
However, in Burundi, Ghana, Liberia, Mali, Niger, Senegal, and
Uganda, fewer than 40% can spontaneously name any modern




Contraceptive users may employ a variety of methods through-
out their lives and should know enough to consider various contracep-
tive methods. The client's choice of a contraceptive depends on several





















EFFECTIVENESS:  "WILL IT WORK?"
 
"Is the condom really effective?"
"Which would be the most effective method for me?"
"Why did one magazine say diaphragms are 98% effective 
and another say they're 80% effective?"
"Can you still get pregnant if you take your pills every day on 
schedule?"
 
"Will it work?" is the question usually asked first and most frequently
about any contraceptive method. Because this question cannot be
answered with certainty for any particular couple, most clinicians and
counselors try to help clients understand something of the difficulty of
quantifying efficacy.
It is useful to distinguish between measures of contraceptive
effectiveness and measures of contraceptive failure. If 18% of women
using the diaphragm became accidentally pregnant in their first year of
use, that does not mean that the diaphragm is 82% effective. The
actual percentage would be lower, because some of those women
would not have become pregnant even if they had used no contracep-
tive. For example, if 90% would have become pregnant had they used
no contraceptive, using the diaphragm reduced the number of
unplanned pregnancies from 90% to 18%, a reduction of 80%. If
only 60% of these women would have become pregnant if they did
not use contraception, the diaphragm’s true efficacy would be only
70%.
However, because no study can say how many women would
have become pregnant had they not used the contraceptive, it is sim-
ply not possible to directly measure effectiveness. Thus, we can speak
only of pregnancy rates—the proportion of users who became preg-


















































Our current understanding of contraceptive efficacy is shown in
Table 11:1. Because many of the studies on contraceptive efficacy have
flaws, we can only estimate the risk of pregnancy. We provide esti-
mated percentages for the following events:




who may not always use the method consistently and cor-
rectly




(someone who uses the method consistently and correctly)














The annual risk of contraceptive failure among methods that
require user compliance should be lower the longer a woman uses the
method, as users prone to fail do so early. As time passes, the group
being studied should have relatively more successful contraceptive
users (or those who are relatively infertile). 
Still, over time the cumulative likelihood of contraceptive failure
grows. For example, suppose that 18% of diaphragm users become
pregnant in the first year, 12% in the second year, and 8% in the third
year. By the end of the third year, 34% will have accidentally become





















Table 11:1 Percentage of women experiencing an unintended 
pregnancy during the first year of perfect use and the first year of 
typical use and the percentage continuing use at the end of the 
first year, United States
 
Percent of women experiencing 
an accidental pregnancy 
within the first year of use





































Parous women 40 26 42
Nulliparous women 20 9 56
Sponge
Parous women 40 20 42











Female (Reality) 21 5 56





Progesterone T 2.0 1.5 81
Copper T 380A 0.8 0.6 78
LNg 20 0.1 0.1 81
Depo-Provera 0.3 0.3 70
Norplant and Norplant-2 0.05 0.05 88
Female sterilization 0.5 0.5 100
Male sterilization 0.15 0.10 100
 
Emergency Contraceptive Pills: 
 
 Treatment initiated within 72 hours after 




Lactational Amernorrhea Method:  
 













































Some methods, such as sterilization, implants, and injectables,
are naturally very effective, and proper and consistent use is nearly
guaranteed. Other methods, such as the pill and intrauterine device
(IUD), are also naturally very effective, but there is still room for the
user to err, by forgetting to take her pills or failing to check for proper
placement of IUD strings. Fertility awareness and barrier methods
have lower natural effectiveness, and users have greater room to use
the method improperly.
 
Table 11:1 Percentage of women experiencing an unintended 
pregnancy failure during the first year of perfect use and the first 
year of typical use and the percentage continuing use at the end of 
the first year, United States — Continued
 










 couples who initiate use of a method (not necessarily for the first time), the percentage 











(both consistently and correctly), the percentage who experience an accidental pregnancy during the 













The percentages becoming pregnant in columns (2) and (3) are based on data from populations where 
contraception is not used and from women who cease using contraception in order to become pregnant. 
Among such populations, about 89% become pregnant within one year. This estimate was lowered 
slightly (to 85%) to represent the percent who would become pregnant within one year among women 












Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body 


















The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 
12 hours after the first dose.  Prevon (one dose is 2 blue pills) is the only dedicated product specifically 
marketed for emergency contraception in the United States.  In addition, the U.S. Food and Drug 
Administration has declared the following brands of oral contraception safe and effective for emergency 
contraception:  Ovral (1 dose is 2 white pills), Alesse or Levlite (1 dose is 5 pink pills), Nordette or 
Levlen (1 dose is 4 light-orange pills), Lo/Ovral or Levora (1 dose is 4 white pills), Triphasil or Tri-




However, to maintain effective protection against pregnancy, another method of contraception must 
be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle 






















Characteristics of the user can affect the probability that a con-





 Imperfect users can expect to have higher
pregnancy rates than perfect (consistent and correct) users.






 Among the characteristics of  per-
fect users, the most important user characteristic that deter-








 Because a woman's biological ability to conceive and
bear a child declines with age, pregnancy rates should decline
with age. The biological decline is likely to be greatest among
those who are routinely exposed to sexually transmitted
infections (STIs) such as chlamydia and gonorrhea. Among
those not so exposed to STIs, the decline is likely to be mod-







however, increasing age is associated with decreasing fre-








In some relationships, a woman
may be pressured or forced into intercourse. In these situa-
tions, she may not be able to use methods that are employed
at the time of intercourse, such as condoms, vaginal barriers,
or spermicides.
User characteristics such as race and income seem to be less
important determinants of contraceptive failure.
 
Influence of the Investigator
 
The competence and honesty of the investigator also affect the
published results. The errors committed by investigators range from






























Family planning providers should know that published studies




 One of the most common problems is the inappro-
priate use of a measure of failure called the Pearl index. This measure is
often used to compare pregnancy rates obtained from studies of
women using the method for different amounts of time. As the risk of
contraceptive failure declines over time because less effective users are
removed as they become pregnant, those still using after a long period
are unlikely to fail. Thus, by running a study a long time, an investiga-
tor can drive the reported pregnancy rate lower and lower. A better
measure of failure is the life table, which is easy to interpret and con-




 Deciding which pregnancies to count
can be a problem. Most studies count only the pregnancies women
observe and report. If, on the other hand, a pregnancy test were
administered every month, the number of pregnancies (and hence the
pregnancy rate) would increase because early fetal losses not observed
by the woman would be added to the pregnancy total. Such routine
pregnancy testing in the more recent pill trials has resulted in higher
pregnancy rates than would otherwise have been obtained and makes





  Many studies of the pill and IUD are conducted
because companies wishing to market them must carry out clinical tri-
als to demonstrate their efficacy. In contrast, there have been few stud-
ies of withdrawal, because there is no financial reward for investigating
this method. Moreover, researchers may have little incentive to report
unfavorable results. Surgeons whose patients have with high preg-
nancy rates following sterilization simply do not write articles calling
attention to their poor surgical skills. Likewise, drug companies do




































Keep these thoughts in mind when counseling about contracep-
tive effectiveness:
1. The best method of contraception is one that actually
will be used correctly and consistently.
2. Pregnancy rate estimates apply to groups, not an individ-
ual user. For example, a 5% probability of pregnancy during
the first year for the pill will not protect the careless user and
may not even apply to very young women, who are less likely
to be compliant. The 20% probability of pregnancy during
the first year from a diaphragm study need not discourage a
careful and disciplined woman who has infrequent inter-
course. Help your clients understand that numbers are not
what protect—correct and consistent use protects.
3. Make sure your staff provides consistent information.
One study of information provided by family planning staff
indicated that providers tended to give the lowest reported
probabilities of pregnancy for pills and IUDs, intermediate
probabilities of pregnancy during typical use for diaphragms
and foam, and higher than typical probabilities of pregnancy
for condoms.21  Thus, family planning providers may exten-
sively bias their client education in favor of methods they
provide most frequently. Despite their safety, condoms and
withdrawal get an undeserved low efficacy score within many
family planning clinics and offices. You can avoid uninten-
tional bias by deciding carefully what pregnancy rates your
clinic or staff members are going to use.
4. Technology fails people just as people fail technology. In
the past, clients were often told that unplanned pregnancies
were their own fault because they did not use their method
correctly or carefully. Contraceptives are imperfect and can
fail even the most diligent user.
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5. Using two methods at once dramatically lowers the risk
of unplanned pregnancy, provided they are used consis-
tently. If one of the methods is a condom or vaginal barrier,
protection from disease transmission is an added benefit. For
example, the probabilities of pregnancy during the first year
of perfect use of condoms and perfect use of spermicides are
estimated to be 3% and 6%, respectively.  During perfect
use, it is reasonable to assume that the contraceptive mecha-
nisms of condoms and spermicides operate independently.
The annual probability of pregnancy during simultaneous
perfect use of condoms and spermicides would be 0.1%, the
same as that achieved by the combined pill (0.1%) and the
Levonorgestrel (LNg 20) IUD (0.1%) during perfect use.
Even if the annual probabilities of pregnancy during perfect
use for the condom and spermicides were twice as high—6%
and 12%, respectively—the annual probability of pregnancy
during simultaneous perfect use would be only 0.4%, com-
parable to that of the minipill (0.5%) and the Copper T
380A IUD (0.6%)!11
6. Methods that protect a person for a long time (steriliza-
tion, implants, IUDs, and long-acting injections) tend to be
associated with higher contraceptive efficacy, primarily
because there is little opportunity for user error.
SAFETY: "WILL IT HURT ME?"
"I smoke. Won't the pill give me a heart attack?"
"Could the IUD puncture my womb?"
"Will I be able to get pregnant after stopping my method?"
In general, contraception poses few serious health risks to users, and
no method poses as great a health risk as does pregnancy. Unplanned
and unwanted pregnancies unnecessarily place women at health risks.
Still, some contraceptives pose potential risk to the user.
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• The method itself may have inherent dangers: it might be associ-
ated with death, hospitalization, surgery, side effects, infections,
loss of reproductive capacity, or pain.
• Unplanned pregnancy is associated with risk: a particular woman
must assess both the likelihood of contraceptive failure and the
dangers a pregnancy would pose to both herself and her child.
(See Chapter 1 on Health Benefits of Family Planning.)
• Future fertility may be influenced by contraceptive choice. (See
Chapter 7 on Infertility.)
MAJOR HEALTH RISKS
For the most serious outcome of all—death—the absolute level
of risk from contraception is extraordinarily low for most women. The
risk of serious illness is also uncommon; the risk is greatest in women
with underlying medical conditions that may be influenced by hor-
monal contraception:
• Cardiovascular disease. The pill has been associated with an
increased risk of myocardial infarction and stroke. About one
death in 100,000 users under the age of 45 has been attribut-
able to the pill.8  Risk from the pill increases with age because
risk factors such as hypertension, thromboembolic disease,
diabetes, and a sedentary lifestyle increase with age. Smoking
is a definite risk factor.
• Cancer. The association between cancer of the breast and
cervix and the use of the pill remains under scrutiny.
— There may be specific subpopulations of users who have
an increased risk of breast cancer.20  Risk factors for breast
cancer include a family history of breast cancer and
delayed or no childbearing.
— Cervical cancer has been reported more often in pill
users, although the correlation may be due to other, uni-
dentified factors that place the oral contraceptive user at a
higher risk.2  Risk factors for cancer include having had
multiple sexual partners and cigarette smoking.
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Conversely, the pill appears to protect users against cancers of the
endometrium3 and ovary.4 Also, barrier methods used in conjunction
with spermicides decrease the user's risk of cervical cancer.15,17
FUTURE FERTILITY
An important issue in helping a couple evaluate the safety of a
contraceptive may be their future childbearing aspirations. There are
several important considerations to keep in mind to protect the future
fertility of contraceptive clients:
• Abstinence is the single most effective and risk-free means of
protecting future fertility.
• Pregnancy and the outcomes of pregnancy carry substantial
risks to future fertility.
• The pill, which has a protective effect against acute gonococ-
cal pelvic inflammatory disease (PID) and decreases the risk
of ovarian cyst surgery and fibromyomata, may be the ideal
contraceptive option for the woman who wants to be sexu-
ally active for a number of years before bearing children.8
Perhaps the best contraceptive option for a young healthy
woman who wishes to delay her childbearing is the combina-
tion of pill and condom.
• Mechanical and chemical barriers combined offer the
greatest protection against damage to the fallopian tubes.5
• Some IUDs, which can increase the risk of PID, are proba-
bly the least desirable option for women who want to pre-
serve fertility.16 The Levonorgestrel IUD, however, may
decrease the risk of PID.
• Sterilization must be considered permanent.
No matter what other methods of contraception a woman is 
using, if she is at any risk because her partner tests positive for 
the human immunodeficiency virus (HIV) or because she does 
not know his status, she should use plastic or latex condoms 
with every sexual act.  No other contraceptive method besides 
abstinence provides the same degree of protection.
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SIDE EFFECTS
Often, the minor side effects of contraceptives, in addition to the
more serious complications, influence whether an individual selects a
certain method. "What physical changes will I undergo?" "Will I be
annoyed by spotting, weight gain, cramping, or the sensation of using
a given method?" Clinicians cannot dismiss the important role that
side effects play when an individual must repeatedly assess whether to
continue using a method or whether to use it consistently.
Side effects can be hormonally or mechanically induced. Head-
aches, weight gain, and depression can be side effects of hormonal
methods. Menstrual changes such as spotting and decreased or
increased bleeding can be caused by hormonal or mechanical meth-
ods. Changes in physical sensations, such as decreased sensitivity of
the penis or a feeling of pressure on the pelvic walls, and the problem
of uterine cramping, are generally caused by mechanical methods. 
For almost all of these side effects, instruction and client educa-
tion can help users accept and understand what is happening. The
appearance of side effects that are not serious is not a medical reason
to avoid using a method.
PRECAUTIONS
Because some women are relatively more likely to encounter
problems with a specific method of birth control, considering the pre-
cautions to the methods is important when a woman chooses her
method. Most of the serious pill and IUD problems could be avoided
by (1) not using the methods to which a woman has medical precau-
tions and (2) teaching the user to recognize the early warning signals
for serious complications.
The authors prefer to use the term “precautions” rather than con-
traindications. In the past, lists of contraindications have created barri-
ers to contraceptive provision and use. Health educators, journalists,
clinicians, and clients need only see the word “contraindication” link-
ing a medical condition and a medication they are considering using,
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and all attempts to qualify the degree of contraindication are virtually
futile. In place of contraindicating the use of a method, a graded scale
of conditions may serve as medical eligibility criteria for starting con-
traceptive methods. The Appendix, developed by the World Health
Organization, lists the conditions and considerations for selection. 
GOALS FOR TEACHING SAFETY
1. Try to educate the client about misconceptions. People
who are afraid do not respond well to rational persuasions.
Many clients hold certain opinions about contraceptives—
that the pill is very dangerous even to healthy, nonsmoking
young women or that injectables lead to permanent sterility
(see Table 11:2). However, if you see you are getting
nowhere, stop. Help each client select a method that can be
used without fear.
2. Make sure that you and your staff know all about the
major side effects of contraceptives, such as the relationship
between pill use and blood clots or reproductive cancers.
Give accurate information.
3. Tell clients what they need to know even if they do not ask.
Clients do not always ask the questions they need answered.
4. Compare the contraceptive risks with the risks a woman
faces if she becomes pregnant. In general, the risks of preg-
nancy, abortion, and delivery are far greater than those for
using a contraceptive.
5. Help clients make a contraceptive choice that will protect
them from both pregnancy and sexually transmitted
infections (STIs). Safety concerns often overlap with worries
about infections.
6. Teach clients the danger signals of the method they select.
If a danger signal appears, the informed user can quickly seek
help.
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NONCONTRACEPTIVE BENEFITS
Although the noncontraceptive benefits provided by certain methods
are not generally the major determinant for selecting a contraceptive
method, they certainly can help clients decide between two or more
suitable methods (see Table 11:3).
As the acquired immunodeficiency syndrome (AIDS) epidemic
continues, methods that reduce the user's risk of acquiring human
immunodeficiency virus (HIV) infection provide a noncontraceptive
benefit that may weigh as heavily as the contraceptive benefit. Any
sexually active person who may be at risk of acquiring infection with
HIV, human papilloma virus (HPV), gonorrhea, syphilis, chlamydia,
herpes, or other STI should consider male (or female) condoms. 
Oral contraceptives offer several noncontraceptive benefits: they
protect against symptomatic PID, cancers of the ovary and endo-
metrium, recurrent ovarian cysts, and benign breast cysts and fibroad-
enomas.8 In addition, as women who have suffered menstrual cramps
and discomforts can attest, the pill eases their discomforts. Make it a
practice to tell your clients about the noncontraceptive benefits of the
various methods. Having additional reasons for using the contracep-
tive will probably improve their motivation to use the method cor-
rectly and consistently.
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Personal Considerations
A method that does not fit the individual's personal lifestyle or
societal norms will not likely be used correctly or consistently, and
possibly will not be used at all. Take into account the woman's and
partner's attitudes as well as their situation (see Table 11:4). Some
issues are relatively easy to manage, such as providing health education
to couples who lack knowledge of contraceptive methods. Other
issues, however, such as a husband's disapproval of contraception,
require great care.
Comfort and Confidence
The best method of birth control for clients is one that will be in
harmony with their wishes, fears, preferences, and lifestyle. Table 11:5
lists questions designed to help clients determine whether a certain
birth control method is a realistic choice. These questions may be used
exactly as written or adapted for local use without permission. "Don't
know" answers point to a need for more thinking, more introspection,
or more information. "Yes" answers may mean the user might not like
or be successful with the method. Most individuals will have a few
"yes" answers. "Yes" answers mean that potential problems may lie in
store. If clients have more than a few "yes" responses, they may want
to talk to their clinician, counselor, partner, or friend. Talking about
their concerns can help them decide whether to use this method, or if
they use it, how to do so in a way that will truly be effective for them.
In general, the more "yes" answers they have, the less likely they are to
use this method consistently and correctly.
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Table 11:3 Noncontraceptive benefits, risks, and side effects
 




tions (stroke, heart attack, 
blood clots, high blood 
pressure), depression, 
hepatic adenomas, possi-
ble increased risk of breast 
and cervical cancers
Nausea, headaches, dizzi-
ness, spotting, weight 
gain, breast tenderness, 
chloasma
Decreases mentrual pain, 
PMS, and blood loss; pro-
tects against symptomatic 
PID, some cancers (ovarian, 
endometrial) and some 
benign tumors (leiomyo-
mata, benign breast masses), 
and ovarian cysts; reduces 
acne






None known except for 
progestin-releasing IUDs, 
which decrease menstrual 
blood loss and pain
Male Condom Anaphylactic reaction to 
latex
Decreased sensation, 
allergy to latex, loss of 
spontaneity
Protects against sexually 
transmitted infections, 
including HIV; delays 
premature ejaculation
Female Condom None known Aesthetically unappealing 
and awkward to use for 
some
Protects against sexually 
transmitted infections
Implant Infection at implant site, 
complicated removals, 
depression
Tenderness at site, 
menstrual changes, hair 
loss, weight gain
Lactation not disturbed; 
may decrease menstrual 
cramps, pain, and blood loss
Injectable Depression, allergic 
reactions, pathologic 
weight gain, possible 
bone loss
Menstrual changes, weight 
gain, headaches, adverse 
effects on lipids
Lactation not disturbed, 
reduces risk of seizures, may 
have protective effects 
against PID and ovarian and 
endometrial cancers
Sterilization Infection; anesthetic 
complications; if 
pregnancy occurs after 
tubal sterilization, high 
risk that it will be ectopic
Pain at surgical site, 
psychological reactions, 
subsequent regret that the 
procedure was performed
Tubal sterilization reduces 
risk of ovarian cancer and 
may protect against PID
Abstinence None known Psychological reactions Prevents infections, 
including HIV
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Reproductive Life Span
A typical African woman spends about 35 years—more than half
her life span of 67 years—at potential biological risk of pregnancy,
during the time from menarche (at about age 13) to natural meno-
pause (at about age 48). What matters most to a woman when she
considers a contraceptive will ordinarily change over the course of her
reproductive life span. As is shown in Table 11:6, different reproduc-
tive stages are associated with distinct fertility goals and sexual behav-
iors. 
• From menarche to first planned birth, the primary fertility
goal is to postpone pregnancy and birth. 
• Between the first and last planned births, the primary goal is
to space pregnancies leading to births. 
• Between the last planned birth and menopause, the goal is to
cease childbearing altogether. 
In the stage between her last birth and menopause, the most
important factor for a woman is a method's efficacy at preventing




Vaginal and urinary tract 
infections, toxic shock 
syndrome
Pelvic pressure, vaginal 
irritation, vaginal 
discharge if left in too 
long, allergy
Provides modest protection 
against some sexually 
transmitted infections




Provides modest protection 





Increased risk of HIV 




Provides excellent nutrition 
for infants under 6 months 
old
Source:  Hatcher et al. (1998)
Table 11:3 Noncontraceptive benefits, risks, and side effects
 (Continued)
Method Dangers Side Effects
Noncontraceptive 
Benefits
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Table 11:5 Contraceptive comfort and confidence scale
Method of birth control you are considering using: 
Length of time you used this method in the past:
Answer YES or NO to the following questions: YES NO
   1. Have I had problems using this method before?
   2. Have I ever become pregnant while using this method?
   3. Am I afraid of using this method?
   4. Would I really rather not use this method?
   5. Will I have trouble remembering to use this method?
   6. Will I have trouble using this method correctly?
   7. Do I still have unanswered questions about this method?
 8. Does this method make menstrual periods longer or more
painful?
   9. Does this method cost more than I can afford?
10. Could this method cause me to have serious complications?
11. Am I opposed to this method because of any religious or moral 
beliefs?
12. Is my partner opposed to this method?
13. Am I using this method without my partner's knowledge?
14. Will using this method embarrass my partner?
15. Will using this method embarrass me?
16. Will I enjoy intercourse less because of this method?
17. If this method interrupts lovemaking, will I avoid using it?
18. Has a nurse or doctor ever told me NOT to use this method?
19. Is there anything about my personality that could lead me to use
    this method incorrectly?
20. Am I at any risk of being exposed to HIV (the AIDS virus) or 
other sexually transmitted infections if I use this method?
Total number of YES answers:
Most individuals will have a few "yes" answers. "Yes" answers mean that potential problems 
may arise. If you have more than a few "yes" responses, you may want to talk with your 
physician, counselor, partner ,or friend to help you decide whether to use this method or how 
to use it so that it will really be effective for you. In general, the more "yes" answers you have, 
the less likely you are to use this method consistently and correctly at every act of intercourse.
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Cost of Contraceptives
We cannot provide contraceptives without considering the cli-
ent's financial circumstances.12  A woman should be told in advance
what her ongoing expenses will be. If cost will impose a major hard-
ship, offer an alternative contraceptive or a means of obtaining the
desired contraceptive less expensively. The economic implications of
using some forms of contraception have become significant. However,
the cost of contraception is substantially less than the cost of deliver-
ing and raising a child.23
















Births postpone postpone space prevent
Ability to have children preserve preserve preserve irrelevant
Sexual behavior
# of partners none multiple? one? one?
Coital frequency zero moderate to high moderate moderate to low
Coital predictability low moderate to high high high
Importance of method 
characteristics





Not coitus-linked high low moderate
Reversibility high high low
Most common methods
Most common pill pill sterilization
Next most common condom condom pill, condom
Source:  Forrest (1993)
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Pattern of Sexual Activity. In considering their contraceptive
choice, both women and men should be influenced by their number
of partners and their frequency of intercourse.
The number of partners affects the risk of STIs. In some cases, it
will be obvious that an individual has more than one partner at any
given time. Less obvious are the individuals who practice serial
monogamy. These persons have only one partner at a time; however,
the relationships are not permanent, and after they end, the individual
will move on to a new partner. The methods that would most protect
individuals from STIs require the commitment, understanding, and
assertiveness of the client. The practitioner recommending the use of
condoms (male or female) or other barrier protection must be pre-
pared to take the time required to discuss risks, encourage behavioral
change, and teach skills.
The frequency of intercourse also has bearing on a person's con-
traceptive choice. For example, the woman who has infrequent inter-
course may not wish to use a method that requires daily medication or
continuous exposure to possible side effects posed by pills, implants,
injections, or IUDs. On the other hand, infrequent intercourse may
also indicate that a client is at risk of unpredicted intercourse. These
clients may need skills in "expecting the unexpected."
Husband's Objections
In sub-Saharan Africa, many women who do not want more chil-
dren still do not use contraception because they say they face opposi-
tion from their husbands.1 (See Table 11:4.) Surprisingly, lack of
discussion may be the reason they believe they face opposition. More
than half of women who report their husbands disapprove of family
planning have never even discussed family planning with them. These
clients need skills in initiating nonthreatening discussions with their
husbands and then selecting methods that would suit the couple's
relationship.
Access to Medical Care. Many women have difficulty gaining
access to the health care system: they do not understand the system,
cannot afford it, or find that it shuns them. Others may find their
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access hampered by too long a wait at the clinic. Studies have shown
that access has great bearing on contraceptive compliance and
choice.26 Access can be eased for all clients by providing a full year's
supply of contraceptives (13 cycles of pills or 100 condoms).
Goals for Teaching About Personal Considerations
Key concepts for discussing and teaching about contraceptive
choice and personal considerations include the following:
1. The client decides which personal considerations matter.
Only the potential user can weigh all the elements for per-
sonal choice, and the clinician will not be able to predict
what matters. Privacy? Lubrication? Light periods? What big
sister uses? Do not guess—ask.
2. It is a long way from the examination room to the bed-
room. We offer methods as medicines in a clinical setting,
and then our clients go home and use them in a sexual set-
ting, be it a bedroom or a field. Remember to help your cli-
ent think through the sexual aspects of contraception.
3. Clients may need permission to make a second (or third)
contraceptive choice. They may not like the first method at
all and will need to know it is a good idea to come back to
try something else. Besides, it is always good to know how to
use several methods.
4. Clients can be encouraged to talk about birth control
issues with their partners. How can one person decide
whether a method of birth control will be compatible with a
couple's personal and sexual styles? Help your clients practice
discussing birth control with their partners if this is new ter-
ritory for them.
5. Personal considerations are likely to change over time.
Teenagers and 35-year-olds will use very different criteria as
they evaluate their contraceptive choices. Encourage clients
to rethink their contraceptive needs as their lives, sexual
drives, and bodies change over time.
6. Teach clients a wise and cautious approach to sexual
activity. All sexually active people need to know the risk fac-
tors for STIs and HIV infection and how to avoid them.
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Lactation and Postpartum 
Contraception
 
A number of women in the community had stopped breastfeed-
ing their babies early, so Dr. N puzzled over how to balance 
what he told the new mother about breastfeeding and about 
contraception. Breastfeeding was important for the baby and a 
contraceptive should not interfere with that. The mother should 
try to space her next pregnancy by about 2 years, so perhaps a 
contraceptive was quite necessary. He knew that women in this 
community generally breastfed their babies on demand for the 
first several months. This very practice would help protect the 
woman from becoming pregnant for about 6 months. Dr. N 
carefully explained breastfeeding practices to his patients, and he 
made certain they had contraceptive supplies at home well 
before the baby's 6-month birthday.
 
Breastfeeding contributes significantly to both birth spacing and child
survival. Breast milk is an ideal source of nutrition for infants and pro-
vides an important level of immunological protection against infec-
tion. In addition, the lactational amenorrhea method (LAM) is a
highly effective method of contraception. Other methods of contra-
ception, such as barrier methods, progestin-only methods, and the
intrauterine device (IUD) are also excellent options for women post-





























Breastfeeding practices vary considerably in Africa. Breastfeeding is
quite prevalent in both North Africa and sub-Saharan Africa, where
about a third of children aged 4 to 6 months are fully breastfed (not
receiving supplemental solid foods or milk). In countries such as





Populations with low contraceptive use in which infants are
intensively and extensively breastfed have lower fertility rates than




Several cultures practice sexual abstinence after childbirth, often while
the mother is breastfeeding. This practice decreases postpartum fertil-
ity and contributes to child spacing. The length of postpartum absti-
nence varies from country to country, with average periods of
abstinence close to a year or longer reported in Burkina Faso, Came-
roon, and Cote d’Ivoire (see Table 12:1).
To provide appropriate advice to postpartum clients, staff should
understand related cultural practices. Traditional beliefs include







However, as countries modernize, the length of both












 while women who live in urban areas and those of
higher socioeconomic status more commonly bottle feed.
 
3 Recently,
the duration of breastfeeding has increased among women in both


















Polygynous marriages may play a role in both




















Women may be infertile for a brief period after giving birth, but the




















that her menstrual cycle is about to resume. The breastfeeding woman
will have a longer period of infertility than will the non-breastfeeding
woman, but neither can predict when fertility will return.
Most nonlactating women resume menses within 4 to 6 weeks of
delivery, but approximately one-third of first cycles are anovulatory,







Fifteen percent of the second and third menstrual cycles are
anovulatory, and a quarter of those that are ovulatory have luteal-
phase defects. Among nonlactating women, the first ovulation occurs
on average 45 days postpartum.
 
Table 12:1 Median duration of any breastfeeding, full breast-













Burkina Faso 1993 25.2 0.6 14.6 18.9 22.2
Cameroon 1991 17.4 1.9 10.4 13.3 16.0
Central African 
Republic 1994-95
20.6 2.1 14.1 10.4 16.4
Cote d’Ivoire 1994 20.3 3.7 12.3 11.8 16.6
Ghana 1993 21.4 2.0 13.0 9.0 16.2
Kenya 1993 21.1 0.7 10.8 3.0 12.9
Madagascar 1992 19.4 1.6 12.5 3.6 13.4
Malawi 1992 21.2 1.2 11.9
Mali 1995-96 21.6 6.8 13.6 2.8 14.4
Namibia 1992 17.3 1.7 8.3 6.0 12.8
Niger 1992 20.9 0.6 15.2 2.0 15.8
Nigeria 1990 19.5 1.5 14.6 10.8 19.0
Rwanda 1992 27.9 5.5 16.6 0.6 17.1
Senegal 1997 20.9 4.5 13.2 2.9 15.1
Sudan 1989-90 19.5 13.9 5.0 15.2
Tanzania 1996 21.5 2.2 12.1 5.6 15.7
Uganda 1995 19.5 3.5 12.6 2.2 13.4
Zambia 1996 20.0 2.5 11.5 4.7 14.1
Zimbabwe 1994 18.5 0.7 12.9 3.5 14.1
 


























Breastfeeding extends postpartum infertility by delaying ovula-
tion and by reducing the likelihood of conception once ovulation or
menses return. After the sixth month postpartum, it is increasingly







However, even after menses return, the hormonal effects





Infant suckling causes both the production of breast milk and the
prevention of ovulation through complex hormonal reflexes. Suckling
stimulates sensory cells in the nipple and areola, which signal the
hypothalamus to release various hormones. One of these hormones,
prolactin, stimulates milk production. Suckling directly reduces the







which in turn suppresses the release of luteinizing hormone
(LH) required for follicle stimulation in the ovary. Suckling also trig-
gers the release of the hormone oxytocin from the posterior hypothal-
amus. Oxytocin causes the muscle cells in the areola to contract and
squeeze out milk, known as milk "let down."  Auditory stimuli (e.g., a
crying baby) and other stimuli can lead to "let down." Maternal con-
ditions such as pain, fatigue, sore breasts, stress, and anxiety may
inhibit this process.
Full or nearly full breastfeeding is associated with longer periods
of lactational amenorrhea and infertility. Frequent, continuous stimu-
lation of the breast by around-the-clock suckling strengthens the reflex






Together, a high frequency
of breastfeeding episodes per day and a longer duration of suckling per




Supplementary use of bottle feeding appears to reduce breastfeeding







However, even partial breastfeeding can inhibit ovulation and
prolong amenorrhea. In summary:
• Breastfeeding delays the onset of ovulation and the return of
menses after childbirth.
• The longer a woman breastfeeds, the more likely she will




















• Breastfeeding decreases fertility even after menstrual bleed-
ing resumes.
• A woman may ovulate before her first menses, especially with
prolonged or supplemented breastfeeding.
• Low frequency and short duration of breastfeeding, some-


























(See  Figure 12:1.) Infants who are breastfed dur-
ing the first 2 months of life have only 37% of the risk of death during







child survival the most in countries with high levels of infant mortality




Figure 12:1 Infant mortality during first year of life by source of milk
 























































Breastfeeding improves infants' chances of survival for two rea-
sons:  (1) breast milk has unique nutritive and anti-infective proper-
ties, and (2) breastfeeding contributes to birth spacing, which in turn
promotes survival. Breast milk contains all the nutrients an infant
needs for the first 4 to 6 months of life. The mixtures of protein, fat,
carbohydrate, and trace elements in breast milk change over time to






The particular combination of min-
erals, vitamins, and amino acids found in human milk is distinct from
that in cow's milk, which has a much higher proportion of protein






Many infant formulas combine pro-
tein, carbohydrates, and electrolytes in good balance, but they are still
inferior to breast milk. However, when the woman cannot breastfeed
or the infant fails to grow, formulas meeting the Codex requirements
are the best option.
Several anti-infective agents are found in human milk. Immuno-
globulins, leukocytes, and the bifidus factor all help guard the new-







These anti-infective agents are always present in
breast milk and are concentrated in the colostrum, the breast milk
available during the first few days of an infant's life. On the other
hand, these agents are absent from infant formula. As a result, breast-












Breastfed infants are less likely to develop allergies, including






Asthma may be less




Decreases in the incidence of otitis media
 







also associated with breastfeeding.
Frequent breastfeeding also improves infant health by lengthen-
ing the time between births. Children born within 2 years of their
immediately older sibling have a 52% to 161% higher probability of
dying within the first 5 years of life than children born more than 2






(See Chapter 1 on Bene-
fits of Family Planning.) This greater risk may be due to maternal


























Thus, the lengthening of the birth interval that




Lower cost is another advantage of breastfeeding over infant for-
mula. Because formula is expensive, some mothers try to save money
by diluting the mixtures, which reduces their nutritional value. Some
families make their own formula by mixing flour and sugar with water






Formula is often contaminated from
using impure water supplies, which can result in diarrhea, a major
killer of infants in developing countries. Exclusive breastfeeding (no




Breastfeeding has several benefits for the mother as well. Breast-
feeding causes the release of oxytocin, which stimulates uterine con-
tractions, and these in turn, help decrease postpartum hemorrhage.
Breastfeeding mothers experience a rapid return of uterine tone. In







Women who have ever breastfed have a lower risk of breast







Although reports are conflicting, breastfeeding may also protect






Finally, extended breastfeeding facil-
itates the emotional bond between mother and infant, which may lead
























Human immunodeficiency virus 1 (HIV-1) can be transmitted by an
infected mother to her infant in utero, during childbirth, and through
breast milk. That HIV-1 can be transmitted by breastfeeding has been con-







Rates of maternal-fetal transmission through all






Most infants who are
infected with HIV-1 acquire the infection in utero or during childbirth.
When the mother is infected prenatally, breastfeeding adds an estimated






When the mother was infected
































transmission of HIV-2 is much lower than the risk of perinatal transmis-
sion of HIV-1.1 (See Chapter 5 on HIV, AIDS, and Reproductive Health.)
All babies born to an HIV-infected mother carry passively
acquired maternal antibodies to HIV. Those infants who are not
infected will gradually lose these antibodies, which nevertheless may
persist in some cases until the infants are 15 months of age. Because
standard tests for HIV detect HIV antibodies and not the virus itself,
they cannot reliably determine which infants born to HIV-positive
mothers have been infected until the child has lost the maternal anti-
bodies.25  Thus, the HIV status of infants born to HIV-infected moth-
ers cannot be ascertained until well after birth. It is possible that new,
inexpensive HIV tests will be developed that will yield positive results
only if the infant is HIV-positive when cord blood is tested. In such
cases, a negative result would not conclusively indicate that the infant
was HIV-negative.57 If such a test is developed, HIV-positive mothers
might be advised that an infant who tests positive could be breastfed.
Clearly, the twin facts that breastfeeding greatly reduces infant
morbidity and mortality on the one hand but that HIV can be trans-
mitted by breastfeeding on the other pose a dilemma.  In particular,
there has been much discussion on whether breastfeeding should be
discouraged in areas where HIV is prevalent.9,13,20,28,32,40,61,77 The
World Health Organization concluded in 1998 that:
When children born to women living with HIV can be ensured
uninterrupted access to nutritionally adequate breast-milk substi-
tutes that are safely prepared and fed to them, they are at less risk
of illness and death if they are not breast-fed.  However, when
these conditions are not fulfilled, in particular in an environment
where infectious diseases and malnutrition are the primary causes
of death during infancy, artificial feeding substantially increases
children’s risk of illness and death.91
NUTRITION FOR BREASTFEEDING WOMEN AND THEIR INFANTS
Breast milk provides the new infant with adequate calories and
protein for the first 6 months of life and offers immunologic protec-
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tion derived from maternal antibodies and other factors. The breastfed
infant is, therefore, less likely to suffer from diarrheal and other infec-
tious diseases.87 For maximum protection, breastfeeding should be
continued for at least 2 years and practiced exclusively for at least 6
months "on demand," day and night, whenever the baby is hungry.
Sustained breastfeeding may not be possible for the mother who
works away from the home. In such cases, she should try to nurse the
infant several times both day and night and make certain her baby is
getting good protein supplements or expressed breast milk. The excel-
lent protein balance in breast milk complements other foods given to
the infant. If a woman must give her infant bottled formulas, she
should prepare and mix them in the correct concentration so that the
baby receives enough protein and calories for healthy growth.
What happens if an infant does not get adequate nutrition?  Two
extreme syndromes that may result are marasmus and kwashiorkor.
Infantile marasmus is often caused by premature weaning from breast
milk, often because the mother is pregnant again and believes she can-
not continue to breastfeed. Substituting grossly inadequate feeding
from other sources deprives the infant of necessary calories and pro-
teins. Kwashiorkor affects a child who is weaned to a diet sufficient in
calories but deficient in proteins and nitrogen. For every case of mar-
asmus or kwashiorkor, however, many other children suffer more
moderate forms of malnutrition.
Women need more calories when they are breastfeeding. They
derive a substantial part of these calories from stores built up during
pregnancy. Any increase in calories or decrease in energy expenditures
will help the breastfeeding mother retain her health, although a bal-
anced diet including protein sources is best. Nursing mothers also
need calcium, iron, and vitamins, which should be supplied through
diet or supplements.92 Family planning can aid a mother's nutrition by
preventing a rapid succession of pregnancies that can drain her
reserves of nutrition built up during pregnancy. If the mother diets or
does not gain sufficient weight during pregnancy, she will need even
more calories and proteins during breastfeeding.
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COMPLICATIONS OF BREASTFEEDING
Breastfeeding is associated with few serious complications. Lac-
tating women may have breast tenderness, breast infections, and other
problems that can be managed with straightforward clinical remedies.
More important, instructing the mother both before and after delivery
on how she can address potential problems can make breastfeeding
easier (see Table 12:2). If a woman is undernourished and breastfeed-
ing, she may be at risk of energy depletion.47 Thus, any intervention in
the postpartum period should include feeding the mother during the
period in which she is breastfeeding the infant. 
When women lactate, their estrogen levels are very low and they
may have less vaginal lubrication than usual. They may need to use a
simple lubricant during sexual intercourse to reduce discomfort. With
sustained breastfeeding and the suppression of estrogens, some women
will experience other symptoms similar to those of menopause: hair
loss, dermatologic changes, and hot flashes.48 These side effects dimin-
ish when menstrual cycles resume or when breastfeeding declines. It is
important not to use estrogen treatment for these symptoms, because
estrogen decreases milk production.
THE LACTATIONAL AMENORRHEA METHOD 
OF CONTRACEPTION
Breastfeeding provides more than 98% protection from pregnancy in
the first 6 months if the infant's diet is not supplemented (or supple-
mented only to a minor extent) and if the woman has not experienced
her first postpartum menses.42 One clinical study of LAM found a
cumulative 6-month pregnancy rate of 0.5% among women who
relied solely on LAM and used the method perfectly.68 Thus, LAM is
an excellent method of contraception and has a pregnancy rate less
than most other reversible methods. (see Figure 12:2).
Breastfeeding in general is an effective contraceptive at the popu-
lation level and can also be an effective contraceptive for an individual
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woman, depending on the frequency and duration of suckling and
whether she is menstruating. Because frequent and exclusive breast-
feeding suppresses ovulation, LAM is an effective temporary, introduc-
tory contraceptive for up to 6 months postpartum, as long as a woman
follows the general guidelines to recognize her return to fertility.
LAM may also be appropriate beyond 6 months or if the infant is
supplemented, as long as she breastfeeds intensely. The 6-month limit
for LAM exists primarily because infant diets need to be supple-
mented after that time to ensure continued growth and development52
and to avoid iron-deficiency anemia.6 Cumulative pregnancy rates
during lactational amenorrhea (regardless of whether the infant
received supplementary food) at 6 and 12 months are 2.9% and 5.9%,
respectively, compared with 0.5% at 6 months for LAM.43  
Table 12:2 Complications of breastfeeding and their 
management 
Problem Description Solution
Sore breasts Mother has pain in
breasts (not nipples) while 
breastfeeding.
Reassure mother this is not 
unusual. Correct position-
ing of infant may help. The 
pain may be related to a 
poorly functioning let-
down response and will 
usually disappear within a 
few weeks.
Engorgement Breasts enlarged with 
generalized tenseness 
and tenderness.
Mother should breastfeed 
frequently and for 10 to 15 
minutes on each side at 
each feeding.
1) In first few days there is 
little milk. This discomfort 
will diminish with time. 
Mother may use mild 
analgesic.
2) If separated from infant 
for long period, mother 
should massage breasts and 
manually empty every 4 
hours until she returns to 
infant.
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Plugged duct Distinct area of breast 
engorged. Not red, no 
fever.
Mother should apply moist 
heat to breast and massage 
the breast beginning behind 
the plugged duct and 
moving toward the nipple. 
The baby should be 
breastfed frequently and 
position changed during 
each feeding to help 
dislodge plug.
Leaking Milk coming from 
nipple unexpectedly.
This is a normal occur-
rence. Mother should not 
stimulate nipple. She 
should apply pressure 
directly over nipples with 




localized area of one 
breast. Fever, flu-like 
symptoms. Baby may be 
irritable. Usually caused 
by staphylococcus.
Keep breast empty. Mother 
should continue breast-
feeding; the infection will 
not harm baby. Antibiotics 
appropriate for staph 
infection should be given. 
Gently massage affected 
area while nursing. Moist 
heat should be applied to 
the breast, the mother 
should be urged to drink 
fluids and to rest in bed. If 
infection localizes or fever 






nipples, with cracks and 
occasional bleeding.
Mother should clean breasts 
with water and expose to 
heat or sunlight after 
feedings. Infant should suck 
for short intervals with 
frequent feedings and may 
need assisted feeding until 
nipples heal. Avoid feeding 
for long periods of time. 
Mother can release suction 
with finger.
Table 12:2 Complications of breastfeeding and their 
management (Continued)
Problem Description Solution
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Thrush or moniliasis Persistently sore nipples 
(no cracks), inflammation 
of nipples and areola; 
baby has white patches 
in mouth.
Treatment with anti- 
monilial cream after each 
feeding if severe. Treat with 
1 tsp. baking soda in 1 cup 
water for mild cases.
Inadequate milk Baby not gaining weight; 
sucking not of interest to 
baby for more than a few 
minutes at a time.
Check infant attachment to 
assure sufficient nipple 
contact. Encourage 
complete emptying of the 
breast by expression. The 
more the mother nurses, 
the more milk that is 
produced. Discourage 
supplementing breast milk 
in the first months. If there 
is weight loss and failure to 
thrive, examine infant in 
clinic and determine if 




Infant unable to grasp 
nipple and suckle 
adequately.
Late in the last trimester is 
the best time to help flat or 
inverted nipples to 
protrude. While support-
ing the breast, draw out 
nipple with thumb and 
index finger. Do 5 to 6 
times a day. Use of a milk 
cup may be helpful in last 
weeks of pregnancy.
CAUTION:  too much 
nipple stimulation late in 
pregnancy can trigger 
uterine contractions
Table 12:2 Complications of breastfeeding and their 
management (Continued)
Problem Description Solution
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Figure 12:2 Use of the Lactational Amenorrhea Method (LAM) for 
child spacing during the first 6 months postpartum
Source:  Labbok et al., (1994)
The perfect-use pregnancy rates during LAM compare favorably
with those for other methods of contraception during perfect use.
Combining breastfeeding and another method of contraception
begun at 6 weeks postpartum (or sooner) should provide even greater
protection. (See Table 12:3.)





3.  Is your baby more than
6 months old?








Your chance of pregnancy is




continue to breastfeed for
your child's health.
There is only a
1% to 2% chance
of pregnancy at this time
When the answer to any one of
these questions becomes Yes
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POSTPARTUM CONTRACEPTION
Because postpartum infertility can be brief and lactational infertility
unpredictable, contraceptive counseling should begin in the prenatal
period. LAM is a contraceptive method that is begun immediately
after delivery. Early postpartum care offers an opportunity to teach
mothers how to breastfeed fully, which can lead to the successful use
of LAM. In addition, the first postpartum visit, recommended around
4 weeks after delivery, is the focal point of many family planning pro-
grams because the woman usually is highly motivated to avoid another
pregnancy. This time can be used to review the LAM criteria for con-
tinuing the method or for initiating another method of birth control.
CONTRACEPTION FOR THE NONBREASTFEEDING WOMAN
Ideally, the nonbreastfeeding woman should begin using a con-
traceptive method immediately postpartum or within 4 weeks post-
partum. After appropriate counseling and consent, all of the following
methods can be initiated in the postpartum period: combined oral
contraceptives, progestin-only contraceptives, diaphragm, cervical cap,
spermicides, IUD, condoms, and tubal ligation.
For most nonbreastfeeding mothers, there are few precautions for
the methods of contraception they can choose. Nonetheless, a few
guidelines for clinicians and clients are worth noting:
• Begin any discussion of immediate postpartum sterilization,
Norplant insertion, IUD insertion, or Depo-Provera injec-
tion well before the delivery. Norplant may be inserted and
Depo-Provera may be safely injected postpartum. Discussing
these options before delivery will help ensure that consent is
fully informed.
• Advise the woman to begin taking combined birth control
pills about 2 to 4 weeks after delivery, because the risk of
thrombophlebitis and thromboembolism is greatest just after
delivery.55,90
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• Avoid use of the diaphragm and cervical cap until 6 weeks
after delivery. The risk of toxic shock syndrome increases
when bleeding is present. (See Chapter 17 on Vaginal Barri-
ers and Spermicides.) A woman should have her diaphragm
or cervical cap refitted at the first postpartum visit.
• Suggest that lubricated condoms are a good option, at least
in the short run before the woman is ready for another, pre-
ferred contraceptive method.
• Caution women that it may be difficult to practice natural
family planning before their cycles are reestablished and
cyclic signs of fertility return. Advise them that substantial
periods of abstinence are necessary if they do not use a back-
up method of contraception.
• Before delivery, discuss the option of inserting the Copper T
380A IUD. Insertion of this IUD within 10 minutes after
expulsion of the placenta may be a good option for some
women.62 However, high rates of IUD expulsion have been
noted (see Chapter 15).  The LNg 20 IUD is also a good
option.
• Inform women about postcoital methods of contraception,
where these are available.
CONTRACEPTION FOR THE BREASTFEEDING WOMAN
Lactational amenorrhea method (LAM) 
LAM provides effective protection against pregnancy for up to 6
months postpartum. Women who wish to use LAM to avoid becom-
ing pregnant should use another method of contraception as soon as
LAM indicates a return to the risk of pregnancy. Breastfeeding women
who do not wish to use LAM could begin using contraceptives either
immediately after delivery or at the first postpartum examination,
preferably no later than 4 weeks after delivery. Clinicians should rein-
force breastfeeding and provide appropriate contraceptive services that
do not interfere with the woman's ability to breastfeed.
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Nonhormonal Methods
Abstinence is 100% effective in preventing pregnancy. A number
of cultures promote a period of abstinence postpartum, although the
length of abstinence varies. In Nigeria, a period of abstinence often
parallels the period of lactation. The husband might sleep in a separate
dwelling or with another of his wives. Some mothers observe tradi-
tional customs that prohibit intercourse for a long period of time,
until some activity of the child marks the end of the abstinent period.
For example, some cultures prohibit intercourse until the youngest
child can carry a bowl of food to the father, lift a three-legged stool, or
walk steadily, all of which might occur between 1 and 2 years of age.
A study in Zaire found a median duration of 4.5 to 8.8 months of
postpartum abstinence. The study found that women who were poorer
and less urbanized abstained for longer periods of time than did urban-
ized, wealthier women. The duration of abstinence was also associated
with duration of breastfeeding.27  Only 18% of women continued to
abstain after they resumed menstruating. In this case, the other 82%
would be the target population for family planning methods.
The woman practicing abstinence should be counseled about
other contraceptive methods if she desires to resume intercourse. In
particular, women should know where and how to obtain emergency
contraceptives in case of unprotected intercourse during a fertile time.
Assure all women that intercourse will in no way harm milk produc-
tion unless they become pregnant. 
Spermicides and barrier methods have no effect on breastfeed-
ing. The lubricated condom protects against sexually transmitted
infections (STIs) and spermicides such as foams, foaming supposito-
ries, creams, and jellies may help offset dryness due to estrogen defi-
ciency. Condoms and spermicides may be used safely even in the
immediate postpartum period. However, the diaphragm cannot be
refitted until the cervix, vagina, and uterus have involuted. The cervi-
cal cap should be refitted at about 6 weeks and should not be used
before that time. Some animal studies have found that the spermicide
nonoxynol-9 is absorbed through the skin and secreted in very small
quantities in breast milk,10 although no negative effects have been
reported.
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Charting menstrual cycles and fertility awareness methods
(FAM) are not recommended before regular menstruation has
resumed. Some FAM rely on detecting minimal changes in cervical
mucus and basal body temperature (BBT) to determine whether ovu-
lation has occurred. Once ovulation resumes, some women can detect
mucus changes during lactation, but reliable determination of ovula-
tion is more difficult in lactating women than in nonbreastfeeding
women. Research is under way to discover what instructions should be
given to nursing women using these methods.73 Because BBT cannot
be measured unless a woman has at least 6 hours of uninterrupted
sleep, mothers who breastfeed at night cannot use FAM that involve
recording BBT.40 Breastfeeding disrupts fertility signs and symptoms
even after menses resume. Thus, a woman may need to have pro-
longed periods of abstinence when she uses FAM before her regular
menstrual pattern returns.50
The IUD also is an excellent choice for the breastfeeding woman.
The copper on the Copper-T does not affect the quantity or quality of
breast milk.88 (See the following section on Hormonal Methods for
information on the IUDs containing natural or synthetic progester-
one.) Some women experience mild uterine cramping when they
breastfeed with an IUD in place, but the cramping does not usually
interfere with lactation or with the effectiveness of the IUD. IUD
insertion is less painful and removal rates for pain and bleeding are
lower for the lactating mother than for other women.8,15
IUDs may be inserted immediately after expulsion of the pla-
centa or during the first week postpartum, but preferably within 48
hours of delivery. Expulsion rates tend to be higher when IUDs are
inserted immediately postpartum, but recent experiences have been
very encouraging (see Chapter 15). IUDs inserted postpartum have a
pregnancy rate of less than 1% at 12 months postpartum.62 Although
a few case reports and a small case-control study have suggested that
the risk of uterine perforation from IUDs inserted at 6 weeks postpar-
tum is higher among breastfeeding women, other studies have found
very low perforation rates in both breastfeeding and nonbreastfeeding
women.8,15,83 
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Tubal ligation is an excellent method for women who do not
want to have more children. A tubal ligation can be performed imme-
diately postpartum, although it can disrupt lactation if it requires gen-
eral anesthesia or separation of mother and infant. Both problems can
be minimized by performing the procedure with only local anesthetics
and analgesics.49 (See Chapter 21 on Voluntary Surgical Contracep-
tion.)  Women may wish to express and store breast milk before the
procedure. For 12 hours following surgery, anesthetics may pass
through to the breast milk. During this period, women can express
and discard their milk and feed the infant on the stored milk.
Hormonal Methods
The use of hormonal contraception in a lactating woman is an
area of dispute among experts.37 All steroids pass through the breast
milk to the infant in very small quantities, which have not been shown
to be harmful. Estrogens, however, decrease the volume of milk, even
in the small doses found in the 30 (and presubably 20) mcg combina-
tion oral contraceptives.
Progestin-only contraceptives such as Norplant, the LNg IUD,
the Progestasert IUD, Depo-Provera, and minipills (progestin-only
pills) appear to have no adverse effects on lactation.44,52 Because
progestin-only pills do not interfere with the infant's growth and
development,12,36,44,54,60,67,79 these methods are excellent options for lac-
tating women who wish to postpone a subsequent pregnancy. The
methods are simple to use and are highly effective.
Even when they are started in the first week postpartum, mini-
pills have demonstrated no adverse effect on lactation or infant
growth.54,60 Likewise, studies of Depo-Provera started 2 to 4 days post-
partum or at 7 days postpartum52 or within 6 weeks postpartum45 have
found no adverse effects. Two studies of Norplant insertions after 30
days postpartum found no negative effect on psychomental develop-
ment and breastfeeding performance.79,80 One study found slightly
smaller early weight gains among exclusively breastfed infants,80 but
the other found no difference in infant growth between women given
Norplant and control subjects.79 (See Chapter 14 on Norplant, Depo-
Provera, and Progestin-only Pills.)
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Although Norplant and Depo-Provera probably have no adverse
effects on lactation or infant health if used immediately postpartum,
opinions vary about whether they should be used. Some clinicians
worry about early exposure of the infant to progestins, regardless of
the amount, although there is no scientific support for this concern.
The provider may wish to share this information with the client and
wait until breastfeeding has been well established before inserting
Norplant rods or giving the Depo-Provera injection. However, if a
breastfeeding woman is unlikely to return for a postpartum visit and
requests Norplant after delivery (especially if she plans to supplement
the infant's diet relatively soon after birth), the contraceptive benefit
of using this method would probably exceed the theoretical risks. In
the case of Depo-Provera, because the hormonal levels are relatively
high in the days immediately following injections, breastfeeding
should be well established before injections begin. Immediate postpla-
cental or postpartum insertion of the LNg IUD and the Progestasert
IUD have not been studied. 
Combined oral contraceptives are not the contraceptive of
choice for breastfeeding mothers. Even in low-dose combined pills,
the estrogen component reduces the milk supply.82,89 Use of combined
pills could also change the composition of breast milk, perhaps
decreasing its mineral content. Still, the available evidence suggests
that use of combined pills during partial nursing does not harm
infants.89 The appropriate time to provide combined pills to lactating
women remains a subject of disagreement. Using low-dose combined
oral contraceptives after the first postpartum examination is less likely
to interfere with breastfeeding, because lactation has already been
established. Nevertheless, milk volume will be reduced. Experts advise
against using combined pills when other alternatives, such as the IUD
or minipill, are available.23
Emergency contraception (postcoital) is an option for both
breastfeeding women and nonbreastfeeding women who suspect they
may have had unprotected intercourse. Women should be aware of
these options for preventing pregnancy. Emergency contraceptive pills
containing estrogen may have a temporary effect on milk production,
although no studies have been conducted in this area. As always, the
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woman should be allowed to make an informed choice based on the
known risks and benefits. (See Chapter 13 on Combined Oral Con-
traceptives and Chapter 15 on Intrauterine Devices.)
Effects of Hormonal Contraception on the 
Breastfed Infant
Although contraceptive steroids taken by the mother can be
transferred to the nursing infant through breast milk, the amounts are
small. The dose consumed by the infant (the equivalent of one pill for
every 4 years of full lactation) is so low that any negative effects on the
infant are unlikely.49 The main concern is that estrogen suppresses the
quantity of milk.
Combined oral contraceptive use during lactation is not the only
possible source of estrogen and progestin exposure for the infant.
When a mother becomes pregnant and continues to breastfeed her
prior infant, that child is exposed to estrogen and progesterone in the
mother's milk. Because dairy cattle may be pregnant when they are
milked, cow's milk and infant formula made from it may have rela-
tively high levels of estrogen and progesterone.
Although early studies of high-dose oral contraceptives demon-
strated some effect of hormones on nursing babies,12 most of those
reports were anecdotal and have not been supported by studies using
low-dose pills. However, although the short-term effects of absorbing
contraceptive steroids through breast milk appear minimal, the long-
term consequences have not been studied.26,37,40 
THE ROLE OF FAMILY PLANNING IN BREASTFEEDING
We conclude that the best public health strategy promotes (1) breast-
feeding, (2) LAM, (3) the availability of a back-up method to LAM
users, and (4) the prompt provision of contraception to women who
do not use LAM postpartum, including those who are breastfeeding
but do not fit the criteria to rely on LAM. In addition, all women
should know about the availability of emergency contraception if the
need arises.
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Oral contraceptives containing estrogen—even those with low-
dose preparations—adversely affect breastfeeding performance82,89 and
should be discouraged. However, breastfeeding women who are
informed of this fact often still choose oral contraception and are even
encouraged to do so by clinicians.56,72 The challenge for family plan-
ning clinicians is to promote both breastfeeding and an appropriate
contraceptive method that complements breastfeeding. Breastfeeding
and contraception are not physiologically incompatible, although in
many societies they might be perceived as incompatible because a lac-
tating woman would not be expected to be sexually active. Neverthe-
less, many women do resume sexual relations while breastfeeding. The
public health challenge is to avoid presenting breastfeeding and con-
traception as mutually exclusive alternatives and instead to promote
them both by emphasizing their health benefits for mothers and chil-
dren.
INSTRUCTIONS FOR BREASTFEEDING AND 
FAMILY PLANNING
1. Breastfeeding is a convenient, inexpensive, and nutritious way to
feed your baby, and it helps to protect the baby against infection
and diarrhea.
2. When you are nursing your child, your own nutrition is impor-
tant. Eat and drink to satisfy your own hunger and thirst. It is
important to take sufficient fluids and extra calcium, iron, and
protein in addition to a regular well-balanced diet. You may have
to use supplements to get the extra vitamins and iron.
3. If you choose to rely on the lactational amenorrhea method
(LAM) as a temporary method of contraception, you must feed
your baby frequently and limit supplemental feeds, especially bot-
tles. Begin using another method of contraception when you
resume menstruation, when you reduce the frequency of breast-
feeds, when you introduce regular supplemental feeds, or when
your baby turns 6 months old.  Always have a back-up method of
contraception available.
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4. Use emergency contraception if you have intercourse at a time
when you might become pregnant. Postcoital contraception is
effective as a one-time method.
5. You can become pregnant while partially breastfeeding your baby,
even before having your first menstrual period. If you are breast-
feeding and providing regular bottle supplements, begin using a
birth control method as soon as your clinician advises, but no later
than the time of your first postpartum exam (4 weeks after deliv-
ery).
6. If you are not breastfeeding, begin using a birth control method
immediately or at the time of the 4-week postpartum visit. You
can become pregnant before your first menstrual period after
childbirth.
7. Intercourse and menstruation do not reduce the quality and quan-
tity of your breast milk. You do not need to stop breastfeeding
because you start having intercourse again or start your period.
You can continue breastfeeding when you start using another
birth control method and even if you conceive another child.
Pregnancy will cause changes in your breast milk, but does not
prevent breastfeeding.
8. Use lubricants, such as lubricating jelly, birth control foam, or
saliva to make intercourse easier after childbirth. Decreased estro-
gen production during breastfeeding causes your vagina to lubri-
cate itself more slowly.
9. If you are infected with HIV, the virus that causes AIDS, you
could transmit the virus to your baby through breast milk. Talk to
a midwife or doctor about the best way to feed your baby. Protect
your partner from acquiring HIV, as well. If your partner has the
infection, you must still protect both yourself and him from other
sexually transmitted infections.
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SPECIFIC COUNSELING ISSUES FOR WOMEN 
AFTER DELIVERY
• Working women can continue to breastfeed. However, LAM
may be a less reliable method for these women because they often
have longer intervals between feeding. They should use a com-
plementary method of contraception.
• Women may need a single-decision, long-term contraceptive
method (IUD, Norplant, sterilization) if transportation to and
from services is a problem. LAM may give the woman time to
make necessary arrangements, such as saving money and organiz-
ing care for her family, so that she may seek these methods.
• Women with other infants can breastfeed their newborn.
Involvement of the other children in the care of the newborn can
promote family bonding.
• Some women are concerned that breastfeeding will cause their
breasts to sag, while other cultures prize the breast that has
"matured." Explain to clients that pregnancy, rather than breast-
feeding, is the cause, and that wearing a support brassiere during
pregnancy and lactation can diminish sagging.
No matter what other methods of contraception a 
woman is using, if she is at any risk because her partner 
tests positive for the human immunodeficiency virus (HIV) 
or because she does not know his HIV status, she should be 
advised to use plastic or latex condoms with every sexual act.  
No other contraceptive method besides abstinence provides 
the same degree of protection.
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Rose was a virgin when she became engaged to Joseph. He was 
not. Before meeting Rose, Joseph had had intercourse with other 
women, including prostitutes, and he had been treated at least 
twice for sexually transmitted infections. However, when Rose 
and Joseph fell in love, he stopped seeing other women. Rose took 
oral contraceptives regularly until she and Joseph decided to start 
a family. When Rose became pregnant, she attended an antepar-
tum clinic. On learning about Joseph's sexual history, the clini-
cian recommended that Rose have an HIV test. The test was 
positive. Rose was overwhelmed with anger and despair. Rose's 
and Joseph's future lives have forever changed.
 
Millions of  women in their reproductive years rely on the oral contra-
ceptive (OC) pill, which is a highly effective contraceptive. The com-
bined OC pill, one of the most extensively studied medications, is
both safe and effective. In many countries, the pill is now available to
women without a prescription. However, the pill provides no protec-
tion against sexually transmitted infections (STIs), including the
human immunodeficiency virus (HIV). Anyone at risk of becoming
infected from or infecting someone else with HIV should use con-


























The terms “birth control pills,” "pills," “combined oral contra-
ceptives,” “oral contraceptives,” and “OCs” refer to pills that contain




 refer to progestin-




In some countries, clinical rules and practices create barriers to getting
OCs for some women. However, the health risks of pregnancy are far
greater than the risks of taking the pill. Thus, many of these clinical
rules do not protect women against harmful pill side effects but
instead expose them to increased risks of pregnancy. Decrease the bar-




1. At each visit, give the woman enough pills to cover 7 to 20
cycles. If your program policy does not allow this, try to provide





access to pills. 
2. Do not prescribe a "rest period" just because a woman has taken
the pill for several years. Women can use pills as long as they are
at risk for pregnancy. However, because pills can increase the risk
of thrombophlebitis, stop pills for 2 weeks before major elective
surgery. When the woman is able to walk again, she can resume
taking the pills.
3. Do not enforce a minimum or maximum age for pills. A woman
can use pills for as long as she is at risk for pregnancy. (See excep-
tions in the section on precautions.)
4. Help make it easy for the woman to remember to take pills. Tell
her to begin the first pack of pills on the first day of menstrual
bleeding, if possible. Otherwise, she can begin pills within 5 days
of the start of her period.
5. Advise use of back-up contraception if a woman is using rifampin
or if she is taking any anticonvulsant medication, other than val-
















woman taking a broad spectrum antibiotic such as ampicillin or
tetracycline should be offered a back-up contraceptive. 





feeding. She may start combined pills within 2 to 3 weeks of
childbirth.
7. Make it easy to obtain pills. Many countries provide pills without
a clinician's prescription. Trained providers (including commu-
nity-based distribution workers) can initiate and resupply pills,
and can make referrals to appropriate facilities if a user has com-
plaints or troublesome symptoms. There are disadvantages to
making pills available without prescription: the woman may not
return for routine examinations, she may not visit her clinician
about problems she is having with the pill, or she may not be a
good candidate for pill use but may still choose to purchase and
use the pills. On the other hand, the pill is a safe method, espe-
cially among the primary users—young, healthy women. 
8. Keep checklists short (see Table 13:1 for an example). Select
questions to identify which women can receive a limited supply
of pills and which should be referred to a clinic.
9. Do not automatically stop the pill if the client is complaining of
a single side effect. Consider other causes of that side effect. 
10. Prescribe the pill even if the woman does not know how to read.





Two estrogenic compounds are used in almost all current OCs: ethinyl
estradiol (EE) and mestranol. EE is pharmacologically active, whereas
mestranol must be converted into EE by the liver before it is pharma-
cologically active. Most of the OCs currently prescribed to new
patients contain either 30 or 35 mcg of EE. Very few pills containing


























OCs prevent pregnancy primarily by suppressing ovulation. Estro-




• Ovulation is inhibited. 
• Secretions within the uterus and the endometrium are altered. 
• The corpus luteum degenerates.
There is scientific debate about the relative potency of the
progestins in currently marketed OCs: norethindrone, norethindrone
acetate, ethynodiol diacetate, norgestrel, levonorgestrel, desogestrel,
norgestimate, and norethynodrel. Levonorgestrel and dextro-norg-
estrel are the two forms of norgestrel—Levonorgestrel is the active
component, and it is twice as potent as dextro-norgestrel. Progesta-




• Ovulation is inhibited. 
• Cervical mucus thickens. 
• Sperm cannot penetrate the ovum as easily.
• Capacitation of sperm may be inhibited. 
• Ovum transport may be slowed or fallopian tube secretions
altered. 









, only about 1 in 1,000 women will
become pregnant within the first year. However, the typical user does
not use the pills perfectly. Among users of OCs in the United States,
about 5% become pregnant during the first year of typical use. Pill
effectiveness can be improved if women reduce the pill-free interval
from 7 days to 4 or 5 days. 
Many women get pregnant when they discontinue pills, do not
begin another method of contraception, and then have unprotected
intercourse. Only 50% to 75% of women continue to use pills for 1
















provide every pill user with a back-up method of contraception, such
as condoms. Instruct women on how to use the back-up method and
encourage them to practice using it.
Because most women who discontinue pills have not developed a
complication or major side effect, you should try to reduce the barriers
to successful pill use (see previous section). Explain how pills are to be
started and used, and make certain the client understands. It is essen-
tial that the new pill user know when to take the first pill, what to do
if she misses a pill, and where to return for supplies. She should be
informed that spotting and some nausea are most likely to occur in the
first cycle or so and that they tend to decrease over time. 
 









 When taken consistently and correctly, pills are






Low-dose combined pills (pills with 20 to 35 mcg of
estrogen) are very safe for almost all women. It is safer to use pills
than to become pregnant and deliver a baby. An African woman's
risk of dying from pregnancy ranges from 100 to 1,500 maternal






 The risk of death from











A contraceptive option throughout the reproductive years.
 
Most women can safely use pills throughout their reproductive
years. A rest period every few years is definitely not recom-





 Pills are an excellent option for women
who want to become pregnant in the future. Pills protect future
fertility, as they prevent ovarian cysts, many forms of pelvic
inflammatory disease (PID), ectopic pregnancy, progression of
































Pills decrease menstrual cramps and pain. Some women con-




Pills prevent ovulation and, therefore, ovulation pain (mit-








Pills decrease menstrual flow by 60% or more in women


















Very low-dose pills (pills with 20 to 30 mcg of
estrogen and lowest dose progestin pills) provide less protec-








Pills can reduce premenstrual symptoms such as anxiety, de-








Prevention of ovarian and endometrial cancer
 
. By age 55, a
woman is less likely to be diagnosed with cancer if she used pills
than if she did not. Women who have used combined OCs for 4
years or less are 30% less likely to develop ovarian cancer than
women who have never used the pill. Women who used pills for
5 to 11 years are 60% less likely; and if they used them for 12 or
more years, 80% less likely. This protection lasts for at least 10
years after pills have been discontinued. Women who start using
OCs at an early age and continue for a long time may be more











a strong family history for this type of ovarian
cancer might be considered an indication for using OCs. Pill







The protective effect lasts for at least 10 years


















Decreased risk for benign breast cysts and fibroadenomas.
 
Pill users are less likely to develop benign breast tumors than are






Prevention of ectopic pregnancy. 
 
By stopping ovulation, pills
prevent all conceptions, including those that implant outside the
uterus (ectopic pregnancies). Ectopic pregnancy is an important
cause of maternal mortality throughout the world. 
9.
 
Prevention of pelvic infection
 
. The combined oral contracep-







Pill users are less likely to develop the more severe forms
of PID than are users of other contraceptives. However, pills may
not protect women against all forms of PID, especially the more

















Reduction of acne and hirsutism.
 
 Combined OCs lower serum






Increased enjoyment of sexual intercourse
 
. Probably because
the fear of pregnancy is diminished, many couples who rely on
the pill enjoy sexual intimacy more. However, in some women,
the pill has just the opposite effect.
12.
 
Improvement of estrogen deficiency symptoms. 
 
Pills suppress
follicle stimulating hormone and luteinizing hormone and pre-
vent hot flashes in women in their 40s. Pills have been shown to
have similar beneficial effects in preventing osteoporosis.
13.
 
Management of endometriosis. 
 
Pills have been used in prevent-








 In many countries, pills are available at a low
cost and without a prescription. The price and availability of pills
vary greatly from country to country.
15.
 
Prevention of hospitalization. 
 
The use of combined OCs pre-
vents more hospitalizations than it causes (see Figure 13:1). In
the United States, the protective effects of pills prevent an esti-






























Use as emergency contraception.
 
 Some types of combined pills
given within 72 hours of unprotected intercourse reduce the risk












 pregnancy occurs.  Emergency contracep-
tive pills (ECPs) have a higher than usual dose of oral contracep-
tives.  When taken within 72 hours after unprotected
intercourse, ECPs can interrupt fertilization and implantation.
One dose is taken soon after intercourse, and a second dose is
taken 12 hours later.  (See Table 13:1.)  Emergency contraception
should not be a routine form of protection for women.
About half the women who use ECPs report nausea; about 20%
vomit.  Nausea and vomiting can be prevented by antinausea
medications such as dimenhydrinate and cyclizine hydrochloride.
 
Table 13:1 Oral contraceptive pills available in Africa that can be 
used as emergency contraceptive pills
 
Brand Name
First dose within 
72 hours of intercourse
Second dose 
12 hours after first dose
 
Anteovin 2 tablets 2 tablets
Eugynon 2 tablets 2 tablets
Eugynon-30 4 tablets 4 tablets
Eugynon-50 2 tablets 2 tablets
Lo-Femenal 4 tablets 4 tablets
Lo-Rondal 4 tablets 4 tablets
Logynon 4 tablets 4 tablets
Microgynon 4 tablets 4 tablets
Microgynon-30 4 tablets 4 tablets
Microvlar 4 tablets 4 tablets
Minidril 4 tablets 4 tablets
Neogynon 2 tablets 2 tablets
Nordette 4 tablets 4 tablets
Nordiol 2 tablets 2 tablets
Normovlar 2 tablets 2 tablets
Ovidon 2 tablets 2 tablets
Ovral 2 tablets 2 tablets
Primovlar 2 tablets 2 tablets
Rigevidon 4 tablets 4 tablets
Stediril 2 tablets 2 tablets
Trinordiol 4 tablets 4 tablets
Triovlar 4 tablets 4 tablets














































































































































































































































































































































































































































































































Pills are a particularly attractive contraceptive option for women
who are motivated to use a method that requires a daily routine and
who have some of the following characteristics:
• Nulliparous
• Young, sexually active 
• Not at risk for STIs, including HIV
• Desiring spontaneous intercourse
• Nonlactating, postpartum 
• Desiring a reversible method
• Bothered by heavy or painful periods
• Acned, hirsute, or having oily skin
• Having a strong family history of ovarian cancer
DISADVANTAGES AND CAUTIONS
Pills provide no known protection against HIV infection.
Women who may be at risk for HIV infection should use condoms
alone or condoms with the pill. (Abstinence and long-term mutually
faithful relationships are the safest approaches to avoiding HIV infec-
tion transmitted by intercourse.)
1. Challenge of daily compliance. Some women may find it com-
plicated to take pills every day. If a woman runs out of her supply
of pills, her contraceptive protection will stop.
2. Expense. Pills are not always available or affordable.
3. Unwanted menstrual cycle changes. Pills may be associated with
menstrual changes such as missed periods, very scanty bleeding,
spotting, and breakthrough bleeding. These changes usually
resolve in 3 to 4 cycles. Some women find these menstrual cycle
changes distressing. (Combined OCs cause fewer bothersome
menstrual cycle changes than do progestin-only pills, Norplant
implants, or progestin-elaborating intrauterine devices [IUDs].)
4. Nausea or vomiting. Nausea may occur in the first cycle or so of
pill use or, less commonly, in subsequent cycles.
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5. Headaches. Headaches may start in a woman with no history of
headaches or they may become worse than they were before pills
were started. On rare occasions, changes in vision accompany the
headaches. If a woman loses her vision while using pills, she
should discontinue their use. 
6. Depression. In some women, pills may stimulate depression
(sometimes severe) and other mood changes.
7. Decreased libido. Some women on pills experience a decreased
interest in sex or a decreased ability to have orgasms. Decreased
libido may be due to decreased levels of free testosterone due to
OC use.
8. Cervical ectopia and chlamydia infection. Chlamydial cervicitis
may be more common in women taking pills.26,31 Pills can cause
cervical ectopia, a condition in which the delicate mucus-secret-
ing columnar cells that normally line the cervical canal cover part
of the external surface near the opening of the cervical canal.
Chlamydia thrives inside these columnar cells, making the cervix
more vulnerable to C. trachomatis infection. However, there is no
evidence to suggest this increased risk for chlamydial infection
places women at greater risk for PID.
9. Thrombophlebitis, pulmonary emboli, and other cardiovascular
diseases. Circulatory diseases are the most serious complications
attributable to oral contraceptive use.14,27 Fortunately, serious
complications are extremely rare with low-dose combined OCs.
Clinically significant hypertension has been associated with both
estrogen and progestin in pills. However, it is not certain whether
clinically significant hypertension is caused by OCs. If a woman's
diastolic blood pressure rises above 90 mmHg on several visits,
discontinue her pills or change to a lower dose. It may be appro-
priate to switch her to a progestin-only pill. Hypercoagulability
and thrombosis are associated with exogenous estrogens. Athero-
genesis is prevented by estrogens, which tend to have desirable
effects on lipids, increasing high-density lipoproteins (HDLs)
and decreasing low-density lipoproteins (LDLs). Androgens and
some progestins have just the opposite effect on HDLs and
LDLs. Recent changes in OC formulations have lowered the
progestins in OCs and have led to new formulations capable of
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producing a more favorable lipoprotein pattern than a woman
had before using pills. The "new progestins," which contain
desogestrel, gestadene, or norgestimate, lead to a favorable HDL:
LDL ratio.11
10. Carbohydrate metabolism. Carbohydrate metabolism is not sig-
nificantly affected by the current low-dose pills. Low-dose com-
bined pills may be provided to some women with a history of
gestational diabetes, a family history of diabetes, and, in some
instances, insulin-dependent diabetes. 
11. Gallbladder disease. Recent studies conclude that OCs are not
an important risk factor for the development of gallstones or gall-
bladder cancer. However, although pills do not cause gallstones,
they may speed the development of gallbladder disease in women
who already are susceptible, such that problems become evident
earlier.14,26
12. Hepatocellular adenomas. Benign liver tumors have been asso-
ciated with the use of combined OCs. However, with the current
low dose pills, the risk of liver tumors is much lower than with
higher dose pills, and pill users may bear no greater risk of these
tumors than do nonusers.
13. Breast cancer and other types of cancer. By age 55, women who
used pills are no more likely to be diagnosed with breast cancer
A woman’s risk for circulatory disease is most 
influenced by characteristics unrelated to pill use—
factors such as smoking, weight, and cholesterol levels.  
Cardiovascular disease is most likely to occur in women who:
• Smoke
• Are overweight
• Get little physical exercise
• Are over 50 years of age
• Are hypertensive, diabetic, or have a history 
of heart or vascular disease
• Have a family history of diabetes or heart attack 
in a relative under the age of 50
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than are women who did not use pills. However, there may be a
group of young women who have used pills that are at greater risk
of having breast cancer diagnosed before the age of 35.15,33 Seven of
13 epidemiologic studies found no significantly increased risk of
cervical neoplasia in OC users, and five found a statistically
increased risk.24,30 A link between OCs and benign hepatocellular
adenomas was established several years ago.23 An association
between OCs and hepatocellular carcinoma is less certain.10,12,17,28
Pills probably have no effect on a woman's likelihood of develop-
ing a malignant melanoma; kidney, colon, or gallbladder cancer;
or pituitary tumors.15,17,20
14. Decreased milk supply. Combined OCs are not the contracep-
tive of choice for breastfeeding mothers. The estrogen in com-
bined pills, even in low-dose pills, reduces milk supply.32 Use of
combined pills may slightly alter the composition of breast milk;
most studies report declines in mineral content. Nevertheless, the
use of combined OCs while nursing does not harm infants.32
15. Other side effects. Women using pills may experience a variety
of other side effects including breast fullness or tenderness,
increased facial pigmentation, acne, weight gain, and hair loss. 
PROVIDING COMBINED PILLS
Each country needs to develop its own protocols for providing and
following up women who receive the pills. Suggestions that may help
establish protocols are listed below. For most women, the advantages
of combined pills clearly outweigh the risks and disadvantages. How-
ever, you should avoid giving pills to women who may have condi-
tions that increase risk. To further reduce any risks and disadvantages
of pill use, do not provide pills with more than 35 mcg of estrogen to
these women and prescribe pills with low dosages of progestin. 
Because misinformation about OCs is widespread, clearly explain
the noncontraceptive benefits of pills, how to use them, and what to
do if problems with the pill should occur. Encourage all smokers to
stop smoking.
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INITIAL VISIT
Weight, blood pressure, a Papanicolaou (Pap) smear, and pelvic
examination are desirable screening tests for all women. For most women,
however, they are not necessary to start taking pills.  At the minimum, mea-
sure blood pressure and use a checklist to evaluate clients annually.
FOLLOW-UP VISITS
Each clinic must decide what medical history should be taken
each time a woman returns for a pill refill. Brief, self-administered
questions can help the pill user decide whether she should stop using
pills if she develops medical problems or experiences a danger sign.
(See Table 13:1 on The Pill Checklist.)
Some programs re-evaluate women after their first 3 to 6 months
of pill use. Although this is not medically necessary, evaluation is an
opportunity for the woman to ask questions about the pill. If a
woman has used the pill for 3 to 6 months, is having no problems, and
wants to continue the pill continuously, seven packets (a 6-month
supply) may be provided. After a woman has used pills for 1 year, a
full year's supply of pills may be provided to discourage pill discontin-
uation. 
Table 13:2 Checklist for the provision of combined oral 
contraceptive pills
Do you have symptoms of pregnancy NOW? ____ YES ____ NO
Have you ever been told NOT to take pills? ____ YES ____ NO
Have you ever had a blood clot, a heart attack, or 
a stroke? ____ YES ____ NO
Have you had severe headaches or severe chest 
pain since starting birth control pills? ____ YES ____ NO
Have you developed blurred vision or loss of 
vision since taking the pill? ____ YES ____ NO
If the answer to any of these questions is "yes," discuss them with your clinician.
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CHOOSING A COMBINED ORAL CONTRACEPTIVE: 
WHICH COMBINED PILL TO PRESCRIBE 
How does a clinician decide which of the many pills to prescribe
for an individual woman?  A flow sheet (see Figure 13:2) can help.  Any
of the sub-50 mcg pills may be used by most women.
OCs provide no protection against STIs, including HIV infec-
tion. Counsel women (and men) to use condoms until they become
committed to a long-term, mutually faithful relationship with some-
one they know is not infected. Consider providing both an OC pill
and condoms. 
Indications and precautions (Step #1)
Some women should not take an OC with an estrogenic compo-
nent. Avoid prescribing pills to women who have conditions that place
them at greater risk of complications. (See Table 13:3 and Figure 13:
2.) On the other hand, today’s OCs are suitable for several categories
of women who have been denied prescriptions in the past:
Women over 35 years of age
Today's pills are available in much lower doses and appear to be a
safe contraceptive choice for women over 35 who do not smoke or
have hypertension, diabetes, or hypercholesteremia.14,21,26  Women
may take the pill until age 50, as long as they have no complications or
risk factors. Screening tests such as mammography and cholesterol
determinations that might reveal complications, however, are unavail-
able for most women in the world. Pills should not be withheld from
women when these tests are not available, unless a woman has other
reasons to avoid pill use.
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Figure 13:2 Choosing a combined oral contraceptive
Step 2Step 1
Can this individual be
prescribed a pill with estrogen?
Definitely refrain from
prescribing a pill with estrogen to
women with a history of a cerebro-
vascular accident; ischemic heart
disease; uncontrolled hypertension;
insulin dependent diabetes with
vascular disease; classic migraine
with neurologic impairment which
has increased with estrogen; breast
cancer; estrogen dependent neo-
plasia; active hepatic disease with
impaired liver function at the
present time; benign or malignant
liver tumor; or deep vein thrombosis.
Some clinicians would make an
exception and provide combined
OCs to women following postpar-
tum pelvic vein thrombosis or
women whose thrombophlebitis
was due to trauma or intravenous
therapy. Also, in most instances,
refrain from providing combined pills
to women over 35 who smoke.
Breast feeding women, in general,
should avoid estrogen.
YES, she can use
an estrogen.
NO, it would be best if she
did not use an estrogen.
Therefore, you can consider:
•  Progestin-only pills, such as:
•  Intrauterine device
•  Condoms (male or female)
•  Diaphragm, Cervical Cap
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Marcia Angle, MD, MPH, Program for International Training and Health (INTRAH)
James Bellinger, PAC, Emory University School of Medicine
Robert A. Hatcher, MD, MPH, Emory University School of Medicine
Michael Policar, MD, MPH, Planned Parenthood Federation of America
Sharon Schnare, CNM, MSN, FNP, Harbor-UCLA Women’s Health Care
Gary S. Stewart, MD, MPH, Planned Parenthood of Sacramento Valley
Susan Wysocki, RNC, BSN, NP, National Association of Nurse Practitioners in Reproductive Health
Graphic Design: Anne Atkinson and Beth Coffey
© Robert A. Hatcher, MD, MPH
April 1993
COMBINED ORAL CONTRACEPTIVES 311
Figure 13:2 Choosing a combined oral contraceptive (Continued)
•  Loestrin 1/20
•  Loestrin 1/20
•  Desogen
•  Levlen




•  Lo-Ovral, Nordette, or Levlen
•  A new progestin pill: Desogen,
     Ortho-Cept, Ortho-Cyclen, or
     Ortho Tri-Cyclen
•  Desogen, Ortho-Cept
•  Ortho Tri-Cyclen
•  Ortho Cyclen
•  Ovcon-35, Brevicon, or Modicon
      (of norethindrone pills)
•  Demulen-35 (of ethnodiol diacetate
      pills)
•  Ortho Cyclen or Ortho Tri-Cyclen
•  Desogen or Ortho-Cept
•  Ovcon-35, Brevicon, or Modicon
    (of norethindrone pills)
Other clinical considerations that might






To minimize the potential risk for
thrombosis due to estrogen in a woman
40–50 years of age or a woman at in-
creased risk for thrombosis due to
another cause (e.g., diabetic or heavy
smoker), prescribe:
To minimize nausea, breast tenderness,
vascular headaches, and estrogen-
mediated side effects, prescribe:
Or a 30 mcg pill, such as:
To minimize spotting and/or
breakthrough bleeding, prescribe:
To minimize androgen effects such as
acne, hirsutism, oily skin, sebaceous
cysts, pilonidal cysts, or weight gain,
prescribe:
To produce the most favorable lipid
profile, prescribe:
Contraceptive Technology 1994–1996
Step 3 Step 4








Number of micrograms of ethinyl estradiol
Availability of pill
Ease of remaining on schedule because of pills
Price of pills to clinic
Price of pills to client
Prior experience of this individual woman or the
clinician caring for this woman with a special pill
Pills are listed from the lowest to the highest number of
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Table 13:3 Precautions in the provision of combined pills   
Low-Dose Oral Contraceptives (COCs)
Containing <50µg of Ethinyl Oestradiol
Condition Category Rationale/Comments
Pregnancy 4 As no method is indicated, any health risk is 
considered unacceptable. However, there is no 











Theoretical concern regarding association of OC 
use and risk of thrombosis. Concern that 
immature neonate may be at risk of exposure to 
steroid hormones.
Use of OCs during breast-feeding diminishes the 
quantity of breast milk and may adversely affect 






Theoretical concern about the use of OCs among 
young adolescents has not been substantiated by 
scientific evidence.
The health risk:benefit ratio may change for 
women with certain risk factors for cardiovascular 










Age modifies the risk associated with smoking.
The risk:benefit ratio changes particularly among 













OC causes only small changes in blood pressure 
among non-hypertensive women. Primary 
concern is risk of underlying vascular disease and 
additional risk of thromboembolism.
The health risk:benefit ratio depends on the 
severity of the condition.
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
History of pre-eclampsia 1 Absence of underlying vascular disease suggests 
no need for restriction of OC use. 
Diabetes






Other vascular disease or 







Not a concern; no need for restriction of OC use.
Although carbohydrate tolerance may change 
with OC use, major concern is vascular disease 
and additional risk of thrombosis.
Venous thromboembolism 
(VTE)


















The increased risk of venous thromboembolism 
associated with OC should have little effect on 
healthy women, but may have substantial impact 
on women otherwise at risk for thrombo-
embolism.
Current and history of 
ischemic heart disease
4 Among women with underlying vascular disease 
or demonstrated predisposition to thrombosis, 
the increased risk of thrombosis with OC should 
be avoided.
Table 13:3 Precautions in the provision of combined pills (Cont.) 
Low-Dose Oral Contraceptives (COCs)
Containing <50µg of Ethinyl Oestradiol
Condition Category Rationale/Comments
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable






Among women with underlying vascular disease 
or demonstrated predisposition to thrombosis, 
the increased risk of thrombosis with OC should 
be avoided.
Severe hyperlipidemia 3 Although these conditions are risk factors for 
vascular disease, routine screening is not needed 
and is inappropriate because of the rarity of the 









Use of OC in complicated valvular heart disease 
is likely to increase the risk of embolic phenom-
enon. 
On anticoagulant drugs 3/4 Among women with underlying thromboembolic 
condition or predisposition to thrombosis, any 






migraine, without focal 
neurologic symptons
recurrent, including 





Not a concern, no need for restriction of OC use.








Changes in menstrual bleeding patterns are 
common among healthy women.
Table 13:3 Precautions in the provision of combined pills (Cont.) 
Low-Dose Oral Contraceptives (COCs)
Containing <50µg of Ethinyl Oestradiol
Condition Category Rationale/Comments
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Unexplained vaginal 






Evaluation of the underlying pathological 





Family history of cancer
Cancer
current
past but no evidence 







No concern related to COC use for women with 
benign breast disease or family history of breast 
disease.
Breast cancer is a hormonally sensitive tumor.  
The risk for progress of the condition may be 
increased among women with current or past 
history of breast cancer.
Cervical intraepithelial 
neoplasia (CIN)
2 Little concern that OC enhances progression of 
CIN to invasive disease.
Cervical cancer
(awaiting treatment)
2 Theoretical concern that OC use may affect 
prognosis of the existing disease.
Cervical ectropion/erosion 1 Not a risk factor, no need for restriction of 
OC use.
Endometrial, ovarian cancer 1 OC use reduces the risk of developing 
endometrial and ovarian cancer. (In general, 
treatment of these conditions renders a woman 
sterile. While awaiting treatment, women may 
use OC.)
Table 13:3 Precautions in the provision of combined pills (Cont.) 
Low-Dose Oral Contraceptives (COCs)
Containing <50µg of Ethinyl Oestradiol
Condition Category Rationale/Comments
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Pelvic inflammatory disease 
(PID)
Past (assuming no current 









pregnancy is not 
desired






Increased risk of STIs 
(e.g. multiple partners or 










OCs provide protection against PID.
STIs:  current or within
3 months
1 Not a concern, no need for restriction of OC use.
HIV/AIDS
HIV+






No confirmation of an association of OC use 
with these conditions.
Table 13:3 Precautions in the provision of combined pills (Cont.) 
Low-Dose Oral Contraceptives (COCs)
Containing <50µg of Ethinyl Oestradiol
Condition Category Rationale/Comments
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable











Estrogen component of OC accelerates the 






History of pregnancy related cholestasis may 










Because OC is metabolized by the liver, its use 
may adversely affect women whose liver function 
is already compromised.
In women with symptomatic viral hepatitis, OC 
should be withheld until liver function returns to 
normal or until 3 months after the woman 
becomes asymptomatic.
Cirrhosis 3/4 Because OC is metabolized by the liver its use 







OC is metabolized by the liver, and use may 
affect prognosis of the existing disease.
OC use substantially increases the risk of 
hepatoma.
Schistosomal fibrosis 1 OC use is not known to predispose to 
schistosomal fibrosis.
Uterine fibroids 1 OCs provide protection against uterine fibroids.
Table 13:3 Precautions in the provision of combined pills (Cont.) 
Low-Dose Oral Contraceptives (COCs)
Containing <50µg of Ethinyl Oestradiol
Condition Category Rationale/Comments
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable








OCs provide protection against ectopic 
pregnancy.








Not a concern, no need for restriction of OC use.
Trophoblast disease
(current and recent history)
1 Not a concern, no need for restriction of OC use.
Sickle cell disease 2 Not a concern, no need for restriction of OC use.
Iron deficiency anaemia 1 OC use may decrease blood loss. No need for 
restrictions of OC use.
Epilepsy 1 The condition per se is not a concern. No need 
for restriction of OC use.
Certain antiepileptic drugs lower OC efficacy. If a 
woman is taking treatment, refer to section on 
drug interactions.
Schistosomiasis 1
Malaria 1 Not a concern, no need for restriction of OC use.
Table 13:3 Precautions in the provision of combined pills (Cont.) 
Low-Dose Oral Contraceptives (COCs)
Containing <50µg of Ethinyl Oestradiol
Condition Category Rationale/Comments
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Drug interactions
Commonly used drugs 












Commonly used liver enzyme inducers are likely 
to reduce the efficacy of OCs.
Use of other contraceptives should be encouraged 







Not a concern. No need for restriction of OC 
use.
Rapid return to fertility 
desired
1 Not a concern. No need for restriction of OC 
use.
Severe dysmenorrhoea 1 OC use may decrease or alleviate symptoms of 
dysmenorrhoea.  No need for restriction of OC 
use.
Source:  WHO (1996)
Table 13:3 Precautions in the provision of combined pills (Cont.) 
Low-Dose Oral Contraceptives (COCs)
Containing <50µg of Ethinyl Oestradiol
Condition Category Rationale/Comments
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Smokers
It is not required or wise to withhold pills from all women who
are heavy smokers but have no other reasons to avoid pill use. Encour-
age smokers to stop smoking. Explain that cigarette smoking interacts
with OCs to increase a woman's risk of myocardial infarction, stroke,
and other clotting injuries. Teach the warning signs when using pills.
Young women
An adolescent woman can start taking the pill when she becomes
sexually active or considers becoming sexually active. The medical and
social risks of pregnancy at a young age exceed the risks of taking OCs,
even if menstrual periods have not begun. No evidence suggests that
the estrogen in current low-dose OCs can limit height due to prema-
ture closure of the epiphyses, even in adolescents who have not begun
menstruating. In menstruating adolescents, epiphyseal closure is well
under way. Tell the young woman who has had very irregular periods
or very late onset of menses that OCs will make her menses more reg-
ular, but that when she stops her OCs in the future to become preg-
nant, her periods may become irregular again and that becoming
pregnant could take a number of months.
Because adolescent pill users may stop using pills because of
minor side effects such as nausea or spotting, take all minor side effects
in adolescents seriously. If nausea or vomiting is a problem, prescribe a
20 mcg pill, the lowest estrogen pill available, or a progestin-only pill.
If acne is a particular concern, one of the new progestin pills may be
the best choice, but all pills are likely to have a beneficial effect on acne. 
Postpartum/lactating women
Because pills may decrease the amount of milk a breastfeeding
woman produces, most women should begin pill use after the baby
has been weaned. The progestin-only pill is probably a better choice
than the combined pill for these women. Contraceptive choices for
breastfeeding women are discussed extensively in Chapter 12 on Lac-
tation and Postpartum Contraception and in Chapter 14 on Nor-
plant, Depo-Provera, and Progestin-Only Pills.
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Alternative options (Step #2)
If a woman should not take estrogen, consider all alternative con-
traception options, including progestin-only methods and IUDs.
Selection (Step #3)
Select any sub-50 mcg combined pill based on its availability,
cost, or on the prior experience of the client or clinician. No single
OC is clearly better than all the rest. Today's combined OCs contain
far less estrogen or progestin than pills of a generation ago. Most of the
noncontraceptive benefits of combined OCs appear to occur in
women using low-dose pills.
Price. It is appropriate to consider price in choosing a pill. Cost
influences decisions about which pill to provide, along with clients in
deciding whether they can use the pill successfully. Find out where cli-
ents can obtain pills most inexpensively.
Dose. Start with the lowest dose pill available:
• A 20 mcg (unavailable in most clinics in Africa) or a 30 mcg
pill
• A pill with just 0.4 or 0.5 mg of norethindrone rather than 1
mg of norethindrone found in 1+35 pills
• The pills with the lowest amount of levonorgestrel available
to your clinic
Clinical considerations (Step #4)
The estrogenic, progestational, and androgenic effects of OCs
affect a number of organs and tissues throughout the body (skin,
uterus, ovaries, brain, breasts, arteries, veins, etc.). A pill may stimulate
a specific organ in a woman quite differently than the natural (endog-
enous) hormones the woman produced before she began using OCs.
A specific pill may suppress hormone production or affect one organ
system or tissue differently in two different women. But, there are
ways to minimize a woman's risk of specific side effects or metabolic
changes brought about by pills:
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Thrombosis. The most serious complication to avoid is throm-
bophlebitis. A client at an increased risk of thrombophlebitis should
use the pill with the least estrogenic potency, such as a 20 or 30 mcg
pill.
Estrogenic side effects. Most women using pills with less than 50
mcg of EE do not experience one of the estrogen-mediated side
effects, which include the following:9,14
• Nausea
• Increased breast size 
• Leukorrhea (whitish vaginal discharge)
• Cervical ectopy (growth of columnar cells onto the surface of
the cervix)
• Thromboembolic complications (blood clots)
• Hepatocellular adenomas (benign liver tumors)
• Growth of leiomyomata (fibroids)
• Telangiectasia (superficial vessels on the skin)
Estrogen- and progestogen-associated side effects include the follow-
ing:
• Breast tenderness 
• Headaches 
• Hypertension 
• Myocardial infarction 
Spotting. Spotting and breakthrough bleeding are more likely to
occur when women use lower dose pills. These symptoms tend to
diminish dramatically over the first few months of pill use. Some
women stop using pills because of these problems, but counseling
users about expected menstrual changes can decrease the likelihood
that they will stop using the pill. However, if a woman does not accept
the pattern of bleeding associated with one type of pill, she may want
to try another type.
 Androgenic effects. Low-dose combined pills tend to have a ben-
eficial effect on acne and oily skin, because they all suppress a woman's
production of testosterone.14,18 The new progestins (desogestrel, norg-
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estimate, and gestodene) appear to further reduce problems such as
hirsutism, oily skin, sebaceous cysts, pilonidal cysts, and weight gain.
These pills are associated with higher sex hormone binding globulin
levels and lower free testosterone levels. In some cases, however, the
progestin component of OCs produces both androgenic and progesta-
tional effects:9
• Increased appetite and weight gain 
• Depression, fatigue, or tiredness 
• Acne or oily skin 
• Increased breast size (alveolar tissue) 
• Increased LDL cholesterol levels 
• Decreased HDL cholesterol levels 
• Diabetogenic effect 
• Pruritus (itching)
• Decreased tolerance of starches and sugars (carbohydrates)
Lipid changes. To produce the most beneficial lipid profile, pre-
scribe one of the new progestin pills containing desogestrel, norgesti-
mate, or gestodene. Generally, these new progestins increase HDL
cholesterol and decrease LDL cholesterol. When prescribing one of the
norethindrone pills, choose one with 0.4 or 0.5 mg of norethindrone.
Other Considerations in Pill Choice
Higher dose estrogens. A woman should not be started on pills
with more than 50 mcg of estrogen. However, there are clinical situa-
tions when a 50 mcg pill may be helpful:
• Occasional spotting or the absence of withdrawal bleeding
cannot be managed on a pill with less than 50 mcg.
• Acne, dysfunctional uterine bleeding, ovarian cysts, and
endometriosis have all been treated occasionally with OCs
containing 50 mcg of estrogen. Dysfunctional bleeding has
been treated by prescribing a variety of OCs in the following
regimen: one tablet four times a day for 5 to 7 days. Ovarian
cysts less than 6 cm in diameter in women of childbearing-
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age have been treated with combined monophasic pills (pills
that contain the same dose of hormones throughout the
active cycle of pills). 
• Low-estrogen symptoms of menopause rarely occur in a
woman taking a 20, 30, or 35 mcg pill and may be elimi-
nated by a 50 mcg pill.
• Pregnancy, despite the perfect use of a 30 to 35 mcg pill, may
signal that the user is a candidate for a 50 mcg pill. A second
approach, which may be preferable, is to decrease the num-
ber of pill-free days from 7 to 4 or 5 (21 active pills followed
by only 4, 5, or 6 days of no OCs before beginning a new
package of pills).
• Rifampin and Dilantin (phenytoin) both accelerate the
breakdown of estrogens in OCs, and women on these medi-
cations should probably be started on a 50 mcg pill.
New progestins. The new progestin pills may be ideal for
women who are beginning to use contraceptives. The new progestins
have several potential advantages over pills previously available:
• Higher HDL cholesterol and lower LDL cholesterol levels.
However, while this biochemical profile might be expected
to be beneficial to women over time, no clinical studies to
date demonstrate clinical advantages. 
• Lower free testosterone levels and higher sex hormone bind-
ing globulin (SHBG) levels. SHBG is increased more by
desogestrel pills than by levonorgestrel pills.
• Reduced amenorrhea. There appear to be no women who go
2 months without a withdrawal bleed. Most women who
take other low-dose OCs are amenorrheic for several cycles
and feel uncertain or uncomfortable about this degree of
menstrual irregularity. 
The disadvantages of the new progestin pills are as follows: 
• They may increase the confusion over the many pill options. 
• Lowering of free testosterone may have negative effects
although preliminary evidence has not shown this to be true. 
COMBINED ORAL CONTRACEPTIVES 325
• The price of some of the new progestins may be higher than
the price of other pills. 
• They present a greater risk of deep vein thrombosis. 
Multinational studies have shown that soon after beginning pills
with gestodene or desogestrel, women have a twofold to fourfold
increase in nonfatal thromboembolic disease that is not affected by
smoking, age, or history of hypertension.34,35
Extensive in vivo and in vitro tests show norgestimate to have less
androgenic effect than previously available progestins. In combination
with EE norgestimate raises SHBG, reduces free testosterone, and ele-
vates HDL cholesterol. It maintains a more favorable LDL:HDL ratio
over a 2-year period than do the progestins levonorgestrel and nore-
thindrone. Norgestimate does not adversely affect clinical coagulation
profiles.
Desogestrel is the progestin most extensively used in pills pre-
scribed in Europe, where a number of progestins have been competing
for the pill market for over a decade. Its metabolic effects are similar to
those described for norgestimate pills. Desogestrel is marketed as a
monophasic pill in much of Africa and Europe as Marvelon and else-
where as Desogen and OrthoCept. 
Gestodene, used extensively in OCs in Europe, has many of the
advantages of norgestimate and desogestrel. 
Triphasic pills. Triphasic pills (pills that vary the dose of hor-
mone taken in the early, middle, and end of the active cycle of pills)
offer no particular advantages to clinicians. Indeed, they may compli-
cate instructions for using pills. Of combined OCs containing
levonorgestrel, the triphasics have the least amount of levonorgestrel.
Pill interactions. The lower the dose of estrogen or progestin
provided to a woman as a contraceptive, the greater the chance that
the effectiveness of a contraceptive pill is reduced. 
• A second medication may induce liver enzymes that cause
breakdown of an estrogen or progestin (microsomal liver
enzyme induction). Rifampin has potent enzyme-inducing
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effects; the antifungal drug griseofulvin may have similar but
less powerful enzyme-inducing properties. The anticonvul-
sants most likely to have this effect are phenobarbital, pheny-
toin, carbamazepine, primidone, and ethosuximide (the
anticonvulsant sodium valproate does not have this effect).5
Pregnancy may occur more often in low-dose OC users on
anticonvulsants.4,8 Women receiving long-term phenobar-
bital therapy should begin with an OC containing 50 mcg of
EE; if they have breakthrough bleeding, the dose should be
increased even more.4
• A second medication may increase plasma SHBG levels,
thereby decreasing the amount of biologically active free ste-
roid.
• A second medication may decrease the amount of hormone
initially absorbed or reabsorbed following passage through
the liver. Antibiotics may decrease OC effectiveness by
decreasing enterohepatic recirculation, increasing fecal or
urinary excretion of steroids, or increasing liver degradation.
However, despite anecdotal case reports of pregnancy occur-
ing among users on antibiotics, no firm pharmacokinetic evi-
dence exists linking antibiotic use to altered steroid blood
levels.5
• Side effects of medication may cause nausea, diarrhea, or
drowsiness or may cause a woman to fail to take OCs. Miss-
ing low-dose OCs may be more deleterious than missing
higher dose pills.
• Spotting or breakthrough bleeding may cause a patient to
skip several pills or discontinue the method altogether, both
of which could lead to unplanned pregnancy. 
Using OCs may affect the pharmacokinetics of other drugs a
woman is taking. For example, OCs decrease clearance of benzodiaz-
epines such as diazepine, nitrazepine, chlordiazepoxide, and alpra-
zolam, and lower doses of these medications may be indicated for
women on pills.1,5 Use of OCs may increase the effects of anti-inflam-
matory corticosteroids by decreasing their clearance and increasing
their half-life. Lower doses of steroids may be indicated in OC users.5
COMBINED ORAL CONTRACEPTIVES 327
Clearance of bronchodilating drugs such as theophylline and amino-
phylline, as well as the closely related drug caffeine, may be reduced by
30% to 40% in pill users.5 Questions remain as to the effects of OCs
on analgesics, antihypertensive agents, and cyclosporin.5
MANAGING OF PROBLEMS AND FOLLOW-UP 
(PROBLEMS FOLLOW IN ALPHABETICAL ORDER)
Acne or oily skin
Combined pills tend to decrease acne. The estrogen in combined
OCs has a beneficial effect on acne, as does the lowering of the circu-
lating level of free testosterone caused by all available pills. Only rarely
does a woman's acne become worse using a combined pill. If this hap-
pens, try a pill with a different formulation.
Amenorrhea and very scanty bleeding
The cyclic buildup of the uterine lining is almost always less in
women using pills than in women experiencing natural cycles. The
amount of vaginal bleeding in the 7 pill-free days may be scant or absent.
Women should be told in advance to anticipate a decrease in bleeding.
Determine whether the patient is pregnant. Check for uterine
enlargement, softening of the cervix, and other signs of pregnancy.
The most important differential diagnosis to consider in a pill user
who has missed periods includes pregnancy (intrauterine or ectopic)
and inadequate buildup of the endometrium due to low-dose pills.
Breakthrough bleeding and spotting between periods
Spotting and breakthrough bleeding are more likely to occur
among women taking low-dose pills than among women using higher
dose pills. However, even women using very low-dose pills have more
regular cycles than women using no birth control pills. Inform clients
that spotting is quite common in the first few months of taking pills,
that it tends to improve over time, and that you may be able to change
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her pill to a different formulation should spotting or breakthrough
bleeding continue and be bothersome to her. Chlamydia infection can
cause spotting or breakthrough bleeding. Consider chlamydia infection
in the differential diagnoses if the woman has had a recent change in
sexual partners.
Breastfeeding problems
Combined pills appear to decrease both the volume and protein
content of breast milk in some breastfeeding women. Small amounts
of the hormones in pills are present in the breast milk. Some studies
have shown normal weight gain in infants whose mothers were using
OCs while breastfeeding. The hormones that pass through breast milk
do not appear to harm the breastfed infant, but breastfeeding women
should use an alternative to combined OCs.14,26 Progestin-only contra-
ceptives are a better choice than combined OCs. If a woman decides
to use combined OCs postpartum, she should not use them until after
she has established a good flow of breast milk. 
Breast fullness or tenderness (mastalgia)
Lowering the amount of estrogen provided in each pill tends to
reduce breast tenderness. The differential diagnosis of breast fullness
or tenderness includes actual growth of breast tissue; cyclic edema due
to either the estrogen or the progestin; early pregnancy; and tender-
ness from benign breast disease, a fibroadenoma, or breast cancer.
After ruling out the possibility of pregnancy and breast cancer, switch
the patient to the lowest estrogen pill available or to a progestin-only
pill. Symptoms may improve if the woman avoids vigorous physical
exercise (which shakes breast tissue) during times of most discomfort.
Chloasma
Pills may cause chloasma (mask of pregnancy), particularly if a
woman is exposed to a lot of sunlight. Darkening of skin pigment usu-
ally occurs on the upper lip, under the eyes, and on the forehead. The
increased pigmentation may be slow to fade when pills are discontin-
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ued. Other skin conditions that may occur in pill users include telang-
iectasia, neurodermatitis, erythema multiforme, erythema nodosum,
eczema, photosensitivity, and loss of hair. 
Depression and other mood changes
If severe depression begins after a woman starts taking pills,
strongly consider advising her to discontinue the pills to see whether
the depression goes away.  She should use a different method of con-
traception that both she and her partner find acceptable. If depression
is related in part to fear of becoming infected with HIV, encourage
condom use. Lowering of the estrogen or the progestin content (or
both) may benefit depression associated with pill use. Because OCs
can deplete the body of some vitamins, use of supplemental vitamins
(especially containing Vitamin B) may help improve depression.
Eye problems such as blurred vision or loss of vision
Vision changes may accompany headaches and a transient
decrease in blood flow (ischemia). If a patient has experienced tran-
sient, total, or partial loss of vision, strongly consider discontinuing
pills immediately to see whether the symptoms go away. If visual
symptoms accompany migraine headaches that have become worse,
discontinue pills immediately.
Headaches
Headaches may be mild, severe, recurrent, or persistent. Women
may note an increase or decrease in the severity of migraine headaches.
Pill-induced headaches are sometimes associated with blurred vision,
loss of vision, nausea, vomiting, or weakness in an extremity. Because
severe headaches may be an early warning of a stroke, they need to be
taken seriously. Pay particular attention if symptoms are increasing.
Definitely consider discontinuing pills if headaches have become
worse. If the woman's headaches are clearly related to beginning oral
contraceptive use, discontinue or change to a pill with lower estrogen
or lower progestogen. Re-evaluate the woman's headaches after 1 or 2
cycles.
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Decreased sex drive or libido
Although some women note a decrease in sex drive, many others
find they enjoy intercourse more because they no longer fear preg-
nancy. If a woman does note an unwanted change in her interest in sex
when she starts on a combined pill, consider giving a different pill.
Nausea
Although less of a problem for women on lower dose pills, nau-
sea is most likely to occur during the first cycle or so of pills or during
the first few pills of each new package. Vomiting is rare. Many women
can control nausea by taking their pills with a meal (the dinner or
evening meal may be best). Taking pills at bedtime has helped some
women. When nausea occurs for the first time after months or years of
taking pills, look for signs of early pregnancy. Nausea may also be
caused by flu or another acute infection rather than the pill. Consider
changing to a combined pill with less estrogen or to a progestin-only
pill containing no estrogen. Inform the patient that if she vomits
within 1 hour of taking a pill, she should take an extra pill from a sep-
arate pack to replace the pill she took just before vomiting.
Pregnancy
Although pills are very effective, they can fail. Inform the patient
that there is no apparent increased risk of birth defects if pills have
been taken during pregnancy. Discontinue pills if a diagnosis of preg-
nancy is made. Refer the patient for prenatal care if she wishes to con-
tinue pregnancy or for a legal abortion if she wishes to terminate the
pregnancy.
Weight change
Pill use may be associated with an increase or decrease in weight.
Weight change is usually minimal and not related to pill use. History
should include questions about change in appetite since starting pills,
cyclicity of weight gain, and symptoms of early pregnancy. There is no
evidence that overweight women require a higher dose pill for the
OCs to be effective. Obese women should start on a low-dose com-
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bined pill. The protective effect of pills against endometrial cancer
may be particularly desirable in overweight women, whose risk of
endometrial cancer is increased.
INSTRUCTIONS FOR USING COMBINED PILLS
Birth control pills do not protect you from HIV or other sexually
transmitted infections. If there is any risk of sexually transmitted
infection, use a condom (male or female) every time you have sexual
intercourse.
The pill is a very effective method of birth control. It works pri-
marily by stopping ovulation (release of an egg). In addition to pre-
venting pregnancy, pills decrease the risk of ovarian cancer, cancer of
the lining of the uterus, benign breast masses, and ovarian cysts. Pills
decrease menstrual blood loss, menstrual cramps, and the chance of
having an ectopic pregnancy—a pregnancy outside the uterus. 
1. Swallow a pill at the same time every day—pills work best if you
keep a steady level of hormones in your system.
2. Choose a back-up method of contraception (such as condoms
or foam) to use with your first pack of pills because the pills may
not fully protect you from pregnancy during this first cycle. A
back-up method is probably not necessary if you start taking pills
on the first day of bleeding (see instruction #3 below). Whether or
not you use a back-up contraceptive your first month on pills,
keep a back-up method handy all the time and learn to use it cor-
rectly in case you do any of the following:
No matter what other methods of contraception 
a woman is using, if she is at any risk because her partner 
tests HIV positive or because she does not know his HIV status, 
she should be advised to use plastic or latex condoms with 
every sexual act.  No other contraceptive method besides 
abstinence provides the same degree of protection.
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• Run out of pills
• Forget to swallow your pill
• Experience a pill warning signal and discontinue pill use
• Want protection from sexually transmitted infections, most
notably the virus which causes AIDS (Condoms provide the
best protection.)
• Have repeated episodes of breakthrough bleeding
3. You may start taking your pills according to one of several differ-
ent schedules:
• First day of menstrual bleeding
• First Sunday after your period begins
• Today if you are certain you are not pregnant
4. Take one pill a day until you finish the pack. Then follow these
directions:
• If you are using a 28-day pack, begin a new pack immediately.
Do not skip days between packages.
• If you are using a 21-day pack, stop taking pills for 1 week and
then start your new pack.
5. Take your pill at the same time you do something else at about the
same time every day, like going to bed, eating a meal, or brushing
your teeth. A regular routine may make it easier to remember your
pills. 
6. Check your pack of birth control pills each morning to make sure
you took your pill the day before.
7. If you have bleeding between periods, try to take your pills at the
same time every day. If you have spotting (light bleeding between
periods) for several cycles, you may want to call your clinician to
see whether you need a different pill. Spotting is more likely to
occur with the current low-dose birth control pills. Because spot-
ting is generally not a sign of a serious problem in young women,
your clinician may take a "watch-and-wait" approach if you are
not concerned or inconvenienced. If you suddenly begin to have
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bleeding between periods and you have not previously had this
problem or have not missed pills or taken pills late, consider hav-
ing your clinician check you for an infection. Spotting between
periods may also signal decreased pill effectiveness. Some clini-
cians recommend a back-up contraceptive for women who have
spotting when they use pills, especially if the woman is taking a
medication that may lower pill effectiveness.
8. Some drugs decrease the effectiveness of birth control pills. Be
sure to tell your clinician whether you are using any of these
drugs: rifampin, Dilantin (phenytoin), carbamazepine, ampicillin,
or tetracycline. Taking vitamin C may actually raise the level of
estrogen in your blood and may lead to increased spotting.14
9. If you forget to take your birth control pill or if you start your
pack late, use your back-up method of birth control for 7
days, and follow the instructions below:
• If you miss 1 pill, take that pill as soon as you remember  it.
Take your next pill at the regular time.
• If you miss 2 pills in a row, take 2 pills as soon as you remem-
ber and take 2 pills the next day. Then return to your regular
schedule.
• If you miss 3 pills in a row, you will probably begin your
period. Whether or not you are menstruating, throw away the
rest of your pack of pills and begin a new pill pack as you did
when you first started using pills. 
For example, if you are a "Sunday starter," begin your next
pack on Sunday. If you started on any other day, simply start
your next pack immediately. 
• If the only pills you miss are from the fourth week of a 28 day
pill pack, simply throw away the missed pills. Then continue
If you miss 3 pills in a row, ask yourself if pills 
are a good method of birth control for you. 
You might be better off choosing a different  method.
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taking pills from your current package of pills on schedule.
The pills in this fourth week do not contain hormones, so
missing these pills does not increase your risk for pregnancy at
all. You do not need to use your back-up method of birth con-
trol.
10. If you have diarrhea or vomiting, use your back-up method of
birth control until your next period. Start using a back-up method
on your first day of diarrhea or vomiting. Many women experi-
ence nausea the first month they take pills. This tends to go away
in the next cycle or so. If nausea continues, switching to the lowest
dose pill may help. Ask your clinician.
11. Women taking pills note that periods tend to be short and scanty,
and you may see no fresh blood at all. A drop of blood or a
brown smudge on your tampon or on your underwear is con-
sidered a period when you are on the pill.
12. If you do not have your menstrual period when expected while
taking birth control pills, you may want to consult your clinician.
• If you have not missed any pills and you miss 1 period without
any other signs of pregnancy, it is unlikely you are pregnant.
Many women who take birth control pills occasionally miss 1
period. Call the clinic if you are worried. You are fairly safe and
can start a new package of pills at the regularly scheduled time.
• If you forget 1 or more pills and miss a period, stop taking pills
and use another method of birth control. Contact your clinic
for a pelvic examination or a sensitive pregnancy test. 
• If you miss 2 periods in a row, come to the clinic for a preg-
nancy test immediately, even if you took your pills every day.
Bring a sample of your first-morning urine in a clean con-
tainer.
13. If you do become pregnant while taking birth control pills, you
must decide whether you want to have a child at this time. The
risk of having a baby with birth defects does not seem to be
increased in pill users who become pregnant. 
14. If you decide you want to become pregnant, stop taking pills.
You may wish to use another method of birth control until you
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have two or three normal menstrual periods off the pill so that
when you become pregnant, your date of delivery will be accurate. 
15. If you see a clinician for any reason or are hospitalized, be sure to
mention that you are taking birth control pills. 
16. If you have problems with any mood changes—depression, irri-
tability, change in sex drive—see your clinician. Switching pill
brands may help if your mood changes are related to the pill. Your
clinician can help tell you what to do.
17. Learn the pill warning signals. Any one of these five symptoms
may mean that you are in serious trouble. Note that the first letter
of each symptom spells out the word "ACHES."
Do not ignore these problems or wait to see whether they disap-
pear. Contact your clinician immediately to tell him or her about your
problem. Birth control pills are safer when you get help as soon as
problems arise.
If you smoke, stop smoking. If you can't, it is all the more
important that you watch for the pill warning signals. If you
smoke you should probably stop taking pills at age 35. 
Early Pill Warning Signs
Caution
A n Abdominal pain (severe)
C n Chest pain (severe), cough, or shortness of breath
H n Headache (severe), dizziness, weakness, or numbness
E n Eye problems (vision loss or blurring) or speech problems
S n Severe leg pain (calf or thigh)
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THREE OF THE MOST COMMONLY ASKED QUESTIONS 
ABOUT PILLS
Do oral contraceptive pills cause cancer?
Studies have not shown that the pill causes cancer; in fact, the pill
protects against cancer of the ovaries and lining of the uterus.
Although the final word is still not in, we have learned more and more
as we have gained experience with pills.7 By age 55, a woman is less
likely to be diagnosed with cancer if she used OCs.
Good News
Pills make women less likely to develop three types of cancer:
• Ovarian cancer
• Endometrial cancer
• Choriocarcinoma (also called trophoblastic disease or molar
pregnancies)
Pills also make women less likely to develop several benign tumors or
masses:




There is one rare tumor of the liver that is more likely to develop in
women using pills. However, this tumor is not a cancer.
Neither Harmful Nor Beneficial Effect
Pills probably have no effect on a woman's likelihood of develop-
ing a malignant melanoma; kidney, colon, or gall bladder cancer; or
pituitary tumors.15,20
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Still Not Sure
• Breast cancer. By age 55, women who did not use pills are just as
likely to be diagnosed with breast cancer as women who used
pills.15,33 However, there is probably a definable group of young
women who have used pills who are at increased risk for having
breast cancer diagnosed before the age of 35.
• Cervical cancer. Some studies have shown an increased risk for
cervical cancer among pill users, while others have not. Women
taking pills should have a Pap smear regularly.
• Cancer of the liver. Some studies have shown an increased risk
for liver cancer,10,17 while others have not.12,28,36
Does the pill cause deformed babies and multiple births?
No. The number of babies born deformed or the number of mul-
tiple births is no different among women who have used pills and
those who have not.3
When a woman stops using the pill, will she have difficulty getting preg-
nant again?
After a woman stops taking the pill, her ovaries begin to work
just as they did before she took the pill. On average, it takes 2 to 3
months after stopping the pill to become fertile. The small number of
women who have trouble getting pregnant after taking the pill would
have had trouble even if they had never taken the pill.3
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and Progestin-Only Pills 
(Minipills)
 
"Ninety-five percent of our patients are using Depo-Provera" 
was the claim of a large Family Planning Association of Kenya 
(FPAK) clinic in northern Kenya in 1980. It took only a 
minute to discover why almost all the women obtaining contra-
ceptives at this clinic were choosing birth control shots. Part of 
the answer was that there was no Depo-Provera at the sur-
rounding Ministry of Health Clinics. The other reason for the 
tremendous popularity of Depo-Provera was the privacy it 
offered. Women could come to the FPAK clinic, obtain their shot 
every 3 months, and maintain their anonymity. No pills to take 
on a daily basis. No permit for a husband to sign before tubal 
ligation. No condoms or spermicides to wrestle with at the time 
of intercourse.
 
Any program offering Norplant, Depo-Provera, progestin-only pills,
or a progestin-releasing intrauterine device (IUD) will be successful
only if providers counsel women in advance about the menstrual
changes that will occur when they use a progestin-only approach to
contraception. Menstrual changes are the most common reason that






























When a woman decides to have Norplant implants inserted, this
single decision may provide her with 5 years of effective birth control.
At the time of insertion, it is important to assure the client that she











Depo-Provera, a form of depo-medroxyprogesterone acetate
(DMPA) is the most commonly used injectable progestin. It is
extremely effective in part because its protection continues even if a
woman returns several days to 2 weeks late for an injection. DMPA
has been used by more than 15 million women worldwide. It is










Injectable contraceptives have played an important role in Africa
because of their availability and their long-term effectiveness and
women’s ability to use them discreetly. Norplant and progestin-only
pills are not as widely used, largely because they are relatively unavail-
able. Education and counseling are the two greatest assets in overcom-
ing barriers to the use of progestin-only contraception.
1. Bleeding irregularities are common among women who use
progestin-only contraceptives. Women who are not aware of this
side effect often discontinue use of the methods. Education and
counseling allow women to realize that irregular bleeding is not
















2. Norplant implants are expensive initially. However, when distrib-
uted over the 5 years the implants remain in place, the cost per
year is reasonable.
3. Norplant implants are sometimes implanted too deeply, making
removal difficult and potentially hazardous. Proper training in
both insertion and removal reduces this problem. Training in





4. An advantage of Depo-Provera injections is that they allow a
woman to use a contraceptive without telling anyone else. Clini-
cians should be sympathetic to women placed in the position of
needing to keep private their contraceptive use.
5. Because minipills have low doses of progestin, it is important




Progestin-only contraceptives may be administered by mouth, injec-





 (Some IUDs also deliver progestin.) Progestin-only
contraceptives may prevent pregnancy via several mechanisms:
• Inhibiting ovulation
• Thickening and decreasing the amount of cervical mucus
(making it more difficult for sperm to penetrate) 
• Creating a thin, atrophic endometrium







With this long-acting contraceptive, steroid levonorgestrel slowly
diffuses through six slender, flexible capsules.  Each of these match-
sized capsules is 34 mm long and has a diameter of 2.4 mm.   (See


























released at a low, steady rate of about 85 mcg per day, decreasing to 50
mcg at 9 months, 35 mcg at 18 months, and 30 mcg thereafter. When
the capsules are removed, the contraceptive effect wears off quickly. 
 
Table 14:1 Delivery systems for progestin-only contraceptives 





























First pass through 
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By woman herself  
at any time












































A deep intramuscular injection of 150 mg of DMPA is given
every 3 months. DMPA injections inhibit ovulation by suppressing
follicle stimulating hormone (FSH) and luteinizing hormone (LH)







Each 150 mg injection actually provides more than 3
months of protection. A long-term user of DMPA has a 2-week "grace
period" (longer in many instances) during which she can be late for






In some women, minipills suppress ovulation. When this hap-
pens, the woman tends to be amenorrheic or have prolonged amenor-
rhea. If ovulation is not suppressed, these progestin-only pills have no
effect on the cyclicity of bleeding, and menstrual bleeding occurs as it
had before the woman started progestin-only pills. If ovulation does
occur, the pills may still have a contraceptive effect because they cause






































If women already pregnant when the
device was implanted are removed from this calculation, the preg-
nancy rate falls to 0.09%. To avoid using this contraceptive in women
who are already pregnant, clinicians should insert implants within 7
days of the onset of menstruation or, for women who have just deliv-
ered, either immediately postpartum or within 3 weeks after delivery.
Pregnancy rates for the second through fifth years are, respec-
tively, 0.5%, 1.2%, 1.6%, and 0.4%. After 5 years, the total (cumula-
tive) pregnancy rate is therefore only 3.7%. 
Because pregnancies increase in the sixth year, women should
have the capsules removed at the end of the fifth year. (Norplant is
approved as a 5-year method.) If a woman wishes to continue using
Norplant, she can have another set of implants inserted at the same
time the first set is removed.
Women who weigh more than 70 kg may have higher pregnancy
rates. However, most pregnancies in overweight Norplant users have
been in women who were provided the hard capsule Norplant
implants. Leiras Oy, the manufacturer, now produces implants only




Continuation rates for Norplant users are high; reported first-



















Depo-Provera is an extremely effective contraceptive with a first-
year probability of pregnancy of only 0.3%. This pregnancy rate
applies to women receiving injections providing 150 mg of DMPA in
















Questions have been raised about the desirability of giving injec-
tions of 150 mg of DMPA every 3 months when DMPA can be given
in much less expensive solutions that provide 400 mg of DMPA per 1
cc of this medication. (With this alternative, only 0.375 cc of solution
is required to deliver 150 mg of DMPA.) However, it is very difficult
to provide exactly 150 mg of DMPA in such a small amount of solu-
tion (0.37 cc), and this way of delivering DMPA is not approved as a
contraceptive. Another approach would be to give 400 mg every 6
months in 1 ml of the 400 mg/ml formulation, but an unpublished
Upjohn-sponsored trial of this alternative found that pregnancies







The concentrated form of DMPA is also more painful. Pain has
been overcome by diluting the very concentrated form of DMPA with
an equal volume of 1% xylocaine.  
In the largest study of U.S. women, continuation rates for









Progestin-only pills are generally less effective than combined
oral contraceptives (OCs). The proportion of women becoming preg-
nant in the first year of typical use ranges from 1.1% to 13.2%. If
minipills were used correctly and consistently; however, only 5 in
1,000 (0.5%) women would become pregnant in the first year. 
The effectiveness of progestin-only pills is highest when ovula-
tion is consistently inhibited. When this happens, a woman tends to
be amenorrheic or to have prolonged periods of time between men-
strual bleeding episodes. 
 
The effectiveness of progestin-only pills is greatest
when the "normal" bleeding pattern is most disturbed
 
. It is particularly
important that progestin-only pills not be taken even a few hours late,
because they will then lose effectiveness. Figure 14:2 illustrates how
the sperm penetration of cervical mucus increases if the time interval
between progestin-only pills is more than 24 hours. In breastfeeding




























Figure 14:2 Sperm penetration test following progestin-only pill
 












Because progestin-only contraceptives contain no
estrogen, they do not cause the serious complications associated
with estrogen, which include thrombophlebitis and pulmonary
embolism. Studies thus far have not shown any serious








 Norplant, Depo-Provera, and
progestin-only pills offer several noncontraceptive benefits:
• Scanty menses or no menses
• Decreased anemia































Note: Minimum reduction in sperm penetration between 4 hours and 22 hours after a single dose of megestrol acetate
















• Suppression of pain associated with ovulation 
(mittelschmerz)
• Decreased risk of developing endometrial cancer, ovarian
cancer, and pelvic inflammatory disease (PID)





Norplant and minipills are immediately reversible.
A woman must use alternative forms of contraception as soon as
Norplant implants are removed or minipills are stopped. Depo-
Provera is reversible, but return of fertility is not as rapid as with




 There is a delay in return of







No surgical procedure is necessary to discon-






long-acting injections are extremely effective long-term contra-
ceptives. In the case of Norplant (and the levonorgestrel IUD), a
single decision leads to long-term contraception. The effective-
ness of implants and injections does not depend on the woman’s
taking day-to-day responsibility for her contraception. DMPA
provides excellent short-term contraception for women who
require protection following rubella immunization, are awaiting
sterilization, or are partners of men undergoing vasectomy.
Women appearing late for their injection of DMPA have a grace
period during which they will not become pregnant. The pack-
age insert defines this period as 2 weeks; others suggest that the
grace period is 4 weeks.
5.
 
Low risk of ectopic pregnancy.
 
Norplant and DMPA reduce a
woman's risk of having an ectopic pregnancy compared to
women using no contraceptive at all. Women using Norplant









the 6.5 per 1,000 women-years for women using no contracep-
tive. Ectopic pregnancy may be more common in heavier women







is very unlikely to occur in women receiving DMPA injections.
Progestin-only pills are less protective against ectopic pregnancies






























Progestin-only contraceptives cause amenorrhea
in some women, but some users may consider the absence of
bleeding an advantage. During the first year of DMPA use, 30%
to 50% of women are amenorrheic; by the end of the second


















Norplant has higher continuation rates
than do other hormonal contraceptives. The percentage of
women continuing to use Norplant at 1 year is 85%. The contin-






Norplant (and to a lesser extent, long-act-
ing injections) is an excellent contraceptive option for women
who have difficulty remembering to take pills or in using methods
requiring interruption of intercourse. For example, Norplant may
be a good option for a woman who abuses drugs or will have dif-














In some cultures, women consider receiv-
ing medications by injection to be desirable. For some women, it
is a desirable option to be able to use a contraceptive without the
knowledge of her partner, husband, or family.
10.
 
No drug interaction. Thus far, there has been no demonstrated
interaction between Depo-Provera and antibiotics or enzyme-
inducing drugs.34 DMPA effectiveness does not depend on a nor-
mally functioning gut. 
11. Fewer seizures. DMPA has been found to decrease the fre-
quency of seizures among women of childbearing age.15
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MINIPILLS
12. Ease of use. Because using the minipill means taking the same
type of pill every single day (same color and hormone content),
some women may find it easier to use this kind of pill than other
OCs.
13. Emergency contraception. An emergency dosing of minipills—
0.75 mg progestin taken within 48 hours of unprotected inter-
course and another dose of 0.75 mg taken 12 hours later—can
reduce the risk of unintentional pregnancy. A pill called Postinor,
available in Europe and Asia, delivers each 0.75 dose in one pill.
All other minipills, which contain far less progestin, require that
20 pills be taken to equal the 0.75 mg dose. One dose of 20
minipills is taken within 48 hours after intercourse and a second
dose of 20 pills is taken 12 hours after the first dose. (See Chapter




Norplant, Depo-Provera, and minipills do not harm lactation,
and some studies suggest that milk volume may increase.12,16 Although
progestins can pass through breast milk, the dose ingested by the
infant is small. Opinions vary about whether Norplant and Depo-
Provera should be provided immediately postpartum. A cautious
approach is to wait until breastfeeding has been well established. (See
Chapter 12 on Lactation and Postpartum Contraception.)
Norplant. If a breastfeeding woman is unlikely to return for a
postpartum visit and requests Norplant before leaving the hospital
after delivery, the real long-term contraceptive benefit of using this
method seems likely to exceed its theoretical risks, especially if the
woman plans to supplement the infant's diet relatively soon after
birth.
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Depo-Provera. Studies of Depo-Provera started 2 to 4 days post-
partum or at 7 days postpartum,16 and within 6 weeks postpartum12
have all found no negative effects. Because the contraceptive benefit to
the lactating woman in obtaining Depo-Provera immediately postpar-
tum is smaller and the theoretical risks might be higher (hormonal lev-
els are relatively high in the immediate post-injection days) than those
for Norplant, it would be less advisable to inject Depo-Provera than to
insert a Norplant before breastfeeding is well established. 
Minipills. Studies of minipills have demonstrated no adverse
effects on lactation or infant growth, even when they are started in the
first week postpartum.17,21
Older Women
Safety and low pregnancy rates make Norplant, Depo-Provera
(and other long-acting injections), and progestin-only pills good
options for older women. A woman may have Norplant inserted when
she is fairly certain she wants no more children. Then, after 3 to 4
years, when she is absolutely certain she wants no more children, she
may choose to have a tubal ligation or her husband may decide to have
a vasectomy,  followed by Norplant removal. For a woman who will be
deciding about sterilization in the next 3 to 12 months, DMPA may
be a better option than Norplant. Progestin-only pills are also an
excellent option for women who are in their late reproductive years;
they are more effective for older women.3 The absence of complica-
tions from thrombosis makes Depo-Provera, Norplant, and progestin-
only pills advantageous for older women and for women planning to
have an operation that might increase their risk for thrombophlebitis. 
Young Women
For younger women, Norplant is desirable because of its
extremely low pregnancy rate and its ready reversibility. The thick cer-
vical mucus produced by implants also protects against PID. Depo-
Provera is less readily reversible, but it has a very low pregnancy rate
and probably protects against PID.
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Women Who Cannot Take Estrogen
Progestin-only pills, as well as the other progestin-only methods,
are particularly desirable for women who want to use an OC but have
reasons to avoid combined pills. Women who have developed severe
headaches or hypertension may be candidates for progestin-only pills.
DISADVANTAGES AND PRECAUTIONS 
The progestin-only methods have few serious disadvantages. The pre-
cautions for prescribing are listed in Table 14:2.
1. Menstrual cycle disturbance. One of the most common reasons
women stop using progestin-only contraceptives is that these
methods change the menstrual cycle.  Many women experience
an increased number of days of light bleeding. Some women
experience amenorrhea, which is most likely to occur in the first
year of Norplant use. While missed menstrual periods become less
common over time among women using Norplant, amenorrhea
becomes more common over time in Depo-Provera users. Occasion-
ally, women using Norplant or DMPA experience an increased
number of days of heavy bleeding. Bleeding changes are usually
not associated with increased blood loss in users of progestin-only
contraceptives. Counsel women to expect changes in their cycles.
2. Weight gain. Some women using progestin-only methods gain
weight or complain of feeling bloated. The weight gain is proba-
bly due to increased appetite stimulated by progestin rather than
fluid retention.34 Over 5 years, weight gain in Norplant users
averages just under 5 pounds. Weight gain is less of a problem in
women on progestin-only pills than in women on combined
OCs.
3. Breast tenderness. Breast tenderness, which is occasionally very
painful, has been noted in some women using Norplant and
Depo-Provera. Always rule out pregnancy as the cause. 
4. Interaction with anticonvulsants. Anticonvulsants (except valp-
roic acid) increase Norplant pregnancy rates and, probably, preg-
nancy rates for progestin-only pills.
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5. Bone density decrease. Decreased bone density has been
reported in a retrospective study of 30 Depo-Provera users.4 One
confounding effect in the study was that the DMPA users (40%)
were more likely to smoke than were the premenopausal control
women (10%). Although this one study does not mean that
women should avoid long-term use of DMPA, the results suggest
that osteoporosis and other effects of low estrogen need to be
carefully considered.
6. Lack of protection against sexually transmitted infections
(STIs), including HIV. No matter what other methods of con-
traception a woman is using, if she is at any risk because her part-
ner is HIV positive or because she does not know her partner’s
HIV status, she should be advised to use condoms with every
sexual act. No other contraceptive method besides abstinence
provides the same degree of protection.
Norplant
7. Difficulty in removing Norplant. Both insertion and removal
require a minor surgical procedure. Removal is particularly likely
to be difficult if the implant was inserted too deeply. Norplant
removal requires a clinic visit and, occasionally, more than one
visit.
8. Expense. The initial cost of Norplant can be high, and if the
implants are removed soon after insertion, this method is
extremely expensive per month of contraception provided.
Encourage long-term use by doing the following: 
• Explaining, in advance, the menstrual cycle changes that are
likely to occur
• Avoiding Norplant insertion for the woman who may
change her mind quickly and want to become pregnant in
the near future
• Avoiding insertions for women who are already pregnant
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Table 14:2 Precautions in the provision of progestin-only 







Pregnancy 4 4 4 As no method is indicated, any health 
risk is considered unacceptable. 
However, the evidence on the possible 
harm to mother and fetus is incomplete.
Breastfeeding
<6 wks postpartum














Concern that immature neonate may be 
at risk for exposure to steroid hormones.
No concern regarding use of POCs in 











For women under 16 years of age, 
concerns regarding hypoestrogenic effect 
due to POC use.













Concern regarding reduced high density 
lipoproteins in women using DMPA 
and Norplant with underlying vascular 
disease or moderate and severe hyper-
tension.
Vascular disease 2 3 2
History of preeclampsia 1 1 1 Absence of underlying vascular disease 
suggests no need for restriction of POC 
use.
Diabetes












POC may influence carbohydrate 
metabolism, but does not present an 
additional risk of thrombosis.
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Nephropathy/retinopathy
Other vascular disease or 








Concern about possible negative effect of 
DMPA on lipid metabolism, possibly 
affecting the progression of nephropathy, 
retinopathy, or other vascular disease.
Venous thromboembolism












No concern regarding risk of thrombosis 
in POC users.
Minor surgery without 
immobilization
1 1 1




Current and history of 
ischemic heart disease
2 3 3 Concern regarding hypoestrogenic effect 











Concern regarding reduced HDL among 
POC users.
Familial hyperlipidemia 1 2 1 Although these conditions are a risk 
factor for vascular disease, routine 
screening is not needed and is 
inappropriate because of rarity of the 
condition and cost of screening.
Table 14:2 Precautions in the provision of progestin-only 








1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable




hypertension, risk of 
arterial fibrillation, 








No concern regarding risk of thrombosis 
in POC users.
On anticoagulant drugs 2 2 2 POC use may be associated with 
prolonged bleeding in the first three 
months. It is unknown if anticoagulants 
aggravate the bleeding.
Headaches




migraine, without focal 
neurologic symptoms
recurrent, including 








Theoretical concern that severe 
headaches may increase in frequency;  
DMPA and Norplant cannot be 
discontinued immediately or effects 





Without heavy bleeding 2 2 2 Changes in menstrual bleeding patterns 
are common among healthy women.
With heavy bleeding 2 2 2 POC use may induce irregular bleeding 
pattern.
Unexplained vaginal 
bleeding (cyclic pattern 
disrupted)
3 4 4 Evaluation of these conditions is 
necessary before initiating POC.
Table 14:2 Precautions in the provision of progestin-only 
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1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Breast disease
Undiagnosed mass 2 2 2
Benign breast disease







No concern related to POC use for 
women with benign breast disease or 
family history of breast disease.
Cancer:
current








Breast cancer is a hormonally sensitive 
tumor. Concerns may be less with POC 
than with combined pills.
Cervical intraepithelial 
neoplasia (CIN)
2 2 2 Little concern that POC enhances 
progression of CIN to invasive disease.
Cervical cancer
(awaiting treatment)
2 2 2 Theoretical concern that use may affect 
prognosis of the existing disease.
Cervical ectropion/erosion 1 1 1 Not a risk factor, no need for restriction 
of POC use.
Endometrial, ovarian cancer 1 1 1 In general, treatment of these conditions 
renders a woman sterile. While awaiting 
treatment, women may use POC.
Pelvic inflammatory disease 
(PID)
Past (assuming no 
current risk factors of 
STIs)
with subsequent 









pregnancy is not 
desired
1 1 1 Not a concern, no need for restriction of 
POC use.
Table 14:2 Precautions in the provision of progestin-only 








1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Pelvic inflammatory disease 
(PID) — continued














Increased risk of STIs 
(e.g. multiple partners or 
partner who has multiple 
partners)
1 1 1
STIs:  current or within 
3 months











No confirmation of an association of 
POC use with these conditions, although 
a modest risk may be present.















Not a concern, no need for restriction on 
POC use.
Asymptomatic 1 1 1
Sickle cell disease 1 1 1
Epilepsy 1 1 1 The condition, per se, is not a concern. 
No need for restriction of POC use.
Certain antiepileptic drugs lower POC 
efficacy. If a women is taking treatment, 
refer to section of drug interactions.
Table 14:2 Precautions in the provision of progestin-only 
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Schistosomiasis 1 1 1 Not a concern, no need for restriction of 
POC use.
Malaria 1 1 1 Not a concern, no need for restriction of 
POC use.
Drug interactions
Commonly used drugs 




Commonly used liver enzymes inducers 






3 2 3 Use of other contraceptives should be 
encouraged for women who are on long- 
term use of any of these drugs.
Other antibiotics* 1 1 1
Parity
Nulliparous 1 1 1 Not a concern. No need for restriction of 
POC use.
 Parous 1 1 1
Rapid return to fertility 
desired
1 3 1 Some delay in return to fertility may 
occur with DMPA use (10 months 
median delay in conception after last 
DMPA injection). No risk for permanent 
infertility.
Severe dysmenorrhoea 1 1 1 Not a concern. No need for restriction of 
POC use.
*Excluding rifampicin + griseofulvin
1 = used in any circumstances
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Table 14:2 Precautions in the provision of progestin-only 









9. Extremely low-dose contraceptive. Because of its low dose,
Norplant's effectiveness is lowered more significantly by anti-sei-
zure medicines (except for valproic acid) and by rifampin than
are other hormonal contraceptives. Norplant pregnancy rates
increase to unacceptable levels if a woman takes any of the fol-
lowing drugs:8,22
carbamazepine primidone
phenytoin (Dilantin) phenylbutazone 
phenobarbital rifampin
All anti-seizure medications are strong inducers of the hepatic
enzymes, which cause breakdown of levonorgestrel. If a Norplant
user begins one of these medications, she should use a back-up
contraceptive.
10. Local inflammation or infection at the site of implants.
First-year users occasionally have infection, skin irritation, or
expulsion of a capsule, but complications do not always occur
immediately after insertion. One-third of infections and two-
thirds of expulsions occur after the first 2 months of use.11
11. Ovarian cysts. Most ovarian cysts regress spontaneously. Cysts
do not need to be evaluated sonographically or laparoscopically
unless they become large, painful, or fail to regress.36
Depo-Provera
12. No immediate discontinuation. Weight gain, depression, breast
tenderness, and menstrual irregularities may continue until the
DMPA is cleared from a woman's body—about 6 to 8 months
after her last injection. A woman becomes fertile again in an
average of 6 months to 1 year after ceasing to use Depo-Prov-
era.34
13. Return visits every 3 months. Some women find the require-
ment of repeated injections unacceptable. However, most women
continue to use DMPA after 1 year.
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14. Lipid changes. High-density lipoprotein cholesterol levels fall
significantly in women using DMPA.20 Adverse changes in lipids
do not occur in women using Norplant.
Minipills
15. Vulnerable efficacy. Progestin-only pills require absolute regular-
ity in pill-taking and attention to timing.
16. Less available. These pills are less likely than OCs to be stocked
by pharmacies, family planning clinics, and hospital formularies. 
17. Less clinician experience. Clinicians are less likely to have had
experience prescribing progestin-only pills and may be less com-
fortable in counseling patients about them. 
18. Ovarian cysts. Minipill users experience an increased risk of
functional ovarian cysts. See the discussion of ovarian cysts under
the section on Norplant.
19. Ectopic pregnancy. Ectopic pregnancy is more likely among
women who become pregnant as a result of minipill failure than
among women who use other OCs. 
PROVIDING NORPLANT
Although Norplant implants produce few side effects or compli-
cations, some women are not ideal candidates. Table 14:3 describes
the precautions for providing Norplant implants. These precautions
replace the outmoded concept of contraindications.
Although hormonal methods are not considered the method of
choice for breastfeeding women. Norplant implants may still be
appropriate for this group. (See the section on Indications in this
chapter and the discussion in Chapter 12 on Lactation and Postpar-
tum Contraception.)
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NORPLANT INSERTION: 20 HELPFUL HINTS
Norplant insertion is a minor surgical procedure performed
under local anesthesia. Using a simple trocar, the clinician places the
implants under the skin on the inside of a woman's upper arm in a
fan-shaped configuration. Norplant implants should be replaced after
5 years. A two-capsule Norplant system is being developed to simplify
both insertion and removal. 
1. Use an arm model to practice insertion. If this is the first, second,
or third time you have inserted Norplant implants, take 3 to 5
minutes to insert a set of implants into the arm model. Practicing
on the model will remind you what to do and what not to do.
2. Reassure your new client that insertion is not painful. Fear of
pain at the time of insertion is the number one concern of
women considering Norplant. 
3. Raise the head of the examination table to make your patient
more comfortable.
4. Use the width of 4 fingers if you are a man, or 5 fingers if you are
a woman, to measure up from the crease of the elbow to the place
where you will make your incision. Mark this site using a tem-
plate and pen.
Table 14:3 Percentage of women reporting regular bleeding 
patterns or amenorrhea while using Depo-Provera injections  
Norplant implants
Depo-Provera Norplant
1 year 5 years 1 year 5 years
Regular cycles* 30 17 27 67
Amenorrhea 25 80 5 9
*Regular cycle is 25 to 34 days for Depo-Provera users and 21 to 35 days for Norplant users.
Source: Shoup, et al. (1993)
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5. Use the template and pen every time you insert a set of Norplant
implants. Make no exceptions. These marks will help you put
your local anesthetic at the precise site your trocar will be placed.
This precision will also make removals easier, because you will
know where to look for the implants.
6. Add sodium bicarbonate to the local anesthetic to decrease sting-
ing as the local anesthetic is injected into the insertion sites. Use
0.5 cc of sodium bicarbonate (NaHCO3) for every 5 cc of 1%
xylocaine (a 1:10 ratio). Xylocaine comes in a 30 cc bottle. With
3 cc of NaHCO3 added, you will have enough local anesthetic
for a number of Norplant insertions in a single session. Throw
away any remaining anesthetic at the end of each insertion ses-
sion, because the NaHCO3 destabilizes the xylocaine over time.
Mix up only as much of the 1:10 solution you will need in a day.
7. Inject the local anesthetic slowly so that the patient feels less dis-
comfort. A slow injection is particularly helpful if you are inject-
ing xylocaine with no sodium bicarbonate. By the time the
injection has been made for the sixth implant, the local anesthe-
sia will be almost ready for the incision to be made.
8. Save 1 cc of local anesthetic for the sixth implant insertion site. If
the anesthetic runs out, the client may experience significant pain
during insertion of the last implant. 
9. Make the incision very small—about 2 to 3 mm. With a small
incision, the scar will be smaller. It is possible to make the inci-
sion with the trocar itself with no increased risk of pain, tender-
ness, edema, ecchymosis, or extensive scarring. Making a small
incision with a scalpel makes introducing the trocar easier.
10. Insert the implants superficially in the tissue—this is the most
important goal of the entire insertion process. Implants inserted
deeper in the tissue layers are more difficult to remove.
11. Do not move the inner plunger as you withdraw the outer part of
the trocar. Do not push on the inner plunger with your thumb or
retract the inner plunger. The plunger should remain fixed.
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12. Allow the trocar to remain inside the incision (under the skin)
between insertion of each individual implant.
13. Once you have inserted an implant, hold it in place while you
advance the trocar to insert the next implant. By holding the
implant in place, you will prevent the trocar from catching and
misplacing an already inserted implant.
14. Locate the distal tips of all six implants following insertion. If
one implant is 5 to 10 mm farther from the incision than the
others, it is often possible to push that implant with your finger-
nail toward the incision before wrapping the arm. Doing so will
simplify removal.
15. Gently clean the area with an alcohol swab before bandaging
your client's arm.
16. Show the client the incision site before you put on the butterfly
bandage or gauze. She will be reassured when she sees the very
small incision.
17. Roll the gauze or bandage over a 4"x 4" folded pad. Do not wrap
it too tightly. Suggest that your client leave the gauze wrapping
on the arm for 3 to 5 days to avoid having people touch the area
while it is still tender.
18. Warn your client that she may have a large bruise when her ban-
dage is removed. Tell her that the bruise will change colors before
going away completely.
19. After insertion, inform the client whether an implant has been
inserted too deeply or too far, or whether the proximal end of
one implant was pulled distally. 
20. After insertion, provide your phone number to your client and
encourage her to call if she has questions or problems. Remind
her that Norplant will cause a change in her menstrual cycle and
that she should call if her new pattern of bleeding is bothersome.
Remind her that medications can improve a bothersome pattern
of bleeding.
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NORPLANT REMOVAL: 20 HELPFUL HINTS
1. Use the arm model to practice removal. Wyeth Laboratories pro-
vides a plastic sheathing into which the implants are placed. The
clinician may practice cutting the plastic sheath to remove
implants. 
2. If possible, perform your first Norplant removal with someone at
your side who has experience removing Norplant implants.
Schedule adequate time. Your first few removals may take 45 to
60 minutes. As you gain experience, the time of removal
decreases to 20 to 30 minutes. 
3. Try the Emory method of Norplant removal to ease the proce-
dure. Some clinicians average less than 15 minutes per removal
by using the following three techniques:26
• Using 6 to 8 cc of local anesthesia rather than 3 cc
• Making an 8 to 10 mm incision rather than a 4 mm incision
• Vigorously disrupting adhesions for 30 seconds by repeat-
edly opening a small curved hemostat in the tissue near the
end of the implants before attempting removal of implants27 
4. Remind the client that removal may be more difficult than inser-
tion. Inform her that removal may take 30 or more minutes and
could require a second visit.
5. Raise the head of the exam table to make the patient more com-
fortable.
6. Be sure you are comfortable as you begin the removal. You may
be more at ease sitting rather than standing and leaning over the
patient’s arm.
7. Identify both the proximal and distal end of each of the six
implants. Mark the ends with a pen.
8. Add sodium bicarbonate to the local anesthetic to decrease sting-
ing. This procedure is described in suggestion #6 in the previous
section on Norplant insertion. 
9. Inject the local anesthetic slowly under the proximal one-third of
the implants. Wyeth instructions recommend that you initially
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inject about 3 cc of 1% xylocaine. Have another 3 to 5 cc of
xylocaine available to provide additional anesthesia in case you
need it later. An alternative approach is to inject 8 to 10 cc of
local anesthesia to permit a longer incision (1 cm) and more vig-
orous breaking up of adhesions with a small curved hemostat.26
10. Rather than making your incision at exactly the same site as the
location of the incision used to insert implants, make the incision
3 to 5 mm above the original incision site. Doing this makes the
removal incision closer to the proximal tips of the six implants.
11. Make the incision for removal a bit longer (5 to 10 mm) than the
incision used for insertion. 
12. Make a second incision if one implant is far from the other
implants.
13. Throughout the procedure, ask the client whether she feels any
pain. Provide additional local anesthetic if needed.
14. Have an assistant help during the removal procedure.
15. With your finger, apply pressure to the distal end of each implant
as you remove it. Push the implant toward the incision.
16. With a sharp blade or a gauze pad, remove the scar tissue cover-
ing the implants.
17. Do not pull an implant too hard; it may break.
18. Warn your client that she may develop a bruise after removal, but
tell her it will go away completely.
19. Advise your client that taking a prostaglandin inhibitor may be
helpful if she has pain in her arm after implant removal.
20. Remind your client that she may become pregnant immediately
following Norplant removal. If she does not want to become
pregnant, discuss contraception.
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MANAGING NORPLANT PROBLEMS AND FOLLOW-UP
A number of side effects may occur in women using Norplant
implants. Table 14:4 lists the side effects that were more common in
women using Norplant than in women using an IUD.18
Various treatments can improve these symptoms. Occasionally,
the implants must be removed to eliminate these complications. The
physiological basis of many Norplant side effects needs clarification
and it is an important research priority. 
Menstrual disturbances. Changes in the pattern of menstrual
bleeding are a common reason for removing Norplant implants, but
counseling can minimize decisions to remove implants because of this
side effect.  Inform women in advance to expect a change in the pat-
tern of bleeding; more than 80% of women will notice a change.16,29
The three most common new patterns are an increased number of
days of very light bleeding, amenorrhea, and increased days of heavy
bleeding. The third pattern is not common. Inform women that sev-
eral medications can help with these bothersome patterns of bleeding.
It is very reassuring for women to know about these symptoms and
that something can be done about them before the first sign of a
bleeding problem appears. Clinicians may find several therapeutic
approaches helpful:
• Several cycles of a low-dose combined OC
• Use of prostaglandin inhibitors
• Exogenous estrogens such as oral 17b estradiol (Estrace),
ethinyl estradiol (Estinyl), or conjugated estrogens (Pre-
marin)
Be sure to inform women that the irregular pattern of bleeding may
return when treatment is stopped. 
Headaches. Headaches may be associated with pregnancy and
with use of OCs and Norplant implants. If severe headaches associated
with blurred vision and papilledema develop as a new symptom fol-
lowing Norplant insertion, removal of implants may need to be done
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quickly. In December 1992, Wyeth Laboratories sent a letter to physi-
cians describing severe headaches, papilledema, and a pseudotumor
cerebri-like syndrome in 14 women using Norplant implants.
Whether Norplant is causally related to these symptoms is not yet
clear. If a client's headaches can be explained by causes other than
Norplant and if headache symptoms are not severe, it may not be nec-
essary to perform a fundoscopic exam.
Breast tenderness. This side effect may occur in some women.
Recommended treatments include Vitamin E (600 units/day), tamox-
ifen (20 mg/day), and danazol (200 mg/day).
Weight gain. Although weight gain is usually due to other
causes, weight gain may accompany Norplant use. Occasionally,
women decide to discontinue the Norplant because of weight gain.
Hair loss. Hair loss has been noted in a few women, occasionally
necessitating Norplant removal.
Acne. Acne has been a problem for some women on Norplant.
Usually it is possible to manage acne without removing the implants.
Table 14:4 Common side effects in Norplant users









Change in appetite 3.5-6.2
Weight gain 3.3-6.2
Ovarian enlargement 3.1-11.6
Hair growth or loss 1.8-2.6
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Suitability Test. "Should I prescribe a minipill containing levonorg-
estrel to a woman for several months to see if she is going to tolerate
Norplant?"  This question is asked repeatedly at Norplant training ses-
sions. Several side effects that could potentially lead to Norplant
removal might be anticipated if a woman underwent a suitability test
by using a levonorgestrel progestin-only pill for 1 or 2 months before
Norplant insertion. Possible indications for using a suitability test for
Norplant include a past history of, or extreme patient concern about,





• Allergy to levonorgestrel
Unfortunately, changes in the menstrual cycle that a Norplant
user might experience are unlikely to show up with a suitability test.
Moreover, the delay in inserting Norplant because of the suitability
test means that the woman would be using a less effective contracep-
tive for a while. Testing a woman with several injections of Depo-
Provera would make no sense at all as the hormones and the fluctua-
tions in hormone levels in the serum are completely different.
INSTRUCTIONS FOR USING NORPLANT IMPLANTS
If inserted in the first 7 days of a menstrual cycle, Norplant is effective
immediately. No back-up method is necessary. If Norplant has been
inserted more than 7 days after your period starts, use a back-up
method contraceptive if you have intercourse during the first 24 hours
after Norplant insertion.
You are using a very effective contraceptive. Your six implants
release levonorgestrel, a hormone-like progesterone that your ovaries
produce. Levonorgestrel is the same hormone millions of women take
each month in different kinds of birth control pills. You are receiving
very low amounts of levonorgestrel constantly. Your contraceptive is
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very safe and remains effective for 5 years, at which point it should be
removed. You may want to get a new set of implants at that time.
You may have your implants removed at any time. The procedure
for Norplant removal takes a bit longer than insertion and may require
two visits. The contraceptive effects of Norplant end as soon as the
implants are removed. Here is some additional information that might
help you:
1. Norplant is one of the most effective contraceptives available.
Only about 1 in 1,000 women who use the method will
become pregnant in the first year. This pregnancy rate is
lower than for the pill or IUD. In the first 2 years of use,
Norplant is about as effective as female sterilization. Women
who weigh more than 70 kg (154 pounds) may have higher
pregnancy rates than those who weigh less. 
2. Norplant becomes effective within 24 hours of insertion. 
3. If you have pain after insertion, return to see your clinician.
You might need antibiotics for an infection. Try to avoid
direct pressure on the insertion area for a few days. After the
incision has healed, you may touch the skin over the
implants. The soft, flexible implants cannot break inside
your body, so you should not be concerned about putting
pressure on the area. 
4. The Norplant implants may cause you to have irregular
bleeding or more days of bleeding. However, if you have an
increased number of days of bleeding, the amount of blood
you lose is rarely enough to produce anemia. In fact, you will
probably tend to lose less menstrual blood than you did
before starting Norplant. A follow-up visit is recommended
if you experience heavy bleeding. 
5. The hormone levels in Norplant are very low. They are so
low that there is very little buildup of the lining of your
uterus. This means that there is very little lining to shed and
you will notice very light periods or no periods at all. Your
bleeding may be irregular. Generally, the amount of blood
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loss is less than before Norplant implants are inserted, and
some women become concerned when they have no bleeding
at all while using Norplant. There is no harm to your health
if you do not get your period. If you want to make sure you
are not pregnant, you may return to the clinic for a preg-
nancy test, but you will probably not be pregnant. In some
women, menstrual bleeding becomes more regular after
implants have been in place for 9 to 12 months.
6. Most women do not have major problems with Norplant.
Common side effects noted by women using implants
include headaches, nervousness, nausea, dizziness, rash, acne,
changes in appetite, weight gain, breast tenderness, hirsut-
ism, and hair loss. Although ovarian cysts sometimes occur
in Norplant users, they usually disappear on their own. Sur-
gery is considered if a cyst remains beyond 10 weeks. Several
other problems noted by women using Norplant may possi-
bly be caused by the implant: breast discharge, inflammation
of the mouth of the womb (cervicitis), mood change, depres-
sion, general malaise, weight loss, hypertension, and itching.
7. If you may be at risk for infection of the virus that causes
AIDS (the human immunodeficiency virus, or HIV) or any
other sexually transmitted infection, continue to use con-
doms throughout the time you use implants.
8. If you are seen by a clinician for a medical problem, mention
that you are using Norplant implants. 
9. Replace the Norplant implants at the end of 5 years; effec-
tiveness decreases after this time. A new set of implants can
be inserted when the old set is removed. 
10. Return to your clinician if you have any questions, and
watch for the following signs of potential problems:
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COMMONLY ASKED QUESTIONS ABOUT NORPLANT IMPLANTS
1. In what situations might Norplant implants be a better choice than
the injectable contraceptive Depo-Provera?
Norplant might be a better option than Depo-Provera when a
woman has the following concerns:
• Weight gain is a major concern.
• The woman would have difficulty returning every 3 months
for an injection.
• She fears repeated shots.
• When the method is discontinued, the client will want to
become pregnant right away. This consideration is particu-
larly important for women in their late reproductive years
who want contraception now but will want to become preg-
nant right away after discontinuing contraception. 
Norplant Warning Signs
Caution
n Severe lower abdominal pain 
(ectopic pregnancy is rare but can occur)
n Heavy vaginal bleeding
n Arm pain
n Pus or bleeding at the insertion site 
(these may be signs of infection)
n Expulsion of an implant
n Delayed menstrual periods after a long interval 
of regular periods
n Migraine headaches, repeated very painful
headaches, or blurred vision
Avoid bumping the area where your Norplant inplants were inserted,
and keep this area dry for several days after insertion.
374 FAMILY PLANNING METHODS AND PRACTICE:  AFRICA
• When she needs a very effective reversible contraceptive for a
long period of time. Some women have situations that contrain-
dicate pregnancy, such as use of Accutane for a year or more,
long-term use of anticoagulants, or chemotherapy for cancer.
• When a decrease in high-density lipoprotein cholesterol
would be unacceptable. 
2. Can anything be done for a woman who has persistent bleeding
while using Norplant?
The problem is usually an atrophic endometrium. Chronic spot-
ting can be controlled temporarily by having the woman take OCs for
a while, which would stimulate the endometrium for 3 weeks and
then remove stimulation for 1 week. Cycle your patient for several
months. The additional hormones should not be a problem for most
women if you use low-dose OCs or a low dose of conjugated estro-
gens, either ethinyl estradiol or estradiol. 
Explain to the woman experiencing this annoying side effect that
repeating the use of these extra hormones would not be harmful, that
the amount of blood loss is probably less than she would have with the
persistent bleeding rather than more; that she can have sexual inter-
course in spite of the spotting; and that you would be happy to do an
hematocrit to reassure her she is not anemic. Keep in mind that she
could have an unrelated problem such as a chlamydia infection, a
fibroid, or a cervical infection. 
PROVIDING DEPO-PROVERA (DMPA)
The World Health Organization makes the reassuring statement: "In
summary, DMPA and NET-EN (norethindrone enanthate) appear to be
acceptable methods of fertility regulation. Clinical evidence from more
than 15 years of use as contraceptive agents shows no additional, and
possibly fewer, adverse effects than are found with other hormonal meth-
ods of contraception. Studies thus far have not shown any serious short-
or long-term effects of DMPA or NET-EN."34  There are a few precau-
tions to the use of Norplant implants. These are noted in Table 14:2.
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Toxicologic studies of DMPA in beagle dogs showed an increase
in mammary gland tumors, some of which became malignant.12 These
studies have raised concern about the possibility of breast cancer in
women using DMPA. Several studies in the United States and else-
where have found no effect in humans.13,33 In a New Zealand study,
891 women with newly diagnosed breast cancer were compared with
1,864 women selected at random.24  Women were interviewed by tele-
phone about their past use of contraceptives and any risk factors for
breast cancer. The overall relative risk of breast cancer associated with
any use of DMPA was 1.0 (in other words, no increased risk relative to
non-users). In women aged 25 to 34 years, the relative risk was 2.0.
The risk was greatest among women who used the drug for 6 years or
longer. This study suggests that DMPA may accelerate the presenta-
tion of breast cancer in young women, perhaps by acting as a pro-
moter in the late stages of carcinogenesis.24 A World Health
Organization collaborative study failed to demonstrate a significantly
increased risk for either breast cancer or cervical cancer among women
using DMPA.35,36
DMPA is usually provided from vials containing 150 mg of
DMPA in each 1 cc of solution. DMPA produced in the United States
is labeled for a 3-year shelf-life. DMPA made in Belgium has a 5-year
shelf-life. The U.S. Agency for International Development expected
that the U.S. Food and Drug Administration (FDA) would approve a
3-year sherunlf-life labeling by the time it started purchasing
DMPA.25 Deep intramuscular injections may be made into the deltoid
or the gluteus maximus muscles. Injections into the deltoid may be
less embarrassing, but slightly more painful. The needle should be 2.5
to 4 cm in length and 21 to 23 gauge; both needle and syringe should
be sterile.34 The area of the injection should NOT be massaged
because this may lower the effectiveness of DMPA. Injections usually
are not painful. 
Injections are scheduled every 3 months, and are performed by
clinicians. In international circles, there has been some discussion of
self-administering injections of DMPA. After a woman has received
several injections, each 150 mg of DMPA has a contraceptive effect
greater than 3 months, which means that the method is forgiving of
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the woman who returns late for her injection. Some programs will
provide injections of DMPA up to 4 weeks late; women are informed
that pregnancies are rare but may occur. When a woman does appear
late for her shot, stress the importance of returning on time for injec-
tions in the future. Try to find out why a woman is late for injections.
Her reasons may include a fear of cancer, changes in the pattern of
menstrual bleeding, other side effects, cost of injections, time lost
coming to the clinic, or partner or family disapproval of the method.
Deal with these barriers sympathetically and try to help your client to
overcome them. Satisfaction with this method may increase if clients
are told to anticipate menstrual irregularity during the first year and
an increasing likelihood of amenorrhea in subsequent years. 
MANAGING DEPO-PROVERA PROBLEMS AND 
FOLLOW-UP
At every 3-month follow-up visit, ask about weight gain and any prob-
lems or concerns a woman may have, the date of her last menstrual
period, and her risk for HIV infection and other STIs. Measure her
weight and blood pressure. Use a simple flow chart to document a his-
tory of depression, severe headaches, and breast tenderness. In one of
the largest studies of DMPA (3,875 users), headaches were noted in
17.1% of users, nervousness in 10.8%, decreased libido in 5.4%,
breast discomfort in 2.7%, and depression in 1.7%.27  Weight gain was
greater among clinic patients than among private patients who were
provided DMPA.27 If the client appears to have a normal annual
examination and is not complaining of unacceptable weight gain or
other unacceptable symptoms, she may continue DMPA injections as
long as desired. At the annual visit, perform a full evaluation, which
includes all that you do at the 3-month intervals plus a complete
exam. You will have an opportunity to discuss a number of subjects.
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MENSTRUAL CHANGES
Women need to be informed in advance of the changes that will
occur in their menstrual cycles. Do not underestimate the effect of
changes in bleeding; they are the major reason many women discon-
tinue this method. Spotting or breakthrough bleeding may be man-
aged most easily in a family planning clinic by offering women a cycle
or so of OCs. Five days of pills could be enough, but it may need to be
repeated. Inform women that the irregular bleeding may return.
Amenorrhea will increase over time and is not harmful. 
ALLERGIC REACTIONS
The U.S. Physicians' Desk Reference (PDR) notes that anaphy-
lactic and anaphylactoid reactions may occur immediately following
Depo-Provera injections. Fortunately, severe anaphylactic reactions to
DMPA are rare. However, since DMPA is irretrievable once injected,
ask the client to wait a half hour before leaving the clinic. You should
have on hand emergency medications such as epinephrine, steroids,
and diphenhydramine.
INSTRUCTIONS FOR USING DEPO-PROVERA 
You have chosen a very effective method of birth control: an injection
every 3 months of Depo-Provera. Birth control shots are used by more
than 6 million women around the world, and Depo-Provera is the
contraceptive most commonly used for these shots. If you wish to get
pregnant, discontinue birth control shots several months before you
plan to conceive. The following information may help you use Depo-
Provera: 
1. Use an additional contraceptive method for 2 weeks after
your first injection. This is not necessary if the first shot is
given during the first 5 days after the beginning of a normal
menstrual period. 
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2. If you may be at risk for infection with the virus that causes
AIDS (human immunodeficiency virus, or HIV) or any
other sexually transmitted infection, continue to use con-
doms throughout the time you use Depo-Provera. 
3. Return to the clinic every 3 months for another injection. 
4. Depo-Provera tends to make a woman's periods less regular,
and spotting between periods is fairly common. Some
women stop having periods completely. If your pattern of
bleeding concerns you, return to the clinic to get a blood test
for anemia, to rule out the possibility of a pregnancy, or to
rule out the possibility of infection. 
5. Weight gain is common in users of Depo-Provera. You will
have to pay close attention to avoiding excessive calories if
you want to avoid this side effect. 









Contact us if you develop any of the above problems.
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COMMONLY ASKED QUESTIONS ABOUT DEPO-PROVERA
1. In what situations might Depo-Provera injections be a better choice
for a woman than Norplant implants?
Depo-Provera might be more acceptable or a wiser choice than
Norplant implants for the woman who    
• Is very concerned about a minor surgical procedure
• Has a history of sickle cell disease or of seizures, both of
which may actually be improved by DMPA14
• Is taking a medication that markedly increases production of
liver enzymes, which speed up the breakdown of levonorg-
estrel (the hormone elaborated by Norplant implants); these
drugs include phenobarbital, phenytoin (Dilantin), primi-
done, carbamazepine, and phenylbutazone 
• Needs highly effective contraception for just a few months
(For example, a tubal sterilization or vasectomy may be
scheduled; she may be receiving rubella immunization; or
she may be using a medication like Accutane (for acne),
which is known to produce severe defects in babies if taken
by a pregnant woman; or she may be taking anticoagulants
or valproic acid.)
• Needs only a year of extremely effective contraception (For
example, she may have recently had a molar pregnancy and
must not become pregnant for 1 year)
• Has a preference for receiving medications by injection
• Wants to keep all information about contraceptive use from
her partner (for example, an abusive husband who does not
want her to use contraception)
2. Can a woman who is breastfeeding her baby receive Depo-Provera
injections?
Yes, this is an excellent option for breastfeeding mothers. Post-
partum bleeding may be somewhat less predictable if DMPA is given
immediately postpartum. 
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3. Why is a method that was considered "bad" 10 years ago by the U.S.
FDA now a good method?
It has always been a good method. By the time Depo-Provera was
approved in the United States, it was already being used by 8 to 9 mil-
lion women throughout the world, in over 90 countries that had
approved Depo-Provera. 
4. What is the most important difference between Depo-Provera
(DMPA) and norethindrone enanthate (NET-EN) injections?
NET-EN injections are injections of norethindrone in an oily
base given at 2 month intervals for the first 6 months of use, after
which injections are every 2 to 3 months.9 DMPA is given every 3
months. Other countries also have injections containing both an
estrogen and a progestin. 
It is important that the woman using NET-EN every 3 months
not be late for her injection. That 3-month interval should not be
exceeded or pregnancy rates will increase. Depo-Provera is more for-
giving of the woman who is late for her injection. 
PROVIDING PROGESTIN-ONLY PILLS (Minipills)
Because few women use minipills, large-scale studies that document
their benefits and side effects have not been conducted. In general,
progestin-only pills have lower effectiveness, more breakthrough
bleeding, and fewer noncontraceptive benefits than do combined
OCs. 
Most of the health benefits of progestin-only pills are probably
similar to those of combined estrogen-progestin pills: decreased men-
strual cramps or pain, less heavy bleeding, a shorter period, decreased
premenstrual syndrome symptoms, and decreased breast tenderness.
In theory, the thick, less penetrable cervical mucus in women taking
progestin-only pills should decrease the risk of PID.
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Progestin-only pills should theoretically be safer than combined
pills.  Progestin-only pills have not been shown to increase the risk of
either cardiovascular complications or cancer and are less likely to
cause headaches, blood pressure elevation, depression, and other side
effects than are higher dose combined OCs.32 However, the FDA-
required class labeling in the package insert for progestin-only pills
does not suggest different contraindications for minipills than for
combined pills. The authors propose that contraindications be
replaced with the precautions noted in Table 14:2. 
Progestin-only pills are not the best choice for women who are
not organized enough to take a pill every single day.7 Missing one or
two progestin-only pills is more likely to lead to a pregnancy than is
missing one or two combined OCs.
MANAGING MINIPILL PROBLEMS AND FOLLOW-UP
The most important problems with progestin-only pills relate to the
patterns of bleeding. Many problems can be managed much as they
are for women using Norplant implants or Depo-Provera. If the
woman has increased days of light or heavy bleeding, spotting, or
amenorrhea, first rule out pregnancy. If she is not pregnant, counsel
her, switch to a combined OC, use supplemental estrogen (in the form
of conjugated estrogens, such as 17-B estradiol or ethinyl estradiol), or
use prostaglandin inhibitors.
INSTRUCTIONS FOR USING MINIPILLS
1. Have on hand a back-up birth control method such as foam,
spermicidal tablets or suppositories, condoms, or a diaphragm. You
will need to use your back-up method: 
• While you are waiting to start progestin-only pills or minipills 
• During your first cycle on minipills 
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• If you miss a minipill, use a back-up method until you restart
or until your next period
Progestin-only pills are very low dose contraceptives. Your mar-
gin of error is not great. Do not count on this method unless you will
be able to take pills every single day. Try to take your minipills at the
same time every day. Some women use a back-up method at all times
to increase the effectiveness of this approach to birth control. (See the
questions at the end of these instructions for more on back-up contra-
ceptives while on minipills.)
2. Swallow 1 pill each day until you finish your pill pack. Then start
your new pack the next day. Never miss a day. The evening meal may
be the best time to take progestin-only pills. 
3. If you miss 1 minipill, take it (yesterday's minipill) as soon as you
remember. Also take today's minipill at the regular time even if that
means taking 2 pills in 1 day. If you are more than 3 hours late taking
a minipill, use your back-up birth control method for the next 48
hours (2 days). 
4. If you miss 2 or more minipills in a row, there is an increased
chance you could become pregnant. Immediately start using your
back-up method. Restart your minipills right away and double up for
2 days. If your menstrual period does not begin within 4 to 6 weeks,
see your clinician for an exam and a pregnancy test. 
5. Keep track of your periods while you take minipills. If you have
more than 45 days with no period, you may want to see your clinician
for an exam and pregnancy test. 
6. If you have spotting or bleeding between periods, keep taking
your minipills on schedule. If your bleeding is very heavy or if you
have cramps, pain, or fever, see your clinician. Your bleeding may be
caused by infection. In most cases, bleeding is not serious and will
often stop after a few days. Bleeding is especially likely if you have
missed 1 or more minipills. Bleeding is common during the first few
months a woman takes minipills. 
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7. If you become ill with vomiting, severe diarrhea, or both, use
your back-up method of birth control along with your minipills until
48 hours (2 days) after your illness is over. Using your back-up
method will give you extra protection in case your illness or the medi-
cation you take for that illness interferes with minipill effectiveness. 
8. If you decide you want to become pregnant, plan to stop using
minipills and change to another method of birth control, such as con-
doms, for 2 or 3 months. Once you are off minipills, your natural
cycle should be reestablished. Your clinician will be able to determine
your pregnancy due date more accurately if you have at least two natu-
ral menstrual periods before you become pregnant. 
9. Stop minipills anytime you want, even in the middle of a pill
pack. Remember, though, that protection from the minipill does not
last after you stop. Begin using another method the very next day. 
10. If you may be at risk for infection with the virus that causes
AIDS (human immunodeficiency virus, or HIV) or any other sexually
transmitted infection, continue to use condoms throughout the time
you use minipills.
11. See your clinician regularly for routine checkups. Be sure to have
a blood pressure check, Pap smear, breast exam, and pelvic exam. 
12. See your clinician right away if you have severe lower abdominal
pain while using minipills. 
Progestin-Only Pills (Minipills) Warning Signals
Caution
n Abdominal pain—May be due to an ovarian 
cyst or an ectopic pregnancy.
(Don’t stop pills but contact us right away)
n Pill taken late—Even if only 3 hours late, use 
a back-up contraceptive for the next 2 days. 
Be careful to take the minipill ON TIME.
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COMMONLY ASKED QUESTIONS ABOUT MINIPILLS
1. What effect do minipills have on ovulation?
Women taking the progestin-only pills will have one of three pat-
terns: (1) they may ovulate every month, and their periods tend to be
quite regular, (2) they may never ovulate, in which case their periods
tend to be very irregular and they may go months without any bleed-
ing, and (3) they may ovulate some months and not others, in which
case their periods are also irregular.
2. During the first cycle of minipills, are back-up contraceptives essential?
No, whether or not a woman ovulates the first month on minip-
ills, the production of a thick cervical mucus starts immediately and
continues as long as minipills are taken every day at about the same
time.
3. During the first cycle of minipills, are back-up contraceptives wise?
Perhaps. Minipills may be forgotten or taken late during that first
cycle. Mistakes are more common the first month on any method of
birth control.
4. Which women might benefit most by using a back-up contraceptive
while on minipills?
Women who might be encouraged to use a back-up contracep-
tive while taking minipills include those who are ?
• In the first cycle (just to make sure pills are remembered and
tolerated well)
• Late in taking a minipill (they should use a back-up contra-
ceptive until back on schedule)
• Very regular in their menstrual cycles (e.g., every 28 days)—
this is presumptive evidence that women are ovulating and
might make them lean toward using a back-up contraceptive
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“Why do I choose the IUD?" the older mother said in response to 
a question asked by her women's group. "It is simple, really. I 
cannot travel so frequently to the clinic. And when I do get to 
the clinic, I sometimes must wait for a long time to be seen. 
When I took the pill, I sometimes heard that my contraceptive 
choice was “not in supply, please come back another day.” The 
IUD is so easy to use. I have as many children as I want." 
 
As contraceptive use increases in Africa, the intrauterine device (IUD)
is becoming one of the most acceptable methods. However, its popu-
larity varies widely throughout the continent. For example, it is the
most popular method in Egypt, where 16% of married women of
reproductive age currently using a contraceptive method have an IUD,
and one of the principal methods in Botswana and Kenya. In other
countries, such as Mali and Uganda, as contraceptive use of any kind






Women with IUDs use them





Some family planning programs have a policy that limits the time


























some programs allow IUD insertion only during menses. Although
the purpose of such a policy is to make sure an IUD is not inserted
into a pregnant woman, it is very inconvenient for clients and inter-
feres with an effective IUD program. In some settings, women have to
travel a long distance to reach a family planning clinic; rejecting their
requests for an IUD because they are not having their periods would
be unfair. In addition, return visits to the clinic cost money and thus
create a barrier to services. As a rule, trust your client when she tells
you she is not at risk of pregnancy, because she has not had intercourse
since her last period or because she has used contraception. This basic
trust contributes to thoughtful, dignified, and high-quality family
planning services. (See Figure 15:1.) Several reasons support inserting
the IUD at any time in the menstrual cycle:
• More options for convenient and flexible appointment times 




inserted during days of menstrual bleeding
• At midcycle, the cervix is just as dilated as it is during menses




Figure 15:1 If you can determine that the woman is not pregnant, 












A panel of experts at the Centers for Disease Control and Preven-




1. Most important, allow the client to choose her own method.
She must be an informed user.
2. Make all presentations, counseling, and educational materi-
als compatible with the language, culture, and education of
the clients. 
3. Set aside time for counseling as a routine part of the clinic
visit. During the initial visit, a woman needs counseling to
help her select a method, then additional counseling imme-
diately after the IUD insertion to learn about checking IUD
strings and watching for signs that suggest problems.
4. Be aware of the local myths and misconceptions about
IUDs. Gaining this awareness may require background
research. Address the misconceptions sensitively but directly.
5. Ask the client to repeat important information about the
IUD to make sure she understands.
6. Give each IUD user an identification card with the name
and picture of the IUD. The card may note the date of inser-
tion and date of recommended removal.
7. If a client is not accustomed to following a calendar, inform
her about the recommended dates for check-ups and IUD
removal.
8. Sample IUDs should be available so that women can handle
and examine them.
9. Provide flip charts, posters, and handouts describing key





























New evidence shows that the IUD’s principal mechanism of
action is to prevent fertilization of the egg. The copper IUD stimulates
a variety of responses, including an increase of uterine and tubal fluids
containing enzymes and white blood cells (macrophages) that con-
sume, damage, or alter the transport of sperm and ovum so that fertil-
ization does not occur. The Lng-20 IUD, which has primarily a
hormonal mechanism of action, thickens cervical mucus, disrupts
ovulatory patterns, alters the endometrium, and changes motility in






The effectiveness of modern IUDs compares favorably with
other long-term contraceptive methods such as Norplant and steriliza-
tion. An IUD’s effectiveness is influenced by its size, shape, and pres-
ence of copper or progesterone as well as by user characteristics such as
age and parity. The pregnancy rate among IUD users also depends on
such factors as ease of insertion, the clinician's experience in inserting
IUDs, the patient's ability to detect IUD expulsion, and the patient's
access to medical services. Pregnancy rates tend to be lower under the
following conditions:
• The IUD is medicated with copper, silver, progesterone, or
another progestin.
• The non-medicated IUD has a large surface area.
• The IUD has a low expulsion rate.
• Partial and complete expulsions are detected quickly.





The Copper T 380A (Cu T 380A) has one of
the lowest pregnancy rates of any contraceptive. The first-year preg-
nancy rate in typical users is 0.8%, whereas the lowest expected preg-






At the end of 7 years,
















Although expensive and not avail-
able in many countries, the Levonorgestrel IUD is the single most
effective method of reversible contraception available in the world
today, with the Cu T 380A running a close second. In the first 7 years,
the total (cumulative) pregnancy rate is only 1.1%.
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MultiLoad Cu 375 (ML Cu 375).
 
The pregnancy rate for the
MultiLoad Cu 375 is 1% after 12 months, 1.3% after 24 months, and






The IUD is a highly effective, safe, long-acting contraceptive
method, and the client needs to make only a single decision to use it.
In contrast, the pill requires daily decisions, and condoms and spermi-
cides require decisions with each act of intercourse.  Although perhaps
more expensive initially than other contraceptives, the IUD is less
costly over its years of use. It is also easier to use than other methods
such as oral contraceptives, condoms, and spermicides. The IUDs that
release progestin or progesterone decrease menstrual blood loss and
menstrual pain (dysmenorrhea). The LNg-IUD reduces the incidence






and is an effective treatment for






In addition, IUDs can pre-
vent and treat Asherman's syndrome (in which the walls of the uterus
are adhered by synechiae), which can occur after uterine surgery. 
Ideal candidates for the IUD include women who have medical
precautions to hormonal methods, who want a long-acting and revers-
ible method, who are in a mutually faithful relationship, or who are
lactating or postpartum. Voluntary contraception and informed con-
sent must always form the basis for contraceptive decision making.
The Copper T 380A has been used as an option for emergency con-
traception. When inserted
 
 within 5 to 7 days
 
 of unprotected intercourse,
this IUD can significantly reduce the risk of pregnancy. Use of the IUD
in this situation can lead to long-term use if the woman selects to keep
the IUD. Only copper-bearing IUDs have been studied. The same pre-
































One of the main concerns about
using the IUD is the possibility of developing PID. Both use of
the IUD and being at high risk for acquiring sexually transmitted




Women increase their risk of acquiring STIs if they have more
than one sexual partner or if their partner has other sexual part-
ners.  The greatest risk of pelvic infection associated with the use






(See Table 15:1.) This
increased risk of infection may be associated with a microbiologi-




   
 
To
reduce the risk of PID, maintain strict asepsis at insertion and
leave the IUD in place for its life span. The 1-year IUD
(Progestasert System) is recommended only in unusual circum-
stances, such as allergies to copper. Compared with a copper-
releasing IUD, the LNg IUD has been shown to provide a








Human Immunodeficiency Virus (HIV). W
 
hether IUDs
increase the risk of acquiring the human immunodeficiency virus
(HIV) is not known. Because information on this issue is sparse,







The effect of IUDs on the uterine lining may create an
environment favorable to HIV transmission. It is possible that the
increased bleeding associated with the use of some IUDs may
increase the transmission of the virus from HIV-positive women
to their partners. According to one study, women who used other
contraceptives or none at all had lower risks of HIV after exposure
 
Table 15:1  Intrauterine device use and pelvic inflammatory 
disease (PID)
 








20 days 1.38 1.00
 
*per 1,000 woman-years


















However, another study from Kenya could










Increased menstrual pain (dysmenorrhea)
may accompany IUD use. From 10% to 15% of IUD users have







However, the blood is usually minor and
of little consequence. The LNg-20 IUD actually decreases bleed-
ing. Inserting this IUD in a woman with heavy bleeding will sub-








From 2% to 10% of IUDs are spontaneously expelled
within the first year. One study found that risk factors for Cu T
380A expulsion were young age, an abnormal amount of menstrual








Half of intrauterine pregnancies that occur with the






If the IUD is







Leaving the IUD in place during pregnancy
increases the risk that the mother will have severe pelvic infection




About 5% of women who become pregnant with an IUD in






Women who use the
Progestasert System have a rate of ectopic pregnancy 6 to 10







labeling may identify never-pregnant (nulliparous) women as a
group that should not receive an IUD, most scientific evidence
indicates that the IUD is an option for nulliparous women.
Nevertheless, the risks that may lead to impaired fertility need to






Informed consent is required of any woman who will have an
IUD inserted. Women at greater risk of complications should consider





























1 = used in any circumstance
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
 







4 As no method is indicated, any health risk is 
considered unacceptable.  However, there is no 





a) <6 wks postpartum 1 Not a concern.  No need for restriction of 
IUD use.








a) Menarche—age 20 2 Concern about risk of expulsion in younger 
age-groups.




a) Age <35 1
b) Age >35
   i) light
  ii) heavy
1
1





a) Mild hypertension 
(<180/105)
1
b) Moderate and severe 
hypertension
1 Not a concern.  No need for restriction of 
IUD use.























1 = used in any circumstance
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
 





 i) non-insulin 
dependent
1
Not a concern.  No need for restriction of 
IUD use.
ii) insulin dependent 1
c) Nephropathy retinopathy 1
d) Other vascular disease or 










a) Current and history of VTE 1
b) Major surgery
 i) with prolonged 
immobilization
1 Not a concern.  No need for restriction of
IUD use.
ii) major surgery without 
            prolonged 
immobilization
1
c) Minor surgery without
      immobilization
1





Current and history of 
ischemic heart disease
 






































1 = used in any circumstance
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable








hypertension, risk of 
arterial fibrillation, history 




Prophylactic antibiotics are advised if the 





2 IUD use may be associated with prolonged 
bleeding in the first few months after insertion.  







 i) recurrent, including 





           neurologic symptoms
1
Not a concern.  No need for restriction of 
IUD use.
ii) recurrent, including
















b) With heavy bleeding
1
2
Changes in menstrual bleeding patterns are 





4 Evaluation of the underlying pathological 
condition (such as pregnancy, pelvic 
malignancy) is required.
d) Trachomatis or 
N. Gonorrhoea
4
e) Vaginitis without  
       purulent cervicitis
2




1 = used in any circumstance
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Unexplained vaginal bleeding
— continued
f ) Increased risk of STDs 
     (e.g. multiple partners or 
     partner who has multiple 
 partners)
3
STIs:  current or within 
3 months
4 Serious concern that IUD increases risk of 
PID.
HIV/AIDS
a) HIV positive 3
b) High risk of HIV 3
c) AIDS 3
Biliary tract disease
a) Symptomatic Not a concern.  No need for restriction of 
IUD use.
i) surgically treated 1




a) Pregnancy-related 1 Not a concern.  No need for restriction of 
IUD use.
b) Past hormone-related 1
Viral hepatitis




Cirrhosis 1 Not a concern.  No need for restriction of 
IUD use.
Table 15:2 Precautions to use of intrauterine devices (copper 
containing)  (Continued)
Condition Category Rational/Comments
398 FAMILY PLANNING METHODS AND PRACTICES:  AFRICA
1 = used in any circumstance
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4 = not to be used
Liver neoplasia
a) Benign (adenoma) 1 Not a concern.  No need for restriction of 
IUD use.
b) Malignant (hepatoma) 1
Schistosomal fibrosis 1 Not a concern.  No need for restriction of 
IUD use.
Past ectopic pregnancy
a) Subsequent pregnancy 
desired




Risk of future ectopic pregnancy is increased 
among women who have had an ectopic 
pregnancy in the past.
Obesity 1 Not a concern.  No need for restriction of 
IUD use.
Thyroid






(current and recent history)
2
Sickle cell disease 2
Iron deficiency anaemia 2 Concern about increased blood loss in initial 
months of use.
Epilepsy 1 Not a concern.  No need for restriction of 
IUD use.
Schistosomiasis 1 Not a concern.  No need for restriction of 
IUD use.
Malaria 1 Not a concern.  No need for restriction of 
IUD use.





a) Antibiotics 1 Not a concern.  No need for restriction of 
IUD use.
b) Drugs affecting liver







Concern that nulliparity is related to risk 
of expulsion and concern about future 
childbearing.
Rapid return to fertility 
desired
1 Return to fertility not affected.
Anatomical abnormalities
a) Distorted uterine cavity 
      (any congenital or 
acquired uterine 
abnormality distorting  
the uterine cavity in a 
manner that is 
incompatible with  
IUD insertion)
4 In the presence of an anatomic abnormality 
that distorts the uterine cavity, proper IUD 
placement may not be possible.
b) Other abnormalities
      (including uterine fibroids,
cervical stenosis, or 
cervicallacerations) not 
distorting the uterine 
cavity or interfering
with IUD insertion
2 Abnormalities not distorting the uterine cavity 
generally do not interfere with proper 
placement.
Severe dysmenorrhoea 2 Dysmenorrhoea may intensify with IUD use.








Slightly increased risk for uterine perforation 
and expulsion if the IUD is inserted early in 
the postpartum period or following second 
trimester abortion.
1 = used in any circumstance
2 = generally used
3 = usually not used unless other more appropriate methods are not available or acceptable
4  = not to be used
Table 15:2 Precautions to use of intrauterine devices (copper 
containing)  (Continued)
Condition Category Rational/Comments
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PROVIDING THE METHOD
Obtain a medical history and advise the client about whether the
IUD is suitable for her. Discuss her risk factors and the safety and
effectiveness of the IUD.
TYPES OF IUDS
IUDs have been made in various shapes, including rings, loops,
spirals, T-shapes, and 7-shapes. The materials used have included sil-
ver, copper, and plastic. There are two categories of IUDs: those that
are medicated and release hormones or copper and those that are not
medicated. In Africa, the most commonly used IUDs are the Cu T
380A, and the Multiload 375 and 250. Those less frequently used
include the Levonorgestrel IUD, the Copper T 200 and 220C, the
stringless single-coil stainless steel ring, the Progestasert System, and
the Cu-Fix. (See Figure 15:1.)
Cu T 380A. This IUD is Africa’s most commonly inserted type
for new IUD users. More than twenty five million Cu T 380A IUDs
have been distributed in 70 countries.18 The Cu T 380A comes in pre-
sterilized packages. The T shape is made with polyethylene. Barium
sulphate is added to create x-ray visibility. Fine copper wire is wound
around the vertical stem, and each of the two horizontal transverse
arms has a sleeve of copper measuring 33 mm. The bottom of the T
has a single filament of clear or whitish polyethylene string that is
knotted after passing through a hole in the T, creating a double string
effect. The upper limbs of the “T” are folded down into the inserter
barrel no more than 5 minutes before insertion. The inserter tube is
inserted so that it just touches the top of the fundus. The outer
inserter tube is then retracted about l cm to release the arms of the
device. The diameter of the inserter is 4.4 mm, but only the tips of the
arms fit in the tube.
Multiload 375 and Multiload 250.  These devices come in pres-
terilized packages and are preloaded in an inserter tube. Insert these
IUDs by retracting the outer barrel over the inserter rod.  The vertical
limbs of these devices have surfaces of 375 mm2 or 250 mm2 of copper.
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Both the Multiload 375 and the Multiload 250 come in three sizes:
standard, short, and SL (mini).
Levonorgestrel IUD. This new IUD is a highly effective contra-
ceptive method developed by Leiras. Its active substance, levonorg-
estrel, is released directly into the uterus at a constant rate of 20 mcg
per day for up to 5 years. This kind of delivery decreases the systemic
effects of the hormone. The levonorgestrel IUD is based on a NOVA
T model polyethylene frame and has a cylinder of polydimethyl-silox-
ane-levonorgestrel molded around its vertical arm. The cylinder is
coated with a membrane that regulates the release of the hormone. 
Copper T 220C. This IUD also comes in a presterilized pack-
age. Insert this IUD using the withdrawal technique. The IUD can be
loaded and cocked into the barrel without the clinician touching the
IUD. Although it may be initially difficult to fold the upper limbs of
the “T” down into the inserter barrel, the procedure becomes easier
with practice. 
Stringless, single-coil stainless steel ring. This ring is the most
widely used IUD in China. Rings come in sizes ranging from A
(smallest) to D (largest). The size of the ring used depends on the
sounding depth of the uterus. The rings come in either prepackaged
sterile units or less expensive packages containing 100 rings that must
be sterilized with an iodine (1:2,500 for Betadine) or benzalkonium
antiseptic solution for 30 minutes before use. The usual method of
insertion involves using an inserter rod to push the device into the
uterine cavity.
Progestasert System. This system is approved for l year of con-
traceptive protection, after which it must be replaced. Because of its
short usable life, the Progestasert System should be used only in
unusual circumstances (such as allergy to copper). This IUD comes in
a separate pre-sterilized package. It is shaped like a “T” and consists of
ethylene vinyl acetate copolymer. The vertical stem contains a reser-
voir of 38 mg progesterone and barium sulphate (for visibility on x-
rays) in a silicone oil base. It releases 65 mg progesterone per day. The
IUD is 36 mm long, 32 mm wide, and when placed in the inserter
barrel, has a diameter of 8 mm. The blue-black double string is
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attached at a hole in the base of the T.  The Progestasert System must
be inserted by the withdrawal technique.
Cu-Fix. This frameless IUD has six copper sleeves strung on a
surgical nylon thread knotted at one end. During insertion this knot is
pushed into the myometrium with a notched needle that works like a
miniature harpoon. It is expected to have low rates of expulsion or
removal for bleeding or pain because it is frameless.29
Figure 15:2 Types of IUDs
Source:  Speroff and Darney (1992)
Lippes loop Saf-T-Coil TCu 200B TCu 380A
TCu 220C Nova T Copper 7 Cu-Fix
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FACTORS TO CONSIDER IN CHOOSING AN IUD
Safety and effectiveness depend more on the skill of the IUD
inserter and the quality of counseling, selection, and follow-up than
on the type of IUD used.34 With appropriate training, nurses, nurse-
midwives, physician assistants, paramedical personnel, and rural vil-
lage midwives can safely perform routine IUD insertions. Clinicians
should practice first on a model, then insert an adequate number of
IUDs under supervision. The clinical supervisor should determine the
criteria for competence. Competence should not be judged simply by
the number of IUDs inserted; it should be based on the ability to con-
sistently demonstrate safe clinical judgment and correct insertion
skills.
IUD INSERTION
The IUD can be inserted any time during the menstrual cycle. It
is not necessary to wait for the woman to have her menses.39 Of
course, the IUD should never be inserted into the uterus of a pregnant
woman. If there is any question of pregnancy, perform a pregnancy
test or delay insertion until the next menstrual flow, which usually
indicates that the woman is not pregnant. A woman who is not preg-
nant may have an IUD inserted at the following times:
• At any time in the menstrual cycle
• Within 7 days of unprotected intercourse, if the woman wants
an emergency (postcoital) contraceptive device
• Immediately following childbirth (within the first 10 min-
utes); if the IUD is inserted l or 2 days after childbirth, there
is a greater risk of expulsion as the uterus contracts42
• Within 6 weeks postpartum
• Immediately after or within 3 weeks of an uncomplicated
first trimester spontaneous or legally induced abortion
• Within 6 months of childbirth if the woman is lactating,
amenorrheic, and normal upon physical exam
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INSERTION TECHNIQUE — GENERAL PRINCIPLES
Teaching clinicians respect for clients and confidence in working
with them is the centerpiece of training. Proceed slowly and gently dur-
ing all phases of IUD insertion. Since insertion methods differ slightly
for the various IUDs, always read and follow the manufacturer’s
instructions on IUD insertion. The methods differ depending on the
size and shape of the IUD, inserter barrel, plunger, packaging, and
strings. (See Figure 15:3.)
1. Explain the IUD insertion procedure to the patient. Answer ques-
tions, eliminate myths about the method, and create a comfort-
able, confident atmosphere for the client.
2. Administer an analgesic agent or antiprostaglandin prior to inser-
tion, which may reduce discomfort.
3. Perform a careful visual and bimanual exam to rule out pregnancy
and active pelvic infection and to diagnose the position of the
uterus. IUD perforations usually occur at 90 degrees to the axis of
the fundus. An unrecognized retroflexed uterus increases the pos-
sibility of uterine perforation at the time of IUD insertion.
4. Use sterile instruments to clean the cervix. After you have inserted
a warm speculum and viewed the cervix, apply an antiseptic solu-
tion such as 1:2,500 iodine in a motion of concentric circles begin-
ning at the os and spiraling outward on the cervix. If the patient is
allergic to iodine, use a chlorhexidine (Hibiclens) solution.
Table 15:3 Intrauterine device termination rates (per 1,000 
women) during first and second months after insertion
Reason for termination
Menstrual cycle day of insertion
1-5 6-10 11-17 18+ All cycle days
Expulsion 50.3 30.5 24.0 22.0 39.6
Pregnancy 3.0 4.1 4.8 6.1 3.7
Pain and bleeding 20.9 20.6 27.2 36.7 22.7
Miscellaneous bleeding 5.9 7.9 4.8 9.8 6.8
Personal 25.6 30.9 17.6 19.6 26.2
Pelvic infection 3.0 3.1 3.2 1.2 2.9
Total 108.7 97.1 81.6 95.4 101.9
Source:  White (1980)
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Figure 15:3 Minimal equipment for IUD insertion
5. In some instances, you may inject intracervical local anesthesia at
this point (see the section on “Paracervical Anesthesia or Paracer-
vical Block”).
6. Grasp the anterior lip of the cervix with a tenaculum about 1.5 to
2.0 cm from the os. Close the single-tooth tenaculum slowly, one
notch at a time. (Using a small amount of local anesthesia may
decrease the discomfort of tenaculum placement.)
7. Sound the uterus slowly and gently. Place a cotton swab at the cervix
when the sound is all the way in. Remove the sound and the swab at
the same time to measure the depth of the fundus to within 0.25 cm.
8. Load the IUD into the inserter barrel. Use sterile conditions. To
minimize the chance of introducing contamination, do not remove
the IUD from the insertion tube before placing it in the uterus. Do
not bend the arms of the “T” more than 5 minutes before it is to
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maintained in the absence of sterile gloves by folding the arms
through the packaging. Use a flat surface and pull the solid rod
partially from the package (so it will not interfere with assembly).
9. Insert the IUD into the cavity of the uterus by retracting the outer
barrel over the plunger (this is the withdrawal technique). (See Fig-
ure 15:4.)  Insertion should be done slowly and without much force.
10. To guarantee high fundal placement, gently push the inserter tube
until resistance is felt.
11. Release the IUD, withdrawing the insertion tube no more than 1
cm while the solid rod is not permitted to move. This movement
releases the arms of the “T”.
12. Withdraw the solid rod while holding the insertion tube stationary.
13. Withdraw the insertion tube from the cervix.
14. Clip the strings. Be sure enough of the strings are visible (2.5 cm)
to facilitate checking for the presence of the IUD. Note the length
of the visible strings in the patient record.
15. Some clinicians have the patient feel for the strings of her IUD
before she leaves the exam room. At the very least, as part of the
counseling process explain to the client how to locate the string.
IUDS IN NULLIPAROUS WOMEN
Women who have never been pregnant may use an IUD safely,
but they may wish to consider another type of contraceptive method.
Compared to women who have given birth (parous women), nullipa-
rous women are more likely to experience an IUD expulsion, cramp-
ing, or bleeding. Insertion also is more difficult because the cervical os
and uterine cavity are smaller.7
Cardinal Rule for IUD Insertion
Everything done at the time of IUD insertion and removal 
CAN and SHOULD be done slowly and gently.
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Figure 15:4 Withdrawal technique
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PROPHYLACTIC ANTIBIOTICS AND IUD INSERTION
There is a general consensus that prophylactic antibiotics should
not be used routinely at IUD insertion as a measure to prevent subse-
quent infection. However, two published studies on the subject are at
odds; one supports this position but the other does not.13,27 Some cli-
nicians provide women with prophylactic antibiotics at the time of
IUD insertion in areas where STIs are common. Observe the follow-
ing guidelines for using prophylactic antibiotics before IUD insertion:
• Assess the patient to make sure she has no precautions to
IUD insertion, no clinically acute infection, and no con-
traindications to taking antibiotics.
• Give the woman 200 mg of doxycycline orally at the time of
insertion and l00 mg 12 hours later.
• Give breastfeeding women 500 mg of erythromycin orally l
hour before insertion or at the time of insertion and 500 mg
orally 6 hours after insertion. (Doxycycline is contraindi-
cated during pregnancy and lactation because of potential
effects on newborns.)
IMMEDIATE POSTPARTUM INSERTION OF IUDS
If labor and delivery were normal, the uterus is firm, and bleeding
has subsided, a Cu T 380A may be inserted. Inserting the IUD imme-
diately following delivery of the placenta (postplacental insertion) or
during the first week after delivery (postpartum insertion) is safe and
convenient. There is no increased risk of infection, perforation, or
bleeding.8,34 To reduce the risk of infection, use a sterile long-sleeved
glove. (See Table 15:4.)
A major drawback to inserting the IUD so soon following deliv-
ery is the high rate of expulsion. Reported rates have ranged from 9%
in a Chinese study44 to 22% in a Family Health International multi-
center trial,9 to 31% to 41% in a WHO multicenter trial.42  The
expulsion rate for copper-bearing IUDs appears to be lower than the
expulsion rate for the stringless, single-coil stainless steel ring.34   The
chance of expulsion can be reduced if the clinician is experienced in
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IUD insertion, an ergot preparation is used to enhance uterine con-
tractility,21 and the following steps are taken: 
1. Massage the uterus until bleeding subsides.
2. Insert the IUD within l0 minutes of delivery of the placenta.
3. Administer methergine (+/-) but no antibiotics, analgesics or
anesthesia.
4. Grasp the IUD with ring forceps.
5. Grasp the cervix with the second ring forceps.
6. Manually place the IUD in the uterine cavity.
7. Grasp the uterus with the hand you have placed on the abdo-
men.
8. Place the IUD high in the fundus.
9. Release the IUD and rotate the ring forceps 45 degrees.
10. Release the forceps and remove.
Discuss with your client the potential for IUD expulsion. This
discussion will help to ensure that the client will return for a follow-up
visit after insertion. Also tell her that, despite higher expulsion rates,
cumulative pregnancy rates for immediate postpartum IUD insertion
are comparable to or lower than those for interval IUD insertions, per-
haps because women are less fertile in the postpartum period.21 With
modern copper IUDs, proper insertion techniques, and adequate fol-
low-up, the pregnancy rate after 24 months following postpartum
IUD insertion is 2.0 to 2.8 per 100 users.21
The string of the Cu T 380A may lie entirely within the uterine
cavity after postplacental insertion. If a postpartum woman is exam-
ined l month after delivery and the string is not visible, determine the
location of the Cu T 380A. Use a sound, alligator forceps, or other
sterile instrument to explore the uterine cavity (pregnancy at 4 weeks
postpartum is very unlikely). If you detect the IUD in the uterus, tease
the string down to the cervical os.  Otherwise, as long as you have con-
firmed the presence of the IUD during sounding, simply leave both
the IUD and the string in the uterine cavity.
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PARACERVICAL ANESTHESIA OR PARACERVICAL BLOCK
A paracervical block using no more than 10 to 20 cc of l%
lidocaine without epinephrine can prevent the pain of an IUD inser-
tion or a difficult removal. Paracervical anesthesia is particularly bene-
ficial at the time of insertion for a woman who has never been
pregnant or for a woman who has a history of vasovagal reactions.
Remember to ask the patient whether she has any known allergies,
especially to iodine or any local anesthetic. A suggested procedure for
performing a paracervical block is as follows: 
l. Perform a bimanual pelvic exam; insert a speculum in the
vagina to obtain good visualization of the cervix.
2. Clean the cervix and vagina with antiseptic material.
3. Ask the patient to inform you if she experiences nausea, diz-
ziness, ringing of the ears, or tingling of the lips from the
procedure. It is not uncommon for these symptoms to occur,
but they will pass quickly.
4. Inject 2 cc of lidocaine at the tenaculum site and then apply
the tenaculum to the upper lip of the cervix.
5. Inject the lidocaine around the cervix. Different clinicians use
different placements of the injections. One technique is to
inject 2 to 5 cc at sites corresponding to 4 o’clock or 5 o’clock
and 7 o’clock or 8 o’clock on a clock face (a total of 4 to 10 cc).
Table 15:4 Advantages and disadvantages of post-placenta or 
immediate postpartum IUD Insertion
Advantages Disadvantages
• Patient already at health facility • Expulsion rates higher
• Contraindication of pregnancy is 
not present
• Continuation rates slightly lower
• Higher rates of missing strings
• Fewer complaints of pain and bleeding • Counseling postpartum is difficult
• Risk of perforation is same or lower
• Lower cost
• Insertion technique is easier to master
• Special instructions needed for 
expulsions
Source: O’Hanley and Huber (1992); Stewart (1993)
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6. Insert the needle just under the mucosa in the connective tis-
sue. This method assures rapid and adequate distribution of
the anesthetic because most of the smaller blood vessels and
capillaries are in this region. Aspirate lightly with each injec-
tion to avoid direct intravenous injection.
A serious reaction will be extremely unlikely to occur if the total
used is less than 20 cc. Anesthesia takes effect in 2 to 5 minutes.
IUD REMOVAL
Follow the rules for IUD removal: 
• Remove the IUD at the time of menses or at midcycle.
Removal at these times may be easier than at other times
during the cycle.
• Use a paracervical block to make the removal easier for both
the provider and the client. A block is especially helpful for
clients who are prone to fainting, have severe cramps, or are
nulliparous.
• Apply gentle, steady traction to prevent the string from
breaking during IUD removal.
• If you do not see the strings, probe for them in the cervical
canal with narrow forceps (or the alligator forceps).
• If you cannot remove the IUD with gentle traction, use a
tenaculum to steady the cervix and reduce the anteversion or
retroversion to assist removal. If this does not work, dilate
the cervix with dilators. Dilators should always be available
in a clinic that manages IUD complications. For difficult
removals, use a laminaria tent to dilate the cervix. 
• When the IUD (with or without its strings) is in the uterus,
probe the endometrial cavity with alligator forceps (with
which the strings or the IUD itself may be grasped), a hook,
uterine packing forceps, or a Novak curette. Proficiency in
removing the IUD with one of these instruments when the
strings are absent or entirely within the uterine cavity can
prevent unnecessary hospitalizations.
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MANAGING PROBLEMS AND FOLLOW-UP
Serious side effects and complications from IUDs are usually pre-
ventable. The rule of thumb is when in doubt, take an IUD out. Seven
potential complications from IUDs are listed in order of increasing
severity.
SPOTTING, BLEEDING, HEMORRHAGE, AND ANEMIA
The average user of a nonmedicated IUD has an increase in
blood loss, which is usually minor and of little consequence. However,
10% to 15% of IUD users will have their IUD removed because of
symptoms and signs associated with bleeding or spotting. Before
inserting an IUD, make the patient aware of the likelihood of bleeding
changes. Abnormal bleeding can also be a sign of pregnancy or infec-
tion—two problems that must always be ruled out during the process
of evaluating IUD clients.
1. If the patient has a
hemoglobin (Hgb) level
of less than 11.5 gm at
insertion
• provide her with FeSO4* (300 mg) 
to take 1 tablet daily for 1 to 2 months
• instruct in proper nutrition, including
iron-rich foods
• repeat Hgb at 3 month follow-up
• reassure the patient that the bleeding 
will likely decline in subsequent cycles
• provide FeSO4* (as in step 1)
• provide ibuprofen† 400 mg t.i.d. for 
first 3 days of cycle
• examine for other pathology 
and/or symptoms such as:
— cancer of the cervix and uterus




— dysfunctional uterine bleeding
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2. If within 3 months of 
insertion the IUD user 
complains of excess bleed-
ing
• reassure the patient that the bleeding
will likely decline in subsequent cycles
• provide FeSO4 (as in #1)
• provide ibuprofen* 400 mg t.i.d. for
first 3 days of cycle
• perform Hgb and treat as steps 1, 6 and 8
• examine for other pathology and/or
symptoms such as:
— cancer of the cervix and uterus




— dysfunctional uterine bleeding
3. If at any time the 
excess bleeding is associ-
ated with pain
• examine the patient to rule out a 
pelvic infection
• consider a sensitive pregnancy test 
to rule out pregnancy (including 
ectopic pregnancy)
4. If the Hgb is less than 
9 gm
• remove IUD
• provide FeSO4 (300 mg) 
daily for 2 months
• repeat Hgb at 1 month
• provide alternative method of 
contraception
5. If there is a Hgb fall of 
>2 gm
• remove IUD
• treat as in #4
6. If bleeding is thought 
to be associated with 
endometritis
• remove IUD
• culture for gonorrhea
• treat with antibiotics (Doxycycline 
for 10 days)
• treat partner 
• provide an alternative method of 
contraception
414 FAMILY PLANNING METHODS AND PRACTICES:  AFRICA
CRAMPING AND PAIN
The patient may feel slight pain at the time of insertion of an
IUD. She may continue over the next 10 to 15 minutes to feel cramp-
ing pain, which soon disappears. Increased menstrual pain (dysmenor-
rhea) may accompany IUD use. Approximately 15% to 40% of IUD
removals are for complaints related to pain. Cramping and abdominal
pain may be a sign of pregnancy or infection, two problems you must
always rule out when evaluating IUD users with abdominal pain.
7. If the client desires 
IUD removal because 
bleeding is not tolerable
• remove IUD
• provide alternative method of 
contraception
8. If the client is over 40 
years old and having pro-
longed menses with inter-
menstrual bleeding
• remove the IUD
• refer for diagnosis and treatment 
if abnormal bleeding continues
*Ferrous gluconate is also acceptable, may be less expensive, and may cause less gastric upset.
†Ibuprofen is an example of one of the nonsteroidal antiinflammatory drugs that can reduce cramping 
and bleeding.
1. Pain with sounding 
of the uterus during 
insertion
• sound slowly and gently
• consider smaller sound
• if severe, stop and check the align-
ment of the uterine cavity, if the cav-
ity is normal, use a paracervical block
2. Cramping/pain 
immediately after inser-
tion, for a day or so 
thereafter and/or with 
each menses
• if severe:
 — consider IUD removal
• if mild:
— provide mild analgesia such as 
acetaminophen 1 gm, every 
4 hours as needed, or ibuprofen 
400 mg, every 4 hours as needed
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3. Pain at time of inser-
tion, persistent and 
increasing, plus addi-
tional signs of abdomi-
nal tenderness
• if strings are present:
— presume partial perforation has
 occurred; remove IUD and treat as 
 pelvic infection
• if strings are present but the IUD is 
not:
— consider the possibility of perfora
tion (see IUD removal section)
— remove the IUD
4. Partial expulsion of 
an IUD
• if there is no infection of cervix or 
uterus:
— insert another IUD
— provide 5-7 days of Doxycycline,
 100 mg every 12 hours
• if there is an infection of the cervix or 
uterus or the possibility of infection:
— remove the IUD
— provide alternative contraception
— treat with antibiotic as above and
insert another IUD after 3 men-
strual cycles
5. Pelvic inflammatory 
disease
• remove IUD, treat as described in the 
section on PID
• provide alternative contraception
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EXPULSION OF THE IUD (PARTIAL AND COMPLETE)
From 2% to 10% of IUD users spontaneously expel their IUD
within the first year. The symptoms of an IUD expulsion include
unusual vaginal discharge, cramping or pain, intermenstrual spotting,
postcoital spotting, pain during intercourse (male and female), length-
ening of the IUD string, and presence of the hard plastic of the IUD
at the cervical os or in the vagina. If in examining the patient you do




• give spirits of ammonia by nasal 
inspiration
• if placement is improper:
— remove the IUD, reevaluate
the uterus, resound, and insert 
another IUD
• if the IUD is felt to be properly 
positioned and the client's pulse is 
less than 60:
— consider giving atrophine
0.4-0.6 mg intramuscularly or 
intravenously
— consider using a paracervical block
— provide pain medication (i.e. 
acetaminophen or ibuprofen)








• treat according to the section on 
Pregnancy
1. If the IUD string is 




2. If a menstrual period 
is delayed
• check for the IUD string and evaluate 
for a pregnancy because this may be 
the first indication of a “silent” expul-
sion and pregnancy
3. If partial expulsion • remove the IUD
• evaluate for pregnancy and/or 
infection
— if present, treat as indicated
• if neither pregnancy nor infection are
present, insert another IUD and give 5 
to 7 days of Doxycycline 100 mg every
12 hours
4. If the expulsion is 
complete
• evaluate for pregnancy
• insert another IUD if patient is not 
pregnant and has no infection
1. Partner is 
irritated by string
• counsel partner at time of insertion that 
he may feel the string, but it usually 
won’t hurt him
• if the string has a short, sharp point com-
ing from the cervix
— the string may be cut shorter and the 
 new length carefully recorded
— the IUD may need to be removed and 
 replaced, and the new string made 
 longer
• if the string is long: 
— try shortening the string
— occasionally, the IUD needs to be
 removed (see next set of instructions)
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2. String is long • rule out expulsion by exam and by 
sounding of cervix
• if the IUD seems to be in place: 
trim the string
• if there is any doubt about the IUD 
being in place: 
— remove the IUD and replace with a 
new IUD
3. String is absent 
(as determined by 
patient or examiner)
• if menses has been missed: 
— rule out pregnancy by exam and 
 test. If both are negative, evaluate as 
noted below. If pregnancy is detected, 
consult the next section.
• if menses has not been missed and no 
abdominal pain is present: 
— use another method of contraception 
 and wait until next menses; examine 
 during next menses
• if the IUD string is not present, then 
prepare the cervix as per IUD insertion 
technique and explore the uterus with 
alligator forceps
i) if the IUD is 
found:
• if the IUD does not seem to be disturbed, 
reposition the string, treat the patient 
with antibiotics, and follow the patient 
routinely
• if there is any question of IUD dislodge-
ment or abnormal placement or position, 
remove the IUD, treat the client with an 
antibiotic, and insert another IUD
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PREGNANCY
Approximately one-third or fewer of IUD-related pregnancies are
attributable to undetected or partial expulsions. Abortion and severe
pelvic infection are more likely if the IUD is left in place during a
pregnancy. About 5% of pregnancies will be ectopic.
• Inform the patient of the risks from a pregnancy with an
IUD in place.
• If abortion is a legal option, determine whether the patient
wishes to continue the pregnancy. If the woman is pregnant
and the IUD has completely perforated the uterus and is in
the abdominal cavity, there may not be any risk to the preg-
nancy. As the degree of perforation is usually not known,
treat the condition as though the IUD were in situ and the
string not seen. 
ii) if the IUD is 
not found:
• refer the client to a higher level facility
• obtain an ultrasound (or X-ray)
a) if the IUD is not seen on ultrasound 
or X-ray:
 — do a pregnancy test
 — insert another IUD per insertion 
guidelines
b) if the IUD is seen on the ultrasound:
— clarify the location of the IUD 
and rule out perforation; 
 may need to insert another IUD; 
take an x-ray or ultrasound of 
the pelvis
— if perforation has occurred, treat 
it accordingly
— if no perforation has occurred, 
then the x-ray should show 2 
IUDs in the uterus (usually both 
will have to be removed and 
another inserted)
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1) If the patient is under-
going a spontaneous 
abortion:
a) If the patient is in 
severe pain:
b) If the patient is 
anemic:
• empty the uterus of conception 
products
• remove the IUD
• provide doxycycline or ampicillin for 
7 days
• check for an ectopic pregnancy
• provide analgesic medication
• give FeSo4
2) If the patient requests 
an abortion
• refer for a legal abortion
3) If the woman wishes 
to continue the preg-
nancy and the IUD 
strings are visible
• remove the IUD
• warn the patient that an ectopic 
pregnancy should be suspected 
• refer the patient for prenatal care
4) If the patient wishes 
to continue the preg-
nancy and the IUD 
strings are not visible
• if signs of an intrauterine infection 
exist:
— counsel the patient about the 
life-threatening situation
— recommend evacuation of the
uterus and treat the patient with 
antibiotics
— evacuate and examine the tissue to 
rule out ectopic pregnancy
— refer the patient for special 
obstetric care 
• if no signs of infection exist:
— inform the patient to watch for 
signs of infection (such as pain, 
discharge, bleeding, fever, muscle 
aches) and of ectopic pregnancy 
and instruct her where to go 
should those complications occur
— refer the client for prenatal care
— warn the client about the possibil-
ity of perforation
— recover the IUD at delivery
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UTERINE PERFORATION, EMBEDDING, AND 
CERVICAL PERFORATION
The incidence of perforation is approximately 1 in 1,000. Perfo-
ration of the uterus by an IUD usually occurs at one of three sites: (1)
in the uterine fundus, (2) in the body of the uterus, or (3) through the
cervical wall itself.  The following guidelines should be used in cases of
perforation.
1) IUD plastic device 
sticking through the 
cervix
• perform a paracervical block, if needed,
to perform the procedure
• provide analgesia
• use alligator forceps to grasp the IUD
inside the cervix in the lower uterine
cavity, push the IUD back into the
uterus, and then remove it through the
cervical os
• treat with antibiotics
• provide alternative contraception or in-
sert a new IUD 
2) IUD string does
not allow IUD to 
be removed with 
significant pressure
• try the recommendations in the section
on String Problems
• provide a paracervical block
• if the IUD is found in the uterus:
— use alligator forceps to grasp the
IUD in the cervix or uterus and
remove
• if the IUD is not removable, refer the 
client for more specialized care
• if the IUD is not found in the uterus or
cervix (and the string is seen):
— refer the client to a gynecologist
— provide an alternative method of
contraception
— provide an antibiotic 
This is one circumstance where expert help
is truly required, because the IUD may be
out of the uterus.
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PELVIC INFLAMMATORY DISEASE (PID)
PID is a serious complication either from the IUD itself or from
exposure to an STI. PID due to the IUD occurs most commonly in
the first few weeks following insertion. Regardless of cause, PID needs
aggressive treatment and follow-up to be certain it is adequately
treated. An IUD should not be reinserted in someone at high risk for
developing another pelvic infection. In any patient, wait at least 3
months following treatment for an acute pelvic infection before you
insert an IUD. The accurate diagnosis of PID is difficult, but the fol-
lowing signs suggest PID:
• An oral temperature of 38˚ C or above
• Suprapubic tenderness and guarding
• Tenderness or pain while moving the cervix during pelvic
exam
3) IUD perforation 
identified by X-ray or 
ultrasound and no 
string visible
• if the client has pain, evidence of bowel
obstruction or pelvic infection
— refer the client to a gynecologist or
a general surgeon
— treat with antibiotics; surgery may
be required
• if the client has no pain or evidence of
obstruction, infection, or pregnancy
— provide the patient with alternative
contraception
— inform the patient of signs of
obstruction or pelvic infection or
where to go if those signs develop
• if the client is pregnant and the IUD is
outside the uterus
— provide information as per 
pregnancy with IUD in situ
Surgery may be an elective alternative.
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• Purulent discharge from the cervix
• Tenderness of the uterus to palpation
• Adnexal tenderness or adnexal palpable mass or masses
Generally, it is best to treat PID by removing the IUD and giving
the woman appropriate antibiotics. If the IUD is left in place, follow-
up may be inadequate and a smoldering infection may persist that can
progress from endometritis to a more generalized infection. Following
an episode of PID, women who want subsequent children should be
encouraged to use a method other than an IUD. Pelvic infection dur-
ing pregnancy can be extremely dangerous. 
If the IUD is left in place while the PID is being treated, give a
full 10 to 14 days of antibiotics. Reexamine the patient after she has
completed her course of treatment. Because the Dalkon Shield is asso-
ciated with a very high risk of PID, any woman still using a Dalkon
Shield should have it removed. 
A chronic, foul vaginal discharge in an IUD user is considered to be PID
until proven otherwise.  
Figure 15:5: Remove the IUD with the first episode of pelvic 
inflammatory disease
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1) If patient is pregnant 
and has symptoms of PID
• see the section on pregnancy
2) If patient has mild 
pelvic infection, which is  
defined as a fever of 38˚ C 
or lower; no abdominal 
guarding; mild suprapu-
bic, uterine, and/or adn-
exal tenderness; and no 
adnexal masses
• remove the IUD
• provide alternative contraception
• provide treatment (see Chapter 6)
• reexamine in 1 week
• advise the patient to seek immediate care
if symptoms worsen
3) If the patient has 
moderate pelvic infection, 
which is defined as a fever 
lower than 39˚ C; 
abdominal guarding; and 
no rebound, adnexal 
masses, or vomiting 
• follow the same directions as in #2
• consider hospitalization
4) If the patient has a 
severe pelvic infection 
with a fever greater than 
39˚ C; guarding or  
rebound, pelvic masses, 
or vomiting and/or 
appears acutely ill
• refer her for hospital care 
This is a serious, life-threatening problem
that needs expert care.
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INSTRUCTIONS FOR USERS
After you have your IUD inserted:
1. Check your strings. Before you leave the office or clinic, learn how
to feel the strings that protrude 2 inches or so into the vagina. If you
cannot feel the strings or if you can feel the plastic part, your IUD
may not be protecting you against pregnancy, and you should use
another method until you can return to the clinic to have your IUD
checked. Your uterus can expel an IUD without your knowing it.
Check for the strings frequently during the first few months you have
the device, after each period, and any time you have abnormal cramp-
ing while menstruating.
2. Beware of infection. When your IUD is inserted, find out where
you can go to be treated if you get an infection. If at any time you have
fever, pelvic pain or tenderness, severe cramping, or unusual vaginal
bleeding, contact your clinician immediately because you may have an
infection. IUDs can cause internal pelvic infection (in contrast to vag-
inal infections) that can lead to chronic pain, hysterectomy, or even
death. Women in mutually faithful relationships appear to have little
increased risk of infection.14 
3. Watch for your periods. If you miss a menstrual period, contact
your family planning worker immediately. The most commonly
reported side effects of the IUD are increased menstrual flow, men-
strual cramping and spotting, and increased mucous discharge.
Remember that if you cannot tolerate the IUD, you can always have it
removed. Heavier menstrual bleeding may be serious if you are ane-
mic. However, a small increase in the menstrual flow is normal with
the IUD, especially during the first 2 to 3 periods.
No matter what other methods of contraception a woman is 
using, if she is at any risk because her partner tests HIV positive 
or because she does not know her partner’s HIV status, 
she should be advised to use latex or plastic condoms with 
every sexual act.  No other contraceptive method besides 
abstinence provides the same degree of protection.
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4. Do not try to remove the IUD yourself. Do not let your partner
pull on the strings. The clinician will have a better idea of the angle at
which the IUD went in. It should come out the same way.
5. Learn and pay attention to the IUD Warning Signs.
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A 24-year-old man who had sexual intercourse with several 
women was worried about sexually transmitted infection. 
Although the doctor found him to be free of any sexually trans-
mitted infection, he learned how uncomfortable the anxiety of 
unprotected sex could be. For two years he used condoms and 
reduced his number of sexual partners.
When the young man married, his wife was an 18-year-old 
woman who had never had intercourse. Because he felt familiar 
with condoms, the couple began their married life using them 
for contraception. Although they remain mutually monoga-
mous, the husband and wife continue using condoms because 
they learned that condom use can be a positive experience and 
that condoms are effective, easy to use, safe to use, and conve-
nient.
 
Condoms are a safe, easy, and effective method of preventing preg-
nancy and the most effective means other than abstinence of prevent-
ing sexual transmission of the human immunodeficiency virus (HIV)
and other sexually transmitted infections (STIs). Next to withdrawal,
condoms are the only readily reversible method of birth control for
men. In this chapter, condom refers to the male condom, a sheath that
covers the penis. The female condom, discussed in Chapter 17 on


























Condom use has become increasingly important in preventing
HIV infection. In Africa, most HIV infections are transmitted by sex-






Because most infected per-
sons have no symptoms for several years, they are unaware of their
infection. Condoms can be used for protection during intercourse
with an HIV-infected person or with a person whose HIV status is
unknown. Although rates of condom use have been low in many areas







beginning to use condoms because of HIV education and prevention
programs, campaigns promoting positive images of condoms, and




Client counseling and education is important for promoting the use of
condoms. First, assess the client's level of knowledge and familiarity
with condoms. Can the client get condoms easily? Is the couple will-
ing to use them? The list of barriers to condom use may be extensive,
and complicated, particularly in areas where condom use is very low,
and they may be personal or socioeconomic. For example, condoms
may be difficult to get because sources, such as drug store dispensaries
or family planning clinics, are not convenient. The price of condoms
could be too high for the client. Some couples may falsely believe that
condoms cause major side effects and are, therefore, unsafe to use.
Others may believe that condoms contribute to impotence (the loss of
erection). Second, show clients the correct method of applying the
condom on a model of a penis and encourage the client to try this
also. (See the section on “Instructions for Using Condoms.”)
In some societies, the use of condoms may be associated with
promiscuous sexual behavior or involvement with prostitution. Today,
however, many sexually active couples use condoms simply for effec-
tive pregnancy protection. Of course, using condoms to protect
against infection is a responsible and necessary act. Table 16:1 lists









Table 16:1 Myths and facts about condom use
 
Myth or Rumor Fact
 
Condoms decrease sexual 
enjoyment for couples
Some men say they have decreased enjoyment 
when using condoms.  However, many couples 
enjoy sexual relations more when using 
condoms because they avoid the fear of 
unplanned pregnancy, and infection.  Condoms 
also make erections last longer for some men.
Only prostitutes and 
promiscuous persons use 
condoms
All around the world, couples use condoms to 
prevent pregnancy.  Any sexually active couple 
may choose condoms for family planning or to 
prevent infection.  
 
It should not be assumed that 
someone who uses a condom has a sexually 
transmitted infection.
 
Condoms make men impotent Condoms may actually prolong intercourse for 
the couple and prevent premature ejaculation.  
Condoms do not cause impotence.
Condoms are unsafe for the 
human body.
Condoms very, very rarely cause medical side 
effects in users.
Condoms show that a man does 
not really trust his partner.
By using condoms, a man shows his partner that 
he cares about her health and welfare.
Condoms show that a woman 
does not really trust her partner.
Using condoms shows that a woman cares about 
the health and welfare of the man, herself, and 
any infant’s that could be conceived.  Using 





not to take liberties with other women just 
because he uses condoms.
The condom might get lost 
inside the woman.
The condom very rarely falls completely off the 
penis during intercourse.  If it does, the condom 
can be easily removed from the vagina.
Condoms do not work. Condoms are very effective in preventing 
pregnancy and infections.  
 





























The condom is a sheath that fits over the penis. The condom prevents
pregnancy by blocking the man's sperm from reaching an egg that has
been released from the woman's ovary. For the condom to effectively





of intercourse. Most condoms are made from rubber and are called
"latex" or "rubber" condoms, but some of the newer condoms being
developed are made of plastic. A small percentage of condoms are
made from the intestine of lambs and are known as "skin" condoms.
Although all condoms can prevent pregnancy, only latex or plastic con-
doms are recommended if the couple desires protection from infection.
Condoms are available in varying sizes, shapes, colors, thick-
nesses, with or without lubricants or spermicides, and with or without
reservoir tips or nipple ends. Some condoms are covered with a lubri-
cant to make entry of the penis into the vagina easier. This lubrication
may decrease the chance of breakage.
 



























































 correctly. The pregnancy rate for couples who use
condoms every time they have intercourse and correctly follow the
instructions each time is estimated to be 3% per year of use.  This has




. It is important to understand what
the method failure rate represents. It does not mean that 3 of every
100 condoms used will lead to unintended pregnancy. What it does
mean is that only 3 of 100 couples who use condoms the right way
every time they have sex will experience an accidental pregnancy in the
first year. If each couple had sex twice per week, the 100 couples
would have had intercourse 10,400 times over the course of a year.
Three pregnancies resulting from approximately 10,400 acts of inter-
course is a remarkably low pregnancy rate per condom used (0.03%). 
  The low method pregnancy rate for condoms is due, in part, to
their high quality. Laboratory tests are conducted on samples of con-
doms from each batch to assess physical characteristics such as
strength and the presence of holes. If the sample condoms do not meet
the minimum test requirements, the batch is discarded. They are not
distributed to clients or providers. In Africa, all condoms that are
donated by the U.S. Agency for International Development (USAID)
have passed United States and international standards for condoms.
The rate of accidental pregnancy for couples who do not use con-





. This user failure rate is estimated to be
14%, more than four times as high as the method failure rate. Most
pregnancies among condom users occur because the condom is not




 time they have intercourse.  
Couples can further increase the condom's effectiveness against
pregnancy by combining condom use with simultaneous use of a second
contraceptive method such as pills, spermicide, foam, or vaginal suppos-
itory. If two methods are correctly used, the risk of pregnancy is dramat-




























Although users often fear that the condom will break or fall off during
intercourse, studies show that these events rarely occur when condoms
are used properly.  Many studies conducted in economically developed
countries have shown that the incidence of condom breakage and slip-
page during vaginal intercourse can be very low. Typical studies indi-
cate that the rate of breakage for good quality condoms is less than 3
or 4 condoms per 100 condoms used, although rates as low as 1% to




Not every condom break occurring during sex leads to pregnancy
or infection. Results from one U.S. survey found only 1 pregnancy






Furthermore, not every con-
dom break will result in HIV infection. The risk of HIV infection
after a single exposure (e.g., after a condom break) to unprotected










Prevention of Sexually Transmitted Infections 
 







herpes simplex virus, chlamydia, cytomegalovirus,




Three studies of couples in which one partner had HIV and the
other did not have shown that condoms are most effective when used
consistently and correctly with each act of intercourse.
 
13-15 In one
study, there was no seroconversion among the 124 couples who used
condoms consistently, but 10% of partners seroconverted among the




 In a similar study, the
seroconversion rate was 2% among the consistent condom-using cou-










Condoms can also be used during other sexual activities, such as
oral sex and anal sex. Like vaginal sex, these types of sex can result in




Condoms may have desirable effects in addition to their benefits
as a contraceptive:
• Help the man to maintain an erection and help prevent or treat





• Provide immediate, visible proof of effectiveness because the ejac-
ulate is contained within the condom
 
Condoms for women's health
 
Four key points are essential for understanding the importance 
of condoms in sexually transmitted infection (STI) prevention:
1. Bacterial and viral STIs, such as gonorrhea and chlamydia, 
are typically more damaging to the reproductive tract of the 
woman than to the man. 
2. Infected men transmit bacterial lower genital tract 
infections (e.g., gonorrhea) to two out of three female sex 
partners. Infected women transmit these STIs to one out of 




3. Condoms help protect women from unplanned pregnancy, 
ectopic pregnancy, vaginitis (lower tract infection), pelvic 
inflammatory disease (upper tract infection), infections that 
can harm a fetus during pregnancy or delivery, tubal infertility, 
genital cancer, and HIV infection.
4. It is a woman's right to insist on condom use. It is a woman's 


























• Encourage male participation in contraception and securing pro-
tection from infection
• Provide a barrier for women and men who do not wish to have
the penis or semen in direct contact with the vagina
• May be a more accessible method of contraception because an
examination, prescription, or fitting is not required; in addition,
condoms can be obtained by both men and women
• Are generally inexpensive and may often be obtained for free
• Provide an option, with virtually no side effects, for women who






The condom may be extremely attractive to the following
groups:
• Persons at risk of getting or passing STIs, including HIV
(these persons include sexually active men and women who
live in areas with high rates of STIs)
• Users of other contraceptive methods (e.g., hormones, vagi-
nal methods, and sterilization) who may be at risk for HIV
or other STIs
• Couples who wish to avoid an unplanned pregnancy
• Clients who are beginning use of other contraceptive meth-
ods (e.g., pills) and who have been encouraged to initially





On the whole, condoms are associated with few disadvantages, and
those usually have relatively minor impacts on health. They may:
1. Reduce feeling and sensitivity for the male, although no objec-








that sensitivity can be increased by applying a thin layer of
lubricant on the head of the penis before putting on the con-
dom)
2. Interrupt sexual spontaneity because the condom must be
put on before intercourse (having the woman put the con-
dom on the man may help to overcome this problem)
3. Rarely cause allergic reactions (to latex)
4. Embarrass either partner to suggest or initiate condom use,
or to obtain condoms
5. Occasionally slip off or break during intercourse
6. Deteriorate if stored in too much heat, sunlight, or humidity
7. Occasionally result in the man being unable to maintain an




Condoms are used around the world by married couples. Using con-
doms does not mean a person is promiscuous or involved in prostitu-
tion.
The most important message to convey is that the condom must




 act of intercourse to effectively
prevent pregnancy and STIs. Do not assume that the client knows
how to correctly use a condom, regardless of the client's past condom
experience. The client may be using them incorrectly each time, which
can lead to pregnancy or infection. It is important that providers and
clients completely understand the instructions on how to use a con-
dom that are presented at the end of this chapter. Several mistakes
commonly made by condom users include the following:
• Not having a condom available when needed
• Starting intercourse without a condom on the penis, then
interrupting intercourse to put on the condom (or deciding
not to use the condom at all)


























• Not holding the rim of the condom when withdrawing the
penis from the vagina, causing condom slippage and leakage
• Forgetting to use the condom altogether
When possible, provide clients with enough condoms so that
they will not need to visit the clinic frequently to get more condoms.
The supply of condoms given to the client should be based on his/her
needs. (A 3-month supply is typically 25 to 50 condoms.) Family
planning providers should know the following:
• Condoms may be obtained free of cost from many public
family planning programs, government dispensaries, and
depot holders. It is important to provide several months'
supply of condoms to clients to encourage their ongoing use,
particularly if they are difficult for the client to obtain.
• Generally, condoms must be supplied to clients at each clinic
visit.
• Good-quality condoms will likely promote good condom
use. In very hot or humid climates, it may be necessary to
improve storage areas to maintain the condom's integrity.
• Condoms can be carried without damaging them for a
month or so in purses or wallets. Carrying condoms does not







  Innovative programs have been shown to dramatically increase
the use of condoms, particularly when men believe that other men in




Social marketing of condoms for HIV prevention has been
implemented in many African countries, including Benin, Burundi,
Cameroon, Ethiopia, Liberia, Nigeria, Sierra Leone, Tanzania,
Uganda, Zaire, Zambia, and Zimbabwe, to make condoms more












One important feature of successful public sector condom distri-
bution programs is the provision of a large number of condoms to
each client. Providing only a few condoms to a client is a very short-
term solution, particularly for clients who find it difficult to get to
health care facilities or who find it embarrassing to return repeatedly
for condoms. In the private sector, where commercial retail sales
through "drug stores" are a major source of condoms, cost may be a
constraint to continued condom use for some clients. However, con-
doms can be obtained freely or cheaply from many sources. 
Tens of millions of condoms have been dispensed in some Afri-
can countries. Among the most creative marketing or public awareness
efforts of condom distribution have been the following:
• In Kigali, Rwanda, an HIV counseling and testing program
offered free condoms and spermicide and showed a video-
tape about the acquired immunodeficiency syndrome
(AIDS) to clients.  This led to increased rates of condom use
among women, where one year into the program, 22% of





• In Uganda, a USAID program called "AIDS in the Work-
place" taught facts about HIV transmission at worksites and





• In Zaire, condoms are extensively advertised and promoted
through television, radio, and posters for family planning




• In Kenya, more than 100,000 condoms have been distri-
buted through a program that places condom vending




























INSTRUCTIONS FOR USING CONDOMS
 
When you have sexual intercourse, the condom provides a barrier
between the penis and the vagina. The most important instruction for





 time you have intercourse.
1. Use latex or plastic, not skin, condoms if you want protec-
tion from HIV infection and STIs.





 the penis is inserted into the vagina. 
3. Unroll the condom down to the base of the penis. (See Fig-
ure 16:1.) If you find that the condom will not unroll
because it is inside out, do not flip it over. Turning it over
may expose your partner to germs and sperm. Discard the
condom and start with a new one. 
4. Make sure that the vagina is well lubricated before penetra-
tion. A condom may be more likely to tear if the vagina is
dry. If extra lubrication is needed, use water, a water-based
jelly, or contraceptive foam, gel, or cream. Do not use petro-
leum-based products with latex condoms; they can weaken
the condom and make it more likely to break during use. 
5. After intercourse, as the penis is pulled from the vagina, hold
the rim of the condom against the base of the penis to pre-
vent spilling any sperm. The penis should be removed from
the vagina soon after ejaculation—if the erection is lost, the
condom can slip off and pregnancy or infection can result.
6. After the penis has been removed from the woman and is
clearly away from the vagina, slowly slide the condom off the
penis without spilling semen. Discard the condom. 
7. If the condom breaks, falls off, leaks, or is not used, immedi-
ately put spermicidal foam, gel, or a suppository into the
vagina (if spermicide is available and you have not already
done so). If spermicide is not available, quickly wash both








fertilization or infection. See your health care worker as soon
as possible; you may be able to get emergency contraceptive
(postcoital) pills if you do not already have them on hand. 
8. Store condoms in a cool, dry place away from direct sun-
light. Heat may cause the rubber to weaken, so don't store
condoms in a place that becomes very hot. If the condoms
are kept dry, sealed, and away from heat, sunlight, humidity,
and fluorescent light, they will generally last at least 3 years.
The date printed on the package of the condom is generally
the date of manufacture, unless it is marked “exp”, which
indicates the expiration date.
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Vaginal Barriers and 
Spermicides
 
She had heard stories of her grandmother and her grandmother's 
mother. They had placed objects in their vaginas to prevent preg-
nancy—it was one of the very few methods they had. She was not 
certain how well her grandmother's barriers and chemicals 
worked, but she could understand how the modern-day 
diaphragm and spermicides could help her space her pregnancies. 
Her husband also liked the idea of a natural method, the type 
handed down through generations. Because she and her husband 
felt comfortable with diaphragms and spermicides, they were 
enthusiastic about using these methods correctly and consistently.
 
Since ancient times, women have placed objects in their vaginas to
prevent pregnancy. Today, women have a number of options: barriers
such as the diaphragm, the cervical cap, the contraceptive sponge, and
the female condom; and spermicides such as those found in foams,
creams, gels, and films.
 
OVERCOMING OBSTACLES TO USE OF 
BARRIER METHODS
 
Historically, the use of vaginal barrier methods has been limited in


























experience to fit vaginal devices and provide client instruction. Many
providers also appear to hold undue bias against the use of vaginal bar-
riers. Practical obstacles, such as device and spermicide cost, and the
necessity for cleaning and sterilizing devices used for fitting also may
play a role. Client reluctance to use a method that requires touching
the genital area is often raised as a concern. However, the success of
research trials in Africa evaluating other vaginal devices (such as vagi-
nal rings), and widespread cultural practices such as douching and use
of vaginal products like drying agents in conjunction with intercourse
suggest that this concern may not accurately reflect client issues.
The future role of spermicides and vaginal barrier methods will
depend on research about their ability to prevent sexually transmitted
infections (STIs) and their record of producing irritation. If research-
ers document reduced infection risk with female condoms, and they
find a dose and frequency for spermicide use that does not adversely
effect the risk of transmitting the human immunodeficiency virus




Spermicide products have two components: a chemical that kills
sperm and a base or carrier (foam, cream, jelly, film, suppository, or
tablet). Spermicidal chemicals in products that are available in various
parts of Africa include nonoxynol-9, octoxynol, menfegol, and ben-
zalkonium chloride. These are detergents that kill sperm by disrupting
the sperm cell membrane.
Vaginal barriers, except for the female condom, combine two
contraceptive mechanisms: a physical barrier to shield the cervix and a
spermicide. The presence of a cap or diaphragm device may help to
hold spermicide in place against the cervix. The female condom pro-























Reported pregnancy rates for typical users range from 0% to more
than 50%. Unfortunately, because clinical trials of spermicide used
alone do not meet modern standards for study design and analysis,
comparisons of efficacy between spermicides and other methods, or
between one spermicide preparation and another, is not truly mean-
ingful using reported rates. The pregnancy rate for typical use (26%) is
based on population survey information for spermicide users in the
United States; the rate for perfect use (6%) is an estimate based on
rates reported and rates found for similar methods.
The diaphragm, female condom, and cervical cap provide com-
parable contraceptive efficacy for women who have never been preg-







have been pregnant, the cap is much less effective than the diaphragm
or female condom. Among these women, the typical use pregnancy
rate for cervical cap use (40%) is double that for the diaphragm. The
perfect use pregnancy rate for the cap among parous women is 26%.
Correct placement and timing are important for all these meth-
ods, especially for the spermicides. The spermicide applicator, tablet,
suppository, or film needs to reach the cervix, which for most women
is deep in the vagina. Suppositories, foaming tablets, and films require
adequate time for dissolution and dispersion.
 Most studies indicate that about half the women who become
pregnant do not use their vaginal barrier correctly. 
 
The other half of
reported pregnancies, however, occur despite correct use
 
. Thus it is mis-
leading to teach clients that improper use entirely explains method
failure. Women who are young and have frequent intercourse are at a
higher risk for pregnancy and are also more likely than average women























































Using two methods simultaneously, such as male condoms along
with spermicide, greatly reduces the risk of pregnancy (see Table 17:1).
The chance that both methods might fail at the same time is very low.
This principle also applies to simultaneous use of a vaginal barrier
method along with oral contraceptives or to any combination of
methods except simultaneous use of male and female condoms. That
combination is not recommended because male and female condoms
might stick to each other and cause one or both to dislodge from their
correct positions. Alternatively, a couple could use two methods
simultaneously during the most fertile week in each cycle (beginning 4




















The clinician can play an important role in helping women
decide wisely about these methods and use them successfully:
1. Discuss any characteristics that indicate higher than average




• Frequent intercourse (3 or more times weekly) 
• Age less than 30 years
• Lifestyle or home situation that makes consistent use of
contraceptives difficult 
 
Table 17:1 Perfect, simultaneous use of spermicide and condoms
 
Method Contraceptive failure within 1 year (%)
 
Condoms used alone 3
Spermicide used alone 6
Spermicide and condom used together 0.02
 




















• Previous contraceptive failure (any method) 
• Uncertainty about the decision to avoid pregnancy 
• Desire to delay (rather than prevent) next pregnancy
2. Talk about possible risk factors for exposure to STIs. If her
risk is high, abstinence is the safest option. Encourage use of
latex male condoms as an alternative or in addition to a dia-
phragm or cervical cap. (Female condoms should not be used
simultaneously with male condoms.)
3. Explain the high efficacy of using two methods simulta-
neously (see Table 17:1).
4. Be sure that every woman is aware that her interval of high-





5. Be sure every woman knows about emergency contraception
options for postcoital treatment (see Chapter 13 on Oral
Contraceptives) and has a supply on hand.
Help the woman choose which of the available spermicide or
barrier options is most likely to meet her needs. These methods differ
in characteristics and in rules for their use (see Table 17:2). Such dif-
ferences may make a particular option easier or more appealing for a
specific woman. If the match between the method and the woman's
personal needs and sexual patterns is comfortable, she may be more
likely to use it consistently and correctly. For example, the diaphragm
method may be cumbersome for a woman whose life involves sexual
intimacy primarily on weekends. The need for extra spermicide with
repeated intercourse and the 24-hour maximum wearing time may be
bothersome requirements. A cap that can be left in place with no addi-
tional spermicide may be easier to use correctly. Similarly, washing and
storing a cap or diaphragm and the need to have a tube of spermicide
available may be obstacles for a woman who is not at her own home or
does not have access to privacy for washing or storage. The contracep-
tive sponge is easy to use but has not had a consistent production




























Spermicides and vaginal barrier methods have many advantages that
make them reasonable for both temporary and long-term contracep-
tion. Spermicides and female condoms can be purchased without a visit
to the clinician, and a woman can take full responsibility for their use.
Spermicides can be used without any help or cooperation. These meth-
ods are a good back-up for women who are just beginning another
method, do not have their other method with them, or want extra pro-
tection.  Spermicides can be used as an emergency measure if a condom
breaks.  An application of spermicide should be quickly inserted in this
instance. Spermicides can be used to provide lubrication during inter-
course and can appropriately be used for lubrication with a condom.  A
vaginal barrier can be available for immediate protection whenever
needed, no matter how long the interval between uses.
 




Pelvic exam required for fitting Yes Yes
Spermicide needed with insertion Yes Yes
Additional spermicide needed for 
repeated intercourse
Yes No
Supplies needed to add spermicide after 
initial insertion
Yes No
Container needed for storage after use Yes Yes
Can be used during menses No No
Duration of protection after insertion 6 hours 48 hours




















There are very few medical problems that might make use of
spermicides or vaginal barriers unwise. Vaginal barriers do not cause
systemic side effects and do not alter a woman's hormone patterns.
For women who are not at risk for STIs, particularly HIV, and who
have access to safe abortion in case of failure, the medical safety of























Laboratory research shows that nonoxynol-9 is lethal to the
organisms that cause gonorrhea, genital herpes, trichomoniasis, syphi-







spermicidal chemicals, such as octoxynol, benzalkonium chloride, and
menfegol, have similar chemical properties and are also effective






Good results in a labora-
tory test tube, however, do not mean that spermicide products can
provide reliable protection in actual use. Even when used correctly, a
vaginal product might fail to protect. For example, a spermicide might
not completely spread through the vagina. Also, using spermicide
causes changes in the normal bacteria of the vagina and in the normal






both of which could interfere with a
woman's natural defenses against infection. Research indicates that
such changes actually do increase risk for urinary tract infection (see
Disadvantages and Precautions, below). Spermicide chemicals also can
cause vaginal irritation, which could increase the user's susceptibility
to infection. Although most of the studies in this area have addressed
nonoxynol-9, similar results should be expected with the other sper-



















Spermicides and vaginal barriers appear to have some efficacy


























Many studies show that women who use these methods have a slightly







that combine a physical barrier, such as the diaphragm or male con-




Research has also confirmed lower risks for pelvic inflammatory dis-






as well as a






Because infection with certain
types of human papillomavirus (HPV) is linked to the most common
form of cervical cancer, the diaphragm may help reduce cervical cancer
risk by lowering the chance of HPV infection.
The female condom, too, may help reduce the risk of STIs.
When used correctly, the female condom shields both the woman and
the man, and traps semen inside the condom. The female condom is
made of polyurethane, which is impermeable to bacteria and viruses.
Protection against the spread of trichomonas infection has been






but studies to document reduced


























Human studies of HIV or AIDS risk in relation to spermicide
use are very limited, and results have been contradictory. The first
study of HIV seroconversion rates and possible spermicide effects
involved 138 sex workers in Nairobi; contraceptive sponges contain-
ing 1,000 mg of nonoxynol-9 were compared with a placebo vaginal
cream that contained no spermicide. Use of spermicide sponges did
not lower the risk of HIV seroconversion, and women using the sper-
micide sponges had more frequent genital irritation and ulceration






This result is of great concern because dis-







in this study, however, had very frequent intercourse, using 14 sponges
per week on average. Thus their total exposure (dose and frequency) to
spermicide was very high.
Two other small studies of HIV infection rates are more encour-






















found that use of nonoxynol-9 suppositories was associated with
reduced incidence of HIV infection; the other reported a similar bene-
fit for Zambian women with HIV-positive partners.
 
12
Several researchers have confirmed that spermicide produced irri-
tation even when women did not have intercourse and have begun to







In a study that provided careful examination, including
colposcopy, irritation effects were documented after daily (or more fre-
quent) use of suppositories containing 150 mg of nonoxynol. The 35
women who used spermicide suppositories every other day in this





It may be that spermicide use is beneficial when the frequency
and dose are moderate but not when the dose is high or use is very fre-
quent. Further research is needed to provide assurance that spermicide
use is not harmful and to better define an optimal dose range and fre-









Skin irritation is the most common problem associated with spermi-
cides and vaginal barriers that involve the use of spermicide. Some
women have cramps, bladder pain, or rectal pain when wearing a dia-
phragm or cap, and men occasionally report penile pain during inter-
course. For diaphragm users, a different size or rim type may resolve
these problems.
Foul odor and vaginal discharge are likely to occur if a diaphragm
or cap is inadvertently left in the vagina for more than a few days.
These symptoms disappear after the device is removed. Rare cases of
vaginal trauma, including abrasion and laceration, have been reported
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Vaginal and Urinary Tract Infections
Sexual intercourse is followed by increased vaginal colonization
with Escherichia coli. Compared with oral contraceptive users, women
who use spermicide alone or in combination with condoms have a
prolonged shift in normal vaginal bacteria; among diaphragm users
the shift if even more prolonged.16,30  This finding is of concern
because bacterial vaginosis may be associated with increased risk for
upper genital tract infection,4 and because it may account for the
increased risk of urinary tract infection (UTI) observed among
women who use the diaphragm or condoms with spermicide.14 The
pressure a diaphragm rim places on the urethra also may contribute to
the risk of developing UTI for some women. 
Women who have used sponges containing nonoxynol-9 spermi-
cide have reported an increased incidence of symptomatic candidiasis
(yeast).22,30 Increased vaginal colonization with Candida species has
been documented after using a diaphragm with spermicide.15 Candida
is much more resistant to the microbicidal effects of nonoxynol-9 than
are other normal, desirable vaginal organisms such as lactobacillus.21
Toxic Shock Syndrome
Toxic shock syndrome (TSS) is an extremely rare but serious dis-
order caused by toxin(s) released by some strains of Staphylococcus
aureus bacteria. Patients using vaginal barriers need to be aware of the
TSS danger signs, and instructions for using the particular method
should be consistent with recommended TSS precautions.33
Systemic Effects
Serious adverse reactions have not been reported for nonoxynol-9
and octoxynol. In animal studies, large doses of nonoxynol-9 have
been associated with liver toxicity and embryotoxic effects.2 Three
studies in humans reported possible adverse associations between sper-
micide exposure and birth defects,17,18,31 but these studies appear to
have had serious methodologic problems. Subsequent research has
not found adverse fetal effects associated with spermicide use.8,13,34,37
Thus, experts believe no true association exists between spermicide use
and fetal defects.8,13,34
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Precautions
The following conditions may make vaginal barrier methods
inadvisable:
1. Allergy to spermicide, rubber, latex, or polyurethane or irri-
tation symptoms related to use of the method
2. Abnormalities in vaginal anatomy that interfere with satisfac-
tory fit or stable placement
4. History of toxic shock syndrome
5. For the diaphragm, repeated urinary tract infections that
persist despite efforts to refit the diaphragm 
6. For the diaphragm and cap, lack of trained personnel to fit
the device and provide instruction
7. For the cap, full-term delivery within the past 6 weeks or
recent spontaneous or induced abortion (caps should not be
used during vaginal bleeding from any cause, including men-
strual flow)
8. For the cap, known or suspected cervical or uterine malig-
nancy, an abnormal Papanicolaou (Pap) smear result, or vag-
inal or cervical infection
9. For spermicides, caution in using these agents is indicated
for a woman who is at high risk for STIs and HIV infection,
or who would need to use the method very frequently (more
than every other day)
PROVIDING VAGINAL BARRIER METHODS AND 
SPERMICIDES 
SPERMICIDES
When providing spermicides in a clinical setting, reinforce instruc-
tions for proper use and remind the user about common errors that
can lead to unintended pregnancy.
454 FAMILY PLANNING METHODS AND PRACTICE:  AFRICA
Foam
Foam is marketed to be used alone, but it can be used satisfacto-
rily with a diaphragm or with a condom. 
Creams and gels
Creams and gels are commonly marketed for use with a dia-
phragm, but they also can be used alone. One application of foam,
cream, or gel provides 80 to 150 mg of spermicide, depending on the
product. Spermicide concentration is 12.5% in foam and ranges from
1% to 5% in gels and creams.
Suppositories and foaming tablets
Spermicide suppositories are intended for use alone or with a
condom. Suppositories provide 100 to 150 mg in a 2.3% to 8.3%
concentration. Allow enough time between insertion and intercourse
(10 to 15 minutes depending on the product) for the suppository to
melt or foam up.
Film
Vaginal contraceptive film can be used alone or with a diaphragm
or condom. Each 2" x 2" paper-thin sheet of film is 28% spermicide
and contains 72 mg of nonoxynol-9. The sheet must be inserted on or
near the cervix (or inside the diaphragm) at least 5 minutes before
intercourse to allow time for the sheet to melt and spermicide to dis-
perse. Placing film on the tip of the penis for insertion is not recom-
mended as a way to use this method because the film will not have
adequate time to dissolve and because the film may not reach its
proper position.
VAGINAL BARRIERS
Make sure the woman can insert and remove her device correctly.
Stress the importance of consistent, correct use, and explain how to
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use spermicide, if it should be used with her barrier. Be sure the
woman understands when to remove her barrier. A female condom
should be removed immediately after intercourse; the condom should
be twisted during removal to trap semen inside. A diaphragm or cervi-
cal cap, on the other hand, must be left in place for at least 6 hours
after intercourse. Remind diaphragm and cap users about TSS danger
signs (see Instructions for Patients in the following section). 
Female condom
The female condom is a thin (0.05 mm) polyurethane sheath,
7.8 cm in diameter and 17 cm long. This soft, loose-fitting sheath con-
tains two flexible polyurethane rings. One ring lies inside the vagina
and serves as an insertion mechanism and internal anchor. The other
ring forms the open edge of the device and remains outside the vagina
after insertion (see Figure 17:1). The external portion of the device
covers part of the perineum. Intended for one-time use, the device
should not be used in conjunction with a latex male condom.
The female condom provides protection for one act of intercourse. It
can be inserted any time (up to 8 hours) before intercourse and must
be removed immediately after intercourse.
Diaphragm
This dome-shaped rubber cup has a flexible rim; it is inserted
into the vagina before intercourse so that the back rim rests in the pos-
terior fornix and the front rim fits snugly behind the pubic bone. The
dome of the diaphragm covers the cervix. Spermicidal cream or jelly is
placed inside the dome prior to insertion.
Once in position, the diaphragm provides effective contraceptive
protection for 6 hours. If a longer interval has elapsed before inter-
course, inserting additional, fresh spermicide with an applicator (with-
out removing the diaphragm) is recommended. An additional
applicator-full of spermicide is recommended whenever intercourse is
repeated. After intercourse, the diaphragm must be left in place for at
least 6 hours. Wearing it for longer than 24 hours is not recommended
because of the possibility of TSS.
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Figure 17:1 Reality female condom
Diaphragms are available in sizes ranging from 50 to 95 (diameter
in mm) and in several styles (see Figure 17:2). The very sturdy arcing
spring rim has firm spring strength. Most women can use this style com-
fortably. The arcing spring rim can often be used successfully even if a
woman has a rectocele, cystocele, or lax vaginal muscle tone. The thin
flat spring rim has a gentle spring strength that is comfortable for
women with very firm vaginal muscle tone. The sturdy coil spring rim
has a firm spring strength suitable for a woman with average muscle
tone and an average pubic arch depth. A plastic diaphragm introducer
(see Figure 17:3) can be used with coil or flat spring styles, but not the
arcing spring rim. The wide-seal rim has a flexible flange approximately
1.5 cm wide attached to the inner edge of its rim. The flange is intended
to hold spermicide in place inside the diaphragm and to create a better
seal between the diaphragm and the vaginal wall. Wide-seal diaphragms
are available with either an arcing spring rim or a coil spring rim.
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Figure 17:2 Types of diaphragms
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Fitting a Diaphragm. Diaphragm manufacturers produce sets of fit-
ting rings that are sample diaphragm rims with no dome. However,
fitting rings are not adequate for patient practice. Whole diaphragms
should be used for fitting so that the patient can practice insertion and
removal with the sample diaphragm. To estimate the diaphragm size
that will be needed:
1. Insert your index and middle fingers into the vagina until
your middle finger reaches the posterior wall of the vagina.
2. Use the tip of your thumb to mark the point at which your
index finger touches the pubic bone. 
3. Extract your fingers. 
4. Place the diaphragm rim on the tip of your middle finger.
The opposite rim should lie just in front of your thumb. 
Insert a sample diaphragm of the size you have selected into cor-
rect position in the patient's vagina. The device should rest snugly in
the vagina, its rim in contact with the lateral walls and posterior
fornix, but without tension against the vaginal walls. There should be
just enough space to insert one finger tip comfortably between the
inside of the pubic arch and the anterior edge of the diaphragm rim.
Choose the largest rim size that is comfortable for the patient.
Try more than one rim size or type before making a final selection. Do
not choose a size that is too small, because vaginal depth increases dur-
ing sexual arousal (3 to 5 cm in nulliparous women), and a diaphragm
that is too small may slip off the cervix. A diaphragm that is too large
may create vaginal pressure, abdominal pain or cramping, vaginal
ulceration, or recurrent UTIs.
Disinfecting Diaphragm Fitting Samples. After each fitting, always
wash and disinfect the sample devices:
• Wash with soap and water, and then auto clave at 121
degrees Centigrade, 15 pounds per square inch (psi) for 20
minutes unwrapped or 30 minutes wrapped; or soak in a
solution of one part chlorine bleach to nine parts water for
30 minutes, rinse with water, then soak in alcohol solution
(70% isopropanol or 80% ethanol) for 15 minutes after each
use.23
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Cervical Cap
The cervical cap is a deep, soft rubber cup with a firm, round rim
(see Figure 17:4). The Prentif cap has a groove along the inner circum-
ference of the rim intended to improve the seal between the inner rim
of the cap and the surface of the cervix. One-third of the cap’s dome
should be filled with spermicide before the cap is inserted; the spermi-
cide is held in place against the cervix until the cap is removed.
Figure 17:4 Two cervical caps
The cap provides continuous protection for 48 hours, no matter
how many times intercourse occurs. Additional spermicide is not nec-
essary for repeated intercourse. Because of the possibility of develop-
ing TSS, wearing a cap for longer than 48 hours is not recommended.
Some women experience odor problems with prolonged use.
Fitting a Cervical Cap. Because of variations in normal anatomy and
the limited number of cap sizes available, it will not be possible to fit
every patient properly. When a Prentif cap is fitted correctly, the inner
diameter of the cap rim must be almost identical to, or just a few mil-
limeters larger than, the base of the cervix. The rim forms a seal with
the cervical surface. The Prentif cap rim should rest at the base of the
Prentif® Cavity Rim Cervical Cap
Dumas Cap
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cervix so that the vaginal walls surround the outer side of the rim. A
Dumas cap rim should rest snugly in the vaginal fornices, close to the
base of the cervix. With either cap, the cervix should be completely
covered. The dome of the cap should be deep enough so that it does
not rest on the cervical os. 
A Prentif cap that is too tight can cause cervical trauma, and one
that is too loose or fails to make a secure seal over the entire circumfer-
ence of the cervix will be more likely to dislodge. A woman whose
uterus is acutely anteflexed, so that her cervical portio faces downward
toward the back of her vagina, may find that her cap (Prentif or
Dumas) dislodges. To fit a cap: 
1. Perform a bimanual exam to determine the position and size
of the uterus and cervix. 
2. Inspect the woman's cervix to estimate the proper cap size.
For a Prentif cap, the cervix must be fairly symmetrical and
without extensive laceration or scarring that could interfere
with uniform contact between the cap rim and cervix around
its full diameter. The cervix must also be long enough to
accommodate the height of the cap. A cervix that is flush or
partially flush with the vaginal vault cannot be fit with a
Prentif cap. In this situation, however, a Dumas cap may fit
properly.
3. To insert the cap, fold the rim and compress the cap dome so
that when it is released in place over the cervix, the unfolding
dome can create suction.
4. Check the fit with one finger around the rim of the cap. For the
Prentif cap, be sure there are no gaps between the cap rim and
the cervix.  Check to see how easily the cap can be dislodged.
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5. Check for evidence of suction after the cap has been in place
for a minute or two. Pinch the cap dome and tug gently. The
dome should remain collapsed, and the cap should resist the
tug and not slide easily out of position. 
6. Try to rotate the cap in place. If it does not rotate at all, it is
too tight; if it rotates too easily or comes off the cervix, it is
too large. 
7. To remove the cap, probe the rim with the end of your index
finger; tip the cap rim to break the seal, then gently pull the
cap down and out. 
8. Try two or more cap sizes to determine the fit.
New cap users should try the cap initially while still using
another method of birth control, such as condoms or oral contracep-
tives, to be sure that the cap remains in position after intercourse.
Disinfecting Cap Fitting Samples. After each fitting, always wash
and disinfect device(s):
• Wash with soap and water, and then auto clave at 121
degrees Centigrade, 15 pounds per square inch (psi) for 20
minutes unwrapped or 30 minutes wrapped; or soak in a
solution of one part chlorine bleach to nine parts water for
30 minutes, rinse with water, then soak in alcohol solution
(70% isopropanol or 80% ethanol) for 15 minutes after each
use.23
Contraceptive Sponge 
The sponge is round, dimpled, and made of polyurethane. It
contain one gram of nonoxynol-9. The sponge protects for up to 24
hours, no matter how many times intercourse occurs. After inter-
course, the sponge is left in place for at least 6 hours. After one 24-
hour period of use, the sponge must be discarded.
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MANAGING PROBLEMS AND FOLLOW-UP
Women using spermicides or vaginal barrier methods do not need spe-
cial follow up unless they experience difficulties using their method or
have symptoms of irritation, UTI, or possible TSS. After pregnancy,
users should have their diaphragms and caps refitted.
Watch for symptoms that may be related to use of spermicide
and barrier methods. In many cases, the woman may not suspect that
her medical problem could be related to the method:
• Recurrent vaginal irritation, with no evidence of vaginal
infection, may indicate allergy or sensitivity to spermicide or
to latex. Changing to a different spermicide product may
resolve the problem, but if it does not, the woman should
avoid further exposure. Special warning is indicated for any
woman who develops irritation: because susceptibility to
infection with HIV may be increased, it is essential to avoid
any possible exposure to STIs.
• Recurrent UTI, recurrent yeast infection, or bacterial vagino-
sis may be associated with using a diaphragm. In some cases,
providing a smaller diaphragm size, a different rim style, or a
cervical cap resolves the UTI problem. If the woman contin-
ues to have infections, she should switch to a another method
of contraception that does not require use of spermicide.
A vaginal barrier user who develops signs or symptoms of TSS
requires urgent, intensive evaluation and treatment. Treat the patient
with antibiotics, and follow her carefully. If her symptoms are severe,
she may need hospitalization. Since women who have had TSS have a
greater risk than other women of getting it in the future, advise your
patient to discontinue barrier methods.
No matter what other methods of contraception a woman 
is using, if she is at any risk because of her partner tests 
HIV positive or because she does not know her partner’s 
HIV status, she should be advised to use plastic or latex 
condoms with every sexual act.  No other contraceptive 
method besides abstinence provides the same degree of 
protection.
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INSTRUCTIONS FOR BARRIER AND 
SPERMICIDE USERS 
1. Use your contraceptive method every time you have inter-
course. Be sure the barrier or spermicide you use is in place
before beginning vaginal intercourse.
2. If you are using a diaphragm, sponge, or cap and have a high
fever and one or more of the danger signs of toxic shock syn-
drome, remove the device immediately and contact your cli-
nician. 
3. Wash your hands carefully with soap and water before insert-
ing, checking, or removing your barrier or spermicide.
4. If you have skin irritation or vaginal irritation, stop using
your contraceptive method; abstain from intercourse or use
an alternative method such as male condoms. If irritation
resolves in a day or two, you can try a different spermicide;
otherwise, see your clinician to be sure you don't have an
infection.
5. If you have repeated bladder or vaginal infections such as
vaginal yeast, discuss this with your clinician. 
6. If you feel unsure about the proper fit or placement of your
barrier, use male condoms and see your clinician.
7. Do not douche right after intercourse.  Douching is not rec-
ommended, but if you choose to do so, you must wait until
at least 6 hours after intercourse, and after you have removed
your device.




n Dizziness, faintness, weakness
n Sore throat, aching muscles and joints
n Rash (like a sunburn)
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8. For extra protection against pregnancy and infection, use
condoms along with your diaphragm or cap.
BEFORE INTERCOURSE 
1. Be sure you have all the supplies you need. If you are using a
diaphragm or cervical cap, you also need spermicidal cream
or jelly. Check to be sure your cap or diaphragm has no
holes, cracks, or tears.
2. Plan ahead about when to insert your method. Follow the
rules for using barriers and spermicides (see below):
USING BARRIERS AND SPERMICIDE
Method When to insert
When to remove 
after intercourse
Number of acts of 
intercourse allowed
Spermicide Allow time for 
product to dissolve 
or spread in vagina
Douching is not 
recommended, but 
if you douche, wait 
at least 6 hours after 
intercourse




Just before or up 
to 8 hours ahead
Immediately after Only 1
Diaphragm Just before or up 
to 6 hours ahead
6 hours after Unlimited with 
additional spermicide
Cervical cap At least 30 minutes 
before
• Leave in for 6 hrs.
after intercourse





Any time before • Leave in for 6 hrs.
after intercourse
• Remove after 24 
hours of wear
Unlimited
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INSERTION 
1. Wash your hands carefully with soap and water.
2. Follow the instructions below for inserting barriers and sper-
micides:
Method Instructions for insertion
Foam Shake the foam container at least 20 times, then use the nozzle to 
fill the plastic applicator.   Insert the applicator deeply into your 
vagina, close to your cervix, then push the plunger.
Jelly or 
cream
Fill the applicator.  Insert as for foam.
Suppository Remove the wrapping and slide the suppository into your vagina. 
Push it along the back wall of your vagina until it rests on or near 
your cervix. 
Film Place one sheet of film on a very dry finger tip and slide it along 
the back wall of your vagina until it rests on or near your cervix.
Female 
condom
Hold the pouch with the open end hanging down. Squeeze the 
inner ring closed. Insert the inner ring and the pouch into the 
vaginal opening and slide it the rest of the way up into the vagina. 
The rim on the open end will stay outside your body. 
Diaphragm Apply a finger length of spermicide inside the dome and around 
the rim. Squeeze the sides of the rim so that the diaphragm folds 
with the spermicide inside. Insert the folded diaphragm in your 
vagina. Push the diaphragm as far as it will go, to the back of the 
cervix. Tuck the front rim behind your pubic bone. Check to be 
sure that your cervix is covered by the soft rubber dome of the 
diaphragm.
Cap Fill one-third of the dome of the cap with spermicide. Fold the 
rim and slide the cap into your vagina as far as it will go. Press the 
rim around the cervix until the cervix is completely covered. 
Sweep your finger around the cap rim to make sure the cervix is 
completely covered. The cervix should not be felt outside the cap. 
Sponge Remove the sponge from the package. Moisten it with a small 
handful of clean water and squeeze it once. Insert the sponge into 
the vagina, with the fabric loop facing toward the outside of the 
body. Sliding the sponge along the back wall, push the sponge to 
the top of the vagina so that it covers the cervix.
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AFTER INTERCOURSE 
1. Remove your female condom immediately after intercourse,
before you stand up. 
2. Leave the cap, diaphragm, or sponge in place for at least 6
hours after intercourse. 
3. It is fine to shower or bathe with a diaphragm, cap, or sponge
in place, but do not use a douche. Douching is not recom-
mended, but if you choose to do so, you must wait until at
least 6 hours after intercourse, and after you have removed
your device.
4. Check the position of your device. If it does not seem to be
in correct position after intercourse, contact your clinician
about emergency birth control. 
REMOVAL
Method Instructions for removal
Female 
condom
Squeeze and twist the outer ring to keep semen inside the pouch.  
Gently pull the condom out of your vagina.
Diaphragm Hook your finger over the front rim or behind it, then pull the 
diaphragm down and out.  Wash the diaphragm with plain soap 
and water and then dry it.  Hold it up to the light to check for 
holes, tears, or cracks.
Cervical cap Locate the cap rim on your cervix.  Press or tip the cap rim until 
the seal against your cervix is broken, then tilt the cap off the 
cervix.  Hook your finger around the rim and pull it sideways out 
of the vagina.  Wash the cap with plain soap and water, and dry it.  
Check the cap for holes, tears, or cracks.
Sponge Gently pull on the fabric loop to remove the sponge from the 
vagina.  Make certain the sponge is whole and no parts are left 
inside the vagina.
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TAKING CARE OF YOUR SPERMICIDE SUPPLIES, 
DIAPHRAGM, OR CAP 
1. Store your supplies in a convenient location that is clean,
cool, and dark. 
2. Wash devices that will be used again. Do not use perfumed
soap or talcum powder.
3. Do not use oil-based vaginal medications or lubricants such
as petroleum jelly, mineral oil, hand lotion, vegetable oil,
cold cream, or cocoa butter or some common vaginal yeast
creams and vaginal hormone creams. If you need extra lubri-
cation for intercourse, try contraceptive jelly or a water-solu-
ble lubricant specifically intended for use with condoms. 
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The woman and her family were undergoing hard times for the 
past 18 months. Because of the chaos in their lives, it had not 
been a good time to get pregnant, she said. At the same time, it 
was impossible to get family planning methods to prevent preg-
nancy because of disruptions in the supply routes. She listened 
carefully to another villager—a traditional birth attendant 
(TBA) who knows about women's cycles. It was from her that 
the woman learned to check her body signs and symptoms and to 
abstain until it was clear that her fertile days had passed. She 
and her husband continued to have sexual relations during the 
time she was not fertile: it helped them feel close and loving and 





 natural family planning,
 
 refers to methods for
planning and preventing pregnancy by observing naturally occurring
signs and symptoms of the fertile and infertile days of the menstrual
cycle. (See Chapter 8 on The Menstrual Cycle and Disturbances.) If
these methods are used to prevent pregnancy, the couple avoids inter-
course on the days during the menstrual cycle when the woman is






























Although sometimes referred to as natural family planning, these
methods are not more "natural" than other methods of contraception.
Some providers prefer the term “fertility awareness” to avoid the sug-
gestion that some methods are more "natural" than others. “Fertility
awareness” is the term used in this chapter. 
Fertility awareness is based on two foundations:
• A scientific knowledge of the anatomy and physiology of the
male and female reproductive systems
• An understanding of the signs and symptoms that occur nat-
urally during the woman's menstrual cycle to indicate when
she is fertile and when she is infertile
 











The calendar rhythm method is based on the fact that most
women ovulate 12 to 16 days before each menstrual bleeding, no mat-
ter how long their menstrual cycle. The fertile phase is identified by
using a mathematical calculation to determine the fertile and infertile
phases. However, many couples who say they use the "rhythm"



















The BBT method is based on the pattern of the body's tempera-
ture at rest. A woman's temperature rises slightly after ovulation and
remains elevated during the rest of her cycle until she menstruates.
Monitoring the rise in temperature makes it possible to determine
when she has ovulated and to calculate when her fertile days have
passed. A woman who uses this method takes her temperature every
day before she rises in the morning and carefully records it on a chart.
She learns how to determine when the temperature shift has occurred.
She abstains from intercourse from the beginning of her menstrual




























The cervical mucus method is based on detecting the changes in
cervical mucus secretions and in the sensations in the vagina. Before
ovulation, the cervical mucus becomes slippery and stretchy. The
mucus changes are greatest around the time of ovulation. After ovula-
tion, cervical mucus becomes thick or may disappear completely. A
couple using this method to avoid pregnancy will abstain from inter-
course when the mucus indicates the woman is fertile. They also
abstain during menstrual bleeding. These couples should avoid inter-
course on alternating days before the appearance of cervical mucus so
that the presence of semen in the vagina does not change the natural










The symptothermal method combines recording the BBT with
observing the cervical mucus and other physical signs of ovulation.
These signs include tenderness of the breasts, midcycle pain, spotting
or bleeding, and abdominal heaviness. A woman also may examine her
cervix for changes in its position, degree of opening, and texture.
When a couple is using the symptothermal method to avoid preg-
nancy, they abstain from intercourse from the first appearance or sen-
sation of wet cervical mucus until after ovulation has been confirmed
by 3 days of elevated temperature or 4 days of post-ovulation mucus.
Abstaining from intercourse on the days of the menstrual cycle
when the woman's signs and symptoms indicate she may become
pregnant is often called “periodic abstinence.” This practice has long
been common in many cultures throughout the world, particularly in
Africa. Unfortunately, periodic abstinence has often been based on a







The challenge to family planning providers is to pro-
vide correct information to African couples and to assist them in


























OVERCOMING BARRIERS TO USE
 
Perhaps the greatest barrier to the use of fertility awareness is that both
clients and providers often lack the knowledge needed to use it effec-
tively. Many women (and men) actually know very little about the
physiology of reproduction. This barrier of ignorance leads to a second
barrier: teaching takes time, and time is a scarce resource for many
health care providers.
Overcoming a lack of knowledge about fertility is important.
Family planning workers can hold group classes just before or after a
session of individual visits. They can also ask knowledgeable clients to
be volunteer class leaders. Traditional birth attendants (TBAs) can be
asked to teach the women whose infants they deliver. On a commu-
nity level, teachers and family planning workers can instruct students
in schools and workers in places of employment.
Another barrier to using fertility awareness is that people have a
prejudice that traditional methods are not as effective as modern ones.
Yet, when the modern methods are not available because the client or
the family planning distributor has run short, traditional methods
such as those based on fertility awareness or withdrawal may be the




Fertility awareness methods are based on two major facts:
• The man's sperm can live in the woman's reproductive tract
for 3 days.





If the couple can estimate when a woman will ovulate at least 4
to 5 days in advance
 
10 and if they can identify when ovulation has
occurred, they can then adjust their sexual practices, depending on


















Effective use of fertility awareness methods requires that couples
understand how to identify fertile days and then appropriately adapt
their sexual behavior. Unintended pregnancies are primarily related to
the user rather than to the method itself. A sizable but unknown por-







Experts at the World Health Organization suspect that
sexual risk-taking during the fertile days accounts for more accidental











Among perfect users, the first-year pregnancy rate should be
much lower, ranging from 1% to 9%. However, some versions of the
method are more effective than others. The calendar rhythm method
would be least likely to predict fertile days accurately and has a first-year






In contrast, when used per-
fectly, the symptothermal method has a first-year pregnancy rate of 2%
and the cervical mucus method has a first-year pregnancy rate of 3%.
Perfect use means that the couple does not have intercourse on the
days their method indicates the woman will be fertile. Imperfect use
means that unprotected intercourse occurs during the fertile time.
Special consideration must be given to women who are breast-
feeding. A breastfeeding woman often has mucus that indicates fertil-







ultrasound to detect ovarian activity have shown that breastfeeding
women experience different patterns of follicular development before






(See Chapter 12 on Lactation and
Postpartum Contraception.) According to studies conducted in
Kenya, Chile, and the United States, breastfeeding women have an
increased risk of unplanned pregnancy (versus nonbreastfeeding
women) when using the cervical mucus method. However, because
breastfeeding in itself decreases fertility, women who were using the
cervical mucus method while breastfeeding had a pregnancy rate com-






























1. Fertility awareness methods produce no physical side effects.
Surveys in many African countries indicate that fear of side
effects is an important reason why women do not use contra-
ceptives.
2. Use of fertility awareness can increase a woman’s self-aware-
ness and couple’s knowledge of the woman's reproductive
system. The woman observes her signs and symptoms of fer-
tility, and a couple gains the information necessary to prac-
tice fertility awareness. Programs in numerous African
countries report that clients are highly interested in and
capable of learning this information.
3. Fertility awareness users develop self-reliance when they have
learned to use the method correctly and do not need to
depend on a family planning program or other source to pro-
vide contraceptives. This is particularly important in Africa,
where family planning services are not available in many
areas and systems for distributing contraceptives are often
unreliable.
4. Fertility awareness entails no cost once the couple has
learned to use the method, unless they are using a tempera-
ture-based method requiring a special thermometer.
5. Fertility awareness requires the man's involvement in family
planning. Several studies of family planning in Africa stress
the importance of male involvement in effective family plan-
ning.
6. While fertility awareness services must be provided by
trained fertility awareness teachers, numerous studies have
shown that community-level personnel, including those with
low literacy, can provide services successfully. Many regions
in Africa have a shortage of skilled medical personnel.






















1. Most couples require at least 3 cycles to use the cervical
mucus method or the symptothermal method correctly.
During the time a couple is learning these methods, they
need frequent contact with the fertility awareness teacher.
When the teacher and client are far apart, as is true in many
rural areas, the need for frequent contact can be an obstacle.





ners are important. Many family planning professionals have
expressed concern about the difficulty of involving men,
especially when the method requires abstinence.
3. The woman must observe and note her fertility signs and
symptoms. For women who lack privacy or who are not liter-
ate, record-keeping may be difficult. Some programs have
developed simplified record-keeping systems. In some set-
tings, programs have developed systems in which the couple
does not need to maintain written records.
4. Fertility awareness methods are less forgiving of user errors,
which means they are less effective than some other methods
of family planning. Studies are needed to determine the
actual use effectiveness of all user-dependent family planning
methods in Africa.
5. When fertility awareness methods are used to prevent preg-
nancy, some couples experience emotional stress as a result of
not being able to have intercourse for several days of the
woman's cycle. In some cultures, it may be acceptable for the
man to have sexual relationships with more than one
woman. In these cases, abstinence may apply only to the
woman and not to the man (this practice could increase the
risk of sexually transmitted infections).
6. Use of fertility awareness methods does not directly protect
against sexually transmitted infections, including HIV. In
areas of high levels of sexually transmitted infections, meth-


























In cultures where abstinence pertains only to the woman, the
man's sexual practices with an alternative partner could
increase the spread of infections.
It has long been thought that if the ovum or sperm is aged,
there is more chance for abnormal development of the
embryo. Two recent studies of pregnancies among women
using fertility awareness methods showed no excess risk of
spontaneous abortion or birth defects in pregnancies con-








Women with the highest risk of reproductive morbidity or mor-
tality should be advised to use the most effective methods for avoiding
pregnancy. For these women, fertility awareness methods may not be
appropriate. In addition, experience has shown that women who are
partially breastfeeding, have infections that produce a vaginal dis-
charge, or experience irregular cycles may have more difficulty using
the method than do healthy women with regular cycles.
Women or couples who have the following characteristics are less
likely than other couples to be able to use fertility awareness methods
successfully:
• Inability to communicate about sexual matters
• Unstable relationship
 
No matter what other methods of contraception a woman 
is using, if she is at any risk because her partner tests 
HIV positive or because she does not know her partner’s 
HIV status, she should be advised to use plastic or latex 
condoms with every sexual act. 
No other contraceptive method besides abstinence 
















• Inability or unwillingness to observe, record, and interpret
fertility signs and symptoms
• Inability or unwillingness to abstain from sexual intercourse
during the fertile phase of the woman's cycle
 
PROVIDING FERTILITY AWARENESS METHODS
 
Surveys in several African countries indicate that many couples use
periodic abstinence as their primary method of avoiding pregnancy. Data
from recent Demographic and Health Surveys are shown in Table 18:1.
The women interviewed for these surveys gave several reasons for
using periodic abstinence, ranging from fear of side effects from mod-
ern methods to religious beliefs to the unavailability of other methods.
Although educational programs to dispel myths and expanded efforts
to increase the availability of modern methods are important (and are
under way in several countries), they are a long-term investment and
likely to have limited impact in Africa during the next decade. So, in
the short term, fertility awareness methods will remain important.
 
Table 18:1 Percent use of family planning and periodic abstinence 







Periodic abstinence as 
% of family planning
 
Burkina Faso 10 4 40
Cameroon 14 7 50
Ghana 20 8 40
Kenya 33 4 12
Senegal 7 1 14
Tunisia 51 7 14
Uganda 15 4 27
 


























Efforts must continue to improve their quality, the public’s knowledge
of them, and the effectiveness with which they are used.
There are also other reasons for supporting the use of fertility
awareness methods in Africa—they may fit well within traditional cul-
tural practices, and using these methods does not require highly skilled
medical providers (although fertility awareness teachers need to be
well trained and supervised). Fertility awareness methods can meet the
needs of couples who live in areas remote from family planning ser-
vices or in areas where distribution systems cannot guarantee a con-
stant supply of contraceptives. Fertility awareness also can be a
low-cost approach when viewed from both the individual family or
the national perspective: there are no imported commodities to buy






















Two issues related to the effectiveness of fertility awareness meth-
ods have particular relevance for Africa: development of services and




A study of fertility awareness programs in Zambia and Liberia
found that women’s risks of unintended pregnancy depended on age,
breastfeeding status, urban/rural residence, employment status, whether
they enrolled when the fertility awareness program was just beginning







The most significant factor for successful use of fertility
awareness methods was the time at which the women enrolled in a pro-
gram. Those who enrolled when the program was just beginning (and
thus had less well developed services) were at significantly higher risk of




Fortunately, a significant effort has been made to develop fertility
awareness programs in Africa. Programs now exist in virtually all
countries in the region and can serve as direct service providers or
















suffer from a lack of funding and technical assistance, they can be
expected to increase the effectiveness of fertility awareness methods in
Africa during the next decade.
 
Availability of trained fertility awareness teachers
 
Fertility awareness is an education-based method rather than a
commodity-based service. Having a knowledgeable, competent
teacher is essential. Teachers in many African countries have been
trained by trainers based outside the region. Only recently have a sig-
nificant number of in-country teacher training programs been devel-
oped; however, follow-up with trainers remains a challenge.
 
INSTRUCTIONS FOR USING FERTILITY AWARENESS 
METHODS
 
Fertility awareness methods increase a woman’s knowledge of her body
and her menstrual physiology, and education and knowledge are two
important ingredients for effective family planning. However, these














Use a standard calendar or a menstrual diary. Record the length
of each menstrual cycle over the most recent cycle or the next 6 to 12
cycles. Call the first day of bleeding in each cycle day 1. The last day of
each cycle is the day before the next menstrual bleeding.
• To find the earliest day on which you are likely to be fertile,
subtract 18 days from the length of your shortest cycle. 
• To find the first day you are no longer likely to be fertile,
subtract 11 days from your longest cycle.
If, for example, your menstrual records show that your shortest
cycle was 27 days and your longest cycle was 30 days, the first fertile








LANNING METHODS AND PRACTICE:  AFRICA
no longer likely to be fertile will be day 19 (30 - 11 = 19). In this case,
you would abstain from day 9 to day 19 of your cycle. Table 18:2
shows the fertile phase, depending on cycle length.
Table 18:2 How to calculate your fertile period
If your shortest 





If your longest 





21* 3rd 21* 10th
22 4th 22 11th
23 5th 23 12th
24 6th 24 13th
25 7th 25 14th
26 8th 26 15th
27 9th 27 16th
28 10th 28 17th
29 11th 29 18th
30 12th 30 19th
31 13th 31 20th
32 14th 32 21st
33 15th 33 22nd
34 16th 34 23rd
35 17th 35 24th
*Day 1 = First day of menstrual bleeding.
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BASAL BODY TEMPERATURE METHOD
During your menstrual cycle, your basal body temperature (BBT),
which is the temperature of your body at rest, rises at least 0.3-0.5o C.
This rise is called the thermal shift.  Ovulation most often occurs on the
day of the thermal shift, 1 to 2 days before the shift, or the day after.
To use this method, follow these directions:
1. Do not have intercourse from the first day of menstrual
bleeding until the thermal shift has occurred and your tem-
perature has stayed at or above the higher level for 3 consecu-
tive days.  To determine your temperature:
• Take your temperature before rising each morning (at the
same time each day) for the first 10 days of the menstrual
cycle.  Record the temperature in the special BBT chart.
• Look at the chart (see Figure 18:1 for an example) to find
the highest of the normal temperatures during the first 10
days of your cycle, but disregard any that are abnormally
high because of fever or other disruptions.
• Draw a line 0.15o C above the highest of these 10 temper-
atures. This line is called the cover line, or the temperature
line.
• Continue taking your temperature every day until your
third consecutive temperature is recorded above the cover
line.
2. You can have intercourse any time after the evening of your
third consecutive high temperature until the beginning of
your next menstrual bleeding.
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Figure 18:1 Basal body temperature variations during a model 
menstrual cycle
CERVICAL MUCUS METHOD
To use the cervical mucus method, you must observe and record
your cervical mucus signs every day, beginning with the day after your
menstrual bleeding ends. The following rules will help you practice
this method. (See Table 18:3 for a summary of signs and symptoms
during the fertile and nonfertile days.)
1. Do not have intercourse during the days of your menstrual
bleeding.
2. During the early infertile phase of your cycle (before ovula-
tion), you can have intercourse on the evening of every other
dry day (the days when you do not have any cervical mucus
or feel any vaginal wetness). Because semen changes the char-
acter of mucus, it is necessary to check cervical mucus on
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Days of Menstrual Cycle
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3. The first day you have any cervical mucus or notice any vagi-
nal wetness is the beginning of your fertile phase. You should
not have intercourse from the beginning to the end of the
fertile phase.
4. The last day you have cervical wetness or vaginal wetness is
called your peak day. When you stop having wet cervical
mucus or experiencing vaginal wetness, continue to abstain
from intercourse for 3 more days.
5. On the morning after your third day of no wet cervical
mucus or wet vaginal sensation, you can have intercourse
until your next menstrual bleeding begins.
Table 18:3 Summary of cervical mucus method
Approximate cycle day: phase How identified Intercourse allowed?
1–5: Menstruation* Bleeding No
6–9: Dry days Absence of cervical 
muscus
On alternate nights only
10: Fecund period begins Onset of sticky mucus 
secretion (gradually 
becomes slippery over 
following days)
No
16: Peak fecund day Last day on which 
slippery mucus 
(resembling raw egg 
white) is observed
No
20: Fecund period ends Evening of the 4th day 
after the peak day
After fecund period ends
21–29: Safe period From end of fecund 
period until onset of 
bleeding
Yes
*The cycle begins on the first day of menstruation.
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SYMPTOTHERMAL METHOD
The symptothermal method has several variations. To use this
method, you will need to note the length of your most recent 6 to 12
menstrual cycles (see Calendar Rhythm Method), take your tempera-
ture daily (see Basal Body Temperature Method), observe and inter-
pret your cervical mucus (see Cervical Mucus Method), and observe
and interpret other signs and symptoms such as changes in the posi-
tion and firmness of your cervix, breast tenderness, and pain between
menstrual cycles. You will need to record this information on a special
chart and interpret it to determine when you are fertile and when you
are infertile.
1. Begin taking your temperature the first day of menstrual
bleeding and continue taking it as described for the basal
body temperature method. Remember to take your tempera-
ture every morning before rising.
2. After your bleeding stops, you can have intercourse on the
evening of every other (alternate) day during the time when
you do not observe any cervical mucus or feel any wet vagi-
nal sensations or until your first fertile day (as calculated by
subtracting 20 from the number of days of your shortest
menstrual cycle, whichever occurs first).
3. Abstain from intercourse as soon as you observe any cervical
mucus, feel any wet vaginal sensation, or until the day of
your cycle indicated by subtracting 20 from the number of
days in your shortest menstrual cycle.
4. When your mucus stops or you do not feel vaginal wetness,
continue abstaining from intercourse for 3 or more days or
until you have three temperatures above the cover line
(whichever occurs last).
5. You can have intercourse after the third day from the end of
your cervical mucus or vaginal wetness or after your third
high temperature, until the beginning of your next men-
strual bleeding.
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Natural Family Planning Chart
The Menstrual Cycle Chart can help you keep track of your signs
and symptoms. (See Figure 18:2).  The chart can also be used for the
other fertility awareness methods.  Follow these instructions to fill out
the chart:
In the Cycle Length Box 
• Write the number of days in the shortest of your previous six
menstrual cycles.
• Subtract 18 from the length of the shortest cycle, and write
this number in the next small box (for example, 28-18=10).
In the Temperature Box
• Record the time of day you usually take your basal body tem-
perature.
In the Menstrual Cycle Day Box
• The line of numbers at the bottom of the temperature chart
represent the days of your menstrual cycle, starting with the
first day of your period. Each day you have sexual inter-
course, circle the corresponding day of your menstrual cycle.
To Record Temperature
• After taking your temperature each morning, put a circle in
the middle of the square which corresponds to your tempera-
ture on that particular date.
• Connect the dots each day with a straight line.
• After recording your temperature for the first 10 days of the
cycle, draw a horizontal line on the line just above the high-
est of the normal low temperatures recorded during those
first 10 days. This is called the “coverline.”
• Once your daily temperature goes above this coverline, draw
a vertical line just before the temperature rise.
• Count 1, 2, 3 temperatures above the coverline.
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To Record Cervical Secretions
• After checking the feel, look, and touch of your secretions
throughout the day, fill in the box that best describes your
most fertile secretion for that day of your cycle. At the end of
each day, shade only one box to show what your secretions
were like:
Wet, slippery, transparent, or stretchy secretions
Non-wet, white, cloudy, or sticky secretions
Dry, no secretions seen or felt
Period, for days of menstrual bleeding
To Record Changes in Your Cervix
• If you choose to check the cervix, fill in the box that best
describes the most fertile position, feel, and openness of the
cervix. At the end of each day, mark the box for only one of
the following options:
Low, firm, or closed cervix
High, soft, or open cervix
To Record Comments
• Use the comments section at the bottom of the chart to
record other signs of fertility, disturbances, changes in your
daily schedule, and other things that may influence your
interpretation of the chart.
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"We live far from the city. A woman must take one entire day to 
visit the family planning clinic. My son will be married next 
month. I have told him about how he can spill his seed outside 
of his wife. Although modern family planning methods are 
best—my own wife gets the injection—there are times when a 
man and woman feel loving but may have run out of their con-
traception. I pray that my son has a healthy family, and that to 
me means also that the children are wanted. My father told me 
about spilling my seed on the ground, and so I tell my son."
 
Trying to control fertility through coitus interruptus, or withdrawal,
was a natural response to the discovery that ejaculation into the vagina







and played a predominant role in the fertility declines that
took place before modern contraceptive methods were developed.
Although few women report using withdrawal as their primary
method of family planning, many couples have probably used the




























Very few barriers exist to discourage couples from using withdrawal as
a contraceptive method. The primary barrier is probably the attitude
among health professionals that withdrawal is ineffective as a contra-
ceptive. This attitude may be transmitted to men and women in the
community. In reality, withdrawal is a reasonably effective method
that can be used by couples who wish to space births and do not have
contraindications to pregnancy or extremely strong desires to avoid
pregnancy. When pregnancy is definitely not wanted, a more effective
contraceptive is needed. For many couples, however, withdrawal
would have a number of advantages, including its being a traditional
method that is always readily available. The attitudinal barrier could
be overcome by education and counseling. Health professionals and





Coitus interruptus prevents fertilization by stopping contact between
spermatozoa and the ovum. The male partner interrupts intercourse




Although coitus interruptus has often been criticized as ineffective, it
probably offers a level of contraceptive protection similar to that pro-
vided by vaginal barrier methods. Its effectiveness depends largely on
the male's ability to withdraw before he ejaculates. How effective the
method would be if used consistently and correctly is unknown. Our

























As a method of birth control, withdrawal has several distinct advan-
tages. It costs nothing, requires no devices, involves no chemicals, is
available in any situation, and causes no medical side effects. Couples
who cannot or do not wish to use other contraceptive methods and
who can accept the possibility of unintended pregnancy would find
withdrawal an acceptable alternative. It is a back-up contraceptive that




Coitus interruptus has several disadvantages. 
• For some couples, interruption of the excitement or plateau
phase of the sexual response cycle may diminish pleasure. 
• The method does not forgive incorrect or inconsistent use.
• Contraceptive failure may be due to the lack of self-control
that is required to use the method. With impending orgasm,
men (and women) experience a mild to extreme clouding of







The man may feel the urge to achieve deeper pene-
tration as he nears orgasm, and he may not withdraw in time
to avoid depositing semen in his partner's vagina or on her
external genitalia. 
• The couple is not protected from sexually transmitted infec-
tions (STIs), including the human immunodeficiency virus
(HIV). Surface lesions, such as those from herpes genitalis or
human papillomavirus, may be infective. Not only does
unintentional ejaculation pose a risk for infection, but so








have not determined the potential of the pre-ejaculate to
infect a man’s sexual partner. In one prospective study, the
condom failed to protect some sexual partners against gonor-
rhea, because they were exposed to infectious secretions




























A study of stable couples in which the man was HIV-infected but
the woman was not showed that coitus interruptus was somewhat bet-
ter than regular, unprotected penile-vaginal intercourse at keeping the
woman from becoming infected. This method reduced the HIV con-











Still, although coitus interruptus may decrease
HIV exposure by reducing the amount of semen that enters the
vagina, the seminal fluid that emerges from the penis prior to ejacula-




Because a significant number of women have become infected with
HIV while their partners consistently practiced withdrawal, caregivers
or educators should not recommend withdrawal as a method for pre-
venting HIV infection in women. 
Studies that have found withdrawal to be beneficial in reducing
HIV infection looked only at stable heterosexual couples. Findings
from these studies may not hold true for women with several
HIV-infected partners. Finally, coitus interruptus has not been studied
as a way to reduce HIV transmission from women to men, but there is
little reason to assume it would be helpful.
It is possible that the pre-ejaculate fluid sometimes carries sperm
into the vagina. Although the pre-ejaculate, a lubricating secretion
produced by the Littre or Cowper's glands, contains no sperm, a pre-
vious ejaculation may have left some sperm hidden within the folds of
the urethral lining. In one study, researchers found no sperm in 16
samples of pre-ejaculate from men who did have sperm in the ejacu-
late.
 





the pre-ejaculate to be free of spermatozoa in 11 of 11 HIV seronega-
tive men but only 4 of 12 HIV- seropositive men. Although the 8
samples that contained spermatozoa revealed only small clumps of a
few hundred sperm, these might still pose a risk of fertilization. In all
likelihood, the spermatozoa left from a previous ejaculation could be



















The clinician or educator cannot assume that a man already knows
how to use the withdrawal method correctly. Discussion about contra-
ception should, therefore, include instructions for using withdrawal. 
Explain that the couple may have penile-vaginal intercourse until
ejaculation is impending, at which time the male partner should with-
draw his penis from the vagina and away from the external genitalia.
The man must rely on his own sensations to determine when he is
about to ejaculate. Because neither the man nor the woman is likely to
notice the release of the pre-ejaculate, which normally happens just
before full ejaculation, they should not rely on that event as a way of
timing withdrawal. The sexually inexperienced man may find it partic-
ularly difficult to achieve the self-control required to practice with-
drawal. You might suggest that the man practice withdrawal by
bringing himself to ejaculation without his partner’s assistance so that
he becomes more aware of his pre-ejaculatory sensations.
Because sperm may be present in semen left behind in the ure-
thra after ejaculation, suggest that the man urinate after intercourse,
especially if he plans to have intercourse again very soon.
 
INSTRUCTIONS FOR COITUS INTERRUPTUS
 
For centuries, African men have used withdrawal to avoid getting their
partners pregnant. However, the man who uses withdrawal must be
aware of the sensations he feels so he can predict when he will ejacu-
late.
1. Before intercourse, the man should urinate, then wipe off the
tip of the penis to remove any remaining sperm from a prior
ejaculation.
2. When he feels he is about to ejaculate, the man should with-
draw his penis from his partner's vagina, making sure that


























3. Withdrawal is not a good contraceptive method under the
following conditions:
• The man cannot predictably withdraw prior to ejacula-
tion.
• The man intends to have repeated orgasms, which may
cause the pre-ejaculate to contain spermatozoa.
4. Withdrawal does not protect against infection with the
human immunodeficiency virus (HIV); it does not protect
against other sexually transmitted infections (STIs) either,
although the question remains to be studied. Abstinence or
condoms provide far better protection against STIs.
5. Withdrawal is a considerably better method of contraception
than no method at all.
6. The couple should learn the options available for postcoital
protection, should any ejaculate come in contact with the
vagina. The couple should have available a supply of emer-
gency contraceptive pills, birth control foam, or some type of
spermicide in case of unintentional ejaculation in or near the
woman's vagina. The woman should use the spermicide as
quickly as possible after ejaculation. (Despite the optimism
of this suggestion, it is probably too late to stop some sperm
from swimming up into the uterus and to protect against
STDs, including HIV.)
 
No matter what other methods of contraception a woman 
is using, if she is at any risk because her partner tests 
HIV positive or because she does not know her partner’s 
HIV status, she should be advised to use latex or plastic 
condoms with every sexual act. 
No other contraceptive method besides abstinence 
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I find that a number of clients who come to the clinic are in 
relationships that involve significant periods of abstinence. I 
make certain that I encourage couples who abstain.  Abstinence, 
with back-up contraception or protection for sexually transmit-
ted infections, is one of the most effective methods I recommend 
in my practice of family planning.
 
Throughout history, sexual abstinence has probably reduced fertility







sexual intercourse for a number of reasons. Some freely choose absti-
nence within a relationship; others choose it by not pursuing a mate.
Some abstain because cultural practices place taboos on intercourse
before marriage or postpartum. Others may have a sexual dysfunction





For some individuals, such as the unmarried, abstinence is not only
encouraged, but expected. Some other individuals, however, face sig-





Providers need to overcome their biases about an































Couples need to communicate. Individu-
als who wish to abstain because of a physical problem, for
example, need to tell their spouses. Fear of an unwanted





The mythologies about abstinence are not true: those
who practice abstinence do not “dry up,” are not necessarily






Cultural and familial expectations that a mar-
ried person must engage in sexual intercourse are often
strong. In some cases, couples may need to communicate
about what abstinence means in their relationship—is the
abstinence short term, for the duration of the postpartum
period, or for the long term, as happens in cultures that
expect an older woman to stop having sexual relations alto-
gether? In other cases, where the roles of husband and wife
are largely defined by the expectation of sexual intercourse,
negotiations about the timing and frequency of intercourse,




The definition of abstinence varies according to each individual or
culture. Some people define abstinence as refraining from all sexual
behavior, including masturbation. Others define abstinence as refrain-
ing from any sexual behavior involving genital contact. In this chapter,
abstinence is defined as refraining from vaginal or anal intercourse.
Contrary to popular belief, both men and women who abstain can
still be sexual. Touching—for nurture, solace, communication, simple
affection—can be very sensual. Most people enjoy sexual touching,










When practiced perfectly, abstinence is absolutely effective. Among
typical users, however, there may be a risk of pregnancy when a form
of the practice allows semen to come in contact with the woman’s gen-




Abstinence protects against unintended pregnancy. When the only
goal of abstinence is to avoid unwanted pregnancy, the couple can still
engage in other forms of sexual expression, except for penis-in-vagina
intercourse or practices that would allow semen to come in contact
with the woman’s genitalia. 
Abstinence, in some variations, can also protect against sexually
transmitted infections (STIs). Couples need to avoid practices that
bring the partner in contact with body fluids such as pre-ejaculatory
fluid, semen, cervical-vaginal secretions, blood, or open sores.
At times, a medical condition may require abstinence: 
• Postoperative pain or tenderness, such as from episiotomy,
hemorrhoidectomy, vasectomy, other procedures
• Pelvic, vaginal, or urinary tract infection
• Gastrointestinal illness or infection
• Painful intercourse (dyspareunia) or other pelvic pain
• Undiagnosed postcoital bleeding
• Untreated postmenopausal atrophic vaginitis
• The woman in the late third trimester of pregnancy, postpar-
tum, or postabortion
• Postmyocardial infarction
• Certain disabling physical conditions


























• The man or woman (or both) is undergoing therapy for a
variety of sexual problems, such as erection difficulty, orgasm
difficulty, or premature ejaculation
Other reasons for abstaining are personal. Individuals may
abstain to observe religious holidays, to pursue other aspects of a rela-
tionship, to remain faithful to a spouse who is absent, to mourn the
death of a spouse, or any other reasons. Abstinence is a normal choice










In sub-Saharan Africa, abstinence has long been associated with
the postpartum period. The purposes of postpartum abstinence in
many cultures were to protect the newborn infant, because semen was
thought to spoil the mother's milk, and to protect the mother during
a period of recuperation. Many African populations considered absti-
nence not as a means for spacing, but as a way of purifying the
mother’s milk. 







taboos against intercourse have been reduced. Postpartum abstinence




The duration of abstinence among women varies by regional and
cultural practice. In Togo and Ghana, for example, where polygyny
(the husband has more than one wife) is common, the period of post-
partum abstinence may last several months to more than a year. A
study in Zaire found postpartum abstinence to be practiced longer by
women who were poor and less educated, had a large number of chil-







length of postpartum abstinence in a number of African nations is
shown in Table 20:1. 
Postpartum abstinence actually doubles protection against preg-
nancy, because it occurs at the same time that the woman has reduced















Africa, however, a declining use of postpartum abstinence not accom-
panied by an increase in the use of modern contraceptives could mean













In many areas, an unmarried woman is expected to avoid sexual







As many as 60% of unmarried adolescent women in
Botswana, 46% in Liberia, 50% in Kenya, and 44% in Senegal report
having had sexual experience. Still, remains high in other regions, such
as Burundi (91%), Zimbabwe (68%), and Namibia (65%). 
 




Burkina Faso 1993 19
Cameroon 1991 13
Central African Republic 1994-95 10









Senegal 1997  3
Sudan 1989-1990 5
Tanzania 1996 6
Tunisia 1988  3






























Premarital abstinence among unmarried men is encouraged in
some cultures but not in others. Clearly, if both men and women were
expected to abstain before marriage, it would be easier for unmarried





Abstinence has few disadvantages. The primary disadvantage occurs
when one partner wants to be abstinent but the other does not.
Because in most cultures married couples are expected to have sexual
intercourse, spouses may believe their partner does not have the right
to abstain. The partner who wants to be abstinent may have to engage
in sexual intercourse anyway or suffer the spouse’s anger, the threat of
divorce, or a partner’s extramarital affair.
 
PROVIDING CARE TO THE ABSTINENT CLIENT
 
The provider can support a couple's or individual's choice to
abstain. For many people, abstinence is a temporary practice that
ceases once an individual's or couple's situation changes. Thus, the
provider should educate all abstinent persons about the other methods
of birth control and safer sex, including:
• Effective non-prescription methods
• Sources for prescription methods
• Emergency contraception
• STI protection skills to avoid contact with body fluids or
open sores on the genitals (See Chapter 16 on Condoms and








INSTRUCTIONS FOR CLIENTS USING ABSTINENCE
 
1. Decide what you want to do about sex at a time when you
are clear headed, sober, and feel good about yourself. If you
have a partner, decide together at a time when you feel close
to each other but not sexual. For example, try talking while
you take a walk and hold hands.
2. Decide in advance what sexual activities you will say "yes" to
and discuss these with your partner.
3. Tell your partner, very clearly and in advance—not at the last
minute—what activities you will not do.
4. Avoid high-pressure sexual situations; stay sober.
5. Learn about birth control and safer sex so that you will be
ready if you change your mind. Always keep condoms
around. Always.
7. Learn about emergency birth control options and keep a
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"You are wise to think about the health of your family and how 
you can provide for the children you already have," the doctor 
told the couple. "I can tell you that either the man or the woman 
can be sterilized. Both ways are very effective and neither the 
man nor the woman suffers an ill effect on health or on the abil-
ity to enjoy sexual relations."  The doctor explained both tubal 
ligation and vasectomy. Then he left the couple for a little while 
so they could discuss the decision between themselves. Because 
the woman was pregnant, the couple decided she would have a 
tubal ligation just after her child was delivered.
 
In 1990, more than 170 million couples of childbearing age in devel-
oping countries used voluntary surgical contraception (VSC), making
it the most widely used method of family planning in the world.
 
31,32
The popularity of sterilization reflects its effectiveness, safety, and high
client satisfaction. In African nations, however, use of tubal steriliza-
tion remains low and use of vasectomy is under 1%.
Many factors have contributed to the improved safety of VSC
over the past 20 years: improved anesthetic methods, better surgical
techniques and asepsis, increased use of local anesthesia with light
sedation, improved training of personnel, and better selection and


























rable in effectiveness, and both are permanent. If both were equally
acceptable to a couple, vasectomy would be medically preferred,





Access to VSC services depends on the attitude of a particular
country’s government toward population growth, the legality of steril-
ization, and the requirements or conditions that must be met for an
individual (especially a woman) to undergo a sterilization procedure.
Some of these conditions have been established to make sterilization
safer, such as requiring that sterilization be performed by a physician.
Some conditions are aimed at preventing a couple from regretting
their decision to have sterilization, such as requiring that couples be a
minimum age or have a minimum number of living children.  Some
countries require approval of a committee. 
Cultural conditions also influence the use of VSC. For example,
23 sub-Saharan countries require the husband's approval for female
sterilization, and seven countries require the wife's approval for vasec-
tomy.  Niger is unique in that, in addition to spousal consent, a





Misconceptions and cultural and religious barriers prevent many
men from being sterilized. Education and counseling are important
ways of helping men to understand the advantages of vasectomy. For








No. Vasectomy blocks the pathway that sperm use to
get into your semen. Your testicles are not removed or damaged
in any way (find the words in the client’s local language that best


























Vasectomy does not affect your manhood. Your penis
will still become erect like before. You will still produce semen








The operation should have no effect on your ability to

















There are no proven long-lasting effects that have been
seen in vasectomized men. Some report that their wives enjoy sex
more because they are no longer worried about getting pregnant.
 
COUNSELING FOR MALE AND FEMALE STERILIZATION
 
Sterilization is a permanent method of contraception; once the surgery
is performed, the individual cannot simply change his or her mind.
Few male or female VSC reversals are performed in Africa. A number
of circumstances, usually hard to predict, may lead users to regret that
the sterilization procedure was performed: losing their children, get-
ting divorced or remarried, or wishing for additional children.
Make certain the individual correctly understands the procedure
and its consequences. Check your local family planning or maternal
and child health (MCH) service policies and standards for guidelines




Explain that a single decision to undergo steril-





























Explain that infection, bleeding, and complications
of anesthesia may occur, and that there is still a slight chance of future
pregnancy. Inform the client that procedures to reverse sterilization are
expensive, involve major surgery and risk, are not available to every-




 protect against sexually transmitted infections (STIs), including
the human immunodeficiency virus (HIV). Instruct clients to  wear




Discuss alternative reversible contraceptive




Encourage the client to ask questions; discuss
myths and correct misinformation.
 
D = Decision to change.
 
The client must be free to decide





Explain in detail the entire procedure and its
possible side effects. Emphasize the permanence of the procedure.
Explain what is known about effects on future health and sexual
response. Inform the clients of any costs they will bear. Give the client




Make notes of the method and timing











The client must be given sufficient time to make a thoughtful,
informed decision about a permanent method of contraception, espe-
cially if the client is a woman considering immediate postpartum or
postabortion (spontaneous or induced) sterilization. Whenever possi-
ble, the woman should have decided she wants a permanent method
well before delivery or a pregnancy-related procedure. Her decision
may be unduly influenced by the emotional and physical stress pro-



























These times are often ones of stress for a woman.
At the appropriate time, service providers can help by exploring a cou-
ple’s attitudes and mentioning all the options. Make very certain the
couple understands that the method is permanent.
After delivery or abortion, wait to counsel the woman until she is
free of the immediate stresses and not under the influence of sedatives.
If the woman clearly desires no more children, she may be a suitable
candidate for VSC. Where appropriate and possible, include the hus-
band in these discussions. Medical problems such as eclampsia, post-
partum hemorrhage, or intrapartum or postpartum infection require
postponing the VSC procedure until the woman is well enough to
undergo surgery.
Staff should be skilled in explaining and providing alternative
postpartum methods, such as an intrauterine device (IUD) or Nor-
plant, that may be inserted immediately following abortion or child-
birth. Women should feel no pressure to decide on sterilization
because of the unavailability of alternative methods or lack of skill to
provide them. Moreover, delayed VSC services should be available so
that if the client is uncertain or there is a medical contraindication, the
procedure can be comfortably scheduled at 4 weeks or later after deliv-
ery.
If the procedure is delayed beyond 4 weeks after delivery and the
woman is not breastfeeding, advise her to use an effective contracep-










Informed consent to undergo a surgical procedure is the volun-
tary decision made by a person who has been fully informed about the
procedure and its consequences. Provide the information in a language
the client can understand and include all the information listed in the
local family planning or MCH policies and standards as well as in the



























The client, along with the surgeon or an authorized representa-
tive, must always sign or mark the informed consent form.  The
authorized representative may be the person with the primary respon-
sibility for counseling the client. Illiterate clients should mark the
informed consent form with a thumbprint or "X"; a witness chosen by
the client must also sign or mark the form. If possible, the witness
should be of the same sex as the client.
 














Sterilization for women involves mechanically blocking the fallo-






When standard techniques are used, sterilization has a lower risk
of pregnancy than do most temporary contraceptive methods. Preg-
nancy rates for sterilization are similar to rates for some of the long-
acting methods, such as implants, injections, and IUDs. Most studies
of the common occlusion techniques—the Pomeroy and Parkland
techniques, rings, clips, and electrocoagulation—have reported preg-






These rates, however, reflect only the
first year or two after sterilization. In a recent study of more than
10,000 women, cumulative pregnancy rates exceeded 1% after 5 years






Sterilization failures may occur for




1. The woman may be pregnant at the time of sterilization.
This situation may be avoided if the sterilization is per-
formed within the first 10 days of the menstrual cycle, if the
patient uses an effective contraceptive until after the steriliza-
tion procedure, or if the patient abstains from intercourse



























errors can be reduced through better training of surgeons,
taking good care of surgical instruments, and accurately
identifying fallopian tubes.
3. Equipment failure can occur when laparoscopic methods are
used.
4. Fistula formation occurs most commonly with the electroco-
agulation method (this method was generally not used in
Africa at the time this book was written).
5. Spontaneous re-anastomosis is related to the method of
occlusion. Carefully using rings, clips, or standard ligation
methods (Pomeroy or Parkland) will decrease the prevalence
of these problems.
The 10-year follow-up of the unipolar and bipolar sterilization
cases in the U.S. Collaborative Review of Sterilization (CREST) study
found higher pregnancy rates with spring clip application and bipolar






The higher pregnancy rates
appeared to be related to surgeon training and to technical problems







trained surgeons, differences in effectiveness rates between occlusion
techniques will probably not be important. However, some techniques
vary in effectiveness depending upon when the woman is sterilized
and which surgical approach is used. (See Occlusion Techniques under
sections Providing Postpartum and Postabortion Surgical Contracep-


























The method is cost effective (when cost is spread over the








































Lovemaking need not be interrupted.
Female sterilization is a safe operative procedure. In developing














Sterilization by minilaparotomy can be per-
formed safely during the immediate postpartum period or in associa-
tion with pregnancy termination, provided that the clients' medical
status is adequately assessed.
Female sterilization is ideal for those persons who are certain they
wish no further children and who need a reliable contraceptive
method. It is also indicated for those in whom subsequent pregnancy



































Sterilization procedures are technically difficult.
 
• The operative procedure requires a surgeon, an operating
room (aseptic conditions), trained assistants, medications,
and surgical equipment.
• The initial expense is high.
• The risk of ectopic pregnancy is high when sterilization fails.
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PROVIDING INTERVAL STERILIZATION
The timing of female sterilization, whether pregnancy-related or
not, is very important in choosing the surgical approach, method of
occlusion, use of counseling, staff and facilities, and organization of
patient flow. Surgical techniques for female sterilization include  (1)
ligation, in which a thread-like material is tied around the fallopian
tubes, (2) mechanical occlusion with clips or rings to close the tubes,
and (3) electrocoagulation (see Figure 21:1). The fallopian tubes are
usually approached through the abdomen via a minilaparotomy inci-
sion or laparoscopy. A surgeon may also perform female sterilization at
the time of a cesarean section or other abdominal surgery. Surgeons
have generally abandoned an approach through the vagina via a colpo-
tomy because of the increased risk of infection and pregnancy.
In the preoperative assessment, make sure the patient has been
appropriately counseled and has consented to surgical sterilization.
Ask about pelvic disease, previous abdominal or pelvic surgery, diabe-
tes mellitus, heart or lung disease, bleeding problems, allergies, and
recent infections. Determine the date of the last menstrual period.
Make certain the woman is not pregnant. When sterilization is per-
formed postpartum or after an abortion, make certain the client has
no pregnancy-related problems and that she is not anemic. Order
appropriate laboratory studies, which usually will include at least a
hemoglobin measurement. Assess the patient's heart, lungs, abdomen,
and her general condition. Perform a careful pelvic examination. Pay
special attention to uterine position and mobility and whether the
patient might have pelvic infection or masses.
Training manuals specific for Africa have been developed by the
Association for Voluntary Surgical Contraception (AVSC) and are
available upon request.3
Suprapubic Minilaparotomy
Suprapubic minilaparotomy for "interval sterilization" (at 4 or
more weeks after delivery) is performed when the uterus is fully invo-
luted. The surgeon makes an abdominal incision 2 to 5 cm in length,
just at the pubic hairline (see Figure 21:2). When healed, the incision
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Figure 21:1 Tubal sterilization techniques
lies within the hairline and is not visible. Using the minilaparotomy
technique may be difficult if the woman is obese, if the uterus is
immobile, or if the tubes have adhesions from infection or previous
surgery. The pelvic organs must be mobile during the surgery so that












Ligate & excise 4–5 cm
of proximal limb; stump
retracts within broad
ligament
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Figure 21:2 Incision site: postpartum and interval 
minilaparotomy
Source:  Stewart et al. (1988)
Anesthesia. Light sedation using a local anesthesia can be given
preoperatively to infiltrate layer by layer of tissue. When using local
anesthesia, continue communicating with the woman during the pro-
cedure to enhance the analgesic effect, reassure her, and, when neces-
sary, elicit her cooperation. 
Procedure. The bladder should be emptied immediately before
the operation. The surgical procedure is generally performed with the
woman in a supine or a semilithotomy position. If the uterus is not
already anteverted, elevate the uterus by hand or with a uterine manip-
ulator (elevator) (see Figure 21:3).
In general, place the incision approximately 1 cm below the site
at which the elevated uterine fundus hits the abdominal wall. If the
incision is placed too high, the tubes will be difficult to reach. If it is
placed too low, the bladder may be incised. Because anatomy varies
from patient to patient, take great care in entering the abdomen.
Locate the fimbria to confirm that you have found the fallopian tube
and not the round ligament. If needed, use a tubal hook or small Bab-
cock forceps to lift the fallopian tube from the abdomen. Surgical
manipulation should be slow, gentle, and sensitive to the patient's
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Figure 21:3 A metal elevator raises the uterus and moves it from 
side to side so that the uterus and tubes will be closer to the 
incision
Source:  Stewart et al. (1988)
Occlusion techniques. The Pomeroy and Parkland techniques,
Silastic rings, the Filshie clip, or spring clips can be used (the last two
with special applicators). Fimbriectomy and the Madlener procedures
have been associated with higher pregnancy rates and have no advan-
tages over the Pomeroy and Parkland techniques for routine cases. The
Pomeroy technique is the most widely used in Africa.
Closing. Use careful aseptic technique and obtain good hemo-
stasis before closing the abdominal wound in layers. Growing evidence
indicates it is unnecessary to suture the peritoneal layer, because small
peritoneal defects will heal without adhesions.44 This rule applies as
well to postpartum subumbilical minilaparotomy.
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Laparoscopy
The laparoscopic approach is used to place rings (bands), apply
clips, or electrocoagulate the oviducts. A laparoscopy may be per-
formed using either a single- or double-puncture technique. The sec-
ond puncture is used to manipulate the organs and occlude the tubes
(see Figure 21:4). With single-puncture laparoscopy, the operating
instrument is passed through the laparoscope.
Figure 21:4 Laparoscopy
Laparoscopy is less painful than a minilaparotomy, has a lower
rate of complications and a shorter operative and recovery time, and
leaves only a small scar (the same equipment and skills can be used for
endoscopic diagnostic procedures).
The disadvantages of laparoscopic sterilization include the need
for a provider with specialized training, equipment that is more diffi-
cult to maintain than minilaparoscopy equipment, and a specially
equipped operating room. Laparoscopic sterilization is not recom-
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Anesthesia. Laparoscopic sterilizations can be performed using
local or general anesthesia. Local anesthesia with light sedation is usu-
ally adequate and offers safety advantages over general anesthesia,
which can lead to compromised cardiorespiratory function.26 
Procedure. Clean the perineal area, vagina, and cervix and scrub
the abdominal site with special emphasis on thoroughly cleaning the
navel. The cervix may be stabilized with a laparoscopic instrument.
The insufflation needle should have a blunt obturator (as does
the Verress needle). Verify correct placement by aspiration, hanging
drop, or pressure test.44 Keep equipment in good working order. Keep
the trocar sharp.
After making a small subumbilical incision, place upward trac-
tion on the abdomen to insert the Verress needle for insufflation.
Advance the needle toward the pelvis and away from the great blood
vessels. Place the patient in the Trendelenburg position and insufflate
1 to 3 liters of gas (the minimum needed for good visualization),
nitrous oxide (N2O), carbon dioxide (CO2), or room air. Withdraw
the needle and insert the trocar, advancing it toward the pelvis and
away from the great vessels as the abdominal wall is firmly elevated.
Remove the trocar from its sleeve (cannula) and insert the laparoscope.
In double-puncture laparoscopy, the second puncture is made
under direct vision through the laparoscope in the abdomen. In sin-
gle-puncture laparoscopy, the operating instruments are inserted
through the operating channel of the laparoscope to grasp and occlude
the oviducts.
It is also possible to perform "open laparoscopy," in which the
peritoneal cavity is opened under direct vision, an approach similar to
that used in subumbilical minilaparotomy. A cannula is then placed
and stabilized for insertion of the laparoscope. This method avoids
blindly entering the abdomen with sharp instruments.12 However,
general use of open laparoscopy has gained little support because it
takes longer than traditional laparoscopy and it remains to be shown
that it is safer.
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Occlusion techniques. Silastic bands, unipolar electrocoagula-
tion, and Filshie clips appear to have similar short-term effectiveness
rates when correctly applied, but the ectopic pregnancy rate appears to
be higher with electrocoagulation (bipolar and unipolar) than with the
bands or clips.39 
Clips are placed on the isthmic portion of the tube at 1 to 2 cm
from the uterus.  Silastic rings (bands) are placed 3 cm from the
uterus. Because the spring clip has a lower force of compression than
the Filshie clip, it requires precise placement at a 90-degree angle
across the tube, with the isthmic portion of the tube positioned at the
hinged part of the jaws to avoid failures.  Electrocoagulation is applied
in the midportion of the tube, away from other structures.48 (See Fig-
ure 21:5.)
Figure 21:5 A laparoscopy instrument grasps one tube in 
preparation for coagulation or application of a ring or clip
Source:  Stewart et al. (1988)
Closing. After both tubes are occluded, inspect the pelvic organs
to ensure that no injury or bleeding has occurred. Under direct vision,
remove the second puncture instruments, carefully expel all the gas,
and remove the laparoscope and the cannula. When removing the can-
nula after all gas has been expelled, reinsert the laparoscope to the end
of the cannula to prevent omentum or bowel from herniating into the
abdominal wall defects as the cannula is removed.44 Close the incision
with sutures.
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Vaginal Approach
The fallopian tubes can be reached and the pelvic organs directly
visualized through a colpotomy, an incision high in the vagina (poste-
rior to the cervix), or by using an endoscopic instrument called a cul-
doscope. However, vaginal approaches are less safe and less effective
than minilaparotomy or laparoscopic approaches. Infection is more
common, and the techniques are generally more difficult to learn and
perform. Thus, the vaginal approach should be used only by a skilled
surgeon familiar with the culdoscope.44
Transcervical Approach
 Most of the hysteroscopic techniques for injecting occlusive
materials into the fallopian tubes are still experimental. These tech-
niques are difficult to learn, equipment is expensive, and the success
rates when they are used for sterilization have generally been disap-
pointing.
Also considered experimental are nonsurgical sterilization tech-
niques using a chemical or other material to occlude the tubes through
the cervix. Several agents, including quinacrine, methyl cyanocrylate,
and phenol, have been used with varying success. Delivery systems are
still being perfected to obtain higher levels of effectiveness.
Quinacrine pellets inserted high in the intrauterine cavity may
cause nonsurgical sterilization. This method can be performed in any
clinical setting equipped and staffed to insert an IUD. In one study,
73% of women had both tubes occluded after two insertions of quina-
crine pellets; both tubes were occluded in 94% after three insertions.6
Researchers in Vietnam found this method to be safe and effective for
female sterilization,13 but many professionals believe that current
information does not warrant its use except in experimental condi-
tions. In a significant number of clients, this method fails to occlude
the fallopian tubes. However, some groups are encouraging the accep-
tance of the transcervical approach because it is simple, nonsurgical,
and can be performed on an outpatient basis.
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Hysterectomy
Hysterectomy, whether performed through the vagina or abdo-
men, carries a much higher risk of serious complications than other
sterilization procedures. Thus it should only be performed for a gyne-
cological disease or condition that justifies a hysterectomy, not solely
for terminating fertility.
PROVIDING POSTPARTUM AND POSTABORTION SURGICAL 
CONTRACEPTION
Immediate postpartum VSC services can be an integral part of
any maternity service. Postpartum VSC can be performed in a simple
procedure room, a delivery suite, or an operating theater.
In many countries, the immediate postpartum period (within 48
hours of delivery) is the most common time to perform female steril-
ization. Postpartum VSC offers greater convenience to the client and
provider, lower costs, greater ease of surgery, and more efficient use of
health resources. Generally, the woman's health status can be assessed
from the delivery and prenatal records.
Subumbilical Minilaparotomy
A woman who undergoes subumbilical minilaparotomy need not
stay longer than she would for a normal delivery (24 hours or less in
many hospitals). If a minilaparotomy is performed 10 or more hours
after delivery, postpartum hemorrhage is unlikely to occur, because the
uterus will be contracted and less likely to relax and, therefore, bleed.
In addition, the baby can be observed and assessed more thoroughly
prior to discharge.29 (See Suprapubic Minilaparotomy for more on
preoperative assessment.)
Anesthesia. Local anesthesia with light sedation is frequently suf-
ficient, because several of the more painful aspects of minilaparotomy
are reduced: the incision is smaller, and intra-abdominal manipulation
of the tubes is less extensive. The patient lies quietly in the supine
position, and there is no need for instruments in the vagina.
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Procedure. For the first 2 days after delivery, the fundus of the
uterus and fallopian tubes lie high in the abdomen. A small (1.5 to 3
cm) incision just below the umbilicus allows the surgeon to reach the
tubes. The tubes are usually easier to reach if both the incision and the
postpartum uterus are aligned with each other.
When a minilaparotomy is not feasible, a laparotomy (defined as
an incision longer than 5 cm) may be performed, usually with general,
spinal, or epidural anesthesia. Laparotomy incisions cause more com-
plications, and the associated anesthesia methods increase the risk and
prolong recovery times. (The laparoscope is not used in the immediate
postpartum period because of the risk of injury to the large, vascular
uterus. Laparoscopic occlusion methods are not appropriate because
the oviducts are edematous and vascular and thus larger.)
Occlusion techniques. Figure 21:1 illustrates several occlusion
techniques. The Pomeroy technique, using plain catgut, is an effective,
safe approach in the immediate postpartum period. In the midportion
of the fallopian tube, create a loop of tube. Close the loop by ligating
with plain catgut suture material. Cut the loop to separate the tube.
The Parkland technique avoids bringing the cut ends together
and preserves more of the tube. Perforate the mesosalpinx in an avas-
cular area. Ligate the tube in two places with chromic one-zero catgut,
and excise the intervening segment of tube.23,29
Use of the Hulka clip in the postpartum period has been shown
to compare favorably with the modified Pomeroy tubal ligation
because of its simplicity and greater potential reversibility.21 The
Filshie clip and the spring clip are not designed for use postpartum
and are, therefore, generally not recommended for postpartum steril-
ization.16 Electrocoagulation is also not recommended, because it is
usually delivered via laparoscopy and appears to be associated with an
increased risk of fistula formation and ectopic pregnancy.
Fimbriectomy, sometimes performed because the ampullar and
fimbrial portions of the tubes are more accessible than the isthmic and
ampullar portions, has fallen from favor. It has high pregnancy rates
and a higher frequency of postoperative complications. Fimbriectomy
is also less reversible and removes more tissue.
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Cesarean Section
Tubal occlusion can be easily accomplished during cesarean sec-
tion. However, because of the greater risks involved with cesarean sec-
tion, health care providers should be discouraged from performing a
cesarean section rather than attempting a vaginal delivery just because
tubal ligation is planned.
The Pomeroy technique has a slightly higher pregnancy rate
when performed at the time of a cesarean section than an interval pro-
cedure; the lack of surgical skill may be a reason. The Parkland tech-
nique is also commonly used during a cesarean section. The Irving
technique (which requires a wide surgical exposure for implanting the
proximal end of the tube into the uterine wall and is thus possible
with cesarean section) is one of the most effective methods of occlud-
ing the tubes and is unlikely to permit an ectopic pregnancy.29
Postabortion VSC
Tubal occlusion via a minilaparotomy or laparoscopy may be per-
formed immediately after a first-trimester spontaneous or medically
induced abortion as long as the patient receives careful counseling.
Note that the tubes will be edematous. (See Minilaparotomy Compli-
cations and Laparoscopy Complications.)
Occlusion techniques. The Pomeroy or Parkland procedures
may be used for occlusion. Silastic rings and spring clips are less likely
to fail when used in the postabortion period than when used in the
immediate postpartum period.
ANESTHESIA
General anesthesia is usually unnecessary for most female VSC
procedures, and its risks far outweigh its benefits. If general anesthesia
is used, it must be provided by trained personnel in appropriate set-
tings. A discussion of general anesthesia is beyond the scope of this
text. 
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Local anesthesia with light sedation is the preferred way of pro-
viding pain relief. Do not compromise the normal physiological con-
trol of vital functions. Avoid high doses of opioid (narcotic) analgesics
and benzodiazepine (tranquilizer) sedatives that can compromise ven-
tilation, sometimes dramatically, and may cause cardiovascular depres-
sion.
Monitor vital signs regularly both during and after the operation
until the patient is fully recovered and alert.
The following is a sample regimen for local anesthesia for minilap-
arotomy. It is also suitable for laparoscopy with some modifications as
noted (doses given are for an average adult body weight of 50 kg).
Premedication
Sedate the patient with 10 mg of diazepam 30 to 60 minutes
before the operation. Midazolam, a new short-acting parenteral ben-
zodiazepine that is three to four times more potent than diazepam,
may be substituted. Give 2.5 to 3 mg midazolam intramuscularly 1
hour preoperatively or 1 to 2.5 mg intravenously in the operating
room. Cost may limit the use of midazolam.
Given in the Operating Room
Atropine. Give 0.4 to 0.6 mg intravenously.
Meperidine (Pethidine). Five 50 mg intravenously. Other opi-
oid analgesics or ketamine can be substituted for meperidine. Compa-
rable doses of analgesia are given in Table 21:1.44 
Cautionary notes on the use of narcotics and other analgesics
• Their onset is rapid but not instantaneous
• Therefore, they should be given incrementally (in small 
repeated doses) while the client is being observed
• Reversal agents (Narcan or other appropriate reversal 
agents) should be immediately available.
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Promethazine (Phenergan). Give 25 mg intravenously.
Lidocaine local anesthesia. Infiltrate the skin and subcutaneous
tissues with 10 to 15 ml of 1% lidocaine (lignocaine) without epi-
nephrine. After the peritoneal cavity is opened, drip 5 ml of 1%
lidocaine onto each tube and the uterus. During laparoscopy this step
is optional if the instrument does not permit lidocaine application.
During double-puncture laparoscopy, the second site will also be infil-
trated. The maximum safe dose of 1% lidocaine (without epineph-
rine) is 5 mg/kg body weight. For example, for a woman weighing 50
kg the maximum safe dose is 250 mg or 25 ml of 1% lidocaine. If only
2% lidocaine is available, dilute it to 1% with 0.9% sodium chloride
only so that you can better obtain adequate volume for local infiltra-
tion and avoid exceeding the safe dose. Some surgeons use sodium
bicarbonate (1 cc of 8.4% sodium bicarbonate [standard vial percent-
age] with 25 cc of 1% lidocaine) to decrease the burning sensation
caused by the anesthesia infiltrating into the subcutaneous space.
MANAGING PROBLEMS AND FOLLOW-UP
Its low rate of complications (0.4% to 1%) makes female steril-
ization quite desirable. Complications include wound infections,
hematoma, perforation of the uterus with the elevating instrument,
bladder injury, and sterilization failure. Most of these complications
Table 21:1 Analgesia substitutes for meperidine
Drug Intravenous dose Analgesic duration
meperidine (Pethidine) 50 mg 2-3 hours
fentanyl (Sublimaze) 0.05-0.06 mg 30-60 minutes
pentazocine (Talwin) 15-20 mg* 3-4 hours
butorphanol (Stadol) 1 mg 3-4 hours
ketamine (Ketalar) 25-30 mg* 10-15 minutes
*Short acting: supplemental doses about one-third less than the initial ketamine dose may be given at 10-
minute intervals.
528 FAMILY PLANNING METHODS AND PRACTICE:  AFRICA
can be prevented by careful screening, using local anesthesia with seda-
tion, careful monitoring of vital signs, asepsis, and careful surgical
technique. The seriousness of complications can often be minimized if
they are recognized early and managed aggressively.
Anesthesia Complications
Anesthesia-related complications can be aggravated if the abdo-
men is filled with gas or is in the Trendelenburg position, especially if
general anesthesia is used. Most complications arising from anesthesia
occur acutely.
Surgical Complications
Because the abdominal wall is thin at the umbilicus, proceed cau-
tiously when dissecting and entering the peritoneal cavity to avoid
cutting the intestine. Handle the tubes gently to avoid profuse bleed-
ing from the engorged postpartum vessels. Postoperative hemorrhage
can occur if ligatures around the tubes are not secure enough to pre-
vent slipping. Reduce the risk of infections by screening clients preop-
eratively and by avoiding surgery on patients who have had prolonged
rupture of membranes with evidence of current infections (with fever).
Prophylactic antibiotics are usually given if the procedure is per-
formed on the third and seventh postpartum day. If the procedure
cannot be performed within 7 days after delivery, wait until 4 to 6
weeks postpartum, because the oviducts are usually difficult to reach
in the interim.29,44 
Minilaparotomy Complications
Minilaparotomy procedures may have the following complications:
 Wound infection. As with all surgical procedures, careful aseptic
technique, proper skin preparation, proper sterilization of instruments
and proper technique in the operating room, as well as good postoper-
ative wound care by the client, decrease the risk of wound infections.
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Uterine perforation with uterine elevator. Reduce trauma by
applying all instruments gently. Carefully determine the position of
the uterus before inserting the elevator.
Bladder injury. This common surgical complication occurs
because the bladder is close to the lower incision. Dissect carefully and
pay attention to landmarks.
Intestinal injury. Take care to identify tissue layers when enter-
ing into the abdominal cavity. Serious complications can result from
an unrecognized injury.
Laparoscopy Complications
The overall mortality rate for laparoscopic sterilization is 2.9
deaths per 100,000, well below the rate for minilaparotomy of 5.9
deaths per 100,000 procedures.18 The rate of laparoscopic complica-
tions depends heavily on the surgeon's skill. The surgeon needs special
training in laparoscopy.
Complications such as mesosalpingeal tears and transection of
the tube can occur with ring application, and may require laparotomy
to control bleeding. Sometimes an additional ring can be placed on
each severed end of the tube to gain hemostasis. Uterine perforation
with the uterine elevator can usually be managed conservatively. Inju-
ries to vessels, intestines, or other organs can occur with the insuffla-
tion needle or the trocar. Make sure general anesthesia is available to
manage the rare complication of severe bleeding from a major vessel.
Bowel burns can occur from electrocoagulation and lead to per-
foration and peritonitis. Most international agencies discontinued
support for electrocoagulation equipment in the early 1980s. Most
laparoscopic injuries, however, are not related to the coagulation but
to use of the trocar or other surgical instruments.20
Long-term Complications
Ectopic pregnancy. Ectopic pregnancy should be ruled out any time
a woman shows signs of pregnancy following tubal occlusion. Ectopic
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pregnancies can occur 6 or more years after sterilization. Ectopic preg-
nancy is most often related to (1) uteroperitoneal fistula after unipolar
electrocoagulation; (2) inadequate coagulation or recanalization after
bipolar procedures; or (3) recanalization or fistula formation after the
Pomeroy, clip, or ring procedure.42
Among nonsterilized women, 0.5% to 1% of pregnancies are
ectopic; the comparable percentages for sterilized women range from
4% to 73%, depending on the procedure used.23  One survey found
that 16% of pregnancies following the clip procedure were ectopic;
38% after the ring, 73% after unipolar occlusion, 59% after bipolar
occlusion, and 44% after Pomeroy occlusion.16 Electrocoagulation has
a threefold greater incidence of ectopic pregnancy than does the use of
the Silastic ring.
 Hormonal changes. Several investigators have suggested that
serum progesterone may decline following tubal occlusion; other
investigators have reached different conclusions. No studies have eval-
uated pre-sterilization and post-sterilization levels of this hormone.15
Levels of luteinizing hormone, follicle stimulating hormone, testoster-
one, and estrogen remain within the normal range.
Menstrual patterns and other changes. A specific, describable
pattern of bleeding after sterilization has not been convincingly dem-
onstrated.28 Further research needs to be conducted.
Psychological problems have not been identified more often in
sterilized than in nonsterilized women.45 A study on the effect of tubal
sterilization and vasectomy on female marital sexuality found not only
that these procedures have no detrimental long-term effects, but also
that sterilized women have intercourse more frequently.33
Hysterectomy and dilation and curettage. In one study,
women who were sterilized at age 20 to 29 years were at greater long-
term risk of having a hysterectomy.36 Hysterectomies and dilation and
curettage (D&C) are sometimes performed because of the mistaken
belief that sterilization procedures lead to hormonal and menstrual
changes.
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SAMPLE INSTRUCTIONS FOR THE FEMALE CLIENT
PREOPERATIVE INSTRUCTIONS
1. You must be certain you understand and desire a permanent
method of birth control. You can change your mind at any time
before the procedure or can postpone the operation if you need
more time to decide.
2. Shower or bathe just before surgery. Carefully clean around
the umbilicus (navel) and the pubic hair.
3. Do not eat or drink in the 8 hours before surgery.
4. Have someone be with you on the day of surgery, on your
way home, and during the first 24 hours following surgery.
5. Ask questions if you have them.
6. Plan a flexible schedule for the week after the sterilization.
7. Be prepared for pain over the incision and occasional pelvic
aching or discomfort. The pain is usually not severe and can be
relieved with mild pain medications.
8. Remember that this method of birth control is permanent.
Reversal surgery is  generally not available in Africa.
POSTOPERATIVE INSTRUCTIONS
1. Rest for 24 hours following surgery. Resume normal activi-
ties as you gradually become more comfortable.
2. Avoid intercourse for 1 week and stop if it is uncomfortable.
3. Avoid strenuous lifting for 1 week to allow the incisions to heal.
4. Take 1 or 2 analgesic tablets at 4- to 6-hour intervals if you need
them for pain (do not use aspirin as it may promote bleeding).
5. You may bathe 48 hours after surgery but avoid putting ten-
sion on the incision and do not rub or irritate the incision for 1
week. Dry the incision site after bathing.
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6. Stitches will dissolve and do not require removal. (Note to
provider: this instruction must be modified if nonabsorbable
sutures, such as silk, are used.)
7. Return to the clinic 1 week after the procedure to make sure
healing is normal.
8. At any time in the future, if you think you are pregnant,
return to the clinic immediately. Although pregnancy after
female surgical contraception is rare, when it does occur, chances
are increased that it will be outside the uterus (an ectopic preg-
nancy). This is a dangerous, life-threatening condition and
must be treated immediately.
9. Return to the clinic or contact the clinic or doctor promptly
if you develop the following signs:
10. If you may be at risk for infection with the virus that causes
AIDS (human immunodeficiency virus, or HIV) or any other
sexually transmitted infection, continue to use condoms.
Danger Signs After the Operation
Caution n
Fever (greater than 39o C)
n Dizziness with fainting
n Abdominal pain that is persistent or increasing
n Bleeding or fluid coming from the incision
n Suspicion of pregnancy—you must be seen im-
mediately
No matter what other methods of contraception a woman 
is using, if she is at any risk because her partner tests 
HIV positive or because she does not know her partner’s 
HIV status, she should be advised to use plastic or latex 
condoms with every sexual act.
No other contraceptive method besides abstinence
provides the same degree of protection.
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VOLUNTARY SURGICAL CONTRACEPTION FOR MEN
MECHANISM OF ACTION
Vasectomy blocks the vasa deferentia and thus prevents the pas-
sage of sperm into the semen.
EFFECTIVENESS
Although vasectomy is not completely foolproof, it is the most
effective contraceptive method for men. The likelihood of operative
failure is reduced if the surgeon has performed the procedure fre-
quently.34 Failure is usually discovered when examination of the semen
indicates the presence of sperm more than 4 to 6 weeks after the oper-
ation or after 10 to 12 ejaculations.5 
ADVANTAGES AND INDICATIONS
Vasectomy is a simpler, safer, and less expensive procedure than
female surgical contraception. Vasectomy offers several advantages:
• It is highly effective.
• It is very safe.
• The procedure can be performed quickly.
• The effects are permanent.
• The costs are low in the long run.
• Most clients find vasectomy highly acceptable.
DISADVANTAGES AND CAUTIONS
Vasectomy has disadvantages as well:
• It requires surgical training, aseptic conditions, medications,
and technical assistance.
• It does not protect against STIs, including HIV.
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• Vasectomy is permanent. Although reversal is possible, it is
expensive, and requires a highly technical and major surgery
for which success cannot be guaranteed.
• About 5% to 10% of patients regret having the procedure. 
• Costs are high in the short term.
Short-term disadvantages. Vasectomy is not effective until the
ejaculate is free of sperm. Complications such as bleeding or infection,
although infrequent, do occur.
Long-term effects. About one-half to two-thirds of men will
develop sperm antibodies following vasectomy. However, having these
antibodies does not appear to lead to any complications.22,27 Extensive
studies have found no increase in heart disease or other adverse effects
following vasectomy.41
One study, however, showed a slightly increased risk of cancer in
men who had been sterilized for 20 or more years.8 Other studies have
found a weak positive association between vasectomy and prostate
cancer;9,10 epidemiological studies on this relationship have conflicted.
The Final Statement from the 1993 Vasectomy and Prostate Cancer
Conference concludes: "Because the results of research to date on
vasectomy and prostate cancer are inconsistent, and associations that
have been found are weak, there is insufficient basis for recommend-
ing a change in clinical and public health practice at this time. In light
of this:
• Providers should continue to offer vasectomy and to perform
the procedure.
• Vasectomy reversal is not warranted to prevent prostate cancer.
• Screening for prostate cancer should not be any different for
men who have had a vasectomy than for those who have
not."40
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PROVIDING MALE STERILZATION
Technical guidelines on providing vasectomy services have been
developed by the World Health Organization.46 These guidelines
should be followed closely.
Ask the patient about his past illnesses and surgeries, bleeding
disorders, allergies (particularly to local anesthetics and pain medica-
tions), heart disease, kidney and bladder infection, diabetes, anemia,
and STIs. Evaluate his general health condition. Measure his pulse and
blood pressure; check for infections in the scrotal or inguinal area and
for a hernia or previous surgery in the inguinal area. Evaluate the scro-
tum for hydrocele, varicocele, and proper descent of the testicles.
Examine the scrotal skin and subcutaneous tissues. Laboratory exami-
nations are not routinely performed but should be available.
Vasectomy
Clip the man's hair from his scrotum and around his penis. Just
before surgery, wash the area with soap and water. Prepare the scro-
tum, thighs, and perineum with an effective antiseptic (usually a
water-based iodine or 4% chlorhexidine solution). Use sterile tech-
nique. Anchor the vasa (two tubular structures, one in each side of the
scrotum) with an atraumatic instrument or your fingers. Incise the
skin and muscle overlying the vas or open these with the "no scalpel"
method (see section on No-Scalpel Vasectomy). Through this small
puncture, isolate and occlude the vas (see Figure 21:6). Perform the
same procedure on the vas on the other side.
Anesthesia. Infiltrate 1% lidocaine (lignocaine) without epi-
nephrine into the area to be incised and then deeply into the perivasal
tissue.
Occlusion techniques. Place a simple ligature using absorbable or
nonabsorbable suture on each end of the cut vas. Be careful not to cut
through the vas with the suture. A segment of the vas may be removed
to obtain greater separation, but this step is not necessary. A fascial bar-
rier may be created between the ends by drawing the sheath over one
end and suturing it;1,44 this technique may decrease the failure rate.
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Sperm granulomas occur more often at the cut ends after the lig-
ature technique, possibly contributing to a somewhat higher failure
rate than when fulguration is used. A recent modification is to leave
the testicular end of the vas open ("open-ended vasectomy") and
fulgurate the abdominal end to a depth of 1.5 cm. A fascial barrier
may then be interposed. This method appears to reduce the frequency
of postoperative congestive epididymitis without increasing the rate of
painful sperm granulomas.1,7,44 Some surgeons report increased failure
rates with this approach, but open-ended vasectomy may reduce post-
operative complaints. Success rates for reversal may also be higher than
when both ends are fulgurated.
Closing. Close the incisions with absorbable suture. Many sur-
geons use only a single midline puncture and do not suture small skin
incisions.1,14,44 If possible, the patient should rest 15 minutes or longer
before he leaves.
Figure 21:6 Sites of vasectomy incisions
Source:  Hatcher et al. (1983)
TUBAL STERILIZATION AND VASECTOMY 537
No-Scalpel Vasectomy
A new, refined "no-scalpel" procedure has been introduced and is
currently being used in many programs around the world.2 It is the
standard vasectomy technique in China, where more than nine mil-
lion men have had the procedure,11 and it is rapidly becoming the pro-
cedure of choice in Thailand, India, and Indonesia.37 
The vasa are approached through a puncture in the scrotum
rather than through a scalpel incision,2 but, thereafter, the surgical
procedure is the same as the scalpel method. However, there may be
fewer bleeding complications with the no-scalpel method than when
the scalpel is used. If these rates are indeed lower, anxiety about pro-
ducing a postsurgical hematoma might be reduced.14
The procedure uses two unique instruments:  a specially designed
ring forceps and a sharp-tipped dissection forceps. After injecting local
anesthetic, encircle and secure the vas with the ring forceps. With the
sharp-tipped dissecting forceps, puncture and stretch a small opening
in the skin and vas sheath. Lift out the vas and occlude it as you do
with other vasectomy techniques. Use the same midline puncture site
to deliver and occlude the other vas in an almost bloodless procedure.
No sutures are needed to close the small wound (see Figure 21:7).
MANAGING PROBLEMS AND FOLLOW-UP
Mortality is extremely rare (about 1 death per 300,000 proce-
dures) when asepsis and surgical skills meet basic standards.30 Compli-
cations following surgery are also rare (see Table 21:2). Careful
surgical technique and keeping the patient from strenuous activity for
a day or two reduces bleeding complications. Prevent hematomas by
controlling any bleeding during the operation. Manage small, non-
infected hematomas with rest and analgesics. Large, painful, or
infected hematomas usually require surgical drainage. 
Prevent infections by using strict aseptic practices and sterilized
equipment.  Have the patient keep the incision clean.  If an infection
does occur, treat it with antibiotics and apply wet heat frequently.   
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Figure 21:7 "No-scalpel vasectomy." The vas (dotted line) is
grasped by special ring forceps and the skin and the vas sheath are
pierced by sharp-tipped dissecting forceps (A). The forceps then
stretch an opening (B) and the vas is lifted out (C).
Source:  Hatcher et al. (1983)
Leakage of sperm from the occluded end of the vas can cause an
inflammatory nodule (granuloma) that generally subsides spontane-
ously, although pain medication may be required. The rare granuloma
that increases in size, is painful, and does not recede may be treated
surgically. Congestive epididymitis may occur due to back pressure in
the occluded vas. With heat treatment and scrotal support, the condi-
tion usually subsides in a week.









Source:  Wortman (1976)
Reprinted with permission from the Population Information Program.
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SAMPLE INSTRUCTIONS FOR THE MALE CLIENT
Preoperative Instructions
1. Remember that a vasectomy is permanent. You can change
your mind at any time before the operation. Reversal surgery is
generally not available in Africa.
2. Before surgery, use scissors to cut hair around the penis and
scrotum to approximately 1/4 inch in length.
3. Shower or bathe. Wash your penis and scrotum thoroughly
to remove all loose hairs.
4. If possible, have someone go home with you when you have
the procedure done. Do not ride a bicycle, walk long distances,
or do anything that may rub or put pressure on the scrotum.
Postoperative Instructions
1. Following the surgery, return home and rest for about 2 or 3
days, after which you may resume your normal activities.
2. Avoid strenuous physical exercise for 1 week. Strenuous exer-
cise means hard physical exertion or lifting or straining that
could bring pressure to the groin or scrotum.
3. Do not shower or bathe for the first 2 days after the vasec-
tomy.
4. The stitches will dissolve and do not have to be removed.
(Note to provider: this instruction must be modified if nonab-
sorbable skin sutures, such as silk, are used or if no skin sutures
are used.)
5. You may resume sexual intercourse after 2 or 3 days if you
think it would be comfortable. Remember, you are not sterile
immediately. For many men, sperm will not be cleared from the
tubes until after about 12 ejaculations. Until then, use condoms
or another method of birth control to prevent pregnancy. The
best way of finding out whether you are sterile is to have the doc-
tor look at your semen under a microscope after you have ejacu-
lated 12 times.
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6. If you have pain or discomfort, simple pain-relieving medi-
cations taken every 4 to 6 hours usually give adequate relief.
(Note to provider: name and dose should be specified.)
7. It is important for you to know what signs are normal or
abnormal following your surgery. You will probably have some
pain and swelling in the scrotal region; the scrotum may be
somewhat discolored. These effects are normal and should not
worry you. Occasionally, blood from a tiny blood vessel may
escape into the scrotum at the time of surgery, and bleeding may
continue. Notify your clinic if you have any of the following dan-
ger signals or if you notice any other unusual body changes. (See
Danger Signs below.)
8. If you may be at risk for infection with the virus that causes
AIDS (the human immunodeficiency virus, or HIV) or any
other sexually transmitted infection, continue to use condoms.
REVERSAL OF FEMALE AND MALE STERILIZATION
Voluntary surgical contraception should be considered permanent,
but even with careful counseling, some women and men will request
reversal following a divorce, a remarriage, or a child's death or if they
desire more children. The following points should be emphasized:
• Reversal is generally not available in Africa.
• Reversal requires major surgery and special skills.
Danger Signs After the Operation
Caution n Fevern Bleeding or pus from the site of the incision
n Increasing pain or swelling
For any of these problems, you must return to the clinic for medical
care without delay.
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• Some clients are not appropriate candidates because of the
way the sterilization was performed, because of the client or
partner's advanced age, or because of the infertility of the
spouse.
• Success cannot be guaranteed, even when the patient is a
good candidate and the surgery is performed by an experi-
enced microsurgeon.
• Reversal surgery is very expensive for both male and female
clients.
In addition, the candidate should understand that anesthesia and
major abdominal or scrotal surgery carry a risk of complications.
There is also a risk of ectopic pregnancy after reversal of female steril-
ization: the rate is about 5% for women who have an electrocoagula-
tion procedure reversed and about 2% for women who have other
occlusion techniques reversed.23
If the woman wishes to proceed after counseling, a laparoscopy is
usually done to determine the condition of the tubes, and infertility
tests may be performed for her and her husband. Most surgeons will
not operate if less than 4 cm of healthy tube remains.
SUCCESS RATES FOR REVERSAL OF FEMALE STERILIZATION
With ligation or mechanical occlusion of the tube, careful micro-
surgical techniques can reverse the sterilization procedure in 50% to
70% of cases. This high success rate, however, reflects reports from
experts who have operated on selected patients. Success rates calcu-
lated by the number of intrauterine pregnancies after reversal surgery
are highest for occlusion techniques that damage the smallest segment
of oviduct (see Table 21:3).23
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Good success rates are generally achieved through the use of
microsurgical techniques that require special training and combine
several features, including the following:
• Use of magnification (loupe, hood, or operating microscope)
• Accurate alignment of the fallopian tube segments and place-
ment of sutures
• Constant irrigation of tissues to prevent drying
• Use of very fine suture and needles
• Bipolar microsurgical electrocautery to minimize bleeding
• Care to keep foreign materials from being left in the wound
SUCCESS RATES FOR REVERSAL OF VASECTOMY
 Microsurgical technique is important when restoring continuity
of the vas. An operating microscope using higher magnification (25
power) is usually employed. Under these circumstances, reported
pregnancy rates range from 16% to 79%, with most rates approaching
50% or above. Higher proportions of men have sperm in the ejacu-
late, however, with rates ranging from 81% to 98%. Clinicians should
not present these high rates as measuring the success of reversal, how-
ever, as pregnancy, not the presence of sperm, is the desired outcome.












Sources: Huber (1988) and Liskin (1985)
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The pregnancy success rate can depend on several factors, includ-
ing the skill of the surgeon or microsurgeon. Several factors may
reduce chances of success: 
• Increased time since the vasectomy was performed4 
• Presence of antisperm antibodies
• Advanced age of the wife
• Characteristics of  the vasectomy that was performed (a long
segment of vas removed, it was performed near the epididy-
mis, or cautery was used)
Attempts to develop a plug, valve, or simple reversible vasectomy
have not been successful.22 Men must accept vasectomy as a perma-
nent procedure even though improved microsurgical techniques have
increased the chances of restoring fertility.
POLICY AND LEGAL ISSUES
Family planning programs in many African countries are making
good progress in providing sterilization. However, appropriate
national authorities need to establish clear guidelines that allow the
procedures to be available to deserving clients. Policies that include
quotas, coercive incentives, "camps," and other similar programmatic
concepts are not acceptable in promoting voluntary surgical contra-
ception.
Establishing policies for providing sterilization to retarded women
and men and determining the legal status of such procedures remain
problems. Health care providers, policy makers, and local leaders should
discuss the ethical and legal issues involved in providing voluntary steril-
ization to those who may not be able to provide informed consent.
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Treating Complications and 
Providing Contraception
 
When she discovered that she was pregnant, 24-year-old Fata-
matu felt she could not have another child so soon after the birth 
of her previous baby. "The baby is still too young. I have to sup-
port that child and my mother on my small income. My hus-
band has moved to the Forest Region to live with his second 
wife." Fatamatu wanted to go to a hospital or a doctor but could 
not afford to do so. A friend told Fatamatu about a woman who 
performed abortions. This woman inserted a rubber catheter 
into Fatamatu's cervix and told her to go home. When she saw 
blood, Fatamata was to pull out the catheter and the products of 
conception would follow on their own. 
Fatamatu began bleeding heavily and felt faint and feverish. 
She returned to the practitioner's home, who was away caring 
for a sick relative in a distant village. Fatamatu's friend took 
her to the city hospital. A physician found retained tissue in the 
uterus and some trauma to the cervix. That afternoon he per-
formed a manual vacuum aspiration procedure and gave her 
antibiotics. Fatamatu remained in the hospital for a few hours. 
She was prescribed oral antibiotics and was advised to rest for 
one week. One of the nurses discussed contraceptive options with 
her. Fatamatu decided to use the hormonal injection that she 




























Most family planning providers will at some time be faced with treat-
ing the potentially lethal complications of an unsafe abortion per-
formed on a desperate woman. These complications represent some of
the few emergencies encountered by family planning providers. The
provider who manages this encounter well can save a life and enlist a
woman in the regular use of effective contraception. No matter the
provider's attitudes on abortion, these women need care, and they
need it immediately.







Each year, between 30 and 40 million induced
abortions are performed throughout the world, and as many as






From 10% to more
than 50% of maternal deaths in Africa have been attributed to compli-






Abortion is legally restricted in
most African countries, but some countries, notably Zambia, Ghana,
Botswana, and Tunisia, have a more liberal policy. 
Even in countries where abortion is illegal, many clinicians feel
morally obligated to treat women with abortion complications and
provide them with postabortion family planning. The 1994 Confer-
ence on Population and Development in Cairo, Egypt, concluded that
"in all cases women should have access to quality services for the man-
agement of complications arising from abortion. Post-abortion coun-
seling, education, and family planning services should be offered
promptly which will also help to avoid repeat abortions."
Women seek induced abortion for medical, economic, or per-
sonal reasons. Africa has exceptionally high rates of unplanned preg-
nancies because many women lack access to family planning services







tion in Africa is most common among young, unmarried, and unem-







also often occurs among women who have achieved their desired fam-
ily size or simply cannot afford the economic burden of an additional
child. In some cases, rape or medical reasons lead women to seek abor-







the percentage may be even higher in areas where












Most unsafe abortions in Africa are performed outside of a clini-
cal setting, usually because legal abortion is not available, somewhat
less often because there are not enough health practitioners trained in
performing induced abortion or because their services are too expen-
sive. Unsafe abortion is characterized by inadequate provider skills,
hazardous techniques, and unsanitary facilities
 
21 in which the proce-
dure becomes a serious threat to the health and well-being of the
patient. The woman herself or a traditional practitioner may attempt
to terminate the pregnancy by inserting foreign bodies or instruments
through the cervix into the uterus or by the woman ingesting modern














































Presence of gonorrhea or other pelvic infection
The signs and symptoms associated with complications from an
unsafe abortion include vaginal bleeding, fever, septicemia, abdominal
pain, cramping, foul-smelling vaginal discharge, and anemia.
 
8,13 Com-
plications following abortion include retained pregnancy tissue, infec-
tion, bleeding, hemorrhage, septic shock, anemia, intra-abdominal
injury (including uterine perforation), cervical or bowel damage, and


























complications may lead to long-term medical problems such as





Some of the early signs of an ectopic pregnancy may be similar to
the signs of abortion complications. A woman with an ectopic preg-
nancy may have pain, irregular bleeding, breast tenderness, nausea, or
a recently delayed or skipped menstrual period. 
Clinicians who treat abortion complications should be careful
not to express disapproval or harsh judgment of the woman on the
basis of her resorting to unsafe abortion, being sexually active, being
young or unmarried, not using contraception, using contraception




Incomplete abortion occurs when a pregnant woman has begun to
abort, either spontaneously or by induction, but has not yet expelled
all the products of conception. There are several signs of retained tis-
sue:
• Abdominal or pelvic pain
• Backache or cramps
• Heavy or persistent bleeding, with or without clots, that may
lead to shock (rapid pulse, sweaty or clammy skin, fainting
or lightheadedness)
• Enlarged, soft, tender uterus noted on pelvic exam
• Tissue visible at cervical os (opening)
Manual vacuum aspiration (MVA) is the treatment of choice for
a nonseptic incomplete abortion where uterine size is equivalent to






Vacuum aspiration involves using a syringe
directly connected to a cannula to empty the uterus. The World
Health Organization (WHO) says that vacuum aspiration is an essen-







studies have found MVA to be safer, more effective, and less expensive


















 MVA is less expensive than SC, as it usually does not
require heavy sedation or an overnight hospital stay and, therefore,






The Kenyatta National Hospital in
Nairobi estimated a savings of US $300,000 during the first year it
used MVA to manage incomplete abortions—hospital stays were
shorter and there were fewer complications.
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MVA requires a hand-held vacuum syringe and flexible plastic
cannula, which may be used as a combined sound and dilator. The
syringe, which is portable, not electric, and either single- or double-





 It can be used for endometrial biopsy, treatment of incom-
plete abortion, and first-trimester abortion or menstrual regulation.
When an incomplete abortion is suspected, conduct a medical history,
and perform both a general physical exam and a pelvic exam. Assess
the uterine size by a bimanual exam and compare the actual size to
that expected from menstrual dates. The uterus is likely to be smaller





Prepare the patient before performing the procedure by following
these steps:  (1) have the patient empty her bladder, (2) place her in
the lithotomy position, (3) allow sufficient time for any premedication
to take effect, ensuring that supportive communication continues
throughout the procedure, (4) drape the patient, and (5) prepare the
vacuum in the syringe.
The following steps for treating incomplete abortion are taken
from the International Population Assistance Services (IPAS) Manual




1. Through a speculum inserted in the vagina, hold the cervix
steady with a tenaculum and gently apply traction to straighten
the cervical canal. Administer paracervical block, if needed.
2. Dilate the cervix (as required). Cervical dilation is necessary
when the cervical canal will not allow passage of a cannula appro-
priate to the uterine size. When required, dilation should be
done gently with mechanical dilators or with cannulae of pro-
gressively increasing size. Avoid causing trauma to the cervix or


























3. While holding the cervix steady, insert the cannula gently
through the cervix into the uterine cavity just past the internal
os. Rotating the cannula with gentle pressure often helps ease
insertion.
4. Push the cannula slowly into the uterine cavity until it
touches the fundus. Note the uterine depth by the dots visible on
the cannula. The dot nearest the tip of the cannula is 6 cm from
the tip, and the other dots are at 1-cm intervals. After measuring
the uterine size, withdraw the cannula slightly.
5. Attach the prepared syringe (vacuum established) to the can-
nula, holding the end of the cannula in one hand and the syringe
in the other. Make sure the cannula does not move forward into
the uterus as you attach the syringe. 
6. Release the pinch valve on the syringe to transfer the vacuum
through the cannula to the uterus. Bloody tissue and bubbles
should begin to flow through the cannula into the syringe.
7. Evacuate the contents of the uterus by moving the cannula
gently and slowly back and forth within the uterine cavity. Rotate
the syringe as you do so. 
8. Check for signs of completion. This procedure is usually
quicker than dilation and curettage (D&C) and is complete
when red or pink foam and no more tissue is seen in the cannula,
a gritty sensation is felt as the cannula passes over the surface of
the evacuated uterus, and the uterus contracts around (grips) the
cannula. Withdraw the cannula and detach the syringe.
9. IPAS instruments are labeled for single use in the United
States. However, reuse of syringes may be permitted in some situ-
ations.  Since the syringe does not come in direct contact with
the patient, decontamination and disinfection are sufficient.  To
decontaminate, remove the instruments from the patient while
you are still wearing gloves. Draw the decontaminating solution
(0.5% chlorine solution is recommended) through the cannula
into the syringe and drop the soiled instruments into the chlo-
rine solution.  Allow the items to soak for at least 10 minutes.
Then, disinfect with chemical disinfection soak (low to mid-level












turer's instructions.  Do not try to disinfect the syringe with heat,
because the valve assembly will crack.  
Uterine evacuation is occasionally followed by an accumula-
tion of blood clots in the uterus after surgery. This condition
(postabortion syndrome, or hematometra) can develop rapidly,
causing severe cramping pain that worsens within the first few
hours after vacuum aspiration. Examination shows a large, tense
uterus that is very tender with little or no bleeding at the cervix.
In this situation, remove the retained tissue or blood clots with
repeat vacuum aspiration or D&C. Consider giving methyler-
gonovine (Ergometrine) or other oxytocics to help maintain firm
uterine muscle tone and to expel any remaining tissue or clots. 
 





Infection often develops with retained pregnancy tissue because
the tissue is an ideal environment for bacterial growth. There are sev-
eral signs of infection:
• Pain in the abdomen or pelvis
• Cramping or backache
• Fever and chills
• Foul-smelling vaginal discharge
• Tenderness of the uterus and adnexa 
Teach patients to watch for these signs and to seek help immedi-
ately if any occur. Most often, signs of an infection appear 2 to 3 days
after the abortion, but the infection can begin earlier or as much as
several weeks later. If you suspect unsafe attempts to terminate the
pregnancy or a long delay in seeking postabortion care, make a pre-
sumptive diagnosis of infection even in the absence of clinical signs. In
these cases, begin antibiotic treatment immediately.
A patient needs urgent hospital care if she is severely ill, weak, has
low blood pressure (shock), or has an infection that extends beyond


























abdominal cavity (peritonitis). Evacuate the uterus of retained preg-
nancy tissue as soon as possible. Give the patient intravenous antibiot-
ics and fluids immediately and continue until she improves (has no
fever for at least 24 hours, for example) and is able to change to oral
treatment. If a hospital is far away, give antibiotics intramuscularly or
orally until the patient arrives at the hospital for intravenous adminis-
tration. 
If the infection is mild (involving only the uterus) and there is no
evidence of tissue remaining in the uterus, hospitalization may not be
necessary. Give the patient oral antibiotics and advise her to rest at
home. If she has improved satisfactorily within 2 or 3 days (she has
less pain, less uterine tenderness, and no fever), evacuation of the
uterus may not be necessary. However, if her symptoms persist or
worsen, or if her uterus is tender or enlarged, uterine evacuation may






Some bleeding is to be expected after treatment of either a spon-
taneous or an induced abortion. Bleeding is often scant (or absent) for
the first 24 to 36 hours, then increases somewhat as the uterine lining
loses the hormonal support of pregnancy. Moderate bleeding, similar
to a menstrual period, may continue intermittently for as long as 6
weeks.
Evaluate bleeding that is heavier than a normal menstrual period
or that continues regularly for more than 3 or 4 weeks. Heavy bleed-
ing may be caused by retained pregnancy tissue or by trauma to the
cervix, vagina, or uterus from instruments or chemicals. Some anes-
thetics, such as halothane, may also cause immediate uterine hemor-
rhage because they interfere with normal uterine contraction.
Prolonged bleeding may indicate retained pregnancy tissue. 
Hemorrhage can also be caused by a disruption in the normal
blood-clotting sequence. This problem (disseminated intravascular
coagulopathy, or DIC) is rare but sometimes occurs when an abortion












spontaneous uterine contractions begin. DIC may occur with severe
infection or may be triggered by an instillation of a hyperosmolar
agent.
Initial treatment for hemorrhage, such as repairing a cervical tear
or removing retained tissue, is often successful. If bleeding is very
heavy or the patient shows signs of shock (rapid pulse, decreasing
blood pressure, weakness, or faintness), begin massaging the uterus to
maintain firm muscle tone. Administer oxytocics or ergometrine and
ensure that arrangements are made for further care, such as intrave-






























Damage to the vagina, cervix, and uterus is a serious problem,
especially after unsafe abortion or when abortion is self-induced.
These injuries may be discovered only during the uterine evacuation.
Uterine perforation and intra-abdominal injury, including damage to
intestines, can result from an attempt to insert a foreign body (such as
a stick) into the uterus. Damage to the cervix or uterus is much less
common during the course of a vacuum aspiration abortion, but it can
occur. More commonly, tears of the cervix are caused by the clamp
(tenaculum) used to stabilize it during surgery. Vaginal injuries can
also occur if caustic chemicals, such as harsh soap or potassium per-
manganate, are used. 
A rapid pulse, weakness, faintness, or decreasing blood pressure
may be a warning that serious internal bleeding is occurring, possibly
as a result of damage to the large uterine blood vessels in the broad lig-
aments adjacent to the uterus. Pain, vomiting, abdominal tenderness
or rigidity, and decreased bowel sounds may be signs of intestinal
injury.
If you detect injuries, immediately discontinue the aspiration.
Further management depends upon whether the aspiration is com-
plete. If the uterus is perforated by a sharp instrument or by the vac-


















































Women who have attempted to induce abortion using drugs and
herbal preparations may show signs of poisoning, including kidney
and liver damage. Collect and measure urine to check for kidney dam-
age. Signs of liver damage include upper abdominal pain and jaun-
dice. Clinicians also may suspect attempted abortion if the vagina
shows ulceration or bleeding from caustic chemicals.
Some women who ingest ergonovine, chloroquine, or quinine to
induce abortion end up taking toxic amounts. Ergonovine poisoning
can cause vomiting, diarrhea, thirst, itching, numbness, and tingling
of the extremities, and can lead to confusion, cold skin, a rapid weak







Chloroquine poisoning causes headache, disturbances in
vision, gastrointestinal upset, itching, and, in some cases, rash. Toxic
doses of quinine cause stomach pain, nausea, vomiting, diarrhea, ring-
ing in the ears, dizziness, and vision disturbances. Severe central ner-
vous system effects of quinine poisoning include headache, fever,
confusion, delirium, faintness, depressed respiration, coma, and death






Aspirin is not an effective medica-




Induced abortion, whenever it occurs, indicates an unwanted preg-
nancy. This immediate postabortion period is an ideal time to discuss
contraceptive options and to understand why the unwanted preg-
nancy occurred. Counseling can help the woman avoid repeating the
experience of unwanted pregnancy and abortion. Tell the woman that
ovulation will return soon after an abortion and that she can become
pregnant again before her next menses. If she wants to become preg-
nant soon, provide information or referral for reproductivehealth ser-
vices. If she does not want to become pregnant soon, educate her
about all the contraceptive methods available and help her make an












1. If there are no complications after the abortion, recommend
that the woman abstain from intercourse until the bleeding
stops, then use any effective contraceptive method as soon as she
resumes intercourse.
2. After a second-trimester abortion or if the genital tract has
been traumatized or infected, the best contraceptive methods to
recommend are oral contraceptives, injectables, and condoms
and a spermicide. Hormonal implants can also be recommended,
but they are not available in all parts of Africa. Female steriliza-





this time. The diaphragm or the cervical cap should not be used
until 6 weeks following the abortion or until any infection or
trauma has healed. 
3. If there has been hemorrhage that has led to severe anemia,
the most appropriate contraceptive methods to recommend are
oral contraceptives, condoms and spermicides, or a progestin-
releasing IUD (if available).  Female sterilization, inert or copper-





until the severe anemia is resolved. However, temporary anemia
related to blood loss usually subsides very quickly. 
4. Although it is difficult to make a decision about long-term
contraception in emergency settings,
 
2,12,20,21 this is an ideal time
for patients to receive counseling and information about various
methods. For couples who want no more children, the postabor-
tion period may provide a convenient time for the male partner
to proceed with sterilization. The woman can recover from her
abortion at the same time her partner recovers from his vasec-
tomy, after which the couple may resume intercourse. 
5. In all cases, discuss the importance of condoms for protec-
tion from sexually transmitted infections (STIs), including the
human immunodeficiency virus (HIV). Condoms should be
























WHAT CLINICIANS CAN DO
Clinicians who provide reproductive health care will almost surely be
asked to evaluate or treat women who are having or have recently had
an abortion, either spontaneous or induced. To reduce complications
and mortality from abortion, clinicians are called upon to do the fol-
lowing: 
1. Improve the availability of comprehensive, high-quality
reproductive health care services, including contraceptive infor-
mation and services. Effective contraception can prevent the
occurrence of future abortions and their complications.
2. Provide supportive and nonjudgmental counseling about the
pregnancy termination. Abortion can cause tremendous emo-
tional and physical distress for women. They deserve to be
treated with dignity and compassion.
3. Providers, particularly at the primary and first referral levels
of care, must receive training in preventing maternal mortality
and morbidity from abortion complications. Increase access to
affordable and safe abortion services that use appropriate and
simple technologies such as the MVA. Recognize and manage the
medical complications of unsafe abortion so that problems can
be identified and treated early. 
4. Encourage active education and involvement of local
women's groups in issues of reproductive health, including sexu-
ality, fertility, contraception, STI prevention, and abortion.7,9,16,23
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Danger Signs After Treatment of Abortion
Caution n Fevern Chills
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n Tenderness in the abdomen in response to pres-
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n Foul-smelling vaginal discharge
n Delay (6 weeks or more) in resuming menstrual 
periods
If any of these signs are present, seek medical care.
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"I came to the clinic for an injection. No one told me that 
Depo-Provera might cause changes in my monthly bleeding. 
It was a frightening experience because I didn't know what was 
happening.  After it was explained to me that nothing was 
wrong, I felt much more comfortable."
 
Almost all family planning clients need information about child spac-
ing and birth control methods. Many have questions. Nearly all will
need instructions on how to use their selected method of contracep-
tion. Teaching facts and skills to your clients is called education.
Some clients also need counseling, which involves exploring the
client's emotions and helping her solve problems. Women may need
counseling on how to encourage their partners to accept family plan-
ning. If a woman has a sexually transmitted infection (STI) or an
abnormal laboratory test, she will need counseling to help her manage
the situation and decide what to do.
Good education and counseling require good communication.
How the provider talks to the client can sometimes mean the differ-
ence between whether the client is a successful user of family planning
or an unsuccessful one. The important elements communication































*(see the BRAIDED list later in this chapter)
In addition to following these general suggestions, the provider






—The skills and knowledge family planning cli-
ents need to make informed decisions and to use their cho-
sen contraceptive methods successfully. Teaching about
specific contraceptive methods should include the basic ele-
ments described in the word BRAIDED, which is discussed






—The help clients need to overcome obstacles
posed by lifestyle, life situations such as a partner who is not




In many parts of Africa, few women are formally educated
beyond the early grades. Thus, few women know much about anat-
omy, the reproductive cycle, or the facts of family planning. Clients
generally already have some information about family planning meth-
ods that they obtain from family and friends or from their own experi-
ence. Their information may be accurate, or it may be dangerously
wrong. The provider's responsibilities include helping correct inaccu-









































The following principles, which are based on ways in which




Allow time for the client to discuss her questions and con-





Involve the client actively. The client learns from what she
does, not from what the provider does.  Have her touch and
handle birth control methods; role play, if necessary. Make
sure the client understands by asking her to repeat the direc-




Teach with stories and examples. Abstract ideas are grasped
more easily when presented in a human context. For exam-
ple, compare two couples, one using birth control and the
other experiencing an accidental pregnancy. Use simple hand




Be gentle in manner and technique. People learn best when
they feel safe and calm. A person coming for a medical exam-




Anxiety and disappointment interfere with learning. People
who learn they are pregnant when they do not want to be,
have a sexually transmitted infection (STI), or are worried
about some aspect of their health often say they remember





The average person understands and remembers about three
messages at one time. Think about the few most important
facts the client must know and teach her those. Almost no cli-




 she needs to know in one visit. Invite her for
a group session; provide take-home materials she can under-
stand; schedule another visit if needed. (See Table 23:1.)
Remember:
— First things first. What's most important?
— Keep it simple. Use words clients understand.



























— Be specific. Do not say "Take your pills on time."
Instead say "Take your pills every morning after break-
fast or pick another time that is better for you."




Give factual, unbiased information about the various birth
control methods. The word BRAIDED can help you















Risks of the method (both major risks and all common 














Decision to withdraw from using the method without penalty 








Documentation that the provider has covered each of the 
previous six points
 
Table 23:1 Education programs in family planning settings
 
• Teach group classes
• Educate and counsel individual clients
• Present 10- to 20-minute audiovisual programs
• Display posters
• Hand out materials (written and pictorial)
• Set up libraries and reading areas
• Demonstrate the use of birth control methods on life-like models
















Consult Chapter 11 on the Essentials of Contraception for summaries
of important information you can use in discussions with clients
about the advantages and disadvantages of contraceptive methods and
instructions for using them.
 
PRINCIPLES OF COUNSELING 
 
Family planning decisions often come from the heart. How to select
when to have a baby, how many children to have, and what contracep-
tive method to use are often emotional choices. Clients facing family
planning decisions may have intense feelings of anger, anxiety, fear,
disappointment, or even joy. Although the provider can offer facts to
help the client choose, the provider must also acknowledge and discuss
the client's feelings as well.







For example, say  "Yes, you are pregnant. Can you tell me




Do not make decisions for the client. The best response to
"What do you think I should do?" is "What do you think? I









Open-ended questions uncover more about the client than




Avoid asking "why" questions. "Why" questions are usually
difficult or impossible to answer. Clients can feel threatened




Help preserve hope, even in the face of a terrible illness such





Cultural values and ideas learned in childhood strongly influence
each person. Cultures vary widely in their attitude toward reproduc-
tive lives. Care providers need to know the cultural values of the client




























• The ideal family size
• Who makes sexual decisions
• The typical marriage age
• How the culture understands the causation of unintended
pregnancy or illness
• Who the powerful healers are
• What the client considers safe to tell the care provider
• How the husband (or wife) will respond to your care
• Whether the cultural communication style is direct or indi-
rect or formal or informal
Balance your understanding of each client's unique personality
with an awareness of and respect for influential cultural values and
characteristics.
 
At the family planning clinic, Mrs. K asked for some way to give her
space and a rest between pregnancies. She had not asked her husband for
permission. However, he learned of her actions and said he would divorce
her if she continued using contraception. She stopped and soon became
pregnant.
 
In many cultures, women often are not given the authority to
make the decision to practice family planning. In sub-Saharan Africa,
there are still many women who do not seek more children but who







(See Chapter 11 on Essentials of Contraception.) However, more
than half of women who report their husbands disapprove of family







women need to know how to initiate nonthreatening discussions with
their husbands, then select methods that would suit the couple's rela-
tionship.
Conversely, men need education about the benefits of family
planning. They need to learn that modern contraception will not
harm them, their wives, or their children. In some cases, providers will
















faces serious consequences from her husband if she makes family plan-
ning decisions on her own. A village leader or wise man, a religious
leader, a respected elder, or a relative may help by talking with the hus-
band and helping him understand the benefits of a planned family.
(See Chapter 1 on the Benefits of Family Planning.) Situations in
which a client's spouse is opposed to family planning are difficult for
both the client and the provider. Solutions are more likely found if the
providers can gain the support of their clients' communities.
 
PRINCIPLES OF BEHAVIOR CHANGE
 
Not all clients are equally ready to undertake changes in their daily
lives that will promote their personal health, such as abstaining from
sex or using condoms when there is a risk of STI, stopping smoking, or
taking birth control pills. However, the health care provider can help
the client move along a continuum, progressing from no change to lit-
tle to moderate to complete change. Because change is incremental,
interventions must be tailored to the client's particular position along













which are detailed in Table 23:2.
In individual counseling, asking one or two questions ("What are
you doing to protect yourself from accidental pregnancy?" "When
would you like to become pregnant?") can help place the client along
the stages of change continuum. Then, you can use the limited time
available for education more effectively.
People change behaviors as a result of acquiring a new skill more
often than as a result of gaining new knowledge. In teaching new
skills, adapt the intervention to the client's own readiness for change.
Setbacks are common with any attempt to change human behav-
ior. Clients whose behaviors slip back to an earlier level will need extra
help with renewed (and perhaps re-thought) goal setting, a boost in






























to “What do you 
do to protect 
yourself from 
AIDS?”




Precontemplative Not aware of 
risk, denies 
risk, no plan 
to change
“Who me?” Teach risk awareness 
facts, show models 
of desired behavior







setting, teach skills 
required for change, 
promote self-efficacy, 
(“You can think for 
yourself.”)
Ready for action Has a plan, 
some action 
steps
“I checked out 
condoms in the 
drugstore the 
other day.  
There must be 
30 brands!”
Assist with personal 
goals, reinforce skills, 
promote self-efficacy
Action Change has 
begun, change 
is new
“From now on, 
no sex without 
condoms!  Got 




efficacy, show models 
of desired behavior
Maintenance Change is in 
place, change 
is sustained






show models of 
desired behavior
 



















Because many African women have only limited reading skills, educa-
tional materials need to be designed that will be suitable for such an
audience. Educational materials can be made more interesting, rele-
vant, and motivating if they use stories, especially because Africa has a
great tradition of storytelling.
In print materials, the text should use simple words, short sen-
tences, and as many pictures as needed to communicate the message.
Print materials in many forms are appropriate, such as pamphlets, fly-
ers, letters, posters, and newspapers.
For many women, the spoken word is more effective. Classes,
group meetings, or messages given during entertainment can get the
information across. A number of nations have found that radio broad-
casts are very helpful in reaching both women and men. Although
rural populations are often targeted, people who live in urban areas
also can benefit from radio broadcasts. Examples of radio dramas




























Table 23:3 Main characters and plots of radio dramas in four 
countries
 





Jonasi Musekiwa and his two 
wives; Herija, Jonasi's best 
friend and coworker; Mbasera, 
a city friend of Jonasi's; and 
Chigwande, a rural health 
worker.
Jonasi, who works in the city, 
struggles to support his 15 
children home in the village. 
Herija encourages Jonasi's 
spendthrift ways and extra-
marital affairs, while Mbasera 
urges him to be more 
responsible.
"Ezi na Uno" 
(Nigeria)
Emeka and Nneka, a married 
couple satisfied with four 
children; Emeka's mother; and 
Obiageli, the woman Emeka's 
mother wanted him to marry.
Emeka's mother demands 
more grandchildren, and 
Obiageli (already the mother 
of seven, but with marital 
difficulties) tries to win Emeka 




Fakube Jarra, a local wise man; 
Fa Abdou and Mba Kujay, a 
monogamous couple with 
three daughters; Jainaba, 
Fa Abdou's widowed sister; 
and Fa Mamodou and Mba 
Hawa, a polygamous couple 
with six sons.
Jainaba and Fa Mamodou 
both have difficulty 
supporting their families but 
try to convince Fa Abdou that 
he should have more children. 




Obo and his two wives, Adodo 
and Kawe; Adodo's mother; 
and GideeGidee, a witch 
masquerading as a traditional 
healer.
Kawe tries to introduce 
modern hygiene into the 
household, but jealous Adodo 
and her mother assume Kawe's 
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Clinical Implications of 
Management Decisions
 
A woman visited a rural family planning clinic for the fifth 
time to get pills.  The first time she received just one cycle of pills; 
each of the four succeeding visits she was given three cycles of 
pills. It took her 3 hours in each direction to come to the clinic 
and 30 minutes to an hour to get her pills. Each clinic visit cost 
her a day away from her field, making life just a bit more diffi-
cult for her. But she loved knowing that she couldn't get preg-
nant, so she returned. She never returned for her sixth pill visit, 
because her child was injured the day before the appointed date. 
Caring for him kept her from returning for the next 3 weeks. 
Without contraceptive protection, she became pregnant. The 
pregnancy was in her tubes. She died during the 3-hour trip to 
the hospital. 
 
Reproductive health care is probably burdened with more laws, rules,
biases, and administrative policies than any other area of medicine.
Each administrative ruling, regulation, or protocol can act as a major
barrier to the provision of high-quality services. For example, a pro-
vider may be limited to dispensing only one to three packages of oral
contraceptives (OCs) at a single visit, even though a woman is far
more likely to continue to take OCs if she can get a year supply of pills


























Medical practice is dramatically influenced by administrative
decisions made because of national laws, decisions made by a ministry
of health or a regional health board, and medical policies established
for a local clinic or even by an individual physician. Administrative
decisions affect not only the services provided but the patient's choice
and successful use of contraceptives. The motivation behind these
administrative decisions and policies is often religious, political, social,
or economic and does not always take into consideration the quality of
the services provided each client. Family planning providers can be
caught in the middle between the administrative decisions and their
personal, professional interpretation of what is needed to provide
high-quality services. Providers may confront serious dilemmas when
forced to choose between compromising the quality of care by adher-
ing to a short-sighted policy and endangering professional relation-
ships by circumventing the policy. 
Thus, it is important that providers play an active role in devel-
oping national service policies, norms, and procedures. In general,
policies state the philosophy guiding family planning services and set
forth rules and regulations. Norms, or standards, specify the mini-
mally acceptable levels of performance expected of the providers. Pro-
cedure guidelines, or protocols, detail the step-by-step instructions for
performing clinical tasks.
Examples of some of the administrative questions that might
affect the clinical management of patients are presented in Table 24:1.










































Reproductive health care providers must be responsive to the
needs of the client. The goal is to provide safe, effective services in a
manner acceptable to the clients. Reproductive health care providers
must evaluate their programs' policies and the effect these policies
have on the health care provided. Some of the administrative decisions
providers should consider, the possible impact of these decisions on
the clients, and current recommended practices are presented in Table
24:2. This table is arranged to correspond to the policy questions
posed in Table 24:1.
Around the world, reproductive health decisions made by indi-
vidual clients and their providers are strongly influenced by the legal,
social, economic, and religious milieu of the place where they are
made. If providers want to change medical practice to improve the
health of individual clients, they must first examine the policies that
affect their clients and their own practice of reproductive care (both
the individual program's policies and the country's laws or policies
that govern reproductive health care). They must review the guidelines
in their national reproductive health programs to make sure they max-
imize both access to and the quality of family planning services. They
must then move out into the legislative arena, religious institutions,
the media, and the field of public health to bring about new or modi-



























Table 24:1 Service delivery policies, norms, and procedures
 














Are antibiotics available to treat pelvic infections, and are they available








Is a policy in effect directing clinicians to remove the Copper T 380A










Must new pill clients have a pelvic exam before beginning pills?  Are Pap




How many packages of pills may a woman obtain initially?  For resupply?









Can nonsmoking women 35 years and older without cardiovascular risks











Is information about the availability of emergency contraception part of




Is the Copper T 380A inserted as an emergency postcoital contraceptive
































How are the surgeons paid who perform sterilization procedures (per




Must husbands or partners sign an authorization form for their wives or








Are there rules indicating how many children a woman must have and





















Are nurses or physician assistants trained to insert and to remove Nor-
plant implants?
 




Do you routinely offer to screen women for infection with the human















































Does the program permit providing contraceptives to unmarried or sin-
gle women?  Unmarried men?  Must an unmarried adolescent have




































Does the form used for the documentation of a contraceptive visit ask
questions about the frequency of intercourse, number of sexual partners,























Is there a steady, dependable flow of contraceptives and supplies from the









Can clients receive resupplies quickly, or must they wait with clients





































A woman must be 
menstruating to have 
an IUD inserted.  The 
policy applies to all 
women, including 
women who have not 
had sexual intercourse 
in the recent past, 
postpartum women, 
and women who have 
traveled long distances.
Insertion of IUD may 
be unnecessarily delayed 
and extra visits and pelvic 
exams required.  
It may be inconvenient, 
uncomfortable, or 
impossible for a women 
to return to a clinic 
during her menstrual 
period.
Permit IUD insertion for 
nonmenstruating women 
or if she:
• is partpartum and has 
not had intercourse 
since delivery
• is postpartum and 
all acts of intercourse 
have been protected
• has not had inter-
course since last 
menses
• has been taking pills 
correctly
• has just had her menses
Uterine sounds are not 
available in busy clinic 
inserting IUDs.
Clinician forced to 
rely on pelvic exam to 
determine size, axis, 
and flexion of the uterus.  
Perforation  
may result when mistakes 
are made.
Adequate sterile sounds 
should routinely be 


































Provider inserting IUDs 
not allowed to manage 
infection. Antibiotics for 
a full 10- to 14-day 
treatment of pelvic 
inflammatory disease are 
not available for clinic to 
dispense.
Clinicians may refuse to 
insert the IUD at all if 
antibiotic treatment is 
unavailable should a 
pelvic infection occur. 
Untreated infections may 
lead to severe compli-
cations. Clinicians may 
be unwilling to insert 
IUDs if they believe 
follow-up is inadequate. 
The clinician who 
diagnoses a borderline 
case of pelvic inflam-
matory disease (PID) may 
use a "watch and wait" 
approach that leads to a 
more serious infection. 
Removing the IUD 
might have been more 
appropriate management.
In most instances, clinic 
providers should be able 
to manage the compli-
cations of the contra-
ceptives they provide, 
including PID in IUD 
users. Alternatively, 
providers should be 
trained to recognize 
symptoms of common 
complications and refer 
patients to a larger clinic 
for treatment. Anti-
biotics such as tetra-
cycline (or doxycycline) 
and ampicillin should be 
available for treating 
women with PID.
The levonorgestrel (LNg 
20) IUD is not available.
An IUD that decreases 
a woman's risk for 
dysmenorrhea, PID, 
menorrhagia, and uterine 
myoma is withheld from 
use.
The LNg 20 IUD should 
be approved by the 
country's regulatory 
agency and made avail-
able and accessible to 
women.
The Copper T 380A 
must be removed after 
4 or 5 years.
Women must have a 
highly effective, well-
tolerated device removed 
too soon.
The Copper T 380A may 
be left in utero for at least 
10 years.
 



































OCs can only be 
prescribed by a physician.
Because most physicians 
in most developing 
countries live in urban 
areas, many rural women 
may be unable to obtain 
pills.
Trained nurses and 
paramedical workers can 
provide pills by using a 
checklist to screen for 
contraindications. 
Physicians can handle 
complications and 
difficult cases and 
supervise the nurses and 
paramedical workers.
A Pap smear must be 
performed before a 
woman can begin oral 
contraceptives. A Pap 
smear must be per-
formed annually for 
every woman given 
oral contraceptives.
If Pap smears are required 
to begin pills, many 
women, especially rural 
women, may have to rely 
on less effective methods 
until they get to a clinic. 
They may become 
pregnant while waiting 
for an opportunity or the 
money to visit a clinic. If 
Pap smears are not done 
at a particular clinic or 
materials are temporarily 
unavailable, oral contra-
ceptives may not be 
offered.
Pap smears are a desirable 
routine medical screen-
ing procedure for sexually 
active women. However, 
because the contraceptive 
and noncontraceptive 
benefits of oral contra-
ceptives give them a 
desirable benefit-to-risk 
ratio in most settings, 
they should be offered to 
women even if routine 
Pap smears are not 
available.
 

































A limit of 1-3 packages 
of OCs is set as the 
maximum provided at 
one visit. Women must 
return to a clinic for 
OCs 4-12 times a year.
Clients may be more 
likely to discontinue 
OCs. Methods that 
involve a "single decision" 
may be far more attractive 
than OCs. For example, 
an IUD may become 
more attractive than OCs 
even if a woman has 
reasons to avoid an IUD. 
Use of OCs is difficult for 
women who must 
frequently travel long 
distances for resupply.
In deciding the number 
of cycles to provide, 
always be aware of the 
distance and cost to the 
client to reach the 
provider. After a woman 
has used OCs correctly 
for 13 months without 
side effects, compli-
cations, or problems, 
strongly consider offer-
ing up to 13 cycles of 
OCs at a time.
A post partum woman 
must have had her first 
period before OCs are 
begun.
OCs are eliminated as an 
option for a woman who 
may ovulate and become 
pregnant before her first 
postpartum menstrual 
period.
• Provide OCs to 
nonbreastfeeding 
women just after 
delivery or encourage 
women to start OCs 2 
to 3 weeks post-
partum.
• If a woman is seen 
6 weeks portpartum, 
is not breastfeeding, 
has not had inter-
course, and has not 
had a menstrual 
period, start OCs but 
have patient use 
condoms in addition 
to the first cycle of 
OCs.





















aged 35 years and older 
are not to be provided 
OCs, even if they have no 
risk factors for 
cardiovascular disease 
other than age.
Providers are unable to 
prescribe a safe, effective 
method of birth control 
to older women. The 
beneficial effects of 
OCs in preventing 
ovarian and endometrial 
cancer are not available 
for these women.
Permit nonsmoking 
women 35 to 40 years of 
age to be provided OCs 
with less than 50 mcg of 
estrogen—as long as they 
have no other risk factors 
for cardiovascular disease, 
such as hypertension or 
diabetes.
Emergency contraceptive pills (ECPs)
ECPs are not readily 
available.
A method that could 
reduce the risk of 
unintended pregnancy by 
75% is denied to women, 
leading to increased 
abortions, many of which 
are illegal and performed 
in a dangerous manner.
Provide information to 
patients and providers 
about ECPs and post-
coital insertion of the 
Copper T 380A. Use 
OCs in high doses within 
72 hours of unprotected 
intercourse to prevent 
unintended pregnancies.
Use of the Copper T 
380A as a postcoital 
contraceptive is 
discouraged.
A method even more 
effective than ECPs is 
denied to women. In 
addition, these women 
miss the opportunity to 
initiate long-term use of 
an extremely effective 
method.
Change policies to 
encourage use of copper-
releasing IUDs as 
emergency postcoital 
contraceptives within 
5 days of unprotected 
intercourse.
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Sterilization
Husband or partner must 
authorize a tubal ligation 
for his wife or partner.
Tubal ligation may be 
eliminated as an option 
for an individual woman 
whose husband or partner 
wishes to control the 
decision as to how many 
children she will have.
Although it is clearly 
desirable for men and 
women to discuss and 
agree, women who bear 
children and carry a 
major share of the 
responsibility for rearing 
them should generally be 
able to decide to stop 
having children.
Emergency gynecologic 
and obstetric procedures 
take precedence over 
tubal ligations when 
operating room time is 
allocated.
Tubal ligations are 
delayed for women or 
never performed at all. 
Unplanned pregnancies 
occur.
Increase the amount of 
operating time, supplies, 
and personnel available to 
perform tubal ligations.
Women must have a 
certain number of 
children (e.g., three) and 
be a certain age (e.g., 30) 
before having a tubal 
ligation.
Women who know they 
want to stop childbearing 
are potentially unable to 
do so. Young women who 
want to finish their child-
bearing must endure the 




laws or medical regu-
lations limiting sterili-
zation to women on the 
basis of the number of 
children they have had 
and their age.
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Sterilization (continued)
Physicians are paid for 
the sterilizations they 
perform on a per-case or 
per-hour basis.
Physicians who are paid 
to work fast to earn more 
money may work too fast 
and thereby increase the 
risk of injury to the 
patient. Physicians who 
are paid on a per-case 
basis may pressure clients 
into sterilization to 
increase their wages and 
may not permit clients to 
change their minds before 
undergoing sterilization.
Clients should freely and 
voluntarily choose 
sterilization without 
pressure and be provided 
as high a quality of 
surgery as possible. 
Consider reimbursing 
physicians with a salary or 
on a per-session basis to 
avoid any possibility of 
coercing patients or 
providing less than the 
best care possible.
Barrier methods
Only 3, 6, or 12 condoms 
may be provided at one 
visit. Condoms in large 
numbers are either 
unavailable, expensive, or 
embarrassing to obtain.
Makes condoms less 
attractive as an interim 
(e.g., between IUD 
removal and initiation of 
OCs) or long-term 
method. Relegates 
condom use to prevent-
ion of STIs. Diminishes 
the desirability and the 
credibility of condoms in 
the eyes of both provi-
ders and patients.
Consider offering large 
numbers of condoms at 
each visit (e.g., 40 to 100 
condoms). Provide 
condoms anonymously 
to men or women. 
Encourage patients to 
give them to friends 
and relatives.
No contraceptive services 
are to be provided 
without documentation, 
including condoms to 
adolescent boys and older 
men.
Usually means that 
everyone receiving any 
contraceptive services 
must have a history taken 
or a physical exam per-
formed. These practices 
can discourage people 
from using services.
Provide contraceptives 
such as condoms and 
vaginal spermicides 
anonymously without 
requiring that individuals 
officially "sign up" or be 
examined.
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Injectables or implants
Norplant implants or 
injectables will be 
available for women who 
want to use these 
methods.
An important "single 
decision method" is 
available that will provide 
highly effective 
contraception for the 
person not wishing to 
consider sterilization at 
this time.
Gaining official clearance 
for Norplant is an 
important priority. 
Training programs for 
inserting and removing 
implants must be 
established. Follow-up 
systems must be 
functional to retrieve 
implants at the time of 
expiration.
Sexually transmitted infections (STIs)
Screening will be 
performed on a routine, 
voluntary basis on family 
planning clinic clients.
Discussion of sexual 
history and explanation 
of HIV infection becomes 
part of patient manage-
ment. Screening is time-
consuming and expen-
sive. Condom use is 
encouraged.
Offer volunteer HIV 
screening and provide 
adequate training and 
personnel to take the 
required history and 
to do the necessary 
counseling.
Sexual history is not 
routinely taken.
Sexual problems are 
not identified.
Several routine questions 
should be asked of all 
patients and included 
on history forms.
Microscopes are not 
provided to local family 
planning clinics for 




and Candida infections 
are more difficult to 
diagnose. Clinicians have 
to guess the diagnosis 






available at all clinic 
sites where pelvic exams 
are performed. Train 
personnel to manage 
STIs syndromically (see 
Chapter 6) in the absence 
of testing capability.
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Adolescent clients
An adolescent female 
must be married, have a 
baby, or have parental 
consent to receive 
contraceptive services.
Unmarried adolescent 
females who are sexually 
active may get pregnant. 
Whatever the policy, it 
may present an ethical 
dilemma for a provider. 
Those who are willing to 
serve an adolescent may 
feel pressure to indicate 
on the chart that they are 
prescribing OCs for 
noncontraceptive indi-
cations such as acne, 
dysmenorrhea, or heavy 





parental consent. Make 
sure they understand that 
abstinence is an option, 
but permit them to 
obtain contraceptives to 
prevent an unwanted 
pregnancy. Sex education 





A complete pelvic exam 
must be performed for 
every adolescent female 
obtaining OCs.
Initial pelvic exam may 
be uncomfortable for 
young women. Initial 
pelvic exam may deter 
adolescents females from 
coming to family 
planning clinics.
Flexibility is particularly 
desirable in this situ-
ation. Permit and 
encourage abbreviated 
exams. Have small 
speculae available to 
minimize discomfort. 
Consider providing OCs 
without the absolute 
requirement of a pelvic 
exam.
An adolescent female 
must have regular periods 
before being given the 
pill.
Pregnancies will occur in 
young teenagers who are 
denied access to OCs. 
Ovulation may precede 
the onset of regular 
menses in some women.
Provide OCs to young 
women who are sexually 
active and do not use 
condoms or another 
contraceptive. Make 
them aware of the risks of 
HIV and other STIs.
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Adolescent clients (continued)
Separate hours or 
facilities for adolescents 
are not provided.
Because young women 
and men may feel 
uncomfortable visiting 
during regular clinic 




separate hours or facilities 
for adolescents. Train 
providers to understand 
the emotional, sexual, 
and reproductive health 
needs of adolescents.
Clinic management
Appointments are made 
on a first-come, first-
served basis.
Tends to produce long 
waits. Permits women 
and men to come to the 
clinic at any time.
Provide care to some 
patients with an appoint-
ment system and make 
every effort to honor 
those appointments. 
Permit some patients to 




pregnancy tests are 
handled like routine 
appointments.
A delay in exam may 
adversely affect the 
outcome in cases of IUD 
expulsion, vaginal and 
pelvic infection, and 
urinary tract infections. 
Pregnancy termination, 
where available, may be 
delayed.
Appointment clerks must 
be taught a system of 
priorities (triage) so that 
women with urgent needs 
can be seen as soon as 
possible. Unprotected 
intercourse that could 
lead to unwanted preg-
nancy should be consi-
dered a high priority.
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Clinic management
Clinic hours limited to 
8 am to 4 pm, Monday 
through Friday or to 
1 day a week. No evening 
or weekend clinics.
Employed women with 
limited leave time are 
unable to attend the 
clinic during these hours. 
Men (partners and 
clients) may also find 
these hours difficult. 
Restricted hours are 
potentially dangerous for 
women with compli-
cations. Clients with 
problems may be forced 
to seek assistance from 
providers they do not 
know.
A wide range of clinic 
appointment times is 
desirable. Specify evening 
and weekend hours. 
Women should be taught 
exactly where to go for 
help should a 
contraceptive problem 
develop outside of clinic 
hours.
Forms in clinic fail to 
include questions about 
frequency of sexual 
intercourse, number of 
sexual partners in the 
past year and over the 
past decade, use of 
illegal intravenous drugs, 
number of STIs in the 
past, or number of acts of 
unprotected intercourse.
Provider's attention not 
directed to women at 
high risk for STIs 
(including HIV), sexual 
problems, or women at 
high risk for unplanned 
pregnancy. Some 
providers may be less 
embarrassed to respond 
to patients' written 
description than to ask 
questions.
Forms should include 
some questions about 
sexual subjects even if the 
provider finds them 
difficult to ask. If clients 
are literate, self-
assessment forms (which 
women may fill out) may 
provide a more complete 
history and minimize 
embarrassment for client, 
provider, or both. 
Provider training should 
include taking a sexual 
history, counseling on 
prevention, enhancing 
client comfort, and 
having an open attitude.
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Clinic management (continued)
A chaperone must be 
present in the exam room 
for all pelvic exams, 
whether the examiner is a 
male or female. 
Patient does not control 
what is happening to her. 
This rule may help the 
clinician to see patients 
more quickly or it may 
have just the opposite 
effect if clinician must 
wait for the chaperone. 
Patient may not ask 
certain personal questions 
if an additional person is 
in the exam room. This 
policy may increase a 
woman's embarrassment 
about being examined.
Be guided to some degree 
by patient's stated 
preference. Some women 
would prefer that only 
one person, the exam-
iner, be present at the 
time of the exam, and this 
preference should be 
respected if possible.
Clients are interviewed in 
front of other women 
waiting for services and 
are examined without 
adequate privacy.
Clients may feel 
uncomfortable discussing 
issues with the provider 
with others present and 
will feel acutely 
embarrassed to be 
examined without 
adequate privacy.
If possible, provide a 
separate room or place a 
curtain near a corner for 
individual counseling of 
clients. Always ensure 
privacy during exams by 
providing screens around 
the examining table and 
by not permitting guests 
to interrupt exams.
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Clinic management (continued)
Providers speak the 
language of the educated 
(using very technical 
terms) to establish a 
professional identity.
Many potential family 
planning users do not 
understand the language 
of the educated provider. 
As a result, they are 
unwilling to seek services 
at the clinic or, if they 
do, they do not under-
stand the instructions 
regarding use of the 
contraceptive method.
Ensure that at least one 
person on the staff speaks 
the language or dialect of 
most of the clients served 
by the clinic or program. 
Make available informa-
tional materials in local 
languages.
To encourage more 
effective contraceptive 
use, providers are paid 
differential incentives 
for encouraging certain 
methods, such as the 
IUD or sterilization.
Providers who are paid 
more (or given incentives) 
for providing IUDs or 
sterilization than for 
other methods may be 
tempted to push these 
methods over others, 
even when they may be 
contraindicated for 
medical or social reasons.
Clients should be 
informed about a range of 
methods and assisted in 
selecting the method 
most appropriate for 
them medically and 
psychologically. The 
client should freely 
choose the method 
without coercion.
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Clinic management (continued)
The procedures for 
ordering and shipping 
contraceptives from 
central stores to local 
clinics and providers 
result in an inconsistent 
local supply.  Although 
contraceptives are very 
inexpensive, particularly 
if donated, their distri-
bution is often handled 
by supply officers who 
attempt to ration 
contraceptives like 
expensive antibiotics, 
thus arbitrarily altering 
supply requests.  In 
response, clinics begin 
tripling their require-
ments in anticipation 
of reductions.  The lack 
of an appropirate supply 
policy leads to clinics 
running out of contra-
ceptive supplies.
Clients may visit 
clinics or providers at 
great cost or may travel 
long distances to discover 
the contraceptive they use 
is unavailable.  They are 
discouraged from 
continuing the method 
and may have an 
unwanted pregnancy.  
The motivations of 
providers as well as their 
reputations suffer when 
they cannot provide 
methods to clients.
Establish a dependable 
supply of contraceptives 
from central depots to 
local providers.  
Encourage providers to 
project contraceptive 
needs and order supplies 
early.  When shortages 
occur, allow providers to 
borrow supplies from one 
another.








































Approaches to Delivery of
Family Planning Services
 
A young married couple with an infant child decided they 
would like to wait a few years before having their second child. 
When the wife went to the well-baby clinic on Friday, she asked 
how she could delay her next pregnancy. The nurse told her to 
return on a Tuesday, which was the day the clinic provided 
family planning services. The young woman knew she would 
not have time to make a separate trip for family planning 
services as well as baby care, so once back in the village she asked 
a friend who used family planning where she went for services. 
The friend promised to ask her community health and family 
planning worker to visit the woman. At the visit a few days 
later, the community worker explained the methods of family 
planning available. They decided that the injectable hormonal 
contraceptive was the best method for the young woman at this 
time. The community worker administered the shot, collected 
the small fee, and said she would return during her next visit to 
the village. Then, if the woman had no problems with the 
method, the community worker would return every three 
months to provide the injections.
 
For a family planning program to meet the needs of its clients and






























wants to use them. The easier it is to obtain contraceptives and ser-





vices meet the following criteria:
• They are relatively 
 
easy to get to
 
.




 clients do not wait too
long for services, providers listen and respond to the needs of
the clients, providers are technically skilled, and clients
receive the services they need. 




.   
• The concept of family planning and the services provided by




 so that everyone who wants
to space, limit, or prevent births knows that there are ways to
do these things, knows about the program, and knows where











explain the contraceptive methods
 
 that are
available so that clients can decide what method is best for
them.   
•
 
An adequate supply 
 
of contraceptives is always available.   





How do the family planning services offered by the health system
in which you work respond to your clients' needs?  How many of the
characteristics listed above describe your program?  Can you provide
each client with the right contraceptive method and medical care if
there are complications?  The range of health and family planning ser-
vices offered in Africa differs considerably from country to country.
Some countries offer family planning services through a well-developed
network of clinic services. Others have established clinic-based systems
but find that shortages of medical personnel and money prevent them
from reaching remote populations. As a result, these countries have
developed community-based approaches to providing health and fam-
ily planning services, including distributing some contraceptives
through commercial sales. Family planning program managers can
choose from a variety of service delivery approaches. In fact, managers
can select a combination of approaches to make their services accessi-


































Service delivery strategies need to be tailored to reach populations in
different locations—urban areas, rural towns, villages, and remote areas.
The most common service delivery sites include clinics, community-
based distribution (CBD) programs, commercial retail sales, workplace
programs, postpartum programs, and private physicians. Advantages

















A clinic-based approach is reasonable in areas where clients do
not live far from the clinic. Clinics often have the advantage over other
service delivery strategies of being able to provide methods that are
more medically complex, such as intrauterine devices (IUDs), hor-
monal implants, injectables, and sterilization. 
In urban areas and rural towns, family planning is most often pro-
vided by clinics that integrate it with other health services for women
and children or offer it only on certain days of the week. (It is prefera-
ble, but not always possible, to have family planning services available
during all the hours that the clinic is open.) Most government-run
clinics are integrated clinics that offer multiple health care services; pri-





 integrated clinic has these features:   
• All staff members are trained to provide family planning ser-
vices.   
• All staff are trained together and thus feel confident of each
other's abilities; one member can readily stand in for
another.   
• One supervisor oversees all staff members.   
• The supply of medicines, contraceptive supplies, and vac-
cines through one channel is dependable.   
• Difficult cases are referred to specialists and the original pro-


























Table 25:1 Advantages and disadvantages of approaches to 






• Clients are seen at each visit by health 
care professionals.
• Problems can be detected and treated 
during the visit.
• A switch in contraceptive method can 
be  accomplished easily at the clinic.
• The whole range of contraceptive 
services can be provided, including 
sterilization, intrauterine devices 
(IUDs), and injectables.
• Clients are limited primarily to those 
living near the clinic.
• The nurse or midwife might not be 
familiar to the client because the 
client may not see the same staff 
member each time.
• Clients are expected to come on their 
own initiative, both initially and for 
follow-up.
• Clients may have a long wait before 
receiving  services.
 
Clinic-based Services: Integrated family planning and maternal and child health
 
• Clinic can attract mothers coming for 
other services and introduce them to 
family planning.
• Users can receive pediatric, obstetric, 
and gynecologic care, along with 
family planning services in one 
setting.
• In theory, there are easier transitions 
from postpartum to family planning 
and from family  planning to prenatal 
care.
• Clients who are uncomfortable with 
the social stigma, if there is one, of 
contraception are not so easily 
identified as users of family planning.
• Family planning can be established as 
an important element in the health of 
women and children.
• Start-up costs of providing family 
planning care are low if maternal and 
child health (MCH) services are 
already available.
• Family planning issues are generally 
considered only after child and 
maternal health problems are 
addressed.
• Administrative functions are more 
complicated,  especially if contra-
ceptive resupply and reporting of 
service statistics for family planning 
services are not integrated with the 
support systems of the MCH 
program.
• Workers who are not specifically 
trained in family planning may lack 
the needed skills and motivation to 
be effective providers.
• The physical facility (clinic or health 
center) may not be able to accom-
































Clinic-based Services: Family planning only
 
• Family planning workers are more 
motivated to deliver family planning.
• More time can be spent counseling 
and educating each client about 
family planning.
• Generally, a better worker-to-client 
ratio exists for family planning.
• Workers who have received special 
training in family planning may be 
more effective.
• Unmarried women without children 
may be more comfortable in this type 
of facility.
• Clients must be motivated to come 
on their own for family planning 
services.
• Transitions are not smooth from the 
postpartum to the time a woman 
needs family planning services or to 
the time she needs prenatal care. 
• Women must visit other facilities to 
receive other health services.
• Clinics cannot offer services that 
attract many mothers who then learn 
about family planning  while at the 
clinic.
• Clients, particularly unmarried ones, 
who are uncomfortable with the 
social stigma of using contraception 





• This option is more convenient for 
clients, who need not travel long 
distances.
• Supplies are distributed by someone 
the client knows and trusts.
• Postpartum mothers can be identified 
and visited.
• Follow-up is easier.
• Client motivation is maintained at a 
high level through continuous 
interaction with the CBD worker.
• CBD is sometimes a cost-effective 
approach.
• Full MCH or family planning 
services are not offered.
• Immediate access to clinical staff for 
managing problems is not available.
• Some health professionals resist 
having the CBD workers or 
volunteers offering services.
• The client may feel there is little 
confidentiality.
• The client may lack confidence in the 
nonmedical worker.
• Initial program costs per client may 
be high.
 
Table 25:1 Advantages and disadvantages of approaches to 




























Unfortunately, many countries do not have enough health workers to
staff their clinics. However, with some supervision by a physician
working part time, trained nurses and midwives can examine women,

















In areas that do not have clinics nearby, family planning services
may be made available through CBD programs. In this approach,
CBD workers, usually village women, are trained to educate their
neighbors about family planning and to distribute certain contracep-
tives. In some programs, CBD workers also provide some primary




• Can reach remote areas not reached 
by other  programs.
• Clients need not travel long 
distances.
• Distributors are motivated because 
they earn profits from sales.
• Availability of methods is well 
publicized.
• Client does not have to wait in a 
clinic to receive the method.
• Client has anonymity.
• Costs to the client and the 
government can be low.
• Resupply to distribution points is 
usually reliable.
• Full services are not offered.
• Clients must go to a clinic for 
management of  their health 
problems.
• Starting a program can be costly.
• Promotion and advertising of 
contraceptives may  be subject to 
criticism.
• Full client education and counseling 
on contraceptive methods may be 
lacking.
 
Table 25:1 Advantages and disadvantages of approaches to 


































In their training, the CBD workers learn the basic concepts of
family planning, how each method must be used, what the precau-
tions and side effects are for each method, and how to keep simple
records and report the information to their supervisor. CBD programs
usually distribute condoms; some also provide pills and spermicides,
and a few have trained CBD workers to administer injectables. In
some programs, the workers receive some kind of payment; in others
they are strictly volunteers. A midwife, family planning nurse, pro-
gram coordinator, or other staff member is usually responsible for
supervising the CBD workers' activities and managing any problems
that occur. 
Family planning administrators may find that CBD services are
most effective when a program is fairly new and people are not famil-
iar with contraceptives. Because local residents bring family planning
services directly to individuals, they make family planning both conve-
nient and culturally sensitive, and these residents are always nearby to
answer questions. Adding CBD services to existing clinic services has
been shown to make family planning more acceptable to a community


















In both urban and rural areas, if people are willing to obtain con-
traceptives from sources outside the health care system, commercial
retail sales (sometimes called social marketing) can make some contra-
ceptive methods very accessible. In this approach, contraceptives such
as oral contraceptive pills, condoms, and spermicides are sold at
reduced, subsidized prices in pharmacies, market stalls, stores, barber
shops, beauty salons, and bars and are advertised on the radio and in
newspapers. Some programs also offer injectables and IUDs, which






When a commercial retail sales approach is used, the retailers are
often the customers' only source of information about the products. These
retailers should be given training in basic information about the products






































Several other service delivery methods have been used. Some





 to reduce health care costs and absenteeism related to




 Some hospitals and maternities





 because that may be the only time that a woman comes in for
health care and is available for family planning education. (This
approach is discussed in detail in Chapter 12, Lactation and Postpar-
tum Contraception.) 





, although generally at a higher cost. Other
approaches involve training paramedics, pharmacists, traditional birth
attendants, midwives, traditional healers, and outreach workers to




 Whatever delivery strategies they
have chosen, African countries have, in recent years, dramatically
increased access to family planning services.
 
FINANCING FAMILY PLANNING SERVICES
 
Family planning services are usually financed through one or more
funding strategies:   
• Government support   
• Private providers, such as family planning associations   
• Client charges (fee for service, registration fee, membership
fees, or copayments)   
• Grants from international or local donors   
• Insurance or other third-party payment mechanisms, in
which the client pays part of the fee and the rest is paid by
the employer, health plan, or insurance company   

































Government support for family planning services is usually lim-
ited to services that can be provided by the government's existing facil-
ities, staff, or projects. 
Private agencies, such as family planning associations affiliated
with the International Planned Parenthood Federation, sometimes
charge enough to cover all costs, but more commonly charge only a
fraction. Such agencies are often located only in larger cities. 
Clients are often charged a flat fee, such as a registration fee,
when they are first seen in a clinic or a fixed service fee at each visit.
Less often, fees are charged for a particular service provided, such as
IUD insertion or sterilization. Charges rendered often cover only part
of the cost of providing the service. Client fees are discussed in greater
detail below. 
Many programs receive assistance directly or indirectly from
international donor agencies. These grants often support specific ele-
ments of programs, such as equipment, contraceptive commodities, or
informational materials. 
In most of Africa, membership fee payments, copayments, insur-
ance coverage, and other third-party coverage are virtually unknown as
a source of revenue. 
Cross-subsidization provides support for one service by charging
extra for another service or by charging more in one location than in
another. This strategy is most often used in an integrated setting where
several services, including curative care, are provided. The revenues
generated from curative care fees can subsidize some costs for other
programs whose benefits are less obvious to clients (preventive services
such as family planning and immunization). In locations where clients
are able to pay more, higher fees may be charged to subsidize lower



























FEE PAYMENT SYSTEMS 
In some countries, clients are asked to pay a small fee for their
contraceptives. However, there are several factors working against
charging fees for services. Family planning and other health services
operated by African governments have often been provided without
charge to patients, for the following reasons:   
• Throughout most of the first half of the 20th century, medi-
cal care was usually provided free of charge by colonial
authorities and missionaries. This pattern has continued
since independence.   
• A commonly held belief is that family planning should be
provided free as a matter of principle. This belief persists
despite evidence that people will pay for goods and services if
they are of good quality and indeed prefer them to those they
can get for free, which they perceive to be of lower quality.
In addition, governments with a limited health budget may
not be able to afford to provide free services or contraceptives
everywhere they are needed, or they can provide only inade-
quate services.   
• Charging fees excludes the very poor from services. Poor cli-
ents may be forced through desperation to pay for acute cur-
ative care, but they are likely to strongly resist paying for
preventive care, including family planning.   
• Many international donors furnish vaccines, medicines, and
contraceptive supplies under the condition that clients receive
them free of charge. (This policy is gradually changing.)   
• Collecting and transferring payments received from clients is
time-consuming and perceived as an inappropriate task for
nurses and other clinic staff who are trained to provide medi-
cal care. In addition, many clinics have difficulty maintaining
accurate accounting or billing records. Sometimes the cost of
managing the money is more than the amount collected.
Despite these barriers, completely subsidized services probably
cannot continue much longer. Neither governments nor donors can
afford to continue to provide free care. Although contraceptives are
often supplied by donors with the requirement that they be provided
APPROACHES TO DELIVERY OF FAMILY PLANNING SERVICES 603
free to clients, it may still be possible for programs to charge clients a
fee for the services provided by clinic staff. Some commercial retail
sales programs have successfully marketed contraceptives for a small
price, which shows that some clients are willing to pay for them. In
fact, studies have shown that people often place a greater value on ser-
vices and contraceptives they purchase with their own money and thus
may be more likely to use them than services and contraceptives that
are free.4 
Setting up a fee payment system to recover some or all program
costs requires several steps:   
• Assessing the clients' willingness and means to pay   
• Eliminating any administrative or legal barriers to collecting
fees 
• Determining how the collected fees will be used   
• Determining what services and goods to charge for   
• Establishing fee levels   
• Setting up a system of administrative controls for all transac-
tions, particularly those involving cash   
• Collecting the fees from the clients
MIX OF CONTRACEPTIVE METHODS USED IN 
A PROGRAM 
Ideally, each family planning program should offer a balanced selec-
tion of family planning methods, although sterilization and insertions
of IUDs and Norplant implants are restricted to sites with appropriate
facilities and trained staff. The methods offered by a program are influ-
enced by the system in which they are distributed as well as by cultural
or religious preferences and the reliability of the logistics system. 
Although clinics and private physicians are generally able to offer
all major contraceptive methods, not all service delivery approaches
can be as comprehensive. Guidelines for offering various contraceptive
methods under three delivery strategies are shown in Table 25:2. 
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Diaphragms and contraceptive creams and jellies are rarely available in
most African clinics, even in urban areas. Clinic-based program staff
should, therefore, concentrate on ensuring that pills, condoms, and
spermicidal tablets are always available.
OBSTACLES TO SERVICE DELIVERY AND POSSIBLE 
SOLUTIONS 
In many African countries, several barriers keep women from obtain-
ing family planning services (in some areas, such services are just sim-
ply not available). These barriers, which can be both physical and
cultural, often differ by area.
RURAL AREAS 
In rural areas, the limited family planning services available are
generally provided by the Ministry of Health or other government
programs; a few missions, private family planning association clinics,
or commercial retail sales programs may also exist. There are few gov-
ernment hospitals or clinics, and those that do exist sometimes lack
water, electricity, equipment, or medicines. In some cases, government
clinics are staffed by only one person and may close altogether if that
person is ill, transferred to another post, or on maternity leave. Medi-
cines are often limited to what has been supplied free to the govern-
ment by international donors. To receive supplies, clinic staff may
have to pick them up from a remote warehouse or store. When trans-
portation is provided, the deliveries may be unreliable or sporadic. In
rural areas, most potential clients are aware of these problems with
health care services, and it is not surprising that they often seek ser-
vices only in emergencies. When the need for family planning is out-
weighed by difficulties in obtaining services and supplies, unplanned
pregnancies could result.
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Oral contraceptives:   Low-dose 
combined pill and progestin-only 
pill. Can potentially be distri-
buted by anyone with a checklist.
X X X
Intrauterine devices (IUDs):  
Must be inserted by a physician, 
nurse, or trained paramedic.                 
X
Sterilization:  Tubal ligation and 
vasectomy. Operation is mainly 
performed by physicians; can be 
performed by trained nurses and 
midwives. Must have the proper 
facilities.                                 
X
Injectable contraceptives:  
Depo-Provera and Noristerat.  
Injection can be given by 
physicians, nurses, or trained 
paramedics.                                 
X              X X
Implants:  Long-acting 
hormonal implants (e.g., 
Norplant).  Must be provided by 
someone, usually a physician, 
who has been trained in insertion 
and removal.                                 
X
Condoms, spermicides, foaming 
tablets:  Nonmedical methods 
can be provided by anyone.                                 
X                 X                                 X
Creams, jellies, foams, 
diaphragms:  Less popular non-
medical methods. Diaphragm is 
usually fitted by a medical 
professional.                                 
X                 X                                 X
Instruction in fertility awareness 
methods: Timing of ovulation, 
abstinence. Trainer must be 
knowledgeable in the methods.          
X  
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 Using a CBD program or a commercial retail sales program with
widespread rural coverage could help alleviate several problems: lack of
access to services, staffing shortages (particularly if the CBD program
uses volunteers), and an emergency-only attitude toward health care
services. A CBD program manager would still have to oversee the
transportation and steady flow of supplies. CBD workers could be
trained to provide some primary health care services.
URBAN AREAS 
Lack of services and barriers to service are problems in urban
areas as well, but family planning clients may find it easier to obtain
services there because of the greater number of hospitals and clinics,
which are better equipped and more fully staffed. Medical equipment
and supplies are more likely to be available in urban areas because the
transportation problems that affect rural areas are less severe. In addi-
tion, electricity and running water are available most of the time. 
In cities, one important barrier to service is long waiting times,
particularly early in the day. In addition, services are sometimes pro-
vided only on certain days (for example, maternal and child health
[MCH] services on Monday, prenatal care on Tuesday, immunization
on Wednesday). Such policies make it difficult for clients to get the
services they want when they need them. 
Because some clients may not be able to return on the day the
service is scheduled, family planning program managers should try to
integrate their services into existing facilities and offer them at the
same time other services are offered. Doing so would be particularly
important in MCH centers and for prenatal and postnatal programs,
which are set up to serve women who are prime candidates for contra-
ceptive services. Women accompanying their children to immuniza-
tion clinics are also potential family planning clients; information on
family planning can be made available to them while they wait. Long
waiting times can often be reduced by studying how health care work-
ers use their time and determining when the clients spend the most
time waiting, then changing office hours or appointment systems. 
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Program managers might explore other ways to provide services
to rural and urban areas, such as developing social marketing pro-
grams and household distribution programs or making referrals to
clinics run by a local private family planning association. 
OTHER OBSTACLES AND SOME SOLUTIONS 
Sterilization 
Sterilization is probably the family planning method most diffi-
cult to obtain in Africa. In rural areas sterilization is almost nonexist-
ent, and in cities it is often unavailable because of the lack of necessary
equipment and trained staff. Because increasing the availability of such
services requires long-term funding for equipment and intensive staff
training, the most practical short-term alternative is to provide clients
with another contraceptive method.
Cultural Barriers 
In many cultures, contraception is resisted by women, men,
other family members, or the community at large. Still, people recog-
nize the need to produce healthy children. Educating both clients and
local leaders can help improve attitudes toward family planning and
child spacing. Clinic staff should describe the health benefits that
child spacing provides to both mothers and children. Staff can explain
how the use of modern contraception serves the same purpose of child
spacing that was traditionally achieved through practices such as absti-
nence and prolonged breastfeeding. Education can also diminish con-
cerns about the side effects of specific methods. The provider should
point out to new clients that complications from too many pregnan-
cies, or even a single pregnancy, are far more dangerous than the side
effects of any of the contraceptive methods. 
Involving community leaders can help gain the confidence of the
local population. The support of community leaders should be genu-
ine and voluntary and derive from their belief that healthier children
are advantageous to the community and put less of a strain on health
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and educational services. Pressuring people to use contraception is eth-
ically unacceptable and ineffective, even in the short term. Informa-
tion and encouragement, however, are entirely appropriate.
Privacy 
Lack of privacy in the provision of contraceptive and other medi-
cal services is a problem in some clinics. There are usually no short-
term solutions to this problem, as it generally requires constructing or
renting more office space. However, rearranging work-space areas or
putting up curtains or screens often can improve the situation. 
Some women want to use family planning but think their hus-
bands will object. Methods that can be used without the knowledge of
the husband are available; injectables are particularly appropriate in
such situations. Sterilization (if available) is suitable when the woman
decides she wants no more children, but she must be made aware that
the procedure is not reversible.
Laws and Policies 
In many African countries, particularly Francophone ones, laws
dating to the early part of the 20th century officially prohibit the use
of contraception. Program managers should work with higher minis-
try staff to gain support for repealing such laws, encouraging instead
the voluntary use of contraception. However, even though such pro-
hibitive laws exist, they are often not enforced, and in most countries,
family planning services can be provided without interference. Many
clinics also provide services to unmarried or teenage clients with little
interference from authorities. To help overcome these barriers, the
Ministry of Health can support providers by establishing client-
oriented national service policies, norms, and protocols until the laws
are changed.
Clinic Management 
Some service delivery problems can be resolved by common-sense
clinic management and by training. For example, a clinic management
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analysis can indicate how staff spend their time and show ways to elim-
inate or change inefficient practices. Staff can be asked for suggestions
on how the clinic could be better run or ways it could serve its clients
better. Clients may also be asked to make suggestions. 
Staff can be trained in improved program management skills or
in new technical skills that allow them to provide additional services.
However, training must be provided wisely. Pressing day-to-day prob-
lems are not solved by sending someone to school; indeed, the service
problems may become worse if no one is available to replace the per-
son being trained. Still, staff training must be a priority for clinic man-
agers so that they can keep up with changes in medical procedures,
diagnosis, and treatment. Fortunately, training in the use of most con-
traceptive methods is fairly simple, and it is possible for supervisors to
conduct individual training sessions with their staff or to train groups
on-site. 
Obstacles to service delivery exist in every location. Family plan-
ning program managers and service providers need to consider what
particular obstacles exist for their clients and potential clients, then
develop solutions to improve access to family planning services.
Obstacles can often be overcome by better management of the pro-
gram itself and by providing better quality services. These topics are
discussed in the next two chapters.
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Effectively Managing Your 
Family Planning Program
 
When Nurse Mutanga took over managing the maternal and 
child health and family planning clinic a year ago, she had no 
idea how complicated the task would be. She had experience in 
supervising staff and had usually been successful at keeping them 
motivated through her enthusiasm, fair treatment, and recogni-
tion of work done well. However, she found she had much to 
learn about hiring and training new staff, properly managing 
contraceptive and drug supplies to avoid shortages or damaged 
contraceptives, making sure every aspect of client care was satis-
factory (the information provided, the setting, the privacy, and 
the counseling and clinical services), and submitting accurate 
reports on time about clinic activities. As if learning how to do 
all these tasks were not enough, there were often last-minute 
emergencies that took her attention away from her daily admin-
istrative duties.
 
A family planning program must be well managed if it is to provide its
clients with good-quality services. This rule is equally true for large
programs and for individual clinics. A well-managed family planning
program has the following characteristics:
• The staff is qualified and trained.


























• Staff members receive the support and guidance they need
from their supervisors.
• Sufficient amounts of contraceptives, other supplies, and
necessary equipment are on hand at all times.
• The staff submits accurate reports on schedule and the clinic
(or other service delivery point) receives feedback from
higher administrative levels.
• Problems are identified early and resolved.
• Clients are treated with respect and are satisfied with the ser-
vices.
• The program's goals and objectives are compatible with
those of the community. 
Good management is vital to the success of a program, but it is
often overlooked. Because the people who administer and supervise
clinics and programs are often health professionals with little or no
management training or guidance, this chapter reviews the basics of
family planning program management: 
• Selecting and training staff
• Supervising staff
• Managing contraceptive supplies
• Collecting, analyzing, and reporting information
The concepts presented here are not specific to programs in
Africa; they apply generally to all programs. We recognize that, in
some countries the administrative structures make it difficult to follow
these recommendations. However, these concepts are presented as ide-
als that programs should try to achieve, not as specific requirements
that must be met.
When managing a program or clinic, a manager can get caught
up in the daily details and crises and forget the program's purpose.
The manager must always remember—and remind staff—that the





























SELECTING AND TRAINING STAFF
 
Staff members are the central part of any service delivery program.
Because staff must be skilled in the services they provide and moti-
vated to serve their clients, it is essential to select appropriate staff
members and to train them well. In a program that provides high-
quality services, the staff safeguards the client's health and the client










Because staff are so critical to the success of a program, they must





 that lists the following:
• Responsibilities and tasks required
• Required attitude toward patient-oriented service delivery
• Qualifications, past work experience, skills, and desired qual-
ities
• The supervisor for the position
The job description serves as a guide to selecting the new
employee and helps the job candidates decide whether the job is right
for them. Later, the job description can also be used for supervision
and performance evaluation.
Attitudes are among the hardest personal characteristics to influ-
ence, yet they set the tone for behavior and behavior change. Explore
the attitudes of potential staff members by posing questions, written
or oral, about situations that might be encountered during the deliv-
ery of services.
In most public programs in Africa, the clinic manager does not
select and hire staff; the personnel department of the ministry or
agency has this responsibility. However, job descriptions remain use-



































Whenever new staff begin work or procedures change, some ori-
entation is necessary to make sure that employees understand exactly
what they are supposed to do. Orientation can be carried out in vari-
ous ways—through a presentation, a workshop, a meeting, or written
communication. Managers should fully inform staff of all policies and
of policy changes so that services are run well and staff morale is main-
tained.
Employees who have just been hired usually receive an orienta-
tion at the central level. A less formal orientation should be conducted
at the clinic where the new employee is assigned. The manager or
supervisor should ensure that by the end of the orientation the
employee is familiar with all the procedures and capable of carrying
out all required tasks.
Both for the orientation itself and for later reference, all staff




, which should include an
overview of the organization's purpose and structure, all personnel
policies (such as benefits, grievance and termination policies, and poli-
cies for time off ), and administrative procedures. The manual should
be in a folder or loose-leaf notebook so that any changes or updates










Staff development means providing employees with opportuni-
ties to improve their skills, both in performing new tasks and in doing
current tasks better. Staff development is important for several reasons.
First, because people often get bored when they have to perform the
same tasks over and over, learning and practicing new skills can
improve both morale and performance. Second, by training staff in
new skills, program administrators are better able to retain valuable
staff who, as a result, become increasingly skilled and qualified. Third,
training current employees is a more cost-effective way of obtaining




























Staff can expand their responsibilities or increase their skills in
numerous ways. Staff members working in just one of a clinic's techni-
cal areas (clinical, administrative, or educational) could learn to take
on responsibilities in another area. In addition, clinical staff can be
trained to take on more advanced clinical tasks, thus increasing the
clinic's ability to provide needed services. For example, in some coun-
tries nurses have been trained to insert intrauterine devices (IUDs)
and Norplant, and nurses' aides have learned to take blood pressure
and conduct other screening tests.
Staff development can take a number of forms: delegating more
responsibility to staff, providing them with reading materials, con-
ducting in-service training sessions, or allowing staff time off to attend
seminars and courses. The greatest influence on staff development,
however, may well be the attitude of the manager or supervisor, who
should encourage staff members to keep learning and advancing and





Supervision is an underappreciated aspect of managing a program.
The purpose of supervision is to guide and support staff so that they
can perform their tasks well. Poor supervision can lead to an inability
to solve problems at service delivery sites, wasted staff skills, poor




The supervisor should be a supportive problem-solver who
notices and recognizes good work as well as problems. Ideally, supervi-
sors should collaborate with staff to identify problems and find solu-
tions; if they do, staff will learn to manage problems on their own and
not leave them for months until the supervisor visits.
Supervision is carried out in two ways: by reviewing written
materials (such as review of service statistics or reports) and through
observing and making personal contact. Personal contact is necessary
to find out what is actually taking place, resolve any problems, and


























occur infrequently, are often the only opportunity for the employee to
get any praise for a difficult job well done.
One problem frequently associated with supervision is the per-
ception that the supervisor acts as a critic or disciplinarian. This per-
ception is particularly strong when a supervisor from outside makes
rare visits, spends them investigating problems, and assigns blame
rather than helping to solve the problem. All supervisors, particularly
higher-level program managers, should avoid acting like punitive dis-
ciplinarians.
Because supervision is essential to an effectively managed pro-
gram, family planning programs should invest in training their super-
visors in essential supervisory skills such as helping service delivery
sites assess their own needs, facilitating group discussions, and guiding


















A supervisor may work at the same site as those being supervised
or may visit periodically from a central or regional office. An employee
may have both kinds of supervisors. In either case, the main function
of a supervisor is to help the staff perform their jobs better by provid-
ing support:
• Guidance and training
• Assistance with resources and logistics
• Support, encouragement, and advocacy for their concerns
and rights
• Regular feedback on their performance
A supervisor's basic functions include the following:
• Setting individual performance objectives (the activities an





























• Managing any performance problems and conflicts that arise
and motivating and encouraging employees to do their best
work
• Having regular contact with employees to motivate them;
help solve their problems; and provide them with feedback,
guidance, assistance, and support
• Developing a supervisor's session plan, then going over
selected items in each supervisory session
• Preparing a schedule of upcoming supervisory sessions with
employees that lists the date of each session and any items
that need to be discussed
• Conducting periodic performance appraisals to review an
employee's job performance to help ensure that performance
objectives are being met
• Reaffirming the mission of the organization; periodically
reminding staff of the organization's values, principles, and
goals; and strengthening staff commitment to them
Although supervisors have their own styles of supervision (some
are task-oriented, others are relationship-oriented), they should con-
sider what type of supervision is appropriate for each employee. Some
employees work best independently and need little direction. Others
work better when they have more interaction with and support from
the supervisor or other staff. In any case, a supervisor should always
consult an employee before making decisions and judgments about
















Supervisors are doing their most important work when they meet
with one or more employees to review and discuss ongoing and com-
pleted work, go over any problems the staff is encountering, and plan
upcoming work.  These meetings can take a variety of forms (day-to-


























or group sessions, or meetings to provide techniques for self-
evaluation), but in all sessions the supervisor will have basic objectives:
• Make sure the staff members have the necessary interper-
sonal skills to provide their clients with the guidance and
support they need.
• Check that the staff members have the knowledge and tech-
nical skills needed to carry out their jobs.











Poor communication between supervisors and employees is com-
mon. A supervisor's job is to provide constructive feedback. It is just as
important, if not more so, to let employees know when they are doing
a good job as it is to alert them to a problem. Although it is good for
staff morale to publicly praise an employee's work, any criticism of
performance should be given in private.





























 (explains how staff can improve their perfor-




































Problems and conflicts occur in every program, and one of a
supervisor's responsibilities is to work with employees to discover and
resolve their problems. Once the supervisor has determined that a
problem exists, the next task is to discover its cause. The supervisor
and employee can begin by asking the following questions:
• What exactly is wrong?
• Where is the problem taking place?
• When did the problem start?
• What are the causes of the problem?  Can they be removed
or changed?
• Who is involved in the problem?
• What is the desired (mutually agreed upon) result?
• What resources will be needed to solve the problem?
Problems can be caused by interpersonal conflicts or by
ill-designed or poorly functioning management systems. In any case,
the supervisor must remember to remain neutral and try to find a
solution acceptable to both the employees and the management.
Another common problem is the perceived poor performance of
an employee. Unsatisfactory  performance may be due to several fac-
tors, including excessive workload, poor working conditions, insuffi-
cient training or qualifications, lack of interest in the work, or personal
problems. The supervisor should investigate thoroughly before taking





out whether the employee has been adequately super-
vised and knows what is expected of her or him.
• Determine the exact nature of the problem.
• Compare the employee's performance objectives and job
description with the work performance, and see whether any
previous action has been taken.
• Try to determine possible reasons for the gap between objec-
tives and results.
• Talk privately with the employee and find out her or his






























Every facility that serves family planning clients must have supplies of
all the contraceptives it offers, including each of the brands it distrib-
utes, on hand at all times. If it runs out of a particular contraceptive,
clients may have to accept a substitute or go without contraceptive
protection; if this happens frequently, clients may give up on family
planning altogether. On the other hand, it is poor management to
have an oversupply of a particular type of contraceptive, because some
may expire before they can be used, resulting in a waste of money and
commodities.
To prevent such shortages and overstocks, every program must





















. For a contraceptive management system to






— The decision makers must select the contraceptive meth-
ods and brands the clients want and provide as full a
selection of methods as possible. 
— The managers must make reasonably accurate estimates
of the demand for each method, taking into account cur-
rent trends in contraceptive use and the program's





— The contraceptives must be shipped from the suppliers to
the warehouses on time.
— The warehouses must store the commodities under ade-
quate conditions and use the first-to-expire, first-out
technique so that contraceptives do not expire in the
warehouse.
— An adequate transportation system must exist to move




























• Documentation and information
— An effective logistics information system must be in place
so managers know what quantities of supplies are on
hand, can see that supplies are maintained in appropriate
amounts, and can ensure that new supplies are ordered
on time (managers must factor in the "lead time"
between when supplies are ordered and when they
arrive).
FORECASTING FUTURE CONTRACEPTIVE NEEDS
Forecasting
In small clinics and health posts, it is often not necessary to use a
formal forecasting technique; the person in charge often has a good
idea of monthly and annual consumption rates and how much is
needed. If there is information on past contraceptive use, simply esti-
mate the program's needs for the future based on this information,
including a small reserve stock level and possibly a small amount for
growth. If there are no reliable data on past distribution, future con-
sumption can be estimated from the service statistics of clients from
the past year. Estimate how many new and continuing family plan-
ning clients you will have in the next year, and use the guidelines in
Table 26:1 to calculate the supplies that would be needed for each
continuing family planning user for a year and for anticipated new
users. (The numbers in the table may seem high, but they factor in
amounts lost to damage or expiration.)
Larger facilities at the provincial and regional levels will need to
go through a more formal forecasting process: Determining the level
of consumption of each contraceptive method and brand in the previ-
ous year, aggregating (summing) the consumption data from the ser-
vice delivery points, then using the results to estimate future demand
while making any necessary adjustments to reflect expected changes in
the level of consumption. Provincial and regional level clinics can use
the guidelines (in Table 26:1) to verify their calculations.
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Monitor both supply levels (to make sure you never run out of
supplies or are overstocked) and the level of consumption (to see
whether demand is changing for any method). Periodically calculate
the average monthly consumption for the past 6 months. More accurate
than an estimate, this approach will indicate whether demand is
changing, in which case the amount ordered should change corre-
spondingly. For these calculations, the average monthly consumption
is used as an approximation of 1 month's supply.
The Maximum/Minimum System
Using the Maximum/Minimum (Max/Min) inventory control
system is a way of making sure that supplies never run out or, on the
other hand, that there is never so much stock on hand that some con-
traceptives expire before they can be used. In the Max/Min system,
maximum and minimum stock levels are set for each facility or type of
facility. These levels are expressed in number of months of supply (for
example, a clinic might have a minimum of 2 months of supply and a
Table 26:1 How to calculate annual supplies for continuing and 
new family planning clients
Method Guideline
Pills 15 cycles per continuing user per year, or 7.5 cycles 
per new user in the current year
Condoms 120 units per continuing user per year, or 60 per  
new user
Intrauterine device (IUD) 1.5 IUDs per new user
Injectables 4 units of Depo-Provera per continuing user, or 2 per 
new user
5 units of Noristerat per continuing user, or 3 per 
new user
Norplant One set of implants per new user
Sterilization kits 2 per doctor
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maximum of 4) so that the right levels are maintained even if demand
changes (that is, if the amount in the average monthly consumption
increases or decreases). Thus, for example, if demand increases, a max-
imum amount of months of supply might grow from 400 pills cycles
to 600, even though the maximum remains set at 4 months.
In the Max/Min system, the minimum level is equal to the safety
stock, the amount held in reserve in case of higher than usual demand.
Some family planning programs set the minimum level at safety stock
plus the lead time stock (the amount of stock used during the time
between placement of an order and when it arrives). 
The maximum level is the largest quantity the facility should ever
keep in stock. This level is set by adding the quantity that will be used
in the time period between routine orders to the minimum stock level.
For example, a clinic with a minimum level of 2 months of supply and
an average monthly consumption of 1,000 condoms that was resup-
plied every 3 months would need a maximum balance of 5,000 con-
doms (2 months of minimum balance plus 3 months of consumption
at 1,000 condoms per month). 
Once the minimum and maximum levels are set, ordering sup-
plies is fairly easy. Stock levels are reviewed periodically, and an order is
placed to bring the level back up to the maximum.
STORING CONTRACEPTIVES
Contraceptive supplies should be stored in a dry, well-ventilated
area. They should be kept cool and protected from direct sunlight.
Generally speaking, if the storage space is comfortable for human
occupation, it will be adequate for storing contraceptives. If new ware-
house space is being set up, remember that the program may expand;
provide enough room to store the quantities of contraceptives the pro-
gram will need in the future.
In facilities that serve as depots and store large quantities of sup-
plies, all boxes should be marked with the expiration date of the con-
traceptives that the boxes contain, and the first-to-expire, first-out
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(FEFO) system should be used so that contraceptives are distributed
and used long before they expire. Supplies should be organized by year
and month of expiration, with supplies that are closest to expiration
placed to the front and distributed first.
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Contraceptives have a limited shelf life; make sure they are not
dispensed if they have expired. (See Chapter 27, Providing Quality
Family Planning Services, for more detail.)  If stored under adequate
conditions, they should have the following shelf lives:
• Pills—5 years from date of manufacture
• Condoms—3 to 5 years from date of manufacture
• IUDs—7 years
• Injectables—4 to 5 years
• Implants—5 years
• Foaming tablets—3 to 5 years
Guidelines for Proper Storage
• Clean and disinfect storeroom regularly.
• Store contraceptives in a dry, well-lit, well-ventilated 
storeroom out of direct sunlight.
• Secure storeroom from water penetration.
• Make sure fire safety equipment is available and accessible.
• Store cartons of condoms away from electric motors and
fluorescent lights.
• Stack contraceptive cartons at least 10 cm (4 inches) off the 
floor, 30 cm (1 foot) away from the walls and other stacks, 
and no more than 2.5 m (8 feet) high.
• Arrange cartons so that identification labels, expiration 
dates, and manufacturing dates are visible.
• Store contraceptives in a manner accessible for the first-to-
expire, first-out (FEFO) system, for counting and for general 
management.
• Store contraceptives separately (away from insecticides, 
chemicals, old files, office supplies, and other materials).
• Separate and dispose of damaged or expired contraceptives 
without delay.
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DOCUMENTING STOCK FLOW
To always have the right amount of contraceptives on hand, you
need to know two things:  how much stock you have, and how much
is being dispensed. You must keep track of this information through
records and reports. Two kinds of records are needed:  stockkeeping
and transaction. Stockkeeping records are stock inventory control cards
on which, for each method and brand, information is recorded on all
receipt and shipment activities, any adjustments made to supply levels
after physical inventories, and any additional records for accountabil-
ity and prevention of theft. Transaction records are used to record the
amount of supplies shipped from one facility to another and the
amounts ordered or dispensed.
Periodically (such as monthly or quarterly), the information from
the records should be aggregated into reports, which should be used for
planning and evaluation. These reports might contain information on
the quantities of each type of contraceptive received and dispensed
within the time period and the number and types of clients served.
Reports are used to forecast needed supplies, assess the demand for the
different contraceptives, and track changes in demand. These reports
need to be accurate and timely.
COLLECTING, ANALYZING, AND REPORTING 
INFORMATION 
Managers and decision makers at every level of a family planning pro-
gram need complete and reliable information on the program's perfor-
mance and operations. A management information system (MIS) is
the system of forms and reports used to collect and aggregate essential
data about the program's activities. These data are compiled in reports
that managers use to monitor the program, make decisions about how
to allocate program resources, and analyze the program's performance
and the reasons for its success. The reports can also be used to deter-
mine ways to improve performance. Although managers often obtain
information through informal channels such as observation and infor-
mal discussions with colleagues, they also need a well-running MIS. 
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The MIS should be designed to collect only data that are neces-
sary and that can be easily summarized to produce reports that are
complete, accurate, and timely. A good MIS can help managers dis-
cover existing and potential problems and make well-informed deci-
sions on topics such as the quantities of contraceptives required and
the most appropriate contraceptive method mix to offer.
Managers also need to consider how often data need to be col-
lected and reported. Many programs collect and process data on a
monthly basis, although a quarterly basis might serve just as well. One
of the problems with monthly systems is that because they take as long
as quarterly reports to generate but must be produced three times as
often, those responsible for processing the reports can easily fall far
behind and become discouraged. It is better to have timely reports of
quarterly data than late reports of monthly data; after all, it is of little
use to learn in August that many locations were out of certain contra-
ceptives last February.
WHAT INFORMATION DOES A PROGRAM NEED?
In general, managers need performance and operational informa-
tion.
Performance information is used for planning and evaluating fam-
ily planning programs. This information is needed to see whether per-
formance objectives are being met, such as keeping waiting times
under 2 hours or developing outreach efforts to bring in members of a
high-risk segment of the population. There are seven categories of per-
formance information you may wish to collect:
• Family planning client characteristics (age, income, residence
[urban or rural], education)
• Fertility characteristics of clients (parity, age at marriage,
duration of method use)
• Contraceptive method mix and the sources of supply
• Contraceptive failure and discontinuation of use
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• Quality of services (See Chapter 27 on Providing Quality
Family Planning Services)
• Level of community participation in and support for the
program
• Contraceptive prevalence
Most program performance information is expensive to collect
because it must be obtained from surveys and client records; not all
programs need complete performance data. The information is used
to develop the program's goals and objectives, determine subgroups
that may need targeted services, and evaluate the program's impact
and reputation.
Operational information, which provides information on how the
program uses time, people, money, and other resources, is used to
assess how well a program is functioning. For example, is every client
receiving human immunodeficiency virus (HIV) counseling?  Are all
client complaints addressed?  Operational information includes the
following data:
• How well work plans are being implemented (activities
accomplished, objectives met)
• Costs and expenditures (whether the program is within bud-
get)
• Contraceptive logistics (shortages, situations of oversupply,
changes in consumption)
• Staffing and supervision (staff shortages, need for training)
WHAT INFORMATION DOES YOUR PROGRAM COLLECT?
Common problems with an MIS are that it collects too much
information and is too complex. An MIS should collect only the
information that managers need to make well-informed decisions
about the program. To make sure your MIS is collecting this informa-
tion and only the necessary information, follow these steps:
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1. Review the goals and objectives of the organization, pro-
gram, department, or service delivery site where you work, and
determine what information is needed to assess whether those
goals and objectives are being met.
2. Identify all the people who are or should be using each type
of information (clinic workers, clinic managers, supervisors, vol-
unteers, etc).
3. After identifying what information is needed by the different
staff, eliminate the information that is being collected but is not
being used.
4. Review the current forms and procedures for collecting,
recording, tabulating, analyzing, and reporting the data and
determine whether anything in these forms is difficult to under-
stand or fill out (past errors or problems using these forms could
serve as a guide).
5. Revise the existing forms and procedures for collecting and
recording information to make them easier to use.
6. Set up or improve the manual or computerized systems for
tabulating, analyzing, and reporting information so that they are
useful for the employees who work with them.
7. Develop procedures that check the accuracy of the data.
8. Train and supervise staff to use the new forms and proce-
dures.
INFORMATION FLOW
Information flow is the movement of information within the
organization. In family planning programs, information should flow
from the service delivery level up to the top management level; feed-
back should then be sent back down the line to service delivery staff.
The kind of information and the format in which it is presented (e.g.,
tables, charts, reports, graphs) should be determined by the following
criteria:
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• Who needs the information
• How the information is used
• What level of detail is needed at each administrative level
The level of detail and the format should always be appropriate
for the needs of the particular information users. As information
moves up the administrative ladder, the amount of detail decreases.
The clinic manager needs to know the details of the clinic's opera-
tions, but the head of the organization or department does not.
The MIS is ultimately based on the routine data that are col-
lected at the lowest level. Routine data are obtained from various
sources by using several types of data collection instruments:
• Individual client records (see Form 1 at the end of this chap-
ter)
• Daily activity registers of family planning clinics (see Form 2
for an example)
• Clinic contraceptive service registers
A family planning program also requires administrative data,
which can be collected using the following instruments:
• Stock card or contraceptive supplies inventory form
• Record of a supervisory session
• Financial records (income and expense reports)
REPORTING INFORMATION
Once collected, the data need to get to the appropriate staff
members in a form they can use (generally in reports of some kind).
Mechanisms are needed to take the following steps:
• Summarizing what has been collected in the records, regis-
ters, and forms
• Analyzing the data so that it can be transformed into usable
information
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• Transmitting the summarized data to others in reports that
can be clearly understood
In the first step, data are summarized as totals, percentages, and
averages. (See Form 3 and Form 4 at the end of this chapter for exam-
ples of such summaries for client visits and contraceptives dispensed.)
In many cases these summaries may provide all the information that is
needed to make decisions. In step two, analysis is conducted by aggre-
gating data from similar service delivery sites to get a broader perspec-
tive. (See Form 4, which could be used at a regional warehouse.)
Charts and graphs can make the information even easier to under-
stand, especially when looking at changes over time. 
In the third step, supervisors provide feedback. Supervisors
should let the staff know how well they have reported information
(this means letting them know when they are doing a good job, not
just bringing up problems) and how the information is being used.
Feedback lets the staff know that the supervisor appreciates the effort
they have made and demonstrates how valuable the reports are to the
supervisor. By acknowledging a job well done, the supervisor can help
ensure that the MIS continues to provide complete, timely, and accu-
rate information for decision making.
As a final step, supervisors should check that appropriate deci-
sions or actions have been made based on the information produced
by the MIS. When reviewing the reports, each supervisor should ask
these questions:
• Is the information in the reports accurate and reliable?
• Have all gaps or insufficiencies in the data been identified?
• Have the data been interpreted and the conclusions included
in the report?
• Does the report indicate decisions made or actions taken
based on the reported information?
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In summary, to see whether your current MIS is effective, evalu-
ate the process:
• Is all the information being collected actually necessary?
• Is the information collected on a routine, ongoing basis?
• Does the MIS operate at all levels of the system?
• Does the MIS contain a mechanism for regular feedback?
• Are reports produced in a timely fashion?
Remember the most important rules of a MIS:  Make sure you
have a reason for collecting each item of information, and make sure
the information you collect is up-to-date, reliable, and accurate.
MEETING THE NEEDS OF THE CLIENT
The driving force of every decision and action should be a desire to
meet the needs of the family planning client. For example, when
deciding what hours of operation the clinic should have, consider the
convenience of the clients. When setting up the waiting rooms, deter-
mine what would make the clients most comfortable both for waiting
to be seen and for receiving information. This client-focused approach
to service delivery is discussed in more detail in the following chapter.
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Form 1




Address (or directions to reach home)________________________________
______________________________________________________________
Age :____ (Estimate if not known) Birth date______________________
Education: ____ None      ______________ Some Secondary
________  Some primary   ______________ Secondary completed or more
________  Primary completed
Religion: ________ Moslem  ________ Christian  ________ Other
Reproductive History:
_________  No. of children born alive
_________  No. of children still living
_________  No. of miscarriages/stillbirths/abortions
Month/year last pregnancy ended: _______/________




_______ Regular  _______ Irregular
Date of Last Menstrual Period:  ________________________
Are you currently breastfeeding?  _________Yes ____________No
Do you want to have more children?
_________  No, wants no more children
_________  Yes, but wants child later (spacing)
_________  Not certain or counseling only
_________  Yes, wants child now
Contraception used prior to this visit?
________ No  _________ Yes (Specify most recent method used)
Method: _______________________________________________
Source: Public_________ Private__________ Other__________
The Individual Record System
Client Record, Page 1
Date ____/_____/_____      Client Reg. Number
































   
   
   














Frequent urinary tract infection or dysuria....... _________Yes _________No
Frequent or severe headaches........................ _________Yes _________No
Sickle Cell Anemia.......................................... _________Yes _________No
Other serious illness or condition................... _________Yes _________No
If yes, specify in box above
Smoker: ___ Yes  ___ No
INITIAL MEDICAL EXAMINATION (Only for those selecting IUD, hormonal, diaphragm,
or sterilization methods)
Blood pressure: ___________/___________  Weight: _______ (kg)
Breasts: _____ Normal ______ Lumps
Liver enlarged: ___Yes ___ No
Vaginal discharge: ___ No




Uterus position: _____________  Anteverted  ________________ Retroverted
Size: __________   Normal ___________ Enlarged  ___________ Other
Laboratory results (as appropriate):  ______________________________________
___________________________________________________________________
Other observations:  __________________________________________________
___________________________________________________________________
Contraceptive selected this visit: _________________________________________
Brand/Size _____________________  Quantity  ____________________________
Date of next appointment  ______________________________________________
Name of examiner   ___________________________________________________
Pregnancies that occur after initial clinic visit
Date pregnancy ended:              Pregnancy outcome:
________/________/_________   Live birth _________  Miscarriage ____________
Stillbirth __________  Live birth died later ______
Complication  ____________________________
________/________/_________   Live birth _________  Miscarriage ____________
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Form 2
Daily Activity Register
Clients Served and Commodities Dispensed
Clinic Name ______________________  Month/Year ______________________
District __________________________  Region ___________________________
Cumulative Totals
Page Totals
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Form 4
Contraceptive Supply Status
Location Code Date of Report  ________/__________/_______
Name of Location _____________________  Region __________________  District _____________

















































































Providing Quality Family 
Planning Services
 
Veronica is from a small African village and has come to the 
family planning clinic in a nearby town. Her sister came last 
year and was given an IUD.  Veronica thinks she would like one 
also, because her sister is happy with hers. After signing in at the 
clinic, she is told she can expect to wait 30 minutes before seeing 
the nurse. While waiting, Veronica looks at the posters on the 
wall that explain the different types of family planning methods 
and the benefits of family planning. After Veronica tells the 
nurse that she is there for an IUD, the nurse asks her several 
questions to find out whether the IUD would be a good method 
for her and to see whether Veronica is interested in considering 
the other methods the clinic offers. After discussing the various 
methods, they both agree that the IUD would be the best 
method for Veronica. However, the nurse asks Veronica to come 
back another day for the IUD insertion because the clinic has 
been out of IUDs for 2 weeks. Because the regional warehouse 
sends the truck only every 3 months to deliver supplies, the nurse 
gives Veronica an appointment the next month and gives her 
some condoms to use in the meantime. Veronica is disappointed 
and feels embarrassed to ask the nurse how to use the condoms or 
how to ask her husband to use them. Also, the nurse seems in a 
hurry to see the next client. Veronica never uses the condoms and 
does not come back for her appointment, because she suspects the 
clinic will still be out of IUDs and because it is difficult for her 


























To help women and men have the number of children they want, fam-
ily planning providers must do more than just provide information,





and contraceptives to safeguard the health of their clients and ensure
their satisfaction with the family planning services. Client satisfaction
with services is very important; when clients are happy with the ser-
vices they receive, they are more likely to continue using them and
practicing family planning.
Many of the principles for improving the quality of services pro-
vided by family planning and health clinics will also apply to commu-
nity health workers and to community-based distribution programs.
The general guidelines presented in this chapter should be adapted for
the specific program of interest. Administrators of each program or
clinic must define "quality" services based on the organization's mis-
sion, the number of staff members and their skills, the technical
resources available, the client population, and the social, cultural, and
political environment in which it operates.  Improvements, great or
small, can be made at any organizational level.
Some family planning providers may find it difficult to imple-
ment some of the suggestions for providing ideal services because they
are restricted by inadequate facilities or by shortages of staff, equip-
ment, supplies, electricity, bathrooms, or even water. Whatever their
circumstances, family planning providers should always provide the




























































Ask the staff at the service delivery site to describe what they
think quality services are and the conditions that are necessary for






They will likely have ideas of how things can
be improved, and if they are involved in evaluating the services, they
will better understand the changes that will take place to improve the
services.
The quality of services can be assessed both objectively and sub-
jectively. To assess services objectively, begin by asking the following




Is a full range of contraceptive methods (short-term, long-





Do the service providers try to understand the clients by ask-
ing them about their background, attitudes, preferences, con-




Do clients receive full information on all contraceptive meth-
ods, including the precautions, possible side effects, and effect




Do service providers let clients know what assistance they
will provide with each method in terms of advice, additional








Do the service providers follow the clinic's guidelines for




Do the service providers encourage continuity of contracep-
tive use by making it easy for the client to obtain supplies,





Do service providers treat clients with respect, empathy, and
understanding? Do they encourage clients to ask questions?





Are the services accessible to the client (i.e., relatively easy to
get to, open at convenient times, affordable, and not requir-


























Because family planning services must be safe, all clinical and
medical standards and protocols must be met. Ideally, the clinic or
other service delivery point should be fully staffed with adequately
trained providers and have the equipment, materials, and supplies nec-
essary for safe services. The medical history of individual clients
should be available to the service provider.




Are the clients satisfied with the services they receive and the









Are the clients satisfied with the contraceptive methods they
are using?
It is better to ask these questions of the clients themselves, but
you can also assess a clinic's quality subjectively by looking at it
through a client's eyes. For example, if you were the client, would you
feel comfortable with the provider and able to ask questions? Would
you receive all the information you need to make an appropriate con-
traceptive choice? Would you be content with the care you received at




















Everyone should have the right to good-quality services—services
that are safe, accessible, and meet their needs. Good-quality services
are much more likely to keep clients coming back and to attract new
ones. Satisfied users are an important source of information for people







 In the long run, providing good-quality ser-





As the opening story illustrated, a number of factors are involved
























vide quality services and actually succeeded by a number of indicators:
the wait was not too long, informational material was available, and
the nurse was trained in family planning and followed protocol by dis-
cussing all the methods with Veronica and providing her with con-
doms when the method she chose was not available.  
However, some elements of good care were missing or not work-
ing properly: the lack of intrauterine devices (IUDs) meant Veronica
could not get the method she wanted right away; the nurse was too
busy to take the time to make sure Veronica understood how to use
the condoms or to encourage her and answer her questions; and the
clinic did not have a follow-up process to contact Veronica about her
missed appointment. Veronica, who was motivated to seek family
planning services, found her needs unmet.
This clinic could raise the quality of its services by (1) improving
its contraceptive ordering procedures to avoid running out of supplies,
(2) stressing to service providers the importance of following guide-
lines and of focusing on the individual client's needs, and (3) develop-
ing a tracking system that allows the clinic to track and contact clients
who miss appointments (perhaps through an outreach program).
 
GUIDELINES FOR IMPROVING THE QUALITY OF 
SERVICES
 










































































The service provider must be technically competent to help cli-
ents use contraceptive methods safely and avoid health risks. If the
quality of the services is not as good as it could be, it may be that pro-
viders are overworked and lack time to deliver services according to
guidelines, or they may not be properly trained to deliver a particular
service. 
When selecting new service providers, make sure the provider is
able to carry out the tasks required. A job description that outlines the
employee's tasks and responsibilities, what her or his authority is, and
what skills or qualifications are necessary to do the job is useful to
both the supervisor and the employee.
Make sure the current staff are well trained and capable of deliv-
ering the services they provide. The supervisor can assess the need for
staff training by comparing the staff member's skills with the skills
listed in the job description and the skills necessary to follow clinic
protocols. When training is necessary, provide it on-site whenever pos-
sible to ensure it is relevant to the staff members' jobs, and involve the
supervisor so that she or he can follow up later. Refresher training














To help the providers do their best and to keep up morale, super-
visors should guide, support, and assist the providers: 
    • Provide on-the-job training when necessary.
    • Convene regular staff meetings to keep everyone informed of
activities, policies, changes, and developments.
    • Meet with staff to develop and review work plans and discuss
problems.
    • Provide staff with feedback (positive as well as negative) on

























    • Listen to the staff's concerns and ideas on how services could



























Every service provider must have and follow service delivery
guidelines to ensure that all clients receive medically safe, well-
informed care that meets their needs. These guidelines should be part
of a clearly written manual available to all health workers. The guide-
lines should encourage staff always to consider their client's needs and
preferences, try to understand them, and then do their best to meet
them.
The guidelines, which should not present medical or logistical



























Guidelines for monitoring the quality of contraceptive prod-



















By informing and counseling clients, the provider helps them
choose the best family planning methods. Providers must be skilled in
counseling, listening to, and communicating with all clients in a non-
judgmental way.
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The relationship between client and provider should be one of
mutual trust, which requires honesty and respect for all clients, what-
ever their level of education, economic status, ethnicity, religion, or
sex. The provider should do the following:
   • Give complete information that is accurate, unbiased, and
culturally appropriate.
   • Provide a full range of methods from which to choose.
   • Encourage clients to ask questions and respond in a non-
judgmental way.
   • Use appropriate materials as teaching aids and outreach.
   • Listen to clients to learn their needs, concerns, and prefer-
ences.
   • Document complaints and other forms of client feedback,
and address them when possible.
In addition, service delivery sites should occasionally use "cus-
tomer interviews" to solicit feedback from their clients on how services
could be improved.
ACCESSIBLE SERVICES
Clinic settings not only need to offer good-quality services but
also need to be accessible in distance, cost, and hours of operation.
The following characteristics describe an acceptable and accessible
clinic setting:
    • The waiting area is large enough and has sufficient seating for all
clients, is pleasant, and has informational activities or materials.
    • Service is prompt.
    • Rooms and equipment are clean and organized.
    • The clients have privacy for counseling and examination.
    • Ventilation is adequate.
    • Toilet facilities with water are available.
    • Signs and directions clearly indicate how to get to the clinic
and find one's way once there.
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    • The clinic's location is known and convenient to the client.
    • Clinic hours are convenient for clients and are well posted.
If family planning services are provided in a location where other
health services (such as obstetric or pediatric care) are provided sepa-
rately, each of the services should cooperate in letting clients know of
all the other services.
GOOD RECORDS
Three kinds of data need to be collected at each service delivery
point for the clinic to provide high-quality services.
Client medical record
Collect information on the client's health status to determine
that a certain method might not be suitable and to help the client
make an informed decision when she or he is choosing a contraceptive
method. The medical record containing this information needs to be
available for charting every time the client returns to the clinic.
Service statistics
Collect information on all the services the program provides so
that both the clinic and the upper management of the family planning
program can monitor the clinic's performance and identify and resolve
any problems.
Contraceptive supply information
Collect information at the service delivery level on contraceptive
supplies, both what is in stock and what is being dispensed, and
promptly report this information. Doing so will help ensure that ade-
quate supplies are always on hand and that accurate forecasts can be
made of future need. (For more information, see Chapter 26 on Effec-
tively Managing Your Family Planning Program.)
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Collecting all of this information is just the first step; the infor-
mation must be used. Review the client's medical record at each visit.
Promptly report information on services provided to the next highest
level of the program. Review information on supplies to make sure an
adequate stock level is maintained, and report to higher program levels
as required.
ENCOURAGEMENT OF CONTINUING CONTRACEPTIVE USE
Some contraceptive methods (such as the pill, condoms, and
injectables) require the client to return periodically for more supplies.
These resupply visits should be as easy and brief as possible while still
providing the necessary medical care (such as checking blood pressure
or asking about side effects). Clients coming only for resupply should
be able to get their supplies quickly without going through the usual
clinic procedures, such as counseling.
Clients are more likely to continue practicing family planning
when the program has a good follow-up system. Following up means
contacting the clients to make sure they understand how the method
works and what side effects to be aware of, answering any questions,
and helping them make informed decisions about their fertility. These
tasks are sometimes carried out in community-based distribution pro-
grams that regularly visit clients at home, but follow-up systems can
take other forms:
    • An appointment or reminder system
    • Monitoring "drop outs" from the program
    • A home visit outreach system
Because well-informed clients are more likely to continue prac-
ticing family planning, providers should make sure that clients know
at least the following about the contraceptive method they use:
    • How to use it correctly
    • Its benefits 
    • Possible side effects 
    • How to get additional supplies 
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    • What examinations are necessary for that method
    • The need to have regular reproductive health exams (Papani-
colaou smear or blood tests)
Providers should also instruct clients in switching contraceptive
methods if they dislike their current method.
FULL RANGE OF REPRODUCTIVE HEALTH SERVICES
Clients will view the program more favorably if all their family
planning and reproductive health needs can be met during one visit or
at one location. To meet all its clients' needs, an ideal clinic would
provide:
    • Gynecological care
    • Diagnosis and treatment of sexually transmitted infections
(STIs)
    • Pap smears
    • Pregnancy tests
    • Laboratory tests
    • Infertility diagnosis and treatment
    • Prenatal care
    • Pediatric services
    • Sexuality counseling
Many clinics are simply too small or lack the resources to offer all
these services, but comprehensiveness at one site is not necessary.
Achieving greater efficiency for its clients is one goal to which every
clinic can aspire; where family planning services are offered along with
maternal and child health services, for example, clients may be able to
take care of their family planning needs and pediatric care in one visit.
Service delivery sites should provide only those services that are
needed and that they can provide well. For any service that a site does
not provide, the staff should be able to refer clients to a site where it is
available.
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PROVIDING GOOD-QUALITY CONTRACEPTIVES
An essential part of providing good-quality care is making sure
that the right contraceptives are available, affordable, and safe to use.
Examining the story at the beginning of the chapter, we can say that
Veronica did not receive the best quality service because she was
unable to obtain the method she had chosen. For clients to receive
good-quality products when they need them, a program needs to have
an efficient, well-functioning supply system with the following ele-
ments:
• Storage consistent with family planning guidelines (see
Chapter 26)
• Timely reporting
• Accurate forecasting of contraceptive needs
• Timely response to requests for supplies         
• Monitoring of product quality 
To properly and efficiently manage a contraceptive logistics sys-
tem, accurate and up-to-date information is needed on the contracep-
tive supplies, such as the amount of contraceptives in storage, where
they are stored, and at what rate they are being dispensed. Every pro-
gram needs a simple, well-designed logistics management information
system, whether manual or computerized, to ensure both the availabil-
ity and the quality of contraceptives.
  Managing contraceptive supplies requires the following cycle:
planning for program needs, procuring the contraceptives, distributing
them to service delivery points, and dispensing the contraceptives to
the client. There are quality considerations at every stage of this cycle. 
In the planning stage, select an appropriate mix of products that
takes into consideration the preferences and needs of the clients, such
as a progestin-only pill for lactating mothers or preferred brands of
condoms for preventing human immunodeficiency virus (HIV) and
other sexually transmitted infections (STIs). Accurately estimate the
quantities that will be needed to avoid understocking or overstocking
contraceptives. (See Chapter 26 on Effectively Managing Your Family
Planning Program, for more information on forecasting contraceptive
needs.)
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The procurement stage, which applies only to the top (central)
level of a family planning program, involves ordering contraceptives
from the manufacturer. During the distribution stage, the central level
of the program is responsible for checking and maintaining the quality
of the contraceptive products as they are received from the manufac-
turer, stored in warehouses, and ordered by and transported to lower-
level warehouses or service delivery points. Storing and transporting
contraceptives in hot or humid environments or where ventilation is
poor is always cause for concern, as these conditions can damage the
quality of contraceptives. Ensuring contraceptive quality requires fol-
lowing sound warehouse practices (see Chapter 26) and developing a
system to monitor the quality of contraceptives at each step on the
way to the client. As a final check, service providers should visually
check the quality of the contraceptives when they dispense them to
the client.5
GUIDELINES FOR ENSURING THE QUALITY OF CONTRACEPTIVES
    • Monitor the shelf life of contraceptive products so that clients
receive them well before the expiration date.
    • Conduct regular visual inspections to look for damage or deterio-
ration.
    • Request laboratory testing when deterioration or poor quality is
suspected.
    • Document all product quality problems.
    • Follow disposal guidelines if contraceptives are unfit for use.
Both during visual inspections and when contraceptives are dis-
pensed, program staff and service providers should look for the warn-
ing signs described below. Service providers should also perform a final
check as they dispense the contraceptive to the client to make sure it
has not expired. Expiration or manufacture dates are generally
stamped on the outside box in which contraceptives are shipped, on
the inside box, and on the individual contraceptive package.
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Contraceptive shelf life and visual warning signs  
Oral Contraceptives Shelf Life: Usually 5 years
• Check to make sure the blister or foil packaging for each packet of pills is not 
broken, that all pills are in the packet, and that all the pills have the correct 
color and are not cracked. If any of these problems are present, do not give 
these pills to clients.
• Check the room temperature. Oral contraceptives supplied by the U.S. 
Agency for International Development have a shelf life of 5 years when stored 
at room temperature (15 to 37˚ C) in dry conditions. Check the shelf life of 
oral contraceptives from other sources.
• If there is any question about the hardness of a batch of oral contraceptives, 
push a pill through the aluminum backing. If it crumbles, do not give these 
pills to clients.
• If there is any problem with one of the packets, check to see whether other 
packets in the box also have the problem.
• Check to see that there is a sheet containing instructions and information on 
pill type and dose in each packet. If a packet is missing this information, it 
should be given to clients only after making sure the client is familiar with the 
information on the missing sheet.
Intrauterine Devices (IUDs)        Shelf Life: 7 years*
• IUDs should be kept away from heat or direct sunlight.
• Check for any breaks in the sterile packaging. If you find any breaks or holes 
in the sterile seal, do not use this IUD unless it is chemically sterilized again 
immediately before insertion. 
• Check to make sure all the product contents are in the sterile wrapper. If 
anything is missing or broken, the IUD is not safe for use.
• IMPORTANT: The copper on some IUDs sometimes gradually darkens. 
This is normal and happens because of oxygen in the air surrounding the 
IUD in the package. Darkening has not been shown to have a clinical effect. 
As long as the device is within its shelf life and the packaging is intact, the 
IUD can be used.
Injectables    Shelf Life: 4 to 5 years*
• The contents of the vials will stay effective until the expiration date if they are 
stored at 15˚ C to 30˚ C. Refrigerate the vials if the manufacturer specifies 
that this be done.
• If the contents of the vial separate, shake the vial just before using it.
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Condoms Shelf Life: 3 to 5 years
• Check the condom packages for discoloration, yellowing, or damage to the 
package seal. Any of these signs indicates that the condom's quality and thus 
its effectiveness may have diminished and that it cannot be used reliably.
• Warning signs that a condom is of poor quality are hard to find. Be aware of 
the conditions where latex condoms are stored because these condoms will 
deteriorate if they are exposed for long periods to any of the following: 
Sunlight
Temperatures above 40˚ C
High humidity
Electric motors (because they generate ozone)
Fluorescent light
Petroleum vapors or other types of liquid solvents
• Condoms that come into contact with petroleum, mineral, or other 
household oils will be damaged. These oils should not be used for lubrication 
or in any other way in which the oil touches the latex condom.
• The shelf life of condoms varies because the latex can be damaged by extreme 
environmental conditions. In hot, humid areas in Africa, closely examine the 
quality of condoms that are more than 2 years old. 
Hormonal Implants Shelf Life: 5 years†
• If the sterile seal enclosing the rods is broken or if any of the rods is missing, 
do not use this package of implants.
• Check to make sure the implants are protected from excessive heat, direct 
sunlight, and moisture.
Diaphragms Shelf Life: Variable
• Do not use diaphragms if they are cracked or have any holes, even very small 
ones. Check for holes by holding the diaphragm up to the light.
• Once the diaphragm has been given to the client, the quality should be 
checked every 2 years and the diaphragm replaced, if necessary.
Spermicidal Jelly     Shelf Life: 3 years
• Check the jelly tube. If you find wrinkles or leaking or cannot get the 
applicator to screw easily onto the tube, do not give the tube to the client.
• Check to see the package has instructions on how to use the product correctly.
Contraceptive shelf life and visual warning signs  (Continued)
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Spermicidal Foam      Shelf Life: 3 years
• Check the storage conditions to make sure the can is not exposed to intense 
heat or extreme fluctuations in temperature or humidity and that it is stored 
upright at temperatures below 50˚ C. Because the contents in the cans are 
under pressure, the cans should not be punctured or burned. 
• If you suspect the foam's quality has deteriorated because of poor storage 
conditions, damaged cans, aging, or complaints from clients, follow the 
instructions and spray some in your hand. Check the foam to make sure it is 
the right consistency and color and comes out of the can the way it should. 
Most brands come out white and foaming.
• Check to see the package has instructions on how to use the foam correctly.
Foaming Tablets      Shelf Life: 5 years
• Feel through the packaging to see whether the tablets feel soft or crumbly or if 
the packaging is puffy; if any of these conditions are present, the tablets 
should not be dispensed.
• If there are broken or missing tablets or tablets that have a different color, do 
not give this package of foaming tablets to a client.
• Make sure the information on the boxes or packages is the same as the 
information printed on the tablet packaging. 
*Follow the manufacturer's expiration date, as different products have different shelf lives.
† The Norplant implant has a shelf life of 5 years from date of manufacture, provided the sterile plastic 
pouch is not damaged or opened. Norplant will remain stable if stored at temperatures ranging from 
20˚ to 50˚ C, but it is essential that the product be stored in a dry location. Once inserted, the implants 
have a 5-year effective use life.
Sources: Wolff et al. (1991); CDC (1993)
Contraceptive shelf life and visual warning signs  (Continued)
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VISUAL INSPECTIONS
Ideally, a visual inspection of contraceptive quality should be
conducted when the following events occur:
• The central warehouse receives the product from the manu-
facturer.
• The regional warehouse receives the product.
• The clinic receives the product.
• You wish to conduct a periodic inventory or you are moni-
toring quality.
• You are investigating complaints about quality.
• The product is about to reach its expiration date or shows
signs of damage.
At the clinic level, a visual inspection must also be done. You
should do the following:
• Examine all the package levels (carton, box, and unit) for
damage.
• Make sure that information inserts (with information for the
user and the clinician on the product and its use) accompany
the product.
• Check for shelf life information (date of manufacture or
expiration).
• Check for tracer information (the lot number and name of
manufacturer).
Contraceptives are shipped by the manufacturer in cartons. Each
carton contains a number of boxes, and each box contains a number
of units of that contraceptive. The amount of contraceptives produced
at one time under the same conditions is known as a lot or batch. Each
lot or batch has its own identity code.
To check contraceptive quality, begin by looking at the condition
of the carton and the labels on the outside of the carton. If there is a
problem, check inner boxes for damage and then the boxes inside of
that; go all the way until you have checked the individual product. (As
you check for package damage, also check products for correct labeling.)
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If there is no reason to suspect problems with quality, check only
a few individual products (a strip of condoms, a couple of packets of
pills, etc.) for problems rather than checking a larger sample. 
If there is reason to suspect the quality of the product because of
any of the problems listed above or because of complaints about the
product, sample more of the products. There is no simple rule for how
many to sample. Use your judgment and consider taking samples from
different boxes, locations, storage conditions, or different dates of
manufacture. The reason for conducting a visual inspection (for exam-
ple, as a routine inventory check, because complaints need to be inves-
tigated, or because storage conditions are poor) will be a factor in
deciding how many to sample. A routine inventory usually involves
collecting a smaller sample than does an inspection because of poor
storage conditions or complaints.
LABORATORY TESTING
Usually, the only laboratory testing performed for contraceptives
is done by the manufacturer and takes place before the products are
shipped. Most laboratory tests for contraceptive products require
sophisticated equipment and can be expensive. If clients complain
about products and a visual inspection does not identify the cause of
the problem, laboratory tests may be requested by appropriate profes-
sional authorities, usually from the central level of the program.
 DOCUMENTING COMPLAINTS
Any time a client reports a problem with a contraceptive, the com-
plaint should be taken seriously and recorded. Family planning service
providers should let clients know their complaints are heard while also
making sure the client understands how to use the method correctly and
that the problem is not caused by improper use. Providers should keep a
well-documented file of complaints about contraceptive products.
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Examples of complaints include clients reporting side effects or
describing problems with contraceptive use or effectiveness, staff not-
ing the lack of information inserts that are supposed to accompany a
product, or warehouse personnel saying they cannot identify the man-
ufacturing or expiration dates. The purpose of documenting com-
plaints is to find the cause of the problem and correct it. To
accomplish this, clinic staff must not only document complaints but
also report them up the chain of command so that regional or central
administrators are aware of the problem and can compile information
that will help them trace the cause and take corrective action. 
Keep a record of the number of complaints and the details of the
problem. Descriptions of the product will help to isolate the problem:
    • Method
    • Brand 
    • Manufacturing or expiration date (printed on individual
contraceptive unit package)
    • When and where it was dispensed to the client
    • The lot number of the product, if possible (this lot number
is generally printed on the outside carton, the inner box, and
the unit package)
    • Any circumstances that may be pertinent to identifying the
extent and nature of the problem, such as unusual storage
conditions
The lot number of the product is used to trace problem products.
For example, suppose clinics report that clients have complained of
condoms breaking during use. While documenting the brand and
expiration date, program staff find that the problems are all with one
brand. At this point, the clinics can continue to supply other brands to
their clients while investigating the brand in question. If the defective
condoms all turn out to have the same lot number, the program
should not dispense from that lot of condoms while the lot is sampled
and sent for testing (however, the program could dispense condoms of
that brand from other lots). Results from the laboratory testing will
determine whether that lot of condoms is safe to dispense or should be
destroyed.
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PRODUCT DISPOSAL
Contraceptive products need to be destroyed when they reach
their expiration date, are severely damaged, or testing shows they are
not effective. Disposal should follow local regulations and, if the prod-
ucts were donated, donor regulations. Disposing of unsafe products
ensures they cannot be mistakenly dispensed or recovered for use or
resale. The most common methods of disposal are burning and bury-
ing, but laws protecting the environment may prohibit one of these
options. 
When disposing of products, record the following:
• Product name
• Quantity
• Date of manufacture or expiration
• Lot number
• Date of destruction
• Method of destruction
• Location of disposal
• Authorization
• Witnesses
EVALUATING THE QUALITY OF SERVICES
How do family planning providers evaluate or measure improve-
ments in the quality of their services? Table 27:1 shows some of the
questions you can ask about your program to give you an idea of the
quality of the services it provides and to establish a base for your eval-
uation. There are two primary ways of evaluating a program that offer
good feedback and are reasonably time-efficient:
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Observation
Directly observe services being provided to examine the amount
of contact between provider and user, check that specifications are fol-
lowed, and examine the setting, equipment, and materials. Provide
feedback to the staff on your observations, and ask them to make sug-
gestions and discuss problems.
Client response
You can conduct:
• Exit interviews with clients
• Follow-up surveys of family planning clients (from your own
program and others)
• Interviews with a sample of women living in the service area
• Focus group discussions with clients
• Analysis of patient flow and use of provider time
Periodically review and revise the program's policies to make sure
they are aimed toward understanding and meeting the clients' needs.
Quality is not a one-time exercise but an ongoing concern and con-
stant responsibility. 
Respect for all people is the force behind improving the quality
of family planning services. Every client visiting the program has a
right to access, choice, safety, privacy, confidentiality, dignity, and
comfort. In addition, the client has the right to information from the
program and to express an opinion.
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Table 27:1 Evaluating quality of services:  Guidelines and practices  
 
Yes No
Availability of contraceptive methods
At least 4 contraceptive methods are offered M M
The clinic offers:
Intrauterine devices (IUDs) M M
If No, is there a place to refer clients? M M
Female sterilization M M
If No, is there a place to refer clients? M M
Male sterilization M M
If No, is there a place to refer clients? M M
Injectables M M
If No, is there a place to refer clients? M M
Norplant M M
If No, is there a place to refer clients? M M
The referral system is effective (clients get the services they need) M M
Counseling
There are guidelines for providing information on contraceptive 
methods and helping the client select one
M M
For each available contraceptive method, 
clients are informed about:
How the method works M M
The side effects of the method M M
How the method is used M M
Possible danger signs of the method M M
Where to go for help M M
How to get additional supplies (if necessary) M M
There are good visual aids to explain each method M M
A checklist covers information the provider should discuss 
during a counseling session
M M
Providers are trained in counseling skills or interpersonal relations M M
The clients have adequate privacy during counseling M M
PROVIDING QUALITY FAMILY PLANNING SERVICES 661
Clinical services
There are written clinical guidelines for providing each method M M
The clinical guidelines are strictly followed M M
The clients have adequate privacy during the examination M M
Infection control procedures are followed M M
Providers are adequately trained M M
If health problems result, the providers are able to treat them M M
If No, is there a place to refer clients? M M
New staff are trained in the clinic's guidelines and procedures M M
Periodic staff refresher training is provided M M
The following items are available for all service providers:
Sterilizing equipment M M
Gloves M M
Blood pressure equipment M M
Specula M M
Adequate lighting M M
All necessary equipment is available and working M M
The equipment is sterile when necessary M M
The equipment is easy to find M M
The clinic or staff can handle HIV, other STIs, and reproductive 
tract infections:
Diagnosis or identification M M
Treatment M M
Referral M M
Table 27:1 Evaluating quality of services:  Guidelines and practices   
(Continued)
Yes No
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Staff responsibilities and attitudes
The providers are motivated to provide high-quality services M M
The providers are supportive, respectful, and helpful 
during their interactions with clients
M M
The providers are able to get all their work done within 
their allotted work hours
M M
The providers know all of the tasks required of them M M
The providers all have job descriptions M M
All staff members are properly supervised M M
Contraceptive supplies
Shortages and stockouts of contraceptives are rare M M
Clients never discontinue contraceptive use because of 
supply shortages
M M
The same brands and doses are always available 
(there may be additions but not substitutions)
M M
What do you do if you cannot provide the client with the method 
she or he wants?   _____________________________________
What percentage of your clients discontinue using any method 
at all?  _____________________________________________
Possible future changes in demand for contraceptives are taken into 
consideration when estimates of future need are made
M M
The contraceptives are stored under good conditions M M
Periodic visual inspections are conducted of the contraceptives to 
check for signs of damage or deterioration and for expiration dates
M M
Complaints about the quality of the contraceptives are documented M M
Client information
Adequate information is kept on all of the clients M M
Client files are easy to find and use M M
Clients are followed up if they do not return when their 
method has run out or they have missed an appointment
M M
Table 27:1 Evaluating quality of services:  Guidelines and practices   
(Continued)
Yes No
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Access to services
The clinic is open at hours convenient to the clients M M
The clinic is easy for the clients to get to M M
The clients are not discouraged by the clinic's location M M
The clinic facilities are clean and pleasant M M
Appointments are taken in order M M
The water supply is adequate M M
The program makes home visits M M
Client Feedback
There are mechanisms for getting feedback and suggestions from 
the clients regarding the quality of services
M M
The client's perspective is a consideration when changes are made 
in the clinic's services or policies 
M M
Evaluating Quality of Services: The Client's Perspective 
[These questions to be answered by the clients]
It was easy to find out where to get family planning services M M
The family planning facility was easy to find M M
I came to this site because: ___________________________
The clinic's hours of operation are convenient for me
If No, a convenient time for me is:  _______________
M M
The family planning provider was easy to talk with M M
The provider answered all questions and encouraged questions M M
I was able to get all the information I needed to make a decision 
about what method to use 
M M
I was treated with respect by the people at the clinic M M
I did not feel rushed and I felt that the provider had enough time 
to address my concerns 
M M
The facilities are pleasant M M
There was enough seating in the waiting area M M
The wait was not too long M M
I was treated courteously at all times M M
Table 27:1 Evaluating quality of services:  Guidelines and practices   
(Continued)
Yes No
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Evaluating Quality of Services: The Client's Perspective  (Continued)
The providers seemed to be knowledgeable about what 
they were doing
M M
The providers answered my questions satisfactorily M M
I had enough privacy during the counseling M M
I had enough privacy during the exam M M
I was able to get the contraceptive method I wanted M M
If Not, I was satisfied with the reason I could not get it M M
I was given an alternate method M M
The contraceptive method I want is affordable M M
I would be comfortable returning to this facility M M
I would be comfortable returning to the providers M M
I would recommend this facility to others M M
The other services I would like to see offered at this site are:
Other comments I have:
Source: Katz et al. (1993)
Table 27:1 Evaluating quality of services:  Guidelines and practices   
(Continued)
Yes No
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In the family planning training course, nearly every student 
said, "There should be more alternatives that are more effective 
for a longer period of time and with fewer side effects. When can 
we offer new contraceptives to our clients?"
 
Researchers are investigating new contraceptive methods that may
appear in the next decade. This chapter briefly presents some of the
methods currently under development.
Hormonal methods, such as pills, implants, and injections, are
popular among African women. Researchers are working to develop
improved versions of these methods. Mothers need hormonal meth-
ods they can take safely while breastfeeding. The prime candidates are







It is too early to say whether any of these methods will be
available by the next decade.
The widespread threat of acquired immunodeficiency syndrome
(AIDS) and other sexually transmitted infections (STIs) created a need
to find contraceptive methods that women could use on their own to
protect themselves. Barrier methods have long been used by women to
avoid both pregnancy and disease. Researchers are working to improve
the contraceptive effectiveness of these barriers and reduce their
annoying side effects. Chemical barriers are also under study as


























The last two to three decades of research notwithstanding, a vac-
cine to prevent pregnancy is not likely to be available for some time.
The most advanced testing has been conducted with vaccines acting






Because these vaccines are
abortifacients, it is unlikely that any company will pursue their devel-
opment vigorously. Other antigens that prevent fertilization, includ-
ing a variety of sperm and zona pellucida antigens, are more promising
politically but are so early in development that none will be available







Implanon Implanon is a single implant effective for 2
to 3 years. The implant is currently undergo-
ing large-scale clinical trials worldwide and




Norplant II Norplant II is an improved version of Nor-
plant that contains two rods instead of six.
It may be on the market soon.
 
5
Biodegradable Biodegradable implants dissolve in the body
implants and do not need to be removed. Pellets the







Another new implant is made from









Levonorgestrel An alternative to depot medroxyprogesterone
butanoate acetate (Depo-Provera), it could be available
in the late 1990s.
Estrogen-containing The World Health Organization has tested a
injectables number of monthly injectables that contain
an estrogen as well as a progestin to minimize













Vaginal rings Vaginal rings, when placed deep in the
vagina, provide another method of continu-
ously delivered progestins. Researchers are
developing devices that are less irritating to
the vagina and that have both estrogen and
progestin.
Natural progesterone Natural progesterone is being tested in vagi-
nal rings, suppositories, and injectable poly-
meric microspheres. The rings stand the
best chance of being approved for routine
clinical use.
ST-1435 ST-1435 is being tested in skin creams,





Female condom Available in Europe and the United States.
Because of its design, the female condom
protects all of the vaginal lining, thus pro-
viding good protection against pathogens.
Lea's shield A one-size-fits-all diaphragm-like device. A
one-way valve allows uterine and cervical
fluids to escape yet prevents sperm from get-
ting into the cervix. This device should be
approved by 2000.
Femcap This cervical cap comes in three sizes; the







Femcap should be approved by the
end of the decade. 
Silicone diaphragm An easy-to-fit silicone diaphragm might well
be more comfortable and easier for women


































Frameless IUD The frameless copper IUD does not press





 A thread secures the sleeves at the fun-
dus.







reduces excessive bleeding and may protect
against pelvic inflammatory disease by thick-
ening the cervical mucus. This IUD is avail-




Vaccines A vaccine using luteinizing hormone-releas-
ing factor (LHRF) linked to tetanus toxoid
shuts down the testes; the user would need
to take testosterone. A vaccine based on fol-
licle stimulating hormone (FSH) tested in
monkeys eliminates sperm while maintain-
ing normal testosterone levels.
Hormones Testosterone enanthate (TE) reduces sperm
production to levels that may be low







the current weekly injection schedule is
impractical. Implants  that can deliver test-





Plastic male condom A search has long been under way to
develop condoms with improved feel and
durability. A new polyurethane condom
with a traditional design may allow the user
more sensitivity, perhaps making the device
more acceptable to many men who dislike
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The expulsion or extraction of the 
products of conception from the uterus before the 
embryo or fetus is capable of independent life. 
Abortions may be spontaneous or induced. Spon-
taneous abortions are commonly called miscar-
riages. Induced abortions are voluntary 
interruptions of pregnancy or therapeutic abor-
tions. Incomplete abortion occurs when some 
products of conception, usually the placenta, 
remain inside the uterus. Missed abortion is when 
the fetus has died in utero and some or all of the 
nonliving products of conception remain in the 








Refraining from sexual intercourse.
 
Acquired immunodeficiency syndrome 
(AIDS)
 
A disease defined by a set of signs and 
symptoms, caused by the human immunodefi-
ciency virus  (HIV), transmitted through body flu-





Any disease of the lymph nodes or 




Abnormal sticking together of body 
tissues, usually by bands of scar tissue that form 




The transition period between 




The appendages and accessory organs of 
the uterus, including the ligaments, ovaries, fallo-









The absence or suppression of 
menstruation. This state is normal before puberty, 





Removal of amniotic fluid from 
the uterus. This procedure may be done to deter-
mine fetal chromosomal and biochemical abnor-




The inner membrane that forms a 
fluid-filled sac surrounding and protecting the 
embryo or fetus. The amnion and the chorion 





The wide upper end of the vas defer-





A natural steroid hormone found in 
males and females. It is responsible for producing 
masculine characteristics (e.g., deep voice, facial 
hair) by stimulating the sex organs of the male. 
Androgens are produced chiefly by the testes but 




A condition in which the quantity of 





A localized edema causes by dila-



















Introduction of semen 
















Disease of the vagina 




A tubal ligation procedure 
done through an incision small enough to be cov-





























A contraceptive method that 
establishes a physical barrier between the sperm 
and ovum, e.g., condom, diaphragm, foam, cervi-
cal cap. Some of the barrier contraceptives are used 




Small glands found on either 
side of the vaginal entrance that secrete small 
amounts of lubricating fluid. Also called vestibular 
glands.
 
Basal body temperature method (BBT)
 
A 
method of fertility regulation that uses daily tem-
perature readings taken immediately after waking 
to identify the time of ovulation; approximately 24 










tion of the pelvic structures performed by inserting 
gloved finger(s) of one hand into the vagina and/or 










 Two different phases, as in biphasic 
basal body temperature.   A rise in temperature in 
the second half of the cycle that indicates ovula-
tion has probably occurred.
 
Birth rate (or crude birth rate)
 
 The number of 
live births per 1,000 of the mid-year population in 





  Bleeding at a time in 
the cycle other than the menstrual period. See 








Caesarean section (also Cesarean)
 
Surgical 





 A genus of yeast-like fungi. Candida is 
part of the normal flora of the skin, mouth, intesti-
nal tract, and vagina but may cause disease when it 










 The process by which sperm 
become capable of penetrating an egg, which 




 A new cancerous growth originating 
in any of the epithelial tissues of the body and 
characterized by invasive growth and rapid spread 









 Use of heat, electricity, or chemicals to 




 Small latex or plastic cap that cov-
ers the cervix. Users of this barrier method of birth 





 Small indentations that line the 
length of the cervical canal and contain mucus; 
may serve as a reservoir for sperm.
 
Cervical intraepithelial neoplasia (CIN)
 
 A sex-
ually transmitted disease exhibiting early cancer-
ous or precancerous changes of cervical epithelial 




 Inflammation of the cervix most 
commonly due to infection, exposure to chemicals 
(e.g., spermicidal agents), foreign bodies (e.g., cer-





The primary lesion of syphilis, which 
appears as a hard, painless sore or ulcer often on 




A sexually transmitted disease 
caused by the Hemophilus ducreyi bacterium and 
characterized by a soft sore on the genitals, which 




 The reproductive age span 
of women, assumed for statistical purposes to be 
15 to 44 years in the United States. In other coun-




  A microorganism that 
can cause vaginitis, urethritis, cervicitis, pelvic 
inflammatory disease, and lymphogranuloma 
venereum (LGV). Also called chlamydia, mucopu-
rulent cervicitis, and nongonococcal urethritis (in 
men). Symptoms include cervical discharge (yel-
low or green), redness, ectopy, tendency to injury, 





Splotchy, brownish skin discolora-
tion associated with high estrogen levels. May  











In males, surgical removal of the 
loose skin (foreskin) covering the end of the penis. 
Often performed shortly after birth. In females, 





A prolonged period of time during 
which there is a decrease in estrogen production, 
characterized by a decrease in the frequency of 
ovulatory cycles and partial atrophy of secondary 
sexual characteristics. Within that time span, the 









A small, pea-sized, hooded, erectile body 
located on the vulva above the vagina. It is situated 
between the labia minora in front of the urethra. It 
is the anatomical equivalent of the penis in the 




A group of people experiencing an 
event (births, marriages, etc.) at the same time 




Entry or penetration of the penis into 




Removing the penis from 
the vagina just prior to ejaculation. Also called 




Technique of viewing the cervix 
and vaginal mucosa magnified 10 to 20 times nor-
mal size, making it possible to see structures invisi-




Incision through the lateral fornices 
or posterior fornix of the vagina into the cavity 




Generally the beginning of preg-
nancy. Conception is usually equated with the fer-
tilization of the ovum by the sperm, but is 
sometimes equated with the implantation of the 




 A barrier method worn during inter-
course as a method of contraception and as a pro-




: A cylindrical sheath of latex, plastic, or 









Wart-like skin growth that may 
appear on the internal and external sex organs or 
anus caused by the Condylomata acuminata, a sex-
ually transmitted condition caused by the human 
papillomavirus. Condyloma acuminata infections 
may lead to cervical, vulvar, and penile cancer. 
Also called venereal warts, flat condylomata, HPV 








A measure of the 
extent of contraceptive practice among a defined 
population group at a point in time. The numera-
tor and denominator generally come from house-
hold surveys with the numerator consisting of the 
number of defined women estimated to be practic-





A medical condition that ren-
ders a course of treatment (that might otherwise 




Hormone-producing cells that 
develop from the ovarian follicle once a ripened 
ovum has been expelled. It produces progesterone 
to prepare the endometrium for implantation. If 
conception does not occur, the corpus luteum 
degenerates, leaving visible scars called the corpora 
albicans. If pregnancy does occur, the corpus 





 Small glands at the base of the 
penis which secrete lubricating fluids into the ure-








 An operation that employs 
extremely decreased temperatures, achieved 
through liquid nitrogen or carbon dioxide, to 
destroy diseased tissue such as precancerous abnor-
malities of the cervix or vaginal walls, or warts on 




 The closed pouch located between 
the anterior surface of the rectum and the poste-




 Aspiration of fluid from the space 
behind the uterus by puncture of the posterior vag-
inal wall or cul-de-sac.   Removal of tissue by 
scraping with a spoon-shaped instrument called a 
curette. Used to remove the endometrial lining of 



















A virus related to the herpes 
virus, capable of producing a sexually transmitted 
infection which is usually asymptomatic but may 
result in nonspecific febrile illness, pneumonitis, 






























Dilation and curettage; dilation of the 
cervix with use of a sound or laminaria, and scrap-





 Dilation and evacuation; dilation of the 





The number of deaths per 1,000 of 
the mid-year population in a given year. Compare 




 The historical shift of 
birth and death rates from high to low levels in a 
population. The decline in mortality has histori-
cally preceded the decline in fertility, resulting in 





 Injectable form of medrox-





 A soft, rubber, dome-shaped device 
worn over the cervix and used with spermicidal 
jelly or cream for contraception. Diaphragms are 
circular, shallow, rubber domes with a firm but 
flexible outer rim. They fit between the posterior 
vaginal wall (posterior fornix) and the recess 




 Heating of body tissues due to their 
resistance to the passage of high-frequency electro-
magnetic radiation, electric currents, or ultrasonic 
waves. In medical diathermy, tissues are warmed 
but not damaged; in surgical diathermy (electroco-




To stretch beyond normal 
dimensions, usually in the context of the cervix. 
The instruments most commonly used to dilate 
the cervical canal are called Hegar dilators. Lami-




 A location farthest from a point of refer-




 Cleansing the vaginal canal with a liq-








 Painful menstruation. Usually 
cramping midline lower abdominal pain. May be 










a Abnormal development of cells or tis-
sues. Dysplasia, as a Pap smear diagnosis, corre-











Generalized seizure related to preg-
nancy occurring after the 24th week of gestation. 
Eclampsia is usually accompanied by high blood 





 Out of place; an ectopic pregnancy 
occurs when the embryo implants outside the 
uterus, usually in the fallopian tube. Much less 
commonly, implantation may occur in the 





 The turning outward of tissue mar-
gin, as may occur on the cervix.  Cervical ectro-
pion can precede cancerous changes but may also 
occur under other circumstances such as during 








  An ovum; a female gamete; an oocyte; a 










 The developing conceptus through the 
first seven to eight weeks of gestation, after which 




  Methods used to 
prevent pregnancy after unprotected intercourse; 





 A method of 
using higher doses of birth control pills following 
unprotected sexual intercourse.  ECPs are a tem-









Ductless glands that secrete 











 A condition in which endome-
trial glands are present outside the uterus in abnor-
mal locations such as the tubes, ovaries, peritoneal 
cavity and bowel; produces abnormal vaginal 
bleeding and dysmenorrhea. It may also produce 




Inflammation of the endometrium 









A group of sexually transmit-
ted infections caused by the bacteria, viruses, pro-





A coiled tubular structure where 
sperm cells mature and are nourished, and which 




 An incision in the perineum to 
facilitate passage during childbirth while minimiz-




  Hardening of the clitoris or penis 





The primary female hormones; any 
natural or artificial substance that induces estro-
genic activity, more specifically, the hormones 
estradiol and estrone produced by the ovary. Estro-
gens are produced chiefly by the ovary but also by 




 Glands that secrete substances, 
such as tears or saliva, through ducts to surfaces 






 Food and Drug Administration in the 
United States. This agency must approve drugs 
used in the United States; many other nations fol-




The physiological capacity of a 





The actual output of births, as opposed 




 A method of birth control 
in which a couple charts cyclic signs of the 
woman's fertility and ovulation, using basal body 
temperature, mucus changes, and other signs to 




 The developing conceptus after 7 to 8 
weeks postfertilization (the end of the embryonic 






Fibrocystic breast disease 
 
Benign breast 
tumor(s) involving multiple cysts in the terminal 
ducts and acini of the breast. Also known as cystic 
mastitis, chronic cystic breast disease, cystic hyper-




 Tumors of the muscle and connective 
tissues of the uterus that usually remain benign. 





 A tumor composed of both 








A small secretory sac or cavity. One type 
of follicle is an ovarian follicle, which is a very 
small sac in the ovary in which an ovum matures 
and from which the egg is released.
Follicle stimulating hormone (FSH) Anterior 
pituitary hormone that stimulates the ovary to 
ripen egg follicles. FSH stimulates sperm produc-
tion in the male testes.
Forceps Grasping instrument used to facilitate 
delivery or rotation of the baby's head; other for-
ceps are used to grasp other tissues, cotton balls, 
intrauterine devices, etc. 
Foreskin A retractable fold of skin over the head 
of the penis. It is removed during circumcision.
FSH See Follicle stimulating hormone.
Fundus The part of a hollow organ farthest 
from its opening. The fundus of the uterus is far-
thest from the cervix.
Fungal infection See moniliasis.
G
Gardnerella See Bacterial vaginosis.
General fertility rate Live births per 1,000 
women aged 15 to 44 years in a given year.
Gonad An organ that produces sex cells (e.g., 
the testis and ovary).
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Gonadotropin A substance having an affinity 
for, or a stimulating effect on, the gonads. There 
are three varieties: anterior pituitary, chorionic 
(from pregnant women's urine), and equine (from 
the serum of pregnant horses).
Gonadotropin releasing hormone  (GnRH) A 
hormone released from the hypothalamus that sig-
nals the pituitary gland to release the gonadotro-
pin's luteinizing hormone (LH) and follicle stimu-
lating hormone (FSH).
Gonorrhea A common sexually transmitted 
infection characterized by a pus-like discharge 
from urethra or cervix and caused by the bacte-
rium Neisseria gonorrhoeae, a gram negative 
diplococcus. This infection is also called GC, clap, 
the drip, and gonococcus.
Granuloma A growth or chronically inflamed 
area; usually firm, nodular, and containing mac-
rophages.
Granuloma inguinale A sexually transmitted 
infection that is characterized by single or multiple 
subcutaneous nodules that erode to form ulcers, 
caused by the bacterium Calymmatobacterium 
granulomatis (formerly called Donovania granulo-
matis).
Gravid Pregnant.
Gravidity The number of pregnancies. 
H
Hematocrit The volume percentage of red 
blood cells in whole blood.
Herpes A group of contagious viral diseases that 
can cause sores on the mouth or the genitals. The 
ulcerous sores on the genitals can increase the risk 
of HIV transmission.
Human chorionic gonadotropin (HCG)  A 
glycoproteinaceous hormone produced by the pla-
centa, which maintains the corpus luteum and 
causes it to secrete estrogen and progesterone. 
Measured in urine and blood to detect pregnancy. 
Human immunodeficiency virus (HIV) The 
virus that causes AIDS. It causes a defect in the 
body's immune system by invading and then mul-
tiplying within white blood cells. 
Human papillomavirus (HPV) A genus of 
viruses that includes those causing papillomas 
(small nipple-like protrusions of the skin or 
mucous membrane) and warts in humans. 
Hydrocele Swelling of the scrotum due to fluid 
build-up in the sac of the membrane covering the 
testicle. 
Hymen A membrane that partially covers the 
entrance to the vagina. Through history, an intact 
hymen has been equated with virginity; however, 
hymens may tear for a number of reasons other 
than intercourse.
Hypophysis The pituitary gland.
Hypothalamus Part of the brain just above the 
pituitary, which helps to regulate basic functions 
such as sleep, appetite, body temperature, and fer-
tility. The hypothalamus is influenced by levels of 
the brain and controls hormone production by the 
pituitary.
Hysterectomy Surgical removal of the uterus. 
Hysterogram An X-ray of the uterus or record 
of the strength of uterine contractions. 
I
Implantation The process whereby an ovum six 
or seven days after fertilization burrows into the 
lining of the uterus and attaches itself firmly. Suc-
cessful implantation is essential to the develop-
ment of the embryo. 
Impotence Inability to have or sustain an erec-
tion.
Infant mortality rate The number of deaths 
among infants under 1 year of age in a given year 
per 1,000 live births in that year. 
Infertility Failure, voluntary or involuntary, to 
produce offspring. Primary infertility: The woman 
has never conceived despite cohabitation, exposure 
to the possibility of pregnancy, and the wish to 
become pregnant for at least 12 months (World 
Health Organization definition). Secondary infer-
tility: The woman has previously conceived but is 
subsequently unable to conceive despite cohabita-
tion, exposure to the possibility of pregnancy, and 
the wish to become pregnant for at least 12 
months (WHO).
Informed consent Explanation to a patient of 
a diagnostic or therapeutic approach so that the 
patient may make a rational decision about it. 
Components of informed consent include expla-
nation of the benefits, risks, and alternatives of an 
approach; the opportunity of the patient to ask 
questions and decide whether to proceed with the 
approach; detailed instructions; and documenta-
tion that those steps have been carried out. 
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Injectable  contraceptives  Hormonal contra-
ceptives given by injection.  Two examples of 
injectable progestins are Depo-Provera (DMPA or 
medroxyprogesterone acetate) and norethindrone 
enanthate. 
In situ Confined to place of origin with no 
spread to other tissues, e.g., carcinoma in situ. 
Intrauterine device (IUD) A flexible, usually 
plastic device inserted into the uterus to prevent 
pregnancy. May contain metal (generally copper) 
or hormones for added effectiveness. It produces a 
local sterile inflammatory response caused by the 
presence of a foreign body in the uterus, which 
causes lysis of the blastocyst and sperm, and/or the 
prevention of implantation. IUDs may also pre-
vent fertilization due to damaging effects on sper-
matozoa as they pass through the uterus.
Introitus The opening of the vagina to the out-
side. 
In vitro Outside the living organism and in an 
artificial environment. 
In vitro  fertilization A procedure in which an 
egg is removed from a ripe follicle and fertilized by 
a sperm cell outside the human body. The fertil-
ized egg is allowed to divide for about two days 
and then is inserted back into the uterus of the 
woman.
Involution The return of the uterus to a nor-
mal, nonpregnant size after parturition.
IUD See Intrauterine device. 
L
Labia A lip or lip-like structure. The labia 
majora are folds of skin on either side of the 
entrance to the vagina and are covered with hair in 
most adult women. The labia minora are the 
smaller hairless folds of tissue just within the labia 
majora.
Lactation The secretion of milk. The ideal 
means for most women to feed their newborn 
infant. Breast milk transfers immunoglobulins, 
albumin, vitamin B12 binding globulin, lactoba-
cilli, lactoferin, macrophages, neutrophils, com-
plement, lactoglobulin, and certain medications 
and drugs from mother to infant. Lactation can 
produce anovulation. 
Laminaria A plug of sterile dried kelp (sea-
weed), which expands when wet. It is often used to 
dilate the cervix. 
Laparoscopy Surgical inspection of the abdomi-
nal cavity and pelvic structures through a narrow 
lighted tube. 
Laparotomy A surgical incision into the abdomen. 
LH See Luteinizing hormone. 
Libido Sexual drive.  See orgasm.
Lice See pediculosis pubis.
Life expectancy The average number of addi-
tional years a person would live if current mortal-
ity trends were to continue. Most commonly cited 
as life expectancy at birth. 
LMP Last menstrual period. Often used to cal-
culate length of pregnancy.
LRF analogs Numerous synthetic chemical sub-
stances similar to naturally produced luteinizing 
hormone releasing factor (LRF), a hypothalamus-
controlled secretion from the anterior pituitary 
gland. They are under study as contraceptives and 
agents to treat infertility.  See GnRH.
Luteinizing hormone (LH)  Anterior pituitary 
hormone that causes a follicle to release a ripened 
ovum and become a corpus luteum. In the male it 
stimulates testosterone production and the pro-
duction of sperm cells.
M
Mammary glands Glands from which milk 
comes during breastfeeding.
Mammography X-rays of the breast to detect 
abnormal tissue.
Marital fertility rate Number of live births per 
1,000 married women aged 15 to 44 years in a 
given year (usually reported as rates within specific 
age groups).
Mask of pregnancy See Chloasma.
Mastalgia Breast discomfort or pain; there may 
be accompanying breast fullness or enlargement.
Mastectomy Surgical removal of the breast; 
simple mastectomy removes only breast tissue 
while radical mastectomy includes removal of 
lymph nodes and chest muscles.
Masturbation Stimulating one's own sex organs 
for pleasure.
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Maternal  mortality ratio The number of 
deaths to women due to pregnancy or childbirth 
complications per 100,000 live births in a given 
year.
Menarche The beginning of menstruation; i.e., 
the first menstrual period. This occurs during 
puberty but may not signify the beginning of full 
adult fecundity because ovulation may be irregular 
or absent for some time. Early cycles tend to be 
anovulatory; however, there are reports of preg-
nancy prior to menarche.
Menorrhagia Increased amount of menstrual 
flow, but not greater than 7 days in duration.  See 
metrorrhagia.
Menopause Cessation of menstruation.  After 
menopause, a woman is permanently sterile. Sur-
gical menopause refers to the removal of a 
woman's ovaries before natural menopause occurs. 
Menses Menstrual flow.
Metrorrhagia 1. Increased duration of men-
strual flow beyond 7 days, or bleeding between 
periods.  See menorrhagia.   2. Postpartum uter-
ine hemorrhage due to insufficient contraction of 
the uterine muscles. 
Minilaparotomy Female sterilization procedure 
in which the fallopian tubes are ligated or cauter-
ized through a small abdominal incision.
Minipill An oral contraceptive containing no 
estrogen and generally less than 1 mg of a proges-
tational agent per pill.
Miscarriage Spontaneous abortion before the 
fetus is viable.  See abortion.
Mites See scabies.
Mittelschmerz Lower abdominal pain associ-
ated with ovulation; this pain occurs in the middle 
of the cycle. The LH peak-induced rise in prostag-
landins causes contractions of the fallopian tube, 
uterus, and/or gastrointestinal tract. The pain of 
mittelschmerz may also be due to a chemical peri-
toneal irritation caused by bleeding from the ovu-
lation site or pressure from the expanding follicle.
Moniliasis Infection caused by yeast-like organ-
isms, usually in the vagina and the vulva or under 
folds of skin in other areas. Usually, the organism 
is Candida albicans. Also called candidiasis, 
monilia, Candida albicans, fungus infection, and 
yeast. Yeast infection causes a thick, white dis-
charge; itching, redness, or swelling around the 
labia; and sometimes itching and redness on the 
upper thighs. Some women have no symptoms at 
all. Men may be symptom-free or may develop 
urethritis, sores on the penis, or inflammation of 
the tip of the penis.
Monophasic A one-level basal body tempera-
ture (BBT) curve demonstrating no rise in temper-
ature during the menstrual cycle. Suggests 
anovulation.
Morning-after birth control See Emergency 
contraceptive pill.
Morning-after pill  A hormonal drug that tem-
porarily disrupts the uterine environment to pre-
vent implantation of the fertilized egg if taken 
within 72 hours after unprotected intercourse. 
Morning-after pills may also prevent ovulation.
Morning sickness Nausea of pregnancy.
Mucus method A method of birth control in 
which a couple charts the cyclic changes in cervical 
mucus patterns and abstains from intercourse dur-
ing fertile days. Also called ovulation method or 
Billings method.  See Periodic abstinence. 
Multipara A woman who has had two or more 
pregnancies resulting in viable fetuses.
Mycoplasma Mycoplasma are the smallest free-
living organisms, somewhere between viruses and 
bacteria in size. In adults most illnesses caused by 
mycoplasma are thought to be sexually transmit-
ted. The two genital mycoplasmas found in the 
reproductive tract of all sexually active men and 
women, Mycoplasma hominis and Ureaplasma 
urealyticum, are poorly understood at present. In 
women, mycoplasma have been associated with 
vaginitis, PID, fever following abortion, fever fol-
lowing delivery, spontaneous abortion, low birth-
weight infants, infertility, pyelonephritis, and 
ectopic pregnancy. 
Mycoses Infections caused by fungi. 
Myometrium The muscle layer of the uterus.
N
Neonatal Pertaining to the first four weeks after 
birth.  Early neonatal: pertaining to the first week 
after birth. 
Node A small, circumscribed swelling or knot 
of cells. 
Nongonococcal urethritis (NGU) Bacterial 
infection other than a gonorrheal infection, often 
associated with chlamydia, with manifesting 
symptoms of discharge, dysuria, and itching. 
Nullipara A woman who has never delivered a 
live infant; also written Para 0. 
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O
Obstetrics That specialty of medicine caring for 
the management of pregnancy and its complica-
tions.
OC See Oral contraceptives. 
Oligomenorrhea Infrequent menstrual flow, 
with intervals between menses longer than 37 days 
and shorter than 90 days. Also scanty menstrual 
flow and irregular intervals are common.
Oocyte The ovum or egg cell in the female.
Oophorectomy Surgical removal of one or both 
ovaries. 
Oral contraceptives (OC) Various progestin/
estrogen or progestin compounds in tablet form 
taken sequentially by mouth; the pill.  Estrogenic 
and progestational agents have contraceptive 
effects by influencing normal patterns of ovula-
tion, sperm or ovum transport, cervical mucus, 
implantation, or placental attachment. 
Orgasm A series of muscular contractions in the 
genital and pelvic areas that occurs at the peak of 
sexual excitement, resulting in a release of sexual 
tension.  Also called climax.
Osteoporosis An abnormal softening, porous-
ness, or reduction in the quantity of bone, result-
ing in structural fragility. Causes appear to include 
estrogen deficiency, thyroid imbalance, calcium 
deficiency, prolonged immobilization, and adre-
nal hyperfunction, which result in more bone 
resorption than formation.
Ovaries The female gonads; glands where ova 
are formed; also the primary source of the female 
hormones estrogen and progesterone. 
Ovulation The release of an ovum from the 
ovarian follicle in the ovary during the female 
menstrual cycle. See periodic abstinence meth-
ods, mucus method. 
Ovum The egg cell. 
Oxytocin A hormone produced by the pituitary 
gland. As the baby suckles, impulses are sent to the 
posterior pituitary. The hormone oxytocin is 
released causing the milk let-down reflex. Oxyto-
cin also causes the uterine muscles to contract.
P
Palpation Feeling with the hands to determine 
information about the condition of the body.
Panhysterectomy The surgical removal of the 
uterus, ovaries, and fallopian tubes.
Papanicolaou  smear (Pap smear) A screening 
test for cervical cancer in which cells scraped from 
the surface of the cervix are placed onto a slide. 
The Pap test may also detect cancer of the uterus, 
ovary, or vagina; infections; or the level of estro-
genic stimulation of the cervix. 
Papillomavirus warts See condyloma.
Parity The number of live births a woman has 
had; a woman of zero parity has had no live births, 
a woman of parity one has had one live birth, etc. 
Parturition The act of giving birth. 
Pearl index The number of pregnancies per 100 
woman-years exposure, usually used as a measure 
of contraceptive failure. 
Pediculosis pubis Infestation of the pubic area 
with pubic lice.  Pubic lice are parasites, small 
blood-sucking insects much like head lice. They 
are usually transmitted by sexual intimacy but may 
be spread by sharing clothing or a bed with an 
infected person. Also called crabs, papillons 
d'amour, and Phthirus pubis. 
Pelvic inflammatory disease (PID)   Inflammation 
of the pelvic structures, especially the uterus and 
tubes. The precipitating or contributing cause 
quite often is a sexually transmitted infection, such 
as gonorrhea, chlamydia, or both. Also called pel-
vic infection, polymicrobial pelvic infection, tubal 
infection, and salpingitis. 
Perinatal The time period from the 28th week 
of pregnancy to 4 weeks after birth. May be 
defined as the time period from the 28th week of 
pregnancy to 1 week after birth.
Periodic abstinence methods Contraceptive 
methods that rely on timing of intercourse to 
avoid the ovulatory phase of a woman's menstrual 
cycle; also called fertility awareness or natural fam-
ily planning. 
1. The basal body temperature (BBT) method 
uses daily temperature readings to identify the 
time of ovulation.
2. In the ovulation or Billings method, women 
identify the relationships of changes in cervical 
mucus to fertile and infertile days.
3. The sympto-thermal method charts changes 
in temperature, cervical mucus and other symp-
toms of ovulation (i.e., intermenstrual pain). 
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Peritoneum The strong, smooth membrane 
that surrounds and contains the abdominal 
organs. Often is punctured in illegal procedures, 
resulting in infection and often death. 
Pessary A device placed in the vagina or the 
uterus to support pelvic structures or prevent preg-
nancy. The diaphragm is a modern form of a pes-
sary. Also a medicated vaginal suppository.
Pituitary gland A small gland located at the 
base of the brain beneath the hypothalamus; serves 
as one of the chief regulators of body functions, 
including fertility. Most endocrine glands in the 
body are controlled by the pituitary. Also known 
as the hypophysis. 
Placenta The circular, flat, vascular structure 
within the pregnant uterus, which provides nour-
ishment and eliminates wastes for the developing 
embryo and fetus and is passed as afterbirth after 
the baby is born.
PMS See Premenstrual syndrome. 
Postpartum After childbirth. 
PPNG Penicillinase-producing Neisseria gonor-
rhoeae; a penicillin-resistant strain of gonorrhea. 
Preeclampsia See eclampsia and toxemia. 
Pregnancy  wastage Occurs when the woman is 
able to conceive but unable to produce a live birth. 
Pregnancy wastage occurs when pregnancy ends in 
miscarriage, stillbirth ,or a nonsurviving prema-
ture infant.
Premature Occurring before the proper time. A 
premature infant is one born before 37 weeks of 
gestation, or sometimes arbitrarily defined as an 
infant weighing 1,000 to 2,499 grams (2.2 to 5.5 
pounds) at birth. In some countries where adults 
are smaller than in the United States, the upper 
limit is 2,250 grams. Other criteria such as crown-
heel length (less than 11.5 cm) have been used.
Premature ejaculation Ejaculation that occurs 
too rapidly relative to a standard set by a man or 
his partner.
Premenstrual syndrome (PMS) A set of physical 
and emotional experiences which may occur dur-
ing the period prior to menses.  Symptoms may 
include the following: breast fullness and tender-
ness, headache, weight gain, bloatedness, thirst, 
increased appetite, acne, lower back pain, cramp-
ing, lower abdominal pain, clumsiness, fear of los-
ing control, violence, irritability, outbursts of 
crying, fatigue, depression, suicidal ideas, confu-
sion, increased sexual desire, forgetfulness, mood 
swings, hyperactivity, and a craving for sweets, salt, 
and alcohol.
Prenatal Existing or occurring before birth. 
Preterm An infant born at any time before 37 
to 38 weeks of gestation.
Primagravida A woman who is pregnant for the 
first time. 
Progesterone A steroid hormone produced by 
the corpus luteum, adrenals, or placenta. It is 
responsible for changes in the uterine endo-
metrium in the second half of the menstrual cycle, 
which are preparatory for implantation of the fer-
tilized ovum, development of maternal placenta 
after implantation, and development of mammary 
glands.
Progestins A large group of synthetic drugs that 
have a progesterone-like effect on the uterus.
Prolactin A hormone produced by the anterior 
lobe of the pituitary gland that stimulates milk 
secretion. As a baby sucks the breast, impulses are 
sent from the areola of the nipple to the vagus 
nerve and then to the anterior pituitary. The ante-
rior pituitary secretes the hormone prolactin, 
which stimulates glands in the breast to produce 
milk. The anterior pituitary and prolactin are 
thought to be important in the long-term mainte-
nance of milk secretion.
Prostaglandin Prostaglandins are produced as 
the endometrial lining degenerates and may cause 
mild to severe menstrual cramps, diarrhea, nausea, 
and vomiting. Oral contraceptives diminish the 
prostaglandins released by the endometrial lining, 
decreasing menstrual cramps in users.
Prostaglandin inhibitors Drugs that inhibit or 
suppress the action of  prostaglandin.  These drugs 
are helpful for dysmenorrhea.
Prostate A male organ, surrounding the neck of 
the bladder and urethra, that contributes acids and 
enzymes to the seminal fluid.
Proximal A location that is near to a point of 
reference;  opposite of distal.
Pruritus Itching.
Psuedotumor cerebri  A condition caused by 
cerebral edema in which increased intracranial 
pressure causes headaches, nausea, vomiting, and 
papilledema without other neurological signs.
Puberty The age when sex organs become func-
tionally operative and secondary sex characteristics 
develop. For a girl, puberty means producing an 
ovum, and for a boy it is manufacturing spermato-
zoa. Secondary sexual characteristics in girls are 
breast development, enlargement of the hips, and 
development of axillary and pubic hair.  In boys 
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they include appearance of pubic, facial, and axil-
lary hair; growth of the penis, testicles and scro-
tum; and deepening of the voice. 
Pubic lice See Pediculosis pubis.
Puerperium The six weeks after childbirth. Also 
called postpartum period. 
Purulent Containing or producing pus.
R
Retroversion Bent backward on its vertical axis, 
i.e., retroverted uterus; also called tipped uterus. 
This is a normal variant occurring in approxi-
mately one-fifth of women. 
Rhythm See Periodic abstinence. 
Rubber See condom.
S
Salpingectomy Surgical removal of the fallopian 
tubes. 
Salpingitis Inflammation of one or both fallo-
pian tubes causing lower abdominal pain, tender-
ness, and cervical discharge. See pelvic 
inflammatory disease.
Scabies A contagious skin disease due to a mite 
that burrows beneath the skin causing intense itch-
ing. Also called mites and Sarcoptes scabiei. 
Scrotum The external pouch containing testi-
cles in men. 
Semen The thick, whitish fluid, which normally 
contains sperm and seminal secretions and is 
ejected during ejaculation.
Seminal vesicles Two glandular structures 
located behind the prostate gland, which secrete a 
component of semen. 
Seminiferous tubules Convoluted tubules in the 
testicles that produce sperm. 
Sepsis (also Septicemia)  The presence of vari-
ous pathogenic bacteria or their toxins in the 
blood or tissues, resulting in chills and fever. See 
toxic shock syndrome. 
Seroconversion When a person infected with 
HIV has detectable antibodies in his/her blood.
Sexually transmitted infection (STI) An infec-
tion that is communicated primarily or exclusively 
through intimate sexual contact. Sexually trans-
mitted infections have been estimated to cause 
from 20% to 40% of infertility in the United 
States.  STIs can adversely affect fertility by three 
primary mechanisms: pregnancy wastage, prenatal 
deaths, and damage to male or female reproductive 
capacity. Also called venereal disease or VD.
Sign Any objective evidence of a disease, as 
opposed to the subjective sensations (symptoms) 
perceived by the patient. 
Sonogram Sound echo images of soft internal 
structures. Also called ultrasonography, can be 
used to determine size and position of the fetus, 
the placenta, a developing follicle, or a tumor. 
Sounding Introducing an elongated probe 
called a sound into the uterine cavity to measure 
its dimensions. 
Speculum An instrument for viewing the inside 
of the vagina and the cervix, or any other canal or 
cavity.
Sperm Male spermatozoa.
Spermatocele A swelling in the scrotum that 
occurs when the epididymis becomes cystic. 
Spermatogenesis The formation of spermato-
zoa.
Spermicide A chemical substance that kills 
sperm, particularly foam, creams, jellies, and sup-
positories used for contraception. The spermicides 
used in almost all currently marketed spermicides 
are surfactants, surface-active compounds that 
destroy sperm cell membranes.
Spinnbarkeit A test to determine cervical 
mucus viscosity. A thread of cervical mucus is 
stretched between two glass slides (or two fingers) 
and its length is measured. The time at which it 
can be drawn to maximum length (lowest viscos-
ity) usually precedes or coincides with the time of 
ovulation.
Spotting A small amount of bleeding at a time 
in the cycle other than menses; light irregular flow, 
often prolonged. Also called metrorrhagia.
Stable population A closed (no migration) pop-
ulation with an unchanging age distribution 
caused by unchanging age-specific fertility and 
mortality rates, and consequently an unchanging 
rate of growth.
Stationary  population A stable population with 
a rate of growth of 0%.
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STD See sexually transmitted infection. 
Sterilization (tubal ligation, vasectomy) A sur-
gical procedure that leaves the male or female inca-
pable of reproduction. Sterilization is the most 
commonly employed method of birth control in 
the world. 
Steroidogenesis The natural production of ste-
roids. The usual progression of hormones is from 
progesterone and other progestins to androgens to 
estrogens. 
Stricture Tightening or narrowing of a duct or 
hollow organ. 
Subcutaneous Beneath the skin.
Suppository A medicine placed in a body orifice 
to dissolve and sometimes to be absorbed. Birth 
control suppositories contain spermicidal chemi-
cals. They dissolve inside the vagina leaving sper-
micide to kill sperm.
Surgical menopause Removal of a woman's 
ovaries before natural menopause occurs.
Symptom Subjective evidence of disease or the 
condition of the patient.  See sign.
Symptothermal method See periodic absti-
nence methods.
Syndrome A set of symptoms, which together 
characterize a condition or disease. 
Syphilis A sexually transmitted infection caused 
by Treponema pallidum, a spirochete with 6-14 
regular spirals and characteristic motility. The pri-
mary stage is characterized by a painless chancre.  
The secondary stage is characterized by rash, 
mucus patches, and condylomata lata.  The latent 
stage has no characteristic sign but sequelae 
include tabes dorsalis, general paresis, thoracic aor-
tic aneurism, aortic insufficiency, and localized 
gumma formation.
T
Telangiectasia A permanent dilation of blood 
vessels that create small red lesions in the skin or 
mucous membranes.
Teratogenic Tending to produce anomalies in 
formation, as in physical defects of the fetus in 
utero.
Testosterone Male sex hormone produced in 
the testes.
Term An infant born any time from the begin-
ning of the 38th week (260 days) to the end of the 
41st week (287 days) of gestating hormone.
Thyroid stimulating hormone (TSH) Anterior 
pituitary hormone that stimulates the thyroid 
gland.
Thyroid function tests Tests done to assess the 
function of the thyroid.  Modern assessment of 
thyroid function is relatively easy utilizing radio-
immunoassay of free T4 (thyroxin), TSH (thyroid 
stimulating hormone), and T3 (triiodothyronine). 
Tipped uterus See retroversion.
Total fertility rate (TFR) The average number 
of children that would be born alive to a woman 
(or group of women) during her lifetime if she 
were to pass through her childbearing years con-
forming to the age-specific fertility rates of a given 
year. 
Toxemia A term applied to hypertension, albu-
minuria, and edema when found in pregnancy. 
The condition usually develops after the 20th 
week of gestation or early in the presence of tro-
phoblastic disease. It can lead to convulsions. Also 
known as preeclampsia. 
Toxic shock syndrome (TSS) A severe illness 
characterized by a sudden high fever, vomiting, 
diarrhea, aches, and a sunburn-like rash. The dis-
ease usually occurs in menstruating women using 
tampons; thought to be caused by a vaginal infec-
tion with Staphylococcus aureus.  See sepsis.
Trichomoniasis Infestation of the vagina with 
microscopic protozoan organisms called tri-
chomonads resulting in irritation, itching, redness, 
an objectionable odor, pain, frequency of urination, 
and/or a yellow-green or a whitish-gray, foul-smell-
ing, watery or frothy discharge. 
TSS See Toxic shock syndrome. 
Tubal infection See pelvic inflammatory disease.
Tubal ligation A surgical procedure in which 
the fallopian tubes are cut, tied, or burned to pre-
vent the passage of ova. It does not interfere with 
menstruation or sexual capability but should be 
regarded as a permanent form of sterilization. Also 
called TL and sterilization. 
Tubal patency Unobstructed fallopian tubes. 
Tubal reanastomosis A surgical procedure in 





Ureter Tube that transports urine from the kid-
neys to the bladder. 
Urethra The tube that drains urine from the 
bladder to the outside of the body. In women, the 
opening of the urethra is between the clitoris and 
the vagina. In men, the urethra travels the length 
of the penis transporting both urine and semen.
Urinary tract infection (UTI) Infections of the 
urethra, bladder, ureters, kidney; often associated 
with trauma from diaphragm use, other barrier 
methods, and frequent intercourse. Symptoms 
include lower back pain and painful urination. 
Uterus The hollow, pear-shaped, muscular, elas-
tic reproductive organ where the fetus develops dur-
ing pregnancy. 
V
Vacuum aspiration Removal of tissue by the 
creation of negative pressure through the removal 
of air. 
Vagina The 3- to 5-inch long muscular tube 
leading from the external genitals of the female to 
the uterus. The external opening called the introi-
tus, may be diminished by a membrane called the 
hymen. Sometimes called the birth canal, the vagina 
is the passageway through which babies are born 
and menstrual fluid flows. The vagina widens and 
lengthens during sexual arousal.
Vaginal  hysterectomy Surgical removal of the 
uterus through the vagina. 
Vaginismus Painful, spastic, usually involuntary 
contraction leading to constriction of the female 
pelvic muscles, which can occur during intercourse 
or during a pelvic examination. It tends to occur 
when a woman senses that something is about to 
penetrate the opening of the vagina.
Vaginitis Inflammation of the vagina. Often 
caused by a change in the vaginal environment by 
factors such as foreign bodies (tampons, cervical 
caps), trauma, broad spectrum antibiotics, exten-
sive douching, IUD expulsion, certain systemic 
diseases, obesity, excessive moisture, tight clothing 
and a number of infectious agents.
Vaginosis See bacterial vaginosis. 
Varicocele Dilated varicose veins in the sper-
matic cord. This condition usually presents as a 
baggy swelling of the scrotum. It may be a cause of 
infertility. 
Vas deferens The tube through which sperm 
pass from the epididymis to the ejaculatory duct 
and then into the urethra. It is this tube that is cut 
in the male sterilization procedure called a vasec-
tomy. Also called ductus deferens. 
Vasectomy A surgical procedure in which seg-
ments of the vas deferens are removed and the ends 
tied to prevent passage of sperm. Vasectomy should 
be regarded as a permanent form of sterilization 
although reversal is possible. 
Venereal disease (VD) See sexually transmitted 
infection. 
Venereal warts See condyloma. 
Vulvovaginitis Inflammation of both vulva and 
vagina. 
W
Wassermann test The original blood test for 
syphilis. Since the Wassermann test is not syphilis 
specific (other diseases can cause a positive test), 
newer tests for syphilis (specific for the agent T. 
pallidum) such as VDRL, FTA, and RPA, have 
been developed. 
Withdrawal See coitus interruptus. 
Withdrawal bleeding Menstrual bleeding that 
occurs when the level of hormonal support to the 
endometrial lining decreases. 
Y
Yeast See Candida and moniliasis. 
Z
Zero growth A population neither growing nor 
shrinking. 












Abstinence, 26(t), 27, 225-226, 499-505
advantages and disadvantages, 501-504
barriers to, 499-500
during STI treatment, 148
effectiveness, 501
effects on fertility, 246
instructions, 505
periodic, 473
postpartum, 26, 262, 276(t), 281, 502-504
premarital, 503-504
sexual response, 225
Abortifacients in traditional practices, 29-30
Abortion, 548-559
in adolescence, 61-62, 64









uterine and cervical injuries, 555
Abortion, illegal, 171, 548 
see also Abortion
Abortion, induced see Abortion
Abortion, spontaneous, 165, 189, 190, 206-207
see also Abortion
Acne and oral contraceptives, 327







fertility, 47, 51, 52(f ), 55-57, [66-67(t)], 
68-69, 70(t)













oral contraceptives, 309, 320
progestin-only contraceptives, 352
Agglutination test see Pregnancy tests
AIDS, 74 see also HIV
AIDS-related complex, 81






in adolescent pregnancy, 59, 60
IUD, 412-413
Anesthesia in female sterilization, 525-527
Anorgasmia, 227-228
Anticonvulsants
and oral contraceptives, 296, 326






Barriers, vaginal see Vaginal barriers
Basal body temperature method, 472, 483, 484(f )
Behavior change, 567, 568(t)
Benzalkonium chloride, 444 
see also Vaginal 
spermicides
Birth defects
age of sperm or egg, 478
oral contraceptives, 334, 337
Birth order, 12








References to information in tables are cited with a (t) and within brackets [ ] if the table 





























oral contraceptives, 322, 327
post-abortion, 9, 554-555
risk of HIV transmission, 90
Blood pregnancy test see Pregnancy tests, blood
Blood transfusion and HIV, 77, 98-99
Bone density and Depo-Provera, 354



















fertility awareness method, 282, 475
health benefits, 265-267
herbal stimulation, 30





oral contraceptives, 320, 328, 351, 352, 379
postpartum non-susceptibility, 40, 41
prevalence, 262
progestin-only contraceptives, 283-284, 
351, 379
and sexual response, 224
socioeconomic status, 262





Calendar rhythm method, 472, 481-482
Calymmatobacterium granulomatis, 124(t)
Cancer see also Breast cancer; Endometrial cancer; 
Ovarian cancer; Uterus, cancer
cervical, 169
genital, 134
oral contraceptives, 245, 336-337
Carbohydrate metabolism and oral 
contraceptives, 306
Candida albicans, 131(t), 452
Cardiovascular disease
hormone replacement therapy, 193
oral contraceptives, 245, 305
Castration, 29
Cephalo-pelvic disproportion, 61
Cervical cap, 88, 459-461
Cervical mucus method, 473, 484-485







Chlamydia/Chlamydia trachomatis, 119, 161-162, 
168
clinical management, 121(t), 126(t), 127(t)
epidemiology, 132
oral contraceptives, 305, 328




Circumcision, female, 29, 57-58, 166
HIV transmission, 90-91
Clinic-based services, 595-598  
see also Family planning services
Clothing and infertility, 166
Coitus interruptus, 24, 491-496








 see Oral contraceptives
Commercial retail sales, 598(t), 599  








Community-based services, 597(t), 598-599  




see also specific contraceptive method listings
access in adolescence, 65
back-up, 296, 331, 370, 384









for nonbreastfeeding women, 275-280






reasons for non-use 254(t)
reproductive life span, 253, 256(t)
risks, [252-253(t)]
safety, 244-248
and sexual function, 223-226






effects on fertility, 246
future technology, 667-670
inventory control, 621-623
knowledge and use, 53
managing supplies, 620-626, 650, 652-654
quality control 651-656
disposal, 658






















see also Breastfeeding; Progestin-only 
contraceptives




instructions for use, 377-378
mechanism of action, 345
in menopause, 193
problems and followup, 376-377
provision of, 374-376
risk of HIV transmission, 86
Depression and oral contraceptives, 329
Desogestrel see Progestins
Diaphragms, 455-459
risk of HIV transmission, 88
protection from STIs, 145, 146(t), 450
sexual response, 225
Dilation and curettage, 170
Discrimination and women, ix-xii, 13










Ectopic pregnancy, 194, 203-205
after sterilization, 529-530
complication of STI, 134
diagnosis, 205
and IUDs, 393
and oral contraceptives, 301
risk, 204(t), 349
uterine cramping, 190






















































Family life education, 63-64
Family planning, 1-18 
see also Breastfeeding; Contraception
benefits, 2, 9-13




unmet needs, 53, 54(t)






diagnosis of STI, 118
evaluation, 658-659, [660-664(t)]
financing and fees, 600-603




policies and procedures, [576-578(t)]
quality assurance and control, 640-664
record keeping, 647-648
service delivery, 593-609
staff selection and training, 613-615
staff supervision, 615-619
Fear and sexual response, 224







Female condoms, 455, 669
Female genital mutilation  see Circumcision, 
female
Female sterilization see also Sterilization







minilaparotomy, 515-518, 523-524, 528-529







effects of age, 158
effects on contraception, 246
female education, 55
methods of decreasing, 26-29
and nutrition, 43
Fertility assessment schedule, 174(t)
Fertility awareness methods, 282, 471-489
advantages and disadvantages, 476-477
barriers to, 474
effectiveness, 475
in postpartum contraception, 277(t)
instructions, 481-489
mechanism of action, 474
precautions, 478-479
protection from STI, 146(t)






Fibroadenoma and oral contraceptives, 300
Fibroid tumors, 190
Filariasis, 162
Filshie clip, 518, 521
Fimbriectomy, 524















Gallbladder disease and oral contraceptives, 306
Gamete intrafallopian tube transfer (GIFT), 179
Gardnerella vaginalis, 120(t)
GATHER communication mnemonic, 561-562
Genital mutilation, 29  
see also Circumcision, female
Genital ulcer disease, 133





Gonorrhea/Neisseria gonorrhoea, 119, 161
in adolescent females, 59
clinical management, 123(t), 127(t)
effects on fertility rate, 42-43
new cases, 132






Hansen's disease and infertility, 163
HBV see Hepatitis B Virus
hCG, 207
Headache, 305, 329
and progestin-only contraceptives, 368-369
Health care workers
risk of HIV transmission, 109
safety and HIV, 107-111
Health service delivery 
see Family planning services




Hepatitis B/Hepatitis B virus, 119
clinical management, 124(t)
transmission in pregnancy, 136, 137(t)
Hepatocellular adenomas, 306
Herpes genitalis, 125(t)
Herpes simplex virus, 119
clinical management, 125(t)
transmission in pregnancy, 136, 137(t)
HIV, 74-111, 119 





and contraceptive methods, 84(t)
diagnosis in infants, 268
education, 94-99
fertility in adolescent females, 59
mortality, 37
progression to AIDS, 78, 80-82
post-exposure prophylaxis, 109-110
in pregnancy and childbirth, 91-92
prevalence, 75-78
prevention, 83, 95-99, 107
primary infection, 78
risk reduction, 95, 96(t)
transmission, 74, 89-91, 103
and IUDs, 392-393













HIV-2, 74, 78, 79(t)
Hookworm, 164
Hormone replacement therapy, 193
Hot flashes, 191
HPV see Human papillomavirus
HSV see Herpes simplex virus
HSV-2 see Herpes simplex virus
Hulka clip, 524
Human chorionic gonadotropin, 207


























Human papillomavirus, 119, 162
clinical management, 122(t)








Immunization and HIV, 101(t)
Implantation, 189
Impotence, 178, 232-234
In vitro fertilization, 179




by source of milk, 265(f ), 266
Infertility, 153-180
categories, 156(t)













Infibulation see Circumcision, female
Information management, 626-632
data collection, 628-629, 633-638
reports, 630-632
Informed consent, 511
Intercourse and infertility, 159-160
Intermediate sensitivity tube tests
see Pregnancy tests, urine
Intrauterine devices (IUDs), 387-426
advantages and disadvantages, 391-393, 
[394-399(t)]
anesthesia, 410-411
barriers to use, 387-389
breastfeeding, 282
copper, 282, 390, 391, [394-399(t)], 400, 
401, 402
effectiveness, 390-391





insertion and removal, 403-411
instructions for use, 425-426
LNg-20, 283-284, 390, 391, 401














types, 400-402, 402(f )














Lactational amenorrhea, 202, 264-265
Lactational amenorrhea method (LAM), 31, 
270-271, 274, 276(t), 280
LAM see Lactational amenorrhea method
Laparoscopy, 177, 519-523
complications, 529
Lead and infertility, 165
Leiomyomata, 207 
see also Uterus, cramping








Levonorgestrel, 167, 324, 343-344 
see also Intrauterine devices, LNg-20; 
Norplant; Progestin-only contraceptives; 
Progestins
LGV (Lymphogranuloma venereum), 126(t)
LH see Luteinizing hormone
Libido, 305, 330
Life expectancy, 35
Lipids and oral contraceptives, 323
LNg IUD see Intrauterine devices
Low birthweight, 59
Luteal phase, 188
Luteinizing hormone, 185, 187, 264
menopause, 191




Malaria and infertility, 162, 164
Male, see also Male condoms; Male sterilization
attitudes toward contraception, 257
contraceptive technology, 670
infertility, 178
sexual dysfunction, 226-227, 231-234
sexual response, 223
Male condoms, 83, 85, 429-441
advantages and disadvantages, 434-437
barriers to use, 430
breakage, 434
counseling and education, 430
effectiveness, 433
effects on fertility, 169, 246
instructions for use, 440-441
mechanism of action, 432
myths and facts, 431(t)
protection from STIs, 145, 146(t), 148
provision and distribution, 437-439
sexual response, 225
Male genital mutilation, 29
Male partners and HIV testing, 96-98
Male sterilization, 533-540









Mammary duct, plugged, 272(t)
Marasmus, 269
Marriage, early, 49, 65
Mastalgia, 328
Mastitis, 272(t)
Maternal age, 6-7, 11
Maternal-child STI transmission 
see Mother-child STI transmission
Mechanical barriers see Female condoms; 
Male condoms; Vaginal barriers
Medroxyprogesterone acetate, 193
Menfegol, 86-87, 444 





regulation, 185, 186(f )
Menstruation, 185
abnormal bleeding, 191, 192(t)






and oral contraceptives, 307
Minilaparotomy, suprapubic, 515-518, 523-524,
528-529
Minipills, 342, 





instructions for use, 381-383
mechanism of action, 345






causes, 9, 10, 36-37
contraceptive-related, 5
infant and child, 5, 7(t), 10, 11(t)
maternal, 3-4, 9
rates, 2-3
Mother-child STI transmission, 77, 136-138, 267


























Mumps and infertility, 163
Mycoplasma hominis, 162




Natural family planning 
see Fertility awareness methods
Nausea and oral contraceptives, 330
Neisseria gonorrhoea 
see Gonorrhea/Neisseria gonorrhoea
NET-EN see Norethindrone enanthate
Nipple trauma, 272(t)
Nipples, flat or inverted, 273(t)
Nonoxynol-9, 86-87, 444, 449, 452, 461 
see also Vaginal spermicides
Norethindrone enanthate (NET-EN), 374, 380
Norgestimate see Progestins





insertion and removal, 363-367
instructions for use, 370-373
mechanism of action, 343-345













see also Vaginal spermicides
Oocyte, 187, 189
Ophthalmia, 136, 138
Opportunistic infections and HIV, 81
Oral contraceptives, 295-337 
see also Breastfeeding
advantages and disadvantages, 190, 299-307
androgenic effects, 322-323





effect on fertility, 246
effect on infants, 283, 285
effectiveness, 298-299
frequently asked questions, 336-337
infertility, 168-169
instructions for use, 331-335
mechanism of action, 297-298
precautions [312-319(t)]
protection from STI, 146
provision of, 307-308
risk of HIV transmission, 86
selection of, 309, [310-311(f )], 321
sexual response, 224
side effects, 322-323, 327-331
Oral contraceptives, combined 
see Oral contraceptives
Oral contraceptives, triphasic, 325
Orchitis, 163
Osteoporosis, 193













Parasitic diseases and infertility, 162-163
Parkland technique, 512, 518, 524
















Pelvic inflammatory disease (PID)
clinical management, [127-128(t)]
complication of STI, 133
fertility in adolescence, 59
fertility, 42






Pesticides and infertility, 165
Physical assessment, 173-177
PID see Pelvic Inflammatory disease
Placenta, 189
PLISSIT counseling model, 220





Postpartum non-susceptibility, 40-41 
see also Lactational amenorrhea
Postpartum period 






Precautions, contraceptive, 247-248 
see also Advantages and disadvantages under 
specific contraceptive method listings
Pregnancy see also Adolescent pregnancy; 
Ectopic pregnancy; Pregnancy tests









patient education and counseling, 213-214




Pregnancy, adolescent see Adolescent pregnancy









Progestasert IUD, 283, 401 
see also Intrauterine devices; Progestin-only 
contraceptives
Progesterone, 185
Progestin-only contraceptives, 341-384 
see also Breastfeeding; Depo-Provera; 
Intrauterine devices; Minipills; Norplant
administration, 344(t)
advantages and disadvantages, 348-362
barriers to use, 342-343
effectiveness, 346-347



















Referral of sex partners, 144
Reproductive health see Sexual physiology
Reproductive health services, 649
Reproductive life plan, 15, 18
Reproductive life span, 253, 256(t)
































family planning services, 604, 606





effects on sexual function, 223-226
methods, 96(t), 97-98




Seminal fluid and HIV virus, 494
Sensitive urine pregnancy test 
see Pregnancy tests, urine
Sepsis, 9
Seroconversion in HIV




influence on contraceptive use, 257
and mortality, 36
risks, 58-59, 135-136









loss of desire, 226-227
male, 223
stages, 222(t)
Sexually transmitted infections see STI
Sickle cell disease, 164
Silastic ring, 518, 521
Sims-Huhner test, 176
Slide pregnancy test see Pregnancy tests, urine
Smoking, 165, 320
Sperm antibodies, 169, 534
Spermicides see Vaginal spermicides
Spinnbarkeit, 188, 202




Staff selection and training, 613-615
Sterilization, 169-170, 507-543 
see also Female sterilization; Male sterilization
barriers to use, 508-509
counseling, 509-511
effect on fertility, 246
legal issues, 543
reversal, 540-543
risk of HIV transmission, 88
STI (Sexually transmitted infections), 117-148
causes, 119
clinical management, [120-131(t)], 146-148
complications, 133-134
contraception, 145-146, 249, 354
curability, 119
diagnosis and treatment, 138-144, 147
drug dosage, 143, 147
drug selection criteria, 142
education, 118, 145
epidemiology and trends, 132-133
fertility, 42-43
infertility, 58-59, 117-118, 161-162
mortality, 37











Symptothermal method, 473, 486-488
Natural Family Planning Chart, 487-488,
489(f )
Syndromic approach to STI diagnosis, 138-144, 
147
Syphilis

















Thrombosis and oral contraceptives, 322
Thrush, 273(t)
Toxemia, 59
Toxic shock syndrome, 452, 463
Toxoplasmosis, 163
Traditional contraceptive practices, 23-34
percentage of use, 24, 25(t)
safety, 32
use in urban/rural settings, 24
Treponema pallidum, 119
clinical management, 129(t)


















family planning services, 606-607
prevalence of HIV-2, 79(t)
use of traditional practices, 24









Vaginal barriers, 443-467, 
see also Cervical cap; Contraceptive sponge; 
Diaphragms; Female Condoms; 
Vaginal spermicides




instructions for use, 448(t), 462-467
mechanism of action, 444






and sexual response, 225
STI, 449-450
toxic shock syndrome, 452
use with vaginal spermicide, 446
Vaginal discharge, 195
algorithms for treatment, 141(f )
Vaginal hygiene, 195
Vaginal irritation, 450, 451
risk of HIV transmission, 90
Vaginal odor, 195
Vaginal spermicides, 28(t), 443-467 
see also Vaginal barriers
HIV, 450-451
protection from STI, 145, 146(t)
providing, 453-454
risk of HIV transmission, 86-87
side effects, 452
use with vaginal barriers, 446
Vaginismus, 230-231
Vaginosis, 120(t)
Vasectomy see Male sterilization
Vertical STI transmission 
see Mother-child STI transmission
Vescovaginal fistula, 61
Vision disturbances and oral contraceptives, 329
Voluntary family planning, 44
































Withdrawal see Coitus Interruptus
Women and safe sex, 97-98, 435
Workplace exposure to HIV, 109






effect on mother-child HIV transmission, 
91-92
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